0001558370-24-01290110-K Rezolute, Inc. 20240919202409191623031623031623031

310001509261rzlt:PreFundedWarrantsMember2024-06-300001509261rzlt:PreFundedWarrants2022Member2024-06-300001509261rzlt:PreFundedWarrants2021Member2024-06-300001509261rzlt:PreFundedWarrantsMember2023-06-300001509261rzlt:SecuritiesExchangeAgreementMemberrzlt:ExchangePreFundedWarrantsMember2024-05-132024-05-130001509261srt:ChiefExecutiveOfficerMemberrzlt:EmploymentAgreementsMemberus-gaap:SubsequentEventMember2024-09-150001509261srt:ChiefExecutiveOfficerMemberrzlt:EmploymentAgreementsMemberus-gaap:SubsequentEventMember2024-09-140001509261srt:ChiefFinancialOfficerMemberrzlt:EmploymentAgreementsMemberus-gaap:SubsequentEventMember2024-09-100001509261rzlt:EmploymentAgreementsMember2024-06-300001509261us-gaap:AdditionalPaidInCapitalMember2023-07-012024-06-3000015092612024-06-3000015092612023-06-3000015092612024-04-012024-06-3000015092612023-12-2900015092612024-09-1300015092612022-07-012023-06-3000015092612023-07-012024-06-30xbrli:sharesiso4217:USDiso4217:USDxbrli:sharesxbrli:pureutr:sqftrzlt:itemrzlt:employeerzlt:subsidiaryrzlt:YTable of Contentsâ€‹â€‹UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549FORM 10-K(Mark One)â€‹â˜Â ANNUAL REPORT PURSUANT TO SECTIONÂ 13 OR 15(d)Â OF THE SECURITIES EXCHANGE ACT OF 1934Â Â Â For the fiscalÂ year ended June 30, 2024Â â˜Â TRANSITION REPORT PURSUANT TO SECTIONÂ 13 OR 15(d)Â OF THE SECURITIES EXCHANGE ACT OF 1934â€‹For the Transition Period from Â Â Â Â Â Â Â Â Â Â Â Â toâ€‹â€‹Commission File Number 001-39683â€‹REZOLUTE, INC.(Exact Name of Company as Specified in its Charter)â€‹NevadaÂ 27-3440894(State or other jurisdiction of incorporation or organization)Â (I.R.S. Employer Identification No.)Â Â Â Â 275 Shoreline Drive, Suite 500Redwood City, CaliforniaÂ 94065(Address of principal executive offices)â€‹(Zip Code)â€‹â€‹â€‹Registrant's telephone number, including area code:Â (650) 206-4507â€‹Securities registered pursuant to Section 12(b) of the Act: â€‹â€‹â€‹â€‹â€‹â€‹Title of each classÂ Â Â Â Trading Symbol(s)Â Â Â Â Name of each exchange on which registeredCommon Stock, par value $0.001â€‹RZLTâ€‹Nasdaq Capital Marketâ€‹Securities registered pursuant to Section 12(g) of the Act: NoneIndicate by check mark if the registrant is a well-known seasoned issuer, as defined in RuleÂ 405 of the Securities Act. Yes â˜Â Â Â No â˜‘Indicate by check mark if the registrant is not required to file reports pursuant to SectionÂ 13 or SectionÂ 15(d)Â of the Act. Yes â˜Â Â Â No â˜ Indicate by check mark whether the Registrant (1)Â has filed all reports required to be filed by SectionÂ 13 or 15(d)Â of the Securities Exchange Act of 1934 during the preceding 12Â months (or for such shorter period that the Company was required to file such reports), and (2)Â has been subject to such filing requirements for the past 90Â days. Yes â˜‘Â Â Â No â˜ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to RuleÂ 405 of Regulation S-T (Â§232.405 of this chapter) during the preceding 12Â months (or for such shorter period that the registrant was required to submit such files). Yes â˜‘Â Â Â No â˜ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. Â See the definitions of â€œlarge accelerated filerâ€, â€œaccelerated filerâ€, â€œsmaller reporting companyâ€, and â€œemerging growth companyâ€ in Rule 12b-2 of the Exchange Act.â€‹â€‹â€‹â€‹â€‹â€‹Large accelerated filer â˜Accelerated filer â˜â€‹â€‹Non-accelerated filer â˜‘Smaller reporting company â˜‘â€‹â€‹â€‹â€‹Emerging growth company â˜â€‹â€‹If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.Â â˜Indicate by check mark whether the registrant has filed a report on and attestation to its managementâ€™s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.Â â˜If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.Â â˜Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrantâ€™s executive officers during the relevant recovery period pursuant to Â§240.10D-1(b).Â â˜Indicate by check mark whether the registrant is a shell company (as defined in RuleÂ 12b-2 of the Exchange Act). YesÂ â˜Â Â Â No â˜‘Â As of December 29, 2023, the last business day of the registrants most recently completed second fiscal quarter, the aggregate market value of the registrantâ€™s voting stock held by non-affiliates, was approximately $33,252,000, based on the last reported sales price of $0.993 as quoted on the Nasdaq Capital Market on such date.The registrant had 55,369,764 shares of its $0.001 par value common stock outstanding as of September 13, 2024.DOCUMENTS INCORPORATED BY REFERENCEPortions of the definitive Proxy Statement to be delivered to shareholders in connection with the Annual Meeting of Shareholders to be held on December 5, 2024 are incorporated by reference into Part III of this Annual Report on Form 10-K.â€‹â€‹ Table of ContentsTABLE OF CONTENTSâ€‹â€‹Â Â Â Â PagePart Iâ€‹â€‹â€‹â€‹â€‹â€‹Item 1. Businessâ€‹1â€‹â€‹â€‹Item 1A. Risk Factorsâ€‹7â€‹â€‹â€‹Item 1B. Unresolved Staff Commentsâ€‹19â€‹â€‹â€‹Item 1C. Cybersecurityâ€‹19â€‹â€‹â€‹Item 2. Propertiesâ€‹20â€‹â€‹â€‹Item 3. Legal Proceedingsâ€‹20â€‹â€‹â€‹Item 4. Mine Safety Disclosuresâ€‹20â€‹â€‹â€‹Part IIâ€‹â€‹â€‹â€‹â€‹â€‹Item 5. Market for Registrantâ€™s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securitiesâ€‹20â€‹â€‹â€‹Item 6. [Reserved]â€‹21â€‹â€‹â€‹Item 7. Managementâ€™s Discussion and Analysis of Financial Condition and Result of Operationsâ€‹21â€‹â€‹â€‹Item 7A. Quantitative and Qualitative Disclosures About Market Riskâ€‹30â€‹â€‹â€‹Item 8. Financial Statements and Supplementary Dataâ€‹31â€‹â€‹â€‹Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosureâ€‹60â€‹â€‹â€‹Item 9A. Controls and Proceduresâ€‹60â€‹â€‹â€‹Item 9B. Other Informationâ€‹61â€‹â€‹â€‹Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspectionsâ€‹62â€‹â€‹â€‹Part IIIâ€‹â€‹â€‹â€‹â€‹â€‹Item 10. Directors, Executive Officers and Corporate Governanceâ€‹62â€‹â€‹â€‹Item 11. Executive Compensationâ€‹62â€‹â€‹â€‹Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Mattersâ€‹62â€‹â€‹â€‹Item 13. Certain Relationships and Related Transactions, and Director Independenceâ€‹63â€‹â€‹â€‹Item 14. Principal Accounting Fees and Servicesâ€‹63â€‹â€‹â€‹Part IVâ€‹â€‹â€‹â€‹â€‹â€‹Item 15. Exhibits and Financial Statement Schedulesâ€‹63â€‹â€‹â€‹Item 16. Form 10-K Summaryâ€‹66â€‹â€‹â€‹Signaturesâ€‹67â€‹â€‹â€‹â€‹-i-- Table of ContentsCAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTSThis Annual Report on FormÂ 10-K for the fiscal year ended June 30, 2024 (â€œAnnual Reportâ€) contains statements reflecting assumptions, expectations, projections, intentions or beliefs about future events that are intended as â€œforward-looking statementsâ€ within the meaning of the Private Securities Litigation Reform Act of 1995.Â All statements included or incorporated by reference in this Annual Report, other than statements of historical fact, that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements.Â These statements appear in a number of places, including, but not limited to â€œManagementâ€™s Discussion and Analysis of Financial Condition and Results of Operations.â€Â These statements represent our reasonable judgment of the future based on various factors and using numerous assumptions and are subject to known and unknown risks, uncertainties and other factors that could cause our actual results and financial position to differ materially from those contemplated by the statements.Â You can identify these statements by the fact that they do not relate strictly to historical or current facts, and use words such as â€œanticipate,â€ â€œbelieve,â€ â€œestimate,â€ â€œexpect,â€ â€œforecast,â€ â€œmay,â€ â€œshould,â€ â€œplan,â€ â€œprojectâ€ and other words of similar meaning.Â In particular, these include, but are not limited to, statements relating to the following:â—our ability to obtain regulatory approvals or remove regulatory holds for clinical trials and our drug candidates; â—expectations regarding clinical development and the timing of clinical trials in the United States and outside of the United States;â—projected operating or financial results, including anticipated cash flows to be used in operating activities;â—expectations regarding capital expenditures, research and development expenses and the timing of milestone payments required under license agreements;â—our beliefs and assumptions relating to our liquidity position, including our ability to obtain additional financing; andâ—our future dependence on third-party manufacturers or strategic partners to manufacture any of our pharmaceutical drugs and diagnostics that receive regulatory approval, and our ability to identify strategic partners and enter into license, co-development, collaboration or similar arrangements.Any or all of our forward-looking statements may turn out to be wrong.Â They can be affected by inaccurate assumptions or by known or unknown risks, uncertainties and other factors including, but not limited to, the risks described in â€œRisk Factorsâ€ in Part I, Item 1A of this Annual Report.In addition, there may be other factors that could cause our actual results to be materially different from the results referenced in the forward-looking statements, some of which are included elsewhere in this Annual Report, including â€œManagementâ€™s Discussion and Analysis of Financial Condition and Results of Operations.â€Â Many of these factors will be important in determining our actual future results.Â Consequently, the accuracy of our forward-looking statements cannot be guaranteed.Â Our actual future results may vary materially from those expressed or implied in any forward-looking statements. All forward-looking statements contained in this Annual Report are qualified in their entirety by this cautionary statement.Â Forward-looking statements speak only as of the date they are made, and we disclaim any obligation to update any forward-looking statements to reflect events or circumstances after the date of this Annual Report, except as otherwise required by applicable law.â€‹â€‹-ii-- Table of ContentsPART IItem 1. Business.Rezolute, Inc. (â€œRezoluteâ€, the â€œCompanyâ€, â€œweâ€ or â€œusâ€) is a late-stage rare disease company focused on significantly improving outcomes for individuals with hypoglycemia caused by hyperinsulinism (â€œHIâ€).Summary of Clinical Assets Ersodetug (formerly RZ358)Our lead clinical asset, ersodetug (formerly RZ358), is a potential treatment for hypoglycemia caused by multiple forms of hyperinsulinism.Ersodetug is an intravenously administered human monoclonal antibody that binds to a unique site (allosteric) on the insulin receptor in insulin target tissues, such as in the liver, fat, and muscle. The antibody down modulates insulinâ€™s binding, signaling, and action thereby counteracting the effects of elevated insulin in the body, and helping to restore glucose to a more normalized range. Ersodetug shows dose dependent pharmacokinetics with a half-life greater than 2 weeks, which has the potential for twice or even once monthly dosing. Therefore, we believe that ersodetug is ideally suited as a potential therapy for conditions characterized by excessive insulin levels, and it is being developed to treat hyperinsulinism and low blood sugar. As ersodetug acts downstream from the beta cells, it has the potential to be universally effective at treating hypoglycemia related to HI, whether genetic or caused by tumors.Ersodetug for congenital HIâ€‹Congenital HI is the most common cause of recurrent and persistent hypoglycemia in children. Individuals with congenital HI typically present with signs or symptoms of hypoglycemia shortly after birth. Hypoglycemia can result in significant brain injury and death if not recognized and managed appropriately. Additionally, recurrent, or cumulative, hypoglycemia can lead to progressive and irreversible damage over time, including serious and devastating brain injury, seizures, neuro-developmental problems, feeding difficulties, and significant impact on patient and family quality of life. In cases that are unresponsive to medical management, surgical removal of the pancreas may be required. In those with diffuse disease where the whole pancreas is affected, a near-total pancreatectomy can be undertaken, although ongoing medical treatment of hypoglycemia is generally required for several years after surgery, before eventual insulin-dependent diabetes ensues. There are no U.S. Food and Drug Administration (â€œFDAâ€) approved therapies for all forms of congenital HI and the current standard of care treatments are suboptimal. The current treatments used by physicians include glucagon, diazoxide, somatostatin analogues and pancreatectomy. We estimate that in the U.S. alone the addressable market for congenital HI is more than 1,500 individuals.â€‹Ersodetug has received Orphan Drug Designation in the U.S. and European Union for the treatment of congenital HI, as well as Rare Pediatric Disease Designation in the U.S., a prerequisite for a request for a Rare Pediatric Disease Priority Review Voucher upon Biologics License Application (â€œBLAâ€) submission. Based on the multinational Phase 2b clinical trial (â€œRIZEâ€) outcomes and the evidence of benefit in this serious condition with substantial unmet medical need, ersodetug was subsequently granted a priority medicines (â€œPRIMEâ€) designation by the European Medicines Agency (â€œEMAâ€) and an Innovation Passport designation by the UK Innovative Licensing and Access Pathway (â€œILAPâ€) Steering Group for the treatment of congenital HI.â€‹Phase 3 sunRIZEâ€‹We are actively enrolling a pivotal Phase 3 clinical study (the â€œsunRIZEâ€ study) of ersodetug for the treatment of hypoglycemia in participants with congenital HI, an ultra-rare pediatric genetic disorder characterized by excessive production of insulin by the pancreas. If untreated, the elevated insulin levels in patients suffering with congenital HI can induce extreme hypoglycemia (low blood sugar) events, increasing the risk of neurological and developmental complications, including persistent feeding problems, learning disabilities, recurrent seizures, brain damage or even death. 1â€‹ Table of ContentsThe sunRIZE study is a randomized, double-blind, placebo-controlled, parallel arm evaluation of ersodetug in participants 3 months of age and older with congenital HI who are not adequately responding to standard of care medical therapies. Specifically, the study is evaluating the safety and efficacy of ersodetug in participants who are unable to achieve control of low blood sugars (â€œhypoglycemiaâ€ [<70 mg/dL]). The study will determine the ability of ersodetug to correct hypoglycemia as assessed by (i) hypoglycemia events using self-monitored blood glucose (â€œSMBGâ€) and (ii) time in hypoglycemia using continuous glucose monitoring (â€œCGMâ€) over 24 weeks of treatment. â€‹To date, we have been screening and enrolling participants outside the U.S. because the FDA had imposed an age restriction of 12 years of age and older on ersodetug clinical studies as well as dose level restrictions based on historical rat toxicology findings. On September 4, 2024, FDA lifted those restrictions and now the Company is conducting study start-up activities at sites in the U.S. in anticipation of enrolling U.S. participants in the sunRIZE study in the first part of 2025. Topline results from the study are anticipated to be available in the second half of calendar 2025. â€‹The study will also measure the levels of ersodetug and its effects on other important blood and clinical markers of hypoglycemia, as well as quality of life measures. The primary and key secondary efficacy endpoints are the following:Â Primary efficacy endpoint:â—Change in average weekly occurrence of hypoglycemia events as measured by SMBG after 24 weeksâ€‹Key secondary efficacy endpoint:â—Change in average daily percent time in hypoglycemia as measured by CGM after 24 weeksâ€‹Approximately 56 participants between 3 months and 45 years of age are intended to be enrolled. Participants between 1 and 45 years of age (approximately 48 participants) will be enrolled in a randomized, double-blind, placebo-controlled fashion to receive ersodetug or placebo at dose levels of 5 or 10 mg/kg while on standard of care. Infant participants between 3 months and 1 year of age (approximately 8 participants) will initially be enrolled in open-label fashion to receive ersodetug at a starting dose level of 5 mg/kg, which may be increased to 10 mg/kg at the discretion of the investigator. Thereafter, pending agreement by an independent Data Monitoring Committee, infant patients may be permitted to be enrolled into the randomized, controlled study. Participants will receive ersodetug as an intravenous infusion every 2 weeks over an initial 4-week loading period (3 doses), followed by monthly doses over an additional 16-week maintenance period (4 doses), for a total of 7 doses over the total 24-week treatment period. Following the study period, participants may proceed into an open-label extension program where investigators shall be permitted to: (i) adjust the dose between 5 and 10 mg/kg; (ii) adjust the dosing frequency between 2 and 4 weeks; and (iii) wean or stop other background hypoglycemia therapies.â€‹In summary, the study will be comprised of the following treatment groups:â€‹â—Participants â‰¥1 year old: 5 mg/kg (n = 16)â—Participants â‰¥1 year old: 10 mg/kg (n = 16)â—Participants â‰¥1 year old: placebo (n = 16)â—Initial Infant Participants: starting at 5 mg/kg (n = 8)â€‹Ersodetug for tumor HIâ€‹Tumor HI may be caused by two distinct types of tumors: neuroendocrine islet cell tumors (â€œICTsâ€) and non-islet cell tumors (â€œNICTsâ€), both of which lead to hypoglycemia due to excessive activation of the insulin receptor. Insulinomas are the most common type of functional ICT and mediate hypoglycemia through excessive insulin production. NICTs are generally associated with relatively large, solid tumors such as hepatocellular carcinoma, fibrosarcoma and mesothelioma, and can cause hypoglycemia by producing and secreting insulin-like paraneoplastic substances such as IGF-2 or related variants that bind to and activate the insulin receptor. This form of hypoglycemia can occur in more than 15 different tumor types. â€‹Current therapies for insulinomas and NICTs can be grouped into two main categories: (a) tumor-directed de-bulking therapies (e.g. surgery, chemotherapy, radiotherapy), which may indirectly and/or eventually lead to decreased levels of 2â€‹ Table of Contentscirculating insulin and/or insulin-like substances, and therefore control HI and related hypoglycemia; and/or (b) medical therapies that directly treat HI and the associated hypoglycemia. Tumor-directed therapies do not directly treat hypoglycemia caused by insulinomas or NICTs. In many cases, tumor-directed therapies are administered concurrently with medical therapies for hypoglycemia and in other cases successful treatment of hypoglycemia often enables the initiation and/or continuation of tumor-directed therapies, as indicated. During the period from diagnosis to surgical treatment, or if surgery is contraindicated or refused, medical treatments are often necessary to directly manage the HI and hypoglycemia induced by the tumor. Additionally, chronic medical management of refractory hypoglycemia is often necessary for patients who cannot be cured by surgery, such as those with extensive disease of the pancreas, multi-focal insulinomas, inoperable or unresectable benign or malignant insulinomas, metastatic insulinomas, non-pancreatic insulinomas, or NICT hypoglycemia resulting from a variety of other tumors. â€‹A significant unmet need exists for treatment options with improved efficacy and tolerability as normalization of glucose levels is crucial to prevent serious signs and symptoms of hypoglycemia, improve patient quality of life and overall function, and even to ensure patients are fit to receive cancer treatment and to reduce mortality. Unfortunately, some patients are unresponsive to the current standard of care medical therapies for tumor HI and experience debilitating hypoglycemia that is otherwise untreatable. Currently available medical therapies are directed at reducing or eliminating insulin production and/or secretion from tumors, which may be challenging when the tumor is differentiated or dysregulated, and therefore not responding to usual control mechanisms for suppressing insulin production. In some cases, commonly utilized somatostatin analog therapies may even worsen hypoglycemia due to suppression of glucagon. Therefore, currently available medical therapies directed at suppressing insulin production may have limited effectiveness in tumor HI. â€‹While we believe the total addressable

market may be larger, the immediately addressable market for the combined indications causing tumor HI is estimated to be approximately 1,500 patients in the U.S. alone, including approximately 500 with islet cell tumor hypoglycemia (â€œICTHâ€) and approximately 1,000 with non-islet cell tumor hypoglycemia (â€œNICTHâ€).â€‹On August 5, 2024, we announced FDA clearance of our Investigational New Drug (â€œINDâ€) application for a Phase 3 registrational study of ersodetug for the treatment of hypoglycemia due to tumor HI. This is the second rare disease program with ersodetug in Phase 3 development. We are initiating start-up activities for the study, which will be primarily conducted in the U.S., and patient enrollment is planned to commence in the first half of calendar 2025.â€‹The Phase 3 registrational study is a double-blind, randomized, placebo-controlled trial of 24 participants who have inadequately controlled hypoglycemia because of tumor HI. Eligible participants will be randomized in 1:1 fashion (12 per treatment arm) to receive ersodetug 9 mg/kg per week or matched placebo, as an add-on to standard of care. Up to 24 additional participants may be enrolled into an open-label arm, in participants whose hypoglycemia is being managed by IV glucose in a hospital setting. Following a 6-week pivotal treatment period, all participants may receive ersodetug in open-label extension. The primary endpoint is the change in Level 2 (moderate) and Level 3 (severe) hypoglycemia events by self-monitored blood glucose. Additional endpoints include overall hypoglycemia events, time in hypoglycemia by continuous glucose monitor, patient reported quality of life, hospitalizations, and change in glucose requirements (for open-label hospitalized participants).â€‹Expanded Access Program â€‹Ersodetug has been shown to counteract excessive insulin action downstream, at the insulin-receptor on target organs. The unique mechanism of action of ersodetug makes the therapy a potential universal treatment for any form of hyperinsulinism.â€‹We maintain an EAP for a variety of HI indications for the purpose of making ersodetug available on a compassionate use basis when available therapeutic options have failed, and an individualâ€™s hypoglycemia is unmanageable. In the fourth quarter of 2022, we received and approved an EAP request from Dr. Mary Elizabeth Patti, Director of the Hypoglycemia Clinic at the Harvard Medical School and Beth Israel Medical Center-affiliated Joslin Diabetes Center, for a patient with intractable hypoglycemia caused by a metastatic insulinoma. Dr. Patti received a single patient IND approval from the FDA's Office of Cardiology, Hematology, Endocrinology and Nephrology - Division of Diabetes, Lipid Disorders, and 3â€‹ Table of ContentsObesity (â€œDivisionâ€) to treat the patient with ersodetug. Dr. Patti reported that the patient safely achieved correction of hypoglycemia with ersodetug, enabling the patient to wean off continuous intravenous dextrose and several other medications for hypoglycemia, leave the hospital after a prolonged stay, and resume receiving concurrent treatment for his cancer with tumor-directed therapies. The patient remained on ersodetug for more than a year until he eventually passed away due to progression of his underlying malignant/metastatic insulinoma. Â We have received and approved several additional requests to date for use of ersodetug in patients with tumor HI caused by metastatic insulinomas and other insulin secreting metastatic cancer (cervical). In the U.S., these requests have all been approved by the Division. These patients have been refractory to usual standard of care therapies for chronic management of hypoglycemia and required continuous high volume/concentration intravenous dextrose or nutritional infusion and were hospitalized and in life-threatening or hospice-bound condition because of uncontrollable hypoglycemia. Further treatment with tumor-directed therapies (e.g., embolization, radiotherapy, chemotherapy) was often deferred as a result of the debilitating hypoglycemia. â€‹Generally, dosing for tumor HI patients has been either 6 mg/kg or 9 mg/kg every 1-2 weeks. In all cases to date, ersodetug has led to substantial improvement in hypoglycemia and has been well tolerated. Within a relatively short period of time after administration of ersodetug, continuous intravenous dextrose was discontinued or substantially reduced and hospitalized patients were able to be discharged and receive maintenance ersodetug doses on an outpatient basis, with durable benefit. In most cases, other background medical therapies for hypoglycemia were able to be weaned or stopped, and patients were able to resume tumor-directed therapies for treatment of their underlying cancer. Patients with metastatic tumor HI often have underlying hepatic injury (abnormal enzymes) at baseline due to hepatic metastases or previous tumor-directed treatments (e.g., partial liver resection or embolization). The patients with hepatic injury that have been treated under the EAP have not exhibited any indication of hepatic toxicity with the use of ersodetug.â€‹RZ402Our second clinical asset, RZ402, is an oral plasma kallikrein inhibitor (â€œPKIâ€) and potential therapy for the chronic treatment of diabetic macular edema (â€œDMEâ€). DME is a vascular complication of diabetes and a leading cause of blindness in the U.S. and elsewhere. Chronic exposure to high blood sugar levels can lead to inflammation, cell damage, and the breakdown of blood vessel walls. Specifically, in DME, retinal blood vessels at the back of the eye become porous and permeable leading to the unwanted infiltration of fluid into the macula. This fluid leakage creates distorted vision, and if left untreated, blindness.In May 2024, we completed a Phase 2 multi-center, randomized, double-masked, placebo-controlled, parallel arm study to evaluate the safety, efficacy, and pharmacokinetics of RZ402 administered as a monotherapy over a 12-week treatment period in participants with DME who are naÃ¯ve to, or have received limited anti-VEGF injections. The study population was comprised of DME patients with mild to moderate non-proliferative diabetic retinopathy. Eligible participants were randomized equally, to one of three RZ402 active treatment arms at doses of 50, 200, and 400 mg, or a placebo control arm, to receive study drug once daily for 12 weeks, before completing a 4-week follow-up. The study enrolled 94 patients in the U.S. The study met both primary endpoints, demonstrating a significant reduction in central subfield thickness (â€œCST") in the study eye at all RZ402 dose levels compared to placebo (up to approximately 50 micron improvement), as well as good safety and tolerability. The program is available for partnering and we are actively engaged in conversations with potential partners to take RZ402 into further development.Intellectual PropertyOur success depends on an intellectual property portfolio that supports our future revenue streams and also erects barriers to our competitors. We are maintaining and building our patent portfolio through filing new patent applications; prosecuting existing applications; and licensing patents and patent applications. Furthermore, we seek to protect our ownership of know-how, trade secrets and trademarks through an active program of legal mechanisms including registrations, assignments, confidentiality agreements, material transfer agreements, research collaborations and licenses. While we have confidence in our agreements and security measures, either may be compromised, and we may not have adequate remedies. In addition, our trade secrets may otherwise become known or independently discovered by competitors.4â€‹ Table of Contentsâ€‹U.S. patents, as well as most foreign patents, are generally effective for 20 years from the date the earliest application was filed. U.S. patents that were issued on applications filed before June 8, 1995, may be effective until 17 years from the issue date, if that is later than the 20-year date. In some cases, the patent term may be extended to recapture a portion of the term lost during regulatory review of the claimed therapeutic or, in the case of the U.S., because of U.S. Patent and Trademark Office (USPTO) delays in prosecuting the application. In the U.S., under the Drug Price Competition and Patent Term Restoration Act of 1984 (commonly known as the Hatch-Waxman Act), a patent that covers a drug approved by the FDA may be eligible for patent term extension (for up to five years, but not beyond a total of 14 years from the date of product approval) as compensation for patent term lost during the FDA regulatory review process. The duration and extension of the term of foreign patents varies in accordance with local law. In the EU, Supplementary Protection Certificates, or SPCs, are available to extend a patent term up to five years to compensate for patent protection lost during regulatory review. Although all EU Member States must provide SPCs, SPCs must be applied for and granted on a country-by-country basis. Limited exceptions apply to the protection conferred by the SPC.â€‹As further described in the â€œXOMA License Agreementâ€ section below, we hold a worldwide, exclusive license from XOMA to patents covering the ersodetug molecule, including 37 issued patents worldwide and in the U.S. (3 U.S.) and pending patent applications with claims directed to compositions of matter and methods of use in therapy. These patents expire between 2030 to 2036. We also are pursuing patent applications relating to formulations of the clinical product candidate. In addition, for certain of our product candidates we also expect to have further exclusivity in the form of data and marketing exclusivity under pharmaceutical regulatory laws, including for example, potentially up to 12 years of exclusivity from the date of first BLA approval of our product candidates. â€‹We also hold a worldwide, exclusive license from ActiveSite to patents covering the RZ402 molecule, certain prodrug forms of RZ402, and uses (as further described in the â€œActiveSite License Agreementâ€ section below), including 9 issued international patents and 7 issued U.S. patents. We have additional patents (2 U.S.) and pending patent applications (3 U.S. and 29 international) with claims directed to formulations, solid forms of RZ402, methods of preparing RZ402, and methods of use in therapy. These patents are expected to expire between 2040 and 2043. We also expect to be granted further exclusivity in the form of data and marketing exclusivity under pharmaceutical regulatory laws in various jurisdictions.Competition We face competition from pharmaceutical and biotechnology companies, academic institutions, governmental agencies, and private research organizations in recruiting and retaining highly qualified scientific personnel and consultants and in the development and acquisition of technologies.There are other companies developing therapies for HI that are potential competitors to ersodetug, including, Amylyx Pharmaceuticals, Hanmi Pharmaceuticals, and Zealand Pharma.There are also companies developing therapies for DME that are potential competitors to our PKI including Curacle, KalVista, Ocuphire Pharma, Oxurion and Verseon.Government RegulationRegulation by governmental authorities in the U.S. and other countries is a significant factor in the development, manufacture and marketing of pharmaceutical products. All of our potential products will require regulatory approval by governmental agencies prior to commercialization. In particular, pharmaceutical therapies are subject to rigorous preclinical testing and clinical trials and other pre-market approval requirements by the FDA and Regulatory Authorities (as defined below) in foreign countries. Various federal, state and foreign statutes and regulations also govern or influence the manufacturing, safety, labeling, storage, record keeping and marketing of such products.In addition, we are subject to various federal, state, and local laws, regulations and recommendations relating to safe working conditions; laboratory and manufacturing practices; the experimental use of animals; and the use and disposal of 5â€‹ Table of Contentshazardous or potentially hazardous substances, including radioactive compounds and infectious disease agents, used in connection with our research, development and manufacturing.Research and DevelopmentWe incurred approximately $55.7 million and $43.8 million in research and development expenses for the fiscal years ended June 30, 2024 and 2023, respectively. For further discussion of activities related to ersodetug and RZ402 product candidates, please refer to the discussion above. For further discussion of our research and development expenses, please refer to the discussion under the caption Results of Operations under Item 7 of this Annual Report.Human Capital ManagementEmployeesAs of June 30, 2024, we had 59 full time employees, of which 42 employees were engaged in research and development, manufacturing, clinical operations, regulatory and quality activities and 17 employees were engaged in administrative functions. Of the 59 employees, all were located in the United States. We have a number of employees who hold Ph.D. degrees and other advanced degrees. None of our employees are covered by a collective bargaining agreement, and we have experienced no work stoppages nor are we aware of any employment circumstances that are likely to disrupt work at any of our facilities. As part of our measures to attract and retain personnel, we provide a number of benefits to our full-time employees, including health insurance, life insurance, retirement plans, paid holiday and vacation time. In addition, we grant stock options to certain key employees as an added incentive to remain in our employment. We believe that we maintain good relations with our employees.Diversity and InclusionDiversity and inclusion are priorities for us. We believe that a rich culture of inclusion and diversity enables us to create, develop and fully leverage the strengths of our workforce. In furtherance of our commitment to inclusion and diversity, on May 30, 2023, we adopted an equity and inclusion policy.Human Resources, Hiring and Professional DevelopmentThe development, attraction and retention of employees is critical to our success. We work diligently to attract the best talent from a diverse range of sources in order to meet the current and future demands of our business. We leverage both formal and informal programs to identify, foster and retain top talent.Business EthicsOur Code of Business Conduct and Ethics is designed to ensure that the conduct of our business is consistent with the highest standards of business ethics. Our Code of Business Conduct and Ethics serves as a critical tool to help employees recognize and report unethical conduct, while preserving our culture of excellence. Our Board of Directors, management and staff are provided with training regarding our Code of Business Conduct and Ethics. On May 30, 2023, we adopted an amended and restated Code of Business Conduct and Ethics. The purpose of amending and restating the prior code was to improve its readability and clarify certain areas of importance, including with respect to compliance with laws, accounting and auditing matters, conflicts of interest, insider trading, confidentiality obligations and the reporting of violations of our Code of Business Conduct and Ethics.Corporate InformationWe were incorporated in Delaware in 2010, and we reincorporated in Nevada in June 2021. We maintain an executive office located at 275 Shoreline Drive, Suite 500, Redwood City, CA 94065 and our phone number is (650) 206-4507. Our website is located at www.rezolutebio.com. We file annual, quarterly, current reports, proxy statements and other information with the Securities and Exchange Commission (â€œSECâ€). The SEC maintains a website that contains our public 6â€‹ Table of Contentsfilings and other information regarding the Company, at www.sec.gov. The information contained in, or that can be accessed through, our website is not part of, and is not incorporated into this document.â€‹â€‹Item 1A. Risk Factors.Investors should consider carefully the following risks before deciding to purchase any of our securities. If any of the events or developments described below actually occur, our business, results of operations and financial condition would likely suffer and investors may lose all or part of their investment. In addition, it is also possible that other risks and uncertainties that affect our business may arise or become material in the future.Risks Related to Our Product Development and CommercializationAny delays in the commencement or completion, or termination or suspension, of our future clinical trials, if any, could result in increased costs to us, delay or limit our ability to generate revenue and adversely affect our commercial prospects.Before obtaining approval from the government authorities or professional bodies with authority to grant regulatory approval for our drug candidates in a particular country, such as the European Medicines Agency (â€œEMAâ€), the Food and Drug Administration of the U.S. Department of Health and Human Services (â€œFDAâ€) and analogous authorities in other jurisdictions outside of the United States (â€œRegulatory Authoritiesâ€), we must conduct extensive clinical studies to demonstrate safety and efficacy. Clinical testing is expensive, time consuming and uncertain as to the outcome. Any delays in the commencement or completion of our ongoing, planned or future clinical trials could significantly increase our costs, slow down our development and approval process and jeopardize our ability to commence product sales and generate revenues. We do not know whether our planned trials will begin on time or at all, or be completed on schedule, if at all. The commencement and completion of clinical trials can be delayed for a number of reasons, including delays related to:â€‹â€”Regulatory Authorities disagreeing as to the design or implementation of our clinical trials or with our recommended dose for any of our pipeline programs;â€—obtaining Regulatory Authority authorization to commence a trial or reaching a consensus with such Regulatory Authorities on trial design;â€—identifying and activating investigators and clinical trial sites to conduct trials;â€—obtaining approval from one or more independent institutional review boards (â€œIRBâ€) or Ethics Committee (â€œECâ€) at each clinical trial site before each trial may be initiated;â€—IRBs/ECs refusing to approve, suspending or terminating the trial at an investigational site, precluding enrollment of additional subjects, or withdrawing their approval of the trial;â€—changes to a clinical trial protocol;â€—clinical sites deviating from trial protocol or dropping out of a trial;â€—failing to manufacture or obtain sufficient quantities of drug candidate, or, if applicable, combination therapies for use in clinical trials;â€—patients failing to enroll or remain in our trial at the rate we expect, or failing to return for post-treatment follow-up;â€—patients choosing an alternative treatment, or participating in competing clinical trials;â€—lack of adequate funding to continue the clinical trial;â€—patients experiencing severe or unexpected drug-related adverse effects;â€—occurrence of serious adverse events in trials of the same class of agents conducted by other companies;â€—selecting or being required to use clinical end points that require prolonged periods of clinical observation or analysis of the resulting data;â€—a facility manufacturing our drug candidates, or any of their components, including without limitation, our own facilities being ordered by Regulatory Authorities to temporarily or permanently shut down due to violations of current good manufacture practices, regulations or other applicable requirements, or infections or cross-contaminations in the manufacturing process;â€—lack of stability of our clinical trial material or any quality issues that arise with the clinical trial material;7â€‹ Table of Contentsâ€—any changes to our manufacturing process that may be necessary or desired;â€—our, or our third-party contractors, not performing data collection or analysis in a timely or accurate manner or improperly disclosing data prematurely or otherwise in violation of a clinical trial protocol; â€—any third-party contractors becoming debarred or suspended or otherwise penalized by Regulatory Authorities or other government or regulatory bodies for violations of regulatory requirements, in which case we may need to find a substitute contractor, and we may not be able to use some or all of the data produced by such contractors in support of our marketing applications;â€—a clinical trial being suspended or terminated by us, by the IRBs/ECs of the institutions in which such trials are being conducted, by a Data Safety Monitoring Board for such trial or by Regulatory Authorities, due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by Regulatory Authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using the product under investigation, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial; orâ€—changes in regulatory requirements and policies and our need to amend clinical trial protocols to comply with these changes and potentially resubmit our clinical trial protocols to IRBs/ECs for reexamination.â€‹Delays in initiating a new phase of clinical trials resulting from action by FDA or any other Regulatory Authority would delay the approval obtainment and commercialization of our product candidates and our ability to generate revenue, which would have an adverse effect on our business.Adverse events in our clinical trials may force us to stop development of our product candidates or prevent regulatory approval of our product candidates.Our product candidates may produce serious adverse events in patients during clinical trials. These adverse events could interrupt, delay or halt clinical trials of our product candidates and could result in the FDA, or other Regulatory Authorities requesting

additional preclinical data or denying approval of our product candidates for any or all targeted indications. An IRB/EC, independent Data Safety Monitoring Board, the FDA, other Regulatory Authorities or the Company itself may suspend or terminate clinical trials at any time. We cannot assure you that any of our product candidates will prove safe for human use.We are exposed to additional risks as we conduct the sunRIZE study outside of the U.S. and may not be successful in meeting the studyâ€™s primary endpoint.Prior to the FDAâ€™s lift of the partial clinical hold in September 2024, we initiated and are advancing the sunRIZE study outside of the U.S. The sunRIZE study may not produce positive results and meet its primary endpoint outside of the U.S. We may need to commence and complete additional clinical trials that satisfy the specified primary endpoint criteria in order to obtain necessary regulatory approvals from the EMA for ersodetug. Conducting clinical trials outside the U.S. also exposes us to additional risks, including risks associated with:â—additional foreign regulatory requirements;â—foreign exchange fluctuations;â—compliance with foreign manufacturing, customs, shipment and storage requirements;â—potential political or economic instability in the jurisdictions where we initiate clinical trials;â—cultural differences in medical practice and clinical research; andâ—diminished protection of intellectual property in some countries.â€‹After the completion of our clinical studies, we cannot predict whether or when we will obtain regulatory approval to commercialize our product candidates and we cannot, therefore, predict the timing of any future revenue from these product candidates.Even if we achieve positive clinical results and file for regulatory approval, we cannot commercialize any of our product candidates until the appropriate Regulatory Authorities have reviewed and approved the applications for such product 8â€‹ Table of Contentscandidates. We cannot provide assurance that the Regulatory Authorities will complete their review processes in a timely manner or that we will obtain regulatory approval for any product candidate we develop. Satisfaction of regulatory requirements typically takes many years, is dependent upon the type, complexity and novelty of the product and requires the expenditure of substantial resources. In addition, we may experience delays or rejections based upon additional government regulation from future legislation or administrative action or changes in Regulatory Authority policy during the period of product development, clinical studies and regulatory review.If we or a Regulatory Authority discovers previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured, a Regulatory Authority may impose restrictions on that product, the manufacturing facility or us, including requiring recall or withdrawal of the product from the market or suspension of manufacturing. If we, our product candidates or the manufacturing facilities for our product candidates fail to comply with applicable regulatory requirements, a Regulatory Authority may: issue warning letters or untitled letters; seek an injunction or impose civil or criminal penalties or monetary fines; suspend or withdraw regulatory approval; suspend any ongoing clinical studies; refuse to approve pending applications or supplements to applications filed by us; suspend or impose restrictions on operations, including costly new manufacturing requirements; or seize or detain products, refuse to permit the import or export of products, or require us to initiate a product recall.The occurrence of any event or penalty described above may inhibit our ability to commercialize our products and generate revenue.If our product candidates do not meet safety or efficacy requirements, they will not receive regulatory approval and we will be unable to market them.The process of drug development, regulatory review and approval typically is expensive, takes many years and the timing of any approval cannot be accurately predicted. If we fail to obtain regulatory approval for our current or future product candidates, we will be unable to market and sell such products and therefore may never be profitable.As part of the regulatory approval process, we must conduct preclinical studies and clinical trials for each product candidate to demonstrate safety and efficacy. The number of preclinical studies and clinical trials that will be required varies depending on the product candidate, the indication being evaluated, the trial results and regulations applicable to any particular product candidate.The results of preclinical studies and initial clinical trials of our product candidates do not necessarily predict the results of later-stage clinical trials. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy despite having progressed through initial clinical trials. We cannot assure you that the data collected from the preclinical studies and clinical trials of our product candidates will be sufficient to support approval by the FDA or a foreign Regulatory Authority. In addition, the continuation of a particular study after review by an independent Data Safety Monitoring Board does not necessarily indicate that our product candidate will achieve the clinical endpoint.The FDA and other Regulatory Authorities can delay, limit or deny approval for many reasons, including: a product candidate may not be safe or effective; our manufacturing processes or facility may not meet the applicable requirements; and changes in Regulatory Authority approval policies or adoption of new regulations may require additional clinical trials or work on our end.Any delay in, or failure to receive or maintain, approval for any of our products could prevent us from ever generating meaningful revenues or achieving profitability.Our product candidates are prone to the risks of failure inherent in drug development. Before obtaining regulatory approvals for the commercial sale of any product candidate for a target indication, we must demonstrate safety in preclinical studies and effectiveness with substantial evidence gathered in well-controlled clinical studies. With respect to approval in the U.S., to the satisfaction of the FDA and, with respect to approval in other countries, to the satisfaction of Regulatory Authorities in those countries, we must demonstrate that the product candidate is safe and effective for use for that target indication and that the manufacturing facilities, processes and controls are adequate.9â€‹ Table of ContentsDespite our efforts, our product candidates may not: offer therapeutic benefit or other improvements over existing, comparable therapeutics; be proven safe and effective in clinical studies; meet applicable regulatory standards; be capable of being produced in sufficient quantities at acceptable costs; be successfully commercialized; or obtain favorable reimbursement.We are not permitted to market any of our other product candidates in the U.S. until we receive approval of a new drug application, or approval of a biologics license application, from the FDA, or in any foreign countries until we receive the requisite approval from such countries. We have not submitted a new drug application or biologics license application or received marketing approval for any of our product candidates.Preclinical testing and clinical studies are long, expensive and uncertain processes. We may spend several years completing our testing for any particular product candidate, and failure can occur at any stage. Negative or inconclusive results or adverse medical events during a clinical study could also cause us, one or more IRBs/ECs at clinical trial sites, a Data Safety Monitoring Board or the FDA or other Regulatory Authority to terminate a clinical study or require that we repeat it or conduct additional studies. Additionally, data obtained from a clinical study is susceptible to varying interpretations and the FDA or other Regulatory Authorities may interpret the results of our clinical studies less favorably than we do. The FDA and equivalent foreign Regulatory Authorities have substantial discretion in the approval process and may decide that our data is insufficient to support a marketing application and require additional preclinical, clinical or other studies.Due to our reliance on contract research organizations or other third parties to conduct clinical trials, we may not have complete control over the timing, conduct and expense of our clinical trials.We rely primarily on third parties to conduct our clinical trials. As a result, we will have less control over the conduct of the clinical trials, the timing and completion of the trials, the required reporting of adverse events and the management of data developed through the trial than would be the case if our own staff conducted all aspects of our clinical trials. Communicating with outside parties can also be challenging, potentially leading to mistakes and difficulties in coordinating activities. Outside parties may have staffing difficulties, may undergo changes in priorities or may become financially distressed, adversely affecting their willingness or ability to conduct our trials. We may experience unexpected increased costs that are beyond our control. Problems with the timeliness or quality of the work of a contract research organization may lead us to seek to terminate the relationship and use an alternative service provider. However, making this change may be costly and may delay our trials, and contractual restrictions may make such a change difficult or impossible. Additionally, it may be impossible to find a replacement organization that can conduct our trials in an acceptable manner and at an acceptable cost.Any failure or delay by our third-party suppliers on which we rely or intend to rely to provide materials necessary to develop and manufacture our drug products may delay or impair our ability to commercialize our product candidates.We rely upon a small number of third-party suppliers for the manufacture of certain raw materials that are necessary to formulate our drug products for preclinical and clinical testing purposes. We intend to continue to rely on them in the future. We also expect to rely upon third parties to produce materials required for the commercial production of our product candidates if we succeed in obtaining necessary regulatory approvals. If we are unable to arrange for third-party sources, or do so on commercially unreasonable terms, we may not be able to complete development of or market our product candidates. In addition, third-party suppliers that we engage may be adversely impacted by COVID-19.It is possible that our raw material suppliers may not be able to sell these raw materials at the times we need them or on commercially reasonable terms due to forces outside of our control including, but not limited to, inflation and global conflicts. We do not have any control over the process or timing of the acquisition of these raw materials by our manufacturers. Our third-party manufacturers and suppliers may encounter delays in providing their services as a result of supply chain constraints. Moreover, we currently do not have any agreements for the commercial production of these raw materials. Although we generally do not begin a clinical study unless we believe we have a sufficient supply of a product candidate to complete the clinical study, any significant delay in the supply of raw material components needed to produce a product candidate for a clinical study due to the need to replace a third-party manufacturer could considerably delay completion of our clinical studies, product testing and potential regulatory approval of our product candidates. If we or our manufacturers are unable to purchase these raw materials after regulatory approval has been obtained for our product 10â€‹ Table of Contentscandidates, the commercial launch of our product candidates would be delayed or there would be a shortage in supply of such product candidates, which would impair our ability to generate revenues from the sale of our product candidates.If we successfully commercialize any of our product candidates, we may be required to establish commercial manufacturing capabilities of larger scale. In addition, as our drug development pipeline increases and matures, we will have a greater need for clinical study and commercial manufacturing capacity. We have no experience manufacturing pharmaceutical products on a commercial scale and we may need to rely on third-party manufacturers with capacity for increased production scale to meet our projected needs for commercial manufacturing, the satisfaction of which on a timely basis may not be met.If we use hazardous and biological materials in a manner that causes injury or violates applicable law, we may be liable for damages.Our research and development activities involve the controlled use of potentially hazardous substances, including toxic chemical and biological materials. We could be held liable for any contamination, injury or other damages resulting from these hazardous substances. In addition, our operations produce hazardous waste products. While third parties are responsible for disposal of our hazardous waste, we could be liable under environmental laws for any required cleanup of sites at which our waste is disposed. Federal, state, foreign and local laws and regulations govern the use, manufacture, storage, handling and disposal of these hazardous materials. If we fail to comply with these laws and regulations at any time, or if they change, we may be subject to criminal sanctions and substantial civil liabilities, which may harm our business. Even if we continue to comply with all applicable laws and regulations regarding hazardous materials, we cannot eliminate the risk of accidental contamination or discharge and our resultant liability for any injuries or other damages caused by these accidents.Guidelines and recommendations published by various organizations may adversely affect the use of any products for which we may receive regulatory approval.Government agencies issue regulations and guidelines directly applicable to us and to our product candidates. In addition, professional societies, practice management groups, private health or science foundations and organizations involved in various diseases from time to time publish guidelines or recommendations to the medical and patient communities. These various sorts of recommendations may relate to such matters as product usage and use of related or competing therapies. For example, organizations like the American Diabetes Association have made recommendations about therapies in the diabetes therapeutics market. Changes to these recommendations or other guidelines advocating alternative therapies could result in decreased use of any products for which we may receive regulatory approval, which may adversely affect our results of operations.Risks Related to Our BusinessChanges in financial accounting standards or policies have affected, and in the future may affect, our reported financial condition or results of operations; there are inherent limitations to our system of internal controls; changes in corporate governance policies and practices may impact our business.â€‹We prepare our consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (â€œGAAPâ€). The preparation of our financial statements in accordance with GAAP requires that we make estimates and assumptions that affect the recorded amounts of assets, liabilities and net income during the reporting period. A change in the facts and circumstances surrounding those estimates could result in a change to our estimates and could impact our future operating results. GAAP is subject to interpretation by the Financial Accounting Standards Board (â€œFASBâ€), the SEC and various bodies formed to interpret and create accounting policies. A change in those policies can have a significant effect on our reported results and may affect our reporting of transactions which are completed before a change is announced. In general, changes to accounting rules or challenges to our interpretation or application of the rules by regulators may have a material adverse effect on our reported financial results or on the way we conduct business.â€‹11â€‹ Table of ContentsOur system of internal and disclosure controls and procedures was designed to provide reasonable assurance of achieving its objectives. However, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been or will be detected. As a result, there can be no assurance that our system of internal and disclosure controls and procedures will be successful in preventing all errors, theft and fraud, or in informing management of all material information in a timely manner. â€‹Finally, corporate governance, public disclosure and compliance practices continue to evolve based upon continuing legislative action, SEC rulemaking and policy positions taken by large institutional stockholders and proxy advisors. As a result, the number of rules, regulations and standards applicable to us may become more burdensome to comply with, could increase scrutiny of our practices and policies by these or other groups and increase our legal and financial compliance costs and the amount of time management must devote to governance and compliance activities. For example, the SEC has recently proposed rules requiring that issuers provide significantly increased disclosures concerning cybersecurity matters and the impact of climate changes on their business and has adopted rules requiring public companies to adopt more stringent executive compensation clawback policies. Increasing regulatory burdens and corporate governance requirements could also make it more difficult for us to attract and retain qualified members of our Board of Directors and qualified executive officers.We have a history of losses and may not achieve profitability in the future. We will need substantial additional capital to fund our operations. If we fail to obtain additional capital, we will be unable to sustain operations.We incurred net losses ofÂ $68.5 millionÂ andÂ $51.8 millionÂ for the fiscal years endedÂ June 30, 2024 and 2023, respectively. As ofÂ June 30, 2024, we had an accumulated deficit ofÂ $329.4 million. Cash used in our operating activities amounted to $57.4 million and $44.5 million for the fiscal years ended June 30, 2024 and 2023, respectively. We expect that the amount of cash used in our operating activities will continue to increase for the next several years. As of June 30, 2024, we had cash and cash equivalents of $70.4 million and investments in marketable debt securities of $56.7 million that is expected to provide us with adequate capital resources to fund planned activities at least through the second quarter of calendar year 2026.â€‹Since our inception, we have not generated meaningful revenue. We expect to continue to incur operating losses for the foreseeable future as we develop and commercialize our product candidate pipeline, and we expect to need additional capital from external sources before we will be able to begin generating revenue, if ever. If we are unable to raise additional capital, we may have to significantly delay, scale back or discontinue one or more of our research and development programs. We may be required to cease operations or seek partners for our product candidates at an earlier stage than otherwise would be desirable and on terms that are less favorable than might otherwise be available. In the absence of additional capital we may also be required to relinquish, license or otherwise dispose of rights to technologies, product candidates or products that we would otherwise seek to develop or commercialize on terms that are less favorable than might otherwise be available. If we are unable to secure additional capital, we may be required to take additional measures to reduce costs in order to conserve our cash in amounts sufficient to sustain operations and meet our obligations. These measures could cause significant delays in the development of our product candidates.â€‹We face potential product liability exposure, and, if successful claims are brought against us, we may incur substantial liability.The use of our product candidates in clinical studies and the sale of any products for which we obtain marketing approval expose us to the risk of product liability claims. Product liability claims might be brought against us by consumers, health care providers, pharmaceutical companies or others selling or otherwise coming into contact with our products. If we cannot successfully defend ourselves against product liability claims, we could incur substantial liabilities. In addition, regardless of merit or eventual outcome, product liability claims may result in: impairment of our business reputation; withdrawal of clinical study participants; costs of related litigation; distraction of managementâ€™s attention from our primary business; substantial monetary awards to patients or other claimants; the inability to commercialize our product candidates; and decreased demand for our product candidates, if approved for commercial sale.We currently have clinical trial insurance for our active clinical programs. This product liability insurance coverage for our clinical studies may not be sufficient to reimburse us for all expenses or losses we may suffer. Moreover, insurance 12â€‹ Table of Contentscoverage is becoming increasingly expensive, and, in the future, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. If and when we obtain marketing approval for any of our product candidates, we intend to expand our insurance coverage to include the sale of commercial products; however, we may be unable to obtain this product liability insurance on commercially reasonable terms. On occasion, large judgments have been awarded in class action lawsuits based on drugs that had unanticipated adverse effects. A successful product liability claim, or series of claims, brought against us could cause our stock price to decline and, if judgments exceed our insurance coverage, could decrease our cash and adversely affect our business.We may not be able to use a significant

portion of our net operating loss carryforwards, which could adversely affect our profitability.Federal and state laws impose substantial restrictions on the utilization of net operating loss (â€œNOLâ€) carryforwards in the event that certain ownership changes occur as defined in Section 382 of the Internal Revenue Code (â€œIRCâ€). Due to our financing activities, we experienced ownership changes that have resulted in significant limitations on the future use of our NOL carryforwards. As of June 30, 2024, we have US federal NOL carryforwards of approximately $171.7 million, of which $33.4 million will expire without any opportunity for utilization due to the limitations set forth in IRC Section 382. Assuming that further IRC Section 382 ownership changes do not occur, the remaining $138.3 million of NOL carryforwards consist of approximately (i) $38.0 million that never expire and are currently available to offset taxable income, (ii) $9.6 million that are currently available to offset taxable income but if not utilized will expire in 2031 through 2035, (iii) $11.7 million that becomes available through 2038 and that expire by June 30, 2038 if not utilized, and (iv) $79.0 million that never expire. With respect to $79.0 million of NOL carryforwards that never expire, this amount will become available in varying annual amounts for an aggregate of approximately $13.2 million through fiscal year 2038, and $1.2 million annually thereafter. It is possible that any future ownership changes could result in further limitations on the use of our NOL carryforwards or other tax attributes, which could adversely affect our future financial position, profitability and cash flows.If we fail to maintain proper and effective internal control over financial reporting, our ability to produce accurate and timely financial statements could be impaired, investors may lose confidence in our financial reporting and the trading price of our common stock may decline.We are subject to Section 404 of The Sarbanes-Oxley Act of 2002 (â€œSection 404â€), and the related rules of the SEC which generally require our management and independent registered public accounting firm to report on the effectiveness of our internal control over financial reporting. Section 404 requires an annual management assessment of the effectiveness of our internal control over financial reporting. Effective April 27, 2020, the SEC adopted amendments to the â€œaccelerated filerâ€ and â€œlarge accelerated filerâ€ definitions in Rule 12b-2 under the Securities and Exchange Act of 1934. The amendments exclude from the â€œaccelerated filerâ€ and â€œlarge accelerated filerâ€ definitions an issuer that is eligible to be a smaller reporting company and that had annual revenues of less than $100 million in the most recent fiscal year for which audited financial statements are available. We determined that our Company does not meet the accelerated or large accelerated filer definitions as of June 30, 2024. For so long as we remain a smaller reporting company and a non-accelerated filer, we intend to take advantage of certain exemptions from various reporting requirements that are applicable to public companies, including, but not limited to, not being required as a non-accelerated filer to comply with the auditor attestation requirements of Section 404(b). An independent assessment by our independent registered public accounting firm of the effectiveness of internal control over financial reporting could detect problems that our managementâ€™s assessment might not. Undetected material weaknesses in our internal control over financial reporting could lead to financial statement restatements and require us to incur the expense of remediation. 13â€‹ Table of ContentsAfter remediation of a material weakness identified during the fiscal quarter ended March 31, 2024, we have determined that our internal control over financial reporting was effective as of June 30, 2024. However, we cannot provide assurance that there will not be material weaknesses or significant deficiencies in our internal control over financial reporting in the future. Any failure to maintain internal control over financial reporting could severely inhibit our ability to accurately report our financial condition, results of operations or cash flows. If we are unable to conclude that our internal control over financial reporting is effective, investors may lose confidence in the accuracy and completeness of our financial reports, the market price of our common stock could decline, and we could be subject to sanctions or investigations by Nasdaq, the SEC or other regulatory authorities. Failure to remediate any material weakness in our internal control over financial reporting, or to implement or maintain other effective control systems required of public companies, could also restrict our future access to the capital markets.Operations outside the United States may be affected by different local politics, business and cultural factors, different regulatory requirements and prohibitions between jurisdictions.We intend to seek regulatory approval in foreign countries for all of our potential products prior to commercialization. Pharmaceutical therapies are subject to rigorous preclinical testing and clinical trials and other pre-market approval requirements by Regulatory Authorities in foreign countries. Operations outside the United States may be affected by different local business and cultural factors, different regulatory requirements and prohibitions between jurisdictions, including the Foreign Corrupt Practices Act and local laws prohibiting corrupt payments, and changes in regulatory requirements for financing activities.Our collection, use, processing, and cross-border transfer of personal information, including individually identifiable health information, is governed by restrictive regulations. Our business is broadly regulated by U.S. and foreign regulatory authorities, and we must comply with all applicable rules and regulations concerning our use, processing, handling, maintenance, and protection of personal information. In the U.S., the Health Insurance Portability and Accountability Act (â€œHIPAAâ€) imposes requirements at the federal level relating to the privacy, security and transmission of individually identifiable health information, while individual states, such as California, have adopted privacy regulations restricting the use of personal information and providing individuals certain rights with respect to the collection and use of their data. Further, the collection and use of personal information in Europe is governed by the EUâ€™s General Data Protection Regulation and the United Kingdomâ€™s implementation of the same, or the GDPR. Failure to comply with the requirements of the GDPR and other applicable data protection laws of the EU member states and the United Kingdom, or other applicable privacy rules and regulations in other countries, may result in significant fines and other administrative penalties. We may be required to put in place additional mechanisms to comply with current and future privacy and data protection regulations applicable to our business. This may interrupt or delay our development activities and/or require us to change our business practices, which could adversely affect our business, financial condition, results of operations and prospects.We could recognize losses on securities held in our marketable debt securities portfolio, particularly if interest rates increase or economic and market conditions deteriorate.â€‹As of June 30, 2024, the fair value of the investments in our marketable debt securities portfolio was approximately $56.7Â million. Factors beyond our control can significantly influence the fair value of securities in our portfolio and can cause potential adverse changes to the fair value of these securities. For example, fixed-rate securities acquired by us are generally subject to decreases in market value when interest rates rise. Additional factors include, but are not limited to, rating agency downgrades of the securities or our own analysis of the value of the security, defaults by the issuer with respect to the underlying securities, and continued instability in the credit markets. Any of the foregoing factors could result in credit-related loss and result in realized losses. The process for determining whether allowances are needed for credit-related losses usually requires difficult, subjective judgments about the futureÂ financial performance of the issuer and any collateral underlying the security in order to assess the probability of receiving all contractual principal and interest payments on the security.â€‹As of June 30, 2024, we had $79,000 in net unrealized losses in our marketable debt securities. Unrealized losses in our marketable debt securities portfolio may increase in the future due to the aforementioned economic factors. While our goal 14â€‹ Table of Contentsis to hold each security until maturity, that may not be possible in light of our policy to preserve capital and liquidity and because investment in securities with unrealized losses has a diminished utility as a source of liquidity prior to maturity. Selling securities with an unrealized loss would result in the realization of such losses, which could have an adverse effect on our financial condition and results of operations.â€‹Unfavorable global and regional economic, political and health conditions could adversely affect our business, financial condition or results of operations.â€‹Our business could be adversely affected by global or regional economic, political and health conditions. Various macroeconomic factors could adversely affect our business, financial condition and results of operations, including changes in inflation, interest rates and overall economic conditions and uncertainties, including those resulting from political instability, trade disputes between nations and the current and future conditions in the global financial markets. For example, beginning in fiscal year ended June 30, 2023, much of the world, including the U.S. and the E.U., began to experience inflation levels not seen in more than 30 years. As a result, prices for many of our inputs have risen, in some cases dramatically. If inflation stays at elevated levels or increases, we may not be able to mitigate the impact of the increased costs we will bear, which could have an impact on our results of operations and financial condition. A global financial crisis or global or regional political and economic instability, wars, terrorism, civil unrest, outbreaks of disease (for example, COVID-19), and other unexpected events, such as supply chain constraints or disruptions, could cause extreme volatility in the capital and credit markets and disrupt our business. Business disruptions could include, among others, disruptions to our commercial activities, including due to supply chain or distribution constraints or challenges, clinical enrollment, clinical site availability, patient accessibility, and conduct of our clinical trials, as well as temporary closures of the facilities of suppliers or contract manufacturers in the biotechnology supply chain. In addition, during certain crises and events, patients may prioritize other items over certain or all of their treatments and/or medications, which could have a negative impact on our commercial sales. A severe or prolonged economic downturn, political disruption or adverse health conditions could result in a variety of risks to our business, including our ability to raise capital when needed on acceptable terms, if at all. Any of the foregoing could harm our business and we cannot anticipate all of the ways in which the political or economic climate and financial market conditions could adversely impact our business.Certain Provisions of Nevada law may have anti-takeover effects.Certain provisions of Nevada law applicable to us could also delay or make more difficult a merger, tender offer or proxy contest involving us, including Sections 78.411 through 78.444 of the Nevada Revised Statutes, which prohibit a Nevada corporation from engaging in any business combination with any "interested shareholder" (as defined in the statute) for a period of two years unless certain conditions are met. In addition, our senior management is entitled to certain payments upon a change in control.Risks Related to Our Intellectual PropertyOur current patent positions and license portfolio may not include all patent rights needed for the full development and commercialization of our product candidates. We cannot be sure that patent rights we may need in the future will be available to license on commercially reasonable terms, or at all.We typically develop our product candidates using compounds that we have acquired or in-licensed, including the original composition of matter patents and patents that claim the activities and methods for such compoundsâ€™ production and use. For example, in 2017 we in-licensed (i) a fully human monoclonal antibody from XOMA Corporation (â€œXOMAâ€) as well as (ii) a plasma kallikrein inhibitor portfolio from ActiveSite Pharmaceuticals (â€œActiveSiteâ€) and in consideration for such licenses, we will owe milestone payments and royalties as we progress product candidates through development.As we learn more about the mechanisms of action and new methods of manufacture and use of these product candidates, we may file additional patent applications for these new inventions, or we may need to ask our licensors to file them. We may also need to license additional patent rights or other rights on compounds, treatment methods or manufacturing processes because we learn that we need such rights during the continuing development of our product candidates.15â€‹ Table of ContentsAlthough our patents may prevent others from making, using or selling similar products, they do not ensure that we will not infringe the patent rights of third parties. We may not be aware of all patents or patent applications that may impact our ability to make, use or sell any of our product candidates or proposed product candidates. For example, because we sometimes identify the mechanism of action or molecular target of a given product candidate after identifying its composition of matter and therapeutic use, we may not be aware until the mechanism or target is further elucidated that a third-party has an issued or pending patent claiming biological activities or targets that may cover our product candidate. U.S. patent applications filed after November 29, 2000 are confidential in the U.S. Patent and Trademark Office for the first 18 months after such applicationsâ€™ earliest priority date, and patent offices in other countries often publish patent applications for the first time six months or more after filing. Furthermore, we may not be aware of published or granted conflicting patent rights. Any conflicts resulting from patent applications and patents of others could significantly reduce the coverage of our patents and limit our ability to obtain meaningful patent protection. If others obtain patents with conflicting claims, we may need to obtain licenses to these patents or to develop or obtain alternative technology.We may not be able to obtain any licenses or other rights to patents, technology or know-how from third parties necessary to conduct our business as described in this Annual Report and such licenses, if available at all, may not be available on commercially reasonable terms. Any failure to obtain such licenses could delay or prevent us from developing or commercializing our drug candidates or proposed product candidates, which would harm our business. Litigation, patent office administrative proceedings or patent interference proceedings may be necessarily brought against us or third parties, as discussed below, to enforce any of our patents or other proprietary rights or to determine the scope and validity or enforceability of the proprietary rights of such third parties.In addition, we may face claims by third parties that our agreements with employees, contractors, or consultants obligating them to assign intellectual property to us are ineffective, or in conflict with prior or competing contractual obligations of assignment, which could result in ownership disputes. In some instances, there may not be adequate written provisions to address clearly the resolution of intellectual property rights that may arise under our agreements, and we may be limited in our ability to use, make or sell these inventions. Litigation may be necessary to resolve these disputes, and if we are not successful, we may be precluded from using certain intellectual property, or may lose our exclusive rights in that intellectual property. Either outcome could have an adverse impact on our business.If our or our licensorsâ€™ patent positions do not adequately protect our product candidates or any future products, others could compete with us more directly, which would harm our business.Our commercial success will depend in part on our and our licensorsâ€™ ability to obtain additional patents and protect our existing patent positions, particularly those patents for which we have secured exclusive rights, as well as our ability to maintain adequate protection of other intellectual property for our technologies, product candidates and any future products in the U.S. and other countries. If we or our licensors do not adequately protect our intellectual property, competitors may be able to use our technologies and erode or negate any competitive advantage we may have, which could materially harm our business, negatively affect our position in the marketplace, limit our ability to commercialize our product candidates and delay or render impossible our achievement of profitability. The laws of some foreign countries do not protect our proprietary rights to the same extent as the laws of the U.S., and we may encounter significant problems in protecting our proprietary rights in these countries.The patent positions of biotechnology and pharmaceutical companies, including our own patent position, involve complex legal and factual questions, and, therefore, validity and enforceability cannot be predicted with certainty. Patents may be challenged, deemed unenforceable, invalidated or circumvented. In addition, the coverage claimed in a patent application can be significantly reduced before the patent is issued, and patent scope can be reinterpreted by the courts after issuance. Moreover, many jurisdictions permit third parties to challenge issued patents in administrative proceedings, which may result in further narrowing or even cancellation of patent claims. We cannot predict whether the patent applications we are currently pursuing will be issued as patents in any particular jurisdiction or whether the claims of any patents, if issued, will provide sufficient protection from competitors. We and our licensors will be able to protect our proprietary rights from unauthorized use by third parties only to the extent that our proprietary technologies, product candidates and any future products are covered by valid and enforceable patents or are effectively maintained as trade secrets.16â€‹ Table of ContentsThe degree of future protection for our proprietary rights is uncertain, and we cannot ensure that:â€”we or our licensors were the first to make the inventions covered by each of our pending patent applications;â€”we or our licensors were the first to file patent applications for these inventions;â€”others will not independently develop similar or alternative technologies or duplicate any of our technologies;â€”any of our or our licensorsâ€™ pending patent applications will result in issued patents;â€”any of our or our licensorsâ€™ patents will be valid or enforceable;â€”any patents issued to us, or our licensors and collaborators will provide a basis for commercially viable products, will provide us with any competitive advantages or will not be challenged by third parties;â€”we will develop additional proprietary technologies or product candidates that are patentable; orâ€”the patents of others will not have an adverse effect on our business.â€‹We may be unable to adequately prevent disclosure of trade secrets and other proprietary information.We rely on trade secrets to protect our proprietary know-how and technological advances, especially where we do not believe patent protection is appropriate or obtainable. However, trade secrets are difficult to protect. We rely in part on confidentiality agreements with our employees, consultants, outside scientific collaborators, sponsored researchers and other advisors to protect our trade secrets and other proprietary information. These agreements may not effectively prevent disclosure of confidential information and may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. In addition, others may independently discover our trade secrets and proprietary information. Costly and time-consuming litigation could be necessary to enforce and determine the scope of our proprietary rights. Failure to obtain or maintain trade secret protection could enable competitors to use our proprietary information to develop products that compete with our products or cause additional, material adverse effects upon our competitive business position.Litigation regarding patents, patent applications and other proprietary rights may be expensive and time consuming. If we are involved in such litigation, it could cause delays in bringing product candidates to market and harm our ability to operate.Our commercial success will depend in part on our ability to manufacture, use, sell and offer to sell our product candidates and proposed product candidates without infringing patents or other proprietary rights of third parties. Although we are not currently aware of any litigation or other proceedings or third-party claims of intellectual property infringement related to our product candidates, the pharmaceutical industry is characterized by extensive litigation regarding patents and other intellectual property rights. Other parties may obtain patents in the future and allege that the use of our technologies infringes these patent claims or that we are employing their proprietary technology without authorization. Likewise, third parties may challenge or infringe upon our or our licensorsâ€™ existing or future patents. Proceedings involving our patents or patent applications or those of others could result in adverse decisions regarding the patentability of our inventions relating to our product candidates or the enforceability, validity or scope of protection offered by our patents relating to our product

candidates.Even if we are successful in these proceedings, we may incur substantial costs and divert managementâ€™s time and attention in pursuing these proceedings. If we are unable to avoid infringing the patent rights of others, we may be required to seek a license, defend an infringement action or challenge the validity of the patents in court. Patent litigation is costly and time-consuming. We may not have sufficient resources to bring these actions to a successful conclusion. In addition, if we do not obtain a license, develop or obtain non-infringing technology, fail to defend an infringement action successfully or have our patents declared invalid, we may incur substantial monetary damages; encounter significant delays in bringing our product candidates to market; or be precluded from participating in the manufacture, use or sale of our product candidates or methods of treatment requiring licenses.17â€‹ Table of ContentsIf our patent and other intellectual property protection is inadequate, future sales and profits may never materialize or competitors could force our products completely out of the market.Patents which prevent the manufacture or sale of our products may be issued to others. We may have to license those patents and pay significant fees or royalties to the owners of the patents in order to keep marketing our products. This would cause profits from any sales to suffer.We have been granted patents or licensed patents in the United States, but patent applications that have been, or may in the future be, filed by us may not result in the issuance of additional patents. The scope of any patent issued may not be sufficient to protect our technology. The laws of foreign jurisdictions in which we intend to sell our products may not protect our rights to the same extent as the laws of the United States.In addition to patent protection, we also rely on trade secrets, proprietary know-how and technological advances. We enter into confidentiality agreements with our employees and others, but these agreements may not be effective in protecting our proprietary information. Others may independently develop substantially equivalent proprietary information or obtain access to our know-how. Litigation, which is expensive, may be necessary to enforce or defend our patents or proprietary rights and may not end favorably for us. We may also choose to initiate litigation against other parties who we come to believe are infringing these patents. If such litigation is unsuccessful or if the patents are invalidated or canceled, we may have to write off the related intangible assets and such an event could significantly reduce our earnings. Any of our licenses, patents or other intellectual property may be challenged, invalidated, canceled, infringed or circumvented and may not provide any competitive advantage to us.Risks Related to Our Common StockExercise or conversion of warrants, stock options and other convertible securities will dilute shareholderâ€™s percentage of ownership.In addition to pre-funded warrants (â€œPFWsâ€), we have issued stock options and other warrants to purchase shares of our common stock. In the future, we may grant additional stock options, warrants and convertible securities. The exercise, conversion or exchange of stock options, warrants and convertible securities will dilute the percentage ownership of our shareholders. The dilutive effect of the exercise or conversion of these securities may adversely affect our ability to obtain additional capital. The holders of these securities may be expected to exercise or convert such stock options, warrants and convertible securities at a time when we would be able to obtain additional equity capital on terms more favorable than such securities or when our common stock is trading at a price higher than the exercise or conversion price of the securities.Our stock price may be volatile.The market price of our common stock is likely to be highly volatile and could fluctuate widely in price in response to various factors, many of which are beyond our control, including (i) limited trading activity on our common stock, (ii) positive or negative results achieved in our clinical activities, including regulatory determinations, (iii) our ability to obtain financing, (iv) additions or departures of key personnel, (v) the specific terms associated with new debt or equity financings, (vi) our ability to execute our business plan, (vii) loss of any strategic relationship, and (viii) economic and other external factors.In addition, the securities markets have from time-to-time experienced significant price and volume fluctuations that are unrelated to the operating performance of particular companies. These market fluctuations may also materially and adversely affect the market price of our common stock.Offers or availability for sale of a substantial number of shares of our common stock may cause the price of our common stock to decline.If our shareholders sell substantial amounts of our common stock in the public market upon the expiration of any statutory holding period or lockup agreements, under Rule 144, or issued upon the exercise of outstanding PFWs, stock options, warrants or other convertible securities, it could create a circumstance commonly referred to as an â€œoverhangâ€ and in 18â€‹ Table of Contentsanticipation of which the market price of our common stock could fall. The existence of an overhang, whether or not sales have occurred or are occurring, also could make more difficult our ability to raise additional financing through the sale of equity or equity-related securities in the future at a time and price that we deem reasonable or appropriate. The shares of our restricted common stock will be freely tradable upon the earlier of: (i) effectiveness of a registration statement covering such shares and (ii) the date on which such shares may be sold without registration pursuant to Rule 144 (or other applicable exemption) under the Securities Act of 1933, as amended (â€œSecurities Actâ€).Investor relations activities and supply and demand factors may affect the price of our common stock.We expect to utilize various techniques such as non-deal road shows and investor relations campaigns in order to generate investor awareness. These campaigns may include personal, video and telephone conferences with investors and prospective investors in which our business practices are described. We may provide compensation to investor relations firms and pay for newsletters, websites, mailings and email campaigns that are produced by third parties based upon publicly-available information concerning us. We do not intend to review or approve the content of such analystsâ€™ reports or other materials based upon analystsâ€™ own research or methods. Investor relations firms should generally disclose when they are compensated for their efforts, but whether such disclosure is made or complete is not under our control. In addition, investors may, from time to time, also take steps to encourage investor awareness through similar activities that may be undertaken at the expense of the investors. Investor awareness activities may also be suspended or discontinued, which may impact the trading market of our common stock.We have no current plan to pay dividends on our common stock and investors may lose the entire amount of their investment.We have never paid cash dividends on our common stock and do not anticipate paying any cash dividends on our common stock for the foreseeable future. Accordingly, any income derived from our common stock would only come from a rise in the market price of our common stock, which is uncertain and unpredictable. We cannot assure investors of a positive return on their investment.â€‹Changes in U.S. tax law could adversely affect our business.Changes to tax laws (which changes may have retroactive application) could adversely affect us or the holders of our common stock. For example, for the fiscal year ended June 30, 2023, we became subject to Internal Revenue Code Section 174 that requires capitalization of the vast majority of research and development costs whereas under prior tax law substantially all of these costs were deductible in the year incurred. Section 174 provides that such newly-capitalized costs may be amortized and become deductible over a period of 5 years for U.S. based costs and 15 years for foreign- based costs.â€‹It cannot be predicted whether, when, in what form, or with what effective dates, new tax laws or regulations may be enacted under existing or new tax laws. This could result in an increase in our tax liability or require changes in our business in order to mitigate any adverse effects of changes in tax laws. â€‹Item 1B. Unresolved Staff Comments.Not required for smaller reporting companies.Item 1C. Cybersecurity.We have established processes for assessing, identifying and managing cybersecurity risks, which are built into our information technology function and are designed to safeguard our information assets and operations from internal and external cyber threats, including protecting employee and patient information from unauthorized access to or attacks on our networks and systems. These processes include physical, procedural and technical safeguards, response plans, regular tests on our systems, incident simulations and routine reviews of our policies and procedures to identify risks and enhance our practices. We also employ processes to identify material risks from cybersecurity threats associated with our use of third-party service providers.19â€‹ Table of Contentsâ€‹We have engaged external parties, including risk management consultants and computer security firms, to enhance our cybersecurity oversight. In an effort to deter and detect cyber threats, we periodically provide training programs to our employees on issues related to privacy and data protection, cybersecurity risks, and the importance of reporting all incidents immediately. Topics include identifying phishing, password protection, securing confidential data, and mobile security. In addition, we use technology-based tools to mitigate cybersecurity risks and to bolster our employee-based cybersecurity programs. We also perform annual vulnerability assessments, conducted by independent, third-party cybersecurity firms.â€‹Additionally, as part of our overall risk mitigation strategy, the Company obtains certain insurance policies. However, such insurance may not be sufficient in type or amount to cover us fully against claims related to security breaches, cyber-attacks and other related breaches.â€‹The Audit Committee of our Board of Directors provides direct cybersecurity risk oversight. Our management provides timely disclosure and related updates to the Audit Committee regarding potential cybersecurity threats, incidents and general risks.â€‹Our management periodically evaluates information provided by its consultants on evolving cybersecurity risks and, based on its assessment of the processes the Company has put in place, does not believe there are currently any known risks from cybersecurity threats that are reasonably likely to materially affect us or our business strategy, results of operations, or financial condition. Further, we have not had any cybersecurity incidents in 2024.Item 2. Properties.In April 2022, we entered into a lease for a new headquarters location at 275 Shoreline Drive, Suite 500, Redwood City California 94065. The leased space contains approximately 9,300 square feet of office space. The lease commenced in October 2022 and provides for average remaining monthly rent of approximately $53,000 through October 2027.In November 2020, we entered into a lease in Bend, Oregon where the leased space consists of approximately 5,000 square feet of office space and provides for monthly rent of approximately $8,400 through the expiration date in February 2024. In October 2023, we entered into a lease extension for this space, which provides for monthly rent of approximately $9,000 through February 2027. We believe our current physical properties are sufficient and adequate to meet our current and projected requirements.â€‹Item 3. Legal Proceedings.For a discussion of the Companyâ€™s legal proceedings, see â€œNotes to Consolidated Financial Statementsâ€‰-â€‰Commitments and Contingenciesâ€ in Part II. Item 8 on this Annual Report on Form 10-K, which is incorporated herein by reference.Item 4. Mine Safety Disclosures.Not applicable.PART IIItem 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.Market InformationSince November 9, 2020, our common stock has traded on Nasdaq under the symbol â€œRZLTâ€.20â€‹ Table of ContentsHoldersAs of September 13, 2024, there were 261 holders of record of our common stock. We believe the number of beneficial owners of our common stock is substantially greater than the number of record holders because a large portion of our outstanding common stock is held of record in broker â€œstreet namesâ€ for the benefit of individual investors.DividendsWe have never paid cash dividends and intend to employ all available funds in the development of our business. We have no plans to pay cash dividends in the foreseeable future. Recent Sales of Unregistered SecuritiesNone.Securities Authorized for Issuance Under Equity Compensation PlansPresented below is information about our equity compensation plans as of June 30, 2024 (shares in thousands):

| â€‹â€‹â€‹

the foreseeable future; therefore, we expect to continue efforts to raise additional capital to maintain our current operating plans over the next several years. We cannot assure you that we will secure such financing or that it will be adequate for the long-term execution of our business strategy. Even if we obtain additional financing, it may be costly and may require us to agree to covenants or other provisions that will favor new investors over our existing shareholders.Key Components of Consolidated Statements of OperationsResearch and development expenses.Â Research and development (â€œR&Dâ€) expenses consist primarily of clinical trial costs, compensation and benefits for our personnel engaged in R&D activities, licensing costs, and consultants and outside services. Our R&D costs include an allocable portion of our cash and share-based compensation, employee benefits, and consulting costs related to personnel engaged in the design and development of product candidates and other scientific research projects. We also allocate a portion of our facilities and overhead costs based on the personnel and other resources devoted to R&D activities.General and administrative expenses.Â General and administrative (â€œG&Aâ€) expenses consist primarily of (i) an allocable portion of our cash and share-based compensation and employee benefits related to personnel engaged in our administrative, finance, accounting, and executive functions, and (ii) an allocable portion of our facilities and overhead costs based on the personnel and other resources devoted to G&A activities. G&A expenses also include travel, legal, auditing, investor relations and other costs primarily related to our operations as a public company.Interest and other income.Â Interest and other income consist primarily of interest income earned on marketable debt securities and temporary cash investments, amortization of investment premiums and accretion of investment discounts.Loss from change in fair value of derivative liabilities.Â We recognize liabilities for financial instruments that are required to be accounted for as derivatives, as well as embedded derivatives in our debt agreements. Warrant and embedded derivative liabilities are adjusted to fair value at the end of each reporting period until the contracts are settled, expire, or otherwise meet the conditions for equity classification. We also recognize liabilities for embedded derivatives that arose in connection with our legacy debt agreement. Changes in fair value are reflected as gains and losses in our consolidated statements of operations. 23â€‹ Table of ContentsCritical Accounting Policies and Significant Judgments and EstimatesOverviewOur managementâ€™s discussion and analysis of financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of the consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, as well as the reported revenue and expenses during the reporting periods. These items are monitored and analyzed for changes in facts and circumstances, and material changes in these estimates could occur in the future. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Changes in estimates are reflected in reported results for the period in which they become known. Actual results may differ from these estimates under different assumptions or conditions.With respect to our significant accounting policies that are described in Note 1 to our consolidated financial statements included in Item 8 of this Annual Report, we believe that the following accounting policies involve a greater degree of judgment and complexity. Accordingly, these are the policies we believe are the most critical to aid in fully understanding and evaluating our consolidated financial condition and results of operations.Investments in Marketable Debt SecuritiesWe account for investments in marketable debt securities as available-for-sale securities whereby they are recorded in our consolidated balance sheets at fair value. Interest income consists of accrued interest earned based on the coupon rate of the security, plus the impact of accreting discounts and amortizing premiums to maturity using the straight-line method which approximates the interest method. Unrealized gains and losses due to subsequent changes in fair value of the investments are reported in shareholdersâ€™ equity as a component of accumulated other comprehensive income (loss). The individual debt securities in our portfolio are subject to credit risk in the event of default by the issuers. We review the components of our portfolio of available-for-sale debt securities, using both quantitative and qualitative factors, to determine if declines in fair value below amortized cost have resulted from a credit-related loss or other factors. To the extent that declines in fair value are due to a deterioration of credit quality of the issuer, we will recognize an allowance for credit losses related to such investments with a corresponding loss in the consolidated statements of operations. Allowances for credit losses may be reversed in subsequent periods if conditions improve and credit-related losses are no longer expected. For a decline in fair value that is solely due to changes in interest rates, impairment is not recognized if we have the ability and intent to hold the investment until maturity. The cost basis of any securities sold prior to maturity will be determined using the specific identification method.Research and DevelopmentResearch and development costs are expensed as incurred. Intangible assets related to in-licensing costs under license agreements with third parties are charged to expense unless we are able to determine that the licensing rights have an alternative future use in other research and development projects or otherwise.Clinical Trial AccrualsClinical trial costs are a component of research and development expenses. We accrue and charge to expenses clinical trial activities performed by third parties based upon estimates of the percentage of work completed over the life of the individual study in accordance with agreements established with clinical research organizations and clinical trial sites. We determine our estimates through discussions with internal clinical personnel and external service providers as to the progress or stage of completion of trials or services and the agreed-upon fee to be paid for such services.24â€‹ Table of ContentsShare-Based Compensation ExpenseWe measure the fair value of services received in exchange for grants of stock options based on the fair value of the award as of the grant date. We compute the fair value of stock options with time-based vesting using the Black-Scholes Merton (â€œBSMâ€) option-pricing model and recognize the cost of the equity awards over the period that services are provided to earn the award. For awards that contain a graded vesting schedule, and the only condition for vesting is a service condition, compensation cost is recognized on a straight-line basis over the requisite service period as if the award was, in substance, a single award. We recognize the impact of forfeitures in the period that the forfeiture occurs, rather than estimating the number of awards that are not expected to vest in accounting for share-based compensation. For stock options that are voluntarily surrendered by employees, all unrecognized compensation is immediately recognized in the period the options are cancelled.Loss from Change in Fair Value of Derivative LiabilitiesWe recognize warrant derivative liabilities based on assessment of the warrantâ€™s specific terms and applicable authoritative guidance set forth by FASB in Accounting Standards Codification (â€œASCâ€) 480, Distinguishing Liabilities from Equity (â€œASC 480â€) and ASC 815, Derivatives and Hedging (â€œASC 815â€). The assessment considers whether the warrants are freestanding financial instruments and meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Companyâ€™s own common shares and whether the warrant holders could potentially require â€œnet cash settlementâ€ in a circumstance outside of the Companyâ€™s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of the end of each subsequent quarterly period while the warrants are outstanding. Liability classified warrants are valued using the BSM option-pricing model at issuance and for each reporting period when applicable. Changes in fair value are reflected as gains and losses in our consolidated statements of operations. We also recognize liabilities for embedded derivatives that arose in connection with a legacy debt agreement.Results of OperationsResults of operations for the fiscal years ended June 30, 2024 and 2023 reflect net losses of approximately $68.5 million and $51.8 million, respectively. Our consolidated statements of operations for the fiscal years ended June 30, 2024 and 2023, along with the changes between fiscal years, are presented below (in thousands, except percentages):â€‹â€‹â€‹

$185.0 million in potential payments to XOMA and $17.5 million to ActiveSite for various sales-based milestones and alternative indication regulatory approvals. No assurance can be provided that commercialization will ever be achieved for either ersodetug or RZ402, whereby none of these future payments may ever be required.In addition to our licensing obligations, we also have long-term contractual obligations under existing operating lease agreements ranging between approximately $0.2 million to $0.8 million for each of the fiscal years ending June 30, 2026 through 2028. Based on our current forecast, we expect that our existing capital resources will be sufficient to fund our contractual obligations and conduct all planned activities to advance our clinical trials at least through the second quarter of calendar year 2026. Therefore, we will need to obtain additional equity or debt financing in order to fund all of our long-term liquidity requirements.Presented below is additional discussion about the ongoing requirements pursuant to our license agreements with XOMA and ActiveSite, along with additional information about our ongoing financing activities that impacted our liquidity and capital resources for the fiscal year ended June 30, 2024.XOMA License AgreementIn December 2017, we entered into a license agreement (â€œXOMA License Agreementâ€) with XOMA through its wholly-owned subsidiary, XOMA (U.S.) LLC, pursuant to which XOMA granted an exclusive global license to develop and commercialize XOMA 358 (formerly X358 or RZ358, now ersodetug) for all indications. In January 2019, the XOMA License Agreement was amended with an updated payment schedule, as well as revisions to the amount we were required to expend on development of ersodetug and related licensed products, and revised provisions with respect to our diligence efforts in conducting clinical studies.Upon the achievement of certain clinical and regulatory events, we will be required to make up to $37.0 million in aggregate milestone payments to XOMA. Milestone payments made to date include a $2.0 million payment in January 2022 for the enrollment of the last patient of the Phase 2 clinical study and $5.0 million paid in May 2024 related to the first patient enrollment in a Phase 3 study. We record a liability for milestone payments in our financial statements on the date that we achieve the milestone event. The next milestone payment of $5.0 million will be due upon the enrollment of the last patient in a Phase 3 study, which we believe will occur in the next twelve months. Additionally, upon the future commercialization of ersodetug, we will be required to pay royalties to XOMA based on the net sales of the related 28â€‹ Table of Contentsproducts, and milestone payments up to an additional $185.0 million if future annual sales related to ersodetug exceed targets ranging from $100.0 million to $1.0 billion. Through June 30, 2024, no events have occurred that would result in the requirement to make additional milestone payments, and no royalties have been incurred.ActiveSite License AgreementIn August 2017, we entered into a Development and License Agreement with ActiveSite (â€œActiveSite License Agreementâ€) pursuant to which we acquired the rights to ActiveSiteâ€™s PKI portfolio.Â We are planning to use the PKI Program to develop, file, manufacture, market and sell products for diabetic macular edema and other therapeutic indications.Â The ActiveSite License Agreement requires various milestone payments ranging from $1.0 million to $10.0 million when milestone events occur, up to an aggregate of $46.5 million of aggregate milestone payments. The first milestone payment for $1.0 million was paid in December 2020 after completion of preclinical work and submission of an IND to the FDA for RZ402. The second milestone payment for $3.0 million became due upon dosing of the first patient in a Phase 2 study in February 2023. Remaining milestone payments under the ActiveSite License Agreement for various clinical and regulatory milestones amount to $25.0 million and milestones after commercial success or alternative indication approvals amount to $17.5 million. We will also be required to pay royalties equal to 2.0% of any sales of products that use the PKI Program. Through June 30, 2024, no events have occurred that would result in the requirement to make additional milestone payments and no royalties have been incurred.Cash Flows SummaryPresented below is a summary of our operating, investing and financing cash flows for the fiscal years ended June 30, 2024 and 2023 (in thousands):â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â 2024Â Â Â Â 2023Â Â Â Â ChangeNet cash provided by (used in):â€‹Â Â â€‹â€‹Â Â â€‹â€‹Â Â â€‹Operating activitiesâ€‹$ (57,368)â€‹$ (44,481)â€‹$ (12,887)Investing activitiesâ€‹Â 48,699â€‹Â (101,464)â€‹Â 150,163Financing activitiesâ€‹Â 63,029â€‹Â 11,571â€‹Â 51,458â€‹Cash Flows Used in Operating ActivitiesFor the fiscal years ended June 30, 2024 and 2023, cash flows used in operating activities amounted to $57.4 million and $44.5 million, respectively. The key components in the calculation of our cash used in operating activities are as follows (in thousands):â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â 2024Â Â Â Â 2023Â Â Â Â Changeâ€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Net lossâ€‹$ (68,459)â€‹$ (51,787)â€‹$ (16,672)Non-cash expensesÂ â€‹ 10,828Â â€‹ 7,655Â â€‹ 3,173Accretion of discounts and amortization of premiums on marketable debt securities, netÂ â€‹ (2,837)Â â€‹ (1,370)Â â€‹ (1,467)Changes in operating assets and liabilities, netÂ â€‹ 3,100Â â€‹ 1,021Â â€‹ 2,079Totalâ€‹$ (57,368)â€‹$ (44,481)â€‹$ (12,887)â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹For the fiscal year ended June 30, 2024, our net loss was $68.5 million compared to $51.8 million for the fiscal year ended June 30, 2023. For further discussion about changes in our operating results for the fiscal years ended June 30, 2024 and 2023, please refer to Results of Operations above.For the fiscal year ended June 30, 2024, our non-cash expenses of $10.8 million primarily consisted of share-based compensation expense of $7.4 million, a loss from change in the fair value of the warrant derivative liability of $2.9 million, and non-cash lease expense of $0.5 million. For the fiscal year ended June 30, 2023, our non-cash expenses of $7.7 million primarily consisted of share-based compensation expense of $7.3 million and non-cash lease expense of $0.4 million.29â€‹ Table of ContentsFor the fiscal year ended June 30, 2024, non-cash gains consisted of the net impact of accreting discounts and amortizing premiums on investments in marketable debt securities of $2.8 million. For the fiscal year ended June 30, 2023, non-cash gains consisted of the net impact of accreting discounts and amortizing premiums on investments in marketable debt securities of $1.4 million. For the fiscal year ended June 30, 2024, net changes in operating assets and liabilities increased operating cash flow by $3.1 million, primarily driven by an increase accounts payable and other accrued liabilities of $3.2 million, partially offset by an increase in prepaid expenses and other assets of $0.1 million associated with prepayments for clinical trials and manufacturing activities. For the fiscal year ended June 30, 2023, net changes in operating assets and liabilities increased operating cash flow by $1.0 million, primarily driven by an increase accounts payable and other accrued liabilities of $2.3 million, partially offset by an increase in prepaid expenses and other assets of $1.3 million associated with prepayments for clinical trials and manufacturing activities.Cash Flows Provided by (Used in) Investing ActivitiesFor the fiscal year ended June 30, 2024, net cash provided by investing activities amounted to $48.7 million, primarily related to the proceeds from maturities of marketable debt securities of $115.1 million, partially offset by cash outflows used in to purchase marketable debt securities of $66.4 million. For the fiscal year ended June 30, 2023, our net cash utilized in investing activities amounted to $101.5 million, primarily related to the purchase of $107.3 million of marketable debt securities, partially offset by cash proceeds of $6.0 million of resulting from maturities of marketable debt securities. Additionally, for the fiscal year ended June 30, 2023, our investing activities used $0.2 million for the purchase of furniture and equipment primarily for use in our new office location in Redwood City, California.Cash Flows Provided by Financing ActivitiesNet cash provided by financing activities for the fiscal year ended June 30, 2024 amounted to $63.0 million. This amount consisted of proceeds of $67.1 million from the 2024 Underwritten Offering. The total proceeds from the 2024 Public Underwritten Offering of $67.1 million were partially offset by underwriter discounts of $4.0 million related to this offering and other offering costs of $0.3 million. For the fiscal year ended June 30, 2024, we also received proceeds of $0.2 million from the exercise of employee stock options to purchase approximately 82,000 shares of common stock.Net cash provided by financing activities for the fiscal year ended June 30, 2023 amounted to $11.6 million. This amount consisted of gross proceeds of $12.3 million received from the 2022 Private Placement. The total proceeds from the 2022 Private Placement of $12.3 million were received in July 2022 and were partially offset by payments of $0.8 million for underwriting commissions and other costs related to this offering.Off-Balance Sheet ArrangementsDuring the fiscal years ended June 30, 2024 and 2023, we did not have any relationships with unconsolidated organizations or financial partnerships, such as structured finance or special purpose entities, which were established for the purpose of facilitating off-balance sheet arrangements.Recently Issued Accounting PronouncementsSee Note 1 to our consolidated financial statements included in Item 8 of this Annual Report regarding the impact of certain accounting pronouncements on our consolidated financial statements.Item 7A. Quantitative and Qualitative Disclosures About Market Risk.We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information under this item.â€‹â€‹30â€‹ Table of Contentsâ€‹Item 8. Financial Statements and Supplementary Data.â€‹TABLE OF CONTENTSâ€‹â€‹Â Â Â Â PageReports of Independent Registered Public Accounting Firms (Grant Thornton, LLP; Newport Beach, California; PCAOB ID: 248) (Plane & Moran, PLLC; Cleveland, Ohio; PCAOB ID: 166)â€‹32â€‹â€‹â€‹Financial Statements:â€‹â€‹â€‹â€‹Consolidated balance sheets as of June 30, 2024 and 2023â€‹34â€‹â€‹â€‹Consolidated statements of operations and comprehensive loss for the fiscal years ended June 30, 2024 and 2023â€‹35â€‹â€‹â€‹Consolidated statements of shareholdersâ€™ equity for the fiscal years ended June 30, 2024 and 2023â€‹36â€‹â€‹â€‹Consolidated statements of cash flows for the fiscal years ended June 30, 2024 and 2023â€‹37â€‹â€‹â€‹Notes to consolidated financial statementsâ€‹39â€‹â€‹â€‹31â€‹ Table of ContentsReport of Independent Registered Public Accounting FirmTo the Board of Directors and Shareholders Rezolute, Inc. and subsidiariesâ€‹Opinion on the financial statementsWe have audited the accompanying consolidated balance sheet of Rezolute, Inc. and subsidiaries (the â€œCompanyâ€) as of June 30, 2024, the related consolidated statements of operations and comprehensive loss, shareholdersâ€™ equity, and cash flows for the year ended June 30, 2024, and the related notes (collectively referred to as the â€œfinancial statementsâ€). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of June 30, 2024, and the results of its operations and its cash flows for the year ended June 30, 2024, in conformity with accounting principles generally accepted in the United States of America.Basis for opinionThese financial statements are the responsibility of the Companyâ€™s management. Our responsibility is to express an opinion on the Companyâ€™s financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (â€œPCAOBâ€) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Companyâ€™s internal control over financial reporting. Accordingly, we express no such opinion.Our audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion.Critical audit mattersCritical audit matters are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. We determined that there are no critical audit matters./s/ GRANT THORNTON LLP We have served as the Companyâ€™s auditor since 2024. Newport Beach, CaliforniaSeptember 19, 2024â€‹â€‹â€‹â€‹32â€‹ Table of ContentsReport of Independent Registered Public Accounting FirmTo the Shareholders and Board of Directors of Rezolute, Inc.Opinion on the Financial StatementsWe have audited the accompanying balance sheet of Rezolute, Inc. (the â€œCompanyâ€) as of June 30, 2023, the related statement of operations, shareholders' equity, and cash flows for year then ended, and the related notes (collectively referred to as the â€œfinancial statementsâ€). In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of the Company as of June 30, 2023, and the results of its operations and its cash flows for the year then ended, in conformity with accounting principles generally accepted in the United States of America.Basis for OpinionThe Company's management is responsible for these financial statements. Our responsibility is to express an opinion on the Companyâ€™s financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (â€œPCAOBâ€) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.Our audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion. â€‹/s/ Plante & Moran, PLLCâ€‹We served as the Companyâ€™s auditor from 2013 to 2024.â€‹Cleveland, OhioSeptember 14, 202333â€‹ Table of ContentsREZOLUTE, INC.Consolidated Balance SheetsJune 30, 2024 and 2023(In Thousands, Except Per Share Amounts)â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â 2024Â Â Â Â 2023Assetsâ€‹â€‹â€‹â€‹â€‹â€‹Current assets:Â â€‹Â Â â€‹â€‹Â Â Cash and cash equivalentsâ€‹$ 70,396â€‹$ 16,036Investments in marketable debt securitiesâ€‹â€‹ 56,478â€‹â€‹ 85,860Prepaid expenses and otherâ€‹â€‹ 1,779â€‹â€‹ 3,014Total current assetsâ€‹Â 128,653â€‹Â 104,910â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Long-term assets:â€‹â€‹â€‹â€‹â€‹â€‹Right-of-use assetsâ€‹Â 1,880â€‹Â 2,054Deposits and otherâ€‹â€‹ 1,838â€‹â€‹ 148Investments in marketable debt securitiesâ€‹â€‹ 263â€‹â€‹ 16,470Property and equipment, netâ€‹Â 103â€‹Â 139Total assetsâ€‹$ 132,737â€‹$ 123,721â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Liabilities and Shareholders' Equity â€‹Â Â â€‹Â Â Current liabilities:â€‹Â Â â€‹Â Â Accounts payable â€‹$ 4,901â€‹$ 3,269Accrued liabilities:â€‹Â â€‹â€‹Â â€‹Accrued clinical and other â€‹â€‹ 2,325â€‹â€‹ 507Compensation and benefitsâ€‹â€‹ 1,812â€‹â€‹ 883Current portion of operating lease liabilitiesâ€‹â€‹ 568â€‹â€‹ 541Total current liabilitiesâ€‹Â 9,606â€‹Â 5,200â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Long-term liabilities:â€‹â€‹â€‹â€‹â€‹â€‹Operating lease liabilities, net of current portionâ€‹Â 1,660â€‹Â 1,937Embedded derivative liabilityâ€‹â€‹ 468â€‹â€‹ 412Total liabilitiesâ€‹Â 11,734â€‹Â 7,549â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Commitments and contingencies (Notes 5, 10 and 11)â€‹Â Â Â Â â€‹Â Â Â Â â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Shareholders' equity:â€‹Â Â Â Â â€‹Â Â Â Â Preferred stock, $0.001 par value; 400 shares authorized; no shares issuedâ€‹Â â€”â€‹Â â€”Common stock, $0.001 par value; 100,000 shares authorized; issued and outstanding 53,246 and 36,827 shares as of June 30, 2024 and 2023, respectivelyâ€‹Â 53â€‹Â 37Additional paid-in capitalâ€‹Â 450,473â€‹Â 377,471Accumulated other comprehensive lossâ€‹â€‹ (79)â€‹â€‹ (351)Accumulated deficitâ€‹Â (329,444)â€‹Â (260,985)Total shareholdersâ€™ equity â€‹Â 121,003â€‹Â 116,172Total liabilities and shareholdersâ€™ equity â€‹$ 132,737â€‹$ 123,721â€‹The accompanying notes are an integral part of these consolidated financial statements.â€‹34â€‹ Table of ContentsREZOLUTE, INC.Consolidated Statements of Operations and Comprehensive LossFor the Fiscal Years Ended June 30, 2024 and 2023(In Thousands, Except Per Share Amounts)â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â â€‹2024Â Â Â Â 2023Operating expenses:Â â€‹â€‹Â Â Â Â â€‹Â Â Research and developmentÂ â€‹$ 55,743â€‹$ 43,813 General and administrativeÂ â€‹â€‹ 14,680â€‹Â 12,177Total operating expensesÂ â€‹â€‹ 70,423â€‹Â 55,990Operating lossÂ â€‹â€‹ (70,423)â€‹Â (55,990)Non-operating income (expense):Â â€‹â€‹Â Â â€‹Â Â Â Â Interest and other income, netâ€‹â€‹â€‹ 4,870â€‹â€‹ 4,208Loss from change in fair value of warrant derivative liabilityâ€‹â€‹â€‹ (2,850)â€‹â€‹ â€”Loss from change in fair value of embedded derivative liabilityâ€‹â€‹â€‹ (56)â€‹â€‹ (5)Total non-operating income, netÂ â€‹â€‹ 1,964â€‹Â 4,203â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Net lossâ€‹â€‹â€‹ (68,459)â€‹â€‹ (51,787)â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Other comprehensive income (loss):â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Net unrealized gain (loss) on marketable debt securitiesâ€‹â€‹â€‹ 272â€‹â€‹ (351)â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Comprehensive lossâ€‹â€‹â€‹ (68,187)â€‹$ (52,138)â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Net loss per common share:â€‹â€‹â€‹â€‹â€‹â€‹â€‹Basic and dilutedâ€‹â€‹â€‹ (1.33)â€‹$ (1.01)â€‹â€‹â€‹â€‹â€‹â€‹â€‹Weighted average number of common shares outstanding:â€‹â€‹Â â€‹â€‹â€‹â€‹Basic and dilutedâ€‹â€‹â€‹ 51,465â€‹Â 51,187â€‹The accompanying notes are an integral part of these consolidated financial statements.â€‹â€‹35â€‹ Table of ContentsREZOLUTE, INC.Consolidated Statements of Shareholdersâ€™ EquityFor the Fiscal Years Ended June 30, 2024 and 2023(In Thousands)â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹

116,172â€‹Proceeds from issuance of equity securities in 2024 Underwritten Offering, net of underwriting discountsâ€‹Common stockÂ 13,037â€‹â€‹ 13â€‹â€‹ 49,004â€‹â€‹ â€”â€‹â€‹ â€”â€‹â€‹ 49,0172024 Pre-Funded Warrantsâ€‹ â€”â€‹â€‹ â€”â€‹â€‹ â€”â€‹â€‹ 14,096â€‹â€‹ â€”â€‹â€‹ â€”â€‹â€‹ â€”â€‹â€‹ 14,096Other equity offering costsâ€‹ â€”â€‹â€‹ â€”â€‹â€‹ (548)â€‹â€‹ â€”â€‹â€‹ â€”â€‹â€‹ (548)Issuance of common stock upon exercise of stock optionsâ€‹ 82â€‹â€‹ â€”â€‹â€‹ 246â€‹â€‹ â€”â€‹â€‹ â€”â€‹â€‹ 246Share-based compensationâ€‹ â€”â€‹â€‹ â€”â€‹â€‹ 7,360â€‹â€‹ â€”â€‹â€‹ â€”â€‹â€‹ 7,360Cashless exercise of pre-funded warrantsâ€‹ 6,300â€‹â€‹ 6â€‹â€‹ (6)â€‹â€‹ â€”â€‹â€‹ â€”â€‹â€‹ â€”Acquisition and retirement of treasury shares pursuant to Exchange Agreementâ€‹ (3,000)â€‹â€‹ (3)â€‹â€‹ (5,697)â€‹â€‹ â€”â€‹â€‹ â€”â€‹â€‹ (5,700)Reclassification of warrant derivative liability to equityâ€‹ â€”â€‹â€‹ â€”â€‹â€‹ 8,547â€‹â€‹ â€”â€‹â€‹ â€”â€‹â€‹ 8,547Net change in accumulated other comprehensive lossâ€‹ â€”â€‹â€‹ â€”â€‹â€‹ â€”â€‹â€‹ 272â€‹â€‹ â€”â€‹â€‹ 272Net loss â€‹ â€”â€‹â€‹ â€”â€‹â€‹ â€”â€‹â€‹ (68,459)â€‹â€‹ (68,459)Balances, JuneÂ 30,Â 2024â€‹ 53,246â€‹$ 53â€‹$ 450,473â€‹$ (79)â€‹$ (329,444)â€‹$ 121,003â€‹The accompanying notes are an integral part of these consolidated financial statements.â€‹36â€‹ Table of ContentsREZOLUTE, INC.Consolidated Statements of Cash FlowsFor the Fiscal Years Ended June 30, 2024 and 2023(In Thousands)â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â 2024Â Â Â Â 2023CASH FLOWS FROM OPERATING ACTIVITIES:Â â€‹Â Â Â â€‹Â Â Net lossâ€‹$ (68,459)â€‹$ (51,787)Share-based compensation expenseâ€‹â€‹ 7,360â€‹â€‹ 7,268Loss from change in fair value of warrant derivative liabilityâ€‹â€‹ 2,850â€‹â€‹ â€”Loss from change in fair value of embedded derivative liabilityâ€‹â€‹ 56â€‹â€‹ 5Non-cash lease expenseâ€‹â€‹ 526â€‹â€‹ 352Accretion of discounts and amortization of premiums on marketable debt securities, netâ€‹â€‹ (2,837)â€‹â€‹ (1,370)Depreciation expenseâ€‹â€‹ 36â€‹â€‹ 30Changes in operating assets and liabilities:â€‹Â Â Â â€‹Â Â Â Increase in prepaid expenses, deposits, and other assetsâ€‹Â (129)â€‹Â (1,320)Increase in accounts payable â€‹Â 1,083â€‹Â 2,136Increase in accrued liabilitiesâ€‹â€‹ 2,146â€‹â€‹ 205Net Cash Used in Operating Activitiesâ€‹Â (57,368)â€‹Â (44,481)â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹CASH FLOWS FROM INVESTING ACTIVITIESâ€‹Â â€‹â€‹â€‹â€‹Purchase of marketable debt securitiesâ€‹â€‹ (66,401)â€‹â€‹ (107,311)Proceeds from maturities of marketable debt securitiesâ€‹â€‹ 115,100â€‹â€‹ 6,000Purchase of property and equipmentâ€‹â€‹ â€”â€‹Â (153)Total Cash Provided by (Used in) Investing Activitiesâ€‹Â 48,699â€‹Â (101,464)â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹CASH FLOWS FROM FINANCING ACTIVITIES:â€‹Â Â Â â€‹â€‹Â Â Proceeds from exercise of stock optionsâ€‹â€‹ 234â€‹â€‹ â€”Net cash payment pursuant to Exchange Agreementâ€‹â€‹ (3)â€‹â€‹ â€”Proceeds from issuance of equity securities in 2024 Underwritten Offering, net of underwriting discountsâ€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Issuance of common stockâ€‹â€‹ 49,017â€‹â€‹ â€”Issuance of pre-funded warrantsâ€‹â€‹ 14,096â€‹â€‹ â€”Gross proceeds from issuance of common stock in 2022 Private Placementâ€‹â€‹ â€”â€‹â€‹ 12,330Payment of commissions and other deferred offering costsâ€‹Â (315)â€‹â€‹ (759)Net Cash Provided by Financing Activitiesâ€‹Â 63,029â€‹Â 11,571â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Net increase (decrease) in cash and cash equivalentsâ€‹â€‹ 54,360â€‹â€‹ (134,374)Cash and cash equivalents at beginning of fiscal yearâ€‹Â 16,036â€‹Â 150,410Cash and cash equivalents at end of fiscal yearâ€‹$ 70,396â€‹$ 16,036â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹The accompanying notes are an integral part of these consolidated financial statements.â€‹37â€‹ Table of Contentsâ€‹â€‹REZOLUTE, INC.Consolidated Statements of Cash Flows, ContinuedFor the Fiscal Years Ended June 30, 2024 and 2023(In Thousands)â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹2024Â Â Â Â 2023SUPPLEMENTARY CASH FLOW INFORMATION:â€‹Â Â Â â€‹Â Â Â Cash paid for interestâ€‹$ â€”â€‹$ â€”Cash paid for income taxes â€‹â€‹ â€”â€‹â€‹ â€”Cash paid for amounts included in the measurement of operating lease liabilitiesâ€‹â€‹ 728â€‹â€‹ 215Operating lease liabilities incurred in exchange for right-of-use assetsâ€‹â€‹ 352â€‹â€‹ 2,204â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹NON-CASH INVESTING AND FINANCING ACTIVITIES:â€‹Â Â Â â€‹Â Â Â Acquisition of treasury shares in exchange for pre-funded warrant derivative liabilityâ€‹$ 5,697â€‹$ â€”Receivable from exercise of stock optionsâ€‹â€‹ 12â€‹â€‹ â€”Payables for offering costs charged to additional paid-in capitalâ€‹â€‹ 548â€‹â€‹ â€”â€‹â€‹The accompanying notes are an integral part of these consolidated financial statements.â€‹â€‹38â€‹ Table of ContentsNOTE 1 â€” NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIESNature of OperationsRezolute, Inc. (the â€œCompanyâ€) is a late-stage rare disease company focused on significantly improving outcomes for individuals with hypoglycemia caused by hyperinsulinism. The Companyâ€™s primary clinical assets consist of (i) ersodetug (formerly known as RZ358), which is a potential treatment for all forms of hyperinsulinism, including congenital hyperinsulinism, an ultra-rare pediatric genetic disorder characterized by excessive production of insulin by the pancreas, and (ii) RZ402, which is an oral plasma kallikrein inhibitor (â€œPKIâ€) being developed as a potential therapy for the chronic treatment of diabetic macular edema.ConsolidationThe Company has two wholly owned subsidiaries consisting of Rezolute (Bio) Ireland Limited, and Rezolute Bio UK, Ltd. The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.Basis of PresentationThe Companyâ€™s consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (â€œGAAPâ€).Comprehensive income (loss) is defined as net income (loss) plus other comprehensive income (loss). Other comprehensive income (loss) is comprised of revenues, expenses, gains, and losses that under GAAP are reported as separate components of shareholdersâ€™ equity instead of net income (loss). For the fiscal years ended June 30, 2024 and 2023, components of comprehensive loss included the Companyâ€™s net loss and unrealized gains (losses) on investments in marketable debt securities.The Companyâ€™s Chief Executive Officer also serves as the Companyâ€™s chief operating decision maker for purposes of allocating resources and assessing performance based on financial information of the Company. Since its inception, the Company has determined that its activities as a clinical stage biopharmaceutical company are classified as a single reportable operating segment.Use of EstimatesThe preparation of financial statements in conformity with GAAP requires management to make judgments, estimates and assumptions that affect the reported amounts in the consolidated financial statements and the accompanying notes. The Company bases its estimates and assumptions on current facts, historical experience, and various other factors that it believes are reasonable under the circumstances, to determine the carrying values of assets and liabilities that are not readily apparent from other sources. The Companyâ€™s significant accounting estimates include, but are not necessarily limited to, determination if an allowance for credit losses is required or if other than temporary impairment exists for marketable debt securities, fair value of an derivative liabilities, fair value of share-based payments, managementâ€™s assessment of going concern, and estimates related to clinical trial accrued liabilities. Actual results could differ from those estimates.Risks and UncertaintiesThe Company's operations may be subject to significant risks and uncertainties including financial, operational, regulatory and other risks associated with a clinical stage company, including the potential risk of business failure discussed in Note 2.39â€‹ Table of ContentsCash and Cash EquivalentsAll highly liquid investments purchased with an original maturity of three months or less that are freely available for the Companyâ€™s immediate and general business use are classified as cash and cash equivalents. Cash and cash equivalents consist primarily of demand deposits with financial institutions, money market funds and corporate commercial paper purchased with a maturity of three months or less.Investments in Marketable Debt SecuritiesUnder the investment policy approved by the Companyâ€™s Board of Directors, eligible investments in fixed income debt securities must be denominated and payable in U.S. dollars, including eligible corporate bonds, corporate commercial paper, U.S. government obligations, and money market funds. This investment policy only permits investments in the debt securities of issuers that meet stringent credit quality ratings on the date of the investment. The investment policy also places restrictions on the length of maturities and concentrations by type and issuer. The Companyâ€™s investments are issued by issuers that management believes are of high credit quality. However, all issuers are exposed to credit risk in the event of default. The Company classifies investments in marketable debt securities that mature in less than one year as short-term assets. For investments that mature in more than one year, the investments are classified as long-term assets unless management intends to liquidate the investments to fund current operations before the scheduled maturity dates.The Company accounts for all of its investments in marketable debt securities as available-for-sale securities whereby they are recorded in the consolidated balance sheet at fair value. Interest income is recognized in the consolidated statement of operations, consisting of accrued interest earned based on the coupon rate of the security, plus the impact of accreting discounts and amortizing premiums to maturity using the straight-line method which approximates the interest method. Unrealized gains and losses due to subsequent changes in fair value of the investments are reported in shareholdersâ€™ equity as a component of accumulated other comprehensive income (loss). The Company reviews the components of its portfolio of available-for-sale debt securities, using both quantitative and qualitative factors, to determine if declines in fair value below amortized cost have resulted from a credit-related loss or other factors. If declines in fair value below amortized costs are due to the deterioration of an issuerâ€™s credit quality, the Company is required to record an allowance for credit losses related to such investments with a corresponding loss recognized in the consolidated statements of operations. Allowances for credit losses may be reversed in subsequent periods if conditions improve and credit-related losses are no longer expected. For declines in fair value that are solely due to changes in interest rates, impairment is not recognized if the Company has the ability and intent to hold the investment until maturity.Â Prepaid Expenses and OtherPrepaid expenses and other includes nonrefundable advance payments for goods and services that will be used or rendered in future research and development activities. These advance payments are deferred and recognized as expenses in the period that the related goods are delivered, or services are performed.LeasesThe Company determines if an arrangement includes a lease as of the date an agreement is entered into. Operating leases are included in right-of-use (â€œROUâ€) assets and operating lease liabilities in the Company's consolidated balance sheets. ROU assets and operating lease liabilities are initially recognized based on the present value of the future minimum lease payments at the commencement date of the lease. The Company generally uses its incremental borrowing rate based on the information available at the lease commencement date to determine the discount rate used to compute the present value of future payments. The Company's leases may include options to extend or terminate the lease; these options are included in the calculation of ROU assets and operating lease liabilities when it is reasonably certain that the Company will exercise the options. Lease expense is recognized on a straight-line basis over the lease term. The Company has elected not to apply the recognition requirements for short-term leases. For lease agreements with lease and non-lease components, the Company generally accounts for them separately.40â€‹ Table of ContentsProperty and EquipmentProperty and equipment consist solely of office furniture and equipment that is recorded at cost. Depreciation expense is calculated using the straight-line method over the estimated useful lives of the assets which range from 3 to 5 years. Maintenance and repairs are expensed as incurred.Research and Development CostsResearch and development costs are expensed as incurred. Intangible assets for in-licensing costs incurred under license agreements with third parties are charged to expense, unless the licensing rights have separate economic value in alternative future research and development projects or otherwise.Clinical Trial AccrualsClinical trial costs are a component of research and development expenses. The Company accrues and expenses clinical trial activities performed by third parties based upon estimates of the percentage of work completed over the life of the individual study in accordance with agreements established with clinical research organizations and clinical trial sites. The Company determines the estimates through discussions with internal clinical personnel and external service providers as to the progress or stage of completion of trials or services and the agreed-upon fee to be paid for such services.Share-Based CompensationThe Company measures the fair value of employee and director services received in exchange for grants of stock options and other equity awards granted, based on the fair value of the award as of the grant date. The Company computes the fair value of stock options using the Black-Scholes-Merton (â€œBSMâ€) option pricing model and recognizes the value of the equity awards over the period that services are provided to earn the award, usually the vesting period. For awards granted which contain a graded vesting schedule, and the only condition for vesting is a service condition, compensation cost is recognized as an expense on a straight-line basis over the requisite service period as if the award was, in substance, a single award. The Company recognizes the impact of forfeitures in the period that the forfeiture occurs, rather than estimating the number of awards that are not expected to vest in accounting for share-based compensation. For stock options that are voluntarily surrendered by employees, all unrecognized compensation is immediately recognized in the period the options are cancelled.Embedded DerivativesWhen the Company enters into a financial instrument such as a debt or equity agreement (the â€œHost Contractâ€), the Company assesses whether the economic characteristics of any embedded features would meet the definition of a derivative instrument, and whether such features are considered clearly and closely related to the primary economic characteristics of the Host Contract. When it is determined that (i) an embedded feature possesses economic characteristics that are not clearly and closely related to the primary economic characteristics of the Host Contract, and (ii) a separate, stand-alone instrument with the same terms would meet the definition of a financial derivative instrument and cannot be classified in shareholdersâ€™ equity, then the embedded feature is bifurcated from the Host Contract and accounted for as a derivative liability. The estimated fair value of the derivative feature is recorded separately from the carrying value of the Host Contract, with subsequent changes in the estimated fair value recorded as a non-operating gain or loss in the Companyâ€™s consolidated statements of operations.Fair Value of WarrantsThe Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrantâ€™s specific terms and applicable authoritative guidance set forth by the Financial Accounting Standards Board (â€œFASBâ€) in Accounting Standards Codification (â€œASCâ€) 480, Distinguishing Liabilities from Equity (â€œASC 480â€) and ASC 815, Derivatives and Hedging (â€œASC 815â€). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the 41â€‹ Table of ContentsCompanyâ€™s own common shares and whether the warrant holders could potentially require â€œnet cash settlementâ€ in a circumstance outside of the Companyâ€™s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and during each subsequent quarterly period while the warrants are outstanding. Liability-classified warrants are valued using the BSM option-pricing model at issuance, and for each subsequent reporting period. Income TaxesThe Company accounts for income taxes using the asset and liability method. Under this method, deferred income tax assets and liabilities that are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using enacted tax rates and laws that are in effect when the differences are expected to be recovered or settled. Realization of deferred income tax assets is dependent upon future taxable income. A valuation allowance is recognized if it is more likely than not that some portion or all of a deferred income tax asset will not be realized based on the weight of available evidence, including expected future earnings.The Company recognizes uncertain tax position in its financial statements when it concludes that a tax position is more likely than not to be sustained upon examination based solely on its technical merits. Only after a tax position passes the first step of recognition will measurement be required. Under the measurement step, the tax benefit is computed as the largest amount of benefit that is more likely than not to be realized upon effective settlement. This calculation is determined on a cumulative probability basis. The full impact of any change in recognition or measurement is reflected in the period in which such change occurs. Interest and penalties related to income taxes will be recognized as a component of income tax expense.Net Loss Per ShareBasic net loss per share is computed by dividing net loss by the weighted average number of outstanding shares of common stock and pre-funded warrants that are accounted for as equity instruments. Common shares associated with pre-funded warrants are included in the computation of both basic and diluted net loss per share since the exercise price is negligible and all of the pre-funded warrants are fully vested and exercisable. To the extent dilutive, during periods in which pre-funded warrants are accounted for as derivative liabilities, the calculation of diluted net loss per share will be further adjusted to eliminate gains on changes in the fair value of such pre-funded warrants, and the related pre-funded warrant shares will be included in the weighted average number of shares outstanding.Diluted net loss per share is computed using the treasury stock method by further giving effect to all potential shares of common stock, including stock options and warrants, to the extent dilutive.For participating warrants that are entitled to participate in dividends declared to holders of shares of common stock, the Company applies the two-class method of allocating earnings if the impact of including the participating warrants is dilutive for the calculation of both basic and diluted net loss per share.Treasury SharesThe Company accounts for purchases of treasury shares under the cost method. Â In accordance with Nevada law, acquired treasury shares may be retired by the Company. Upon retirement, the treasury shares are no longer accounted for as issued and outstanding.Recent Accounting PronouncementsRecently Adopted Accounting Standard. The following accounting standard was adopted in the fiscal year ended June 30, 2024:In June 2016, the FASB issued Accounting Standards Update (â€œASUâ€) 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. ASU 2016-13 amends the guidance on the impairment of financial instruments. This update adds an impairment model (known as the current expected credit losses 42â€‹ Table of Contentsmodel) that is based on expected losses rather than incurred losses. Under the expected credit loss model, if declines in fair value below amortized costs are due to the deterioration of an issuerâ€™s credit quality, the Company is required to record an allowance for credit losses related to such investments with a corresponding loss recognized in the consolidated statements of operations. Allowances for credit losses may be reversed in subsequent periods if conditions improve and credit-related losses are no longer expected. For declines in fair value that are solely due to changes in interest rates, impairment is not recognized if the Company has the ability and intent to hold the investment until maturity. Effective as of July 1, 2023, the Company implemented the guidance in ASU 2016-13. The adoption of ASU 2016-13 did not have any impact on the accompanying consolidated financial statements.Standard Required to be Adopted in Future Periods.Â The following accounting

standard has not yet been adopted by the Company:â€‹In December 2023, the FASB issued ASU 2023-09, â€œIncome Taxes (Topic 740) â€“ Improvements to Income Tax Disclosuresâ€. ASU 2023-09 requires disclosure of additional income tax information, primarily related to the rate reconciliation and income taxes paid. This ASU is intended to enhance the transparency and decision usefulness of income tax disclosures. ASU 2023-09 is effective for annual periods beginning after December 15, 2024. Management has not determined the timing for adoption of this standard.â€‹The adoption of ASU 2023-09 and other accounting standards that have been issued or proposed by the FASB that do not require adoption until a future date are not currently expected to have a material impact on the Companyâ€™s consolidated financial statements upon adoption.â€‹NOTEÂ 2 â€” LIQUIDITYThe Company is in the clinical stage and has not yet generated any revenues. For the fiscal year ended June 30, 2024, the Company incurred a net loss of $68.5 million and net cash used in operating activities amounted to $57.4 million. As of June 30, 2024, the Company had an accumulated deficit of $329.4 million, and the Companyâ€™s capital resources consisted of cash and cash equivalents of $70.4 million and in marketable debt securities totaling $56.7 million. As discussed in Note 7, the Company completed the 2024 Underwritten Offering in June 2024 that resulted in the issuance of approximately 13.0 million shares of common stock and 3.8 million prefunded warrants for net proceeds of $62.6 million after underwriting discounts and other offering costs. As of June 30, 2024, the Company had total liabilities of $11.7 million, including total current liabilities of $9.6 million. As discussed in Note 5, the Company is subject to license agreements that provide for future contractual payments upon achievement of various milestone events. Pursuant to the XOMA License Agreement (as defined below), a $5.0 million milestone payment will be due upon dosing of the last patient in a Phase 3 clinical trial for ersodetug. The commitment to pay the last patient dosing milestone of $5.0 million for the ersodetug Phase 3 clinical trial is expected to be recognized as a liability within 12 months. As discussed in Note 15, in July 2024 the Company received net proceeds of approximately $6.0 million related to a private placement of 1.5 million shares of common stock.Management believes the Companyâ€™s cash and cash equivalents, investments in marketable debt securities, and additional proceeds from the July 2024 private placement, will be adequate to meet the Companyâ€™s contractual obligations and carry out ongoing clinical trials and other planned activities through September 2025, at a minimum.43â€‹ Table of ContentsNOTEÂ 3 â€” INVESTMENTS IN MARKETABLE DEBT SECURITIESInvestments in marketable debt securities are classified as follows in the consolidated balance sheets as of June 30, 2024 and 2023 (in thousands):â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹2024Â Â Â Â 2023Short-term investments$ 56,478â€‹$ 85,860Long-term investmentsâ€‹ 263â€‹â€‹ 16,470Total investments$ 56,741â€‹$ 102,330â€‹The Company only invests in liquid, high quality debt securities. Nonetheless, all of these investments are subject to interest rate and credit risk that may result in fluctuations in the fair value of the investments. To minimize the exposure due to an adverse shift in interest rates, the Company generally invests in securities with expected maturities of two years or less while maintaining a weighted average maturity of one year or less. As of June 30, 2024 investments in marketable debt securities with an aggregate fair value of $56.5 million are scheduled to mature during the 12-month period ending June 30, 2025. All of the remaining investments with a fair value of $0.3 million, are scheduled to mature during the 12-month period ending June 30, 2026.During the fiscal year ended June 30, 2024, marketable debt securities for $115.1 million matured and approximately $66.4 million of the proceeds were reinvested in additional marketable debt securities. The Company did not sell any marketable debt securities prior to the scheduled maturity dates for the fiscal year ended June 30, 2024. Accrued interest receivable on all marketable debt securities amounted to $0.4 million and $0.3 million as of June 30, 2024 and 2023, respectively. Accrued interest is included in other current assets in the accompanying consolidated balance sheet. For the fiscal years ended June 30, 2024 and 2023, the Company did not recognize any allowance for credit losses or other than temporary impairment related to investments in marketable debt securities. The following table summarizes the unrealized gains and losses that result in differences between the amortized cost basis and fair value of the Companyâ€™s marketable debt securities held as of June 30, 2024 (in thousands):â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹

million as of May 13, 2024 when the Exchange PFWs were amended to permit equity classification. Accordingly, the derivative liability was reclassified to shareholdersâ€™ equity on May 13, 2024. 48â€‹ Table of ContentsJefferies Open Market Sales AgreementOn November 14, 2023, the Company and Jefferies LLC (the â€œAgent) entered into an open market sales agreement (the â€œSales Agreementâ€) that provides for an â€œat the marketâ€ offering for the sale of up to $50.0 million in shares of the Companyâ€™s common stock (the â€œPlacement Sharesâ€) through the Agent. The Agent is acting as sales agent and is required to use commercially reasonable efforts to sell all of the Placement Shares requested to be sold by the Company, consistent with the Agentâ€™s normal trading and sales practices, on mutually agreed terms between the Agent and the Company. The Sales Agreement will terminate when all of the Placement Shares have been sold, or earlier upon the election of either the Company or the Agent.The Company has no obligation to sell any of the Placement Shares under the Sales Agreement. The Company intends to use the net proceeds, if any, from amounts sold under the Sales Agreement for general corporate purposes, including working capital. Under the terms of the Sales Agreement, the Company agreed to pay the Agent a commission equal to 3.0% of the gross sales price of the Placement Shares plus certain expenses incurred by the Agent in connection with the offering.For the fiscal year ended June 30, 2024, the Company sold no shares of its common stock pursuant to the Sales Agreement. Accordingly, the maximum amount remaining for sale under the Sales Agreement amounts to $50.0 million as of June 30, 2024.2022 Private PlacementIn May 2022, the Company entered into securities purchase agreements (the â€œ2022 SPAsâ€) with Handok, Inc. (â€œHandokâ€) and certain of its affiliates. Handok is an affiliate of a member of the Companyâ€™s Board of Directors. In July 2022, the Company entered into amended 2022 SPAs for a private placement of common stock. The private placement resulted in gross proceeds of $12.3 million in exchange for the issuance of approximately 3.2 million shares of common stock. The Company incurred approximately $0.8 million for underwriting commissions and other offering costs, resulting in net proceeds of $11.6 million. NOTE 8 â€” SHARE-BASED COMPENSATION AND WARRANTSStock Option PlansPresented below is a summary of the number of shares authorized, outstanding, and available for future grants under the Companyâ€™s stock option plans and the Inducement Grant (defined below) as of June 30, 2024 (in thousands):â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â Number of SharesDescriptionÂ Â Â Â AuthorizedÂ Â Â Â OutstandingÂ Â Â Â Available—————2015 PlanÂ 17Â 17Â â€”2016 PlanÂ 123Â 123Â â€”2019 PlanÂ 200Â 200Â â€”2021 Planâ€‹ 10,618â€‹ 10,276â€‹ 342Inducement Grantâ€‹ 275â€‹ 275â€‹ â€”TotalÂ 11,233Â 10,891Â 342â€‹The Company currently has one active stock option plan, the 2021 Equity Incentive Plan (the â€œ2021 Equity Planâ€). On March 31, 2021, the Companyâ€™s Board of Directors adopted the 2021 Equity Plan that will terminate on March 31, 2031. On May 26, 2021, the 2021 Equity plan was approved by the Companyâ€™s shareholders with authority to issue up to 1.2 million shares of common stock. Pursuant to the 2021 Equity Plan, no awards may be granted under the three legacy stock option plans shown in the table above, but all outstanding awards previously granted under those plans shall remain outstanding and subject to the terms of the respective plans. On June 16, 2022, the Companyâ€™s shareholders approved an amendment to the 2021 Equity Plan, increasing the number of shares of common stock to be issued under the plan up to 49â€‹ Table of Contents10.7 million shares of common stock. Stock options outstanding under these plans expire pursuant to their contractual provisions on various dates through 2034.2022 Employee Stock Purchase PlanOn June 16, 2022, the Companyâ€™s shareholders approved the adoption of the 2022 Employee Stock Purchase Plan (the â€œ2022 ESPPâ€). The 2022 ESPP provides an opportunity for employees to purchase shares of the Companyâ€™s common stock through accumulated payroll deductions.The 2022 ESPP permits consecutive offering periods that begin approximately every 6 months commencing on the first trading day on or after July 1 and terminating on the last trading day of the offering period ending on December 31 and commencing on the first trading day on or after January 1 and terminating on the last trading day of the offering period ending on June 30. The 2022 ESPP reserves 0.5 million shares for purchases. There have been no offering periods under the 2022 ESPP through June 30, 2024. Stock Options OutstandingThe following table sets forth a summary of the combined activity under all of the Companyâ€™s stock option plans, including Inducement Grant discussed below, for the fiscal years ended June 30, 2024 and 2023 (shares in thousands):â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹

thousands):â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â 2024Â Â Â Â 2023â€‹â€‹â€‹â€‹â€‹â€‹â€‹Money market fundsâ€‹$ 61,249â€‹$ 5,464Demand deposits at single financial institutionâ€‹â€‹ 9,147â€‹â€‹ 6,091Commercial paperâ€‹â€‹ â€”â€‹â€‹ 4,481â€‹â€‹â€‹â€‹â€‹â€‹â€‹Totalâ€‹$ 70,396â€‹$ 16,036â€‹The money market funds and commercial paper included in the table above were purchased with an original maturity of three months or less. These investments and the demand deposits are freely available for the Companyâ€™s immediate and general business use.Property and EquipmentProperty and equipment consisted of the following as of June 30, 2024 and 2023 (in thousands):â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â 2024Â Â Â Â 2023â€‹â€‹â€‹â€‹â€‹â€‹â€‹Office furniture and equipment â€‹$ 210â€‹$ 210Less accumulated depreciation â€‹Â (107)â€‹Â (71)â€‹â€‹â€‹â€‹â€‹â€‹â€‹Totalâ€‹$ 103â€‹$ 139â€‹Depreciation expense related to property and equipment amounted to approximately $36,000 and $30,000 for the fiscal years ended June 30, 2024 and 2023, respectively.55â€‹ Table of ContentsNOTE 13 â€” NET LOSS PER SHAREBasic net loss per share is computed by dividing net loss by the weighted average number of outstanding shares of common stock and PWFs during periods when the PFWs are accounted for as equity instruments. Common shares associated with PFWs that are accounted for as equity instruments are included in the computation of basic and diluted net loss per share since the exercise price is negligible and all of the PFWs are fully vested and exercisable. For the calculation of diluted net loss per share for the fiscal year ended June 30, 2024, during the period when PFWs were accounted for as derivative liabilities, such PFWs were excluded from the calculation since the impact of PFWs was antidilutive. â€‹Calculation of the weighted average number of shares outstanding for purposes of diluted net loss per share is also required to include the dilutive effect, if any, of stock options, Legacy Warrants, and other common stock equivalents computed using the treasury stock method. For the fiscal years ended June 30, 2024 and 2023, all of such common stock equivalents were antidilutive and excluded from the calculations. In addition, the impact of applying the two-class method related to the Participating Warrants, was antidilutive for the calculation of both basic and diluted net loss per share.â€‹Presented below are the calculations of the numerators and the denominators for basic and diluted net loss per share for the fiscal years ended June 30, 2024 and 2023 (in thousands except per share amounts):â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â 2024â€‹Â Â Â Â 2023Calculation of Numerators:â€‹â€‹â€‹â€‹â€‹â€‹â€‹Net loss for calculation of basic and diluted net loss per shareâ€‹$ (68,459)â€‹$ (51,787)â€‹â€‹â€‹â€‹â€‹â€‹â€‹Calculation of Denominators:â€‹â€‹â€‹â€‹â€‹â€‹Weighted average number of common shares outstandingâ€‹â€‹ 39,499â€‹â€‹ 36,605Weighted average shares related to pre-funded warrants:â€‹â€‹â€‹â€‹â€‹â€‹2021 PFWsâ€‹â€‹ 1,195â€‹â€‹ 1,6612022 PFWsâ€‹â€‹ 10,245â€‹â€‹ 12,921Exchange PFWsâ€‹â€‹ 393â€‹â€‹ â€”2024 PFWsâ€‹â€‹ 133(1)â€‹ â€”Weighted average shares for basic and diluted net loss per shareâ€‹â€‹ 51,465â€‹â€‹ 51,187â€‹â€‹â€‹â€‹â€‹â€‹â€‹Net loss per share of common stock:â€‹â€‹â€‹â€‹â€‹â€‹Basicâ€‹$ (1.33)â€‹$ (1.01)Dilutedâ€‹$ (1.33)â€‹$ (1.01)_____(1)Represents the weighted average number of shares related to the Exchange PFWs discussed in Note 7 for the period when they became equity-classified on May 13, 2024 through June 30, 2024.As of June 30, 2024 and 2023, the following potential common stock equivalents were excluded from the calculation of diluted net loss per share since the impact of inclusion was anti-dilutive (in thousands):â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹2024â€‹2023â€‹â€‹â€‹â€‹â€‹Stock optionsâ€‹ 10,891â€‹ 8,745Legacy warrantsâ€‹ 861â€‹ 888Totalâ€‹ 11,752â€‹ 9,633â€‹â€‹â€‹56â€‹ Table of Contentsâ€‹NOTE 14 â€” FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONSFair Value MeasurementsFair value is defined as the price that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants on the measurement date. When determining fair value, the Company considers the principal or most advantageous market in which it transacts and considers assumptions that market participants would use when pricing the asset or liability. The Company applies the following fair value hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement:Level 1â€”Quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date.Level 2â€”Other than quoted prices included in Level 1 that are observable for the asset and liability, either directly or indirectly through market corroboration, for substantially the full term of the asset or liability.Level 3â€”Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any market activity for the asset or liability at the measurement date.Assets Measured at Fair Value on a Recurring BasisThe following table presents information about the Companyâ€™s financial assets measured at fair value on a recurring basis and indicates the fair value hierarchy classification of such fair values as of June 30, 2024. â€‹Fair Value Measurement of Assets as of June 30, 2024â€‹â€‹Totalâ€‹Level 1â€‹Level 2â€‹Level 3Cash and cash equivalents:â€‹Money market fundsâ€‹$ 61,249â€‹$ 61,249â€‹$ â€”â€‹$ â€”Marketable debt securities:â€‹Corporate commercial paperâ€‹â€‹ 20,929â€‹â€‹ â€”â€‹â€‹ 20,929â€‹â€‹ â€”U.S. Government agenciesâ€‹â€‹ 1,997â€‹â€‹ â€”â€‹â€‹ 1,997â€‹â€‹ â€”U.S. Government treasuriesâ€‹â€‹ 2,720â€‹â€‹ â€”â€‹â€‹ 2,720â€‹â€‹ â€”Corporate notes and bondsâ€‹â€‹ 30,832â€‹â€‹ â€”â€‹â€‹ 30,832â€‹â€‹ â€”Asset-backed securitiesâ€‹â€‹ 263â€‹â€‹ â€”â€‹â€‹ 263â€‹â€‹ â€”Total â€‹$ 117,990â€‹$ 61,249â€‹$ 56,741â€‹$ â€”â€‹57â€‹ Table of ContentsThe following table presents information about the Companyâ€™s financial assets measured at fair value on a recurring basis and indicates the fair value hierarchy classification of such fair values as of June 30, 2023.â€‹Fair Value Measurement of Assets as of June 30, 2023â€‹â€‹Totalâ€‹Level 1â€‹Level 2â€‹Level 3Cash and cash equivalents:â€‹Money market fundsâ€‹$ 5,464â€‹$ 5,464â€‹$ â€”â€‹$ â€”Corporate commercial paperâ€‹â€‹ 4,481â€‹â€‹ 4,481â€‹â€‹ â€”â€‹â€‹ â€”Marketable debt securities:â€‹Corporate commercial paperâ€‹â€‹ 41,597â€‹â€‹ â€”â€‹â€‹ 41,597â€‹â€‹ â€”U.S. Government agenciesâ€‹â€‹ 26,394â€‹â€‹ â€”â€‹â€‹ 26,394â€‹â€‹ â€”U.S. Government treasuriesâ€‹â€‹ 10,404â€‹â€‹ 10,404â€‹â€‹ â€”â€‹â€‹ â€”Corporate notes and bondsâ€‹â€‹ 19,240â€‹â€‹ â€”â€‹â€‹ 19,240â€‹â€‹ â€”Asset-backed securitiesâ€‹â€‹ 4,694â€‹â€‹ â€”â€‹â€‹ 4,694â€‹â€‹ â€”Total â€‹$ 112,274â€‹$ 20,349â€‹$ 91,925â€‹$ â€”â€‹Marketable debt securities classified as Level 2 within the valuation hierarchy generally consist of U.S. government agency securities, corporate bonds, and commercial paper. The Company determines the fair value of marketable debt securities based upon valuations obtained from third-party pricing sources. Except for the amounts shown in the table above, the Company did not have any other assets measured at fair value on a recurring basis as of June 30, 2024 and 2023.â€‹Liabilities Measured at Fair Value on a Recurring BasisFor the fiscal years ended June 30, 2024 and 2023, the Companyâ€™s liabilities that are required to be measured and recorded at fair value on a recurring basis consist of the embedded derivative liability discussed in Note 6 and the warrant derivative liability discussed in Note 7. The warrant derivative liability is classified under Level 2 of the fair value hierarchy and the embedded derivative liability is classified under Level 3 of the fair value hierarchy. Fair value of the warrant liability is predominantly based on the market price of the Companyâ€™s shares of common stock. Fair value of the embedded derivative liability is determined based on managementâ€™s assessment of the probability and timing of occurrence for the Exit Events discussed in Note 6 using a discount rate equal to the effective interest rate under the Loan Agreement prior to termination. The fair value of the Exchange PFWs was computed using the BSM option-pricing model. Key inputs to this valuation model as of May 13, 2024 included the exercise price of $0.001 per share, the market price of the Companyâ€™s common stock of $2.85 per share, the risk-free interest rate of 5.5%, an expected term of 1-day, and historical volatility of 100%. Key inputs to this valuation model as of March 8, 2024 included the exercise price of $0.001 per share, the market price of the Companyâ€™s common stock of $1.90 per share, the risk-free interest rate of 5.5%, an expected term of 1-day, and historical volatility of 100%.â€‹The following table sets forth a summary of changes in the fair value of the Companyâ€™s liabilities for which fair value was determined on a recurring basis for the fiscal years ended June 30, 2024 and 2023 (in thousands):â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹

with its Chief Financial Officer, Mr. Daron Evans (the â€œEmployment Agreementâ€). Pursuant to the Employment Agreement effective September 15, 2024, Mr. Evans was granted an increase of $185,000 to his yearly salary, making his base salary $460,000 annually. Mr. Evans is entitled to employee benefits and an annual performance bonus of up to 40% of his base salary, in addition to a discretionary bonus. If Mr. Evansâ€™ employment is terminated by the Company for Cause or by Mr. Evans without Good Reason then he is entitled to (i) accrued, but unpaid salary through the effective date of his termination, (ii) any reimbursements owed for business expenses validly incurred on or prior to his, (iii) any earned but unpaid bonuses or other incentive payments approved by the Board of Directors but not paid, and (iv) any accrued but unpaid benefits due and owing to Mr. Evans 61â€‹ Table of Contents(the â€œAccrued Obligationsâ€). Upon Mr. Evansâ€™ termination without Cause, he will be entitled to the Accrued Obligations and a severance comprised of (i) 12 monthsâ€™ salary, (ii) a pro-rata bonus payment equal to the pro-rata bonus amount of the bonus earned as of the date of termination without Cause, (iii) 12 months of COBRA premiums, collectively payable in equal monthly installments following his termination, and (iv) any granted but unvested stock options under any relevant Company stock option plan or agreement will have 12 months acceleration and an exercise period of 6 months following his termination. Further, if, within 12 months of a Change in Control Event Mr. Evansâ€™ employment is terminated by the Company without Cause or by Mr. Evans with Good Reason, then he is entitled to receive the Accrued Obligations, and a severance comprised of (i) 18 monthsâ€™ salary, (ii) a pro-rata bonus payment equal to the pro-rata bonus amount earned as of the date of termination, (iii) 18 months of COBRA premiums, collectively payable in equal monthly installments following the termination, and (iv) all of his granted but unvested stock options under any relevant company stock option plan or agreement will immediately vest and will also have an exercise period of 6 months following his termination without Cause. Mr. Evans and the Company had previously entered into an offer letter dated January 23, 2024 (the â€œOffer Letterâ€). The Employment Agreement replaces and supersedes in its entirety, any prior employment agreements or understandings between Mr. Evans and the Company including the Offer Letter. The definition of â€œCause,â€ â€œGood Reason,â€ and â€œChange in Control Eventâ€ is found in the Employment Agreement, along with other material terms. The Employment Agreement is attached hereto as Exhibit 10.4.â€‹Other Executive Compensation mattersIn addition to entering into the Employment Agreement, the Company agreed to grant stock options to Mr. Evans for 100,000 shares of common stock pursuant to the Companyâ€™s 2021 Equity Incentive Plan (the â€œOptionsâ€). The Compensation Committee will grant Mr. Evans the Options following the Companyâ€™s blackout period. â€‹Additionally, Nevan Elam, the Companyâ€™s Chief Executive Officer and Chairman, was granted an increase in his base salary. Mr. Elam is now entitled to an annual base salary of $ 625,000. â€‹â€‹Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.None.â€‹PART IIIItem 10. Directors, Executive Officers and Corporate Governance.The information required by the Item is set forth in our 2024 Proxy Statement to be filed with the SEC within 120 days of June 30, 2024, and is incorporated by reference into this Annual Report on Form 10-K.â€‹â€‹Item 11. Executive Compensation.The information required by the Item is set forth in our 2024 Proxy Statement to be filed with the SEC within 120 days of June 30, 2024, and is incorporated by reference into this Annual Report on Form 10-K.â€‹â€‹Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.The information required by Item 403 of Regulation S-K is set forth in our 2024 Proxy Statement to be filed with the SEC within 120 days of June 30, 2024, and is incorporated by reference into this Annual Report on Form 10-K.â€‹â€‹â€‹62â€‹ Table of ContentsItem 13. Certain Relationships and Related Transactions and Director Independence.The information required by the Item is set forth in our 2024 Proxy Statement to be filed with the SEC within 120 days of June 30, 2024, and is incorporated by reference into this Annual Report on Form 10-K.â€‹Item 14. Principal Accounting Fees and Services.The information required by the Item is set forth in our 2024 Proxy Statement to be filed with the SEC within 120 days of June 30, 2024, and is incorporated by reference into this Annual Report on Form 10-K.â€‹PART IVItem 15. Exhibit and Financial Statement Schedules.(a)(1) Financial StatementsReference is made to Item 8 of Part II for the Companyâ€™s consolidated financial statements filed as part of this Report.(a)(2) Financial Statement SchedulesAll financial statement schedules are omitted because they are not applicable, or the amounts are immaterial, not required, or the required information is presented in the financial statements and notes thereto included in Item 8 of Part II of this Report.(a)(3) ExhibitsCertain of the agreements filed as exhibits to this Report contain representations and warranties by the parties to the agreements that have been made solely for the benefit of the parties to the agreement. These representations and warranties:â—may have been qualified by disclosures that were made to the other parties in connection with the negotiation of the agreements, which disclosures are not necessarily reflected in the agreements;â—may apply standards of materiality that differ from those of a reasonable investor; andâ—were made only as of specified dates contained in the agreements and are subject to subsequent developments and changed circumstances.Accordingly, these representations and warranties may not describe the actual state of affairs as of the date that these representations and warranties were made or at any other time. Investors should not rely on them as statements of fact.The following exhibits of Rezolute, Inc. are filed or incorporated by reference as part of this Report.Â For exhibits that are incorporated by reference, we have indicated the document previously filed with the SEC in which the exhibit was included.â€‹ExhibitNo.Â Â Â Â Descriptionâ€‹â€‹â€‹1.1â€‹Underwriting Agreement, dated as of June 13, 2024, by and between the Company and Jefferies LLC (incorporated by reference to Exhibit 1.1 of the Companyâ€™s Form 8-K filed on June 14, 2024)1.2â€‹Underwriting Agreement, dated as of October 12, 2021, by and between the Company and Oppenheimer & Co., Inc. (incorporated by reference to Exhibit 1.1 of the Company's Form 8-K filed on October 13, 2021)1.3â€‹Underwriting Agreement, dated as of May 1, 2022, by and between the Company and Jefferies LLC (incorporated by reference to Exhibit 1.1 of the Companyâ€™s Form 8-K filed on May 4, 2022)63â€‹ Table of Contents2.1â€‹Agreement and Plan of Merger dated as of June 18, 2021, by and between Rezolute, Inc. and Rezolute Nevada Merger Corporation (incorporated by reference to Exhibit 2.1 of the Companyâ€™s Form 8-K filed on June 21, 2021)3.1â€‹Delaware Certificate of Merger, effective as of June 18, 2021 (incorporated by reference to Exhibit 3.1 of the Companyâ€™s Form 8-K filed on June 21, 2021)3.2â€‹Nevada Articles of Merger, effective as of June 18, 2021 (incorporated by reference to Exhibit 3.3 of the Companyâ€™s Form 8-K filed on June 21, 2021)3.3â€‹Amended and Restated Articles of Incorporation of Rezolute Nevada Merger Corporation (incorporated by reference to Exhibit 3.3 of the Companyâ€™s Form 8-K filed on June 21, 2021)3.4â€‹Certificate of Amendment, as filed with the Secretary of State of the State of Nevada on June 16, 2022 (incorporated by reference to Exhibit 3.1 of the Companyâ€™s Form 8-K filed on June 17, 2022)3.5â€‹Amended and Restated Bylaws of Rezolute Nevada Merger Corporation (incorporated by reference to Exhibit 3.4 of the Companyâ€™s Form 10-K filed on September 15, 2021)4.1â€‹Description of Securities*10.1â€‹Amended and Restated Employment Agreement of Nevan Elam, dated January 8, 2023 (incorporated by reference to Exhibit 10.1 of the Companyâ€™s Form 10-Q filed on May 11, 2023)10.2â€‹Amended and Restated Employment Agreement of Brian Roberts, dated January 8, 2023 (incorporated by reference to Exhibit 10.2 of the Companyâ€™s Form 10-Q filed on May 11, 2023)10.3â€‹Offer Letter for Daron Evans, dated January 23, 2024 (Incorporated by reference to Exhibit 10.1 of the Companyâ€™s Form 8-K filed on January 29, 2024)10.4â€‹Employment Agreement of Daron Evans, dated September 15, 2024*10.5â€‹AntriaBio, Inc. 2015 Non Qualified Stock Option Plan (incorporated by reference to Exhibit 10.5 of the Companyâ€™s Form 8-K filed on February 24, 2015)10.6â€‹AntriaBio, Inc. 2016 Non Qualified Stock Option Plan (incorporated by reference to Exhibit 10.2 of the Companyâ€™s Form 8-K filed on November 4, 2016)10.7â€‹AntriaBio, Inc. 2016 Non Qualified Stock Option Plan, as Amended (incorporated by reference to Exhibit 10.25 of the Companyâ€™s Form 10-K filed on September 21, 2017)10.8â€‹Rezolute, Inc. First Amendment to the 2016 Non-Qualified Stock Option Plan (incorporated by reference to Exhibit C to the Companyâ€™s Schedule 14A definitive proxy statement filed on April 5, 2019)10.9â€‹2019 Non Qualified Stock Option Plan (incorporated by reference to Exhibit 10.3 of the Companyâ€™s Form 8-K filed on August 6, 2019)10.10â€‹Rezolute, Inc. Amended and Restated 2021 Equity Incentive PlanÂ (incorporated by reference to Exhibit 10.23 of the Companyâ€™s Form 10-K filed on September 15, 2022)10.11â€‹Rezolute, Inc. 2022 Employee Stock Purchase Plan (Incorporated by reference to Exhibit 4.2 of the Registration Statement on Form S-8 filed on November 7, 2022)10.12â€‹2021 Incentive Compensation Plan Amendment (incorporated by reference to Appendix A of the Companyâ€™s Schedule 14A definitive proxy statement filed on April 15, 2024) 10.13â€‹Development and License Agreement with ActiveSite Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.1 of the Companyâ€™s Form 8-K filed on August 7, 2017)10.14â€‹License Agreement with XOMA (US) LLC (incorporated by reference to Exhibit 10.1 of the Companyâ€™s Form 10-Q filed on February 14, 2018)10.15â€‹Amendment No. 2 to the Stock Purchase Agreement with XOMA (US) LLC (incorporated by reference to Exhibit 10.1 of the Company's Form 10-Q filed on February 14, 2019)10.16â€‹Amendment No. 2 to the License Agreement with XOMA (US) LLC (incorporated by reference to Exhibit 10.2 of the Company's Form 10-Q filed on February 14, 2019)10.17â€‹Amendment No. 3 to the License Agreement with XOMA (US) LLC (incorporated by reference to Exhibit 10.1 of the Companyâ€™s Form 10-Q filed on May 14, 2020)10.18â€‹License Agreement with Handok, Inc. entered into on September 15, 2020 (incorporated by reference to Exhibit 10.21 of the Companyâ€™s Form 10-K filed on October 13, 2020)64â€‹ Table of Contents10.19â€‹Registration Rights Agreement, dated as of October 8, 2020, by and between Rezolute, Inc., and the Investors identified therein (incorporated by reference to Exhibit 10.2 of the Companyâ€™s Form 8-K filed on October 13, 2020)10.20â€‹Loan and Security Agreement, dated as of April 14, 2021 by and among Rezolute, Inc., SLR Investment Corp, as collateral agent and lender, and the other lenders named therein (incorporated by reference to Exhibit 10.1 of the Companyâ€™s Form 10-Q filed on May 17, 2021)10.21â€‹Exit Fee Agreement, dated as of April 14, 2021 by and among Rezolute, Inc., SLR Investment Corp, as collateral agent and lender, and the other lenders named therein (incorporated by reference to Exhibit 10.2 of the Companyâ€™s Form 10-Q filed on May 17, 2021)10.22â€‹Form of Subscription Agreement, dated October 12, 2021 (incorporated by reference to Exhibit 10.1 of the Companyâ€™s Form 8-K filed on October 13, 2021) 10.23â€‹Registration Rights Agreement, dated as of May 4, 2022, by and between Rezolute, Inc., and the purchasers identified therein (incorporated by reference to Exhibit 10.1 of the Companyâ€™s Form 8-K filed on May 4, 2022) 10.24â€‹Placement Agency Agreement, dated as of May 1, 2022, by and between the Company and Jefferies LLC (incorporated by reference to Exhibit 10.2 of the Companyâ€™s Form 8-K filed on May 4, 2022)10.25â€‹Form of Amended and Restated Securities Purchase Agreement, dated as of July 22, 2022 (incorporated by reference to Exhibit 10.22 of the Companyâ€™s Form 10-K filed on September 15, 2022)10.26â€‹Open Market Sale Agreement by and between Rezolute, Inc. and Jefferies, LLC (incorporated by reference to Exhibit 1.2 of the Registration Statement on Form S-3 filed on November 14, 2023)10.27â€‹Form of Financing Warrant (incorporated by reference to Exhibit 4.1 of the Company's Form 8-K filed on April 3, 2018)10.28â€‹Form of Common Stock Purchase Warrant by and between the Company and the Investor identified therein (incorporated by reference to Exhibit 4.1 the Companyâ€™s Form 8-K filed on October 13, 2020)10.29â€‹Form of Pre-Funded Warrant to Purchase Common Stock (Incorporated by reference to Exhibit 4.1 of the Companyâ€™s Form 8-K filed on October 13, 2021)10.30â€‹Form of Class A Pre-Funded Warrant (incorporated by reference to Exhibit 4.1 of the Companyâ€™s Form 8-K filed on May 4, 2022)10.31â€‹Form of Class B Pre-Funded Warrant (incorporated by reference to Exhibit 4.2 of the Companyâ€™s Form 8-K filed on May 4, 2022)10.32â€‹Form of Exchange Warrant (incorporated by reference to Exhibit 4.1 of the Companyâ€™s Form 8-K filed on March 14, 2024)10.33â€‹Form of Securities Exchange Agreement (incorporated by reference to Exhibit 4.2 of the Companyâ€™s Form 8-k filed on March 14, 2024)10.34â€‹Form of Pre-funded Warrant to Purchase Common Stock (incorporated by reference to Exhibit 4.1 of the Companyâ€™s Form 8-K filed on June 14, 2024)10.35â€‹Form of Pre-funded Warrant to Purchase Common Stock (incorporated by reference to Exhibit 4.1 of the Companyâ€™s Form 8-K filed on June 14, 2024) 10.36â€‹Form of Securities Purchase Agreement, dated June 25, 2024, by and between Rezolute, Inc., and the purchasers identified therein*10.37â€‹Registration Rights Agreement, dated June 25, 2024, by and between Rezolute, Inc., and the purchasers identified therein* 14.1â€‹Rezolute, Inc. Code of Ethics, as amended and restatedÂ as of May 30, 2023 (incorporated by reference to Exhibit 14.1 of the Companyâ€™s Form 8-K filed on June 2, 2023)21.1â€‹Listing of Subsidiaries*23.1â€‹Consent of Grant Thornton, LLP*23.2â€‹Consent of Plante & Moran, PLLC*31.1â€‹Certifications of Chief Executive Officer and Principal Financial Officer as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002*65â€‹ Table of Contents32.1â€‹Certifications of Chief Executive Officer and Principal Financial Officer as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002*97â€‹Clawback Policy*101.INSâ€‹Inline XBRL Instance Document*101.SCHâ€‹Inline XBRL Taxonomy Extension Schema*101.CALâ€‹Inline XBRL Taxonomy Extension Calculation Linkbase*101.DEFâ€‹Inline XBRL Taxonomy Extension Definition Linkbase*101.LABâ€‹Inline XBRL Taxonomy Extension Label Linkbase*101.PREâ€‹Inline XBRL Taxonomy Extension Presentation Linkbase*104â€‹Cover Page Interactive Data File, formatted in Inline XBRL (included as Exhibit 101)â€‹*Filed herewith.In accordance with SEC Release 33-8238, Exhibit 32.1 is being furnished and not filed.â€‹Item 16. Form 10-K Summary.Not applicableâ€‹66â€‹ Table of ContentsSIGNATURESPursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.â€‹â€‹â€‹â€‹â€‹â€‹REZOLUTE, INC.â€‹â€‹â€‹Date: September 19, 2024By:/s/ Nevan Charles Elamâ€‹â€‹Nevan Charles Elamâ€‹â€‹Acting Chair of the Board of Directors and Chief Executive Officer (Principal Executive and Financial Officer)â€‹Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.â€‹Date: September 19, 2024By:/s/ Nevan Charles Elamâ€‹â€‹Nevan Charles Elamâ€‹â€‹Acting Chair of the Board of Directors and Chief Executive Officer (Principal Executive and Financial Officer)â€‹â€‹â€‹Date: September 19, 2024By:/s/ Gil Labrucherieâ€‹â€‹Gil Labrucherieâ€‹â€‹Directorâ€‹â€‹Date: September 19, 2024By:/s/ Nerissa Kreherâ€‹â€‹Nerissa Kreherâ€‹â€‹Directorâ€‹â€‹Date: September 19, 2024By:/s/ Philippe Fauchetâ€‹â€‹Philippe Fauchetâ€‹â€‹Directorâ€‹â€‹Date: September 19, 2024By:/s/ Young-Jin Kimâ€‹â€‹Young-Jin Kimâ€‹â€‹Directorâ€‹â€‹Date: September 19, 2024By:/s/ Wladimir Hogenhuisâ€‹â€‹Wladimir Hogenhuisâ€‹â€‹Directorâ€‹â€‹67â€‹ EX-4.1 2 rzlt-20240630xex4d1.htm EX-4.1 Â EXHBIT 4.1â€‹DESCRIPTION OF SECURITIESÂ GeneralÂ The following description summarizes the most important terms of our capital stock. It is subject to and qualified in its entirety by reference to our Amended and Restated Articles of Incorporation, as amended (â€œArticles of Incorporationâ€) and Amended and Restated Bylaws (â€œBylawsâ€), which are included as exhibits to our annual report on Form 10-K, of which this Exhibit 4.1 is a part. We encourage you to read our Articles of Incorporation, our Bylaws and the applicable provisions of the Nevada Revised Statutes (the â€œNRSâ€), for additional information.Â â€‹Common StockÂ Our Articles of Incorporation provide authority for us to issue up to 100,000,000 shares of common stock, par value $0.001 per share (the â€œCommon Stockâ€). Under the NRS, stockholders generally are not personally liable for our debts or obligations solely as a result of their status as stockholders. Our outstanding shares of Common Stock are fully paid and nonassessable.Â Voting Rights. Holders of our Common Stock are entitled to one vote per share on all matters submitted to our stockholders for a vote. There are no cumulative voting rights in the election of directors. All elections of our Board of Directors at any meeting of our stockholders shall be determined by a plurality of the votes cast. Except as otherwise required by law, our Bylaws or the rules of any stock exchange upon which our companyâ€™s securities are listed, all other matters determined by our stockholders at a meeting shall be determined by a majority of the votes cast affirmatively or negatively.â€‹Dividend Rights. Our shares of Common Stock are entitled to receive such dividends as may be declared and paid by our Board of Directors out of funds legally available therefor and to share ratably in the net assets, if any, of our company upon liquidation. â€‹Preemptive Rights. Our stockholders have no preemptive rights to purchase any shares of our capital stock. â€‹Choice of Forum. Our Articles of Incorporation provides that the Eighth Judicial District Court of Clark County, Nevada shall be the sole and exclusive forum for (i)Â any derivative action or proceeding brought on our behalf, (ii)Â any action asserting a claim for breach of a fiduciary duty owed by any of our directors, officers, employees or agents to us or our stockholders, (iii)Â any action asserting a claim arising pursuant to any provision of the NRS Chapters 78 or 92A, our Articles of incorporation or our Bylaws or (iv)Â any action asserting a claim governed by the internal affairs doctrine. Notwithstanding this exclusive forum provision, the exclusive forum provision shall not preclude or contract the scope of exclusive federal or concurrent jurisdiction for actions brought under the Securities Exchange Act of 1934, as amended (the â€œExchange Actâ€) or the Securities Act of 1933, as amended (the â€œSecurities Actâ€) or the respective rulesÂ and regulations promulgated thereunder.Â Preferred StockÂ Our Articles of Incorporation provides authority for us to issue up to 400,000 shares of preferred stock, par value $0.001 per share. Our Board of Directors is authorized, without further stockholder action, to establish various series of preferred stock from time to time and to determine the rights, preferences and privileges of any unissued series including, among other matters, any dividend rights, dividend rates, conversion rights, voting rights, terms of redemption, liquidation preferences, sinking fund terms, the number of shares constituting any such series, and the description thereof and to issue any such shares. Â The rights of the holders of our Common Stock will be subject to, and may be adversely affected by, the rights of holders of any preferred stock that may be issued in the future. Such rights may include voting and conversion rights which could adversely affect the holders of the Common Stock. Satisfaction of any dividend or liquidation preferences of outstanding preferred stock would reduce the amount of funds available, if any, for the payment of dividends or liquidation amounts on Common Stock.â€‹WarrantsÂ 2024 Pre-Funded Warrantsâ€‹In June 2024, we issued and sold Pre-Funded Warrants (the â€œ2024 Pre-Funded Warrantsâ€) to purchase an aggregate of 3,750,000 shares of common stock at a public offering price of $3.999 per 2024 Pre-Funded Warrant in an underwritten public offering pursuant to a shelf registration on Form S-3.â€‹Each 2024 Pre-Funded Warrant entitles the holder to purchase one share of our common stock at an exercise price of $0.001 per share. The 2024 Pre-Funded warrants do not expire and may be exercised at any time after their original issuance.â€‹Under the 2024 Pre-Funded Warrants, we many not effect the exercise of any 2024 Pre-Funded Warrant, and a holder will not be entitled to exercise any portion

of any 2024 Pre-Funded Warrant, which, upon giving effect to such exercise, would cause (i) the aggregate number of shares of our common stock beneficially owned by the holder (together with its affiliates) to exceed 4.99%, 9.99% or 19.99%, as applicable to the holder, of the number of shares of our common stock outstanding immediately after giving effect to the exercise, or (ii) the combined voting power of our securities beneficially owned by the holder of the 2024 Pre-Funded Warrant (together with its affiliates) to exceed 4.99%, 9.99% or 19.99%, as applicable to the holder, of the combined voting power of all of our securities then outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the 2024 Pre-Funded Warrants. However, any holder may increase or decrease such percentage to any other percentage upon at least 61 daysâ€™ prior notice from the holder to us; provided, that a holder of a 2024 Pre-Funded Warrants may not increase such percentage to a percentage in excess of 19.99%.The exercise price of the 2024 Pre-Funded Warrants and the number of shares of our common stock issuable upon exercise of the 2024 Pre-Funded Warrants is subject to appropriate adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting our common stock and also upon any distributions of assets, including cash, stock or other property to our stockholders. The 2024 Pre-Funded Warrants also contain provisions that provide certain rights to holders in the event of a fundamental transaction, including a merger or consolidation with or into another entity, such as the right to receive the same amount and kind of consideration paid to the holders of our common stock in the fundamental transaction. The 2024 Pre-Funded Warrants do not entitle the holders to any voting rights or any of the other rights or privileges to which holders of common stock are entitled.â€‹As of September 13, 2024, we have 3,750,000 shares underlying the 2024 Pre-Funded Warrants outstanding, of which there have been no exercises.â€‹2024 Exchange Pre-Funded Warrantsâ€‹In March 2024, we entered into a securities exchange agreement with certain of our stockholders, whereby we purchased 3,000,000 shares of common stock. These shares were immediately cancelled whereby they will remain as authorized shares for future issuance in accordance with Nevada law. Consideration for the acquisition of the shares consisted of (i) a cash payment to the exchanging shareholders of $3,000, and (ii) the issuance of pre-funded warrants (the â€œExchange Pre-Funded Warrantsâ€) to the exchanging shareholders. Each of the Exchange Pre-Funded Warrant entitles the holder to purchase one share of our common stock at an exercise price of $0.001 per share. The 2024 Exchange Pre-Funded Warrants do not expire and may be exercised at any time after their original issuance.â€‹Under the Exchange Pre-Funded Warrants, we many not effect the exercise of any Exchange Pre-Funded Warrant, and a holder will not be entitled to exercise any portion of any Exchange Pre-Funded Warrant, which, upon giving effect to such exercise, would cause (i) the aggregate number of shares of our common stock beneficially owned by the holder (together with its affiliates) to exceed 9.99% of the number of shares of our common stock outstanding immediately after giving effect to the exercise, or (ii) the combined voting power of our securities beneficially owned by the holder of the Exchange Pre-Funded Warrant (together with its affiliates) to exceed 9.99% of the combined voting power of all of our securities then outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the Exchange Pre-Funded Warrants. However, any holder may increase or decrease such percentage to any other percentage upon at least 61 daysâ€™ prior notice from the holder to us; provided, that a holder of an Exchange Pre-Funded Warrants may not increase such percentage to a percentage in excess of 19.99%.The exercise price of the Exchange Pre-Funded Warrants and the number of shares of our common stock issuable upon exercise of the Exchange Pre-Funded Warrants is subject to appropriate adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting our common stock and also upon any distributions of assets, including cash, stock or other property to our stockholders. The Exchange Pre-Funded Warrants also contain provisions that provide certain rights to holders in the event of a fundamental transaction, including a merger or consolidation with or into another entity, such as the right to receive the same amount and kind of consideration paid to the holders of our common stock in the fundamental transaction. The Exchange Pre-Funded Warrants do not entitle the holders to any voting rights or any of the other rights or privileges to which holders of common stock are entitled.â€‹As of September 13, 2024, there have been exercises of 610,404 shares underlying the Exchange Pre-Funded Warrants, with 2,389,596 shares underlying the Exchange Pre-Funded Warrants have not been exercised.â€‹Class A Pre-Funded Warrantsâ€‹In May 2022, we issued and sold Class A Pre-Funded Warrants (the â€œClass A Pre-Funded Warrantsâ€) to purchase an aggregate of 1,973,684 shares of our common stock at an offering price of $3.799 per Class A Pre-Funded Warrant in an underwritten public offering pursuant to a shelf registration on Form S-3. Â Each Class A Pre-Funded Warrant entitles the holder to purchase one share of our common stock at an exercise price of $0.001 per share. The Class A Pre-Funded Warrants do not expire and may be exercised at any time after their original issuance. â€‹Under the Class A Pre-Funded Warrants, we may not effect the exercise of any Class A Pre-Funded Warrant, and a holder will not be entitled to exercise any portion of any Class A Pre-Funded Warrant, which, upon giving effect to such exercise, would cause (i) the aggregate number of shares of our common stock beneficially owned by the holder (together with its affiliates) to exceed 4.99% of the number of shares of our common stock outstanding immediately after giving effect to the exercise, or (ii) the combined voting power of our securities beneficially owned by the holder of the Class A Pre-Funded Warrant (together with its affiliates) to exceed 4.99% of the combined voting power of all of our securities then outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the Class A Pre-Funded Warrants. However, any holder may increase or decrease such percentage to any other percentage upon at least 61 daysâ€™ prior notice from the holder to us; provided, that a holder of a Class A Pre-Funded Warrants may not increase such percentage to a percentage in excess of 19.99%.The exercise price of the Class A Pre-Funded Warrants and the number of shares of our common stock issuable upon exercise of the Class A Pre-Funded Warrants is subject to appropriate adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting our common stock and also upon any distributions of assets, including cash, stock or other property to our stockholders. The Class A Pre-Funded Warrants also contain provisions that provide certain rights to holders in the event of a fundamental transaction, including a merger or consolidation with or into another entity, such as the right to receive the same amount and kind of consideration paid to the holders of our common stock in the fundamental transaction. The Class A Pre-Funded Warrants do not entitle the holders to any voting rights or any of the other rights or privileges to which holders of common stock are entitled.â€‹As of September 13, 2024, all 1,973,684 shares underlying the Class A Pre-Funded Warrants have been exercised. â€‹Class B Pre-Funded Warrantsâ€‹In May 2022, we issued and sold Class B Pre-Funded Warrants (the â€œClass B Pre-Funded Warrantsâ€) to purchase an aggregate of 10,947,371 shares of our common stock at an offering price of $3.799 per Class B Pre-Funded Warrant in an underwritten public offering pursuant to a shelf registration on Form S-3. Â Each Class B Pre-Funded Warrant entitles the holder to purchase one share of our common stock at an exercise price of $0.01 per share. The Class B Pre-Funded Warrants do not expire and may be exercised at any time after their original issuance. â€‹Under the Class B Pre-Funded Warrants, we may not effect the exercise of any Class B Pre-Funded Warrant, and a holder will not be entitled to exercise any portion of any Class B Pre-Funded Warrant, which, upon giving effect to such exercise, would cause (i) the aggregate number of shares of our common stock beneficially owned by the holder (together with its affiliates) to exceed 4.99%, 9.99% or 19.99%, as applicable to the holder, of the number of shares of our common stock outstanding immediately after giving effect to the exercise, or (ii) the combined voting power of our securities beneficially owned by the holder of the Class B Pre-Funded Warrant (together with its affiliates) to exceed 4.99%, 9.99% or 19.99%, as applicable to the holder, of the combined voting power of all of our securities then outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the Class B Pre-Funded Warrants. However, any holder may increase or decrease such percentage to any other percentage upon at least 61 daysâ€™ prior notice from the holder to us; provided, that a holder of a Class B Pre-Funded Warrants may not increase such percentage to a percentage in excess of 19.99%.The exercise price of the Class B Pre-Funded Warrants and the number of shares of our common stock issuable upon exercise of the Class B Pre-Funded Warrants is subject to appropriate adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting our common stock and also upon any distributions of assets, including cash, stock or other property to our stockholders. The Class B Pre-Funded Warrants also contain provisions that provide certain rights to holders in the event of a fundamental transaction, including a merger or consolidation with or into another entity, such as the right to receive the same amount and kind of consideration paid to the holders of our common stock in the fundamental transaction. The Class B Pre-Funded Warrants do not entitle the holders to any voting rights or any of the other rights or privileges to which holders of common stock are entitled.â€‹As of September 13, 2024, there have been exercises of 2,800,000 shares underlying the Class B Pre-Funded Warrants, with 8,147,371 shares underlying the Class B Pre-Funded Warrants have not been exercised. â€‹October 2021 Pre-Funded Warrantsâ€‹In October 2021, we issued and sold pre-funded warrants (the â€œ2021 Pre-Funded Warrantsâ€) to purchase an aggregate of 1,661,461 shares of our common stock at an offering price of $6.49 per 2021 Pre-Funded Warrant in an underwritten public offering pursuant to a shelf registration on Form S-3. Â Each 2021 Pre-Funded Warrant entitles the holder to purchase one share of our common stock at an exercise price of $0.01 per share. The 2021 Pre-Funded Warrants do not expire and may be exercised at any time after their original issuance. â€‹Under the 2021 Pre-Funded Warrants, we may not effect the exercise of any 2021 Pre-Funded Warrant, and a holder will not be entitled to exercise any portion of any 2021 Pre-Funded Warrant, which, upon giving effect to such exercise, would cause (i) the aggregate number of shares of our common stock beneficially owned by the holder (together with its affiliates) to exceed 4.99% or 19.99%, as applicable to the holder, of the number of shares of our common stock outstanding immediately after giving effect to the exercise, or (ii) the combined voting power of our securities beneficially owned by the holder of the 2021 Pre-Funded Warrant (together with its affiliates) to exceed 4.99% or 19.99%, as applicable to the holder, of the combined voting power of all of our securities then outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the 2021 Pre-Funded Warrants. However, any holder may increase or decrease such percentage to any other percentage upon at least 61 daysâ€™ prior notice from the holder to us; provided, that a holder of a 2021 Pre-Funded Warrants may not increase such percentage to a percentage in excess of 19.99%.The exercise price of the 2021 Pre-Funded Warrants and the number of shares of our common stock issuable upon exercise of the 2021 Pre-Funded Warrants is subject to appropriate adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting our common stock and also upon any distributions of assets, including cash, stock or other property to our stockholders. The 2021 Pre-Funded Warrants also contain provisions that provide certain rights to holders in the event of a fundamental transaction, including a merger or consolidation with or into another entity, such as the right to receive the same amount and kind of consideration paid to the holders of our common stock in the fundamental transaction. The 2021 Pre-Funded Warrants do not entitle the holders to any voting rights or any of the other rights or privileges to which holders of common stock are entitled.â€‹As of September 13, 2024, there have been exercises of 1,538,461 shares underlying the 2021 Pre-Funded Warrants, with 123,000 shares underlying the 2021 Pre-Funded Warrants have not been exercised. â€‹Participating Warrantsâ€‹In October 2020, we issued and sold 820,001 warrants (the â€œParticipating Warrantsâ€), and each 2020 Warrant entitles the holder to purchase 0.33 shares of our common stock at an exercise price of $19.50 per share of our common stock. Each 2020 Warrant is exercisable on or after October 9, 2020 and will expire on or prior to 5:00 p.m. (New York City time) on October 9, 2027. The 2020 Warrant were subsequently registered for resale by certain selling stockholders pursuant to a registration statement on Form S-3.â€‹Under the Participating Warrants, we may not effect the exercise of any 2020 Warrant, and a holder will not be entitled to exercise any portion of any 2020 Warrant, which, upon giving effect to such exercise, would cause the aggregate number of shares of our common stock beneficially owned by the holder (together with its affiliates) to exceed 4.99% or 19.99%, as applicable to the holder, of the number of shares of our common stock outstanding immediately after giving effect to the exercise. However, any holder may increase or decrease such percentage to any other percentage; provided, that a holder of 2020 Warrant may not increase such percentage to a percentage in excess of 9.99% of the number of shares of the common stock outstanding immediately after giving effect to the issuance of shares of common stock upon exercise of the 2020 Warrant held by the holder. Any increase in such percentage will not be effective until the 61st day after such notice is delivered to the company. The exercise price of the Participating Warrants and the number of shares of our common stock issuable upon exercise of the 2020 Warrant is subject to appropriate adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting our common stock and also upon any distributions of assets, including cash, stock or other property to our stockholders. The Participating Warrants also contain provisions that provide certain rights to holders in the event of a fundamental transaction, including a merger or consolidation with or into another entity, such as (i) the right to receive the same amount and kind of consideration paid to the holders of our common stock in the fundamental transaction and (ii) the right to require the company to repurchase the unexercised portion of certain warrants at the warrantâ€™s respective fair value using the Black Scholes option pricing formula. The Participating Warrants do not entitle the holders to any voting rights or any of the other rights or privileges to which holders of common stock are entitled.â€‹As of September 13, 2024, we have 820,001 shares underlying the Participating Warrants outstanding, of which there have been no exercises. â€‹Other Warrantsâ€‹The Company has issued warrants in conjunction with debt and equity financings and for services from 2015 to 2019. Such warrants have various expiration dates and exercise prices.â€‹Anti-Takeover ProvisionsÂ Provisions of the NRS, our Articles of Incorporation, and our Bylaws, as amended from time to time, could have the effect of delaying or preventing a third-party from acquiring us, even if the acquisition would benefit our stockholders. Such provisions of the NRS, our Articles of Incorporation, and our Bylaws are intended to enhance the likelihood of continuity and stability in the composition of our Board of Directors and in the policies formulated by the Board of Directors and to discourage certain types of transactions that may involve an actual or threatened change of control of our company. These provisions are designed to reduce our vulnerability to an unsolicited proposal for a takeover that does not contemplate the acquisition of all of our outstanding shares, or an unsolicited proposal for the restructuring or sale of all or part of our company.Â Authorized but Unissued SharesÂ Â Our authorized but unissued shares of Common Stock are available for our Board of Directors to issue without stockholder approval, subject to the rules of any stock exchange upon which our securities are listed. We may use these additional shares for a variety of corporate purposes, including raising additional capital, corporate acquisitions and employee stock plans. The existence of our authorized but unissued shares of Common Stock could render it more difficult or discourage an attempt to obtain control of our company by means of a proxy context, tender offer, merger or other transaction since our Board of Directors can issue large amounts of capital stock as part of a defense to a take-over challenge. In addition, we have authorized in our Articles of Incorporation 400,000 shares of preferred stock. Our board acting alone and without approval of our stockholders, subject to the rules of any stock exchange upon which our securities are listed, can designate and issue one or more series of preferred stock containing super-voting provisions, enhanced economic rights, rights to elect directors, or other dilutive features, that could be utilized as part of a defense to a take-over challenge.Â BylawsIn addition, various provisions of our Bylaws may also have an anti-takeover effect. These provisions may delay, defer or prevent a tender offer or takeover attempt of our company that a stockholder might consider in his or her best interest, including attempts that might result in a premium over the market price for the shares held by our stockholders. Our Bylaws contain limitations as to who may call special meetings as well as require advance notice of stockholder matters to be brought at a meeting. Additionally, our Bylaws also provide that subject to the rights of the holders of any series of preferred stock then outstanding, any director, or the entire Board of Directors, may be removed only for cause and only by the affirmative vote of the holders of at least eighty percent (80%) of the voting power of all of the then outstanding shares of our company then entitled to vote at an election of directors, voting together as a single class. Our Bylaws also reserve the exclusive right of the Board of Directors to establish the number of directors and fill any vacancies and newly created directorships. These provisions will prevent a stockholder from increasing the size of our Board of Directors and gaining control of our Board of Directors by filling the resulting vacancies with its own nominees.Our Bylaws also establish an advance notice procedure for stockholder proposals to be brought before an annual meeting of our stockholders, including proposed nominations of persons for election to the Board of Directors. Stockholders at an annual meeting will only be able to consider proposals or nominations specified in the notice of meeting or brought before the meeting by or at the direction of the Board of Directors or by a stockholder who was a stockholder of record on the record date for the meeting, who is entitled to vote at the meeting and who has given us timely written notice, in proper form, of the stockholderâ€™s intention to bring that business before the meeting. Although our Bylaws do not give the Board of Directors the power to approve or disapprove stockholder nominations of candidates or proposals regarding other business to be conducted at a special or annual meeting, our Bylaws may have the effect of precluding the conduct of certain business at a meeting if the proper procedures are not followed or may discourage or deter a potential acquirer from conducting a solicitation of proxies to elect its own slate of directors or otherwise attempting to obtain control of our company.â€‹Nevada Anti-Takeover StatutesÂ Business Combination StatuteÂ We are subject to the â€œbusiness combinationâ€ provisions of Sections 78.411 to 78.444 of the NRS. In general, such provisions prohibit a Nevada corporation with 200 or more stockholders from engaging in various â€œcombinationâ€ transactions with any interested stockholder for a period of two years after the date of the transaction in which the person became an interested stockholder, unless the transaction is approved by the Board of Directors prior to the date the interested stockholder obtained such status or the combination is approved by the Board of Directors and thereafter is approved at a meeting of stockholders by the affirmative vote of stockholders representing at least 60% of the outstanding

voting power held by disinterested stockholders, and extends beyond the expiration of the two-year period, unless (a) the transaction by which the person first became an interested stockholder was approved by the Board of Directors before the person became an interested stockholder; (b) the combination is later approved by a majority of the voting power held by disinterested stockholders; or (c) if the consideration to be paid by the interested stockholder is at least equal to the highest of: (i) the highest price per share paid by the interested stockholder within the two years immediately preceding the date of the announcement of the combination or in the transaction in which it became an interested stockholder, whichever is higher, or (ii) the market value per share of common stock on the date of announcement of the combination and the date the interested stockholder acquired the shares, whichever is higher.Â A â€œcombinationâ€ is generally defined to include mergers or consolidations or any sale, lease, exchange, mortgage, pledge, transfer, or other disposition, in one transaction or a series of transactions, with an â€œinterested stockholderâ€ or any affiliate or associate of an interested stockholder having: (a) an aggregate market value equal to more than 5% of the aggregate market value of the assets of the corporation, (b) an aggregate market value equal to more than 5% of the aggregate market value of all outstanding voting shares of the corporation, and (c) more than 10% of the earning power or net income of the corporation.Â An â€œinterested stockholderâ€ is generally defined to mean a beneficial owner of at least 10% of the outstanding voting power or an affiliate or associate of the corporation that has been a 10% beneficial owner within the preceding 2 years. The statutes could prohibit or delay mergers or other takeover or change in control attempts and, accordingly, may discourage attempts to acquire our company even though such a transaction may offer our stockholders the opportunity to sell their stock at a price above the prevailing market price.Â Acquisition of Controlling Interest StatuteÂ Nevadaâ€™s Acquisition of Controlling Interest Statute (NRS Sections 78.378-78.3793) applies only to Nevada corporations with at least 200 stockholders, including at least 100 stockholders of record who are Nevada residents, which conduct business directly or indirectly in Nevada and whose articles of incorporation or bylaws in effect 10 days following the acquisition of a controlling interest by an acquiror do not prohibit its application. As of the date of this prospectus, we do not believe we have 100 stockholders of record who are residents of Nevada, although there can be no assurance that in the future the acquisition of controlling interest statutes will not apply to us.Nevadaâ€™s Acquisition of Controlling Interest Statute, prohibits an acquiror, under certain circumstances, from voting shares of a target corporationâ€™s stock after crossing certain threshold ownership percentages, unless the acquiror obtains the approval of the target corporationâ€™s stockholders. The statute specifies three thresholds that constitute a controlling interest: (a) at least one-fifth but less than one-third; (b) at least one-third but less than a majority; and (c) a majority or more, of the outstanding voting power. Once an acquiror crosses one of these thresholds, shares which it acquired in the transaction exceeding the threshold (or within ninety days preceding the date thereof) become â€œcontrol sharesâ€ which could be deprived of the right to vote until a majority of the disinterested stockholders restore that right.A special stockholders meeting may be called at the request of the acquiror to consider the voting rights of the acquirorâ€™s shares. If the acquiror requests a special meeting and gives an undertaking to pay the expenses of said meeting, then the meeting must take place no earlier than 30 days (unless the acquiror requests that the meeting be held sooner) and no more than 50 days (unless the acquiror agrees to a later date) after the delivery by the acquiror to the corporation of an information statement which sets forth the range of voting power that the acquiror has acquired or proposes to acquire and certain other information concerning the acquiror and the proposed control share acquisition.If no such request for a stockholders meeting is made, consideration of the voting rights of the acquirorâ€™s shares must be taken at the next special or annual stockholders meeting. If the stockholders fail to restore voting rights to the acquiror, or if the acquiror fails to timely deliver an information statement to the corporation, then the corporation may, if so provided in its articles of incorporation or bylaws, call certain of the acquirorâ€™s shares for redemption at the average price paid for the control shares by the acquiror.In the event the stockholders restore full voting rights to a holder of control shares that owns a majority of the voting stock, then all other stockholders who do not vote in favor of restoring voting rights to the control shares may demand payment for the â€œfair valueâ€ of their shares as determined by a court in dissenters rights proceeding pursuant to Chapter 92A of the NRS.Limitation on Liability and Indemnification of Directors and OfficersSection 78.138 of the NRS provides that, unless the corporationâ€™s articles of incorporation provide otherwise, a director or officer will not be individually liable unless the presumption that it is acting in good faith and on an informed basis with a view to the interests of the corporation has been rebutted, and it is proven that (i) the directorâ€™s or officerâ€™s acts or omissions constituted a breach of his or her fiduciary duties, and (ii) such breach involved intentional misconduct, fraud, or a knowing violation of the law.Section 78.7502 of the NRS provides that a corporation may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative, except an action by or in the right of the corporation, by reason of the fact that he is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses, including attorneysâ€™ fees, judgments, fines and amounts paid in settlement actually and reasonably incurred by him in connection with the action, suit or proceeding if he: (a) is not liable pursuant to NRS 78.138; or (b) acted in good faith and in a manner which he reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe his conduct was unlawful. The termination of any action, suit or proceeding by judgment, order, settlement, conviction or upon a plea of nolo contendere or its equivalent, does not, of itself, create a presumption that the person is liable pursuant to NRS 78.138 or did not act in good faith and in a manner which he reasonably believed to be in or not opposed to the best interests of the corporation, or that, with respect to any criminal action or proceeding, he had reasonable cause to believe that his conduct was unlawful.Section 78.7502 of the NRS also provides that a corporation may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action or suit by or in the right of the corporation to procure a judgment in its favor by reason of the fact that he is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against expenses, including amounts paid in settlement and attorneysâ€™ fees actually and reasonably incurred by him in connection with the defense or settlement of the action or suit if he: (a) as not liable pursuant to NRS 78.138; or (b) acted in good faith and in a manner which he reasonably believed to be in or not opposed to the best interests of the corporation. Indemnification may not be made for any claim, issue or matter as to which such a person has been adjudged by a court of competent jurisdiction, after exhaustion of all appeals therefrom, to be liable to the corporation or for amounts paid in settlement to the corporation, unless and only to the extent that the court in which the action or suit was brought or other court of competent jurisdiction determines upon application that in view of all the circumstances of the case, the person is fairly and reasonably entitled to indemnity for such expenses as the court deems proper.Section 78.751 of the NRS provides that to the extent that a director, officer, employee or agent of a corporation has been successful on the merits or otherwise in defense of any action, suit or proceeding referred to above, or in defense of any claim, issue or matter therein, the corporation shall indemnify him against expenses, including attorneysâ€™ fees, actually and reasonably incurred by him in connection with the defense.Unless otherwise restricted by the articles of incorporation, bylaws, or an agreement made by the corporation, Section 78.751 of the NRS permits a Nevada company to indemnify its officers and directors against expenses incurred by them in defending a civil or criminal action, suit, or proceeding as they are incurred and in advance of final disposition thereof upon receipt of an undertaking by or on behalf of the director or officer to repay the amount if it is ultimately determined by a court of competent jurisdiction that the director or officer is not entitled to be indemnified by the corporation. The articles of incorporation, bylaws, or an agreement made by the corporation may require a corporation to advance such expenses upon receipt of such an undertaking. Section 78.751 of the NRS further permits a Nevada company to grant its directors and officers additional rights of indemnification under its articles of incorporation, bylaws, or other agreement; provided, however, that unless advanced or otherwise ordered by a court, indemnification may not be made to or on behalf of any director or officer finally adjudged by a court, after exhaustion of appeals, to be liable for intentional misconduct, fraud, or a knowing violation of law that was material to the cause of action.Section 78.752 of the NRS provides that a Nevada company may purchase and maintain insurance or make other financial arrangements on behalf of any person who is or was a director, officer, employee, or agent of the company, or is or was serving at the request of the company as a director, officer, employee, or agent of another company, partnership, joint venture, trust, or other enterprise, for any liability asserted against him and liability and expenses incurred by him in his capacity as a director, officer, employee, or agent, or arising out of his status as such, whether or not the company has the authority to indemnify him against such liability and expenses.Our Articles of Incorporation provides that an indemnitee shall also have the right to be paid by our company the expenses (including attorneyâ€™s fees) incurred in defending any such proceeding in advance of its final dispositionÍ¾ provided, however, that, if NRS requires, an advancement of expenses incurred by an indemnitee in his capacity as a director or officer (and not in any other capacity in which service was or is rendered by such indemnitee, including, without limitation, service to an employee benefit plan) shall be made only upon delivery to our company of an undertaking, by or on behalf of such indemnitee, to repay all amounts so advanced if it shall ultimately be determined by final judicial decision from which there is no further right to appeal that such indemnitee is not entitled to be indemnified for such expenses or otherwise.In addition, we have entered into indemnification agreements with each of our directors and executive officers. These agreements, among other things, require us to indemnify our directors and executive officers for certain expenses, including attorneysâ€™ fees, judgments and fines incurred by a director or executive officer in any action or proceeding arising out of their services as one of our directors or executive officers or any other company or enterprise to which the person provides services at our request.We maintain a directorsâ€™ and officersâ€™ insurance policy pursuant to which our directors and officers are insured against liability for actions taken in their capacities as directors and officers. We believe these provisions in the Articles of Incorporation and the Bylaws and these indemnification agreements are necessary to attract and retain qualified persons as directors and officers.Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers, or control persons, in the opinion of the United States Securities and Exchange Commission, such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable.Transfer Agent and RegistrarÂ The transfer agent of our Common Stock is Issuer Direct Corporation. Their address is One Glenwood Avenue, SuiteÂ 1001, Raleigh, NC 27306.â€‹Stock Exchange Listingâ€‹Our Common Stock is listed on The Nasdaq Capital Market under the symbol â€œRZLTâ€. EX-10.4 3 rzlt-20240630xex10d4.htm EX-10.4 EMPLOYMENT AGREEMENTThis EMPLOYMENT AGREEMENT (this â€œAgreementâ€) is entered into as of September 18, 2024 (the â€œEffective Dateâ€) by and between Daron Evans, (â€œEmployeeâ€), and Rezolute, Inc. Â (the â€œCompanyâ€). WHEREAS, the Company wishes to continue to employ Employee in accordance with the terms of this Agreement;WHEREAS, Employee wishes to accept continued employment with the Company according to the terms of this Agreement; andWHEREAS, this Agreement shall replace and supersede in its entirety any prior employment agreements or understandings between Employee and the Company including the agreement dated January 23, 2024 (the â€œPrior Agreementâ€).NOW, THEREFORE, in consideration of the mutual covenants contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto, intending to be legally bound, agree as follows:1.Employment. Â The Company hereby continues to employ Employee, and Employee hereby accepts continued employment by the Company, upon the terms and conditions set forth in this Agreement for the period beginning on the Effective Date and ending pursuant to the termination procedures described in SectionÂ 4(a) (the â€œEmployment Periodâ€).2.Position and Duties.(a)During the Employment Period, Employee shall serve as the Chief Financial Officer, and in connection therewith Employee shall render services to the Company and have the responsibilities and authority which are consistent with Employeeâ€™s position, subject to the power and authority of the officers and the Board of Directors of the Company (the â€œBoardâ€) to expand or limit such duties, responsibilities, functions and authority.(b)Employee shall report to the Chief Executive Officer (or such other person as shall be designated by the Board). Â Employee shall perform Employeeâ€™s duties and responsibilities to the best of Employeeâ€™s abilities in a diligent, trustworthy, businesslike and efficient manner Employee shall devote Employeeâ€™s full business time, energies and attention (except for permitted vacation periods and periods of illness or other temporary incapacity) to the business and affairs of the Company. However, Employee may seek approval for external obligations from the Board by disclosing such activities on the Conflict of Interest Disclosure form attached hereto as ExhibitÂ A. Â So long as Employee is employed by the Company, Employee shall not, without the prior written consent of the Board, accept other employment or perform other services for compensation or that interfere with Employeeâ€™s employment with the Company; provided, however, that Employee may serve as an officer or director of or otherwise participate in purely educational, welfare, social, religious and civic organizations so long as such activities are not in competition with the Company or do not interfere with Employeeâ€™s ability to carry out Employeeâ€™s duties under this Agreement.(c)Employee shall comply with all lawful rules, policies, procedures, regulations and administrative directions now or hereafter reasonably established by the Board for employees of the Company.(d)The Company shall have the right to assign Employee new duties and to change Employeeâ€™s title subject to SectionÂ 4 of this Agreement.3.Salary and Benefits.(a)Salary. Â During the Employment Period, the Company shall pay Employee a base salary at the annual rate of $460,000 (effective September 15, 2024), payable in regular installments in accordance with the Companyâ€™s usual payment practices subject to required withholdings and taxes (the â€œSalaryâ€). Â Employee may receive increases in Employeeâ€™s Salary to the extent such an increase is approved in the sole discretion of the Board.(b)Bonus. Â During the Employment Period, Employee will be eligible to receive an annual performance bonus of up to Forty (40%) of Employeeâ€™s base salary (the â€œTarget Bonusâ€). Â Determination of the actual bonus amount shall be based on the Companyâ€™s performance as well as Employeeâ€™s individual performance for the year. Â Employeeâ€™s discretionary bonus, if any, will be earned on December 31st of each calendar year. Â In order to remain eligible to receive an annual performance bonus, Employee must continue to be employed by the Company, in good standing, through the date that the bonus is earned. Notwithstanding anything herein to the contrary, subsequent to the approval of the board of directors, any bonus amount due to Employee will be paid on or before February 15th of the year following the date that the bonus was earned.(c)Benefits. Â During the Employment Period, Employee shall be entitled to paid vacation (to be scheduled at times mutually agreeable to the Employee and to the needs of the business), paid holidays and to participate in all employee benefit plans of the Company, including without limitation all health insurance plans, retirement plans (including 401(k)), life insurance plans and other perquisite plans and programs (collectively, the â€œBenefit Plansâ€) for which employees of Employeeâ€™s rank in the Company are generally eligible, in each case consistent with the Companyâ€™s then-current practice. Â The foregoing shall not be construed to require the Company to establish such Benefit Plans or to prevent the modification or termination of such Benefit Plans once established, and no such action or failure thereof shall affect this Agreement. Â Employee recognizes that the Company and its affiliates have the right, in their sole discretion, to amend, modify or terminate any Benefit Plans without creating any rights in Employee.(d)Business Expenses. Â During the Employment Period, the Company shall reimburse Employee for all reasonable business expenses incurred by Employee in the course of performing Employeeâ€™s duties under this Agreement; provided such expenses are consistent with the Companyâ€™s policies in effect from time to time with respect to travel, entertainment and other business expenses. Â As a condition to being issued such reimbursements, Employee shall submit to the Company on a timely basis business expense reports, including substantiation in accordance with the Companyâ€™s policy as in effect from time to time.â€‹4.Employment Period.2(a)The Employment Period shall begin on the Effective Date and shall continue until Employeeâ€™s employment hereunder is terminated in accordance with SectionÂ 4(b).(b)The Employment Period and Employeeâ€™s employment hereunder (i)Â shall terminate upon Employeeâ€™s death or permanent disability or incapacity, (ii)Â may be terminated by the Company at any time with or without Cause (as defined in SectionÂ 4(g)), and (iii)Â may be terminated by Employee at any time with or without Good Reason (as defined in SectionÂ 4(h)).(c)If Employeeâ€™s employment hereunder is terminated by the Company for Cause or by Employee without Good Reason during the Employment Period, then Employee shall be entitled to receive only Employeeâ€™s accrued, but unpaid Salary through the effective date of Employeeâ€™s termination of employment (the â€œTermination Dateâ€), any reimbursements owed for business expenses validly incurred on or prior to the Termination Date and reimbursable in accordance with SectionÂ 3(d), any earned but unpaid Bonuses or other incentive payments approved by the Board but not paid to Employee as of the Termination Date, and any accrued but unpaid benefits due and owing to Employee under the Benefit Plans (the â€œAccrued Obligationsâ€). Â Board approval of the payment of Bonuses or other incentive payments as part of Accrued Obligations shall be subject to the Companyâ€™s current financial condition as of the Termination Date.(d)If Employeeâ€™s employment hereunder is terminated without Cause by the Company during the Employment Period, then Employee shall be entitled to receive the Accrued Obligations and, provided Employee signs and does not revoke a general release of claims against the Company and its affiliates (through a form of release agreement substantially similar to that attached as Exhibit B, modified as necessary in the Companyâ€™s sole reasonable discretion), and subject to Employeeâ€™s compliance with each obligation pursuant to SectionÂ 5, Employee shall also be entitled to receive severance (â€œSeveranceâ€) comprised of (i) twelve (12)Â monthsâ€™ Salary, (ii) a pro-rata bonus payment equal to the pro-rata bonus amount of the Target Bonus earned as of the date of termination without Cause and (iii) 12 months of Employeeâ€™s COBRA premiums, collectively payable in equal monthly installments following the Termination Date, and any granted but unvested stock options under any relevant Company Stock Option Plan or Agreement will have 12

months of accelerated vesting (meaning that any of Employeeâ€™s granted but unvested stock options that would otherwise vest over the next 12 months after the termination without Cause will immediately vest) and will also have an exercise period of 6 months following Employeeâ€™s termination without Cause. Â The exercise of vested options, including those vested under this Section 4(e), shall otherwise be governed by the applicable Stock Option Plan or Agreement.(e)If, within 12Â months of a Change in Control Event as defined in SectionÂ 4(i), Employeeâ€™s employment hereunder is terminated (i)Â by the Company without Cause or (ii)Â by Employee with Good Reason, then Employee shall be entitled to receive the Accrued Obligations and, provided Employee signs and does not revoke a general release of claims against the Company and its affiliates (through a form of release agreement substantially similar to that attached as Exhibit B, modified as necessary in the Companyâ€™s sole reasonable discretion), and subject to Employeeâ€™s compliance with each post-employment obligation under this Agreement, Employee shall also be entitled to receive severance (â€œSeveranceâ€) comprised of (i) 18Â monthsâ€™ Salary, (ii) a pro-rata bonus payment equal to the pro-rata bonus amount earned as of the date of termination 3without Cause and (iii) 18 months of Employeeâ€™s COBRA premiums, collectively payable in equal monthly installments following the Termination Date, and all of Employeeâ€™s granted but unvested stock options under any relevant Company Stock Option Plan or Agreement will immediately vest and will also have an exercise period of 6 months following Employeeâ€™s termination without Cause, Â provided that before the Employee may terminate employment for Good Reason, the Company must fail to cure within the thirty day period provided in SectionÂ 4(h). Â The exercise of vested options, including those vested under this SectionÂ 4(e), shall be governed by the applicable Stock Option Plan or Agreement.(f)If Employeeâ€™s employment hereunder is terminated as a result of Employeeâ€™s death, permanent disability or incapacity during the Employment Period, Employee or Employeeâ€™s representatives or beneficiaries shall be entitled to receive only the Accrued Obligations and any rights to continuation of coverage and to benefits under any Benefit Plans required under applicable law.(g)For purposes of the Agreement, â€œCauseâ€ shall mean Employeeâ€™s (i)Â commission or conviction of or entering a guilty plea or plea of no contest to any felony or any crime involving moral turpitude, dishonesty, fraud, misrepresentation, embezzlement, theft or sexual harassment, (ii)Â failure to perform the duties required of Employee by this Agreement, (iii)Â breach of this Agreement (or any other agreement entered into between Employee and the Company), (iv)Â dishonesty, fraud or misconduct with respect to the business or affairs of the Company or its affiliates, or any act of embezzlement or other misappropriation, (v)Â participation in any fraud or dishonesty against or affecting the Company or any subsidiary, affiliate, customer, supplier, client, agent, or employee thereof, (vi)Â breach of any fiduciary or similar duty owned to the Company or its affiliates, (vii)Â refusal to carry out the legitimate directives or instructions of the Board (or such other person to whom Employee reports as may be designated from time to time by the Board), or (viii)Â other act that the Company reasonably determines constitutes misconduct materially detrimental to the Company or any subsidiary, affiliate, customer, supplier, client, agent, or employee thereof, including, but not limited to, unethical practices, dishonesty, disloyalty, or any other acts harmful to the Company.(h)For purposes of this Agreement, â€œGood Reasonâ€ shall mean Employeeâ€™s resignation following the initial occurrence (without Employeeâ€™s consent) of any of the following, provided Employee has provided the Company with written notice setting forth in reasonable detail the grounds for such resignation within 15Â days following such initial occurrence, and provided further the Company has failed to remedy the stated grounds for such resignation within 30Â days following its receipt of such notice: Â (i)Â the Company substantially reduces Employeeâ€™s duties, authority or responsibilities; (ii)Â the Company substantially reduces the aggregate value of Employeeâ€™s Salary or the benefits provided to Employee under the Benefit Plans; (iii)Â the Company requires that the Employee be based at any office or geographic location more than 75 miles from the Employeeâ€™s primary work location; or (iv)Â any other action or inaction that constitutes a material breach of this Agreement by the Company. Â A resignation with Good Reason may occur only within 60Â days following the expiration of the Companyâ€™s 30Â day cure period described above.(i)For purposes of this Agreement, â€œChange in Control Eventâ€ shall mean either the following: Â (i)Â sale of substantially all the Companyâ€™s assets or (ii)Â merger, consolidation 4or reorganization resulting in a change in more than 50% of the board of directors combined with a transfer of majority ownership or equity of the Company.(j)For purposes of this Agreement, Employeeâ€™s permanent disability or incapacity shall be determined in accordance with the Companyâ€™s long-term disability insurance policy, if such a policy is then in effect, or, if no such policy is then in effect, then such permanent disability or incapacity shall be deemed to have occurred upon Employeeâ€™s inability to perform the essential functions of the position set forth in SectionÂ 2(a), after reasonable accommodation by the Company, for a period of at least 180 days, in the aggregate, during any period of 365 calendar days, unless further time is required as a reasonable accommodation under the Americans with Disabilities Act.5.Confidentiality.(a)Employee will not at any time (whether during or after Employeeâ€™s employment with the Company) (x)Â retain or use for the benefit, purposes or account of Employee or any other person; or (y)Â disclose, divulge, reveal, communicate, share, transfer or provide access to any person outside the Company (other than its professional advisers who are bound by confidentiality obligations), any non-public, proprietary or confidential information including without limitation trade secrets, know-how, research and development, software, databases, inventions, processes, formulae, technology, designs and other intellectual property, information concerning finances, investments, profits, pricing, costs, products, services, vendors, customers, clients, partners, investors, personnel, compensation, recruiting, training, advertising, sales, marketing, promotions, government and regulatory activities and approvals-concerning the past, current or future business, activities and operations of the Company, its subsidiaries or affiliates and/or any third party that has disclosed or provided any of same to the Company on a confidential basis (â€œConfidential Informationâ€) without the prior written authorization of the Board; provided, that Employee may disclose such information to Employeeâ€™s legal and/or financial advisor for the limited purpose of enforcing Employeeâ€™s rights under this Agreement so long as Employee requires that such legal and/or financial advisors not disclose such information and Employee shall be liable for any disclosure by such legal and/or financial advisors.(b)Confidential Information shall not include any information that is: Â (i)Â generally known to the industry or the public other than as a result of Employeeâ€™s breach of this covenant or any breach of other confidentiality obligations by third parties; (ii)Â made legitimately available to Employee by a third party without breach of any confidentiality obligation; or (iii)Â required by applicable law to be disclosed; provided that Employee shall give prompt written notice to the Company of such requirement, disclose no more information than is so required, and cooperate with any attempts by the Company to obtain a protective order or similar treatment.(c)Employee acknowledges, agrees, and understands that (1)Â nothing in this Agreement prohibits Employee from reporting to any governmental authority or attorney information concerning suspected violations of law or regulation, provided that Employee does so consistent with 18 U.S.C. 1833, and (2)Â Employee may disclose trade secret information to a government official or to an attorney and use it in certain court proceedings without fear of prosecution or liability, provided that Employee does so consistent with 18 U.S.C. 1833.5(d)Except as required by applicable law, Employee will not disclose to anyone, other than Employeeâ€™s spouse, legal or financial advisors or members of the Companyâ€™s senior management, the existence or contents of this Agreement.(e)Upon termination of Employeeâ€™s employment with the Company for any reason, Employee shall: Â (x)Â cease and not thereafter commence use of any Confidential Information or intellectual property (including, without limitation, any patent, invention, copyright, trade secret, trademark, trade name, logo, domain name or other source indicator) owned or used by the Company, its subsidiaries or affiliates; (y)Â immediately return to the Company, at the Companyâ€™s option, all originals and copies in any form or medium (including memoranda, books, papers, plans, computer files, letters and other data) in Employeeâ€™s possession or control (including any of the foregoing stored or located in Employeeâ€™s office, home, laptop or other computer, whether or not Company property) that contain Confidential Information or otherwise relate to the business of the Company, its affiliates and subsidiaries, except that Employee may retain only those portions of any personal notes, notebooks and diaries that do not contain any Confidential Information or are not related to the Companyâ€™s business; and (z)Â notify and fully cooperate with the Company regarding the delivery of any other Confidential Information of which Employee is or becomes aware.6.Intellectual Property.(a)If Employee has created, invented, designed, developed, contributed to or improved any works of authorship, inventions, intellectual property, materials, documents or other work product (including, without limitation, research, reports, software, databases, systems, applications, presentations, textual works, content or audiovisual materials) (â€œWorksâ€), either alone or with third parties, prior to execution of this Agreement, that are relevant to or implicated by this employment (â€œPrior Worksâ€), Employee hereby grants the Company a perpetual, non exclusive, royalty-free, worldwide, assignable, sub-licensable license under all rights and intellectual property rights (including rights under patent, industrial property, copyright, trademark, trade secret, unfair competition and related laws) therein for all purposes in connection with the Companyâ€™s current and future business. Â Employee shall provide the Company with a list of all Prior Works within 15Â days of the Effective Date.(b)If Employee creates, invents, designs, develops, contributes to or improves any Works, either alone or with third parties, at any time during Employeeâ€™s employment by the Company and within the scope of such employment and/or with the use of any Company resources (â€œCompany Worksâ€), Employee shall promptly and fully disclose the same to the Company and hereby irrevocably assigns, transfers and conveys, to the maximum extent permitted by applicable law, all rights and intellectual property rights therein (including rights under patent, industrial property, copyright, trademark, trade secret, unfair competition and related laws) to the Company to the extent ownership of any such rights does not vest originally in the Company.(c)Employee agrees to keep and maintain adequate and current written records (in the form of notes, sketches, drawings and any other form or media requested by the Company) of all Company Works. Â The records will be available to and remain the sole property and intellectual property of the Company at all times.6(d)Employee shall take all requested actions and execute all requested documents (including any licenses or assignments required by a government contract) at the Companyâ€™s expense (but without further remuneration) to assist the Company in validating, maintaining, protecting, enforcing, perfecting, recording, patenting or registering any of the Companyâ€™s rights in the Prior Works and Company Works. Â If the Company is unable for any other reason to secure Employeeâ€™s signature on any document for this purpose, then Employee hereby irrevocably designates and appoints the Company and its duly authorized officers and agents as Employeeâ€™s agent and attorney in fact, to act for and in Employeeâ€™s behalf and stead to execute any documents and to do all other lawfully permitted acts in connection with the foregoing.(e)Employee shall not improperly use for the benefit of, bring to any premises of, divulge, disclose, communicate, reveal, transfer or provide access to, or share with the Company any confidential, proprietary or non-public information or intellectual property relating to a former employer or other third party without prior written permission of such third party. Â Employee shall comply with all relevant policies and guidelines of the Company regarding the protection of confidential information and intellectual property and potential conflicts of interest. Â Employee acknowledges that the Company may amend any such policies and guidelines from time to time, and that Employee remains at all times bound by their most current version that has been communicated to Employee.(f)In accordance with SectionsÂ 2870 and 2872 of the California Labor Code, this SectionÂ 6 does not require Employee to assign or offer to assign to the Company any Works that Employee developed entirely on his or her own time without using the Companyâ€™s equipment, supplies, facilities or trade secret information, except for those inventions that either (i)Â relate at the time of conception or reduction to practice of the invention to the Companyâ€™s business, or actual or demonstrably anticipated research or development of the Company, or (ii)Â result from any work performed by Employee for the Company. Â To the extent a provision in this Agreement purports to require Employee to assign any Works otherwise excluded from being required to be assigned pursuant to this SectionÂ 6(f), the provision is against the public policy of the State of California and is unenforceable. Â Employee bears the burden of proving that any Works created by Employee should be excluded pursuant to this SectionÂ 6(f).7.Enforcement. Â If, at the time of enforcement of SectionÂ 5 or SectionÂ 6, a court holds that the restrictions stated herein are unreasonable under circumstances then existing, the parties hereto agree that the maximum period or scope reasonable under such circumstances shall be substituted for the stated period or scope. Â It is specifically understood and agreed that any breach of the provisions of SectionÂ 5 or SectionÂ 6 are likely to result in irreparable injury to the Company and the parties hereto agree that money damages would be an inadequate remedy for any such breach. Â Therefore, in the event of a breach or threatened breach of SectionÂ 5 or SectionÂ 6, the Company or its successors or assigns shall, in addition to other rights and remedies existing in their favor, be entitled to specific performance and/or injunctive or other relief in order to enforce, or prevent any violations of, SectionÂ 5 or SectionÂ 6.8.Return of Company Property. Â At the termination of the Employment Period and at any other time upon the request of the Company, Employee shall deliver to the Company any and all of the Companyâ€™s documents, plans, records, computer tapes, software, drawings, notes, memoranda, specifications, devices (including, without limitation, any cellular phone or 7computer), and formulas relating to the Companyâ€™s business, together with all copies thereof, which is in the possession of Employee.9.Successors and Assigns. Â This Agreement shall bind and inure to the benefit of and be enforceable by Employee and the Company and their respective heirs, successors and permitted assigns. Â Neither party may assign any of its rights or assign or delegate any of its obligations hereunder without the prior written consent of the other party hereto; provided, however, that the Company shall be permitted to assign this Agreement to any successor to all or substantially all of its assets that agrees in writing to assume all of the Companyâ€™s obligations hereunder.10.Notices. Â All notices, demands or other communications to be given or delivered under or by reason of the provisions of this Agreement shall be in writing and shall be deemed to have been given (a)Â on the date established by the sender as having been delivered personally, (b)Â on the date delivered by a private courier as established by the sender by evidence obtained from such courier, (c)Â on the date sent by facsimile or e-mail transmission (with acknowledgement of complete transmission), or (d)Â on the fifth day after the date mailed, by certified or registered mail, return receipt requested, postage prepaid. Â Notices, demands or communications to any party hereto will, unless another address is specified in writing pursuant to this SectionÂ 10, be sent to the addresses on file with the Company.11.Severability. Â Whenever possible, each provision of this Agreement will be interpreted in such manner as to be valid under applicable law; but, if any provision of this Agreement is held to be invalid, illegal or unenforceable in any respect under any applicable law or rule in any jurisdiction, such invalidity, illegality or unenforceability will not affect any other provision or any other jurisdiction, but except as otherwise set forth in this Agreement, this Agreement will be reformed, construed and enforced in such jurisdiction as if such invalid, illegal or unenforceable provision had never been contained herein.12.Complete Agreement. Â This Agreement embodies the complete agreement and understanding between the parties with respect to Employeeâ€™s employment with the Company and supersedes and preempts any prior understandings, agreements or representations by or among the parties, written or oral, which may have related to Employeeâ€™s employment with the Company in any way, excluding any Prior Agreement as defined above.13.Signatures; Counterparts. Â This Agreement may be executed in one or more counterparts, each of which will be deemed an original but all of which together will constitute one and the same instrument. Â For purposes hereof, a facsimile signature, portable document format (.pdf) signature or signature sent by electronic transmission will be considered an original signature.14.Governing Law. Â All issues and questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed by, and construed in accordance with, the internal laws of the State of California, without giving effect to any choice of law or conflict of law rules or provisions (whether of the State of California or any other jurisdiction).815.Survival. Â The provisions of SectionÂ 5, SectionÂ 6, SectionÂ 7, SectionÂ 8, SectionÂ 9, SectionÂ 10, SectionÂ 11, SectionÂ 12, SectionÂ 14, this SectionÂ 15, SectionÂ 17, SectionÂ 18, SectionÂ 20, SectionÂ 21, and SectionÂ 22 shall survive the termination of Employeeâ€™s employment and the termination of this Agreement for any reason.16.Tax Withholdings. Â The Company shall deduct or withhold from any amounts owing from the Company to Employee any federal, state, local or foreign withholding taxes, excise tax, or employment taxes imposed with respect to Employeeâ€™s compensation or other payments from the Company or Employeeâ€™s ownership interest in the Company, if any (including, without limitation, wages, bonuses, dividends, the receipt or exercise of equity options and/or the receipt or vesting of restricted equity).17.Headings; No Strict Construction. Â The headings of the paragraphs and sections of this Agreement are inserted for convenience only and shall not be deemed a part of or affect the construction or interpretation of any provision hereof. Â The language used in this Agreement shall be deemed to be the language chosen by the parties hereto to express their mutual intent, and no rule of strict construction shall be applied against any party.18.Employeeâ€™s Cooperation. Â During the Employment Period and thereafter, Employee shall, subject to the Company reimbursing Employee for out-of-pocket expenses, cooperate with the Company in any internal investigation or administrative, regulatory or judicial proceeding as reasonably requested by the Company (including, without limitation, Employee being available to the Company upon reasonable notice for interviews and factual investigations, appearing at the Companyâ€™s request to give testimony without requiring service of a subpoena or other legal process, volunteering to the Company all pertinent information and turning over to the Company all relevant documents which are or may come into Employeeâ€™s possession, all at times and on schedules that are reasonably consistent with Employeeâ€™s other permitted activities and commitments).19.Corporate Opportunity. Â During the Employment Period, Employee shall submit to the Board all business, commercial and investment opportunities or offers presented to Employee or of which Employee becomes aware which relate to the business of the Company at any time during the Employment Period (â€œCorporate Opportunitiesâ€). Â Unless approved by the Board, Employee shall not accept or pursue, directly or indirectly, any Corporate Opportunities on Employeeâ€™s own behalf.20.SectionÂ 409A Compliance. Â The intent of the parties is that payments and benefits under this Agreement comply with SectionÂ 409A of the Internal Revenue Code of 1986, as amended, and the regulations and guidance promulgated thereunder (collectively, â€œCode SectionÂ 409Aâ€) and, accordingly, to the maximum extent permitted, this

Agreement shall be interpreted to be in compliance therewith. Â To the extent that any provision hereof is modified in order to comply with Code SectionÂ 409A, such modification shall be made in good faith and shall, to the maximum extent reasonably possible, maintain the original intent and economic benefit to Employee and the Company of the applicable provision without violating the provisions of Code SectionÂ 409A. In no event whatsoever shall the Company be liable for any additional tax, interest or penalty that may be imposed on Employee by Code SectionÂ 409A or damages for failing to comply with Code SectionÂ 409A. Â Notwithstanding anything herein to the contrary, a termination 9of employment shall be deemed to have occurred at the time such termination constitutes a â€œseparation from serviceâ€ within the meaning of Code SectionÂ 409A for purposes of any provision of this Agreement providing for the payment of any amounts or benefits in connection with a termination of employment and, for purposes of any such provision of this Agreement, references to a â€œtermination,â€ â€œtermination of employmentâ€ or like terms shall mean a â€œseparation from service.â€ Â Notwithstanding any other provision to the contrary, in no event shall any payment under this Agreement that constitutes â€œdeferred compensationâ€ for purposes of Code SectionÂ 409A be subject to offset by any other amount unless otherwise permitted by Code SectionÂ 409A.21.Amendment and Waiver. Â The provisions of this Agreement may be amended or waived only with the prior written consent of the Company and Employee, and no course of conduct or failure or delay in enforcing the provisions of this Agreement shall affect the validity, binding effect or enforceability of this Agreement.22.Read and Understood. Employee has read this Agreement carefully and understands each of its terms and conditions. Â Employee has sought independent legal counsel of Employeeâ€™s choice to the extent Employee deemed such advice necessary in connection with the review and execution of this Agreement.IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first written above.The Company:Rezolute, Inc.By: â€‹ â€‹Nevan ElamCEOEmployee:â€‹ â€‹â€‹Daron Evansâ€‹10EXHIBITÂ ACONFLICT OF INTERESTACKNOWLEDGEMENT/DISCLOSURE FORM1CONFLICTING ORGANIZATIONSI am a director, trustee, officer, representative of, or have a financial or beneficial interest in the following organizations that have or may have a conflict with the interests of the Company:Organization and Title or Interest:â€ŒÂ â€‹â€ŒÂ â€‹2CONFLICTING ACTIVITIES/OBLIGATIONSI am involved in no activity or transaction, nor am I a party to any contract involving interests that are or could be found to be adverse to the Company, except for the following:â€ŒÂ â€‹â€ŒÂ â€‹3CONFLICTING BUSINESS OPPORTUNITIES/COMMITMENTSI have not committed to, nor am I pursuing, any business opportunity that does or might adversely affect the Company, except for the following:â€ŒÂ â€‹â€ŒÂ â€‹4OTHER POTENTIAL CONFLICTSAny other concerns I may have regarding actual or potential conflicts of interest are listed below:â€ŒÂ â€‹â€ŒÂ â€‹To the best of my knowledge, I have accurately answered the above questions.â€ŒÂ â€‹Signatureâ€‹â€ŒÂ â€‹Dateâ€‹11EXHIBIT BSEPARATION AGREEMENT AND GENERAL RELEASE OF CLAIMSThis is a Separation Agreement and General Release of Claims (â€œAgreementâ€) dated as of [INSERT DATE] between Rezolute, Inc. (the â€œCompanyâ€), and Daron Evans (â€œEmployeeâ€). Â Employee and the Company are referenced together herein as the â€œParties.â€RECITALSA.WHEREAS, Employeeâ€™s employment or other relationships with any of the Company Releasees (as defined below) will separate effective [INSERT DATE] (â€œSeparation Dateâ€). B.Though this Agreement, Employee and Company mutually desire to settle all claims Employee has or might have against the Company through the date of execution hereof, including but not limited to those arising out of or relating to Employeeâ€™s prior service to the Company, and/or any Company Releasee, and/or the termination thereof.TERMS AND SETTLEMENT1.Effective Date. Â This Agreement shall become effective eight (8) days after the later of a) the Separation Date, or b) the date of signature date of this Agreement, if signed after the Separation date (â€œEffective Dateâ€).2.No Admission of Liability. Â None of the Parties, by entering into and fulfilling this Agreement, admit to any wrongdoing or liability, and each party denies any allegation of wrongdoing. Â The Parties intend, by their actions pursuant to this Agreement, merely to avoid the expense, delay, uncertainty, and burden of potential litigation.3.Consideration by the Company. Â In consideration for Employeeâ€™s promises made herein, the Company agrees to the following, which Employee acknowledges and agrees is full and adequate consideration for Employeeâ€™s execution of this Agreement:3.1.Severance. Â Provided that Employee meets all of Employeeâ€™s promises and obligations under this Agreement, including signing, and not revoking, the release of claims under the ADEA, the Company will pay Employee the gross amount of $[INSERT AMOUNT OF SEVERANCE], less all applicable withholdings and deductions, which amount shall be paid to Employee in 12 equal monthly payments of $[INSERT AMOUNT], less applicable taxes and withholding beginning on the first regular payroll date after the Effective Date. Furthermore, [INSERT APPROPRIATE STOCK VESTING TERMS]. Employee agrees and acknowledges that Employee would have no right to the severance benefits provided by this Agreement but for Employeeâ€™s execution and compliance with the terms of this Agreement, and that such severance includes all severance due and owing to Employee under the terms of Employeeâ€™s [INSERT DATE] Amended and Restated Employment Agreement.124.Entire Consideration. Â Employee agrees that the consideration set forth in Paragraph 3 and its subparts shall constitute the entire consideration provided in return for Employeeâ€™s promises and agreements herein, and that Employee will not seek any further remuneration or payment from the Company for wage, damage, interest, penalty, expense, action, attorneysâ€™ fees or cost, either individually or as part of a class, in connection with the matters encompassed by the Agreement and/or arising out of Employeeâ€™s services to the Company and/or the termination thereof. Â 5.Taxes. Â Employee shall pay in full and be solely responsible for all taxes, interest or penalties relating to the consideration, and agrees to indemnify the Company against any assessment, and is not relying on any representations by the Company on this subject matter.6.Return of the Companyâ€™s Property. Â Employee represents that as of the Separation Date, Employee has returned any and all confidential and/or proprietary information of the Company (including but not limited to those of its clients and prospective clients) and other property of the Company in Employeeâ€™s possession. Â Such property includes, but is not limited to, all tangible and intangible property belonging to the Company and relating to Employeeâ€™s services to the Company, including computer/network password(s). Â By executing this Agreement, Employee represents and warrants that Employee has not retained any copies, electronic or otherwise, of such property.7.Payment of Salary. Â Employee acknowledges and represents that the Company has paid all salary, wages, bonuses, accrued vacation/paid time off, housing allowances, relocation costs, interest, severance, outplacement costs, fees, stock, stock options, vesting, commissions and any and all other benefits and compensation due to Employee, provided that the foregoing shall not relieve the Company of its obligation to pay Employeeâ€™s earned and unpaid salary through the Separation Date. Â Such amounts are not consideration for this Agreement.8.Release of Claims. Â In consideration for the promises set forth in this Agreement, Employee does hereby â€” for Employee and for Employeeâ€™s heirs, spouse, representatives, attorneys, executors, administrators, successors, relatives and assigns â€” release the Company and all of its current and former corporate subsidiaries, brother/sister companies, affiliates, partners, predecessors, successors and assigns, and all of their current and former owners, directors, officers, supervisors or managers, employees, agents, representatives, and attorneys and all persons acting under, by, through, or in concert with any of them (collectively â€œCompany Releaseesâ€), from any and all claims, debts, liabilities, demands, obligations, liens, promises, acts, agreements, costs and expenses Â (including but not limited to attorneysâ€™ fees), damages, of whatever kind or nature, including but not limited to any statutory, civil, administrative, or common law claims, whether known or unknown, suspected or unsuspected, fixed or contingent, apparent or concealed, arising out of any act or omission occurring before the Effective Date of this Agreement, including but not limited to any claims based on, arising out of, or related to Employeeâ€™s employment with Company or the termination thereof, any claims for any alleged physical or emotional injuries, and/or any claims arising from rights under federal, state, and/or local laws relating to the regulation of federal or state tax payments or accounting; federal, state or local laws that prohibit harassment, discrimination or retaliation on the basis of race, national origin, age, religion, sex, gender, age, marital status, bankruptcy status, disability, perceived disability, ancestry, sexual orientation, family and medical leave, or any other form of harassment, discrimination, or retaliation; statutory or common law claims of any kind, including but not limited to:13a.Title VII of the Civil Rights Act of 1964, the Americans with Disability Act of 1990, as amended, the California Family Rights Act (Cal. Govt. Code Â§ 12945.2 et seq.), the California Fair Employment and Housing Act (Cal. Govt. Code Â§ 12900 et. seq.);b.California Labor Code, including for penalties under Labor Code Â§ 2699, et. seq., and the Fair Labor Standards Act, the Employee Retirement Income Security Act of 1971, as amended; c.Any statutory provision regarding retaliation/discrimination including retaliation prohibited by Labor Code ÂsÂ§ 1102.5, 232.5, and 132(a), the Occupational Safety and Health Act, as amended, the Sarbanes-Oxley Act of 2002; d.Contract, tort, and property rights, breach of contract, breach of implied-in-fact contract, breach of the implied covenant of good faith and fair dealing, tortious interference with contract or current or prospective economic advantage, fraud, deceit, invasion of privacy, unfair competition, misrepresentation, defamation, wrongful termination, tortious infliction of emotional distress (whether intentional or negligent), breach of fiduciary duty, violation of public policy, or any other common law claim of any kind whatsoever; any claim for damages or declaratory or injunctive relief of any kind; e.The federal Fair Credit Reporting Act and California Investigative Consumer Reporting Agencies Act;f.Any common law claims whatsoever, claims for equity, stock options or any other benefits; and g.Any amounts allegedly due as wages, benefits, penalties or damages as a result of the employment relationship. Nothing in this Agreement shall be construed to prohibit Employee from filing a charge or complaint, including a challenge to the validity of the waiver provision of this Agreement, with a government agency, including the National Labor Relations Board or the Equal Employment Opportunity Commission. Â However, Employee agrees he or she is waiving the right to monetary damages or other equitable or monetary relief as a result of such proceedings. Â Nothing in this agreement prohibits Employee from seeking a whistleblower award pursuant to Section 21F of the Securities Exchange Act. 9.No Workerâ€™s Compensation Pending. Â Employee expressly represents and warrants that Employee has not suffered any workplace injury during Employeeâ€™s performance of services for the Company, and has not filed, and has no intention of filing and/or pursuing any claim for workersâ€™ compensation benefits against the Company. Â The Company expressly relies on Employeeâ€™s representation as a material inducement to enter into this Agreement.1410.Civil Code Section 1542. Â In furtherance of this settlement, Employee expressly waives any rights Employee may have under California Civil Code Section 1542, or other stateâ€™s similar statutes. Â Section 1542 provides:A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS THAT THE CREDITOR OR RELEASING PARTY DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE AND THAT, IF KNOWN BY HIM OR HER, WOULD HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR OR RELEASED PARTY.11.ADEA Release. Â Employee specifically agrees and acknowledges: a.That Employeeâ€™s waiver of rights under this Agreement includes a release of all claims relating to Employeeâ€™s age and is knowing and voluntary as required under the Age Discrimination in Employment Act, 29 U.S.C. Â§ 621 et seq. ("ADEA") and the Older Workers Benefit Protection Act ("OWPA");b.That Employee understands the terms of this Agreement; c.That Employee has been advised to consult with an attorney prior to executing this Agreement; d.That Employeeâ€™s waiver under this Agreement is in exchange for consideration which Employee is not otherwise entitled to;e.That the Company has given Employee a period of up to twenty-one (21) days within which to consider this Agreement; f.That, following Employeeâ€™s execution of this Agreement, Employee has seven (7) days in which to revoke Employeeâ€™s agreement to this Agreement by notifying the Company in writing and that, if Employee chooses not to so revoke, the Agreement shall then become effective and enforceable and the payment listed above shall then be made to Employee in accordance with the terms of this Agreement; g.This Agreement does not release ADEA and OWPA claims occurring after the date of signing.12.No Filings and Covenant Not to Sue. Â A â€œcovenant not to sueâ€ is a legal term that means a person promises not to file a lawsuit or other legal proceeding. Â It is different from the release of claims contained above. Â Besides waiving and releasing the claims above, Employee promises never to file or prosecute any legal claim of any kind against any of the Company Releasees identified in Paragraph 8 in any forum for any reason based on any act, omission, event, occurrence, or nonoccurrence, from the beginning of time to the Effective Date, including but not limited to claims, laws or theories covered by the General Release. Â Excluded from this covenant not to sue (which means that Employee still may file certain charges) is the right to file charges with, or assist/participate in an investigation conducted by, any agency that expressly prohibits 15waiver of such rights, such as the U.S. Equal Employment Opportunity Commission. Â Employee understands and agrees that Employee is waiving, however, any right to monetary recovery, including but not limited to compensatory or punitive damages, attorneysâ€™ fees or costs, or other damages or recovery should such an agency, or any other person, entity or group, pursue any claim on Employeeâ€™s behalf. Â Employee represents that, as of the date Employee executes this Agreement, Employee has not filed or caused to be filed any claims against any of the Company Releasees. Â Nothing in this agreement prohibits Employee from seeking a whistleblower award pursuant to Section 21F of the Securities Exchange Act.13.Confidentiality. Â Employee agrees that Employee will not disclose the terms of this Agreement to any individual or entity, except to Employeeâ€™s spouse, attorney, tax consultant, accountant, state and federal tax authorities, or as required by law. Employee also agrees to abide by the continuing obligations in any confidentiality, nondisclosure, or arbitration agreements executed during his or her employment, and specifically agrees to hold in the strictest confidence, and not to use or to disclose, to any person, firm or corporation, any non-public information that relates to the actual or anticipated business, research or development of the Company, or to the Companyâ€™s technical data, trade secrets or know-how, including, but not limited to, research, product plans or other information regarding the Companyâ€™s products or services and markets therefor, customer lists and customers, suppliers and vendors, software, developments, inventions, processes, formulas, technology, prototypes, designs, sketches, drawings, engineering, hardware configuration information, marketing plans, finances, pilot projects, and other business information (â€œCompany Confidential Informationâ€). Â Company Confidential Information does not include any of the foregoing items to the extent the same have become publicly known and made generally available through no wrongful act of Employee or others. Notwithstanding any other provision in this Agreement, nothing in this agreement prevents Employee from discussing or disclosing information about unlawful acts in the workplace, such as harassment or discrimination or any other conduct that you have reason to believe is unlawful.14.Cooperation. Â Employee agrees to reasonably cooperate with the Companyâ€™s reasonable requests for information after the Separation Date (including in connection with any pending litigation, arbitration, or other legal dispute which may relate to Employeeâ€™s job duties or tasks during his employment). Â The Company will only make such requests when it deems necessary, and when the information sought is not otherwise available within the Company.15.No Attorneysâ€™ Fees and Costs. The Parties agree that they shall bear their own respective costs and fees, including attorneysâ€™ fees, in the negotiation and execution of this Agreement. Â 16.Full and Independent Knowledge. Â The Parties represent that they have thoroughly discussed all aspects of this Agreement with their respective attorneys (or have been provided the right to do so), fully understand all of the provisions of the Agreement, and are voluntarily and knowingly entering into this Agreement.17.Ownership of Actions. Â Employee has not transferred or assigned, or purported to transfer or assign, to any person or entity, any action described in this Agreement. Â Employee further agrees to indemnify and hold harmless each and all of the Company Releasees against any and all actions based upon, arising out of, or in any way connected with any such actual or purported transfer or assignment.1618.Governing Law. Â This Agreement shall be governed by and interpreted under the laws of the State of California applicable to contracts made and to be performed entirely within California.19.Severability. Â Should any provision in this Agreement be determined to be invalid, the validity of the remaining provisions shall not be affected thereby, and the invalid provision shall be deemed not to be part of this Agreement, and all remaining provisions shall remain valid and enforceable.20.Entire Agreement. Â This Agreement sets forth the entire agreement between the Parties and supersedes any prior agreements between the Parties pertaining to the subject matter of this Agreement.21.No Representations. Â The Parties acknowledge that, except as expressly set forth herein, no representations of any kind or character have been made by any other Party or that Partyâ€™s agents, representatives, or attorneys to induce the execution of this Agreement. Â It is further understood and agreed that Employee has not relied upon any advice whatsoever from the Company or its counsel.22.No Modification or Waiver. Â No modification or waiver of the terms of this Agreement shall be effective unless it appears in a writing signed by all Parties to this Agreement. Â 23.Interpretation of Agreement. Â The language of all parts in this Agreement shall be construed as a whole, according to fair meaning, and not strictly for or against any party. Â The headings provided in underline are inserted for the convenience of the Parties and shall not be construed to limit or modify the text of this Agreement.24.Successors. Â This Agreement shall be binding upon the Parties, and their heirs, representatives, executors, administrators, successors, and assigns, and shall inure to the benefit of each and all of the Company Releasees, and to their heirs, representatives, executors, administrators, successors, and assignees.25.Counterparts. Â This Agreement may be executed in one or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Â Furthermore, signatures delivered via facsimile transmission or portable document format (PDF) shall have the same force effect as the originals thereof, except that any Party has the right to insist on receipt of the original signature of the other Party before complying with its own obligations under this Agreement.1726.Notification. Â Notice to be given under this Agreement shall be sent to the Company care of Human Resources and to Employee at the addresses listed on the signature page hereto.THE UNDERSIGNED STATE THAT THEY HAVE CAREFULLY READ THE AGREEMENT, HAVE BEEN ADVISED OF THEIR RIGHT TO CONSULT WITH COUNSEL CONCERNING THIS AGREEMENT, AND KNOW AND UNDERSTAND ITS CONTENTS.AGREEING PARTIESâ€‹Dated: _____â€‹ â€‹Daron EvansAddress:â€‹ â€‹â€‹ â€‹â€‹Dated: _____Rezolute, Inc. â€‹Sign:â€‹ â€‹ [COMPANY SIGNATORY]18 EX-10.36 4 rzlt-20240630xex10d36.htm EX-10.36 SECURITIES PURCHASE AGREEMENTTHIS SECURITIES PURCHASE AGREEMENT (this â€œAgreementâ€) is made as of June 27, 2024, by and among Rezolute, Inc., a Nevada corporation (the â€œCompanyâ€), and each of those persons and entities,

severally and not jointly, identified as a Purchaser on the Schedule of Purchasers attached as Exhibit A hereto (the â€œSchedule of Purchasersâ€). Such persons and entities together with their permitted successors and assigns, are referred to collectively as the â€œPurchasersâ€ and each individually as a â€œPurchaserâ€. The Company and the Purchasers may each be referred to herein individually as a â€œPartyâ€ and collectively as the â€œParties.â€RECITALSA.The Parties are executing and delivering this Agreement in reliance upon the exemption from securities registration afforded by Section 4(a)(2) of the Securities Act of 1933, as amended (the â€œSecurities Actâ€) and the provisions of Regulation D (â€œRegulation Dâ€) or other applicable exemptions from registration, as promulgated by the U.S. Securities and Exchange Commission (the â€œSECâ€) under the Securities Act.B.The Purchasers wish to purchase, severally but not jointly, from the Company, and the Company wishes to sell and issue to the Purchasers, upon the terms and conditions stated in this Agreement, 1,250,000 shares of the Companyâ€™s common stock, par value $0.001 per share (the â€œCommon Stockâ€) for an aggregate purchase price of $5,000,000 (the â€œSharesâ€), with Jefferies LLC and Cantor Fitzgerald & Co. acting as placement agents (the â€œPlacement Agentsâ€)C.Contemporaneously with the execution and delivery of this Agreement, the Parties will execute and deliver a Registration Rights Agreement, in the form attached hereto as Exhibit B (the â€œRegistration Rights Agreementâ€), pursuant to which the Company agrees to provide certain registration rights with respect to the Shares under the Securities Act and applicable state securities Laws.In consideration of the mutual promises made herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows:1.Definitions. In addition to those terms defined elsewhere in this Agreement, for the purposes of this Agreement, the following terms shall have the meanings set forth below:â€œAffiliateâ€ means, with respect to any Person, any other Person directly or indirectly controlled by, controlling or under common control with, the Person, but only for so long as such control shall continue.â€œBusiness Dayâ€ means any day, other than a Saturday or Sunday, on which banks in New York City are open for the general transaction of business.â€œClosing Dateâ€ means the Trading Day when all of the Transaction Documents have been executed and delivered by the applicable parties thereto, and all of the conditions set forth in Section 6.1 and Section 6.2 hereof are satisfied or waived by the Required Purchasers, as the case may be, or such other date as the Company and the Required Purchasers may agree.4891-0304-4295\10â€œCompany Counselâ€ means Dorsey & Whitney LLP, with offices located at 1400 Wewatta Street, Suite 400, Denver, CO 80202-5549.â€œCompany Intellectual Property Counselâ€ means Marshall, Gerstein & Borun LLP and Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.â€œCompanyâ€™s Knowledgeâ€ means with respect to any statement made to the knowledge of the Company, that the statement is based upon the actual knowledge of the officers of the Company who, as of the date hereof, have responsibility for the matter or matters that are the subject of the statement, and the knowledge that each such person would have reasonably obtained in the performance of each such personâ€™s duties as an officer of the Company.â€œContractâ€ means any written agreement, contract, subcontract, lease, understanding, arrangement, instrument, note, option, warranty, purchase order, license, sublicense, insurance policy, benefit plan or legally binding commitment or undertaking of any nature.â€œControlâ€ (including the terms â€œcontrolling,â€ â€œcontrolled byâ€ or â€œunder common control withâ€) means the possession, direct or indirect, of (a) the power to direct or cause direction of the management and policies of a Person (whether through ownership of securities or partnership or other ownership interests, by contract or otherwise), or (b) at least 50% of the voting securities (whether directly or pursuant to any option, warrant or other similar arrangement) or other comparable equity interests.â€œExchange Actâ€ means the Securities Exchange Act of 1934, as amended, or any successor statute, and the rules and regulations promulgated thereunder.â€œInsiderâ€ means each director, executive officer, other officer of the Company participating in the offering, any beneficial owner of twenty percent (20%) or more of the Companyâ€™s outstanding voting equity securities, calculated on the basis of voting power, and any promoter connected with the Company in any capacity on the date hereof.â€œLawâ€ or â€œLawsâ€ means any federal, state, local, municipal, foreign or other law, statute, constitution, principle of common law, resolution, ordinance, code, edict, decree, rule, regulation, ruling or requirement issued, enacted, adopted, promulgated, implemented or otherwise put into effect by or under the authority of any governmental authority.â€œOrderâ€ means any order, writ, injunction, judgment or decree.â€œPersonâ€ means an individual, corporation, partnership, limited liability company, trust, business trust, association, joint stock company, joint venture, sole proprietorship, unincorporated organization, governmental authority or any other form of entity not specifically listed herein.â€œRegistration Statementâ€ has the meaning set forth in the Registration Rights Agreement.4891-0304-4295\10â€œRequired Purchasersâ€ means the Purchasers beneficially owning (calculated in accordance with Rule 13d-3 under the Exchange Act) a majority of the aggregate outstanding Shares.â€œSecurities Actâ€ means the Securities Act of 1933, as amended, or any successor statute, and the rules and regulations promulgated thereunder.â€œShare Purchase Priceâ€ means $4.00 per Share.â€œSubscription Amountâ€ means, with respect to each Purchaser, the aggregate amount to be paid for the Shares purchased by such Purchaser hereunder as indicated on such Purchaserâ€™s signature page hereto next to the heading â€œAggregate Purchase Price (Subscription Amount)â€ in United States dollars.â€œTrading Marketâ€ means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the New York Stock Exchange, OTCQB or OTCQX (or any successors to any of the foregoing).â€œTransaction Documentsâ€ means this Agreement and the Registration Rights Agreement.2.Purchase and Sale of the Shares. Subject to the terms and conditions of this Agreement, at the Closing, each Purchaser shall severally, and not jointly, purchase, and the Company shall sell and issue to such Purchaser, such number of Shares described in the Schedule of Purchasers attached as Exhibit C hereto, equal to the quotient resulting from dividing (i) the Subscription Amount for such Purchaser by (ii) the Purchase Price, rounded down to the nearest whole Share. 3.Closing. The closing of the issuance and sale of the Shares (the â€œClosingâ€) shall occur remotely via the exchange of documents and signatures on the Closing Date. At the Closing, each Purchaser shall deliver or cause to be delivered to the Company the Subscription Amount for such Purchaser, via wire transfer of immediately available funds pursuant to the wire instructions delivered to such Purchaser by the Company prior to the Closing. Promptly after the Closing, the Company shall deliver to each Purchaser the uncertificated Shares registered in the name of such Purchaser. 4.Representations and Warranties of the Company. The Company hereby represents and warrants to the Purchasers that, except as disclosed to the Purchasers or in the SEC Filings (as defined below), as of the date hereof and as of the Closing Date as follows:4.1.Incorporation and Good Standing of the Company. The Company has been duly incorporated and is validly existing as a corporation in good standing under the laws of the jurisdiction of its incorporation and has the corporate power and authority to own, lease and operate its properties and to conduct its business as disclosed to the Purchasers and/or described in the SEC filings and to enter into and perform its obligations under this Agreement. The Company is duly qualified as a foreign corporation to transact business and is in good standing in the State of 4891-0304-4295\10Nevada and each other jurisdiction in which such qualification is required, whether by reason of the ownership or leasing of property or the conduct of business.4.2.Subsidiaries. Each of the Companyâ€™s â€œsubsidiariesâ€ (for purposes of this Agreement, as defined in Rule 405 under the Securities Act) has been duly incorporated or organized, as the case may be, and is validly existing as a corporation, partnership or limited liability company, as applicable, in good standing under the laws of the jurisdiction of its incorporation or organization and has the power and authority (corporate or other) to own, lease and operate its properties and to conduct its business as described in the SEC Filings. Each of the Companyâ€™s subsidiaries is duly qualified as a foreign corporation, partnership or limited liability company, as applicable, to transact business and is in good standing in each jurisdiction in which such qualification is required, whether by reason of the ownership or leasing of property or the conduct of business. All of the issued and outstanding capital stock or other equity or ownership interests of each of the Companyâ€™s subsidiaries have been duly authorized and validly issued, are fully paid and nonassessable and are owned by the Company, directly or through subsidiaries, free and clear of any security interest, mortgage, pledge, lien, encumbrance or adverse claim. None of the outstanding capital stock or equity interest in any subsidiary was issued in violation of preemptive or similar rights of any security holder of such subsidiary. The constitutive or organizational documents of each of the subsidiaries comply in all material respects with the requirements of applicable laws of its jurisdiction of incorporation or organization and are in full force and effect. The Company does not own or control, directly or indirectly, any corporation, association or other entity other than the subsidiaries listed in Exhibit 21 to the Companyâ€™s Annual Report on Form 10-K for the fiscal year ended June 30, 2023.4.3.Non-Contravention of Existing Instruments; No Further Authorizations or Approvals Required. Neither the Company nor any of its subsidiaries is in violation of its charter or by-laws, partnership agreement or operating agreement or similar organizational documents, as applicable, or is in default (or, with the giving of notice or lapse of time, would be in default) (â€œDefaultâ€) under any indenture, loan, credit agreement, note, lease, license agreement, contract, franchise or other instrument (including, without limitation, any pledge agreement, security agreement, mortgage or other instrument or agreement evidencing, guaranteeing, securing or relating to indebtedness) to which the Company or any of its subsidiaries is a party or by which it or any of them may be bound, or to which any of their respective properties or assets are subject (each, an â€œExisting Instrumentâ€), except for such Defaults as could not be expected, individually or in the aggregate, to result in a Material Adverse Change (as defined below). The Companyâ€™s execution, delivery and performance of this Agreement and the Shares, consummation of the transactions contemplated hereby and the issuance and sale of the Shares (i) have been duly authorized by all necessary corporate action and will not result in any violation of the provisions of the charter or by-laws, partnership agreement or operating agreement or similar organizational documents, as applicable, of the Company or any subsidiary (ii) will not conflict with or constitute a breach of, or Default or a Debt Repayment Triggering Event (as defined below) under, or result in the creation or imposition of any lien, charge or encumbrance upon any property or assets of the Company or any of its subsidiaries pursuant to, or require the consent of any other party to, any Existing Instrument and (iii) will not result in any violation of any law, administrative regulation or administrative or court decree applicable to the Company or any of its subsidiaries. No consent, approval, authorization or other order of, or registration or filing with, any court or other governmental or regulatory authority or agency, is required for the Companyâ€™s execution, delivery 4891-0304-4295\10and performance of this Agreement, and consummation of the transactions contemplated hereby. As used herein, a â€œDebt Repayment Triggering Eventâ€ means any event or condition which gives, or with the giving of notice or lapse of time would give, the holder of any note, debenture or other evidence of indebtedness (or any person acting on such holderâ€™s behalf) the right to require the repurchase, redemption or repayment of all or a portion of such indebtedness by the Company or any of its subsidiaries4.4.Capitalization and Other Capital Stock Matters. The authorized, issued and outstanding capital stock of the Company is as disclosed to the Purchasers and/or set forth in the SEC Filings (other than for subsequent issuances, if any, pursuant to employee benefit plans, upon the exercise of outstanding options or warrants, or as otherwise disclosed to the Purchasers and/or described in the SEC Filings). All of the issued and outstanding shares of Common Stock have been duly authorized and validly issued, are fully paid and nonassessable and have been issued in compliance with all federal and state securities laws. None of the outstanding shares of Common Stock was issued in violation of any preemptive rights, rights of first refusal or other similar rights to subscribe for or purchase securities of the Company. There are no authorized or outstanding options, warrants, preemptive rights, rights of first refusal or other rights to purchase, or equity or debt securities convertible into or exchangeable or exercisable for, any capital stock of the Company or any of its subsidiaries other than those disclosed to the Purchasers and/or described in the SEC Filings. The descriptions of the Companyâ€™s stock option, stock bonus and other stock plans or arrangements, and the options or other rights granted thereunder, set forth in the SEC Filings and/or disclosed to the Purchasers, accurately and fairly presents the information required to be shown with respect to such plans, arrangements, options and rights.4.5.Authorization of the Shares. The Shares have been duly authorized for issuance and sale pursuant to this Agreement and, when issued and delivered by the Company against payment therefor pursuant to this Agreement, will be validly issued, fully paid and nonassessable, and the issuance and sale of the Shares is not subject to any preemptive rights, rights of first refusal or other similar rights to subscribe for or purchase the Shares. 4.6.No Applicable Registration or Other Similar Rights. There are no persons with registration or other similar rights to have any equity or debt securities registered for sale included in the offering contemplated by this Agreement, except for such rights as have been duly waived.4.7.SEC Filings.(a)The Company has filed all reports, schedules, forms, statements and other documents required to be filed by it under the Exchange Act for the three (3)-year period preceding the date hereof (or such shorter period as the Company was required by Law to file such material) (the foregoing materials, including the exhibits thereto and documents incorporated by reference therein, being collectively referred to herein as the â€œSEC Filingsâ€).(b)At the time of filing thereof, or to the extent corrected by a subsequent filing, the SEC Filings complied as to form in all material respects with all applicable requirements of the Exchange Act and did not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make the 4891-0304-4295\10statements made therein, in the light of the circumstances under which they were made, not misleading.(c)Each registration statement and any amendment thereto filed by the Company during the three (3) year period preceding the date hereof pursuant to the Securities Act, as of the date such statement or amendment became effective, complied as to form in all material respects with the Securities Act and did not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make the statements made therein not misleading; and each prospectus filed during the three (3) year period preceding the date hereof pursuant to Rule 424(b) under the Securities Act, as of its issue date and as of the closing of any sale of securities pursuant thereto, did not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make the statements made therein, in the light of the circumstances under which they were made, not misleading.4.8.No Material Adverse Change. Except as otherwise disclosed to the Purchasers, (i) there has been no material adverse change, or any development that could be expected to result in a material adverse change, in (A) the condition, financial or otherwise, or in the earnings, business, properties, operations, operating results, assets, liabilities or prospects, whether or not arising from transactions in the ordinary course of business, of the Company and its subsidiaries, considered as one entity or (B) the ability of the Company to consummate the transactions contemplated by this Agreement or perform its obligations hereunder (any such change being referred to herein as a â€œMaterial Adverse Changeâ€); (ii) the Company and its subsidiaries, considered as one entity, have not incurred any material liability or obligation, indirect, direct or contingent, including without limitation any losses or interference with their business from fire, explosion, flood, earthquakes, accident or other calamity, whether or not covered by insurance, or from any strike, labor dispute or court or governmental action, order or decree, that are material, individually or in the aggregate, to the Company and its subsidiaries, considered as one entity, and have not entered into any transactions not in the ordinary course of business; and (iii) there has not been any material decrease in the capital stock or any material increase in any short-term or long-term indebtedness of the Company or its subsidiaries and there has been no dividend or distribution of any kind declared, paid or made by the Company or, except for dividends paid to the Company or other subsidiaries, by any of the Companyâ€™s subsidiaries on any class of capital stock, or any repurchase or redemption by the Company or any of its subsidiaries of any class of capital stock.4.9.Tax Law Compliance. The Company and its subsidiaries have filed all necessary federal, state and foreign income and franchise tax returns or have properly requested extensions thereof and have paid all taxes required to be paid by any of them and, if due and payable, any related or similar assessment, fine or penalty levied against any of them except as may be being contested in good faith and by appropriate proceedings. The Company has made adequate charges, accruals and reserves in the applicable financial statements referred to in Section 4.13 below in respect of all federal, state and foreign income and franchise taxes for all periods as to which the tax liability of the Company or any of its subsidiaries has not been finally determined.4.10.Transfer Taxes. There are no transfer taxes or other similar fees or charges under Federal law or the laws of any state, or any political subdivision thereof, required to be paid 4891-0304-4295\10in connection with the execution and delivery of this Agreement or the issuance by the Company or sale by the Company of the Securities.4.11.Insurance. Each of the Company and its subsidiaries are insured by recognized, financially sound and reputable institutions with policies in such amounts and with such deductibles and covering such risks as are generally deemed adequate and customary for their businesses including, but not limited to, policies covering real and personal property owned or leased by the Company and its subsidiaries against theft, damage, destruction, acts of vandalism and earthquakes and policies covering the Company and its subsidiaries for product liability claims and clinical trial liability claims. The Company has no reason to believe that it or any of its subsidiaries will not be able (i) to renew its existing insurance coverage as and when such policies expire or (ii) to obtain comparable coverage from similar institutions as may be necessary or appropriate to conduct its business as now conducted and at a cost that could not be expected to result in a Material Adverse Change. Neither the Company nor any of its subsidiaries has been denied any insurance coverage which it has sought or for which it has applied.4.12.No Material Actions or Proceedings. There is no action, suit, proceeding, inquiry or investigation brought by or before any legal or governmental entity now pending or, to the knowledge of the Company, threatened, against or affecting the Company or any of its subsidiaries, which could be expected, individually or in the aggregate, to result in a Material Adverse Change or materially and adversely affect the consummation of the transactions contemplated by this Agreement or the performance by the Company of its obligations hereunder. No material labor dispute with the employees of the Company or any of its subsidiaries, or with the employees of any principal supplier, manufacturer, customer or contractor of the Company, exists or, to the knowledge of the Company, is threatened or imminent.4.13.Financial Statements. The financial statements filed with the SEC present fairly the consolidated financial position of the Company and its subsidiaries as of the

dates indicated and the results of their operations, changes in stockholdersâ€™ equity and cash flows for the periods specified. Such financial statements have been prepared in conformity with generally accepted accounting principles applied on a consistent basis throughout the periods involved, except as may be expressly stated in the related notes thereto. The interactive data in eXtensible Business Reporting Language included or incorporated by reference in the SEC Filings fairly presents the information called for in all material respects and has been prepared in accordance with the Commissionâ€™s rules and guidelines applicable thereto. No other financial statements or supporting schedules are required to be included in the SEC Filings. The financial data set forth in the SEC Filings fairly present the information set forth therein on a basis consistent with that of the audited financial statements contained in the SEC Filings. Any disclosures contained in the SEC Filings that constitute non-GAAP financial measures (as defined by the rules and regulations under the Securities Act and the Exchange Act) comply with Regulation G under the Exchange Act and Item 10 of Regulation S-K under the Securities Act, as applicable. To the Companyâ€™s knowledge, no person who has been suspended or barred from being associated with a registered public accounting firm, or who has failed to comply with any sanction pursuant to Rule 5300 promulgated by the Public Company Accounting Oversight Board (â€œPCAOBâ€), has participated in or otherwise aided the preparation of, or audited, the financial statements, supporting schedules or other financial data filed with the SEC as a part of the SEC Filings.4891-0304-4295\104.14.Independent Accountants. Plante & Moran, PLLC, which has expressed its opinion with respect to the financial statements (which term as used in this Agreement includes the related notes thereto) and Grant Thornton have each filed with the Commission as a part of the SEC Filings, is (i) an independent registered public accounting firm as required by the Securities Act, the Exchange Act, and the rules of the PCAOB, (ii) in compliance with the applicable requirements relating to the qualification of accountants under Rule 2-01 of Regulation S-X under the Securities Act and (iii) a registered public accounting firm as defined by the PCAOB whose registration has not been suspended or revoked and who has not requested such registration to be withdrawn.4.15.Companyâ€™s Accounting System. The Company and each of its subsidiaries make and keep accurate books and records and maintain a system of internal accounting controls sufficient to provide reasonable assurance that: (i) transactions are executed in accordance with managementâ€™s general or specific authorization; (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with generally accepted accounting principles and to maintain accountability for assets; (iii) access to assets is permitted only in accordance with managementâ€™s general or specific authorization; (iv) the recorded accountability for assets is compared with existing assets at reasonable intervals and appropriate action is taken with respect to any differences; and (v) the interactive data in eXtensible Business Reporting Language included or incorporated by reference in the SEC Filings fairly presents the information called for in all material respects and is prepared in accordance with the Commissionâ€™s rules and guidelines applicable thereto.4.16.Disclosure Controls and Procedures; Deficiencies in or Changes to Internal Control Over Financial Reporting. The Company has established and maintains disclosure controls and procedures (as defined in Rules 13a-15 and 15d-15 under the Exchange Act), which (i) are designed to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to the Companyâ€™s principal executive officer and its principal financial officer by others within those entities, particularly during the periods in which the periodic reports required under the Exchange Act are being prepared; (ii) have been evaluated by management of the Company for effectiveness as of the end of the Companyâ€™s most recent fiscal quarter; and (iii) are effective in all material respects to perform the functions for which they were established. Since the end of the Companyâ€™s most recent audited fiscal year, there have been no significant deficiencies or material weakness in the Companyâ€™s internal control over financial reporting (whether or not remediated) and no change in the Companyâ€™s internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, the Companyâ€™s internal control over financial reporting. The Company is not aware of any change in its internal control over financial reporting that has occurred during its most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Companyâ€™s internal control over financial reporting.4.17.Intellectual Property Rights. The Company and its subsidiaries own, or have obtained valid and enforceable licenses for, the inventions, patent applications, patents, trademarks, trade names, service names, copyrights, trade secrets and other intellectual property described in the SEC Filings as being owned or licensed by them or which are necessary for the conduct of their respective businesses as currently conducted or as currently proposed to be conducted (collectively, â€œIntellectual Propertyâ€) and the conduct of their respective businesses 4891-0304-4295\10does not and will not infringe, misappropriate or otherwise conflict in any material respect with any such rights of others. The Intellectual Property has not been adjudged by a court of competent jurisdiction to be invalid or unenforceable, in whole or in part, and the Company is unaware of any facts which would form a reasonable basis for any such adjudication. To the Companyâ€™s knowledge: (i) there are no third parties who have rights to any Intellectual Property, except for customary reversionary rights of third-party licensors with respect to Intellectual Property that is disclosed in the SEC Filings as licensed to the Company or one or more of its subsidiaries; and (ii) there is no infringement by third parties of any Intellectual Property. There is no pending or, to the Companyâ€™s knowledge, threatened action, suit, proceeding or claim by others: (A) challenging the Companyâ€™s rights in or to any Intellectual Property, and the Company is unaware of any facts which would form a reasonable basis for any such action, suit, proceeding or claim; (B) challenging the validity, enforceability or scope of any Intellectual Property, and the Company is unaware of any facts which would form a reasonable basis for any such action, suit, proceeding or claim; or (C) asserting that the Company or any of its subsidiaries infringes or otherwise violates, or would, upon the commercialization of any product or service described in the SEC Filings as under development, infringe or violate, any patent, trademark, trade name, service name, copyright, trade secret or other proprietary rights of others, and the Company is unaware of any facts which would form a reasonable basis for any such action, suit, proceeding or claim. The Company and its subsidiaries have complied with the terms of each agreement pursuant to which Intellectual Property has been licensed to the Company or any subsidiary, and all such agreements are in full force and effect. To the Companyâ€™s knowledge, there are no material defects in any of the patents or patent applications included in the Intellectual Property. The Company and its subsidiaries have taken all reasonable steps to protect, maintain and safeguard their Intellectual Property, including the execution of appropriate nondisclosure, confidentiality agreements and invention assignment agreements and invention assignments with their employees, and no employee of the Company is in or has been in violation of any term of any employment contract, patent disclosure agreement, invention assignment agreement, non-competition agreement, non-solicitation agreement, nondisclosure agreement, or any restrictive covenant to or with a former employer where the basis of such violation relates to such employeeâ€™s employment with the Company. The duty of candor and good faith as required by the United States Patent and Trademark Office during the prosecution of the United States patents and patent applications included in the Intellectual Property have been complied with; and in all foreign offices having similar requirements, all such requirements have been complied with. None of the Intellectual Property or technology (including information technology and outsourced arrangements) employed by the Company or its subsidiaries has been obtained or is being used by the Company or its subsidiary in violation of any contractual obligation binding on the Company or its subsidiaries or any of their respective officers, directors or employees or otherwise in violation of the rights of any persons. The product candidates described in the SEC Filings as under development by the Company or any subsidiary fall within the scope of the claims of one or more patents owned by, or exclusively licensed to, the Company or any subsidiary.4.18.Disclosure. The Company understands and confirms that the Purchasers will rely on the foregoing representations in effecting transactions in securities of the Company. To the Knowledge of the Company, all due diligence materials regarding the Company, its subsidiaries, their businesses and the transactions contemplated hereby, furnished by or on behalf of the Company or its subsidiaries to the Purchasers upon their request are, when taken together with the SEC Filings, true and correct in all material respects and do not contain any untrue 4891-0304-4295\10statement of a material fact or omit to state any material fact necessary in order to make the statements made therein, in light of the circumstances under which they were made, not misleading.4.19.Contracts. Each franchise, contract or other document of a character required to be described in the SEC Filings or to be filed as an exhibit to the SEC Filings under the Securities Act and the rules and regulations promulgated thereunder (collectively, the â€œMaterial Contractsâ€) is so described or filed.4.20.Compliance with Laws. The Company and its subsidiaries have been and are in compliance with all applicable laws, rules and regulations, except where failure to be so in compliance could not be expected, individually or in the aggregate, to result in a Material Adverse Change.4.21.Compliance with Health Care Laws. The Company and its subsidiaries are, and at all times have been, in compliance with all Health Care Laws. For purposes of this Agreement, â€œHealth Care Lawsâ€ means: (i) the Federal Food, Drug, and Cosmetic Act (21 U.S.C. Section 301 et seq.), the Public Health Service Act (42 U.S.C. Section 201 et seq.), and the regulations promulgated thereunder; (ii) all applicable federal, state, local and foreign health care fraud and abuse laws, including, without limitation, the Anti-Kickback Statute (42 U.S.C. Section 1320a-7b(b)), the Civil False Claims Act (31 U.S.C. Section 3729 et seq.), the criminal false statements law (42 U.S.C. Section 1320a-7b(a)), 18 U.S.C. Sections 286 and 287, the health care fraud criminal provisions under the U.S. Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health Act (collectively, â€œHIPAAâ€), (42 U.S.C. Section 1320d et seq.), the Stark Law (42 U.S.C. Section 1395nn), the civil monetary penalties law (42 U.S.C. Section 1320a-7a), the exclusion law (42 U.S.C. Section 1320a-7), the Physician Payments Sunshine Act (42 U.S.C. Section 1320-7h), and applicable laws governing government funded or sponsored healthcare programs; (iii) HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (42 U.S.C. Section 17921 et seq.); (iv) the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010; (v) licensure, quality, safety and accreditation requirements under applicable federal, state, local or foreign laws or regulatory bodies; and (vi) all other local, state, federal, national, supranational and foreign laws, relating to the regulation of the Company or its subsidiaries, and (vii) the directives and regulations promulgated pursuant to such statutes and any state or non-U.S. counterpart thereof. Neither the Company nor any of its subsidiaries has received written notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from any court or arbitrator or governmental or regulatory authority or third party alleging that any product operation or activity is in violation of any Health Care Laws nor, to the Companyâ€™s knowledge, is any such claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action threatened. The Company and its subsidiaries have filed, maintained or submitted all material reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments as required by any Health Care Laws, and all such reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments were complete and accurate on the date filed in all material respects (or were corrected or supplemented by a subsequent submission). Neither the Company nor any of its subsidiaries is a party to any corporate integrity agreements, monitoring agreements, consent decrees, settlement orders, or similar 4891-0304-4295\10agreements with or imposed by any governmental or regulatory authority. Additionally, neither the Company, any of its subsidiaries nor any of their respective employees, officers, directors, or agents has been excluded, suspended or debarred from participation in any U.S. federal health care program or human clinical research or, to the knowledge of the Company, is subject to a governmental inquiry, investigation, proceeding, or other similar action that could reasonably be expected to result in debarment, suspension, or exclusion.4.22.Clinical Data and Regulatory Compliance. The preclinical tests and clinical trials, and other studies (collectively, â€œstudiesâ€) that are described in, or the results of which are referred to in, the SEC Filings and/or disclosed to the Purchasers were and, if still pending, are being conducted in all material respects in accordance with the protocols, procedures and controls designed and approved for such studies and with standard medical and scientific research procedures; each description of the results of such studies is accurate and complete in all material respects and fairly presents the data derived from such studies, and the Company and its subsidiaries have no knowledge of any other studies the results of which are inconsistent with, or otherwise call into question, the results described or referred to in the SEC Filings and/or disclosed to the Purchasers; the Company and its subsidiaries have made all such filings and obtained all such approvals as may be required by the Food and Drug Administration of the U.S. Department of Health and Human Services or any committee thereof or from any other U.S. or foreign government or drug or medical device regulatory agency, or health care facility Institutional Review Board (collectively, the â€œRegulatory Agenciesâ€); neither the Company nor any of its subsidiaries has received any notice of, or correspondence from, any Regulatory Agency requiring the termination, suspension or modification of any clinical trials that are described or referred to in the SEC Filings and/or disclosed to the Purchasers; and the Company and its subsidiaries have each operated and currently are in compliance in all material respects with all applicable rules, regulations and policies of the Regulatory Agencies.4.23.Cybersecurity. The Company and its subsidiariesâ€™ information technology assets and equipment, computers, systems, networks, hardware, software, websites, applications, and databases (collectively, â€œIT Systemsâ€) are adequate for, and operate and perform in all material respects as required in connection with the operation of the business of the Company and its subsidiaries as currently conducted, free and clear of all material bugs, errors, defects, Trojan horses, time bombs, malware and other corruptants. The Company and its subsidiaries have implemented and maintained commercially reasonable physical, technical and administrative controls, policies, procedures, and safeguards to maintain and protect their material confidential information and the integrity, continuous operation, redundancy and security of all IT Systems and data, including â€œPersonal Data,â€ used in connection with their businesses. â€œPersonal Dataâ€ means (i) a natural personâ€™s name, street address, telephone number, e-mail address, photograph, social security number or tax identification number, driverâ€™s license number, passport number, credit card number, bank information, or customer or account number; (ii) any information which would qualify as â€œpersonally identifying informationâ€ under the Federal Trade Commission Act, as amended; (iii) â€œpersonal dataâ€ as defined by the European Union General Data Protection Regulation (â€œGDPRâ€) â€œ) (EU 2016/679); (iv) any information which would qualify as â€œprotected health informationâ€ under HIPAA; and (v) any other piece of information that allows the identification of such natural person, or his or her family, or permits the collection or analysis of any data related to an identified personâ€™s health or sexual orientation. There have been no breaches, violations, outages or unauthorized uses of or accesses to same, except for those that have been 4891-0304-4295\10remedied without material cost or liability or the duty to notify any other person, nor any incidents under internal review or investigations relating to the same. The Company and its subsidiaries are presently in material compliance with all applicable laws or statutes and all judgments, orders, rules and regulations of any court or arbitrator or governmental or regulatory authority, internal policies and contractual obligations relating to the privacy and security of IT Systems and Personal Data and to the protection of such IT Systems and Personal Data from unauthorized use, access, misappropriation or modification.4.24.Compliance with Data Privacy Laws. The Company and its subsidiaries are, and at all prior times were, in material compliance with all applicable state and federal data privacy and security laws and regulations, including without limitation HIPAA, and the Company and its subsidiaries have taken commercially reasonable actions to prepare to comply with, and since May 25, 2018, have been and currently are in compliance with, GDPR (collectively, the â€œPrivacy Lawsâ€). To ensure compliance with the Privacy Laws, the Company and its subsidiaries have in place, comply with, and take appropriate steps reasonably designed to ensure compliance in all material respects with their policies and procedures relating to data privacy and security and the collection, storage, use, disclosure, handling, and analysis of Personal Data (the â€œPoliciesâ€). The Company and its subsidiaries have at all times made all disclosures to users or customers required by applicable laws and regulatory rules or requirements, and none of such disclosures made or contained in any Policy have, to the knowledge of the Company, been inaccurate or in violation of any applicable laws and regulatory rules or requirements in any material respect. The Company further certifies that neither it nor any subsidiary: (i) has received notice of any actual or potential liability under or relating to, or actual or potential violation of, any of the Privacy Laws, and has no knowledge of any event or condition that would reasonably be expected to result in any such notice; (ii) is currently conducting or paying for, in whole or in part, any investigation, remediation, or other corrective action pursuant to any Privacy Law; or (iii) is a party to any order, decree, or agreement that imposes any obligation or liability under any Privacy Law.4.25.Company Not an â€œInvestment Companyâ€. The Company is not, and will not be, either after receipt of payment for the Shares or after the application of the proceeds therefrom, required to register as an â€œinvestment companyâ€ under the Investment Company Act of 1940, as amended.4.26.All Necessary Permits, etc. The Company and its subsidiaries possess such valid and current certificates, authorizations or permits required by state, federal or foreign regulatory agencies or bodies to conduct their respective businesses as currently conducted and as described in the SEC Filings (â€œPermitsâ€). Neither the Company nor any of its subsidiaries is in violation of, or in default under, any of the Permits or has received any notice of proceedings relating to the revocation or modification of, or non-compliance with, any such certificate, authorization or permit.4.27.Title to Properties. The Company and its subsidiaries have good and marketable title to all of the real and personal property and other assets reflected as owned in the financial statements referred to in Section 4.13 above (or elsewhere in the SEC Filings), in each case free and clear of any security interests, mortgages, liens, encumbrances, equities, adverse claims and other defects. The real property, improvements, equipment and personal property held under lease by the Company or any of its subsidiaries are held under valid and enforceable leases, 4891-0304-4295\10with such exceptions as are not material and do not materially interfere with the use made or proposed to be made of such real property, improvements, equipment or personal property by the Company or such subsidiary.4.28.ERISA Compliance. The Company and its subsidiaries and any â€œemployee benefit planâ€ (as defined under the Employee Retirement Income Security Act of 1974, as amended, and the regulations and published interpretations thereunder (collectively, â€œERISAâ€)) established or maintained

by the Company, its subsidiaries or their â€œERISA Affiliatesâ€ (as defined below) are in compliance in all material respects with ERISA. â€œERISA Affiliateâ€ means, with respect to the Company or any of its subsidiaries, any member of any group of organizations described in Sections 414(b), (c), (m) or (o) of the Internal Revenue Code of 1986, as amended, and the regulations and published interpretations thereunder (the â€œCodeâ€) of which the Company or such subsidiary is a member. No â€œreportable eventâ€ (as defined under ERISA) has occurred or is reasonably expected to occur with respect to any â€œemployee benefit planâ€ established or maintained by the Company, its subsidiaries or any of their ERISA Affiliates. No â€œemployee benefit planâ€ established or maintained by the Company, its subsidiaries or any of their ERISA Affiliates, if such â€œemployee benefit planâ€ were terminated, would have any â€œamount of unfunded benefit liabilitiesâ€ (as defined under ERISA). Neither the Company, its subsidiaries nor any of their ERISA Affiliates has incurred or reasonably expects to incur any liability under (i) Title IV of ERISA with respect to termination of, or withdrawal from, any â€œemployee benefit planâ€ or (ii) Sections 412, 4971, 4975 or 4980B of the Code. Each employee benefit plan established or maintained by the Company, its subsidiaries or any of their ERISA Affiliates that is intended to be qualified under Section 401(a) of the Code is so qualified and nothing has occurred, whether by action or failure to act, which would cause the loss of such qualification.4.29.Compliance with Environmental Laws. Except as could not be expected, individually or in the aggregate, to result in a Material Adverse Change: (i) neither the Company nor any of its subsidiaries is in violation of any federal, state, local or foreign statute, law, rule, regulation, ordinance, code, policy or rule of common law or any judicial or administrative interpretation thereof, including any judicial or administrative order, consent, decree or judgment, relating to pollution or protection of human health, the environment (including, without limitation, ambient air, surface water, groundwater, land surface or subsurface strata) or wildlife, including, without limitation, laws and regulations relating to the release or threatened release of chemicals, pollutants, contaminants, wastes, toxic substances, hazardous substances, petroleum or petroleum products (collectively, â€œHazardous Materialsâ€) or to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials (collectively, â€œEnvironmental Lawsâ€); (ii) the Company and its subsidiaries have all permits, authorizations and approvals required under any applicable Environmental Laws and are each in compliance with their requirements; (iii) there are no pending or threatened administrative, regulatory or judicial actions, suits, demands, demand letters, claims, liens, notices of noncompliance or violation, investigation or proceedings relating to any Environmental Law against the Company or any of its subsidiaries; and (iv) there are no events or circumstances that might reasonably be expected to form the basis of an order for clean-up or remediation, or an action, suit or proceeding by any private party or governmental body or agency, against or affecting the Company or any of its subsidiaries relating to Hazardous Materials or any Environmental Laws.4891-0304-4295\104.30.Anti-Corruption and Anti-Bribery Laws. Neither the Company nor any of its subsidiaries nor any director, officer, or employee of the Company or any of its subsidiaries, nor to the knowledge of the Company, any agent, affiliate or other person acting on behalf of the Company or any of its subsidiaries has, in the course of its actions for, or on behalf of, the Company or any of its subsidiaries (i) used any corporate funds for any unlawful contribution, gift, entertainment or other unlawful expenses relating to political activity; (ii) made or taken any act in furtherance of an offer, promise, or authorization of any direct or indirect unlawful payment or benefit to any foreign or domestic government official or employee, including of any government-owned or controlled entity or public international organization, or any political party, party official, or candidate for political office; (iii) violated or is in violation of any provision of the U.S. Foreign Corrupt Practices Act of 1977, as amended (the â€œFCPAâ€), the UK Bribery Act 2010, or any other applicable anti-bribery or anti-corruption law; or (iv) made, offered, authorized, requested, or taken an act in furtherance of any unlawful bribe, rebate, payoff, influence payment, kickback or other unlawful payment or benefit . The Company and its subsidiaries and, to the knowledge of the Company, the Companyâ€™s affiliates have conducted their respective businesses in compliance with the FCPA and have instituted and maintain policies and procedures designed to ensure, and which are reasonably expected to continue to ensure, continued compliance therewith.4.31.Money Laundering Laws. The operations of the Company and its subsidiaries are, and have been conducted at all times, in compliance with applicable financial recordkeeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the money laundering statutes of all applicable jurisdictions, the rules and regulations thereunder and any related or similar applicable rules, regulations or guidelines, issued, administered or enforced by any governmental agency (collectively, the â€œMoney Laundering Lawsâ€) and no action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company or any of its subsidiaries with respect to the Money Laundering Laws is pending or, to the best knowledge of the Company, threatened.4.32.Sanctions. Neither the Company nor any of its subsidiaries, directors, officers, or employees, nor, to the knowledge of the Company, after due inquiry, any agent, affiliate or other person acting on behalf of the Company or any of its subsidiaries is currently the subject or the target of any U.S. sanctions administered by the Office of Foreign Assets Control of the U.S. Department of the Treasury (â€œOFACâ€) or the U.S. Department of State, the United Nations Security Council, the European Union, Her Majestyâ€™s Treasury of the United Kingdom, or other relevant sanctions authority (collectively, â€œSanctionsâ€); nor is the Company or any of its subsidiaries located, organized or resident in a country or territory that is the subject or the target of Sanctions, including, without limitation, Crimea, Cuba, Iran, North Korea, and Syria; and the Company will not directly or indirectly use the proceeds of this offering, or lend, contribute or otherwise make available such proceeds to any subsidiary, or any joint venture partner or other person or entity, for the purpose of financing the activities of or business with any person, or in any country or territory, that at the time of such financing, is the subject or the target of Sanctions or in any other manner that will result in a violation by any person (including any person participating in the transaction whether as underwriter, advisor, investor or otherwise) of applicable Sanctions. For the past ten years, the Company and its subsidiaries have not knowingly engaged in and are not now knowingly engaged in any dealings or transactions with any person 4891-0304-4295\10that at the time of the dealing or transaction is or was the subject or the target of Sanctions or with any Sanctioned Country.4.33.Stock Exchange Listing. The shares of Common Stock are registered pursuant to Section 12(b) or 12(g) of the Exchange Act and are listed on The Nasdaq Capital Market (â€œNASDAQâ€). The Company shall cause the Shares to be listed on NASDAQ prior to the effectiveness of the Registration Statement and shall use its best efforts to maintain the continued listing of such Shares. The Company has taken no action designed to, or likely to have the effect of, terminating the registration of the Shares under the Exchange Act or delisting the Shares from NASDAQ, nor has the Company received any notification that the Commission or NASDAQ is contemplating terminating such registration or listing. To the Companyâ€™s knowledge, it is in compliance with all applicable listing requirements of NASDAQ.4.34.No Unlawful Contributions or Other Payments. Neither the Company nor any of its subsidiaries nor, to the best of the Companyâ€™s knowledge, any employee or agent of the Company or any subsidiary, has made any contribution or other payment to any official of, or candidate for, any federal, state or foreign office in violation of any law or of the character required to be disclosed in the SEC Filings.4.35.No Outstanding Loans or Other Extensions of Credit. The Company does not have any outstanding extension of credit, in the form of a personal loan, to or for any director or executive officer (or equivalent thereof) of the Company except for such extensions of credit as are expressly permitted by Section 13(k) of the Exchange Act.4.36.No Contract Terminations. Neither the Company nor any of its subsidiaries has sent or received any communication regarding termination of, or intent not to renew, any of the contracts or agreements referred to or described in or filed as an exhibit to the SEC Filings, and no such termination or non-renewal has been threatened by the Company or any of its subsidiaries or, to the Companyâ€™s knowledge, any other party to any such contract or agreement, which threat of termination or non-renewal has not been rescinded as of the date hereof.4.37.Dividend Restrictions. No subsidiary of the Company is prohibited or restricted, directly or indirectly, from paying dividends to the Company, or from making any other distribution with respect to such subsidiaryâ€™s equity securities or from repaying to the Company or any other subsidiary of the Company any amounts that may from time to time become due under any loans or advances to such subsidiary from the Company or from transferring any property or assets to the Company or to any other subsidiary.4.38.No Integrated Offering. Assuming the accuracy of the representations and warranties of the Purchasers set forth in Section 5, the Company has not, directly or indirectly through any agent, made any offers or sales of, or solicited any offers to buy, any Company â€œsecurityâ€ (as defined in the Securities Act) under circumstances that would adversely affect reliance by the Company on Section 4(a)(2) for the exemption from registration for the transactions contemplated hereby or would require registration of any of the Securities under the Securities Act.4891-0304-4295\104.39.No Price Stabilization or Manipulation; Compliance with Regulation M. Neither the Company nor any of its subsidiaries has taken, directly or indirectly, any action designed to or that might cause or result in stabilization or manipulation of the price of the Shares or of any â€œreference securityâ€ (as defined in Rule 100 of Regulation M under the Exchange Act (â€œRegulation Mâ€)) with respect to the Shares, whether to facilitate the sale or resale of the Shares or otherwise, and has taken no action which would directly or indirectly violate Regulation M.4.40.Brokers. Except pursuant to the Transaction Documents, there is no broker, finder or other party that is entitled to receive from the Company any brokerage or finderâ€™s fee or other fee or commission as a result of any transactions contemplated by this Agreement.4.41.Private Placement. Assuming the accuracy of the representations and warranties of the Purchasers set forth in Section 5, and in reliance thereon, the offer and sale of the Shares to the Purchasers as contemplated hereby is exempt from the registration requirements of the Securities Act.4.42.Shell Company. The Company is not, and was not within the past three (3) years, an â€œineligible issuerâ€ (as defined in Rule 405 promulgated under the Securities Act).4.43.Use of Form S-3. The Company meets the registration and transaction requirements for use of Form S-3 for the registration of the resale of the Shares by the Purchasers, subject to the SECâ€™s guidance and interpretations regarding secondary offerings being considered primary offerings.4.44.No Stop Order. No stop order or suspension of trading has been imposed as of the date hereof by the OTC Markets Group, the Financial Industry Regulatory Authority (â€œFINRAâ€), the SEC or any other governmental authority or regulatory body with respect to public trading in the Common Stock.4.45.Sarbanes-Oxley Act. There is, and has been, no failure on the part of the Company or any of the Companyâ€™s directors or officers, in their capacities as such, to comply with any applicable provision of the Sarbanes-Oxley Act of 2002, as amended and the rules and regulations promulgated in connection therewith, including Section 402 related to loans and Sections 302 and 906 related to certifications.5.Representations and Warranties of the Purchasers. Each Purchaser hereby severally, and not jointly, represents and warrants to the Company that, as of the date hereof and as of the Closing Date as follows:5.1.Organization and Existence. Such Purchaser is a duly organized, validly existing corporation, limited partnership or limited liability company and in good standing under the Laws of the jurisdiction of its organization.5.2.Authorization. Such Purchaser has the requisite corporate (or similar) power and authority and has taken all requisite action on the part of such Purchaser, its officers, directors, members and stockholders necessary for (i) the authorization, execution and delivery of the Transaction Documents to which such Purchaser is a party and (ii) the authorization of the performance of all obligations of the Purchaser hereunder or thereunder. The Transaction 4891-0304-4295\10Documents to which such Purchaser is a party constitute the legal, valid and binding obligations of the Purchaser, enforceable against such Purchaser in accordance with their terms, subject to bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium and similar Laws of general applicability, relating to or affecting creditorsâ€™ rights generally and to general equitable principles.5.3.No Conflict, Breach, Violation or Default. The execution, delivery and performance of the Transaction Documents by such Purchaser will not (i) conflict with or result in a material breach or material violation of (a) any of the terms and provisions of, or constitute a material default under, its organizational documents, as in effect as of immediately prior to the Closing, or (b) any Law or Order of any governmental agency or body or any court, domestic or foreign, in each case having jurisdiction over such Purchaser or any of its assets or properties, or (ii) conflict with, or constitute a default (or an event that with notice or lapse of time or both would become a default) under, result in the creation of any lien, encumbrance or other adverse claim upon any of the properties or assets of such Purchaser or give to others any rights of termination, amendment, acceleration or cancellation (with or without notice, lapse of time or both) of, any material agreement, indenture or instrument to which such Purchaser is a party; except in the case of clauses (i)(b) and (ii) such as would not have a material adverse effect on the ability of such Purchaser to perform its obligations hereunder.5.4.Purchase Entirely for Own Account. The Shares to be received by such Purchaser hereunder, will be acquired for such Purchaserâ€™s own account, not as nominee or agent, and not with a view to the resale or distribution of any part thereof in violation of the Securities Act, and such Purchaser has no present agreement, understanding or intention of selling, granting any participation in, or otherwise distributing the same in violation of the Securities Act without prejudice, subject, however, to such Purchaserâ€™s right at all times to sell or otherwise dispose of all or any part of such Securities in compliance with applicable federal and state securities Laws.5.5.Investment Experience. Such Purchaser acknowledges that it can bear the economic risk and complete loss of its investment in the Securities and has such knowledge and experience in financial or business matters that it is capable of evaluating the merits and risks of the investment contemplated hereby.5.6.Disclosure of Information. Such Purchaser has had an opportunity to review all information related to the Company requested by it and to ask questions of and receive answers from the Company regarding the Company, its business and the terms and conditions of the offering of the Shares. Such Purchaser acknowledges that copies of the SEC Filings have been made available to it. Such Purchaser has sought such accounting, legal and tax advice as it has considered necessary to make an informed decision with respect to its acquisition of the Shares. Based on the information such Purchaser has deemed appropriate, and without reliance upon the Placement Agent, it has independently made its own analysis and decision to enter into the Transaction Documents. Such Purchaser is relying exclusively on its own investment analysis and due diligence (including professional advice it deems appropriate) with respect to the execution, delivery and performance of the Transaction Documents and the business, condition (financial and otherwise), management, operations, properties and prospects of the Company, including but not limited to all business, legal, regulatory, accounting, credit and tax matters. Such Purchaser has 4891-0304-4295\10not relied on any advice furnished by or on behalf of the Placement Agent in connection with the transactions contemplated hereby. 5.7.Restricted Securities. Such Purchaser understands that the Shares are characterized as â€œrestricted securitiesâ€ under the U.S. federal securities Laws inasmuch as they are being acquired from the Company in a transaction not involving a public offering and that under such Laws the Securities may be resold without registration under the Securities Act only in certain limited circumstances. Such Purchaser understands that except as provided in the Registration Rights Agreement: (i) the Shares have not been and are not being registered under the Securities Act or any state securities Laws, and may not be offered for sale, sold, assigned or transferred unless (a) subsequently registered thereunder, (b) such Purchaser shall have delivered to the Company an opinion of counsel, in a form reasonably acceptable to the Company, to the effect that such Shares to be sold, assigned or transferred may be sold, assigned or transferred pursuant to an exemption from such registration, or (c) such Purchaser provides the Company with reasonable assurance that such Shares can be sold, assigned or transferred pursuant to Rule 144 or Rule 144A promulgated under the Securities Act, as amended, (or a successor rule thereto) (collectively, â€œRule 144â€); (ii) any sale of the Shares made in reliance on Rule 144 may be made only in accordance with the terms of Rule 144 and further, if Rule 144 is not applicable, any resale of the Shares under circumstances in which the seller (or the Person through whom the sale is made) may be deemed to be an underwriter (as that term is defined in the Securities Act) may require compliance with some other exemption under the Securities Act or the rules and regulations of the SEC thereunder; and (iii) neither the Company nor any other Person is under any obligation to register the Shares under the Securities Act or any state securities Laws or to comply with the terms and conditions of any exemption thereunder.5.8.Purchaser Status. Such Purchaser is an institutional â€œaccredited investorâ€ as defined in Rule 501(a)(1), (a)(2), (a)(3) or (a)(7) under the Securities Act or a â€œqualified institutional buyerâ€ within the meaning of Rule 144A under the Securities Act. Such Purchaser is a sophisticated â€œinstitutional accountâ€ as defined in FINRA Rule 4512(c), with sufficient knowledge and experience in investing in private placement transactions to properly evaluate the risks and merits of its purchase of the Shares. Such Purchaser is not a registered broker-dealer registered under Section 15(a) of the Exchange Act, or a member of FINRA or an entity engaged in the business of being a broker-dealer. Such Purchaser is not affiliated with any broker-dealer registered under Section 15(a) of the Exchange Act, or a member of FINRA or an entity engaged in the business of being a broker-dealer.5.9.Reliance on Exemptions. Such Purchaser understands that the Shares are being offered and sold to it in reliance on specific exemptions from the registration requirements of federal and state securities Laws and that the Company is relying in part upon the truth and accuracy of, and such Purchaserâ€™s compliance with, the representations, warranties, agreements, acknowledgments and understandings of such Purchaser set forth in the Transaction Documents in order to determine the availability of such exemptions and the eligibility of such Purchaser to acquire the Shares.5.10.No General Solicitation. Such Purchaser did not learn of the investment in the Shares as a result of any general solicitation or general advertising.4891-0304-4295\105.11.Brokers and Finders. No Person will have, as a result of the transactions contemplated by the Transaction Documents, any valid right, interest or claim against or upon the Company, any subsidiary thereof or any Purchaser for any commission, fee or other compensation pursuant to any agreement, arrangement or understanding entered into by or on behalf of such Purchaser.5.12.Prohibited Transactions. Since the earlier of (i) such time as such Purchaser was first contacted by the Company or any other Person acting on behalf of the Company regarding the transactions contemplated hereby or (ii) thirty (30) days prior to the date hereof, neither such Purchaser nor any Affiliate of such Purchaser which (a) had knowledge of the transactions contemplated hereby, (b) has or shares discretion relating to such Purchaserâ€™s investments or trading or information concerning such Purchaserâ€™s investments, including in

respect of the Securities, or (c) is subject to such Purchaserâ€™s review or input concerning such Affiliateâ€™s investments or trading has, directly or indirectly, effected or agreed to effect any short sale, whether or not against the box, established any â€œput equivalent positionâ€ (as defined in Rule 16a-1(h) under the Exchange Act) with respect to the Common Stock, granted any other right (including, without limitation, any put or call option) with respect to the Common Stock or with respect to any security that includes, relates to or derived any significant part of its value from the Common Stock or otherwise sought to hedge its position in the Shares. Such Purchaser acknowledges that the representations, warranties and covenants contained in this Section 5.12 are being made for the benefit of the Purchasers as well as the Company and that each of the other Purchasers shall have an independent right to assert any claims against such Purchaser arising out of any breach or violation of the provisions of this Section 5.12.5.13.Rule 506(d) Representation. Such Purchaser represents that it is not a person of the type described in Section 506(d) of Regulation D under the Securities Act that would disqualify the Company from engaging in a transaction pursuant to Section 506 of Regulation D under the Securities Act.5.14.Residency. Such Purchaser is a resident of that jurisdiction specified on such Purchaserâ€™s signature page hereto.5.15.Placement Agent. Such Purchaser hereby acknowledges and agrees that (a)Â the Placement Agent is acting solely as a placement agent in connection with the execution, delivery and performance of the Transaction Documents and are not acting as an underwriter, initial purchaser, dealer or in any other such capacity and are not and shall not be construed as a fiduciary for such Purchaser, the Company or any other person or entity in connection with the execution, delivery and performance of the Transaction Documents, (b)Â it is not relying upon, and has not relied upon, any statement, representation or warranty made by the Placement Agent, any of their respective affiliates or any of their respective control persons, officers, directors and employees, in making its investment or decision to invest in the Company, (c)Â the Placement Agent has not made and will not make any representation or warranty, whether express or implied, of any kind or character, and have not provided any advice or recommendation in connection with the execution, delivery and performance of the Transaction Documents, (d)Â the Placement Agent will not have any responsibility with respect to (i)Â any representations, warranties or agreements made by any person or entity under or in connection with the execution, delivery and performance of the Transaction Documents, or the execution, legality, validity or enforceability (with respect 4891-0304-4295\10to any person) thereof, or (ii)Â the business, affairs, financial condition, operations, properties or prospects of, or any other matter concerning the Company, and (e)Â the Placement Agent will not have any liability or obligation (including without limitation, for or with respect to any losses, claims, damages, obligations, penalties, judgments, awards, liabilities, costs, expenses or disbursements incurred by such Purchaser, the Company or any other person or entity), whether in contract, tort or otherwise, to such Investor, or to any person claiming through it, in respect of any action heretofore or hereafter taken or omitted to be taken by any of them in connection with any Purchasers purchase of the Shares or the execution, delivery and performance of the Transaction Documents.6.Conditions to Closing.6.1.Conditions to the Purchasersâ€™ Obligations. The obligation of each Purchaser to purchase the Shares at the Closing is subject to the fulfillment to satisfaction, on or prior to the Closing Date, of the following conditions, any of which may be waived by such Purchaser (as to itself only):(a)The representations and warranties made by the Company in Section 4 hereof shall be true and correct in all material respects (except for those representations and warranties that are qualified by materiality or Material Adverse Change, which shall be true and correct in all respects) as of the Closing Date, except to the extent any such representation or warranty expressly speaks as of an earlier date, in which case such representation or warranty shall be true and correct in all material respects (except for those representations and warranties that are qualified by materiality or Material Adverse Change, which shall be true and correct in all respects) as of such earlier date. The Company shall have performed in all material respects all obligations and covenants herein required to be performed by it on or prior to the Closing Date.(b)The Company shall have performed, satisfied and complied in all material respects with all covenants, agreements and conditions required by the Transaction Documents to be performed, satisfied or complied with by it at or prior to the Closing Date.(c)a Certificate of the Secretary of the Company, dated as of the Closing Date, shall be delivered (i) certifying the resolutions adopted by the Board of Directors of the Company and any duly authorized committee thereof relating to the transactions contemplated by this Agreement and the other Transaction Documents and the issuance of the Shares, (ii) certifying the current versions of the certificate of incorporation, as amended, and bylaws of the Company and (iii) certifying as to the signatures and authority of persons signing the Transaction Documents and related documents on behalf of the Company, in form and substance reasonably acceptable to the Purchasers (the â€œSecretaryâ€™s Certificateâ€);(d)No judgment, writ, order, injunction, award or decree of or by any court, or judge, justice or magistrate, including any bankruptcy court or judge, in each case having authority over the Company or its subsidiaries, or any order of or by any applicable governmental authority, shall have been issued, and no action or proceeding shall have been instituted by any governmental authority, enjoining or preventing the consummation of the transactions contemplated hereby or in the other Transaction Documents.4891-0304-4295\10(e)The Company shall have delivered a Certificate, executed on behalf of the Company by its Chief Executive Officer or its Chief Financial Officer, dated as of the Closing Date, certifying to the fulfillment of the conditions specified in subsections (a) and (b), of this Section 6.1.(f)The Purchasers shall have received an opinion of (i) Company Counsel dated as of the Closing Date and (ii) Company Intellectual Property Counsel, each in a form and substance reasonably acceptable to the Purchasers.(g)The Company shall have executed and delivered the Transaction Documents to each Purchaser.(h)No stop order or suspension of trading shall have been imposed or threatened in writing by the Trading Market, FINRA, the SEC or any other governmental or regulatory body with respect to public trading in the Common Stock.6.2.Conditions to the Companyâ€™s Obligations. The Companyâ€™s obligation to sell and issue the Shares at the Closing to each Purchaser is subject to the fulfillment on or prior to the Closing Date of the following conditions, any of which may be waived by the Company:(a)The representations and warranties made by such Purchaser in Section 5 hereof shall be true and correct in all material respects (except for those representations and warranties that are qualified by materiality, which shall be true and correct in all respects) as of the date hereof as of the Closing Date, except to the extent any such representation or warranty expressly speaks as of an earlier date, in which case such representation or warranty shall be true and correct in all material respects (except for those representations and warranties that are qualified by materiality, which shall be true and correct in all respects) as of such earlier date. Each Purchaser shall have performed in all material respects all obligations and covenants herein required to be performed by it on or prior to the Closing Date.(b)Each Purchaser shall have delivered its applicable portion of the Purchase Price to the Company.(c)Each Purchaser shall have executed and delivered the Transaction Documents to the Company.6.3.Termination of Obligations to Effect Closing; Effects.(a)The obligations of the Company, on the one hand, and the Purchasers, on the other hand, to effect the Closing shall terminate as follows:(i)Upon the mutual written consent of the Company and the Purchasers;(ii)By the Company if any of the conditions set forth in Section 6.2 shall have become incapable of fulfillment, and shall not have been waived by the Company;4891-0304-4295\10(iii)By a Purchaser (with respect to itself only) if any of the conditions set forth in Section 6.1 shall have become incapable of fulfillment, and shall not have been waived by such Purchaser; or(iv)By either the Company or any Purchaser (with respect to itself only) if the Closing has not occurred prior to 11:59 PM (New York time) on July 30, 2024; provided, however, that, except in the case of clause (i) above, the party seeking to terminate its obligation to effect the Closing shall not then be in breach of any of its representations, warranties, covenants or agreements contained in this Agreement or the other Transaction Documents if such breach has resulted in the circumstances giving rise to such partyâ€™s seeking to terminate its obligation to effect the Closing.(b)In the event of termination by the Company or any Purchaser of its obligations to effect the Closing pursuant to this Section 6.3, written notice thereof shall forthwith be given to the other Purchasers by the Company and the other Purchasers shall have the right to terminate their obligations to effect the Closing upon written notice to the Company and the other Purchasers. Nothing in this Section 6.3 shall be deemed to release any party from any liability for any breach by such party of the terms and provisions of this Agreement or the other Transaction Documents or to impair the right of any party to compel specific performance by any other party of its obligations under this Agreement or the other Transaction Documents.7.Other Covenants and Agreements of the Parties.7.1.[Reserved]7.2.Legends. The Shares shall bear the following legends:(a)â€THIS SECURITY HAS NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE â€œSECURITIES ACTâ€), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT WITH A REGISTERED BROKER-DEALER OR OTHER LOAN WITH A FINANCIAL INSTITUTION THAT IS AN â€œACCREDITED INVESTORâ€ AS DEFINED IN RULE 501(a) UNDER THE SECURITIES ACT OR OTHER LOAN SECURED BY SUCH SECURITIES.â€(b)If required by the authorities of any state in connection with the issuance of sale of the Shares, the legend required by such state authority.7.3.Removal of Legends. (a)In connection with any sale, assignment, transfer or other disposition of the Shares by a Purchaser pursuant to Rule 144 or pursuant to any other exemption 4891-0304-4295\10under the Securities Act such that the purchaser acquires freely tradable securities and upon compliance by such Purchaser with the requirements of this Agreement, if requested by such Purchaser, the Company shall cause the Transfer Agent to timely remove any restrictive legends related to the book entry account holding such Shares and make a new, unlegended entry for such book entry Shares sold or disposed of without restrictive legends, provided that the Company has received from the Purchaser customary representations and other documentation reasonably acceptable to the Company in connection therewith.(b)Subject to receipt from the Purchaser by the Company and the Transfer Agent of customary representations and other customary documentation reasonably acceptable to the Company and the Transfer Agent in connection therewith, upon the earliest of (i) the Shares being subject to an effective registration statement covering the resale of the Shares, (ii) such time as the Shares have been sold pursuant to Rule 144, or (iii) such time as the Shares are eligible for resale under Rule 144(b)(1) or any successor provision, the Company shall (A) deliver to the Transfer Agent irrevocable instructions that the Transfer Agent shall make a new, unlegended entry for such book entry Shares, together with either (1) a customary representation by the Purchaser that Rule 144 applies to the Shares represented thereby or (2) a statement by the Purchaser that such Purchaser has sold the Shares represented thereby in accordance with the plan of distribution contained in the Registration Statement, and (B) cause its counsel to deliver to the Transfer Agent one or more opinions to the effect that the removal of such legends in such circumstances may be effected under the Securities Act if required by the Transfer Agent to effect the removal of the legend in accordance with the provisions of this Agreement. The Company agrees that following such time as such legend is no longer required under this Section 7.3, it will, upon a Purchaserâ€™s written request and compliance with the immediately preceding sentence, deliver or cause to be delivered to such Purchaser, a certificate representing that such Shares are free from all restrictive and other legends. Shares subject to legend removal hereunder shall be transmitted by the Transfer Agent to the Purchaser by crediting the account of the Purchaserâ€™s custodian as directed by such Purchaser.7.4.Furnishing of Information. In order to enable the Purchasers to sell the Shares under Rule 144, until the date that the Shares cease to be Registrable Securities (as defined in the Registration Rights Agreement), the Company shall use its commercially reasonable efforts to timely file (or obtain extensions in respect thereof and file within the applicable grace period) all reports required to be filed by the Company after the date hereof pursuant to the Exchange Act. During such period, if the Company is not required to file reports pursuant to the Exchange Act, it will prepare and furnish to the Purchasers and make publicly available in accordance with Rule 144(c) such information as is required for the Purchasers to sell the Shares under Rule 144.7.5.Indemnification of Purchasers. Subject to the provisions of this Section 7.5, the Company will indemnify and hold each Purchaser harmless from any and all losses, liabilities, obligations, claims, contingencies, damages, costs and expenses, including all judgments, amounts paid in settlements, court costs and reasonable attorneysâ€™ fees and costs of investigation, that any such Purchaser may suffer or incur as a result of or relating to any breach of any of the representations, warranties, covenants or agreements made by the Company in this Agreement; provided, however, that the aggregate liability of the Company to each Purchaser under this Section 7.5 shall not exceed the amount paid by such Purchaser to the Company pursuant to Section 3. Promptly after receipt by any Purchaser (the â€œIndemnified Personâ€) of notice of any 4891-0304-4295\10demand or claim from any Person that would or might give rise to a claim or the commencement of any action, proceeding or investigation in respect of which indemnification may be sought pursuant to this Section 7.5 (a â€œThird Party Claimâ€), such Indemnified Person shall promptly notify the Company in writing, and in reasonable detail, of such Third Party Claim. Thereafter, the Indemnified Person will deliver to the Company, within five (5) Business Days after the Indemnified Personâ€™s receipt thereof, copies of all notices and documents (including court papers) received by the Indemnified Person relating to the Third Party Claim. If a Third Party Claim is made against the Company, the Company will be entitled to participate in the defense thereof and, if it so chooses, to assume the defense thereof (subject to a reservation of rights) with counsel selected by the Company by giving the Indemnified Person notice within twenty (20) days of the Companyâ€™s receipt of notice of the Third Party Claim pursuant to this Section 7.5. If the Company does not give such notice to the Indemnified Person of the Companyâ€™s intent to assume the defense of the Third Party Claim, the Indemnified Person shall be entitled to assume the defense thereof. Should the Company so elect to assume the defense of a Third Party Claim, the Company will not be liable to the Indemnified Person for legal expenses subsequently incurred by the Indemnified Person in connection with the defense thereof. If the Company assumes such defense, the Indemnified Person will have the right to participate in the defense thereof and to employ counsel, at its own expense, separate from the counsel employed by the Company, it being understood, however, that the Company will control such defense. If the Company chooses to defend any Third Party Claim, then all the Parties will cooperate in the defense or prosecution of such Third Party Claim. The Indemnified Person will not admit any liability with respect to, or settle, compromise or discharge, any Third Party Claim without the prior written consent of the Company. Notwithstanding any other provision of this Agreement, the Company shall not enter into settlement of any Third Party Claim without the prior written consent of the Indemnified Person (which consent shall not be unreasonably withheld), unless such settlement requires only the payment of money that the Company is obligated to pay.7.6.Equal Treatment of Purchasers. No consideration shall be offered or paid to any Person to amend or consent to a waiver or modification of any provision of any of the Transaction Documents unless the same consideration is also offered to all of the Parties to the Transaction Documents. For clarification purposes, this provision constitutes a separate right granted to each Purchaser by the Company and negotiated separately by each Purchaser, and is intended for the Company to treat the Purchasers as a class and shall not in any way be construed as the Purchasers acting in concert or as a group with respect to the purchase, disposition or voting of Shares or otherwise.7.7.Compliance with Laws. Notwithstanding any other provision of this Agreement, each Purchaser covenants that the Shares may be disposed of only pursuant to an effective registration statement under, and in compliance with the requirements of, the Shares Act, or pursuant to an available exemption from, or in a transaction not subject to, the registration requirements of the Securities Act, and in compliance with any applicable state and federal securities Laws. In connection with any transfer of the Shares other than (i) pursuant to an effective registration statement, (ii) to the Company, (iii) pursuant to Rule 144 (provided that the Purchaser provides the Company with reasonable assurances (in the form of seller and, if applicable, broker representation letters) that the Shares may be sold pursuant to such rule), or (iv) to its Affiliates, the Company may require the transferor thereof to provide to the Company an opinion of counsel selected by the transferor and reasonably acceptable to the Company, the form and substance of 4891-0304-4295\10which opinion shall be reasonably satisfactory to the Company, to the effect that such transfer does not require registration of such transferred Shares under the Securities Act. As a condition of transfer, any such transferee shall agree in writing to be bound by the terms of this Agreement and shall have the rights of a Purchaser under this Agreement with respect to such transferred Shares.7.8.Disclosure of Material Non-Public Information. The Company shall not disclose material non-public information to the Purchasers, or to advisors to or representatives of the Purchasers, unless prior to disclosure of such information the Company identifies such information as being material non-public information and provides the Purchasers, such advisors and representatives with the opportunity to accept or refuse to accept such material non-public information for review and any Purchaser wishing to obtain such information enters into an appropriate confidentiality agreement with the Company with respect thereto.7.9.Termination of Certain Obligations. The provisions of Section 7.8 shall terminate and be of no further force and effect on the date on which the Companyâ€™s obligations under the Registration Rights Agreement to register or maintain the effectiveness of any registration covering the Registrable Securities (as defined in the Registration Rights Agreement) shall terminate.7.10.[Reserved].8.Survival. The representations, warranties, covenants and agreements contained in this Agreement shall survive for a period of one (1) year following the Closing.9.Miscellaneous.9.1.Assignment. This Agreement may not be assigned by a party hereto without the prior written consent of the Company or the Purchasers, as applicable.9.2.Successors. This Agreement shall be binding solely on, and inure solely to the benefit of, each of the undersigned and their respective successors and permitted assigns, and nothing set forth in this Agreement shall be construed to confer upon or give to any Person other than each of the undersigned and their respective successors and permitted assigns any benefits, rights or remedies under or by reason of, or any rights to enforce or cause the Company to enforce, the equity commitment or any provisions of this Agreement.9.3.Counterparts; Faxes; Electronic Mail. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same

instrument. This Agreement may also be executed via facsimile or electronic mail, each of which shall be deemed an original.9.4.Titles and Subtitles. The titles and subtitles used in this Agreement are used for convenience only and are not to be considered in construing or interpreting this Agreement.9.5.Notices. Unless otherwise provided, any notice required or permitted under this Agreement shall be given in writing and shall be deemed effectively given as hereinafter described: (i) if given by personal delivery, then such notice shall be deemed given upon such delivery; (ii) if given by facsimile, then such notice shall be deemed given upon receipt of 4891-0304-4295\10confirmation of complete transmittal; (iii) if given by mail, then such notice shall be deemed given upon the earlier of (A) receipt of such notice by the recipient or (B) three (3) days after such notice is deposited in first class mail, postage prepaid; and (iv) if given by an internationally recognized overnight air courier, then such notice shall be deemed given one (1) Business Day after delivery to such carrier. All notices shall be addressed to the party to be notified at the address as follows, or at such other address as such party may designate by ten (10) daysâ€™ advance written notice to the other party:If to the Company:Rezolute, Inc.275 Shoreline Drive, Suite 500Redwood City, CA 94065Attn: Nevan Elam, CEOWith a copy to:Dorsey & Whitney LLP,1400 Wewatta Street, Suite 400Denver, CO 80202-5549Attn: Anthony W. Epps, Esq.If to the Purchasers:to the addresses set forth on the signature pages hereto.9.6.Amendments and Waivers. Any term of this Agreement may be amended and the observance of any term of this Agreement may be waived (either generally or in a particular instance and either retroactively or prospectively) only with the written consent of the Company and the Required Purchasers. Any amendment or waiver effected in accordance with this paragraph shall be binding upon each holder of any Shares purchased under this Agreement at the time outstanding, each future holder of all such Shares, and the Company.9.7.Publicity. Except as set forth below, no public release or announcement concerning the transactions contemplated hereby shall be issued by the Company or the Purchasers without the prior written consent of the Company (in the case of a release or announcement by the Purchasers), the Placement Agent or the Required Purchasers (in the case of a release or announcement by the Company) (which consents shall not be unreasonably withheld), except (i) as such release or announcement may be required by Law or the applicable rules or regulations of the SEC, any securities exchange or securities market, in which case the Company or the Purchasers, as the case may be, shall allow the Purchasers or the Company, as applicable, to the extent reasonably practicable in the circumstances, reasonable time to comment on such release or announcement in advance of such issuance or (ii) a public release or announcement in connection with discussions to investors not including the Required Purchasers, in which case such consent shall not be required. Notwithstanding the foregoing, no Purchaser may be named in a public release or announcement concerning the transactions contemplated hereby without such Purchasers prior written consent. The Purchasers hereby acknowledge and agree that no later than 4891-0304-4295\10the fourth (4th) Business Day after the date hereof, the Company shall (x) issue a press release reasonably acceptable to the Required Purchasers and (y) file a Current Report on Form 8-K describing the terms of the transactions contemplated by the Transaction Documents in the form required by the Exchange Act and attaching the material Transaction Documents (including, without limitation, this Agreement (and all schedules and exhibits to this Agreement) and the Registration Rights Agreement, as exhibits to such filing (including all attachments)). In addition, the Company will make such other filings and notices in the manner and time required by the SEC or NASDAQ and the Registration Rights Agreement.9.8.Severability. Any provision of this Agreement that is prohibited or unenforceable in any jurisdiction shall, as to such jurisdiction, be ineffective to the extent of such prohibition or unenforceability without invalidating the remaining provisions hereof but shall be interpreted as if it were written so as to be enforceable to the maximum extent permitted by applicable Law, and any such prohibition or unenforceability in any jurisdiction shall not invalidate or render unenforceable such provision in any other jurisdiction. To the extent permitted by applicable Law, the Parties hereby waive any provision of Law which renders any provision hereof prohibited or unenforceable in any respect.9.9.Entire Agreement. This Agreement, including the Exhibits and the Registration Rights Agreement constitute the entire agreement among the Parties with respect to the subject matter hereof and thereof and supersede all prior agreements and understandings, both oral and written, among the Parties with respect to the subject matter hereof and thereof.9.10.Further Assurances. The Parties shall execute and deliver all such further instruments and documents and take all such other actions as may reasonably be required to carry out the transactions contemplated hereby and to evidence the fulfillment of the agreements herein contained.9.11.Governing Law; Consent to Jurisdiction; Waiver of Jury Trial. This Agreement shall be governed by, and construed in accordance with, the internal Laws of the State of Nevada without regard to the choice of law principles thereof. Each of the Parties irrevocably submits to the exclusive jurisdiction of the courts of the State of Nevada and any state appellate court therefrom within the State of Nevada and any state appellate court therefrom within the State of Nevada for the purpose of any suit, action, proceeding or judgment relating to or arising out of this Agreement and the transactions contemplated hereby. Service of process in connection with any such suit, action or proceeding may be served on each party hereto anywhere in the world by the same methods as are specified for the giving of notices under this Agreement. Each of the Parties irrevocably consents to the jurisdiction of any such court in any such suit, action or proceeding and to the laying of venue in such court. Each party hereto irrevocably waives any objection to the laying of venue of any such suit, action or proceeding brought in such courts and irrevocably waives any claim that any such suit, action or proceeding brought in any such court has been brought in an inconvenient forum. EACH OF THE PARTIES WAIVES ANY RIGHT TO REQUEST A TRIAL BY JURY IN ANY LITIGATION WITH RESPECT TO THIS AGREEMENT AND REPRESENTS THAT COUNSEL HAS BEEN CONSULTED SPECIFICALLY AS TO THIS WAIVER.4891-0304-4295\109.12.Disclaimer. Except as expressly set forth in this Agreement, no Party makes any representation or warranty to any other Party of any nature, express or implied. Each Purchaser acknowledges and agrees that in evaluating its investment in the Shares, it is not relying on any representations, warranties or information (including the accuracy or completeness thereof) other than the representations and warranties contained herein and the information contained in the SEC Filings.9.13.Independent Nature of Purchasersâ€™ Obligations and Rights. The obligations of each Purchaser under any Transaction Document are several and not joint with the obligations of any other Purchaser, and no Purchaser shall be responsible in any way for the performance of the obligations of any other Purchaser under any Transaction Document. The decision of each Purchaser to purchase Shares pursuant to the Transaction Documents has been made by such Purchaser independently of any other Purchaser. Nothing contained in any Transaction Document, and no action taken by any Purchaser pursuant thereto, shall be deemed to constitute the Purchasers as a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Purchasers are in any way acting in concert or as a group with respect to such obligations or the transactions contemplated by the Transaction Documents. Each Purchaser acknowledges that no other Purchaser has acted as agent for such Purchaser in connection with making its investment hereunder and that no Purchaser will be acting as agent of such Purchaser in connection with monitoring its investment in the Shares or enforcing its rights under the Transaction Documents. Each Purchaser shall be entitled to independently protect and enforce its rights, including, without limitation, the rights arising out of the Transaction Documents, and it shall not be necessary for any other Purchaser to be joined as an additional party in any proceeding for such purpose. The Company acknowledges that each of the Purchasers has been provided with the same Transaction Documents for the purpose of closing a transaction with multiple Purchasers and not because it was required or requested to do so by any Purchaser.9.14.No Third Party Beneficiaries. This Agreement is intended for the benefit of the parties hereto and their respective permitted successors and assigns, and is not for the benefit of, nor may any provision hereof be enforced by, any other Person except as provided in the next paragraph.9.15.Reliance by the Placement Agent. The parties agree and acknowledge that the Placement Agent may rely on the representations, warranties, agreements and covenants of the Company contained in this Agreement and may rely on the representations and warranties of the respective Purchasers contained in this Agreement as if such representations, warranties, agreements, and covenants, as applicable, were made directly to the Placement Agent. The parties further agreement that the Placement Agent may rely on or, if the Placement Agent so request, be specifically named as an addressee of, the legal opinions to be delivered pursuant to Section 6(f) of this Agreement.(a)The Placement Agent, and its affiliates and its respective representatives shall be entitled to (1) rely on, and shall be protected in acting upon, any certificate, instrument, opinion, notice, letter or any other document or security delivered to any of it by or on behalf of the Company, and (2) be indemnified by the Company for acting as Closing Agent in connection with the transactions contemplated by the Transaction Documents pursuant the indemnification provisions set forth in the Engagement Letter.4891-0304-4295\10[Signature pages follow]â€‹4891-0304-4295\10IN WITNESS WHEREOF, the Parties have executed this Agreement as of the date first indicated above.The Company:REZOLUTE, INC.â€‹By:Name: Nevan ElamIts: Chief Executive Officerâ€‹â€[Signature Page to PIPE â€“ Securities Purchase Agreement]â€‹4891-0304-4295\10IN WITNESS WHEREOF, the Parties have executed this Agreement as of the date first above written.[â€¢]By:Name: [â€¢]Its: Chairman and Chief Executive OfficerAggregate Purchase Price (Subscription Amount): [â€¢]Number of Shares to be Acquired: [â€¢]â€‹Address for Notice/Residency of Purchaser: [â€¢]_____Telephone No.: [â€¢]Facsimile No.:_ [â€¢]E-mail Address: [â€¢]Attention: _____â€‹â€Delivery Instructions:(if different than above)c/o _____Street: _____City/State/Zip: _____Attention: _____Telephone No.: _____[Signature Page to PIPE â€“ Securities Purchase Agreement]â€‹4891-0304-4295\10Exhibit ASchedule of Purchasersâ€‹4891-0304-4295\10Exhibit BRegistration Rights Agreement4891-0304-4295\10 EX-10.37 5 rzlt-20240630xex10d37.htm EX-10.37 â€‹REGISTRATION RIGHTS AGREEMENTThis Registration Rights Agreement (this â€œAgreementâ€) is made and entered into as of June __, 2024 between Rezolute, Inc., a Nevada corporation (the â€œCompanyâ€), and each of the several purchasers signatory hereto (each such purchaser, a â€œPurchaserâ€ and, collectively, the â€œPurchasersâ€).The Company and each Purchaser hereby agrees as follows:1.Definitions.Capitalized terms used and not otherwise defined herein that are defined in the Securities Purchase Agreement shall have the meanings given such terms in the Securities Purchase Agreement. As used in this Agreement, the following terms shall have the following meanings:â€œAdviceâ€ shall have the meaning set forth in Section 6(c).â€œEffectiveness Dateâ€ means, with respect to the Initial Registration Statement required to be filed hereunder, the 60th calendar day following the date hereof (or, in the event of a â€œfull reviewâ€ by the Commission, the 90th calendar day following the date hereof), and with respect to any additional Registration Statements which may be required pursuant to Section 2(c) or Section 3(c), the 60th calendar day following the date on which the Company first knows, that an additional Registration Statement is required to be filed hereunder (or, in the event of a â€œfull reviewâ€ by the Commission, the 90th calendar day following the date on which the Company first knows, that such additional Registration Statement is required to be filed hereunder); provided, however, that in the event the Company is notified by the Commission that one or more of the above Registration Statements will not be reviewed or is no longer subject to further review and comments, the Effectiveness Date as to such Registration Statement shall be the fifth Trading Day following the date on which the Company is so notified if such date precedes the dates otherwise required above; and provided, further, if such Effectiveness Date falls on a day that is not a Trading Day, then the Effectiveness Date shall be the next succeeding Trading Day.â€œEffectiveness Periodâ€ shall have the meaning set forth in Section 2(a).â€œEventâ€ shall have the meaning set forth in Section 2(d).â€œEvent Dateâ€ shall have the meaning set forth in Section 2(d).â€œFiling Dateâ€ means, with respect to the Initial Registration Statement required hereunder, the thirtieth Â calendar day following the receipt of payment of the Securities, and, with respect to any additional Registration Statements which may be required pursuant to Section 2(c) or Section 3(c), the earliest practical date on which the Company is permitted by SEC Guidance to file such additional Registration Statement related to the Registrable Securities.â€œHolderâ€ or â€œHoldersâ€ means the holder or holders, as the case may be, from time to time of Registrable Securities.4879-0208-0199\1â€‹â€œIndemnified Partyâ€ shall have the meaning set forth in Section 5(c).â€œIndemnifying Partyâ€ shall have the meaning set forth in Section 5(c).â€œInitial Registration Statementâ€ means the initial Registration Statement filed pursuant to this Agreement.â€œLossesâ€ shall have the meaning set forth in Section 5(a).â€œPlan of Distributionâ€ shall have the meaning set forth in Section 2(a).â€œProspectusâ€ means the prospectus included in a Registration Statement (including, without limitation, a prospectus that includes any information previously omitted from a prospectus filed as part of an effective registration statement in reliance upon Rule 430A promulgated by the Commission pursuant to the Securities Act), as amended or supplemented by any prospectus supplement, with respect to the terms of the offering of any portion of the Registrable Securities covered by a Registration Statement, and all other amendments and supplements to the Prospectus, including post-effective amendments, and all material incorporated by reference or deemed to be incorporated by reference in such Prospectus.â€œRegistrable Securitiesâ€ means, as of any date of determination, (a) all Shares and Warrant Shares then issued or to be issued and (b) any securities issued, dividend or other distribution, stock split, recapitalization or similar event with respect to the foregoing; provided, however, that any such Registrable Securities shall cease to be Registrable Securities (and the Company shall not be required to maintain the effectiveness of any, or file another, Registration Statement hereunder with respect thereto) for so long as (a) a Registration Statement with respect to the sale of such Registrable Securities is declared effective by the Commission under the Securities Act and such Registrable Securities have been disposed of by the Holder in accordance with such effective Registration Statement, (b) such Registrable Securities have been previously sold in accordance with Rule 144, or (c) such securities become eligible for resale without volume or manner-of-sale restrictions and without current public information pursuant to Rule 144 as set forth in a written opinion letter to such effect, addressed, delivered and acceptable to the Transfer Agent and the affected Holders (assuming that such securities and any securities issuable upon exercise, conversion or exchange of which, or as a dividend upon which, such securities were issued or are issuable, were at no time held by any Affiliate of the Company, and all Warrants are exercised by â€œcashless exerciseâ€), as reasonably determined by the Company, upon the advice of counsel to the Company.â€œRegistration Statementâ€ means any registration statement required to be filed hereunder pursuant to Section 2(a) and any additional registration statements contemplated by Section 2(c) or Section 3(c), including (in each case) the Prospectus, amendments and supplements to any such registration statement or Prospectus, including pre- and post-effective amendments, all exhibits thereto, and all material incorporated by reference or deemed to be incorporated by reference in any such registration statement.â€œRule 415â€ means Rule 415 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted from time to time, or any similar rule 4879-0208-0199\1â€‹or regulation hereafter adopted by the Commission having substantially the same purpose and effect as such Rule.â€œRule 424â€ means Rule 424 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect as such Rule.â€œSelling Stockholder Questionnaireâ€ shall have the meaning set forth in Section 3(a).â€œSEC Guidanceâ€ means (i) any publicly-available written or oral guidance of the Commission staff, or any comments, requirements or requests of the Commission staff and (ii) the Securities Act.2.Shelf Registration. (a)On or prior to each Filing Date, the Company shall prepare and file with the Commission a Registration Statement covering the resale of all of the Registrable Securities that are not then registered on an effective Registration Statement for an offering to be made on a continuous basis pursuant to Rule 415. Each Registration Statement filed hereunder shall be on Form S-3 (except if the Company is not then eligible to register for resale the Registrable Securities on Form S-3, in which case such registration shall be on another appropriate form in accordance herewith, subject to the provisions of Section 2(e)) and shall contain (unless otherwise directed by at least 50.1% in interest of the Holders) substantially the â€œPlan of Distributionâ€ attached hereto as Annex A and a â€œSelling Stockholderâ€ section of the type that is customary for transactions of this kind; provided, however, that no Holder shall be required to be named as an â€œunderwriterâ€ without such Holderâ€™s express prior written consent. Subject to the terms of this Agreement, the Company shall use commercially reasonable efforts to cause a Registration Statement filed under this Agreement (including, without limitation, under SectionÂ 3(c)) to be declared effective under the Securities Act as promptly as possible after the filing thereof, but in any event no later than the applicable Effectiveness Date, and shall use its reasonable best efforts to keep such Registration Statement continuously effective under the Securities Act until the date that all Registrable Securities covered by such Registration Statement (i) have been sold thereunder or pursuant to Rule 144, or (ii) may be sold without volume or manner-of-sale restrictions pursuant to Rule 144 and without the requirement for the Company to be in compliance with the current public information requirement under Rule 144, as determined by the counsel to the Company pursuant to a written opinion letter to such effect, addressed and acceptable to the Transfer Agent and the affected Holders (the â€œEffectiveness Periodâ€). The Company shall telephonically request effectiveness of a Registration Statement as of 5:00 p.m. (New York City time) on a Trading Day. The Company shall promptly notify each Holder of the effectiveness of a Registration Statement on the same Trading Day that the Company telephonically confirms effectiveness with the Commission, which shall be the date requested for effectiveness of such Registration Statement. The Company shall, in compliance with the requirements of the Securities Act, file a final Prospectus with the Commission as required by Rule 424.4879-0208-0199\1â€‹(b)Notwithstanding the registration obligations set forth in Section 2(a), if the Commission informs the Company that all of the Registrable Securities cannot, as a result of the application of Rule 415, be registered for resale as a secondary offering on a single registration statement, the Company agrees to promptly inform each of the Holders thereof and use its commercially reasonable efforts to file amendments to the Initial Registration Statement as required by the Commission, covering the maximum number of Registrable Securities permitted to be registered by the Commission, on Form S-3 or such other form available to register for resale the Registrable Securities as a secondary offering, subject to the provisions of Section 2(e); with respect to filing on Form S-3 or other appropriate form, and subject to the provisions of Section 2(d) with respect to the payment of liquidated damages; provided, however,

that prior to filing such amendment, the Company agrees to use commercially reasonable efforts to advocate with the Commission for the registration of all of the Registrable Securities in accordance with the SEC Guidance, including without limitation, Compliance and Disclosure Interpretation 612.09. The Company shall not be liable for any damages under this Agreement in connection with any Registrable Securities not registered for resale on a particular Registration Statement pursuant to this Section 2(b).(c)Notwithstanding any other provision of this Agreement, if the Commission or any SEC Guidance sets forth a limitation on the number of Registrable Securities permitted to be registered on a particular Registration Statement as a secondary offering (and notwithstanding that the Company used commercially reasonable efforts to advocate with the Commission for the registration of all or a greater portion of Registrable Securities), unless otherwise directed in writing by a Holder as to its Registrable Securities, the number of Registrable Securities to be registered on such Registration Statement will be reduced as follows:a.First, the Company shall reduce or eliminate any securities to be included other than Registrable Securities;b.Second, the Company shall reduce Registrable Securities represented by Warrant Shares (applied, in the case that some Warrant Shares may be registered, to the Holders on a pro rata basis based on the total number of unregistered Warrant Shares held by such Holders); andc.Third, the Company shall reduce Registrable Securities represented by Shares (applied, in the case that some Shares may be registered, to the Holders on a pro rata basis based on the total number of unregistered Shares held by such Holders).In the event of a cutback hereunder, the Company shall give the Holder at least five (5) Trading Days prior written notice along with the calculations as to such Holderâ€™s allotment. In the event the Company amends the Initial Registration Statement in accordance with the foregoing, the Company will use its reasonable best efforts to file promptly with the Commission one or more registration statements on Form S-3 or such other form available to register for resale those Registrable Securities that were not registered for resale on the Initial Registration Statement, as amended. The Company shall not be liable for any damages under this Agreement in connection with any Registrable Securities not registered for resale on a particular Registration Statement pursuant to Sections 2(b) or 2(c).4879-0208-0199\1â€‹(d)If: (i) the Initial Registration Statement is not filed on or prior to its Filing Date (if the Company files the Initial Registration Statement without affording the Holders the opportunity to review and comment on the same as required by Section 3(a) herein, the Company shall be deemed to have not satisfied this clause (i)), or (ii) the Company fails to file with the Commission a request for acceleration of a Registration Statement in accordance with Rule 461 promulgated by the Commission pursuant to the Securities Act, within five Trading Days of the date that the Company is notified (orally or in writing, whichever is earlier) by the Commission that such Registration Statement will not be â€œreviewedâ€ or will not be subject to further review, or (iii) prior to the effective date of a Registration Statement, the Company fails to file a pre-effective amendment and otherwise respond in writing to comments made by the Commission in respect of such Registration Statement within ten (10) calendar days after the receipt of comments by or notice from the Commission that such amendment is required in order for such Registration Statement to be declared effective, or (iv) a Registration Statement registering for resale all of the Registrable Securities is not declared effective by the Commission by the Effectiveness Date of the Initial Registration Statement (subject to any reductions to such Registrable Securities being registered pursuant to Sections 2(b) or 2(c), which reductions shall, for the avoidance of doubt, not cause any damages under this Section 2(d)), or (v) after the effective date of a Registration Statement, such Registration Statement ceases for any reason to remain continuously effective as to all Registrable Securities included in such Registration Statement, or the Holders are otherwise not permitted to utilize the Prospectus therein to resell such Registrable Securities, for more than ten (10) consecutive calendar days or more than an aggregate of fifteen (15) calendar days (which need not be consecutive calendar days) during any 12-month period (any such failure or breach being referred to as an â€œEventâ€, and for purposes of clauses (i) and (iv), the date on which such Event occurs, and for purpose of clause (ii) the date on which such five (5) Trading Day period is exceeded, and for purpose of clause (iii) the date which such ten (10) calendar day period is exceeded, and for purpose of clause (v) the date on which such ten (10) or fifteen (15) calendar day period, as applicable, is exceeded, being referred to as â€œEvent Dateâ€), then, in addition to any other rights the Holders may have hereunder or under applicable law, on each such Event Date and on each monthly anniversary of each such Event Date (if the applicable Event shall not have been cured by such date) until the earlier of (1)Â applicable Event is cured or (2) the Registrable Securities are eligible for resale pursuant to Rule 144 without manner of sale or volume restrictions, the Company shall pay to each Holder an amount in cash, as partial liquidated damages and not as a penalty, equal to the product of 2.0% multiplied by the aggregate amount paid by such Holder for any unregistered Registrable Securities then held by such Holder. If the Company fails to pay any partial liquidated damages pursuant to this Section in full within seven days after the date payable, the Company will pay interest thereon at a rate of 18% per annum (or such lesser maximum amount that is permitted to be paid by applicable law) to the Holder, accruing daily from the date such partial liquidated damages are due until such amounts, plus all such interest thereon, are paid in full. The parties agree that (1) notwithstanding anything to the contrary herein, no liquidated damages shall be payable with respect to any period after the expiration of the Effectiveness Period so long as the Registrable Securities are eligible for resale pursuant to Rule 144 without manner of sale or volume restrictions. The effectiveness deadline for a Registration Statement shall be extended without default or liquidated damages hereunder in the event that the Companyâ€™s failure to obtain the effectiveness of the Registration on a timely basis results from the failure of a Holder to timely provide the Company with information requested by the Company and necessary to complete the Registration Statement in accordance with the requirements of the Securities Act (in 4879-0208-0199\1â€‹which the effectiveness deadline would be extended with respect to the Registrable Securities held only by such Holder). The partial liquidated damages pursuant to the terms hereof shall apply on a daily pro rata basis for any portion of a month prior to the cure of an Event.(e)If Form S-3 is not available for the registration of the resale of Registrable Securities hereunder, the Company shall (i) register the resale of the Registrable Securities on another appropriate form and (ii) undertake to register the Registrable Securities on Form S-3 as soon as such form is available, provided that the Company shall maintain the effectiveness of the Registration Statement then in effect until such time as a Registration Statement on Form S-3 covering the Registrable Securities has been declared effective by the Commission.3.Registration Procedures.In connection with the Companyâ€™s registration obligations hereunder, the Company shall:(a)Not less than three (3) Trading Days prior to the filing of each Registration Statement and not less than one (1) Trading Day prior to the filing of any related Prospectus or any amendment or supplement thereto, the Company shall (i) furnish to each Holder copies of all such documents proposed to be filed, which documents will be subject to the review of such Holders, and (ii) use commercially reasonable efforts to cause its officers and directors, counsel and independent registered public accountants to respond to such inquiries as shall be necessary, in the reasonable opinion of respective counsel to each Holder, to conduct a reasonable investigation within the meaning of the Securities Act. Notwithstanding the foregoing, the Company shall not be required to furnish to the Holders any prospectus supplement being prepared and filed solely to name new or additional selling securityholders unless such Holders are named in such filing. The Company shall not file a Registration Statement or any such Prospectus or any amendments or supplements thereto to which the Holders of a majority of the Registrable Securities shall reasonably object in good faith, provided that, the Company is notified of such objection in writing no later than two (2) Trading Days after the Holders have been so furnished copies of a Registration Statement or one (1) Trading Day after the Holders have been so furnished copies of any related Prospectus or amendments or supplements thereto. Each Holder agrees to furnish to the Company a completed questionnaire in the form attached to this Agreement as Annex B (a â€œSelling Stockholder Questionnaireâ€) on a date that is not less than two (2) Trading Days prior to the Filing Date or by the end of the second (2nd) Trading Day following the date on which such Holder receives draft materials in accordance with this Section.(b)(i) Prepare and file with the Commission such amendments, including post-effective amendments, to a Registration Statement and the Prospectus used in connection therewith as may be necessary to keep a Registration Statement continuously effective as to the applicable Registrable Securities for the Effectiveness Period and prepare and file with the Commission such additional Registration Statements in order to register for resale under the Securities Act all of the Registrable Securities, (ii) cause the related Prospectus to be amended or supplemented by any required Prospectus supplement (subject to the terms of this Agreement), and, as so supplemented or amended, to be filed pursuant to Rule 424, (iii) respond as promptly as reasonably possible to any comments received from the Commission with respect to a Registration Statement or any amendment thereto and provide as promptly as reasonably possible to the Holders true and complete copies of all correspondence from and to the Commission relating to a Registration 4879-0208-0199\1â€‹Statement (provided that, the Company shall excise any information contained therein which would constitute material non-public information regarding the Company or any of its Subsidiaries), and (iv) comply in all material respects with the applicable provisions of the Securities Act and the Exchange Act with respect to the disposition of all Registrable Securities covered by a Registration Statement during the applicable period in accordance (subject to the terms of this Agreement) with the intended methods of disposition by the Holders thereof set forth in such Registration Statement as so amended or in such Prospectus as so supplemented.(c)If during the Effectiveness Period, the number of Registrable Securities at any time exceeds 100% of the number of shares of Common Stock then registered in a Registration Statement, then the Company shall file as soon as reasonably practicable, but in any case prior to the applicable Filing Date, an additional Registration Statement covering the resale by the Holders of not less than the number of such Registrable Securities.(d)Notify the Holders of Registrable Securities to be sold (which notice shall, pursuant to clauses (iii) through (vi) hereof, be accompanied by an instruction to suspend the use of the Prospectus until the requisite changes have been made) as promptly as reasonably possible (and, in the case of (i)(A) below, not less than one (1) Trading Day prior to such filing) and (if requested by any such Person) confirm such notice in writing no later than one (1) Trading Day following the day: (i)(A) when a Prospectus or any Prospectus supplement or post-effective amendment to a Registration Statement is proposed to be filed, (B) when the Commission notifies the Company whether there will be a â€œreviewâ€ of such Registration Statement and whenever the Commission comments in writing on such Registration Statement, and (C) with respect to a Registration Statement or any post-effective amendment, when the same has become effective, (ii) of any request by the Commission or any other federal or state governmental authority for amendments or supplements to a Registration Statement or Prospectus or for additional information that pertains to the Holders as Selling Stockholders of the Plan of Distribution, (iii) of the issuance by the Commission or any other federal or state governmental authority of any stop order suspending the effectiveness of a Registration Statement covering any or all of the Registrable Securities or the initiation of any Proceedings for that purpose, (iv) of the receipt by the Company of any notification with respect to the suspension of the qualification or exemption from qualification of any of the Registrable Securities for sale in any jurisdiction, or the initiation or threatening of any Proceeding for such purpose, (v) of the occurrence of any event or passage of time that makes the financial statements included in a Registration Statement ineligible for inclusion therein or any statement made in a Registration Statement or Prospectus or any document incorporated or deemed to be incorporated therein by reference untrue in any material respect or that requires any revisions to a Registration Statement, Prospectus or other documents so that, in the case of a Registration Statement or the Prospectus, as the case may be, it will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading, and (vi) of the occurrence or existence of any pending corporate development with respect to the Company that the Company believes may be material and that, in the determination of the Company, makes it not in the best interest of the Company to allow continued availability of a Registration Statement or Prospectus; provided, however, that in no event shall any such notice contain any information which would constitute material, non-public information regarding the Company or any of its Subsidiaries.4879-0208-0199\1â€‹(e)Use its reasonable best efforts to avoid the issuance of, or, if issued, obtain the withdrawal of (i) any order stopping or suspending the effectiveness of a Registration Statement, or (ii) any suspension of the qualification (or exemption from qualification) of any of the Registrable Securities for sale in any jurisdiction, at the earliest practicable moment.(f)Furnish to each Holder, without charge, at least one conformed copy of each such Registration Statement and each amendment thereto, and all exhibits to the extent reasonably requested by such Person (including those previously furnished or incorporated by reference) promptly after the filing of such documents with the Commission, provided that any such item which is available on the EDGAR system (or successor thereto) need not be furnished in physical form.(g)Subject to the terms of this Agreement, the Company hereby consents to the use of such Prospectus and each amendment or supplement thereto by each of the selling Holders in connection with the offering and sale of the Registrable Securities covered by such Prospectus and any amendment or supplement thereto, except after the giving of any notice pursuant to Section 3(d).(h)Prior to any resale of Registrable Securities by a Holder, use its commercially reasonable efforts to register or qualify or cooperate with the selling Holders in connection with the registration or qualification (or exemption from the Registration or qualification) of such Registrable Securities for the resale by the Holder under the securities or Blue Sky laws of such jurisdictions within the United States as any Holder reasonably requests in writing, to keep each registration or qualification (or exemption therefrom) effective during the Effectiveness Period and to do any and all other acts or things reasonably necessary to enable the disposition in such jurisdictions of the Registrable Securities covered by each Registration Statement, provided that the Company shall not be required to qualify generally to do business in any jurisdiction where it is not then so qualified, subject the Company to any material tax in any such jurisdiction where it is not then so subject or file a general consent to service of process in any such jurisdiction.(i)If requested by a Holder, cooperate with such Holder to facilitate the timely preparation and delivery of certificates representing Registrable Securities to be delivered to a transferee pursuant to a Registration Statement, which certificates shall be free of all restrictive legends, and to enable such Registrable Securities to be in such denominations and registered in such names as any such Holder may request.(j)Upon the occurrence of any event contemplated by Section 3(d), as promptly as reasonably possible under the circumstances taking into account the Companyâ€™s good faith assessment of any adverse consequences to the Company and its stockholders of the premature disclosure of such event, prepare a supplement or amendment, including a post-effective amendment, to a Registration Statement or a supplement to the related Prospectus or any document incorporated or deemed to be incorporated therein by reference, and file any other required document so that, as thereafter delivered, neither a Registration Statement nor such Prospectus will contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading. If the Company notifies the Holders in accordance with clauses (iii) 4879-0208-0199\1â€‹through (vi) of Section 3(d) above to suspend the use of any Prospectus until the requisite changes to such Prospectus have been made, then the Holders shall suspend use of such Prospectus. The Company will use its reasonable best efforts to ensure that the use of the Prospectus may be resumed as promptly as is practicable. The Company shall be entitled to exercise its right under this Section 3(j) to suspend the availability of a Registration Statement and Prospectus, subject to the payment of partial liquidated damages otherwise required pursuant to Section 2(d), for a period not to exceed 60 calendar days (which need not be consecutive days) in any 12-month period. (k)Otherwise use commercially reasonable efforts to comply with all applicable rules and regulations of the Commission under the Securities Act and the Exchange Act that are applicable to any Registration Statement or to the Registrable Holders file any final Prospectus, including any supplement or amendment thereof, with the Commission pursuant to Rule 424 under the Securities Act, or promptly inform the Holders in writing if, at any time during the Effectiveness Period, the Company does not satisfy the conditions specified in Rule 172 and, as a result thereof, the Holders are required to deliver a Prospectus in connection with any disposition of Registrable Securities and take such other actions as may be reasonably necessary to facilitate the registration of the Registrable Securities hereunder.(l)Use its reasonable best efforts to maintain eligibility for use of Form S-3 (or any successor form thereto) for the registration of the resale of Registrable Securities.(m)The Company may require each selling Holder to furnish to the Company a certified statement as to the number of shares of Common Stock beneficially owned by such Holder and, if required by the Commission, the natural persons thereof that have voting and dispositive control over the shares. During any periods that the Company is unable to meet its obligations hereunder with respect to the registration of the Registrable Securities solely because any Holder fails to furnish such information within three (3) Trading Days of the Companyâ€™s request, any liquidated damages that are accruing at such time as to such Holder only shall be tolled and any Event that may otherwise occur solely because of such delay shall be suspended as to such Holder only, until such information is delivered to the Company.4.Registration Expenses. All fees and expenses incident to the performance of or compliance with, this Agreement by the Company shall be borne by the Company whether or not any Registrable Securities are sold pursuant to a Registration Statement. The fees and expenses referred to in the foregoing sentence shall include, without limitation, (i) all registration and filing fees (including, without limitation, fees and expenses of the Companyâ€™s counsel and independent registered public accountants) (A) with respect to filings made with the Commission, (B) with respect to filings required to be made with any Trading Market on which the Common Stock is then listed for trading, and (C) in compliance with applicable state securities or Blue Sky laws reasonably agreed to by the Company in writing (including, without limitation, fees and disbursements of counsel for the Company in connection with Blue Sky qualifications or exemptions of the Registrable Securities), (ii) printing expenses (including, without limitation, expenses of printing certificates for Registrable Securities), (iii) messenger, telephone and delivery expenses, (iv) fees and disbursements of counsel for the Company, (v) Securities Act liability insurance, if the Company so desires such insurance, and (vi) fees and expenses of all other Persons retained by the Company in connection with the consummation of the transactions contemplated by this Agreement. In addition, the Company shall be responsible for all of its internal expenses 4879-0208-0199\1â€‹incurred in connection with the consummation of the transactions contemplated by this Agreement

(including, without limitation, all salaries and expenses of its officers and employees performing legal or accounting duties), the expense of any annual audit and the fees and expenses incurred in connection with the listing of the Registrable Securities on any securities exchange as required hereunder. In no event shall the Company be responsible for any broker or similar commissions of any Holder or, except to the extent provided for in the Transaction Documents, any legal fees or other costs of the Holders.5.Indemnification.(a)Indemnification by the Company. The Company shall, notwithstanding any termination of this Agreement, indemnify and hold harmless each Holder, the officers, directors, members, partners, agents, and employees (and any other Persons with a functionally equivalent role of a Person holding such titles, notwithstanding a lack of such title or any other title) of each of them, each Person who controls any such Holder (within the meaning of SectionÂ 15 of the Securities Act or Section 20 of the Exchange Act) and the officers, directors, members, stockholders, partners, agents and employees (and any other Persons with a functionally equivalent role of a Person holding such titles, notwithstanding a lack of such title or any other title) of each such controlling Person, to the fullest extent permitted by applicable law, from and against any and all losses, claims, damages, liabilities, costs (including, without limitation, reasonable attorneysâ€™ fees) and expenses (collectively, â€œLossesâ€), as incurred, arising out of or relating to (1) any untrue or alleged untrue statement of a material fact contained in a Registration Statement, any Prospectus or any form of prospectus or in any amendment or supplement thereto or in any preliminary prospectus, or arising out of or relating to any omission or alleged omission of a material fact required to be stated therein or necessary to make the statements therein (in the case of any Prospectus or supplement thereto, in light of the circumstances under which they were made) not misleading or (2) any violation or alleged violation by the Company of the Securities Act, the Exchange Act or any state securities law, or any rule or regulation thereunder, in connection with the performance of its obligations under this Agreement, except to the extent, but only to the extent, that (i) such untrue statements or omissions are based solely upon information regarding such Holder furnished in writing to the Company by such Holder expressly for use therein, or to the extent that such information relates to such Holder or such Holderâ€™s proposed method of distribution of Registrable Securities and was reviewed and expressly approved in writing by such Holder expressly for use in a Registration Statement, such Prospectus or in any amendment or supplement thereto (it being understood that the Holder has approved Annex A hereto for this purpose) or (ii) in the case of an occurrence of an event of the type specified in Section 3(d)(iii)-(vi), the use by such Holder of an outdated, defective or otherwise unavailable Prospectus after the Company has notified such Holder in writing that the Prospectus is outdated, defective or otherwise unavailable for use by such Holder and prior to the receipt by such Holder of the Advice contemplated in Section 6(c). The Company shall notify the Holders promptly of the institution, threat or assertion of any Proceeding arising from or in connection with the transactions contemplated by this Agreement of which the Company is aware. Such indemnity shall remain in full force and effect regardless of any investigation made by or on behalf of such indemnified person and shall survive the transfer of any Registrable Securities by any of the Holders in accordance with Section 6(f).4879-0208-0199\1â€‹(b)Indemnification by Holders. Each Holder shall, severally and not jointly, indemnify and hold harmless the Company, its directors, officers, agents and employees, each Person who controls the Company (within the meaning of Section 15 of the Securities Act and Section 20 of the Exchange Act), and the directors, officers, agents or employees of such controlling Persons, to the fullest extent permitted by applicable law, from and against all Losses, as incurred, to the extent arising out of or based solely upon: any untrue or alleged untrue statement of a material fact contained in any Registration Statement, any Prospectus, or in any amendment or supplement thereto or in any preliminary prospectus, or arising out of or relating to any omission or alleged omission of a material fact required to be stated therein or necessary to make the statements therein (in the case of any Prospectus or supplement thereto, in light of the circumstances under which they were made) not misleading (i) to the extent, but only to the extent, that such untrue statement or omission is contained in any information so furnished in writing by such Holder to the Company expressly for inclusion in such Registration Statement or such Prospectus or (ii) to the extent, but only to the extent, that such information relates to such Holderâ€™s information provided in the Selling Stockholder Questionnaire or the proposed method of distribution of Registrable Securities and was reviewed and expressly approved in writing by such Holder expressly for use in a Registration Statement (it being understood that the Holder has approved Annex A hereto for this purpose), such Prospectus or in any amendment or supplement thereto. In no event shall the liability of a selling Holder be greater in amount than the dollar amount of the proceeds (net of all expenses paid by such Holder in connection with any claim relating to this Section 5 and the amount of any damages such Holder has otherwise been required to pay by reason of such untrue statement or omission) received by such Holder upon the sale of the Registrable Securities included in the Registration Statement giving rise to such indemnification obligation.(c)Conduct of Indemnification Proceedings. If any Proceeding shall be brought or asserted against any Person entitled to indemnity hereunder (an â€œIndemnified Partyâ€), such Indemnified Party shall promptly notify the Person from whom indemnity is sought (the â€œIndemnifying Partyâ€) in writing, and the Indemnifying Party shall have the right to assume the defense thereof, including the employment of counsel reasonably satisfactory to the Indemnified Party and the payment of all fees and expenses incurred in connection with defense thereof, provided that the failure of any Indemnified Party to give such notice shall not relieve the Indemnifying Party of its obligations or liabilities pursuant to this Agreement, except (and only) to the extent that it shall be finally determined by a court of competent jurisdiction (which determination is not subject to appeal or further review) that such failure shall have materially and adversely prejudiced the Indemnifying Party.An Indemnified Party shall have the right to employ separate counsel in any such Proceeding and to participate in the defense thereof, but the fees and expenses of such counsel shall be at the expense of such Indemnified Party or Parties unless: (1) the Indemnifying Party has agreed in writing to pay such fees and expenses, (2) the Indemnifying Party shall have failed promptly to assume the defense of such Proceeding and to employ counsel reasonably satisfactory to such Indemnified Party in any such Proceeding, or (3) the named parties to any such Proceeding (including any impleaded parties) include both such Indemnified Party and the Indemnifying Party, and counsel to the Indemnified Party shall reasonably believe that a material conflict of interest is likely to exist if the same counsel were to represent such Indemnified Party and the Indemnifying Party (in which case, if such Indemnified Party notifies the Indemnifying Party in writing that it 4879-0208-0199\1â€‹elects to employ separate counsel at the expense of the Indemnifying Party, the Indemnifying Party shall not have the right to assume the defense thereof and the reasonable fees and expenses of no more than one separate counsel shall be at the expense of the Indemnifying Party). The Indemnifying Party shall not be liable for any settlement of any such Proceeding effected without its written consent, which consent shall not be unreasonably withheld or delayed. No Indemnifying Party shall, without the prior written consent of the Indemnified Party, effect any settlement of any pending Proceeding in respect of which any Indemnified Party is a party, unless such settlement includes an unconditional release of such Indemnified Party from all liability on claims that are the subject matter of such Proceeding. Each Indemnified Party shall furnish such information regarding itself or the claim in question as an Indemnifying Party may reasonably request in writing and as shall be reasonably required in connection with defense of such claim and litigation resulting therefrom.Subject to the terms of this Agreement, all reasonable fees and expenses of the Indemnified Party (including reasonable fees and expenses to the extent incurred in connection with investigating or preparing to defend such Proceeding in a manner not inconsistent with this Section) shall be paid to the Indemnified Party, as incurred, within ten Trading Days of written notice thereof to the Indemnifying Party, provided that the Indemnified Party shall promptly reimburse the Indemnifying Party for that portion of such fees and expenses applicable to such actions for which such Indemnified Party is finally determined by a court of competent jurisdiction (which determination is not subject to appeal or further review) not to be entitled to indemnification hereunder.(d)Contribution. If the indemnification under Section 5(a) or 5(b) is unavailable to an Indemnified Party or is insufficient to hold an Indemnified Party harmless for any Losses, then each Indemnifying Party shall contribute to the amount paid or payable by such Indemnified Party, in such proportion as is appropriate to reflect the relative fault of the Indemnifying Party and Indemnified Party in connection with the actions, statements or omissions that resulted in such Losses as well as any other relevant equitable considerations. The relative fault of such Indemnifying Party and Indemnified Party shall be determined by reference to, among other things, whether any action in question, including any untrue or alleged untrue statement of a material fact or omission or alleged omission of a material fact, has been taken or made by, or relates to information supplied by, such Indemnifying Party or Indemnified Party, and the partiesâ€™ relative intent, knowledge, access to information and opportunity to correct or prevent such action, statement or omission. The amount paid or payable by a party as a result of any Losses shall be deemed to include, subject to the limitations set forth in this Agreement, any reasonable attorneysâ€™ or other fees or expenses incurred by such party in connection with any Proceeding to the extent such party would have been indemnified for such fees or expenses if the indemnification provided for in this Section was available to such party in accordance with its terms.The parties hereto agree that it would not be just and equitable if contribution pursuant to this Section 5(d) were determined by pro rata allocation or by any other method of allocation that does not take into account the equitable considerations referred to in the immediately preceding paragraph. In no event shall the contribution obligation of a Holder of Registrable Securities be greater in amount than the dollar amount of the proceeds (net of all expenses paid by such Holder in connection with any claim relating to this Section 5 and the amount of any damages such Holder has otherwise been required to pay by reason of such untrue 4879-0208-0199\1â€‹or alleged untrue statement or omission or alleged omission) received by it upon the sale of the Registrable Securities giving rise to such contribution obligation.The indemnity and contribution agreements contained in this Section are in addition to any liability that the Indemnifying Parties may have to the Indemnified Parties.6.Miscellaneous.(a)Remedies. In the event of a breach by the Company or by a Holder of any of their respective obligations under this Agreement, each Holder or the Company, as the case may be, in addition to being entitled to exercise all rights granted by law and under this Agreement, including recovery of damages, shall be entitled to specific performance of its rights under this Agreement. Each of the Company and each Holder agrees that monetary damages would not provide adequate compensation for any losses incurred by reason of a breach by it of any of the provisions of this Agreement and hereby further agrees that, in the event of any action for specific performance in respect of such breach, it shall not assert or shall waive the defense that a remedy at law would be adequate.(b)No Piggyback on Registrations; Prohibition on Filing Other Registration Statements. Except as set forth on Schedule 6(b) attached hereto, neither the Company nor any of its security holders (other than the Holders in such capacity pursuant hereto) may include securities of the Company in any Registration Statements other than the Registrable Securities. The Company shall not file any other registration statements until all Registrable Securities are registered pursuant to a Registration Statement that is declared effective by the Commission, provided that this Section 6(b) shall not prohibit the Company from filing amendments to registration statements filed prior to the date of this Agreement so long as no new securities are registered on any such existing registration statements.(c)Discontinued Disposition. By its acquisition of Registrable Securities, each Holder agrees that, upon receipt of a notice from the Company of the occurrence of any event of the kind described in Section 3(d)(iii) through (vi), such Holder will forthwith discontinue disposition of such Registrable Securities under a Registration Statement until it is advised in writing (the â€œAdviceâ€) by the Company that the use of the applicable Prospectus (as it may have been supplemented or amended) may be resumed. The Company will use its reasonable best efforts to ensure that the use of the Prospectus may be resumed as promptly as is practicable. The Company agrees and acknowledges that any periods during which the Holder is required to discontinue the disposition of the Registrable Securities hereunder shall be subject to the provisions of Section 2(d).(d)Amendments and Waivers. The provisions of this Agreement, including the provisions of this sentence, may not be amended, modified or supplemented, and waivers or consents to departures from the provisions hereof may not be given, unless the same shall be in writing and signed by the Company and the Holders of 50.1% or more of the then outstanding Registrable Securities (for purposes of clarification, this includes any Registrable Securities issuable upon exercise or conversion of any Security), provided that, if any amendment, modification or waiver disproportionately and adversely impacts a Holder (or group of Holders), the consent of such disproportionately impacted Holder (or group of Holders) shall be required. If 4879-0208-0199\1â€‹a Registration Statement does not register all of the Registrable Securities pursuant to a waiver or amendment done in compliance with the previous sentence, then the number of Registrable Securities to be registered for each Holder shall be reduced pro rata among all Holders and each Holder shall have the right to designate which of its Registrable Securities shall be omitted from such Registration Statement. Notwithstanding the foregoing, a waiver or consent to depart from the provisions hereof with respect to a matter that relates exclusively to the rights of a Holder or some Holders and that does not directly or indirectly affect the rights of other Holders may be given only by such Holder or Holders of all of the Registrable Securities to which such waiver or consent relates; provided, however, that the provisions of this sentence may not be amended, modified, or supplemented except in accordance with the provisions of the first sentence of this Section 6(d). No consideration shall be offered or paid to any Person to amend or consent to a waiver or modification of any provision of this Agreement unless the same consideration also is offered to all of the parties to this Agreement.(e)Notices. Unless otherwise provided, any notice required or permitted under this Agreement shall be given in writing and shall be deemed effectively given as hereinafter described: (i) if given by personal delivery, then such notice shall be deemed given upon such delivery; (ii) if given by facsimile, then such notice shall be deemed given upon receipt of confirmation of complete transmittal; (iii) if given by mail, then such notice shall be deemed given upon the earlier of (A) receipt of such notice by the recipient or (B) three (3) days after such notice is deposited in first class mail, postage prepaid; and (iv) if given by an internationally recognized overnight air courier, then such notice shall be deemed given one (1) Business Day after delivery to such carrier. All notices shall be addressed to the party to be notified at the address as follows, or at such other address as such party may designate by ten (10) daysâ€™ advance written notice to the other party:If to the Company:Rezolute, Inc.275 Shoreline Drive, Suite 500Redwood City, CA 94065Attn: Nevan Elam, CEOWith a copy to:Dorsey & Whitney LLP,1400 Wewatta Street, Suite 400Denver, CO 80202-5549Attn: Anthony W. Epps, Esq.If to the Holders:to the addresses set forth on the signature pages hereto.â€‹(f)Successors and Assigns. This Agreement shall inure to the benefit of and be binding upon the successors and permitted assigns of each of the parties and shall inure to the 4879-0208-0199\1â€‹benefit of each Holder. The Company may not assign (except by merger) its rights or obligations hereunder without the prior written consent of all of the Holders of the then outstanding Registrable Securities. Each Holder may assign their respective rights hereunder in the manner and to the Persons as permitted under the Warrant.(g)No Inconsistent Agreements. Neither the Company nor any of its Subsidiaries has entered, as of the date hereof, nor shall the Company or any of its Subsidiaries, on or after the date of this Agreement, enter into any agreement with respect to its securities, that would have the effect of impairing the rights granted to the Holders in this Agreement or otherwise conflicts with the provisions hereof.(h)Execution and Counterparts. This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other party, it being understood that both parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission or by e-mail delivery of a â€œ.pdfâ€ format data file, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or â€œ.pdfâ€ signature page were an original thereof.(i)Governing Law. This Agreement shall be governed by and construed in accordance with the internal laws of the State of Nevada applicable to agreements made and to be performed in such state. Any legal suit, action or proceeding arising out of or based upon this Agreement or the transactions contemplated hereby (â€œRelated Proceedingsâ€) may be instituted in the federal courts of the United States of America located in the courts of the State of Nevada (collectively, the â€œSpecified Courtsâ€), and each party irrevocably submits to the exclusive jurisdiction (except for proceedings instituted in regard to the enforcement of a judgment of any such court (a â€œRelated Judgmentâ€), as to which such jurisdiction is non-exclusive) of such courts in any such suit, action or proceeding. Service of any process, summons, notice or document by mail to such partyâ€™s address set forth above shall be effective service of process for any suit, action or other proceeding brought in any such court. The parties irrevocably and unconditionally waive any objection to the laying of venue of any suit, action or other proceeding in the Specified Courts and irrevocably and unconditionally waive and agree not to plead or claim in any such court that any such suit, action or other proceeding brought in any such court has been brought in an inconvenient forum.(j)Cumulative Remedies. The remedies provided herein are cumulative and not exclusive of any other remedies provided by law.(k)Severability. If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that they would 4879-0208-0199\1â€‹have executed the remaining terms, provisions, covenants and restrictions without including any of such that may be hereafter declared invalid, illegal, void or unenforceable.(l)Headings. The headings in this Agreement are for convenience only, do not constitute a part of the Agreement and shall not be deemed to limit or affect any of the provisions hereof.(m)Independent Nature of Holdersâ€™ Obligations and Rights. The obligations of each Holder hereunder are several and not joint with the obligations of any other Holder hereunder, and no Holder shall be responsible in any way for the performance of the obligations of any other Holder hereunder. Nothing contained herein or in any other agreement or document delivered at any closing, and no action taken by any Holder pursuant hereto or thereto, shall be deemed to constitute the Holders as a partnership, an association, a joint venture or any other kind of group or entity, or create a presumption that the

Holders are in any way acting in concert or as a group or entity with respect to such obligations or the transactions contemplated by this Agreement or any other matters, and the Company acknowledges that the Holders are not acting in concert or as a group, and the Company shall not assert any such claim, with respect to such obligations or transactions. Each Holder shall be entitled to protect and enforce its rights, including without limitation the rights arising out of this Agreement, and it shall not be necessary for any other Holder to be joined as an additional party in any proceeding for such purpose. The use of a single agreement with respect to the obligations of the Company contained in this Agreement was solely in the control of the Company, not the action or decision of any Holder, and was done solely for the convenience of the Company and not because it was required or requested to do so by any Holder. It is expressly understood and agreed that each provision contained in this Agreement is between the Company and a Holder, solely, and, except as described herein, is not between the Company and the Holders collectively and not between and among Holders.(n)Furnishing of Information; Compliance. Each Holder shall furnish in writing to the Company such information regarding itself, the Registrable Securities held by it and the intend method of disposition of the Registrable Securities held by it, as shall be reasonably requested by the Company to effect the registration of such Registrable Securities and shall execute such documents in connection with such registration as the Company may reasonably request. Each Holder covenants and agrees that it will comply with the prospectus delivery requirements of the Securities Act as applicable to it in connection with sales of Registrable Securities pursuant to the Registration Statement.********** (Signature Pages Follow)â€‹4879-0208-0199\1â€‹IN WITNESS WHEREOF, the parties have executed this Registration Rights Agreement as of the date first written above.Rezolute, Inc.By:Name: Nevan ElamTitle: Chief Executive Officerâ€‹[SIGNATURE PAGE OF HOLDERS FOLLOWS]â€‹4879-0208-0199\1â€‹Name of Holder: _____Address of Holder: _____Signature of Authorized Signatory of Holder: _____Name of Authorized Signatory: _____Title of Authorized Signatory: _____â€‹4879-0208-0199\1â€‹Annex APlan of DistributionEach Selling Stockholder (the â€œSelling Stockholdersâ€) of the securities and any of their pledgees, assignees and successors-in-interest may, from time to time, sell any or all of their securities covered hereby on the principal Trading Market or any other stock exchange, market or trading facility on which the securities are traded or in private transactions. These sales may be at fixed or negotiated prices. A Selling Stockholder may use any one or more of the following methods when selling securities:â—ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers;â—block trades in which the broker-dealer will attempt to sell the securities as agent but may position and resell a portion of the block as principal to facilitate the transaction;â—purchases by a broker-dealer as principal and resale by the broker-dealer for its account;â—an exchange distribution in accordance with the rules of the applicable exchange;â—privately negotiated transactions;â—settlement of short sales;â—in transactions through broker-dealers that agree with the Selling Stockholders to sell a specified number of such securities at a stipulated price per security;â—through the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise;â—a combination of any such methods of sale; orâ—any other method permitted pursuant to applicable law.The Selling Stockholders may also sell securities under Rule 144 or any other exemption from registration under the Securities Act of 1933, as amended (the â€œSecurities Actâ€), if available, rather than under this prospectus.Broker-dealers engaged by the Selling Stockholders may arrange for other brokers-dealers to participate in sales. Broker-dealers may receive commissions or discounts from the Selling Stockholders (or, if any broker-dealer acts as agent for the purchaser of securities, from the purchaser) in amounts to be negotiated, but, except as set forth in a supplement to this Prospectus, in the case of an agency transaction not in excess of a customary brokerage commission in compliance with FINRA Rule 2121; and in the case of a principal transaction a markup or markdown in compliance with FINRA Rule 2121.4879-0208-0199\1â€‹In connection with the sale of the securities or interests therein, the Selling Stockholders may enter into hedging transactions with broker-dealers or other financial institutions, which may in turn engage in short sales of the securities in the course of hedging the positions they assume. The Selling Stockholders may also sell securities short and deliver these securities to close out their short positions, or loan or pledge the securities to broker-dealers that in turn may sell these securities. The Selling Stockholders may also enter into option or other transactions with broker-dealers or other financial institutions or create one or more derivative securities which require the delivery to such broker-dealer or other financial institution of securities offered by this prospectus, which securities such broker-dealer or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction).The Selling Stockholders and any broker-dealers or agents that are involved in selling the securities may be deemed to be â€œunderwritersâ€ within the meaning of the Securities Act in connection with such sales. In such event, any commissions received by such broker-dealers or agents and any profit on the resale of the securities purchased by them may be deemed to be underwriting commissions or discounts under the Securities Act. Each Selling Stockholder has informed the Company that it does not have any written or oral agreement or understanding, directly or indirectly, with any person to distribute the securities.The Company is required to pay certain fees and expenses incurred by the Company incident to the registration of the securities. The Company has agreed to indemnify the Selling Stockholders against certain losses, claims, damages and liabilities, including liabilities under the Securities Act.We agreed to keep this prospectus effective until the earlier of (i) the date on which the securities may be resold by the Selling Stockholders without registration and without regard to any volume or manner-of-sale limitations by reason of Rule 144, without the requirement for the Company to be in compliance with the current public information under Rule 144 under the Securities Act or any other rule of similar effect or (ii) all of the securities have been sold pursuant to this prospectus or Rule 144 under the Securities Act or any other rule of similar effect. The resale securities will be sold only through registered or licensed brokers or dealers if required under applicable state securities laws. In addition, in certain states, the resale securities covered hereby may not be sold unless they have been registered or qualified for sale in the applicable state or an exemption from the registration or qualification requirement is available and is complied with.Under applicable rules and regulations under the Exchange Act, any person engaged in the distribution of the resale securities may not simultaneously engage in market making activities with respect to the common stock for the applicable restricted period, as defined in Regulation M, prior to the commencement of the distribution. In addition, the Selling Stockholders will be subject to applicable provisions of the Exchange Act and the rules and regulations thereunder, including Regulation M, which may limit the timing of purchases and sales of the common stock by the Selling Stockholders or any other person. We will make copies of this prospectus available to the Selling Stockholders and have informed them of the need to deliver a copy of this prospectus to each purchaser at or prior to the time of the sale (including by compliance with Rule 172 under the Securities Act).â€‹4879-0208-0199\1â€‹Annex BRezolute, Inc.Selling Stockholder Notice and QuestionnaireThe undersigned beneficial owner of common stock (the â€œRegistrable Securitiesâ€) of Rezolute, Inc., a Nevada corporation (the â€œCompanyâ€), understands that the Company has filed or intends to file with the Securities and Exchange Commission (the â€œCommissionâ€) a registration statement (the â€œRegistration Statementâ€) for the registration and resale under Rule 415 of the Securities Act of 1933, as amended (the â€œSecurities Actâ€), of the Registrable Securities, in accordance with the terms of the Registration Rights Agreement (the â€œRegistration Rights Agreementâ€) to which this document is annexed. A copy of the Registration Rights Agreement is available from the Company upon request at the address set forth below. All capitalized terms not otherwise defined herein shall have the meanings ascribed thereto in the Registration Rights Agreement.Certain legal consequences arise from being named as a selling stockholder in the Registration Statement and the related prospectus. Accordingly, holders and beneficial owners of Registrable Securities are advised to consult their own securities law counsel regarding the consequences of being named or not being named as a selling stockholder in the Registration Statement and the related prospectus.NOTICEThe undersigned beneficial owner (the â€œSelling Stockholderâ€) of Registrable Securities hereby elects to include the Registrable Securities owned by it in the Registration Statement.The undersigned hereby provides the following information to the Company and represents and warrants that such information is accurate:QUESTIONNAIRE1.Name.(a)Full Legal Name of Selling Stockholderâ€‹ â€‹â€‹(b)Full Legal Name of Registered Holder (if not the same as (a) above) through which Registrable Securities are held:â€‹ â€‹â€‹(c)Full Legal Name of Natural Control Person (which means a natural person who directly or indirectly alone or with others has power to vote or dispose of the securities covered by this Questionnaire):â€‹ â€‹â€‹4879-0208-0199\1â€‹2.Address for Notices to Selling Stockholder:â€‹ â€‹â€‹Telephone: â€‹ â€‹Fax: â€ŒContact Person: â€‹ â€‹3.Broker-Dealer Status:(a)Are you a broker-dealer?Yes â˜ No â˜(b)If â€œyesâ€ to Section 3(a), did you receive your Registrable Securities as compensation for investment banking services to the Company?Yes â˜ No â˜Note:If â€œnoâ€ to Section 3(b), the Commissionâ€™s staff has indicated that you should be identified as an underwriter in the Registration Statement.(c)Are you an affiliate of a broker-dealer?Yes â˜ No â˜(d)If you are an affiliate of a broker-dealer, do you certify that you purchased the Registrable Securities in the ordinary course of business, and at the time of the purchase of the Registrable Securities to be resold, you had no agreements or understandings, directly or indirectly, with any person to distribute the Registrable Securities?Yes â˜ No â˜Note:If â€œnoâ€ to Section 3(d), the Commissionâ€™s staff has indicated that you should be identified as an underwriter in the Registration Statement.4.Beneficial Ownership of Securities of the Company Owned by the Selling Stockholder.Except as set forth below in this Item 4, the undersigned is not the beneficial or registered owner of any securities of the Company other than the securities issuable pursuant to the Underwriting Agreement.(a)Type and Amount of other securities beneficially owned by the Selling Stockholder:â€‹ â€‹â€‹5.Relationships with the Company:Except as set forth below, neither the undersigned nor any of its affiliates, officers, directors or principal equity holders (owners of 5% of more of the equity securities of the 4879-0208-0199\1â€‹undersigned) has held any position or office or has had any other material relationship with the Company (or its predecessors or affiliates) during the past three years.State any exceptions here:â€‹ â€‹â€‹The undersigned agrees to promptly notify the Company of any material inaccuracies or changes in the information provided herein that may occur subsequent to the date hereof at any time while the Registration Statement remains effective; provided, that the undersigned shall not be required to notify the Company of any changes to the number of securities held or owned by the undersigned or its affiliates.By signing below, the undersigned consents to the disclosure of the information contained herein in its answers to Items 1 through 5 and the inclusion of such information in the Registration Statement and the related prospectus and any amendments or supplements thereto. The undersigned understands that such information will be relied upon by the Company in connection with the preparation or amendment of the Registration Statement and the related prospectus and any amendments or supplements thereto.IN WITNESS WHEREOF the undersigned, by authority duly given, has caused this Notice and Questionnaire to be executed and delivered either in person or by its duly authorized agent.Date:Beneficial Owner:By:Name:Title:â€‹PLEASE FAX A COPY (OR EMAIL A .PDF COPY) OF THE COMPLETED AND EXECUTED NOTICE AND QUESTIONNAIRE TO:4879-0208-0199\1 EX-21.1 6 rzlt-20240630xex21d1.htm EX-21.1 ExhibitÂ 21.1Â Subsidiaries of the Registrant Â Name of EntityÂ FormationDateÂ Jurisdiction ofÂ IncorporationÂ Holder of StockÂ Â Â Â Â Â Â Rezolute Bio UK, LtdÂ July 11, 2019Â United KingdomÂ Rezolute, Inc.Rezolute (Bio) Ireland LimitedÂ July 19, 2019Â IrelandÂ Rezolute, Inc.â€‹ EX-23.1 7 rzlt-20240630xex23d1.htm EX-23.1 Exhibit 23.1CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRMâ€‹We have issued our report dated September 19, 2024 with respect to the consolidated financial statements included in the Annual Report of Rezolute, Inc. on Form 10-K for the year ended June 30, 2024. We consent to the incorporation by reference of said report in the Registration Statement of Rezolute, Inc. on Forms S-1 (File Nos. 333-234766 and 333-233310); Forms S-3 (File Nos. 333-250073, 333-251498, 333-265703, 333-268046, 333-275562 and 333-281257); and Forms S-8 (File Nos. 333-258222 and 333-268221).â€‹/s/ GRANT THORNTON LLPâ€‹Newport Beach, CaliforniaSeptember 19, 2024 EX-23.2 8 rzlt-20240630xex23d2.htm EX-23.2 Exhibit 23.2Â CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRMÂ Â We hereby consent to the incorporation by reference in the Registration Statements on Form S-1 (File Nos. 333-234766 and 333-233310); S-3 (File Nos. 333-250073, 333-251498, 333-265703, 333-268046, 333-275562 and 333-281257); and Form S-8 (File Nos. 333-258222 and 333-268221) of our report dated September 14, 2023 with respect to the consolidated financial statements of Rezolute, Inc. as of and for the year ended June 30, 2023, that appears in this Annual Report on Form 10-K.Â /s/ Plante & Moran, PLLCÂ September 19, 2024Cleveland, Ohio EX-31.1 9 rzlt-20240630xex31d1.htm EX-31.1 EXHIBIT 31.1â€‹Â CERTIFICATIONSÂ I, Nevan Charles Elam, certify that:Â 1.I have reviewed this annual report on Form 10-K of Rezolute, Inc.;Â 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.Â 3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects, the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report.Â 4.As the Registrant's certifying officer, I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have:Â a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;Â b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;Â c)Evaluated the effectiveness of the Registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; andÂ d)Disclosed in this report any change in the Registrant's internal control over financial reporting that occurred during the Registrant's most recent fiscal quarter (fourth quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant's internal control over financial reporting; andÂ 5.As the Registrant's certifying officer, I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the Registrant's auditors and the audit committee of the Registrant's board of directors:Â a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant's ability to record, process, summarize and report financial information; andÂ b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant's internal control over financial reporting.Â Date:September 19, 2024Â Â By:/s/ Nevan Charles ElamÂ Â Nevan Charles ElamÂ Â Chief Executive Officer(Principal Executive and Financial Officer)â€‹ EX-32.1 10 rzlt-20240630xex32d1.htm EX-32.1 â€‹Â EXHIBIT 32.1Â CERTIFICATION PURSUANT TO18 U.S.C. SECTION 1350,AS ADOPTED PURSUANT TOSECTION 906 OF THE SARBANES-OXLEY ACT OF 2002Â In connection with the annual report of Rezolute, Inc. (the â€œCompanyâ€) on Form 10-K for the period ended June 30, 2024, as filed with the Securities and Exchange Commission on the date hereof (the â€œReportâ€), I, Nevan Charles Elam, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:Â (1)The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; andÂ (2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.Â Date:September 19, 2024Â Â By:/s/ Nevan Charles ElamÂ Â Nevan Charles ElamÂ Â Chief Executive Officer(Principal Executive and Financial Officer)Â â€‹A signed original of this written statement required by Section 906 has been provided to Rezolute, Inc. and will be retained by Rezolute, Inc. Inc. to be furnished to the Securities and Exchange Commission or its staff upon request. EX-97 11 rzlt-20240630xex97.htm EX-97 â€‹Exhibit 97REZOLUTE, INC.INCENTIVE COMPENSATION RECOVERY POLICY1.Introduction.The Board of Directors of Rezolute, Inc., a Nevada corporation (the â€œCorporationâ€) believes that it is in the best interests of the Corporation and its shareholders to create and maintain a culture that emphasizes integrity and accountability and that reinforces the Corporation's compensation philosophy. The Board has therefore adopted this policy, which provides for the recovery of erroneously awarded incentive compensation in the event that the Corporation is required to prepare an accounting restatement due to material noncompliance of the Corporation with any financial reporting requirements under the federal securities laws (the â€œPolicyâ€). This Policy is designed to comply with SectionÂ 10D of the Securities Exchange Act of 1934, as amended (the â€œExchange Actâ€), related rules and the listing standards of The Nasdaq Stock Market or any other securities exchange on which the Corporationâ€™s shares are listed in the future.2.Administration.This Policy shall be administered by the Board or, if so designated by the Board, the Compensation Committee (the â€œCommitteeâ€), in which case, all references herein to the Board shall be deemed references to the Committee. Any determinations made by the Board shall be final and binding on all affected individuals.3.Covered Executives.Unless and until the Board determines otherwise, for purposes of this Policy, the term â€œCovered Executiveâ€ means a current or former employee who is or was identified by the Corporation as the Corporationâ€™s president, principal financial officer, principal accounting officer (or if there is no such accounting officer, the controller), any vice-president of the Corporation in charge of a principal business unit, division, or function (such as sales, administration, or finance), any other officer who performs a policy-making function, or any other person (including any executive officer of the Corporationâ€™s subsidiaries or affiliates) who performs similar policy-making functions for the Corporation. â€œPolicy-making functionâ€ excludes policy-making functions that are not significant. Â â€œCovered Executivesâ€ will include, at minimum, the executive officers identified by the Corporation pursuant to Item 401(b) of Regulation S-K of the Exchange Act. Â For the avoidance of doubt, â€œCovered Executivesâ€ will include at least the following Corporation officers:

CEO, CMO, CFO and any other officer who performs these functions. This Policy covers Incentive Compensation received by a person after beginning service as a Covered Executive and who served as a Covered Executive at any time during the performance period for that Incentive Compensation. Â 1â€‹â€‹4.Recovery: Accounting Restatement.In the event of an â€œAccounting Restatement,â€ the Corporation will Â recover reasonably promptly any excess Incentive Compensation received by any Covered Executive during the three completed fiscal years immediately preceding the date on which the Corporation is required to prepare an Accounting Restatement, including transition periods resulting from a change in the Corporationâ€™s fiscal year as provided in Rule 10D-1 of the Exchange Act. Â Incentive Compensation is deemed â€œreceivedâ€ in the Corporationâ€™s fiscal period during which the Financial Reporting Measure specified in the Incentive Compensation award is attained, even if the payment or grant of the Incentive Compensation occurs after the end of that period. Â (a)Definition of Accounting Restatement.For the purposes of this Policy, an â€œAccounting Restatementâ€ means the Corporation is required to prepare an accounting restatement of its financial statements filed with the Securities and Exchange Commission (the â€œSECâ€) due to the Corporationâ€™s material noncompliance with any financial reporting requirements under the federal securities laws (including any required accounting restatement to correct an error in previously issued financial statements that is material to the previously issued financial statements, or that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period). Â The determination of the time when the Corporation is â€œrequiredâ€ to prepare an Accounting Restatement shall be made in accordance with applicable SEC and national securities exchange rules and regulations. An Accounting Restatement does not include situations in which financial statement changes did not result from material non-compliance with financial reporting requirements, such as, but not limited to retrospective: (i) application of a change in accounting principles; (ii) revision to reportable segment information due to a change in the structure of the Corporationâ€™s internal organization; (iii) reclassification due to a discontinued operation; (iv) application of a change in reporting entity, such as from a reorganization of entities under common control; (v) adjustment to provision amounts in connection with a prior business combination; and (vi) revision for stock splits, stock dividends, reverse stock splits or other changes in capital structure.(b)Definition of Incentive Compensation.For purposes of this Policy, â€œIncentive Compensationâ€ means any compensation that is granted, earned, or vested based wholly or in part upon the attainment of a Financial Reporting Measure, including, for example, bonuses or awards under the Corporationâ€™s short and long-term incentive plans, grants and awards under the Corporationâ€™s equity incentive plans, and contributions of such bonuses or awards to Â the Corporationâ€™s deferred compensation plans or other employee benefit plans. Â Incentive Compensation does not include awards which are granted, earned and 2â€‹â€‹vested without regard to attainment of Financial Reporting Measures, such as time-vesting awards, discretionary awards and awards based wholly on subjective standards, strategic measures or operational measures.(c)Financial Reporting Measures.â€œFinancial Reporting Measuresâ€ are those that are determined and presented in accordance with the accounting principles used in preparing the Corporationâ€™s financial statements (including non-GAAP financial measures) and any measures derived wholly or in part from such financial measures. For the avoidance of doubt, Financial Reporting Measures include stock price and total shareholder return. Â A measure need not be presented within the financial statements or included in a filing with the SEC to constitute a Financial Reporting Measure for purposes of this Policy.(d)Excess Incentive Compensation: Amount Subject to Recovery.The amount(s) to be recovered from the Covered Executive will be the amount(s) by which the Covered Executiveâ€™s Incentive Compensation for the relevant period(s) exceeded the amount(s) that the Covered Executive otherwise would have received had such Incentive Compensation been determined based on the restated amounts contained in the Accounting Restatement. Â All amounts shall be computed without regard to taxes paid.For Incentive Compensation based on Financial Reporting Measures such as stock price or total shareholder return, where the amount of excess compensation is not subject to mathematical recalculation directly from the information in an Accounting Restatement, the Board will calculate the amount to be reimbursed based on a reasonable estimate of the effect of the Accounting Restatement on such Financial Reporting Measure upon which the Incentive Compensation was received. The Corporation will maintain documentation of that reasonable estimate and will provide such documentation to the applicable national securities exchange.(e)Method of Recovery.The Board will determine, in its sole discretion, the method(s) for recovering reasonably promptly excess Incentive Compensation hereunder. Such methods may include, without limitation:(i)requiring reimbursement of compensation previously paid;(ii)forfeiting any compensation contribution made under the Corporationâ€™s deferred compensation plans, as well as any matching amounts and earnings thereon;(iii)offsetting the recovered amount from any compensation that the Covered Executive may earn or be awarded in the future (including, for the avoidance of doubt, recovering amounts earned or awarded in the future to 3â€‹â€‹such individual equal to compensation paid or deferred into taxâ€“qualified plans or plans subject to the Employee Retirement Income Security Act of 1974 (collectively, â€œExempt Plansâ€); provided that, no such recovery will be made from amounts held in any Exempt Plan of the Corporation); (iv)taking any other remedial and recovery action permitted by law, as determined by the Board; or(v)some combination of the foregoing.5.No Indemnification or Advance.Subject to applicable law, the Corporation shall not indemnify, including by paying or reimbursing for premiums for any insurance policy covering any potential losses, any Covered Executives against the loss of any erroneously awarded Incentive Compensation, nor shall the Corporation advance any costs or expenses to any Covered Executives in connection with any action to recover excess Incentive Compensation.6.Interpretation.The Board is authorized to interpret and construe this Policy and to make all determinations necessary, appropriate or advisable for the administration of this Policy. It is intended that this Policy be interpreted in a manner that is consistent with the requirements of SectionÂ 10D of the Exchange Act and any applicable rules or standards adopted by the SEC or any national securities exchange on which the Corporation's securities are listed.7.Effective Date.The effective date of this Policy is October 2, 2023 (the â€œEffective Dateâ€). Â This Policy applies to Incentive Compensation received by Covered Executives on or after the Effective Date that results from attainment of a Financial Reporting Measure based on or derived from financial information for any fiscal period ending on or after the Effective Date. Â Without limiting the scope or effectiveness of this Policy, Incentive Compensation granted or received by Covered Executives prior to the Effective Date will be subject to this Policy. Â In addition, this Policy is intended to be and will be incorporated as an essential term and condition of any Incentive Compensation agreement, plan or program that the Corporation establishes or maintains on or after the Effective Date.8.Amendment and Termination.The Board may amend this Policy from time to time in its discretion, and shall amend this Policy as it deems necessary to reflect changes in regulations adopted by the SEC under Section 10D of the Exchange Act and to comply with any rules or standards adopted by The Nasdaq Stock Market or any other securities exchange on which the Corporationâ€™s shares are listed in the future. 4â€‹â€‹9.Other Recovery Rights.The Board intends that this Policy will be applied to the fullest extent of the law. Upon receipt of this Policy, each Covered Executive is required to complete the Receipt and Acknowledgement attached as Schedule A to this Policy. The Board may require that any employment agreement or similar agreement relating to Incentive Compensation received on or after the Effective Date shall, as a condition to the grant of any benefit thereunder, require a Covered Executive to agree to abide by the terms of this Policy. Any right of recovery under this Policy is in addition to, and not in lieu of, any (i)Â other remedies or rights of compensation recovery that may be available to the Corporation pursuant to the terms of any similar policy in any employment agreement, or similar agreement relating to Incentive Compensation, unless any such agreement expressly prohibits such right of recovery, and (ii)Â any other legal remedies available to the Corporation. Â The provisions of this Policy are in addition to (and not in lieu of) any rights to repayment the Corporation may have under Section 304 of the Sarbanes-Oxley Act of 2002 and other applicable laws.10.Impracticability.The Corporation shall recover any excess Incentive Compensation in accordance with this Policy, except to the extent that certain conditions are met and the Board has determined that such recovery would be impracticable, all in accordance with Rule 10D-1 of the Exchange Act and The Nasdaq Stock Market or any other securities exchange on which the Corporationâ€™s shares are listed in the future.11.Successors.This Policy shall be binding upon and enforceable against all Covered Executives and their beneficiaries, heirs, executors, administrators or other legal representatives.5â€‹ EX-101.SCH 12 rzlt-20240630.xsd EX-101.SCH 99900 - Disclosure - Standard And Custom Axis Domain Defaults link:presentationLink link:calculationLink link:definitionLink 995200100 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 995200200 - Statement - Consolidated Statements of Operations and Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 995200400 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 99940301 - Disclosure - INVESTMENTS IN MARKETABLE DEBT SECURITIES - Investments in Marketable Securities (Details) link:presentationLink link:calculationLink link:definitionLink 99940303 - Disclosure - INVESTMENTS IN MARKETABLE DEBT SECURITIES - Cash and Cash Equivalents and Marketable Securities Held (Details) link:presentationLink link:calculationLink link:definitionLink 99940402 - Disclosure - LEASES - Assets and Operating Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 99940404 - Disclosure - LEASES - Future Operating Lease Payments (Details) link:presentationLink link:calculationLink link:definitionLink 40404 - Disclosure - OPERATING LEASES - Future Operating Lease Payments (Details) (Calc 2) link:presentationLink link:calculationLink link:definitionLink 99940902 - Disclosure - INCOME TAXES - Income Tax Expense (Details) link:presentationLink link:calculationLink link:definitionLink 99940903 - Disclosure - INCOME TAXES - Deferred Income Tax Assets and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 99941202 - Disclosure - SUPPLEMENTAL FINANCIAL INFORMATION - Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 995200105 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 995200300 - Statement - Consolidated Statements of Shareholders' Equity link:presentationLink link:calculationLink link:definitionLink 99930703 - Disclosure - SHAREHOLDERS' EQUITY (Tables) link:presentationLink link:calculationLink link:definitionLink 99930803 - Disclosure - SHARE-BASED COMPENSATION AND WARRANTS (Tables) link:presentationLink link:calculationLink link:definitionLink 99940101 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) link:presentationLink link:calculationLink link:definitionLink 99940201 - Disclosure - LIQUIDITY (Details) link:presentationLink link:calculationLink link:definitionLink 99940401 - Disclosure - LEASES - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 99940403 - Disclosure - LEASES - Operating Lease Expense (Details) link:presentationLink link:calculationLink link:definitionLink 99940501 - Disclosure - LICENSE AGREEMENTS (Details) link:presentationLink link:calculationLink link:definitionLink 99940601 - Disclosure - EMBEDDED DERIVATIVE LIABILITY (Details) link:presentationLink link:calculationLink link:definitionLink 99940701 - Disclosure - SHAREHOLDERS' EQUITY - Pre-Funded Warrants (Details) link:presentationLink link:calculationLink link:definitionLink 99940702 - Disclosure - SHAREHOLDERS' EQUITY - 2024 Underwritten Offering (Details) link:presentationLink link:calculationLink link:definitionLink 99940703 - Disclosure - SHAREHOLDERS' EQUITY - Exchange Agreement (Details) link:presentationLink link:calculationLink link:definitionLink 99940704 - Disclosure - SHAREHOLDERS' EQUITY - Jefferies Open Market Sales Agreement (Details) link:presentationLink link:calculationLink link:definitionLink 99940705 - Disclosure - SHAREHOLDERS' EQUITY - 2022 Private Placement (Details) link:presentationLink link:calculationLink link:definitionLink 99940801 - Disclosure - SHARE-BASED COMPENSATION AND WARRANTS - Stock Option Plans (Details) link:presentationLink link:calculationLink link:definitionLink 99940802 - Disclosure - SHARE-BASED COMPENSATION AND WARRANTS - 2022 Employee Stock Purchase Plan (Details) link:presentationLink link:calculationLink link:definitionLink 99940803 - Disclosure - SHARE-BASED COMPENSATION AND WARRANTS - Stock Options Outstanding (Details) link:presentationLink link:calculationLink link:definitionLink 99940804 - Disclosure - SHARE-BASED COMPENSATION AND WARRANTS - Weighted Average Assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 99940805 - Disclosure - SHARE-BASED COMPENSATION AND WARRANTS - Share Based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 99940806 - Disclosure - SHARE-BASED COMPENSATION AND WARRANTS - Inducement Grant (Details) link:presentationLink link:calculationLink link:definitionLink 99940807 - Disclosure - SHARE-BASED COMPENSATION AND WARRANTS - Pre-Funded Warrants (Details) link:presentationLink link:calculationLink link:definitionLink 99940808 - Disclosure - SHARE-BASED COMPENSATION AND WARRANTS - Summary of Legacy Warrants (Details) link:presentationLink link:calculationLink link:definitionLink 99940901 - Disclosure - INCOME TAXES - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 99941001 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) link:presentationLink link:calculationLink link:definitionLink 99941101 - Disclosure - RELATED PARTY TRANSACTIONS (Details) link:presentationLink link:calculationLink link:definitionLink 99941201 - Disclosure - SUPPLEMENTAL FINANCIAL INFORMATION - Cash and Cash Equivalents (Details) link:presentationLink link:calculationLink link:definitionLink 99941301 - Disclosure - NET LOSS PER SHARE - Schedule of basic and diluted net loss per share (Details) link:presentationLink link:calculationLink link:definitionLink 99941302 - Disclosure - NET LOSS PER SHARE - Anti-dilutive (Details) link:presentationLink link:calculationLink link:definitionLink 99941401 - Disclosure - FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS - Fair Value on a Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 99941402 - Disclosure - FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS - Valuation Model Inputs of Exchange PFWs (Details) link:presentationLink link:calculationLink link:definitionLink 99941403 - Disclosure - FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS - Summary of Changes in the Fair Value (Details) link:presentationLink link:calculationLink link:definitionLink 99941404 - Disclosure - FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS - Significant Concentrations (Details) link:presentationLink link:calculationLink link:definitionLink 99941501 - Disclosure - SUBSEQUENT EVENTS (Details) link:presentationLink link:calculationLink link:definitionLink 995200090 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink 995210101 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 995210201 - Disclosure - LIQUIDITY link:presentationLink link:calculationLink link:definitionLink 995210301 - Disclosure - INVESTMENTS IN MARKETABLE DEBT SECURITIES link:presentationLink link:calculationLink link:definitionLink 995210401 - Disclosure - LEASES link:presentationLink link:calculationLink link:definitionLink 995210501 - Disclosure - LICENSE AGREEMENTS link:presentationLink link:calculationLink link:definitionLink 995210601 - Disclosure - EMBEDDED DERIVATIVE LIABILITY link:presentationLink link:calculationLink link:definitionLink 995210701 - Disclosure - SHAREHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 995210801 - Disclosure - SHARE-BASED COMPENSATION AND WARRANTS link:presentationLink link:calculationLink link:definitionLink 995210901 - Disclosure - INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 995211001 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 995211101 - Disclosure - RELATED PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 995211201 - Disclosure - SUPPLEMENTAL FINANCIAL INFORMATION link:presentationLink link:calculationLink link:definitionLink 995211301 - Disclosure - NET LOSS PER SHARE link:presentationLink link:calculationLink link:definitionLink 995211401 - Disclosure - FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS link:presentationLink link:calculationLink link:definitionLink 995211501 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 99920102 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 99930303 - Disclosure - INVESTMENTS IN MARKETABLE DEBT SECURITIES (Tables) link:presentationLink link:calculationLink link:definitionLink 99930403 - Disclosure - LEASES (Tables) link:presentationLink link:calculationLink link:definitionLink 99930903 - Disclosure - INCOME TAXES (Tables) link:presentationLink link:calculationLink link:definitionLink 99931203 - Disclosure - SUPPLEMENTAL FINANCIAL INFORMATION (Tables) link:presentationLink link:calculationLink link:definitionLink 99931303 - Disclosure - NET LOSS PER SHARE (Tables) link:presentationLink link:calculationLink link:definitionLink 99931403 - Disclosure - FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS (Tables) link:presentationLink link:calculationLink link:definitionLink 99940302 - Disclosure - INVESTMENTS IN MARKETABLE DEBT SECURITIES - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 13 rzlt-20240630_cal.xml EX-101.CAL EX-101.DEF 14 rzlt-20240630_def.xml EX-101.DEF EX-101.LAB 15 rzlt-20240630_lab.xml EX-101.LAB Document And Entity Information [Abstract] Document Type Document Annual Report Document Period End Date Document Transition Report Securities Act File Number Entity Registrant Name Entity Incorporation, State or Country Code Entity Tax Identification Number Entity Address, Address Line One Entity Address, City or Town Entity Address, State or Province Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security Trading Symbol Security Exchange Name Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company ICFR Auditor Attestation Flag Document Financial Statement Error Correction [Flag] Entity Shell Company Entity Public Float Entity Common Stock, Shares Outstanding Auditor Name Auditor Location Auditor Firm ID Entity Central Index Key Current Fiscal Year End Date Document Fiscal Year Focus Document Fiscal Period Focus Amendment Flag Consolidated Balance Sheets Assets [Abstract] Assets Assets, Current [Abstract] Current assets: Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents Marketable Securities, Current Investments in marketable debt securities Short-term investments Prepaid Expense and Other Assets, Current Prepaid expenses and other Assets, Current Total current assets Assets, Noncurrent [Abstract] Long-term assets: Operating Lease, Right-of-Use Asset Right-of-use assets Deposits Assets, Noncurrent Deposits and other Marketable Securities, Noncurrent Investments in marketable debt securities Long-term investments Property, Plant and Equipment, Net Property and equipment, net Total Assets Total

assets Liabilities and Equity [Abstract] Liabilities and Shareholders' Equity Liabilities, Current [Abstract] Current liabilities: Accounts Payable, Current Accounts payable Accrued Liabilities, Current [Abstract] Accrued liabilities: Amount of accrued for clinical liabilities. Accrued Clinical, Current Accrued clinical and other Employee-related Liabilities, Current Compensation and benefits Operating Lease, Liability, Current Current Current portion of operating lease liabilities Liabilities, Current Current liabilities Total current liabilities Liabilities, Noncurrent [Abstract] Long-term liabilities: Operating Lease, Liability, Noncurrent Non-current operating lease liabilities Operating lease liabilities, net of current portion Fair value as of the balance sheet date of the warrants derivative classified as a liability. Warrant Derivative Liability, Non-Current Warrant derivative liability Embedded Derivative, Fair Value of Embedded Derivative Liability Embedded derivative liability Liabilities Total liabilities Total liabilities Commitments and Contingencies Commitments and contingencies (Notes 5, 10 and 11) Equity, Attributable to Parent [Abstract] Shareholders' equity: Preferred Stock, Value, Issued Preferred stock, $0.001 par value; 400 shares authorized; no shares issued Common Stock, Value, Issued Common stock, $0.001 par value; 100,000 shares authorized; issued and outstanding 53,246 and 36,827 shares as of June 30, 2024 and 2023, respectively Additional Paid in Capital Additional paid-in capital Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated other comprehensive loss Retained Earnings (Accumulated Deficit) Accumulated deficit Equity, Attributable to Parent Balance ending Balance beginning Total shareholders' equity Liabilities and Equity Total liabilities and shareholders' equity Statement [Table] Statement [Line Items] Preferred Stock, Par or Stated Value Per Share Preferred stock, par value (in dollars per share) Preferred Stock, Shares Authorized Preferred stock, shares authorized Preferred Stock, Shares Issued Preferred stock, shares, issued Common Stock, Par or Stated Value Per Share Common stock, par value (in dollars per share) Common Stock, Shares Authorized Common stock, shares authorized Common Stock, Shares, Issued Common stock, shares issued Common Stock, Shares, Outstanding Common stock, shares outstanding Consolidated Statements of Operations and Comprehensive Loss Derivative Instrument [Axis] Derivative Contract [Domain] Warrant derivative instrument. Warrant Derivative Financial Instruments [Member] Warrant derivative Embedded Derivative Financial Instruments [Member] Embedded derivative Operating Expenses [Abstract] Operating expenses: Research and Development Expense Research and development General and Administrative Expense General and administrative Operating Expenses Total operating expenses Operating Income (Loss) Operating loss Nonoperating Income (Expense) [Abstract] Non-operating income (expense): Interest and Other Income Interest and other income, net Gain (Loss) on Derivative Instruments, Net, Pretax Loss from change in fair value of derivative liabilities Loss from change in fair value of derivative liabilities Nonoperating Income (Expense) Total non-operating income, net Net loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract] Other comprehensive income (loss): OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax Net unrealized gain (loss) on marketable debt securities Net change in accumulated other comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Comprehensive loss Earnings Per Share, Basic Net loss per common share - basic (in dollars per share) Net loss per share of common stock - basic (in dollars per share) Earnings Per Share, Diluted Net loss per common share - diluted (in dollars per share) Net loss per share of common stock - diluted (in dollars per share) Weighted Average Number of Shares Outstanding, Basic Weighted average number of common shares outstanding - basic (in shares) Weighted average shares for basic net loss per share Weighted Average Number of Shares Outstanding, Diluted Weighted average number of common shares outstanding - diluted (in shares) Weighted average shares for diluted net loss per share Consolidated Statements of Shareholders' Equity Equity Components [Axis] Equity Component [Domain] Common Stock [Member] Common Stock Additional Paid-in Capital [Member] Additional Paid-in Capital AOCI Attributable to Parent [Member] Accumulated Other Comprehensive Loss Retained Earnings [Member] Accumulated Deficit Sale of Stock [Axis] Sale of Stock [Domain] Private Placement [Member] Private Placement Represents the information pertaining to underwritten Public Offering. Underwritten Public Offering [Member] Underwritten Public Offering Underwritten Public Offering Class of Warrant or Right [Axis] Class of Warrant or Right [Domain] Represents information pertaining to pre-funded warrants. Pre Funded Warrants [Member] Pre-funded warrants Shares, Outstanding Balance ending (in shares) Balance beginning (in shares) Stock Issued During Period, Value, New Issues Proceeds from issuance of equity securities Stock Issued During Period, Shares, New Issues Number of shares issued Proceeds from issuance of equity securities (in shares) Number of shares issued Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs Other equity offering costs Stock Issued During Period, Value, Stock Options Exercised Issuance of common stock upon exercise of stock options Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Exercises Issuance of common stock upon exercise of stock options (in shares) APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Share-based compensation Value of stock issued upon exercise of pre-funded warrants Stock Issued During Period, Value, Exercise of Pre-funded Warrants Cashless exercise of pre-funded warrants Number of shares issued upon exercise of pre-funded warrants. Stock Issued During Period, Shares, Exercise of Pre-funded Warrants Exercise of pre-funded warrants (in shares) Cashless exercise of pre-funded warrants (in shares) Stock Repurchased and Retired During Period, Value Acquisition and retirement of treasury shares pursuant to Exchange Agreement Stock Repurchased and Retired During Period, Shares Acquisition and retirement of treasury shares pursuant to Exchange Agreement (in shares) Amount of increase in additional paid in capital (APIC) resulting from the reclassification of warrant derivative liability to equity. Adjustments to Additional Paid in Capital, Reclassification of Warrant Derivative Liability to Equity Reclassification of warrant derivative liability to equity Consolidated Statements of Cash Flows Represents information relating to pre-funded 2024 warrants. Pre Funded Warrants 2024 Pre Funded Warrants 2024 2024 PFWs Net Cash Provided by (Used in) Operating Activities [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES: Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net loss Share-Based Payment Arrangement, Noncash Expense Share-based compensation expense Amount representing the non cash lease expense. Non Cash Lease Expense Non-cash lease expense Accretion (Amortization) of Discounts and Premiums, Investments Accretion of discounts and amortization of premiums on marketable debt securities, net Depreciation, Depletion and Amortization, Nonproduction Depreciation expense Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities: Increase (Decrease) in Prepaid Expense and Other Assets Increase in prepaid expenses, deposits, and other assets Increase (Decrease) in Accounts Payable Increase in accounts payable Increase (Decrease) in Accrued Liabilities Increase in accrued liabilities Net Cash Provided by (Used in) Operating Activities Net Cash Used in Operating Activities Net cash used in operating activities Net Cash Provided by (Used in) Investing Activities [Abstract] CASH FLOWS FROM INVESTING ACTIVITIES Payments to Acquire Marketable Securities Purchase of marketable debt securities Investment in marketable securities Proceeds from Sale and Maturity of Marketable Securities Proceeds from maturities of marketable debt securities Payments to Acquire Property, Plant, and Equipment Purchase of property and equipment Net Cash Provided by (Used in) Investing Activities Total Cash Provided by (Used in) Investing Activities Net Cash Provided by (Used in) Financing Activities [Abstract] CASH FLOWS FROM FINANCING ACTIVITIES: Proceeds from Stock Options Exercised Proceeds from exercise of stock options Payments for Repurchase of Common Stock Net cash payment pursuant to Exchange Agreement Cash payment to exchanging shareholders Proceeds from Issuance of Common Stock Proceeds from issuance of common stock Proceeds from issuance of equity securities in 2024 Underwritten Offering, net of underwriting discounts, Issuance of common stock Proceeds from Issuance of Warrants Proceeds from warrants issued Proceeds from issuance of equity securities in 2024 Underwritten Offering, net of underwriting discounts, Issuance of pre-funded warrants Proceeds from Issuance of Private Placement Gross proceeds from issuance of common stock in 2022 Private Placement Payment for commissions and other deferred offering costs. Payment of Commissions and Other Deferred Offering Costs Payment of commissions and other deferred offering costs Net Cash Provided by (Used in) Financing Activities Net Cash Provided by Financing Activities Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Net increase (decrease) in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Cash and cash equivalents at end of fiscal year Cash and cash equivalents at beginning of fiscal year SUPPLEMENTAL FINANCIAL INFORMATION SUPPLEMENTARY CASH FLOW INFORMATION: Operating Lease, Payments Cash paid for amounts included in the measurement of operating lease liabilities Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Operating lease liabilities incurred in exchange for right-of-use assets Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] NON-CASH INVESTING AND FINANCING ACTIVITIES: Acquisition of treasury shares in exchange for issuing pre-funded warrant liability Acquisition Of Treasury Shares In Exchange For Issuing Pre-Funded Warrant Liability Acquisition of treasury shares in exchange for pre-funded warrant derivative liability Amount of receivable from exercise of stock options in non-cash investing or financing transactions. Receivable From Exercise of Stock Options Receivable from exercise of stock options The amount of offering costs that were incurred during a noncash or partial noncash transaction. Payables For Offering Costs, Noncash or Partial Noncash Transaction Payables for offering costs charged to additional paid-in capital NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block] NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES No definition available. LIQUIDITY Substantial Doubt about Going Concern [Text Block] LIQUIDITY INVESTMENTS IN MARKETABLE DEBT SECURITIES Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] INVESTMENTS IN MARKETABLE DEBT SECURITIES LEASES Lessee, Operating Leases [Text Block] LEASES n/a LICENSE AGREEMENTS The entire disclosure for information about License agreements. LICENSE AGREEMENTS [Text block] LICENSE AGREEMENTS EMBEDDED DERIVATIVE LIABILITY Discussion of Hybrid Instruments and Embedded Derivatives [Text Block] EMBEDDED DERIVATIVE LIABILITY SHAREHOLDERS' EQUITY Equity [Text Block] SHAREHOLDERS' EQUITY SHARE-BASED COMPENSATION AND WARRANTS Share-Based Payment Arrangement [Text Block] SHARE-BASED COMPENSATION AND WARRANTS INCOME TAXES Income Tax Disclosure [Text Block] INCOME TAXES COMMITMENTS AND CONTINGENCIES. Commitments and Contingencies Disclosure [Text Block] COMMITMENTS AND CONTINGENCIES RELATED PARTY TRANSACTIONS Related Party Transactions Disclosure [Text Block] RELATED PARTY TRANSACTIONS Additional Financial Information Disclosure [Text Block] SUPPLEMENTAL FINANCIAL INFORMATION NET LOSS PER SHARE Earnings Per Share [Text Block] NET LOSS PER SHARE FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS Financial Instruments Disclosure [Text Block] FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS SUBSEQUENT EVENTS Subsequent Events [Text Block] SUBSEQUENT EVENTS Nature of Operations [Text Block] Nature of Operations Consolidation, Policy [Policy Text Block] Consolidation Basis of Accounting, Policy [Policy Text Block] Basis of Presentation Use of Estimates, Policy [Policy Text Block] Use of Estimates Disclosure of accounting policy for the risks and uncertainties during the reporting period. Risks and Uncertainties [Policy Text Block] Risks and Uncertainties Cash and Cash Equivalents, Policy [Policy Text Block] Cash and Cash Equivalents Marketable Securities, Policy [Policy Text Block] Investments in Marketable Debt Securities Disclosure of accounting policy of prepaid expenses and other assets. Prepaid Expenses and Other Assets [Policy Text Block] Prepaid Expenses and Other Lessee, Leases [Policy Text Block] Leases Property, Plant and Equipment, Policy [Policy Text Block] Property and Equipment Research and Development Expense, Policy [Policy Text Block] Research and Development Costs Represents the accounting policy on clinical trial accruals. Clinical Trial Accruals [Policy Text Block] Clinical Trial Accruals Share-Based Payment Arrangement [Policy Text Block] Share-Based Compensation Derivatives, Policy [Policy Text Block] Embedded Derivatives Disclosure of Accounting policy of fair value of warrants. Fair Value of Warrants [Policy Text Block] Fair Value of warrants Income Tax, Policy [Policy Text Block] Income Taxes Earnings Per Share, Policy [Policy Text Block] Net Loss Per Share Treasury Stock [Text Block] Treasury Shares New Accounting Pronouncements, Policy [Policy Text Block] Recent Accounting Pronouncements Marketable Securities [Table Text Block] Schedule of investments in marketable debt securities Schedule of Available-for-Sale Securities Reconciliation [Table Text Block] Summary of unrealized gains and losses that result in differences between the amortized cost basis and fair value of the Company's marketable debt securities The tabular disclosure of carrying value of ROU assets and operating lease liabilities. Lessee, Operating Lease, Right Of Use Assets And Operating Lease Liabilities Schedule of carrying value of right-of-use assets and operating lease liabilities Lease, Cost [Table Text Block] Schedule of operating lease expense Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Schedule of future payments under operating lease agreements Class of Warrant or Right [Table] Class of Warrant or Right [Line Items] Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] Schedule of warrant activity Represents the information pertaining to legacy warrants. Legacy Warrants [Member] Legacy warrants The tabular disclosure of the number of shares authorized, outstanding, and available for future grants under stock option. Share-based Payment Arrangement, Option, Shares Authorized, Outstanding, and Available for Future Grants Schedule of the number of shares authorized, outstanding, and available for future grants under stock option Share-Based Payment Arrangement, Option, Activity [Table Text Block] Schedule of the stock option plans Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Schedule of the fair value of stock options Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Schedule of share-based compensation expense Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Schedule of effective income tax rate reconciliation Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Schedule of deferred tax assets and liabilities Schedule of Cash and Cash Equivalents [Table Text Block] Schedule of cash and cash equivalents Property, Plant and Equipment [Table Text Block] Summary of property and equipment Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Schedule of basic and diluted net loss per share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Schedule of potential common stock equivalents were excluded from the computation of diluted net loss per share Fair Value, Assets Measured on Recurring Basis [Table Text Block] Schedule of financial assets measured at fair value on a recurring basis Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Schedule of changes in the fair value of the company's derivative liabilities, fair value, level 3 inputs Statistical Measurement [Axis] Statistical Measurement [Domain] Minimum [Member] Minimum Maximum [Member] Maximum Represents the number of wholly owned subsidiaries. Number of Wholly Owned Subsidiaries Number of wholly owned subsidiaries Property, Plant and Equipment, Useful Life Estimated useful lives of the assets Counterparty Name [Axis] Counterparty Name [Domain] XOMA Corporation [Member] XOMA Corporation [Member] XOMA Corporation XOMA (US) LLC [Member] XOMA (US) LLC [Member] XOMA (US) LLC Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Research and Development Arrangement, Contract to Perform for Others, Type [Domain] License Agreement Terms [Member] License agreement Phase 3 Clinical Trial Rz 358 [Member]. Phase 3 Clinical Trial RZ 358 (ersodetug) Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement [Member] Collaborative Arrangement Xoma License Agreement [Member] Xoma License Agreement [Member] Xoma License Agreement Scenario [Axis] Scenario [Domain] Scenario, Plan [Member] Scenario, Plan Plan Represents information pertaining to dosing of the last patient milestones. Scenario, Upon Dosing Of The Last Patient [Member] Scenario, Upon Dosing Of The Last Patient Represents the information pertaining to at the market offering. At the Market Offering [Member] At the Market Offering Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Event [Member] Subsequent Event Marketable Securities Marketable debt securities Total investments Maximum amount agreed to sell as per open market sales agreement. Sale of Stock, Maximum Amount Agreed to Sell as Per Open Market Sales Agreement Amount agreed to sell as per open market sales agreement The number of warrants issued. Class of Warrant or Right, Issued Warrants issued The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity net of underwriting discounts, commissions and other fees. Proceeds From Issuance Or Sale Of Equity, Net Of Underwriting Discounts And Commissions Proceeds after underwriting discounts and other offering costs The cash inflow from the additional capital contribution to the entity net of underwriting discounts, commissions and other fees. Proceeds From Issuance Of Common Stock, Net Of Underwriting Discounts And Commissions Net cash proceeds Amount of milestone payment made during the period. Milestone Closing Payment Milestone closing payment Debt Securities, Available-for-Sale, Term Debt securities, available-for-sale, term Weighted average period of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Debt Securities, Available-for-Sale, Weighted Average Term Debt securities, available-for-sale, weighted average term Debt Securities, Available-for-Sale, Accrued Interest, after Allowance for Credit Loss, Current Interest receivable Debt Securities, Available-for-Sale, Accrued Interest, after Allowance for Credit Loss, Current, Statement of Financial Position [Extensible Enumeration] Debt Securities, Available-for-Sale, Amortized Cost, Allowance for Credit Loss, Excluding Accrued Interest, Current Allowance for credit losses related to investments in marketable debt securities Debt Securities, Available-for-Sale [Table] Financial Instrument [Axis] Financial Instruments [Domain] Commercial Paper [Member] Corporate commercial paper Commercial paper US Government Agencies Debt Securities [Member] U.S. Government agencies Obligations of U.S. government agencies US Treasury Securities [Member] U.S. Government treasuries U.S. Treasury obligations Corporate Debt Securities [Member] Corporate notes and bonds Corporate notes and bonds Asset-Backed Securities [Member] Asset-backed securities Debt Securities, Available-for-Sale [Line Items] INVESTMENTS IN MARKETABLE DEBT SECURITIES Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, before Allowance for Credit Loss Amortized Cost Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Gross Unrealized Gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Gross Unrealized Losses Debt Securities, Available-for-Sale, Excluding Accrued Interest Fair Value Property, Plant and Equipment [Table] Name

of Property [Axis] Name of Property [Domain] Represents the information pertaining to office space in Bend, Oregon. Office space in Bend Office space in Bend, Oregon Represents information pertaining to lease agreement for corporate headquarters. Corporate Headquarters Property, Plant and Equipment [Line Items] Represents the amount of space being leased. Lessee, Operating Lease, Operating Lease Space Lease space Lessee, Operating Lease, Liability, to be Paid Total base rent payments Total lease payments The operating lease rent abatement period. Lessee, Operating Lease, Abatement Period Abatement period The amount of lease allowance provided for furniture and equipment. Lessee, Operating Lease, Furniture And Equipment Allowance Lease provided an allowance for the purchase of furniture and equipment Lessee, Operating Lease, Term of Contract Operating lease term of contract The amount of base rent payable monthly. Lessee, Operating Lease, Base Rent Expense Average base rent payable in cash Lessee, Operating Lease, Renewal Term Variable Lease, Cost Aggregate amount of variable payments exclude from operating lease liabilities Operating Lease, Weighted Average Remaining Lease Term Weighted average remaining lease term under operating leases Operating Lease, Weighted Average Discount Rate, Percent Weighted average discount rate for operating lease liabilities Operating Lease, Liability Operating lease liability Total Present value of operating lease liabilities Lessee, Operating Lease, Discount Rate Lessee operating lease discount rate Assets and Liabilities, Lessee [Abstract] Carrying value of right-of-use assets and operating lease liabilities Operating Lease, Liability [Abstract] Operating lease liabilities: Lessee, Lease, Description [Table] Statement of Income Location, Balance [Axis] Statement of Income Location, Balance [Domain] Research and Development Expense [Member] Research and Development Expense General and Administrative Expense [Member] General and Administrative Expense Lessee, Lease, Description [Line Items] Operating Lease, Cost Operating lease expense Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract] Future lease payments related to operating lease agreements Lessee, Operating Lease, Liability, to be Paid, Year One 2025 Lessee, Operating Lease, Liability, to be Paid, Year Two 2026 Lessee, Operating Lease, Liability, to be Paid, Year Three 2027 Amount of lessee's undiscounted obligation for lease payment for operating lease due after third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). Lessee, Operating Lease, Liability, to be Paid, after Year Three Thereafter Lessee, Operating Lease, Liability, Undiscounted Excess Amount Less imputed interest Research and Development, Contract to Perform for Others [Table] Represent the information pertaining to ActiveSite Pharmaceuticals, Inc. ActiveSite Pharmaceuticals, Inc N/A. Phase 1 Clinical Trial RZ402 N/A. Phase 2 Clinical Trial RZ402 N/A. Phase 2 Clinical Trial RZ358 (ersodetug) Phase 3 Clinical Trial Rz 402 [Member]. Phase 3 Clinical Trial RZ 402 Development And License Agreement [Member] Development And License Agreement [Member] Development And License Agreement Represents information pertaining to upon the clinical and regulatory milestones. Scenario, Upon Clinical and Regulatory Milestones [Member] Upon Clinical and Regulatory Milestones Represents information pertaining to after the clinical and regulatory milestones. Scenario, After Clinical and Regulatory Milestones [Member] After Clinical and Regulatory Milestones Research and Development Arrangement, Contract to Perform for Others [Line Items] License Agreements The maximum amount of milestone event which need to occur for making specific range of milestone payment. Maximum Amount of Milestone Events Maximum amount of milestone events Represents the percentage of royalties. Development and License Agreement, Royalties Percentage Royalties percentage Schedule of Long-Term Debt Instruments [Table] Debt Instrument [Line Items] Line of Credit Facility, Maximum Borrowing Capacity Maximum borrowing capacity Proceeds from Issuance of Debt Gross proceeds from issuance of debt Represents the exit fee on the funded principal balance. Debt Instrument, Exit Fee Exit fee on the funded principal balance Amount of expenses associated with exit fees on the funded principal balance. Debt Instrument, Exit Fee Amount Exit fee amount Represents the percentage of entity's shares held by investors. Percentage Of Entity's Shares Held By Investors Percentage of entity's shares held by investors Stock, Class of Stock [Table] Represents information relating to pre-funded 2021 warrants. Pre Funded Warrants 2021 [Member] 2021 Pre-Funded Warrants 2021 PFWs Represents information relating to pre-funded 2022 warrants. 2022 Pre-Funded Warrants 2022 PFWs Represents information relating to Class A pre-funded warrants. Class A Pre-Funded Warrants Class A pre-funded warrants Represents information relating to Class B pre-funded warrants. Class B Warrants Class B Pre-Funded Warrants Represents information relating to exchange pre-funded warrants. Exchange Pre Funded Warrants [Member] Exchange Pre-Funded Warrants Exchange PFWs Information of agreement. Agreement [Axis] Information of agreement. Agreement [Domain] Represents information pertaining to securities exchange agreement. Securities Exchange Agreement [Member] Securities exchange agreement Class of Stock [Line Items] Class of Warrant or Right, Number of Securities Called by Warrants or Rights Warrants to purchase shares of common stock Pre-funded warrants to purchase shares of common stock Number of shares of common stock called by warrants issued Represents the designated ownership percentage by holder not exceeding the specified percentage for exercise of warrants. Warrants Exercisable, Ownership Blocker Percentage Warrants exercisable, ownership blocker percentage Class of Warrant or Right, Outstanding Warrants outstanding, ending (In shares) Warrants outstanding, beginning (In shares) Warrants outstanding (In shares) Number of warrants or rights surrendered. Class of Warrant or Right, Warrants Surrendered Shares surrendered for exercise price Number of warrants or rights exercised. Class of Warrant or Right, Exercised Exercise of warrants Warrants exercised Shares Issued, Price Per Share Shares issue price Class of Warrant or Right, Exercise Price of Warrants or Rights Warrants Outstanding, Ending Price (in dollars per share) Warrants Outstanding, Beginning Price (in dollars per share) Warrant price (per share) Warrants exercise price Underwriters Option. Underwriters Option [Member] Underwriters Option Sale of Stock, Price Per Share Sale of stock, price per share Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the additional shares option of a stock transaction. Sale of stock, Additional Shares Option, price per share Represent the maximum number of additional shares offered. Maximum Number Of Additional Shares Issued Maximum number of additional shares issued Proceeds from Issuance or Sale of Equity Gross proceeds from sale of equity The percentage of underwriting discounts and commissions. Underwriting Discounts and Commissions Underwriting discounts and commissions (In percentage) Related to other offering costs Other Offering Costs Other offering costs The costs for underwriter discounts, commissions and other fees. Underwriting Discounts And Commissions Expense Underwriting discounts and commissions expense Treasury Stock, Shares, Acquired Purchased shares of common stock The percentage of stock acquired to the total of outstanding shares. Percentage of Treasury Stock Acquired, of Shares Outstanding Outstanding shares percentage Treasury Stock, Value, Acquired, Cost Method Fair value of shares Warrants and Rights Outstanding Estimated fair value of warrants The amount of change in fair value of warrant derivative liability. Change in Fair Value of Warrant Derivative Liability Change in fair value of derivative liability Percentage of commission agreed to pay as a percentage on gross sales price. Sale of Stock, Commission Agreed to Pay as a Percentage on Gross Sales Price Percentage of commission agreed Sale of Stock, Number of Shares Issued in Transaction Common stock to sales agreement Maximum amount remaining for sale as per open market sales agreement. Sale of Stock, Maximum Amount Remaining for Sale as Per Open Market Sales Agreement Sales agreement amounts Represents information pertaining to July 2022 financing. July 2022 Financing Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Plan Name [Axis] Plan Name [Domain] Represents information pertaining to 2015 plan. 2015 Plan Represents information pertaining to 2016 plan. 2016 Plan Represents information pertaining to year 2019 plan. 2019 Plan Represents information pertaining to year 2021 plan. 2021 Plan Represents information pertaining to the inducement grant. Inducement Grant Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] The number of active stock option plans. Number Of Active Stock Option Plans Number of active stock option plans Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Number of shares authorized Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Outstanding, ending Outstanding, beginning Number of shares outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Number of shares available Employee Stock [Member] Employee Stock Purchase Plan Common Stock, Capital Shares Reserved for Future Issuance Shares reserved for purchase Stock Issued During Period, Shares, Employee Stock Purchase Plans Shares purchases Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Number of Options Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Grants to employees Stock options granted Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period Expired Shares Issued, Shares, Share-Based Payment Arrangement, Forfeited Forfeited Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares Vested, ending Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Outstanding, ending Outstanding, beginning Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Exercise price of stock options Granted Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Exercises Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Expired Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Forfeited Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value Vested, ending Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract] Weighted Average Remaining Contractual Life Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Remaining contractual term (years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Vested (years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value Total intrinsic value of exercised Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Intrinsic value of outstanding options Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value Aggregate intrinsic value of vested stock options Fair value of options granted. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock. Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grant in Period, Fair Value Fair value of options granted Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Weighted average grant date fair value, granted Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price Market price of common stock on grant date Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Expected volatility Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Risk free interest rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Expected term (years) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Dividend yield Share-Based Payment Arrangement, Expense Compensation cost Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Expected to be recognized over a remaining weighted average period Employee Stock Option Title and Position [Axis] Title and Position [Domain] Chief Financial Officer [Member] Chief Financial Officer Vesting [Axis] Vesting [Domain] Share-Based Payment Arrangement, Tranche One [Member] Tranche one Share-Based Payment Arrangement, Tranche Two [Member] Tranche two Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage Vesting percentage Number of warrants or rights expired. Class of Warrant or Right, Expirations Warrant expirations (In shares) Exercise price per share or per unit of warrants or rights expired. Class of Warrant or Right, Expiration, Exercise Price of Warrants or Rights Warrant expirations, Price (in dollars per share) Warrants and Rights Outstanding, Term Weighted average remaining contractual term Number of warrants exercised or granted. Warrants Exercised or Granted Warrants granted or exercised Operating Loss Carryforwards [Table] Income Tax Jurisdiction [Axis] Income Tax Jurisdiction [Domain] Domestic Tax Jurisdiction [Member] Domestic Tax Authority Represents information relating to expiration in 2031 through 2035. Expiration in 2031 Through 2035 Expiration in 2031 Through 2035 Represents information relating to amount available through fiscal year 2038 and that expires by June 30, 2038 Available Through Fiscal Year 2038 And Expires By June 30, 2038 Available Through Fiscal Year 2038 And Expires By June 30, 2038 Represents information relating to not subject to expiry and amount available over next 2023 and thereafter years. Not Subject To Expiry And Available For Use Over 2038 And Thereafter Years Not Subject To Expiry And Available For Use Over 2038 And Thereafter Years Geographical [Axis] Geographical [Domain] UNITED STATES UNITED STATES Operating Loss Carryforwards [Line Items] Operating Loss Carryforwards Operating loss carryforwards Amount of the limitations under IRC section 382 on the use of all operating loss carryforwards available to reduce future taxable income. Operating Loss Carryforwards, Subject to Limitations on Use Operating loss carryforwards, subject to limitations Amount of the operating loss carryforwards available to reduce future taxable income no limitation on use. Operating loss carryforwards, subject to no limitations Operating loss carryforwards, subject to no limitations Amount of operating loss carryforward not subject to expiration available to offset taxable income. Operating Loss Carryforwards, Amount Not Subject to Expiration Available To Offset Taxable Income Operating loss carryforward not subject to expiration available to offset taxable income Amount of operating loss carryforward subject to expiration available to offset taxable income. Operating Loss Carryforwards, Amount Subject to Expiration Available To Offset Taxable Income Operating loss carryforward subject to expiration available to offset taxable income Amount of operating loss carryforward, not subject to expiration, available to reduce future taxable income under enacted tax laws. Operating Loss Carryforwards, Amount Not Subject to Expiration Operating loss carryforward, not subject to expiration, available to reduce future taxable income Amount of operating loss carryforward, not subject to expiration, available for use to reduce future taxable income under enacted tax laws. Operating Loss Carryforwards, Amount Not Subject to Expiration, Available for Use Operating loss carryforward, not subject to expiration, available for use to reduce future taxable income Amount of operating loss carryforward per year not subject to expiration, available for use to reduce future taxable income under enacted tax laws. Operating Loss Carryforwards, Amount Per Year Not Subject to Expiration, Available for Use Operating loss carryforward per year not subject to expiration, available for use to reduce future taxable income Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount Increase in valuation allowance Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract] Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount Income tax benefit at statutory U.S. federal rate Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount Income tax benefit attributable to U.S. states Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount Impact of reduction in Colorado tax rate Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to non-taxable derivative gains (losses). Effective Income Tax Rate Reconciliation, Non-Taxable Derivative Gains (Losses), Amount Non-taxable derivative loss Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount Non-deductible expenses Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to stock option expiration. Effective Income Tax Rate Reconciliation, Stock Option Expirations Stock option expirations Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to net operating loss expirations. Income Tax Reconciliation, Net Operating Loss Expirations NOL expirations Effective Income Tax Rate Reconciliation, Other Adjustments, Amount Other Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount Change in valuation allowance Income Tax Expense (Benefit) Total income tax expense Deferred Tax Assets, Net [Abstract] Deferred income tax assets: Deferred Tax Assets, Operating Loss Carryforwards Net operating loss carryforwards Deferred Tax Asset, In-Process Research and Development Research and experimental costs Deferred Tax Assets, Goodwill and Intangible Assets Intangible assets Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost Share-based compensation Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from operating lease liability. Deferred Tax Assets Operating Lease Liabilities Operating lease liabilities Deferred Tax Assets, Other Accrued expenses and other Deferred Tax Assets, Gross Total deferred income tax assets Deferred Tax Assets, Valuation Allowance Valuation allowance for deferred income tax assets Deferred Tax Assets, Net of Valuation Allowance Deferred income tax assets, net of valuation allowance Deferred Tax Liabilities, Net [Abstract] Deferred tax liabilities Amount of deferred tax liability attributable to taxable right of use asset. Deferred Tax Liabilities Right-Of-Use Assets Deferred income tax liability right-of-use assets Deferred Tax Assets, Net Net deferred income tax assets This table lists the commitments and contingencies. Commitments And Contingencies [Table] Other Commitments [Axis] Other Commitments [Domain] Represents information pertaining to employment agreement. Employment Agreements Employment Agreements Executive Officer [Member] Executive Officers Chief Executive Officer [Member] Chief Executive Officer Employees with designation of Chief Executive Officer and Chief Medical Officer. Chief Executive Officer And Chief Medical Officer [Member] Chief Executive Officer And Chief Medical Officer Person with designation of chief medical officer. Chief Medical Officer [Member] Chief Medical Officer The line items identify information about the commitments and contingencies. Commitments And

Contingencies [Line Items] COMMITMENTS AND CONTINGENCIES Represents information pertaining to number of officers. Number of Officers Number of officers Represents information pertaining to number of employees. Number of Employees Number of employees Represents the aggregate annual base salaries. Aggregate Annual Base Salaries Aggregate annual base salaries Period during which stock options will immediately vest if either of individuals is terminated outside of a change in control event and without cause, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Employment Agreement, Termination, Vesting Period, Change In Control Event and Without Cause Vesting period, change in control event Period during which stock options will remain exercisable if either of individuals is terminated outside of a change in control event and without cause, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Employment Agreement, Termination, Exercisable Period, Change In Control Event and Without Cause Exercisable period, change in control event and without cause Period during which stock options will remain exercisable if either of individuals is terminated outside of a change in control event, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Employment Agreement, Termination, Exercisable Period, Change In Control Event Exercisable period, change in control event Term of salary for calculation of severance payment other than change in control event under employment agreement. Employment Agreement, Severance Payment Based on Term of Salary, Other Than Change In Control Event Severance payment based on term of salary Term of health insurance coverage other than change in control event under employment agreement. Employment Agreement, Health Insurance Coverage Term Other Than Change In Control Event Term of health insurance coverage other than change in control event Period during which unvested stock options will immediately vest if either of individuals is terminated outside of a change in control event, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Employment Agreement, Termination, Unvested Stock Options, Vesting Period, Change In Control Event Unvested stock options, vesting period, change in control event Period during which unvested stock options will remain exercisable if either of individuals is terminated outside of a change in control event, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Employment Agreement, Termination, Unvested Stock Options, Exercisable Period, Change In Control Event Unvested stock options, exercisable period, change in control event Term of salary for calculation of severance payment on termination of employment agreement due to change of control event. Employment Agreement, Termination, Severance Payment Based on Term of Salary, Change of Control Event Severance payment based on term of salary, change of control event Term of health insurance coverage following termination of employment agreement due to change of control event. Employment Agreement, Termination, Term of Health Insurance Coverage due to Change of Control Event Term of health insurance coverage, change in control Defined Contribution Plan, Employer Matching Contribution, Percent of Match Employer matching contributions (as a percent) Defined Contribution Plan, Employer Discretionary Contribution Amount Total contributions by the company Related Party Transaction [Table] Related and Nonrelated Parties [Axis] Related and Nonrelated Parties [Domain] Related Party [Member] Related Party Related Party Transaction [Axis] Related Party Transaction [Domain] Represents the information pertaining to Handok License agreement Handok License Agreement [Member] Handok License Agreement Handok, Inc. [Member] Handok, Inc. [Member] Handok, Inc. Related Party Transaction [Line Items] Term of pharmaceutical license agreement in years. Pharmaceutical License Agreement, Term License term (in years) The amount of milestone payments to be incurred for the approval of license. Pharmaceutical License Agreement, Milestone Payment Milestone payments The percentage of transfer price on sale of products. Pharmaceutical License Agreement, Transfer Price Transfer price (in percent) The amount of milestone payments earned by the entity. Pharmaceutical License Agreement Milestone Payment Earned Milestone payments earned Cash and Cash Equivalent [Table] Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Domain] Money Market Funds [Member] Money Market Mutual Fund Money market funds Demand Deposits [Member] Demand deposits at a single financial institution Cash and Cash Equivalents [Line Items] SUPPLEMENTAL FINANCIAL INFORMATION Property, Plant and Equipment, Gross Office furniture and equipment Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Less accumulated depreciation Depreciation Depreciation expense related to property and equipment Antidilutive Security, Excluded EPS Calculation [Table] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] NET LOSS PER SHARE Net Income (Loss) Available to Common Stockholders, Basic [Abstract] Calculation of Numerators: Net Income (Loss) Available to Common Stockholders, Basic Net loss for calculation of basic net loss per share Net Income (Loss) Available to Common Stockholders, Diluted Net loss for the calculation of diluted net loss per share Weighted Average Number of Shares Outstanding, Diluted [Abstract] Calculation of Denominators: Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Total Fair Value, Recurring and Nonrecurring [Table] Measurement Frequency [Axis] Measurement Frequency [Domain] Fair Value, Recurring [Member] Recurring Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Domain] Fair Value, Inputs, Level 1 [Member] Level 1 Fair Value, Inputs, Level 2 [Member] Level 2 Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS Cash and Cash Equivalents, Fair Value Disclosure Cash and cash equivalents Assets, Fair Value Disclosure Financial assets measured at fair value Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Measurement Input Type [Axis] Measurement Input Type [Domain] Measurement Input, Exercise Price [Member] Exercise price Measurement Input, Share Price [Member] Market price of common stock Measurement Input, Risk Free Interest Rate [Member] Risk-free interest rate Measurement Input, Expected Term [Member] Expected term Measurement Input, Price Volatility [Member] Historical volatility Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS Warrants and Rights Outstanding, Measurement Input Warrants and rights outstanding, measurement input Liability Class [Axis] Fair Value by Liability Class [Domain] This item represents warrant derivative instrument obligations meeting the definition of a liability which are reported as of the balance sheet date. Warrants, Derivative Financial Instruments, Liabilities [Member] Warrant This item represents embedded derivative instrument obligations meeting the definition of a liability which are reported as of the balance sheet date. Embedded Derivative, Derivative Financial Instruments, Liabilities [Member] Embedded Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Balance at the end Balance at the beginning Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances Warrant liability incurred on March 8, 2024 Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Changes in fair value Amount of reclassification of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Reclassification to Equity Reclassification of warrant derivative liability to equity on May 13, 2024 Industry Sector [Axis] Industry Sector [Domain] Financial Services Sector [Member] Banking and Financial Services Industries Government Sector [Member] U.S. government Concentration Risk, Credit Risk, Uninsured Deposits Concentration risk, credit risk, uninsured deposits Subsequent Event [Table] Subsequent Event [Line Items] Percentage of calendar year target bonus payable by the company. Percentage Of Calendar Year Target Bonus Percentage of calendar year target bonus payable EX-101.PRE 16 rzlt-20240630_pre.xml EX-101.PRE XML 18 R1.htm IDEA: XBRL DOCUMENT v3.24.3 Document And Entity Information - USD ($) 12 Months Ended Jun. 30, 2024 Jun. 30, 2023 Sep. 13, 2024 Dec. 29, 2023 Document And Entity Information [Abstract] Â Â Â Â Document Type 10-K Â Â Â Document Annual Report true Â Â Â Document Period End Date Jun. 30, 2024 Â Â Â Document Transition Report false Â Â Â Securities Act File Number 001-39683 Â Â Â Entity Registrant Name REZOLUTE, INC. Â Â Â Entity Incorporation, State or Country Code NV Â Â Â Entity Tax Identification Number 27-3440894 Â Â Â Entity Address, Address Line One 275 Shoreline Drive, Suite 500 Â Â Â Entity Address, City or Town Redwood City Â Â Â Entity Address, State or Province CA Â Â Â Entity Address, Postal Zip Code 94065 Â Â Â City Area Code 650 Â Â Â Local Phone Number 206-4507 Â Â Â Title of 12(b) Security Common Stock, par value $0.001 Â Â Â Trading Symbol RZLT Â Â Â Security Exchange Name NASDAQ Â Â Â Entity Well-known Seasoned Issuer No Â Â Â Entity Voluntary Filers Yes Â Â Â Entity Current Reporting Status Yes Â Â Â Entity Interactive Data Current Yes Â Â Â Entity Filer Category Non-accelerated Filer Â Â Â Entity Small Business true Â Â Â Entity Emerging Growth Company false Â Â Â ICFR Auditor Attestation Flag false Â Â Â Document Financial Statement Error Correction [Flag] false Â Â Â Entity Shell Company false Â Â Â Entity Public Float Â Â Â $ 33,252,000 Entity Common Stock, Shares Outstanding Â Â 55,369,764 Â Auditor Name Grant Thornton, LLP Plante & Moran, PLLC Â Â Auditor Location Newport Beach, California Cleveland, Ohio Â Â Auditor Firm ID 248 166 Â Â Entity Central Index Key 0001509261 Â Â Â Current Fiscal Year End Date --06-30 Â Â Â Document Fiscal Year Focus 2024 Â Â Â Document Fiscal Period Focus FY Â Â Â Amendment Flag false Â Â Â X - DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission. + ReferencesNo definition available. + Details Name: dei_AmendmentFlag Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionPCAOB issued Audit Firm Identifier + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-K -Number 249 -Section 310Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 20-F -Number 249 -Section 220 -Subsection fReference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 40-F -Number 249 -Section 240 -Subsection f + Details Name: dei_AuditorFirmId Namespace Prefix: dei_ Data Type: dei:nonemptySequenceNumberItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-K -Number 249 -Section 310Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 20-F -Number 249 -Section 220 -Subsection fReference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 40-F -Number 249 -Section 240 -Subsection f + Details Name: dei_AuditorLocation Namespace Prefix: dei_ Data Type: dei:internationalNameItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-K -Number 249 -Section 310Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 20-F -Number 249 -Section 220 -Subsection fReference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 40-F -Number 249 -Section 240 -Subsection f + Details Name: dei_AuditorName Namespace Prefix: dei_ Data Type: dei:internationalNameItemType Balance Type: na Period Type: duration X - DefinitionArea code of city + ReferencesNo definition available. + Details Name: dei_CityAreaCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCover page. + ReferencesNo definition available. + Details Name: dei_CoverAbstract Namespace Prefix: dei_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionEnd date of current fiscal year in the format --MM-DD. + ReferencesNo definition available. + Details Name: dei_CurrentFiscalYearEndDate Namespace Prefix: dei_ Data Type: xbrli:gMonthDayItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as an annual report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-K -Number 249 -Section 310Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 20-F -Number 249 -Section 220 -Subsection fReference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 40-F -Number 249 -Section 240 -Subsection f + Details Name: dei_DocumentAnnualReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionIndicates whether any of the financial statement period in the filing include a restatement due to error correction. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection wReference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-K -Number 249 -Section 310Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 20-F -Number 249 -Section 220 -Subsection fReference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 40-F -Number 249 -Section 240 -Subsection f + Details Name: dei_DocumentFinStmtErrorCorrectionFlag Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalPeriodFocus Namespace Prefix: dei_ Data Type: dei:fiscalPeriodItemType Balance Type: na Period Type: duration X - DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalYearFocus Namespace Prefix: dei_ Data Type: xbrli:gYearItemType Balance Type: na Period Type: duration X - DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + ReferencesNo definition available. + Details Name: dei_DocumentPeriodEndDate Namespace Prefix: dei_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as a transition report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1 + Details Name: dei_DocumentTransitionReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'. + ReferencesNo definition available. + Details Name: dei_DocumentType Namespace Prefix: dei_ Data Type: dei:submissionTypeItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 1 such as Attn, Building Name, Street Name + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine1 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the City or Town + ReferencesNo definition available. + Details Name: dei_EntityAddressCityOrTown Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCode for the postal or zip code + ReferencesNo definition available. + Details Name: dei_EntityAddressPostalZipCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the state or province. + ReferencesNo definition available. + Details Name: dei_EntityAddressStateOrProvince Namespace Prefix: dei_ Data Type: dei:stateOrProvinceItemType Balance Type: na Period Type: duration X - DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityCentralIndexKey Namespace Prefix: dei_ Data Type: dei:centralIndexKeyItemType Balance Type: na Period Type: duration X - DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. + ReferencesNo definition available. + Details Name: dei_EntityCommonStockSharesOutstanding Namespace Prefix: dei_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionIndicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesNo definition available. + Details Name: dei_EntityCurrentReportingStatus Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionIndicate if registrant meets the emerging growth company criteria. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityEmergingGrowthCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. + ReferencesNo definition available. + Details Name: dei_EntityFileNumber Namespace Prefix: dei_ Data Type: dei:fileNumberItemType Balance Type: na Period Type: duration X - DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityFilerCategory Namespace Prefix: dei_ Data Type: dei:filerCategoryItemType Balance Type: na Period Type: duration X - DefinitionTwo-character EDGAR code representing the state or country of incorporation. + ReferencesNo definition available. + Details Name: dei_EntityIncorporationStateCountryCode Namespace Prefix: dei_ Data Type: dei:edgarStateCountryItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was

required to submit such files). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-T -Number 232 -Section 405 + Details Name: dei_EntityInteractiveDataCurrent Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionThe aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter. + ReferencesNo definition available. + Details Name: dei_EntityPublicFloat Namespace Prefix: dei_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityRegistrantName Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityShellCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionIndicates that the company is a Smaller Reporting Company (SRC). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntitySmallBusiness Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityTaxIdentificationNumber Namespace Prefix: dei_ Data Type: dei:employerIdItemType Balance Type: na Period Type: duration X - DefinitionIndicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. + ReferencesNo definition available. + Details Name: dei_EntityVoluntaryFilers Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionIndicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 405 + Details Name: dei_EntityWellKnownSeasonedIssuer Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-K -Number 249 -Section 310Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 20-F -Number 249 -Section 220 -Subsection fReference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 40-F -Number 249 -Section 240 -Subsection f + Details Name: dei_IcfrAuditorAttestationFlag Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionLocal phone number for entity. + ReferencesNo definition available. + Details Name: dei_LocalPhoneNumber Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionTitle of a 12(b) registered security. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b + Details Name: dei_Security12bTitle Namespace Prefix: dei_ Data Type: dei:securityTitleItemType Balance Type: na Period Type: duration X - DefinitionName of the Exchange on which a security is registered. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1 + Details Name: dei_SecurityExchangeName Namespace Prefix: dei_ Data Type: dei:edgarExchangeCodeItemType Balance Type: na Period Type: duration X - DefinitionTrading symbol of an instrument as listed on an exchange. + ReferencesNo definition available. + Details Name: dei_TradingSymbol Namespace Prefix: dei_ Data Type: dei:tradingSymbolItemType Balance Type: na Period Type: duration XML 19 R2.htm IDEA: XBRL DOCUMENT v3.24.3 Consolidated Balance Sheets - USD ($) $ in Thousands Jun. 30, 2024 Jun. 30, 2023 Current assets: Â Â Cash and cash equivalents $ 70,396 $ 16,036 Investments in marketable debt securities 56,478 85,860 Prepaid expenses and other 1,779 3,014 Total current assets 128,653 104,910 Long-term assets: Â Â Right-of-use assets 1,880 2,054 Deposits and other 1,838 148 Investments in marketable debt securities 263 16,470 Property and equipment, net 103 139 Total assets 132,737 123,721 Current liabilities: Â Â Accounts payable 4,901 3,269 Accrued liabilities: Â Â Accrued clinical and other 2,325 507 Compensation and benefits 1,812 883 Current portion of operating lease liabilities 568 541 Total current liabilities 9,606 5,200 Long-term liabilities: Â Â Operating lease liabilities, net of current portion 1,660 1,937 Embedded derivative liability 468 412 Total liabilities 11,734 7,549 Commitments and contingencies (Notes 5, 10 and 11) Shareholders' equity: Â Â Preferred stock, $0.001 par value; 400 shares authorized; no shares issued Common stock, $0.001 par value; 100,000 shares authorized; issued and outstanding 53,246 and 36,827 shares as of June 30, 2024 and 2023, respectively 53 37 Additional paid-in capital 450,473 377,471 Accumulated other comprehensive loss (79) (351) Accumulated deficit (329,444) (260,985) Total shareholders' equity 121,003 116,172 Total liabilities and shareholders' equity $ 132,737 $ 123,721 X - DefinitionAmount of accrued for clinical liabilities. + ReferencesNo definition available. + Details Name: rzlt_AccruedClinicalCurrent Namespace Prefix: rzlt_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10 + Details Name: us-gaap_AccountsPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AccruedLiabilitiesCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14AReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14 + Details Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AdditionalPaidInCapital Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 12: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Assets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards

Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_AssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AssetsCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AssetsNoncurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionRepresents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommitmentsAndContingencies Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_CommonStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_DepositsAssetsNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFair value as of the balance sheet date of the embedded derivative or group of embedded derivatives classified as a liability. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4B + Details Name: us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_EmployeeRelatedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 15: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details Name: us-gaap_Liabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(32)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LiabilitiesAndStockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -

Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_LiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesNoncurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of investment in marketable security, classified as current. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_MarketableSecuritiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of investment in marketable security, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_MarketableSecuritiesNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_PreferredStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 20 R3.htm IDEA: XBRL DOCUMENT v3.24.3 Consolidated Balance Sheets (Parenthetical) - $ / shares shares in Thousands Jun. 30, 2024 Jun. 30, 2023 Consolidated Balance Sheets Â Â Preferred stock, par value (in dollars per share) $ 0.001 $ 0.001 Preferred stock, shares authorized 400 400 Preferred stock, shares, issued 0 0 Common stock, par value (in dollars per share) $ 0.001 $ 0.001 Common stock, shares authorized 100,000 100,000 Common stock, shares issued 53,246 36,827 Common stock, shares outstanding 53,246 36,827 X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting

Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_PreferredStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StatementOfFinancialPositionAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 21 R4.htm IDEA: XBRL DOCUMENT v3.24.3 Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands 12 Months Ended Jun. 30, 2024 Jun. 30, 2023 Operating expenses: Â Â Research and development $ 55,743 $ 43,813 General and administrative 14,680 12,177 Total operating expenses 70,423 55,990 Operating loss (70,423) (55,990) Non-operating income (expense): Â Â Interest and other income, net 4,870 4,208 Total non-operating income, net 1,964 4,203 Net loss (68,459) (51,787) Other comprehensive income (loss): Â Â Net unrealized gain (loss) on marketable debt securities 272 (351) Comprehensive loss $ (68,187) $ (52,138) Net loss per common share - basic (in dollars per share) $ (1.33) $ (1.01) Net loss per common share - diluted (in dollars per share) $ (1.33) $ (1.01) Weighted average number of common shares outstanding - basic (in shares) 51,465 51,187 Weighted average number of common shares outstanding - diluted (in shares) 51,465 51,187 Warrant derivative Â Â Non-operating income (expense): Â Â Loss from change in fair value of derivative liabilities $ (2,850) Â Embedded derivative Â Â Non-operating income (expense): Â Â Loss from change in fair value of derivative liabilities $ (56) $ (5) X - DefinitionAmount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5 + Details Name: us-gaap_ComprehensiveIncomeNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_ComprehensiveIncomeNetOfTaxAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 4A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A + Details Name: us-gaap_GainLossOnDerivativeInstrumentsNetPretax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 + Details Name: us-gaap_GeneralAndAdministrativeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business). + ReferencesNo definition available. + Details Name: us-gaap_InterestAndOtherIncome Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -

Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_NonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NonoperatingIncomeExpenseAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionGenerally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. + ReferencesNo definition available. + Details Name: us-gaap_OperatingExpenses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OperatingExpensesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe net result for the period of deducting operating expenses from operating revenues. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11 + Details Name: us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details Name: us-gaap_ResearchAndDevelopmentExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=rzlt_WarrantDerivativeFinancialInstrumentsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_EmbeddedDerivativeFinancialInstrumentsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 22 R5.htm IDEA: XBRL DOCUMENT v3.24.3 Consolidated Statements of Shareholders' Equity - USD ($) shares in Thousands, $ in Thousands Common Stock Private Placement Common Stock Underwritten Public Offering Common Stock Additional Paid-in Capital Private Placement Additional Paid-in Capital Underwritten Public Offering Pre-funded warrants Additional Paid-in Capital Underwritten Public Offering Additional Paid-in Capital Accumulated Other Comprehensive Loss Accumulated Deficit Private Placement Underwritten Public Offering Pre-funded warrants Underwritten Public Offering Total Balance beginning at Jun. 30, 2022 Â Â $ 34 Â Â Â $ 358,635 Â $ (209,198) Â Â Â $ 149,471 Balance beginning (in shares) at Jun. 30, 2022 Â Â 33,582 Â Â Â Â Â Â Â Â Â Â Â Proceeds from issuance of equity securities $ 3 Â Â $ 12,327 Â Â Â Â Â Â $ 12,330 Â Â Â Proceeds from issuance of equity securities (in shares) 3,245 Â Â Â Â Â Â Â Â Â Â Â Other equity offering costs Â Â Â Â Â Â (759) Â Â Â Â Â (759) Share-based compensation Â Â Â Â Â Â 7,268 Â Â Â Â Â Â 7,268 Net change in accumulated other comprehensive loss Â Â Â Â Â Â Â $ (351) Â Â Â Â (351) Net Income (Loss) Â Â Â Â Â Â Â Â (51,787) Â Â Â (51,787) Balance ending at Jun. 30, 2023 Â Â $ 37 Â Â Â 377,471 (351) (260,985) Â Â Â 116,172 Balance ending (in shares) at Jun. 30, 2023 Â Â 36,827 Â Â Â Â Â Â Â Â Â Â Â Proceeds from issuance of equity securities Â $ 13 Â Â $ 14,096 $ 49,004 Â Â Â Â $ 14,096 $ 49,017 Â Proceeds from issuance of equity securities (in shares) Â 13,037 Â Â Â Â Â Â Â Â Â Â 13,000 Â Other equity offering costs Â Â Â Â Â Â (548) Â Â Â Â Â Â (548) Issuance of common stock upon exercise of stock options Â Â Â Â Â Â 246 Â Â Â Â Â Â $ 246 Issuance of common stock upon exercise of stock options (in shares) Â Â 82 Â Â Â Â Â Â Â Â Â Â 82 Share-based compensation Â Â Â Â Â Â 7,360 Â Â Â Â Â Â $ 7,360 Cashless exercise of pre-funded warrants Â Â $ 6 Â Â Â (6) Â Â Â Â Â Â Â Cashless exercise of pre-funded warrants (in shares) Â Â 6,300 Â Â Â Â Â Â Â Â Â Â Â Acquisition and retirement of treasury shares pursuant to Exchange Agreement Â Â $ (3) Â Â Â (5,697) Â Â Â Â Â (5,700) Acquisition and retirement of treasury shares pursuant to Exchange Agreement (in shares) Â Â (3,000) Â Â Â Â Â Â Â Â Â Â Reclassification of warrant derivative liability to equity Â Â Â Â Â 8,547 Â Â Â Â Â 8,547 Net change in accumulated other comprehensive loss Â Â Â Â Â Â 272 Â Â Â Â 272 Net Income (Loss) Â Â Â Â Â Â Â Â (68,459) Â Â Â (68,459) Balance ending at Jun. 30, 2024 Â Â $ 53 Â Â Â $ 450,473 $ (79) $ (329,444) Â Â Â $ 121,003 Balance ending (in shares) at Jun. 30, 2024 Â Â 53,246 Â Â Â Â Â Â Â Â Â Â X - DefinitionAmount of increase in additional paid in capital (APIC) resulting from the reclassification of warrant derivative liability to equity. + ReferencesNo definition available. + Details Name: rzlt_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantDerivativeLiabilityToEquity Namespace Prefix: rzlt_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares issued upon exercise of pre-funded warrants. + ReferencesNo definition available. + Details Name: rzlt_StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants Namespace Prefix: rzlt_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionValue of stock issued upon exercise of pre-funded warrants + ReferencesNo definition available. + Details Name: rzlt_StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants Namespace Prefix: rzlt_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12 + Details Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235

-SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11 + Details Name: us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares issued which are neither cancelled nor held in the treasury. + ReferencesNo definition available. + Details Name: us-gaap_SharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionEquity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionValue of stock issued as a result of the exercise of stock options. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares that have been repurchased and retired during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockRepurchasedAndRetiredDuringPeriodShares Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionEquity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockRepurchasedAndRetiredDuringPeriodValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards

Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 23 R6.htm IDEA: XBRL DOCUMENT v3.24.3 Consolidated Statements of Cash Flows - USD ($) $ in Thousands 12 Months Ended Jun. 30, 2024 Jun. 30, 2023 CASH FLOWS FROM OPERATING ACTIVITIES: Â Â Net loss $ (68,459) $ (51,787) Share-based compensation expense 7,360 7,268 Non-cash lease expense 526 352 Accretion of discounts and amortization of premiums on marketable debt securities, net (2,837) (1,370) Depreciation expense 36 30 Changes in operating assets and liabilities: Â Â Increase in prepaid expenses, deposits, and other assets (129) (1,320) Increase in accounts payable 1,083 2,136 Increase in accrued liabilities 2,146 205 Net Cash Used in Operating Activities (57,368) (44,481) CASH FLOWS FROM INVESTING ACTIVITIES Â Â Purchase of marketable debt securities (66,401) (107,311) Proceeds from maturities of marketable debt securities 115,100 6,000 Purchase of property and equipment Â (153) Total Cash Provided by (Used in) Investing Activities 48,699 (101,464) CASH FLOWS FROM FINANCING ACTIVITIES: Â Â Proceeds from exercise of stock options 234 Â Net cash payment pursuant to Exchange Agreement (3) Â Gross proceeds from issuance of common stock in 2022 Private Placement Â 12,330 Payment of commissions and other deferred offering costs (315) (759) Net Cash Provided by Financing Activities 63,029 11,571 Net increase (decrease) in cash and cash equivalents 54,360 (134,374) Cash and cash equivalents at beginning of fiscal year 16,036 150,410 Cash and cash equivalents at end of fiscal year 70,396 16,036 SUPPLEMENTARY CASH FLOW INFORMATION: Â Â Cash paid for amounts included in the measurement of operating lease liabilities 728 215 Operating lease liabilities incurred in exchange for right-of-use assets 352 2,204 NON-CASH INVESTING AND FINANCING ACTIVITIES: Â Â Acquisition of treasury shares in exchange for pre-funded warrant derivative liability 5,697 Â Receivable from exercise of stock options 12 Â Payables for offering costs charged to additional paid-in capital 548 Â Warrant derivative Â Â CASH FLOWS FROM OPERATING ACTIVITIES: Â Â Loss from change in fair value of derivative liabilities 2,850 Â Embedded derivative Â Â CASH FLOWS FROM OPERATING ACTIVITIES: Â Â Loss from change in fair value of derivative liabilities 56 $ 5 Underwritten Public Offering Â Â CASH FLOWS FROM FINANCING ACTIVITIES: Â Â Proceeds from issuance of equity securities in 2024 Underwritten Offering, net of underwriting discounts, Issuance of common stock 49,017 Â Underwritten Public Offering | Pre-funded warrants Â Â CASH FLOWS FROM FINANCING ACTIVITIES: Â Â Proceeds from issuance of equity securities in 2024 Underwritten Offering, net of underwriting discounts, Issuance of pre-funded warrants $ 14,096 Â X - DefinitionAcquisition of treasury shares in exchange for issuing pre-funded warrant liability + ReferencesNo definition available. + Details Name: rzlt_AcquisitionOfTreasurySharesInExchangeForIssuingPreFundedWarrantLiability Namespace Prefix: rzlt_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount representing the non cash lease expense. + ReferencesNo definition available. + Details Name: rzlt_NonCashLeaseExpense Namespace Prefix: rzlt_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe amount of offering costs that were incurred during a noncash or partial noncash transaction. + ReferencesNo definition available. + Details Name: rzlt_PayablesForOfferingCostsNoncashOrPartialNoncashTransaction Namespace Prefix: rzlt_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPayment for commissions and other deferred offering costs. + ReferencesNo definition available. + Details Name: rzlt_PaymentOfCommissionsAndOtherDeferredOfferingCosts Namespace Prefix: rzlt_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of receivable from exercise of stock options in non-cash investing or financing transactions. + ReferencesNo definition available. + Details Name: rzlt_ReceivableFromExerciseOfStockOptions Namespace Prefix: rzlt_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_DepreciationAndAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 4A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A + Details Name: us-gaap_GainLossOnDerivativeInstrumentsNetPretax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccruedLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in prepaid expenses, and assets classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeasePayments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow to reacquire common stock during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsForRepurchaseOfCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash outflow for purchase of marketable security. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11 + Details Name: us-gaap_PaymentsToAcquireMarketableSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow from the additional capital contribution to the entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow associated with the amount received from entity's raising of capital via private rather than public placement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfPrivatePlacement Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfWarrants Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period. + ReferencesNo definition available. + Details Name: us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow from exercise of option under share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher

FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2A -Subparagraph (a) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A + Details Name: us-gaap_ProceedsFromStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 31: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4KReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_ProfitLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase in right-of-use asset obtained in exchange for operating lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_SupplementalCashFlowInformationAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=rzlt_WarrantDerivativeFinancialInstrumentsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_EmbeddedDerivativeFinancialInstrumentsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=rzlt_UnderwrittenPublicOfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=rzlt_PreFundedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 24 R7.htm IDEA: XBRL DOCUMENT v3.24.3 NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES 12 Months Ended Jun. 30, 2024 NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Â NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES NOTE 1 â€” NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIESNature of OperationsRezolute, Inc. (the â€œCompanyâ€) is a late-stage rare disease company focused on significantly improving outcomes for individuals with hypoglycemia caused by hyperinsulinism. The Companyâ€™s primary clinical assets consist of (i) ersodetug (formerly known as RZ358), which is a potential treatment for all forms of hyperinsulinism, including congenital hyperinsulinism, an ultra-rare pediatric genetic disorder characterized by excessive production of insulin by the pancreas, and (ii) RZ402, which is an oral plasma kallikrein inhibitor (â€œPKIâ€) being developed as a potential therapy for the chronic treatment of diabetic macular edema.ConsolidationThe Company has two wholly owned subsidiaries consisting of Rezolute (Bio) Ireland Limited, and Rezolute Bio UK, Ltd. The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.Basis of PresentationThe Companyâ€™s consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (â€œGAAPâ€).Comprehensive income (loss) is defined as net income (loss) plus other comprehensive income (loss). Other comprehensive income (loss) is comprised of revenues, expenses, gains, and losses that under GAAP are reported as separate components of shareholdersâ€™ equity instead of net income (loss). For the fiscal years ended June 30, 2024 and 2023, components of comprehensive loss included the Companyâ€™s net loss and unrealized gains (losses) on investments in marketable debt securities.The Companyâ€™s Chief Executive Officer also serves as the Companyâ€™s chief operating decision maker for purposes of allocating resources and assessing performance based on financial information of the Company. Since its inception, the Company has determined that its activities as a clinical stage biopharmaceutical company are classified as a single reportable operating segment.Use of EstimatesThe preparation of financial statements in conformity with GAAP requires management to make judgments, estimates and assumptions that affect the reported amounts in the consolidated financial statements and the accompanying notes. The Company bases its estimates and assumptions on current facts, historical experience, and various other factors that it believes are reasonable under the circumstances, to determine the carrying values of assets and liabilities that are not readily apparent from other sources. The Companyâ€™s significant accounting estimates include, but are not necessarily limited to, determination if an allowance for credit losses is required or if other than temporary impairment exists for marketable debt securities, fair value of an derivative liabilities, fair value of share-based payments, managementâ€™s assessment of going concern, and estimates related to clinical trial accrued liabilities. Actual results could differ from those estimates.Risks and UncertaintiesThe Company's operations may be subject to significant risks and uncertainties including financial, operational, regulatory and other risks associated with a clinical stage company, including the potential risk of business failure discussed in Note 2.Cash and Cash EquivalentsAll highly liquid investments purchased with an original maturity of three months or less that are freely available for the Companyâ€™s immediate and general business use are classified as cash and cash equivalents. Cash and cash equivalents consist primarily of demand deposits with financial institutions, money market funds and corporate commercial paper purchased with a maturity of three months or less.Investments in Marketable Debt SecuritiesUnder the investment policy approved by the Companyâ€™s Board of Directors, eligible investments in fixed income debt securities must be denominated and payable in U.S. dollars, including eligible corporate bonds, corporate commercial paper, U.S. government obligations, and money market funds. This investment policy only permits investments in the debt securities of issuers that meet stringent credit quality ratings on the date of the investment. The investment policy also places restrictions on the length of maturities and concentrations by type and issuer. The Companyâ€™s investments are issued by issuers that management believes are of high credit quality. However, all issuers are exposed to credit risk in the event of default. The Company classifies investments in marketable debt securities that mature in less than one year as short-term assets. For investments that mature in more than one year, the investments are classified as long-term assets unless management intends to liquidate the investments to fund current operations before the scheduled maturity dates.The Company accounts for all of its investments in marketable debt securities as available-for-sale securities whereby they are recorded in the consolidated balance sheet at fair value. Interest income is recognized in the consolidated statement of operations, consisting of accrued interest earned based on the coupon rate of the security, plus the impact of accreting discounts and amortizing premiums to maturity using the straight-line method which approximates the interest method. Unrealized gains and losses due to subsequent changes in fair value of the investments are reported in shareholdersâ€™ equity as a component of accumulated other comprehensive income (loss). The Company reviews the components of its portfolio of available-for-sale debt securities, using both quantitative and qualitative factors, to determine if declines in fair value below amortized cost have resulted from a credit-related loss or other factors. If declines in fair value below amortized costs are due to the deterioration of an issuerâ€™s credit quality, the Company is required to record an allowance for credit losses related to such investments with a corresponding loss recognized in the consolidated statements of operations. Allowances for credit losses may be reversed in subsequent periods if conditions improve and credit-related losses are no longer expected. For declines in fair value that are solely due to changes in interest rates, impairment is not recognized if the Company has the ability and intent to hold the investment until maturity.Â Prepaid Expenses and OtherPrepaid expenses and other includes nonrefundable advance payments for goods and services that will be used or rendered in future research and development activities. These advance payments are deferred and recognized as expenses in the period that the related goods are delivered, or services are performed.LeasesThe Company determines if an arrangement includes a lease as of the date an agreement is entered into. Operating leases are included in right-of-use (â€œROUâ€) assets and operating lease liabilities in the Company's consolidated balance sheets. ROU assets and operating lease liabilities are initially recognized based on the present value of the future minimum lease payments at the commencement date of the lease. The Company generally uses its incremental borrowing rate based on the information available at the lease commencement date to determine the discount rate used to compute the present value of future payments. The Company's leases may include options to extend or terminate the lease; these options are included in the calculation of ROU assets and operating lease liabilities when it is reasonably certain that the Company will exercise the options. Lease expense is recognized on a straight-line basis over the lease term. The Company has elected not to apply the recognition requirements for short-term leases. For lease agreements with lease and non-lease components, the Company generally accounts for them separately.Property and EquipmentProperty and equipment consist solely of office furniture and equipment that is recorded at cost. Depreciation expense is calculated using the straight-line method over the estimated useful lives of the assets which range from 3 to 5 years. Maintenance and repairs are expensed as incurred.Research and Development CostsResearch and development costs are expensed as incurred. Intangible assets for in-licensing costs incurred under license agreements with third parties are charged to expense, unless the licensing rights have separate economic value in alternative future research and development projects or otherwise.Clinical Trial AccrualsClinical trial costs are a component of research and development expenses. The Company accrues and expenses clinical trial activities performed by third parties based upon estimates of the percentage of work completed over the life of the individual study in accordance with agreements established with clinical research organizations and clinical trial sites. The Company determines the estimates through discussions with internal clinical personnel and external service providers as to the progress or stage of completion of trials or services and the agreed-upon fee to be paid for such services.Share-Based CompensationThe Company measures the fair value of employee and director services received in exchange for grants of stock options and other equity awards granted, based on the fair value of the award as of the grant date. The Company computes the fair value of stock options using the Black-Scholes-Merton (â€œBSMâ€) option pricing model and

recognizes the value of the equity awards over the period that services are provided to earn the award, usually the vesting period. For awards granted which contain a graded vesting schedule, and the only condition for vesting is a service condition, compensation cost is recognized as an expense on a straight-line basis over the requisite service period as if the award was, in substance, a single award. The Company recognizes the impact of forfeitures in the period that the forfeiture occurs, rather than estimating the number of awards that are not expected to vest in accounting for share-based compensation. For stock options that are voluntarily surrendered by employees, all unrecognized compensation is immediately recognized in the period the options are cancelled.Embedded DerivativesWhen the Company enters into a financial instrument such as a debt or equity agreement (the â€œHost Contractâ€), the Company assesses whether the economic characteristics of any embedded features would meet the definition of a derivative instrument, and whether such features are considered clearly and closely related to the primary economic characteristics of the Host Contract. When it is determined that (i) an embedded feature possesses economic characteristics that are not clearly and closely related to the primary economic characteristics of the Host Contract, and (ii) a separate, stand-alone instrument with the same terms would meet the definition of a financial derivative instrument and cannot be classified in shareholdersâ€™ equity, then the embedded feature is bifurcated from the Host Contract and accounted for as a derivative liability. The estimated fair value of the derivative feature is recorded separately from the carrying value of the Host Contract, with subsequent changes in the estimated fair value recorded as a non-operating gain or loss in the Companyâ€™s consolidated statements of operations.Fair Value of WarrantsThe Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrantâ€™s specific terms and applicable authoritative guidance set forth by the Financial Accounting Standards Board (â€œFASBâ€) in Accounting Standards Codification (â€œASCâ€) 480, Distinguishing Liabilities from Equity (â€œASC 480â€) and ASC 815, Derivatives and Hedging (â€œASC 815â€). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Companyâ€™s own common shares and whether the warrant holders could potentially require â€œnet cash settlementâ€ in a circumstance outside of the Companyâ€™s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and during each subsequent quarterly period while the warrants are outstanding. Liability-classified warrants are valued using the BSM option-pricing model at issuance, and for each subsequent reporting period. Income TaxesThe Company accounts for income taxes using the asset and liability method. Under this method, deferred income tax assets and liabilities that are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using enacted tax rates and laws that are in effect when the differences are expected to be recovered or settled. Realization of deferred income tax assets is dependent upon future taxable income. A valuation allowance is recognized if it is more likely than not that some portion or all of a deferred income tax asset will not be realized based on the weight of available evidence, including expected future earnings.The Company recognizes uncertain tax position in its financial statements when it concludes that a tax position is more likely than not to be sustained upon examination based solely on its technical merits. Only after a tax position passes the first step of recognition will measurement be required. Under the measurement step, the tax benefit is computed as the largest amount of benefit that is more likely than not to be realized upon effective settlement. This calculation is determined on a cumulative probability basis. The full impact of any change in recognition or measurement is reflected in the period in which such change occurs. Interest and penalties related to income taxes will be recognized as a component of income tax expense.Net Loss Per ShareBasic net loss per share is computed by dividing net loss by the weighted average number of outstanding shares of common stock and pre-funded warrants that are accounted for as equity instruments. Common shares associated with pre-funded warrants are included in the computation of both basic and diluted net loss per share since the exercise price is negligible and all of the pre-funded warrants are fully vested and exercisable. To the extent dilutive, during periods in which pre-funded warrants are accounted for as derivative liabilities, the calculation of diluted net loss per share will be further adjusted to eliminate gains on changes in the fair value of such pre-funded warrants, and the related pre-funded warrant shares will be included in the weighted average number of shares outstanding.Diluted net loss per share is computed using the treasury stock method by further giving effect to all potential shares of common stock, including stock options and warrants, to the extent dilutive.For participating warrants that are entitled to participate in dividends declared to holders of shares of common stock, the Company applies the two-class method of allocating earnings if the impact of including the participating warrants is dilutive for the calculation of both basic and diluted net loss per share.Treasury SharesThe Company accounts for purchases of treasury shares under the cost method. Â In accordance with Nevada law, acquired treasury shares may be retired by the Company. Upon retirement, the treasury shares are no longer accounted for as issued and outstanding.Recent Accounting PronouncementsRecently Adopted Accounting Standard. The following accounting standard was adopted in the fiscal year ended June 30, 2024:In June 2016, the FASB issued Accounting Standards Update (â€œASUâ€) 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. ASU 2016-13 amends the guidance on the impairment of financial instruments. This update adds an impairment model (known as the current expected credit losses model) that is based on expected losses rather than incurred losses. Under the expected credit loss model, if declines in fair value below amortized costs are due to the deterioration of an issuerâ€™s credit quality, the Company is required to record an allowance for credit losses related to such investments with a corresponding loss recognized in the consolidated statements of operations. Allowances for credit losses may be reversed in subsequent periods if conditions improve and credit-related losses are no longer expected. For declines in fair value that are solely due to changes in interest rates, impairment is not recognized if the Company has the ability and intent to hold the investment until maturity. Effective as of July 1, 2023, the Company implemented the guidance in ASU 2016-13. The adoption of ASU 2016-13 did not have any impact on the accompanying consolidated financial statements.Standard Required to be Adopted in Future Periods.Â The following accounting standard has not yet been adopted by the Company:â€‹In December 2023, the FASB issued ASU 2023-09, â€œIncome Taxes (Topic 740) â€“ Improvements to Income Tax Disclosuresâ€. ASU 2023-09 requires disclosure of additional income tax information, primarily related to the rate reconciliation and income taxes paid. This ASU is intended to enhance the transparency and decision usefulness of income tax disclosures. ASU 2023-09 is effective for annual periods beginning after December 15, 2024. Management has not determined the timing for adoption of this standard.â€‹The adoption of ASU 2023-09 and other accounting standards that have been issued or proposed by the FASB that do not require adoption until a future date are not currently expected to have a material impact on the Companyâ€™s consolidated financial statements upon adoption.â€‹ X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContentReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 275 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/275/tableOfContentReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/810/tableOfContentReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 250 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/250/tableOfContent + Details Name: us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 25 R8.htm IDEA: XBRL DOCUMENT v3.24.3 LIQUIDITY 12 Months Ended Jun. 30, 2024 LIQUIDITY Â LIQUIDITY NOTEÂ 2 â€” LIQUIDITYThe Company is in the clinical stage and has not yet generated any revenues. For the fiscal year ended June 30, 2024, the Company incurred a net loss of $68.5 million and net cash used in operating activities amounted to $57.4 million. As of June 30, 2024, the Company had an accumulated deficit of $329.4 million, and the Companyâ€™s capital resources consisted of cash and cash equivalents of $70.4 million and in marketable debt securities totaling $56.7 million. As discussed in Note 7, the Company completed the 2024 Underwritten Offering in June 2024 that resulted in the issuance of approximately 13.0 million shares of common stock and 3.8 million prefunded warrants for net proceeds of $62.6 million after underwriting discounts and other offering costs. As of June 30, 2024, the Company had total liabilities of $11.7 million, including total current liabilities of $9.6 million. As discussed in Note 5, the Company is subject to license agreements that provide for future contractual payments upon achievement of various milestone events. Pursuant to the XOMA License Agreement (as defined below), a $5.0 million milestone payment will be due upon dosing of the last patient in a Phase 3 clinical trial for ersodetug. The commitment to pay the last patient dosing milestone of $5.0 million for the ersodetug Phase 3 clinical trial is expected to be recognized as a liability within 12 months. As discussed in Note 15, in July 2024 the Company received net proceeds of approximately $6.0 million related to a private placement of 1.5 million shares of common stock.Management believes the Companyâ€™s cash and cash equivalents, investments in marketable debt securities, and additional proceeds from the July 2024 private placement, will be adequate to meet the Companyâ€™s contractual obligations and carry out ongoing clinical trials and other planned activities through September 2025, at a minimum. X - ReferencesNo definition available. + Details Name: rzlt_LiquidityAbstract Namespace Prefix: rzlt_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 40 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/205-40/tableOfContent + Details Name: us-gaap_SubstantialDoubtAboutGoingConcernTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 26 R9.htm IDEA: XBRL DOCUMENT v3.24.3 INVESTMENTS IN MARKETABLE DEBT SECURITIES 12 Months Ended Jun. 30, 2024 INVESTMENTS IN MARKETABLE DEBT SECURITIES Â INVESTMENTS IN MARKETABLE DEBT SECURITIES NOTEÂ 3 â€” INVESTMENTS IN MARKETABLE DEBT SECURITIESInvestments in marketable debt securities are classified as follows in the consolidated balance sheets as of June 30, 2024 and 2023 (in thousands):â€‹â€‹â€‹â€‹â€‹â€‹â€‹2024Â Â Â Â 2023Short-term investments$ 56,478â€‹$ 85,860Long-term investmentsâ€‹ 263â€‹â€‹ 16,470Total investments$ 56,741â€‹$ 102,330â€‹The Company only invests in liquid, high quality debt securities. Nonetheless, all of these investments are subject to interest rate and credit risk that may result in fluctuations in the fair value of the investments. To minimize the exposure due to an adverse shift in interest rates, the Company generally invests in securities with expected maturities of two years or less while maintaining a weighted average maturity of one year or less. As of June 30, 2024 investments in marketable debt securities with an aggregate fair value of $56.5 million are scheduled to mature during the 12-month period ending June 30, 2025. All of the remaining investments with a fair value of $0.3 million, are scheduled to mature during the 12-month period ending June 30, 2026.During the fiscal year ended June 30, 2024, marketable debt securities for $115.1 million matured and approximately $66.4 million of the proceeds were reinvested in additional marketable debt securities. The Company did not sell any marketable debt securities prior to the scheduled maturity dates for the fiscal year ended June 30, 2024. Accrued interest receivable on all marketable debt securities amounted to $0.4 million and $0.3 million as of June 30, 2024 and 2023, respectively. Accrued interest is included in other current assets in the accompanying consolidated balance sheet. For the fiscal years ended June 30, 2024 and 2023, the Company did not recognize any allowance for credit losses or other than temporary impairment related to investments in marketable debt securities. The following table summarizes the unrealized gains and losses that result in differences between the amortized cost basis and fair value of the Companyâ€™s marketable debt securities held as of June 30, 2024 (in thousands):â€‹â€‹â€‹â€‹â€‹â€‹â€‹

weighted-average discount rate used to determine the operating lease liabilities was 6.8%.Future Lease PaymentsFuture payments under all operating lease agreements as of June 30, 2024 are as follows (in thousands):â€‹â€‹â€‹â€‹Fiscal year ending JuneÂ 30,Â Â Â

-Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18 + Details Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 31 R14.htm IDEA: XBRL DOCUMENT v3.24.3 SHARE-BASED COMPENSATION AND WARRANTS 12 Months Ended Jun. 30, 2024 SHARE-BASED COMPENSATION AND WARRANTS Â SHARE-BASED COMPENSATION AND WARRANTS NOTE 8 â€” SHARE-BASED COMPENSATION AND WARRANTSStock Option PlansPresented below is a summary of the number of shares authorized, outstanding, and available for future grants under the Companyâ€™s stock option plans and the Inducement Grant (defined below) as of June 30, 2024 (in thousands):â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â Number of SharesDescriptionÂ Â Â Â AuthorizedÂ Â Â Â OutstandingÂ Â Â Â Availableâ€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹2015 PlanÂ 17Â 17Â â€”2016 PlanÂ 123Â 123Â â€”2019 PlanÂ 200Â 200Â â€”2021 Planâ€‹ 10,618â€‹ 10,276â€‹ 342Inducement Grantâ€‹ 275â€‹ 275â€‹ â€”TotalÂ 11,233Â 10,891Â 342â€‹The Company currently has one active stock option plan, the 2021 Equity Incentive Plan (the â€œ2021 Equity Planâ€). On March 31, 2021, the Companyâ€™s Board of Directors adopted the 2021 Equity Plan that will terminate on March 31, 2031. On May 26, 2021, the 2021 Equity plan was approved by the Companyâ€™s shareholders with authority to issue up to 1.2 million shares of common stock. Pursuant to the 2021 Equity Plan, no awards may be granted under the three legacy stock option plans shown in the table above, but all outstanding awards previously granted under those plans shall remain outstanding and subject to the terms of the respective plans. On June 16, 2022, the Companyâ€™s shareholders approved an amendment to the 2021 Equity Plan, increasing the number of shares of common stock to be issued under the plan up to 10.7 million shares of common stock. Stock options outstanding under these plans expire pursuant to their contractual provisions on various dates through 2034.2022 Employee Stock Purchase PlanOn June 16, 2022, the Companyâ€™s shareholders approved the adoption of the 2022 Employee Stock Purchase Plan (the â€œ2022 ESPPâ€). The 2022 ESPP provides an opportunity for employees to purchase shares of the Companyâ€™s common stock through accumulated payroll deductions.The 2022 ESPP permits consecutive offering periods that begin approximately every 6 months commencing on the first trading day on or after July 1 and terminating on the last trading day of the offering period ending on December 31 and commencing on the first trading day on or after January 1 and terminating on the last trading day of the offering period ending on June 30. The 2022 ESPP reserves 0.5 million shares for purchases. There have been no offering periods under the 2022 ESPP through June 30, 2024. Stock Options OutstandingThe following table sets forth a summary of the combined activity under all of the Companyâ€™s stock option plans, including Inducement Grant discussed below, for the fiscal years ended June 30, 2024 and 2023 (shares in thousands):â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹

Executive Officer and Chief Medical Officer provides that if either of the individuals is terminated outside of a change in control event and without cause, (i) all of their stock options that are subject to ongoing vesting conditions over subsequent periods ranging from 12 to 18 months will immediately vest, and (ii) such stock options will remain exercisable for periods ranging from 6 to 12 months following the occurrence of the termination event. In addition, if either of the executive officers are terminated solely due to a change of control event, all of their respective unvested stock options will immediately vest and all outstanding stock options will remain exercisable for periods ranging from 6 to 12 months following the occurrence of the termination event.The Chief Medical Officerâ€™s employment agreement, as amended, provides that upon the occurrence of a termination event other than a change of control, the Company is required to (i) make severance payments equal to 12 months of salary, a pro-rata bonus, and health insurance coverage for 12 months following the termination date, and (ii) all unvested stock options subject to vest over the subsequent 12 month period after the termination event will become immediately exercisable and all outstanding stock options will remain exercisable for 6 months following the termination event. In addition, upon the occurrence of a termination solely due to a change of control event, the Company is required to (i) make severance payments equal to 18 months of salary, a pro-rata bonus, and health insurance coverage for 18 months following the termination event.401(k) Plan The Company has a defined contribution employee benefit plan under section 401(k) of the Internal Revenue Code (the â€œ401(k) Planâ€). The 401(k) Plan covers all eligible employees who are entitled to participate beginning six months after the commencement of employment. The Company matches contributions up to 4% of the participating employeeâ€™s compensation with such matching contributions vested immediately. Total contributions by the Company to the 401(k) Plan amounted to approximately $0.4 million and $0.3 million for the fiscal years ended June 30, 2024 and 2023, respectively. Legal MattersFrom time to time, the Company may be involved in litigation relating to claims arising out of operations in the normal course of business. As of June 30, 2024, there were no pending or threatened lawsuits that could reasonably be expected to have a material effect on the Companyâ€™s results of operations or financial position. At each reporting period, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under ASC 450, Contingencies. Legal fees are expensed as incurred. X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for commitments and contingencies. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 405 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/405-30/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/450/tableOfContentReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 440 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 440 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/440/tableOfContent + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 34 R17.htm IDEA: XBRL DOCUMENT v3.24.3 RELATED PARTY TRANSACTIONS 12 Months Ended Jun. 30, 2024 RELATED PARTY TRANSACTIONS Â RELATED PARTY TRANSACTIONS NOTE 11 â€” RELATED PARTY TRANSACTIONSRelated Party Licensing AgreementOn September 15, 2020, the Company entered into an exclusive license agreement with Handok (the â€œHandok Licenseâ€) for the territory of the Republic of Korea. The Handok License relates to pharmaceutical products in final dosage form containing the pharmaceutical compounds developed or to be developed by the Company, including those related to ersodetug and RZ402. The Handok License is in effect for a period of 20 years after the first commercial sale of each product and requires (i) milestone payments of $0.5 million upon approval of a New Drug Application (â€œNDAâ€) for each product in the territory, and (ii) the Company will sell products ordered by Handok at a transfer price equal to 70% of the net selling price of the products. To date, no milestone payments have been earned by the Company.Investors in 2022 Private PlacementHandok and certain of its affiliates were the sole investors in the 2022 Private Placement discussed in Note 7. X - ReferencesNo definition available. + Details Name: us-gaap_RelatedPartyTransactionsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(g)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(e)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/850/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1 + Details Name: us-gaap_RelatedPartyTransactionsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 35 R18.htm IDEA: XBRL DOCUMENT v3.24.3 SUPPLEMENTAL FINANCIAL INFORMATION 12 Months Ended Jun. 30, 2024 SUPPLEMENTAL FINANCIAL INFORMATION Â SUPPLEMENTAL FINANCIAL INFORMATION NOTE 12 - SUPPLEMENTAL FINANCIAL INFORMATIONCash and cash equivalentsCash and cash equivalents consisted of the following as of June 30, 2024 and 2023 (in thousands):â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â 2024Â Â Â Â 2023â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Money market fundsâ€‹$ 61,249â€‹$ 5,464Demand deposits at a single financial institutionâ€‹â€‹ 9,147â€‹â€‹ 6,091Commercial paperâ€‹â€‹ â€”â€‹â€‹ 4,481â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Totalâ€‹$ 70,396â€‹$ 16,036â€‹The money market funds and commercial paper included in the table above were purchased with an original maturity of three months or less. These investments and the demand deposits are freely available for the Companyâ€™s immediate and general business use.Property and EquipmentProperty and equipment consisted of the following as of June 30, 2024 and 2023 (in thousands):â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â 2024Â Â Â Â 2023â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Office furniture and equipment â€‹$ 210â€‹$ 210Less accumulated depreciation â€‹Â (107)â€‹Â (71)â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Totalâ€‹$ 103â€‹$ 139â€‹Depreciation expense related to property and equipment amounted to approximately $36,000 and $30,000 for the fiscal years ended June 30, 2024 and 2023, respectively. X - DefinitionThe entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement. + ReferencesNo definition available. + Details Name: us-gaap_AdditionalFinancialInformationDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_SupplementalCashFlowInformationAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 36 R19.htm IDEA: XBRL DOCUMENT v3.24.3 NET LOSS PER SHARE 12 Months Ended Jun. 30, 2024 NET LOSS PER SHARE Â NET LOSS PER SHARE NOTE 13 â€” NET LOSS PER SHAREBasic net loss per share is computed by dividing net loss by the weighted average number of outstanding shares of common stock and PWFs during periods when the PFWs are accounted for as equity instruments. Common shares associated with PFWs that are accounted for as equity instruments are included in the computation of basic and diluted net loss per share since the exercise price is negligible and all of the PFWs are fully vested and exercisable. For the calculation of diluted net loss per share for the fiscal year ended June 30, 2024, during the period when PFWs were accounted for as derivative liabilities, such PFWs were excluded from the calculation since the impact of PFWs was antidilutive. â€‹Calculation of the weighted average number of shares outstanding for purposes of diluted net loss per share is also required to include the dilutive effect, if any, of stock options, Legacy Warrants, and other common stock equivalents computed using the treasury stock method. For the fiscal years ended June 30, 2024 and 2023, all of such common stock equivalents were antidilutive and excluded from the calculations. In addition, the impact of applying the two-class method related to the Participating Warrants, was antidilutive for the calculation of both basic and diluted net loss per share.â€‹Presented below are the calculations of the numerators and the denominators for basic and diluted net loss per share for the fiscal years ended June 30, 2024 and 2023 (in thousands except per share amounts):â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â 2024â€‹â€‹Â Â Â Â 2023Calculation of Numerators:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Net loss for calculation of basic and diluted net loss per shareâ€‹$ (68,459)â€‹$ (51,787)â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Calculation of Denominators:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Weighted average number of common shares outstandingâ€‹â€‹ 39,499â€‹â€‹ 36,605Weighted average shares related to pre-funded warrants:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹2021 PFWsâ€‹â€‹ 1,195â€‹â€‹ 1,6612022 PFWsâ€‹â€‹ 10,245â€‹â€‹ 12,921Exchange PFWsâ€‹â€‹ 393â€‹â€‹ â€”2024 PFWsâ€‹â€‹ 133(1)â€‹â€‹ â€”Weighted average shares for basic and diluted net loss per shareâ€‹â€‹ 51,465â€‹â€‹ 51,187â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Net loss per share of common stock:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Basicâ€‹$ (1.33)â€‹$ (1.01)Dilutedâ€‹$ (1.33)â€‹$ (1.01)_____(1)Represents the weighted average number of shares related to the Exchange PFWs discussed in Note 7 for the period when they became equity-classified on May 13, 2024 through June 30, 2024.As of June 30, 2024 and 2023, the following potential common stock equivalents were excluded from the calculation of diluted net loss per share since the impact of inclusion was anti-dilutive (in thousands):â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹2024â€‹2023â€‹â€‹â€‹â€‹â€‹â€‹Stock optionsâ€‹ 10,891â€‹ 8,745Legacy warrantsâ€‹ 861â€‹ 888Totalâ€‹ 11,752â€‹ 9,633â€‹ X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for earnings per share. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/260/tableOfContentReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3 + Details Name: us-gaap_EarningsPerShareTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 37 R20.htm IDEA: XBRL DOCUMENT v3.24.3 FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS 12 Months Ended Jun. 30, 2024 FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS Â FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS NOTE 14 â€” FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONSFair Value MeasurementsFair value is defined as the price that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants on the measurement date. When determining fair value, the Company considers the principal or most advantageous market in which it transacts and considers assumptions that market participants would use when pricing the asset or liability. The Company applies the following fair value hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement:Level 1â€”Quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date.Level 2â€”Other than quoted prices included in Level 1 that are observable for the asset and liability, either directly or indirectly through market corroboration, for substantially the full term of the asset or liability.Level 3â€”Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any market activity for the asset or liability at the measurement date.Assets Measured at Fair Value on a Recurring BasisThe following table presents information about the Companyâ€™s financial assets measured at fair value on a recurring basis and indicates the fair value hierarchy classification of such fair values as of June 30, 2024. â€‹Fair Value Measurement of Assets as of June 30, 2024â€‹â€‹Totalâ€‹Level 1â€‹Level 2â€‹Level 3Cash and cash equivalents:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Money market fundsâ€‹$ 61,249â€‹$ 61,249â€‹$ â€”â€‹$ â€”Marketable debt securities:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Corporate commercial paperâ€‹â€‹ 20,929â€‹â€‹ â€”â€‹â€‹ 20,929â€‹â€‹ â€”U.S. Government agenciesâ€‹â€‹ 1,997â€‹â€‹ â€”â€‹â€‹ 1,997â€‹â€‹ â€”U.S. Government treasuriesâ€‹â€‹ 2,720â€‹â€‹ â€”â€‹â€‹ 2,720â€‹â€‹ â€”Corporate notes and bondsâ€‹â€‹ 30,832â€‹â€‹ â€”â€‹â€‹ 30,832â€‹â€‹ â€”Asset-backed securitiesâ€‹â€‹ 263â€‹â€‹ â€”â€‹â€‹ 263â€‹â€‹ â€”Total â€‹$ 117,990â€‹$ 61,249â€‹$ 56,741â€‹$ â€”â€‹The following table presents information about the Companyâ€™s financial assets measured at fair value on a recurring basis and indicates the fair value hierarchy classification of such fair values as of June 30, 2023.â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Fair Value Measurement of Assets as of June 30, 2023â€‹â€‹Totalâ€‹Level 1â€‹Level 2â€‹Level 3Cash and cash equivalents:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Money market fundsâ€‹$ 5,464â€‹$ 5,464â€‹$ â€”â€‹$ â€”Corporate commercial paperâ€‹â€‹ 4,481â€‹â€‹ 4,481â€‹â€‹ â€”â€‹â€‹ â€”Marketable debt securities:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Corporate commercial paperâ€‹â€‹ 41,597â€‹â€‹ â€”â€‹â€‹ 41,597â€‹â€‹ â€”U.S. Government agenciesâ€‹â€‹ 26,394â€‹â€‹ â€”â€‹â€‹ 26,394â€‹â€‹ â€”U.S. Government treasuriesâ€‹â€‹ 10,404â€‹â€‹ 10,404â€‹â€‹ â€”â€‹â€‹ â€”Corporate notes and bondsâ€‹â€‹ 19,240â€‹â€‹ â€”â€‹â€‹ 19,240â€‹â€‹ â€”Asset-backed securitiesâ€‹â€‹ 4,694â€‹â€‹ â€”â€‹â€‹ 4,694â€‹â€‹ â€”Total â€‹$ 112,274â€‹$ 20,349â€‹$ 91,925â€‹$ â€”â€‹Marketable debt securities classified as Level 2 within the valuation hierarchy generally consist of U.S. government agency securities, corporate bonds, and commercial paper. The Company determines the fair value of marketable debt securities based upon valuations obtained from third-party pricing sources. Except for the amounts shown in the table above, the Company did not have any other assets measured at fair value on a recurring basis as of June 30, 2024 and 2023.â€‹Liabilities Measured at Fair Value on a Recurring BasisFor the fiscal years ended June 30, 2024 and 2023, the Companyâ€™s liabilities that are required to be measured and recorded at fair value on a recurring basis consist of the embedded derivative liability discussed in Note 6 and the warrant derivative liability discussed in Note 7. The warrant derivative liability is classified under Level 2 of the fair value hierarchy and the embedded derivative liability is classified under Level 3 of the fair value hierarchy. Fair value of the warrant liability is predominantly based on the market price of the Companyâ€™s shares of common stock. Fair value of the embedded derivative liability is determined based on managementâ€™s assessment of the probability and timing of occurrence for the Exit Events discussed in Note 6 using a discount rate equal to the effective interest rate under the Loan Agreement prior to termination. The fair value of the Exchange PFWs was computed using the BSM option-pricing model. Key inputs to this valuation model as of May 13, 2024 included the exercise price of $0.001 per share, the market price of the Companyâ€™s common stock of $2.85 per share, the risk-free interest rate of 5.5%, an expected term of 1-day, and historical volatility of 100%. Key inputs to this valuation model as of March 8, 2024 included the exercise price of $0.001 per share, the market price of the Companyâ€™s common stock of $1.90 per share, the risk-free interest rate of 5.5%, an expected term of 1-day, and historical volatility of 100%.â€‹The following table sets forth a summary of changes in the fair value of the Companyâ€™s liabilities for which fair value was determined on a recurring basis for the fiscal years ended June 30, 2024 and 2023 (in thousands):â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹2024â€‹2023â€‹â€‹Warrantâ€‹EmbeddedÂ Warrantâ€‹EmbeddedFair value, beginning of fiscal yearâ€‹$ â€”â€‹$ 412â€‹$ â€”â€‹$

407Warrant liability incurred on March 8, 2024â€‹â€‹ 5,697â€‹â€‹ â€”â€‹â€‹ â€”â€‹â€‹ â€”â€‹â€‹ â€”Changes in fair valueâ€‹â€‹ 2,850â€‹â€‹ 56â€‹â€‹ â€”â€‹â€‹ 5Reclassification of warrant derivative liability to equity on May 13, 2024â€‹â€‹ (8,547)â€‹â€‹ â€”â€‹â€‹ â€”â€‹â€‹ â€”Fair value, end of fiscal yearâ€‹$ â€”â€‹$ 468â€‹$ â€”â€‹$ 412â€‹Due to the relatively short maturity of the respective instruments, the fair value of cash and cash equivalents, accounts payable, and accrued liabilities approximated their carrying values as of June 30, 2024 and 2023. The Companyâ€™s policy is to recognize asset or liability transfers among Level 1, Level 2 and Level 3 as of the actual date of the events or change in circumstances that caused the transfer. During the fiscal years ended June 30, 2024 and 2023, the Company did not have any transfers of its assets or liabilities between levels of the fair value hierarchy.Significant ConcentrationsFinancial instruments that subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents and investments in marketable debt securities. The Company maintains its cash in demand accounts at a high-quality financial institution. As of and for the fiscal years ended June 30, 2024 and 2023, cash deposits have exceeded the amount of insurance provided on such deposits by the Federal Deposit Insurance Corporation. â€‹As of June 30, 2024, the Company had an aggregate of $26.6 million invested in marketable debt securities of issuers in the banking and financial services industries. As of June 30, 2023, the Company had an aggregate of $54.0 million invested in marketable debt securities of issuers in the banking and financial services industries, and an aggregate of $26.5 million invested in marketable debt securities of a single agency of the U.S. government. While the Companyâ€™s investment policy requires investments in highly rated securities, a wide variety of broad economic factors and issuer-specific factors could result in credit agency downgrades below the Companyâ€™s minimum credit rating requirements that could result in losses regardless of whether the Company elects to sell the securities or hold them until maturity. X - ReferencesNo definition available. + Details Name: us-gaap_FairValueDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures. + ReferencesNo definition available. + Details Name: us-gaap_FinancialInstrumentsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 38 R21.htm IDEA: XBRL DOCUMENT v3.24.3 SUBSEQUENT EVENTS 12 Months Ended Jun. 30, 2024 SUBSEQUENT EVENTS Â SUBSEQUENT EVENTS NOTE 15 â€” SUBSEQUENT EVENTS2024 Private PlacementOn June 25, 2024, the Company entered into a securities purchase agreement (the â€œ2024 SPAâ€) with Handok and one other investor (the â€œ2024 Purchasersâ€) relating to a private placement (the â€œ2024 Private Placementâ€), pursuant to which the Company agreed to sell 1,500,000 shares of common stock at a purchase price of $4.00 per share for gross proceeds of $6.0 million.Closing of the 2024 Private Placement occurred in July 2024, whereby the Company received net proceeds of $6.0 million after deduction of underwriting discounts and other offering costs. As required pursuant to the 2024 SPA, the Company filed a registration statement with the U.S. Securities and Exchange Commission (â€œSECâ€) in August 2024 to register the shares of common stock issued in the 2024 Private Placement. The Company entered into a registration rights agreement with the 2024 Purchasers whereby the Company was required to have the registration statement (the â€œ2024 Private Placement Registration Statementâ€) declared effective within 60 days after the signing date of the 2024 SPA. The 2024 Private Placement Registration Statement was declared effective by the SEC on August 14, 2024. The Company will be obligated to pay certain liquidated damages to the 2024 Purchasers if the Company fails to maintain the effectiveness of the 2024 Private Placement Registration Statement.Investments in Marketable Debt SecuritiesIn July 2024, the Company utilized approximately $59.7 million of cash and cash equivalents to purchase investments in marketable debt securities with maturities that range from October 2024 through December 2025.â€‹Exchange PFW Warrant Exerciseâ€‹In July 2024, a holder of Exchange PFWs provided notice of cashless exercise of 610,404 Exchange PFWs, which resulted in the issuance of 610,273 shares of common stock.â€‹Executive Compensationâ€‹On September 10, 2024, the Board of Directors approved an employment agreement, effective September 15, 2024, with the Companyâ€™s Chief Financial Officer that provides for an annual base salary of $460,000, plus a calendar year target bonus of 40%. The agreement provides that if the Chief Financial Officer is terminated outside of a change in control event and without cause, (i) make severance payments equal to 12 months of base salary, a pro-rata bonus through the termination date, and health insurance coverage for 12 months following the termination date, and (ii) all unvested stock options subject to vest over the subsequent 12 month period after the termination event will become immediately exercisable and all such stock options will remain exercisable for 6 months following the termination event. In addition, upon the occurrence of a termination solely due to a change of control event, the Company is required to (i) make severance payments equal to 18 months of salary, a pro-rata bonus through the termination date, and health insurance coverage for 18 months following the termination event.â€‹Effective September 15, 2024, the Board of Directors approved an increase from approximately $557,000 to $625,000 in the annual base compensation set forth in the employment agreement discussed in Note 10 for the Companyâ€™s Chief Executive Officer. X - ReferencesNo definition available. + Details Name: us-gaap_SubsequentEventsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/855/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2 + Details Name: us-gaap_SubsequentEventsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 39 R22.htm IDEA: XBRL DOCUMENT v3.24.3 Pay vs Performance Disclosure - USD ($) $ in Thousands 12 Months Ended Jun. 30, 2024 Jun. 30, 2023 Pay vs Performance Disclosure Â Â Net Income (Loss) $ (68,459) $ (51,787) X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 1 + Details Name: ecd_PvpTable Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 40 R23.htm IDEA: XBRL DOCUMENT v3.24.3 Insider Trading Arrangements 3 Months Ended Jun. 30, 2024 Trading Arrangements, by Individual Â Rule 10b5-1 Arrangement Adopted false Non-Rule 10b5-1 Arrangement Adopted false Rule 10b5-1 Arrangement Terminated false Non-Rule 10b5-1 Arrangement Terminated false X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph A + Details Name: ecd_TradingArrByIndTable Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 41 R24.htm IDEA: XBRL DOCUMENT v3.24.3 NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) 12 Months Ended Jun. 30, 2024 NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Â Nature of Operations Nature of OperationsRezolute, Inc. (the â€œCompanyâ€) is a late-stage rare disease company focused on significantly improving outcomes for individuals with hypoglycemia caused by hyperinsulinism. The Companyâ€™s primary clinical assets consist of (i) ersodetug (formerly known as RZ358), which is a potential treatment for all forms of hyperinsulinism, including congenital hyperinsulinism, an ultra-rare pediatric genetic disorder characterized by excessive production of insulin by the pancreas, and (ii) RZ402, which is an oral plasma kallikrein inhibitor (â€œPKIâ€) being developed as a potential therapy for the chronic treatment of diabetic macular edema. Consolidation ConsolidationThe Company has two wholly owned subsidiaries consisting of Rezolute (Bio) Ireland Limited, and Rezolute Bio UK, Ltd. The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. Basis of Presentation Basis of PresentationThe Companyâ€™s consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (â€œGAAPâ€).Comprehensive income (loss) is defined as net income (loss) plus other comprehensive income (loss). Other comprehensive income (loss) is comprised of revenues, expenses, gains, and losses that under GAAP are reported as separate components of shareholdersâ€™ equity instead of net income (loss). For the fiscal years ended June 30, 2024 and 2023, components of comprehensive loss included the Companyâ€™s net loss and unrealized gains (losses) on investments in marketable debt securities.The Companyâ€™s Chief Executive Officer also serves as the Companyâ€™s chief operating decision maker for purposes of allocating resources and

assessing performance based on financial information of the Company. Since its inception, the Company has determined that its activities as a clinical stage biopharmaceutical company are classified as a single reportable operating segment. Use of Estimates Use of EstimatesThe preparation of financial statements in conformity with GAAP requires management to make judgments, estimates and assumptions that affect the reported amounts in the consolidated financial statements and the accompanying notes. The Company bases its estimates and assumptions on current facts, historical experience, and various other factors that it believes are reasonable under the circumstances, to determine the carrying values of assets and liabilities that are not readily apparent from other sources. The Companyâ€™s significant accounting estimates include, but are not necessarily limited to, determination if an allowance for credit losses is required or if other than temporary impairment exists for marketable debt securities, fair value of an derivative liabilities, fair value of share-based payments, managementâ€™s assessment of going concern, and estimates related to clinical trial accrued liabilities. Actual results could differ from those estimates. Risks and Uncertainties Risks and UncertaintiesThe Company's operations may be subject to significant risks and uncertainties including financial, operational, regulatory and other risks associated with a clinical stage company, including the potential risk of business failure discussed in Note 2. Cash and Cash Equivalents Cash and Cash EquivalentsAll highly liquid investments purchased with an original maturity of three months or less that are freely available for the Companyâ€™s immediate and general business use are classified as cash and cash equivalents. Cash and cash equivalents consist primarily of demand deposits with financial institutions, money market funds and corporate commercial paper purchased with a maturity of three months or less. Investments in Marketable Debt Securities Investments in Marketable Debt SecuritiesUnder the investment policy approved by the Companyâ€™s Board of Directors, eligible investments in fixed income debt securities must be denominated and payable in U.S. dollars, including eligible corporate bonds, corporate commercial paper, U.S. government obligations, and money market funds. This investment policy only permits investments in the debt securities of issuers that meet stringent credit quality ratings on the date of the investment. The investment policy also places restrictions on the length of maturities and concentrations by type and issuer. The Companyâ€™s investments are issued by issuers that management believes are of high credit quality. However, all issuers are exposed to credit risk in the event of default. The Company classifies investments in marketable debt securities that mature in less than one year as short-term assets. For investments that mature in more than one year, the investments are classified as long-term assets unless management intends to liquidate the investments to fund current operations before the scheduled maturity dates.The Company accounts for all of its investments in marketable debt securities as available-for-sale securities whereby they are recorded in the consolidated balance sheet at fair value. Interest income is recognized in the consolidated statement of operations, consisting of accrued interest earned based on the coupon rate of the security, plus the impact of accreting discounts and amortizing premiums to maturity using the straight-line method which approximates the interest method. Unrealized gains and losses due to subsequent changes in fair value of the investments are reported in shareholdersâ€™ equity as a component of accumulated other comprehensive income (loss). The Company reviews the components of its portfolio of available-for-sale debt securities, using both quantitative and qualitative factors, to determine if declines in fair value below amortized cost have resulted from a credit-related loss or other factors. If declines in fair value below amortized costs are due to the deterioration of an issuerâ€™s credit quality, the Company is required to record an allowance for credit losses related to such investments with a corresponding loss recognized in the consolidated statements of operations. Allowances for credit losses may be reversed in subsequent periods if conditions improve and credit-related losses are no longer expected. For declines in fair value that are solely due to changes in interest rates, impairment is not recognized if the Company has the ability and intent to hold the investment until maturity.Â Prepaid Expenses and Other Prepaid Expenses and OtherPrepaid expenses and other includes nonrefundable advance payments for goods and services that will be used or rendered in future research and development activities. These advance payments are deferred and recognized as expenses in the period that the related goods are delivered, or services are performed. Leases LeasesThe Company determines if an arrangement includes a lease as of the date an agreement is entered into. Operating leases are included in right-of-use (â€œROUâ€) assets and operating lease liabilities in the Company's consolidated balance sheets. ROU assets and operating lease liabilities are initially recognized based on the present value of the future minimum lease payments at the commencement date of the lease. The Company generally uses its incremental borrowing rate based on the information available at the lease commencement date to determine the discount rate used to compute the present value of future payments. The Company's leases may include options to extend or terminate the lease; these options are included in the calculation of ROU assets and operating lease liabilities when it is reasonably certain that the Company will exercise the options. Lease expense is recognized on a straight-line basis over the lease term. The Company has elected not to apply the recognition requirements for short-term leases. For lease agreements with lease and non-lease components, the Company generally accounts for them separately. Property and Equipment Property and EquipmentProperty and equipment consist solely of office furniture and equipment that is recorded at cost. Depreciation expense is calculated using the straight-line method over the estimated useful lives of the assets which range from 3 to 5 years. Maintenance and repairs are expensed as incurred. Research and Development Costs Research and Development CostsResearch and development costs are expensed as incurred. Intangible assets for in-licensing costs incurred under license agreements with third parties are charged to expense, unless the licensing rights have separate economic value in alternative future research and development projects or otherwise. Clinical Trial Accruals Clinical Trial AccrualsClinical trial costs are a component of research and development expenses. The Company accrues and expenses clinical trial activities performed by third parties based upon estimates of the percentage of work completed over the life of the individual study in accordance with agreements established with clinical research organizations and clinical trial sites. The Company determines the estimates through discussions with internal clinical personnel and external service providers as to the progress or stage of completion of trials or services and the agreed-upon fee to be paid for such services. Share-Based Compensation Share-Based CompensationThe Company measures the fair value of employee and director services received in exchange for grants of stock options and other equity awards granted, based on the fair value of the award as of the grant date. The Company computes the fair value of stock options using the Black-Scholes-Merton (â€œBSMâ€) option pricing model and recognizes the value of the equity awards over the period that services are provided to earn the award, usually the vesting period. For awards granted which contain a graded vesting schedule, and the only condition for vesting is a service condition, compensation cost is recognized as an expense on a straight-line basis over the requisite service period as if the award was, in substance, a single award. The Company recognizes the impact of forfeitures in the period that the forfeiture occurs, rather than estimating the number of awards that are not expected to vest in accounting for share-based compensation. For stock options that are voluntarily surrendered by employees, all unrecognized compensation is immediately recognized in the period the options are cancelled. Embedded Derivatives Embedded DerivativesWhen the Company enters into a financial instrument such as a debt or equity agreement (the â€œHost Contractâ€), the Company assesses whether the economic characteristics of any embedded features would meet the definition of a derivative instrument, and whether such features are considered clearly and closely related to the primary economic characteristics of the Host Contract. When it is determined that (i) an embedded feature possesses economic characteristics that are not clearly and closely related to the primary economic characteristics of the Host Contract, and (ii) a separate, stand-alone instrument with the same terms would meet the definition of a financial derivative instrument and cannot be classified in shareholdersâ€™ equity, then the embedded feature is bifurcated from the Host Contract and accounted for as a derivative liability. The estimated fair value of the derivative feature is recorded separately from the carrying value of the Host Contract, with subsequent changes in the estimated fair value recorded as a non-operating gain or loss in the Companyâ€™s consolidated statements of operations. Fair Value of warrants Fair Value of WarrantsThe Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrantâ€™s specific terms and applicable authoritative guidance set forth by the Financial Accounting Standards Board (â€œFASBâ€) in Accounting Standards Codification (â€œASCâ€) 480, Distinguishing Liabilities from Equity (â€œASC 480â€) and ASC 815, Derivatives and Hedging (â€œASC 815â€). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Companyâ€™s own common shares and whether the warrant holders could potentially require â€œnet cash settlementâ€ in a circumstance outside of the Companyâ€™s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and during each subsequent quarterly period while the warrants are outstanding. Liability-classified warrants are valued using the BSM option-pricing model at issuance, and for each subsequent reporting period. Income Taxes Income TaxesThe Company accounts for income taxes using the asset and liability method. Under this method, deferred income tax assets and liabilities that are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using enacted tax rates and laws that are in effect when the differences are expected to be recovered or settled. Realization of deferred income tax assets is dependent upon future taxable income. A valuation allowance is recognized if it is more likely than not that some portion or all of a deferred income tax asset will not be realized based on the weight of available evidence, including expected future earnings.The Company recognizes uncertain tax position in its financial statements when it concludes that a tax position is more likely than not to be sustained upon examination based solely on its technical merits. Only after a tax position passes the first step of recognition will measurement be required. Under the measurement step, the tax benefit is computed as the largest amount of benefit that is more likely than not to be realized upon effective settlement. This calculation is determined on a cumulative probability basis. The full impact of any change in recognition or measurement is reflected in the period in which such change occurs. Interest and penalties related to income taxes will be recognized as a component of income tax expense. Net Loss Per Share Net Loss Per ShareBasic net loss per share is computed by dividing net loss by the weighted average number of outstanding shares of common stock and pre-funded warrants that are accounted for as equity instruments. Common shares associated with pre-funded warrants are included in the computation of both basic and diluted net loss per share since the exercise price is negligible and all of the pre-funded warrants are fully vested and exercisable. To the extent dilutive, during periods in which pre-funded warrants are accounted for as derivative liabilities, the calculation of diluted net loss per share will be further adjusted to eliminate gains on changes in the fair value of such pre-funded warrants, and the related pre-funded warrant shares will be included in the weighted average number of shares outstanding.Diluted net loss per share is computed using the treasury stock method by further giving effect to all potential shares of common stock, including stock options and warrants, to the extent dilutive.For participating warrants that are entitled to participate in dividends declared to holders of shares of common stock, the Company applies the two-class method of allocating earnings if the impact of including the participating warrants is dilutive for the calculation of both basic and diluted net loss per share.Treasury SharesThe Company accounts for purchases of treasury shares under the cost method. Â In accordance with Nevada law, acquired treasury shares may be retired by the Company. Upon retirement, the treasury shares are no longer accounted for as issued and outstanding. Treasury Shares Treasury SharesThe Company accounts for purchases of treasury shares under the cost method. Â In accordance with Nevada law, acquired treasury shares may be retired by the Company. Upon retirement, the treasury shares are no longer accounted for as issued and outstanding. Recent Accounting Pronouncements Recent Accounting PronouncementsRecently Adopted Accounting Standard. The following accounting standard was adopted in the fiscal year ended June 30, 2024:In June 2016, the FASB issued Accounting Standards Update (â€œASUâ€) 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. ASU 2016-13 amends the guidance on the impairment of financial instruments. This update adds an impairment model (known as the current expected credit losses model) that is based on expected losses rather than incurred losses. Under the expected credit loss model, if declines in fair value below amortized costs are due to the deterioration of an issuerâ€™s credit quality, the Company is required to record an allowance for credit losses related to such investments with a corresponding loss recognized in the consolidated statements of operations. Allowances for credit losses may be reversed in subsequent periods if conditions improve and credit-related losses are no longer expected. For declines in fair value that are solely due to changes in interest rates, impairment is not recognized if the Company has the ability and intent to hold the investment until maturity. Effective as of July 1, 2023, the Company implemented the guidance in ASU 2016-13. The adoption of ASU 2016-13 did not have any impact on the accompanying consolidated financial statements.Standard Required to be Adopted in Future Periods.Â The following accounting standard has not yet been adopted by the Company:â€‹In December 2023, the FASB issued ASU 2023-09, â€œIncome Taxes (Topic 740) â€“ Improvements to Income Tax Disclosuresâ€. ASU 2023-09 requires disclosure of additional income tax information, primarily related to the rate reconciliation and income taxes paid. This ASU is intended to enhance the transparency and decision usefulness of income tax disclosures. ASU 2023-09 is effective for annual periods beginning after December 15, 2024. Management has not determined the timing for adoption of this standard.â€‹The adoption of ASU 2023-09 and other accounting standards that have been issued or proposed by the FASB that do not require adoption until a future date are not currently expected to have a material impact on the Companyâ€™s consolidated financial statements upon adoption. X - DefinitionRepresents the accounting policy on clinical trial accruals. + ReferencesNo definition available. + Details Name: rzlt_ClinicalTrialAccrualsPolicyTextBlock Namespace Prefix: rzlt_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of Accounting policy of fair value of warrants. + ReferencesNo definition available. + Details Name: rzlt_FairValueOfWarrantsPolicyTextBlock Namespace Prefix: rzlt_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy of prepaid expenses and other assets. + ReferencesNo definition available. + Details Name: rzlt_PrepaidExpensesAndOtherAssetsPolicyTextBlock Namespace Prefix: rzlt_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for the risks and uncertainties during the reporting period. + ReferencesNo definition available. + Details Name: rzlt_RisksAndUncertaintiesPolicyTextBlock Namespace Prefix: rzlt_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). + ReferencesNo definition available. + Details Name: us-gaap_BasisOfAccountingPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1 + Details Name: us-gaap_CashAndCashEquivalentsPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1 + Details Name: us-gaap_ConsolidationPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for its derivative instruments and hedging activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 815 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(n)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1AReference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4Reference 7: http://fasb.org/us-

gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-7 + Details Name: us-gaap_DerivativesPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2 + Details Name: us-gaap_EarningsPerSharePolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(h)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1 + Details Name: us-gaap_IncomeTaxPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for leasing arrangement entered into by lessee. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1 + Details Name: us-gaap_LesseeLeasesPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for investment classified as marketable security. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 320 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477268/942-320-50-5 + Details Name: us-gaap_MarketableSecuritiesPolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Topic 275 -Publisher FASB -URI https://asc.fasb.org/275/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1 + Details Name: us-gaap_NatureOfOperations Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact. + ReferencesNo definition available. + Details Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 6 -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1 + Details Name: us-gaap_ResearchAndDevelopmentExpensePolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.C.Q3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.D.1.Q5) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.D.3.Q2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.D.2.Q6) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContentReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/505-30/tableOfContent + Details Name: us-gaap_TreasuryStockTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 11 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 12 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8 + Details Name: us-gaap_UseOfEstimates Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 42 R25.htm IDEA: XBRL DOCUMENT v3.24.3 INVESTMENTS IN MARKETABLE DEBT SECURITIES (Tables) 12 Months Ended Jun. 30, 2024 INVESTMENTS IN MARKETABLE DEBT SECURITIES Â Schedule of investments in marketable debt securities Investments in marketable debt securities are classified as follows in the consolidated balance sheets as of June 30, 2024 and 2023 (in thousands):â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹2024Â Â Â Â 2023Short-term investments$ 56,478â€‹$ 85,860Long-term investmentsâ€‹ 263â€‹â€‹ 16,470Total investments$ 56,741â€‹$ 102,330 Summary of unrealized gains and losses that result in differences between the amortized cost basis and fair value of the Company's marketable debt securities The following table summarizes the unrealized gains and losses that result in differences between the amortized cost basis and fair value of the Companyâ€™s marketable debt securities held as of June 30, 2024 (in thousands):â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹

â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹2021â€‹2022â€‹Exchangeâ€‹2024â€‹â€‹â€‹PFWsâ€‹PFWsâ€‹PFWsâ€‹PFWsâ€‹TotalOutstanding, June 30, 2023 1,661,461(1) 12,921,055(2) â€”â€‹ â€”â€‹ 14,582,516Issuance of Exchange PFWs in March 2024 â€”â€‹ â€”â€‹ 3,000,000(3)â€‹â€‹ 3,000,000Issuance of 2024 PFWs in June 2024 â€”â€‹ â€”â€‹â€‹â€‹ 3,750,000(4) 3,750,000Cashless exercise of PFWs:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Shares surrendered for exercise price (8,571)â€‹ (3,494)â€‹ â€”â€‹ â€”â€‹ (12,065)Shares of common stock issued (1,529,890)â€‹ (4,770,190)â€‹ â€”â€‹ â€”â€‹ (6,300,080)Outstanding, June 30, 2024 123,000â€‹ 8,147,371â€‹ 3,000,000â€‹ 3,750,000â€‹ 15,020,371(1)In connection with an underwritten offering in October 2021, PFWs were issued to purchase 1,661,461 shares of common stock at an issuance price of $6.49 per share (the â€œ2021 PFWsâ€). The exercise price of the 2021 PFWs is $0.01 per share.(2)In connection with a registered direct offering in May 2022, the Company issued 1,973,684 Class A PFWs and 10,947,371 Class B PFWs to purchase an aggregate of 12,921,055 shares of common stock at an issuance price of $3.799 per warrant (collectively, the â€œ2022 PFWsâ€). The exercise price of the 2022 PFWs is $0.001 per share. The 2022 PFWs were classified within shareholdersâ€™ equity for the entirety of the fiscal years ended June 30, 2024 and 2023.(3)As discussed below under the caption Exchange Agreement, the Company issued 3,000,000 Exchange PWFs on March 8, 2024. The exercise price of the Exchange PFWs is $0.001 per share. The Exchange PFWs were initially classified as a derivative liability until May 13, 2024 when the terms were amended to permit reclassification within shareholdersâ€™ equity.(4)As discussed below under the caption 2024 Underwritten Offering, the Company issued 2024 PWFs for the purchase of 3,750,000 shares of common stock on June 24, 2024. The exercise price of the 2024 PFWs is $0.001 per share. X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_ClassOfWarrantOrRightLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-1 + Details Name: us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=rzlt_PreFundedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 45 R28.htm IDEA: XBRL DOCUMENT v3.24.3 SHARE-BASED COMPENSATION AND WARRANTS (Tables) 12 Months Ended Jun. 30, 2024 Class of Warrant or Right [Line Items] Â Schedule of the number of shares authorized, outstanding, and available for future grants under stock option Presented below is a summary of the number of shares authorized, outstanding, and available for future grants under the Companyâ€™s stock option plans and the Inducement Grant (defined below) as of June 30, 2024 (in thousands):â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â Number of SharesDescriptionÂ Â Â Â AuthorizedÂ Â Â Â OutstandingÂ Â Â Â Availableâ€‹â€‹â€‹â€‹â€‹â€‹â€‹2015 PlanÂ 17Â 17Â â€”2016 PlanÂ 123Â 123Â â€”2019 PlanÂ 200Â 200Â â€”2021 Planâ€‹ 10,618â€‹ 10,276â€‹ 342Inducement Grantâ€‹ 275â€‹ 275â€‹ â€”TotalÂ 11,233Â 10,891Â 342 Schedule of the stock option plans The following table sets forth a summary of the combined activity under all of the Companyâ€™s stock option plans, including Inducement Grant discussed below, for the fiscal years ended June 30, 2024 and 2023 (shares in thousands):â€‹2024â€‹2023â€‹Â Â Â Â SharesÂ Â Â Â PriceÂ (1)Â Â Â Â TermÂ (2)â€‹SharesÂ Â Â Â PriceÂ (1)Â Â Â Â TermÂ (2)â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹

future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 49 R32.htm IDEA: XBRL DOCUMENT v3.24.3 FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS (Tables) 12 Months Ended Jun. 30, 2024 FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS Â Schedule of financial assets measured at fair value on a recurring basis â€‹â€‹â€‹

URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_LiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of investment in marketable security. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_MarketableSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=rzlt_AtMarketOfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=rzlt_UnderwrittenPublicOfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=rzlt_PreFundedWarrants2024Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=rzlt_XomaUsLlcMember Namespace Prefix: Data

Type: na Balance Type: Period Type: X - Details Name: us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=rzlt_Phase3ClinicalTrialRz358Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=rzlt_XomaLicenseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=rzlt_ScenarioUponDosingOfLastPatientMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 52 R35.htm IDEA: XBRL DOCUMENT v3.24.3 INVESTMENTS IN MARKETABLE DEBT SECURITIES - Investments in Marketable Securities (Details) - USD ($) $ in Thousands Jun. 30, 2024 Jun. 30, 2023 INVESTMENTS IN MARKETABLE DEBT SECURITIES Â Â Short-term investments $ 56,478 $ 85,860 Long-term investments 263 16,470 Total investments $ 56,741 $ 102,330 X - DefinitionAmount of investment in marketable security. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_MarketableSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_MarketableSecuritiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of investment in marketable security, classified as current. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_MarketableSecuritiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of investment in marketable security, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_MarketableSecuritiesNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 53 R36.htm IDEA: XBRL DOCUMENT v3.24.3 INVESTMENTS IN MARKETABLE DEBT SECURITIES - Additional Information (Details) - USD ($) $ in Thousands 12 Months Ended Jun. 30, 2024 Jun. 30, 2023 INVESTMENTS IN MARKETABLE DEBT SECURITIES Â Â Debt securities, available-for-sale, term 2 years Â Debt securities, available-for-sale, weighted average term 1 year Â Short-term investments $ 56,478 $ 85,860 Long-term investments 263 16,470 Proceeds from maturities of marketable debt securities 115,100 6,000 Investment in marketable securities 66,401 107,311 Interest receivable $ 400 $ 300 Debt Securities, Available-for-Sale, Accrued Interest, after Allowance for Credit Loss, Current, Statement of Financial Position [Extensible Enumeration] Prepaid Expense and Other Assets, Current Prepaid Expense and Other Assets, Current Allowance for credit losses related to investments in marketable debt securities $ 0 $ 0 X - DefinitionWeighted average period of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesNo definition available. + Details Name: rzlt_DebtSecuritiesAvailableForSaleWeightedAverageTerm Namespace Prefix: rzlt_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionAmount, after allowance for credit loss, of accrued interest on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2A -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2AReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 3A -Publisher FASB -URI https://asc.fasb.org/1943274/2147479106/326-30-50-3A + Details Name: us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionIndicates line item in statement of financial position that includes accrued interest, after allowance for credit loss, on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 3A -Publisher FASB -URI https://asc.fasb.org/1943274/2147479106/326-30-50-3A + Details Name: us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrentStatementOfFinancialPositionExtensibleList Namespace Prefix: us-gaap_ Data Type: enum2:enumerationSetItemType Balance Type: na Period Type: instant X - DefinitionAmount excluding accrued interest, of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1 + Details Name: us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterestCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPeriod between issuance and maturity of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_DebtSecuritiesAvailableForSaleTerm Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_MarketableSecuritiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of investment in marketable security, classified as current. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_MarketableSecuritiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of investment in marketable security, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_MarketableSecuritiesNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash outflow for purchase of marketable security. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11 + Details Name: us-gaap_PaymentsToAcquireMarketableSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period. + ReferencesNo definition available. + Details Name: us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 54 R37.htm IDEA: XBRL DOCUMENT v3.24.3 INVESTMENTS IN MARKETABLE DEBT SECURITIES - Cash and Cash Equivalents and Marketable Securities Held (Details) - USD ($) $ in Thousands Jun. 30, 2024 Jun. 30, 2023 INVESTMENTS IN MARKETABLE DEBT SECURITIES Â Â Amortized Cost $ 56,820 $ 102,681 Gross Unrealized Gains Â 3 Gross Unrealized Losses (79) (354) Fair Value 56,741 102,330 Corporate commercial paper Â Â INVESTMENTS IN MARKETABLE DEBT SECURITIES Â Â Amortized Cost 20,941 41,670 Gross Unrealized Losses (12) (73) Fair Value 20,929 41,597 Obligations of U.S. government agencies Â Â INVESTMENTS IN MARKETABLE DEBT SECURITIES Â Â Amortized Cost 2,001 26,565 Gross Unrealized Losses (4) (170) Fair Value 1,997 26,395 U.S. Treasury obligations Â Â INVESTMENTS IN MARKETABLE DEBT SECURITIES Â Â Amortized Cost 2,727 10,416 Gross Unrealized Gains Â 2 Gross Unrealized Losses (7) (14) Fair Value 2,720 10,404 Corporate notes and bonds Â Â INVESTMENTS IN MARKETABLE DEBT SECURITIES Â Â Amortized Cost 30,888 19,253 Gross Unrealized Gains Â 1 Gross Unrealized Losses (56) (14) Fair Value 30,832 19,240 Asset-backed securities Â Â INVESTMENTS IN MARKETABLE DEBT SECURITIES Â Â Amortized Cost 263 4,777 Gross Unrealized Losses Â (83) Fair Value $ 263 $ 4,694 X - DefinitionAmount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2 + Details Name: us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2 + Details Name: us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmortized cost excluding accrued interest, before allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1 + Details Name: us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1 + Details Name: us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aaa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3 + Details Name: us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 55 R38.htm IDEA: XBRL DOCUMENT v3.24.3 LEASES - Additional Information (Details) 1 Months Ended 12 Months Ended Oct. 31, 2023 USD ($) Apr. 30, 2022 USD ($) ftÂ² Jun. 30, 2024 USD ($) Jun. 30, 2023 USD ($) Property, Plant and Equipment [Line Items] Â Â Â Â Total base rent payments Â Â $ 2,492,000 Â Operating Lease, Payments Â Â 728,000 $ 215,000 Aggregate amount of variable payments exclude from operating lease liabilities Â Â $ 100,000 Â Weighted average remaining lease term under operating leases Â Â 3 years 3 months 18 days 4 years 3 months 18 days Weighted average discount rate for operating lease liabilities Â Â 7.20% 6.80% Right-of-use assets Â Â $ 1,880,000 $ 2,054,000 Non-current operating lease liabilities Â Â 1,660,000 1,937,000 Operating lease liability Â Â $ 2,228,000 $ 2,478,000 Office space in Bend, Oregon Â Â Â Â Property, Plant and Equipment [Line Items] Â Â Â Â Lessee, Operating Lease, Renewal Term 36 months Â Â Â Â Operating Lease, Payments $ 9,000 Â Â Â Right-of-use assets 351,000 Â Â Â Operating lease liability $ 345,000 Â Â Â Lessee operating lease discount rate 10.00% Â Â Â Corporate Headquarters Â Â Â Â Property, Plant and Equipment [Line Items] Â Â Â Â Lease space | ftÂ² Â 9,300 Â Â Total base rent payments Â $ 2,900,000 Â Â Abatement period Â 6 months Â Â Lease provided an allowance for the purchase of furniture and equipment Â $ 100,000 Â Â Operating lease term of contract Â 60 months Â Â Average base rent payable in cash Â $ 48,000 Â Â Right-of-use assets Â 2,300,000 Â Â Non-current operating lease liabilities Â $ 2,200,000 Â Â X - DefinitionThe operating lease rent abatement period. + ReferencesNo definition available. + Details Name: rzlt_LesseeOperatingLeaseAbatementPeriod Namespace Prefix: rzlt_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionThe amount of base rent payable monthly. + ReferencesNo definition available. + Details Name: rzlt_LesseeOperatingLeaseBaseRentExpense Namespace Prefix: rzlt_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe amount of lease allowance provided for furniture and equipment. + ReferencesNo definition available. + Details Name: rzlt_LesseeOperatingLeaseFurnitureAndEquipmentAllowance Namespace Prefix: rzlt_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionRepresents the amount of space being leased. + ReferencesNo definition available. + Details Name: rzlt_LesseeOperatingLeaseOperatingLeaseSpace Namespace Prefix: rzlt_ Data Type: dtr-types:areaItemType Balance Type: na Period Type: duration X - DefinitionDiscount rate used by lessee to determine present value of operating lease payments. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeOperatingLeaseDiscountRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease. + ReferencesReference 1:

http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTerm of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeOperatingLeaseRenewalTerm Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionTerm of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeOperatingLeaseTermOfContract Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeasePayments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionWeighted average discount rate for operating lease calculated at point in time. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionWeighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A + Details Name: us-gaap_PropertyPlantAndEquipmentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_VariableLeaseCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=rzlt_OfficeSpaceInBendMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=rzlt_CorporateHeadquartersMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 56 R39.htm IDEA: XBRL DOCUMENT v3.24.3 LEASES - Assets and Operating Lease Liabilities (Details) - USD ($) $ in Thousands Jun. 30, 2024 Jun. 30, 2023 Carrying value of right-of-use assets and operating lease liabilities Â Â Right-of-use assets $ 1,880 $ 2,054 Operating lease liabilities: Â Â Current 568 541 Non-current operating lease liabilities 1,660 1,937 Total $ 2,228 $ 2,478 X - ReferencesNo definition available. + Details Name: us-gaap_AssetsAndLiabilitiesLesseeAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_OperatingLeaseLiabilityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 57 R40.htm IDEA: XBRL DOCUMENT v3.24.3 LEASES - Operating Lease Expense (Details) - USD ($) $ in Thousands 12 Months Ended Jun. 30, 2024 Jun. 30, 2023 Lessee, Lease, Description [Line Items] Â Â Operating lease expense $ 680 $ 607 Research and Development Expense Â Â Lessee, Lease, Description [Line Items] Â Â Operating lease expense 484 453 General and Administrative Expense Â Â Lessee, Lease, Description [Line Items] Â Â Operating lease expense $ 196 $ 154 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeLeaseDescriptionLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 58 R41.htm IDEA: XBRL DOCUMENT v3.24.3 LEASES - Future Operating Lease Payments (Details) - USD ($) $ in Thousands Jun. 30, 2024 Jun. 30, 2023 Future lease payments related to operating lease agreements Â Â 2025 $ 748 Â 2026 770 Â 2027 750 Â Thereafter 224 Â Total lease payments 2,492 Â Less imputed interest (264) Â Present value of operating lease liabilities $ 2,228 $ 2,478 X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease due after third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesNo definition available. + Details Name: rzlt_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree Namespace Prefix: rzlt_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 59 R42.htm IDEA: XBRL DOCUMENT v3.24.3 LICENSE AGREEMENTS (Details) - USD ($) $ in Millions 1 Months Ended 12 Months Ended Apr. 30, 2024 Feb. 28, 2023 Jan. 31, 2022 Dec. 31, 2020 Aug. 31, 2017 Jun. 30, 2024 XOMA (US) LLC | Xoma License Agreement | Upon Clinical and Regulatory Milestones | Maximum Â Â Â Â Â Â License Agreements Â Â Â Â Â Â Maximum amount of milestone events Â Â Â Â Â Â $ 30.0 XOMA (US) LLC | Xoma License Agreement | After Clinical and Regulatory Milestones | Maximum Â Â Â Â Â Â Â License Agreements Â Â Â Â Â Â Maximum amount of milestone events Â Â Â Â Â Â 185.0 XOMA (US) LLC | Phase 2 Clinical Trial RZ358 (ersodetug) | Xoma License Agreement Â Â Â Â Â Â Â License Agreements Â Â Â Â Â Â Milestone closing payment Â Â $ 2.0 Â Â Â Â XOMA (US) LLC | Phase 3 Clinical Trial RZ 358 (ersodetug) | Xoma License Agreement Â Â Â Â Â Â Â License Agreements Â Â Â Â Â Â Milestone closing payment $ 5.0 Â Â Â Â Â Â XOMA (US) LLC | Phase 3 Clinical Trial RZ 358 (ersodetug) | Xoma License Agreement | Scenario, Upon Dosing Of The Last Patient Â Â Â Â Â Â Â License Agreements Â Â Â Â Â Â Milestone closing payment Â Â Â Â Â 5.0 ActiveSite Pharmaceuticals, Inc | Development And License Agreement Â Â Â Â Â Â Â License Agreements Â Â Â Â Â Â Royalties percentage Â Â Â Â 2.00% Â ActiveSite Pharmaceuticals, Inc | Development And License Agreement | Scenario, Plan | Maximum Â Â Â Â Â Â Â License Agreements Â Â Â Â Â Â Maximum amount of milestone events Â Â Â Â $ 46.5 Â ActiveSite Pharmaceuticals, Inc | Phase 1 Clinical Trial RZ402 | Development And License Agreement Â Â Â Â Â Â Â License Agreements Â Â Â Â Â Â Milestone closing payment Â Â Â $ 1.0 Â Â ActiveSite Pharmaceuticals, Inc | Phase 2 Clinical Trial RZ402 | Development And License Agreement Â Â Â Â Â Â Â License Agreements Â Â Â Â Â Â Milestone closing payment Â $ 3.0 Â Â Â Â ActiveSite Pharmaceuticals, Inc | Phase 3 Clinical Trial RZ 402 | Development And License Agreement | Scenario, Plan Â Â Â Â Â Â Â License Agreements Â Â Â Â Â Â Milestone closing payment Â Â Â Â Â Â $ 5.0 X - DefinitionRepresents the percentage of royalties. + ReferencesNo definition available. + Details Name: rzlt_DevelopmentAndLicenseAgreementRoyaltiesPercentage Namespace Prefix: rzlt_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe maximum amount of milestone event which need to occur for making specific range of milestone payment. + ReferencesNo definition available. + Details Name: rzlt_MaximumAmountOfMilestoneEvents Namespace Prefix: rzlt_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of milestone payment made during the period. + ReferencesNo definition available. + Details Name: rzlt_MilestoneClosingPayment Namespace Prefix: rzlt_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 730 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1 + Details Name: us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: srt_CounterpartyNameAxis=rzlt_XomaUsLlcMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=rzlt_XomaLicenseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name:

srt_StatementScenarioAxis=rzlt_ScenarioUponClinicalAndRegulatoryMilestonesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=rzlt_ScenarioAfterClinicalAndRegulatoryMilestonesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=rzlt_Phase2ClinicalTrialRz358Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=rzlt_Phase3ClinicalTrialRz358Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=rzlt_ScenarioUponDosingOfLastPatientMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=rzlt_ActivesitePharmaceuticalsIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=rzlt_DevelopmentAndLicenseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=us-gaap_ScenarioPlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=rzlt_Phase1ClinicalTrialRz402Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=rzlt_Phase2ClinicalTrialRz402Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=rzlt_Phase3ClinicalTrialRz402Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 60 R43.htm IDEA: XBRL DOCUMENT v3.24.3 EMBEDDED DERIVATIVE LIABILITY (Details) - USD ($) $ in Thousands Apr. 14, 2021 Jun. 30, 2024 Jun. 30, 2023 Debt Instrument [Line Items] Â Â Â Embedded derivative liability Â $ 468 $ 412 Embedded Derivative Financial Instruments [Member] Â Â Â Debt Instrument [Line Items] Â Â Â Maximum borrowing capacity $ 30,000 Â Â Gross proceeds from issuance of debt $ 15,000 Â Â Exit fee on the funded principal balance 4.00% Â Â Exit fee amount $ 600 Â Â Embedded derivative liability Â $ 500 $ 400 Percentage of entity's shares held by investors 35.00% Â Â X - DefinitionRepresents the exit fee on the funded principal balance. + ReferencesNo definition available. + Details Name: rzlt_DebtInstrumentExitFee Namespace Prefix: rzlt_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionAmount of expenses associated with exit fees on the funded principal balance. + ReferencesNo definition available. + Details Name: rzlt_DebtInstrumentExitFeeAmount Namespace Prefix: rzlt_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionRepresents the percentage of entity's shares held by investors. + ReferencesNo definition available. + Details Name: rzlt_PercentageOfEntitySSharesHeldByInvestors Namespace Prefix: rzlt_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 26: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1 + Details Name: us-gaap_DebtInstrumentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFair value as of the balance sheet date of the embedded derivative or group of embedded derivatives classified as a liability. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4B + Details Name: us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionMaximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_EmbeddedDerivativeFinancialInstrumentsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 61 R44.htm IDEA: XBRL DOCUMENT v3.24.3 SHAREHOLDERS' EQUITY - Pre-Funded Warrants (Details) - $ / shares 1 Months Ended 12 Months Ended Mar. 08, 2024 May 31, 2022 Jun. 30, 2024 Jun. 30, 2023 Jun. 24, 2024 Oct. 31, 2021 Pre-funded warrants Â Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Â Number of shares of common stock called by warrants issued Â Â 21,300,000 Â Â Â Warrants outstanding, beginning (In shares) Â Â 14,582,516 14,582,516 Â Â Warrants issued Â Â Â 0 Â Â Shares surrendered for exercise price Â Â (12,065) Â Â Â Exercise of warrants Â Â (6,300,080) 0 Â Â Warrants outstanding, ending (In shares) Â Â 15,020,371 14,582,516 Â Â Pre-funded warrants | Securities exchange agreement Â Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Â Warrants issued Â Â 3,000,000 Â Â Â Pre-funded warrants | Securities exchange agreement | Maximum Â Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Â Warrants exercisable, ownership blocker percentage Â Â 19.99% Â Â Â Pre-funded warrants | Underwritten Public Offering Â Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Â Warrants issued Â Â 3,750,000 Â Â Â 2021 Pre-Funded Warrants Â Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Â Number of shares of common stock called by warrants issued Â Â Â Â Â 1,661,461 Warrants outstanding, beginning (In shares) Â Â 1,661,461 Â Â Â Shares surrendered for exercise price Â Â (8,571) Â Â Â Exercise of warrants Â Â (1,529,890) Â Â Â Warrants outstanding, ending (In shares) Â Â 123,000 1,661,461 Â Â Shares Issued, Price Per Share Â Â Â Â Â Â $ 6.49 Warrant price (per share) Â Â Â Â Â Â $ 0.01 2022 Pre-Funded Warrants Â Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Â Number of shares of common stock called by warrants issued Â 12,921,055 Â Â Â Â Warrants outstanding, beginning (In shares) Â Â 12,921,055 Â Â Â Shares surrendered for exercise price Â Â (3,494) Â Â Â Exercise of warrants Â Â (4,770,190) Â Â Â Warrants outstanding, ending (In shares) Â Â 8,147,371 12,921,055 Â Â Shares Issued, Price Per Share Â $ 3.799 Â Â Â Â Warrant price (per share) Â $ 0.001 Â Â Â Â Class A pre-funded warrants Â Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Â Warrants issued Â 1,973,684 Â Â Â Â Class B Warrants Â Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Â Warrants issued Â 10,947,371 Â Â Â Â Exchange Pre-Funded Warrants Â Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Â Warrants outstanding, ending (In shares) Â Â 3,000,000 Â Â Â Exchange Pre-Funded Warrants | Securities exchange agreement Â Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Â Number of shares of common stock called by warrants issued 3,000,000 Â Â Â Â Â Warrants issued 3,000,000 Â 3,000,000 Â Â Â Warrant price (per share) $ 0.001 Â Â Â Â Â Exchange Pre-Funded Warrants | Securities exchange agreement | Maximum Â Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Â Warrants exercisable, ownership blocker percentage 19.99% Â Â Â Â Â Pre Funded Warrants 2024 Â Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Â Warrants outstanding, ending (In shares) Â Â 3,750,000 Â Â Â Pre Funded Warrants 2024 | Underwritten Public Offering Â Â Â Â Â Â Class of Stock [Line Items] Â Â Â Â Â Â Number of shares of common stock called by warrants issued Â Â Â Â 3,750,000 Â Warrants issued Â Â 3,750,000 Â Â Â Warrant price (per share) Â Â Â Â $ 0.001 Â X - DefinitionNumber of warrants or rights exercised. + ReferencesNo definition available. + Details Name: rzlt_ClassOfWarrantOrRightExercised Namespace Prefix: rzlt_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe number of warrants issued. + ReferencesNo definition available. + Details Name: rzlt_ClassOfWarrantOrRightIssued Namespace Prefix: rzlt_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of warrants or rights surrendered. + ReferencesNo definition available. + Details Name: rzlt_ClassOfWarrantOrRightWarrantsSurrendered Namespace Prefix: rzlt_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionRepresents the designated ownership percentage by holder not exceeding the specified percentage for exercise of warrants. + ReferencesNo definition available. + Details Name: rzlt_WarrantsExercisableOwnershipBlockerPercentage Namespace Prefix: rzlt_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(27)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic

946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 + Details Name: us-gaap_ClassOfStockLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of warrants or rights outstanding. + ReferencesNo definition available. + Details Name: us-gaap_ClassOfWarrantOrRightOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionPer share or per unit amount of equity securities issued. + ReferencesNo definition available. + Details Name: us-gaap_SharesIssuedPricePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=rzlt_PreFundedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: rzlt_AgreementAxis=rzlt_SecuritiesExchangeAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=rzlt_UnderwrittenPublicOfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=rzlt_PreFundedWarrants2021Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=rzlt_PreFundedWarrants2022Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=rzlt_ClassPreFundedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=rzlt_ClassBPreFundedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=rzlt_ExchangePreFundedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=rzlt_PreFundedWarrants2024Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 62 R45.htm IDEA: XBRL DOCUMENT v3.24.3 SHAREHOLDERS' EQUITY - 2024 Underwritten Offering (Details) - USD ($) $ / shares in Units, $ in Thousands 12 Months Ended Jun. 24, 2024 Jun. 30, 2024 Pre-funded warrants Â Â Class of Stock [Line Items] Â Â Pre-funded warrants to purchase shares of common stock Â 21,300,000 Underwritten Public Offering Â Â Class of Stock [Line Items] Â Â Number of shares issued 11,250,000 13,000,000.0 Sale of stock, price per share $ 4.00 Â Proceeds from issuance of common stock $ 45,000 $ 49,017 Gross proceeds from sale of equity $ 67,100 Â Underwriting discounts and commissions (In percentage) 6.00% Â Other offering costs $ 500 Â Underwriting discounts and commissions expense 4,500 Â Net cash proceeds $ 62,600 Â Underwritten Public Offering | Pre-funded warrants Â Â Class of Stock [Line Items] Â Â Proceeds from warrants issued Â $ 14,096 Underwritten Public Offering | Pre Funded Warrants 2024 Â Â Class of Stock [Line Items] Â Â Sale of stock, price per share $ 3.999 Â Warrant price (per share) $ 0.001 Â Pre-funded warrants to purchase shares of common stock 3,750,000 Â Proceeds from warrants issued $ 15,000 Â Underwriters Option Â Â Class of Stock [Line Items] Â Â Number of shares issued 1,786,589 Â Sale of stock, Additional Shares Option, price per share $ 4.00 Â Proceeds from issuance of common stock $ 7,100 Â Maximum number of additional shares issued 2,250,000 Â X - DefinitionRepresent the maximum number of additional shares offered. + ReferencesNo definition available. + Details Name: rzlt_MaximumNumberOfAdditionalSharesIssued Namespace Prefix: rzlt_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionRelated to other offering costs + ReferencesNo definition available. + Details Name: rzlt_OtherOfferingCosts Namespace Prefix: rzlt_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow from the additional capital contribution to the entity net of underwriting discounts, commissions and other fees. + ReferencesNo definition available. + Details Name: rzlt_ProceedsFromIssuanceOfCommonStockNetOfUnderwritingDiscountsAndCommissions Namespace Prefix: rzlt_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPer share amount received by subsidiary or equity investee for each share of common stock issued or sold in the additional shares option of a stock transaction. + ReferencesNo definition available. + Details Name: rzlt_SaleOfStockAdditionalSharesOptionPricePerShare Namespace Prefix: rzlt_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe percentage of underwriting discounts and commissions. + ReferencesNo definition available. + Details Name: rzlt_UnderwritingDiscountsAndCommissions Namespace Prefix: rzlt_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe costs for underwriter discounts, commissions and other fees. + ReferencesNo definition available. + Details Name: rzlt_UnderwritingDiscountsAndCommissionsExpense Namespace Prefix: rzlt_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(27)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 + Details Name: us-gaap_ClassOfStockLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe cash inflow from the additional capital contribution to the entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfWarrants Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 + Details Name: us-gaap_ProceedsFromIssuanceOrSaleOfEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPer share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction. + ReferencesNo definition available. + Details Name: us-gaap_SaleOfStockPricePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=rzlt_PreFundedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=rzlt_UnderwrittenPublicOfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=rzlt_PreFundedWarrants2024Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=rzlt_UnderwritersOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 63 R46.htm IDEA: XBRL DOCUMENT v3.24.3 SHAREHOLDERS' EQUITY - Exchange Agreement (Details) - USD ($) 12 Months Ended May 13, 2024 Mar. 08, 2024 Jun. 30, 2024 Cash payment to exchanging shareholders Â Â $ 3,000 Securities exchange agreement Â Â Â Purchased shares of common stock Â 3,000,000 Â Outstanding shares percentage Â 7.00% Â Fair value of shares Â $ 5,700,000 Â Cash payment to exchanging shareholders Â $ 3,000 Â Pre-funded warrants Â Â Â Warrants to purchase shares of common stock Â Â 21,300,000 Pre-funded warrants | Maximum | Securities exchange agreement Â Â Â Warrants exercisable, ownership blocker percentage Â Â 19.99% Exchange Pre-Funded Warrants | Securities exchange agreement Â Â Â Outstanding shares percentage Â 7.00% Â Estimated fair value of warrants Â $ 5,697,000 Â Warrants to purchase shares of common stock Â 3,000,000 Â Warrants exercise price Â $ 0.001 Â Change in fair value of derivative liability $ 2,900,000 Â Â Warrant derivative liability $ 8,500,000 $ 5,700,000 Â Exchange Pre-Funded Warrants | Maximum | Securities exchange agreement Â Â Â Warrants exercisable, ownership blocker percentage Â 19.99% Â X - DefinitionThe amount of change in fair value of warrant derivative liability. + ReferencesNo definition available. + Details Name: rzlt_ChangeInFairValueOfWarrantDerivativeLiability Namespace Prefix: rzlt_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe percentage of stock acquired to the total of outstanding shares. + ReferencesNo definition available. + Details Name: rzlt_PercentageOfTreasuryStockAcquiredOfSharesOutstanding Namespace Prefix: rzlt_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionFair value as of the balance sheet date of the warrants derivative classified as a liability. + ReferencesNo definition available. + Details Name: rzlt_WarrantDerivativeLiabilityNonCurrent Namespace Prefix: rzlt_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionRepresents the designated ownership percentage by holder not exceeding the specified percentage for exercise of warrants. + ReferencesNo definition available. + Details Name: rzlt_WarrantsExercisableOwnershipBlockerPercentage Namespace Prefix: rzlt_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI

https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe cash outflow to reacquire common stock during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsForRepurchaseOfCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares that have been repurchased during the period and are being held in treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_TreasuryStockSharesAcquired Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionEquity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 30 -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1 + Details Name: us-gaap_TreasuryStockValueAcquiredCostMethod Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionValue of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_WarrantsAndRightsOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: rzlt_AgreementAxis=rzlt_SecuritiesExchangeAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=rzlt_PreFundedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=rzlt_ExchangePreFundedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 64 R47.htm IDEA: XBRL DOCUMENT v3.24.3 SHAREHOLDERS' EQUITY - Jefferies Open Market Sales Agreement (Details) - At the Market Offering - USD ($) $ in Millions 12 Months Ended Nov. 14, 2023 Jun. 30, 2024 Class of Stock [Line Items] Â Â Amount agreed to sell as per open market sales agreement $ 50.0 Â Percentage of commission agreed 3.00% Â Common stock to sales agreement Â 0 Sales agreement amounts Â $ 50.0 X - DefinitionPercentage of commission agreed to pay as a percentage on gross sales price. + ReferencesNo definition available. + Details Name: rzlt_SaleOfStockCommissionAgreedToPayAsPercentageOnGrossSalesPrice Namespace Prefix: rzlt_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionMaximum amount agreed to sell as per open market sales agreement. + ReferencesNo definition available. + Details Name: rzlt_SaleOfStockMaximumAmountAgreedToSellAsPerOpenMarketSalesAgreement Namespace Prefix: rzlt_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionMaximum amount remaining for sale as per open market sales agreement. + ReferencesNo definition available. + Details Name: rzlt_SaleOfStockMaximumAmountRemainingForSaleAsPerOpenMarketSalesAgreement Namespace Prefix: rzlt_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(27)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 + Details Name: us-gaap_ClassOfStockLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe number of shares issued or sold by the subsidiary or equity method investee per stock transaction. + ReferencesNo definition available. + Details Name: us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=rzlt_AtMarketOfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 65 R48.htm IDEA: XBRL DOCUMENT v3.24.3 SHAREHOLDERS' EQUITY - 2022 Private Placement (Details) - July 2022 Financing shares in Millions, $ in Millions 1 Months Ended Jul. 31, 2022 USD ($) shares Class of Stock [Line Items] Â Proceeds from issuance of equity securities (in shares) | shares 3.2 Proceeds from Issuance of Common Stock $ 12.3 Underwriting discounts and commissions expense 0.8 Proceeds From Issuance Of Common Stock, Net Of Underwriting Discounts And Commissions $ 11.6 X - DefinitionThe cash inflow from the additional capital contribution to the entity net of underwriting discounts, commissions and other fees. + ReferencesNo definition available. + Details Name: rzlt_ProceedsFromIssuanceOfCommonStockNetOfUnderwritingDiscountsAndCommissions Namespace Prefix: rzlt_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe costs for underwriter discounts, commissions and other fees. + ReferencesNo definition available. + Details Name: rzlt_UnderwritingDiscountsAndCommissionsExpense Namespace Prefix: rzlt_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(27)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 + Details Name: us-gaap_ClassOfStockLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe cash inflow from the additional capital contribution to the entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=rzlt_JulyTwoThousandTwentyTwoFinancingMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 66 R49.htm IDEA: XBRL DOCUMENT v3.24.3 SHARE-BASED COMPENSATION AND WARRANTS - Stock Option Plans (Details) shares in Thousands Jun. 30, 2024 item shares Jun. 30, 2023 shares Jun. 30, 2022 shares Jun. 16, 2022 shares May 26, 2021 shares Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Â Number of active stock option plans | item 1 Â Â Â Â Â Number of shares authorized 11,233 Â Â Â Â Â Number of shares outstanding 10,891 8,745 8,506 Â Â Number of shares available 342 Â Â Â Â Â 2015 Plan Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Â Number of shares authorized 17 Â Â Â Â Â Number of shares outstanding 17 Â Â Â Â Â 2016 Plan Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Â Number of shares authorized 123 Â Â Â Â Â Number of shares outstanding 123 Â Â Â Â Â 2019 Plan Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Â Number of shares authorized 200 Â Â Â Â Â Number of shares outstanding 200 Â Â Â Â Â 2021 Plan Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Â Number of shares authorized 10,618 Â Â 10,700 1,200 Number of shares outstanding 10,276 Â Â Â Â Â Number of shares available 342 Â Â Â Â Â Inducement Grant Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Â Number of shares authorized 275 Â Â Â Â Â Number of shares outstanding 275 Â Â Â Â Â X - DefinitionThe number of active stock option plans.

+ ReferencesNo definition available. + Details Name: rzlt_NumberOfActiveStockOptionPlans Namespace Prefix: rzlt_ Data Type: xbrli:integerItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares authorized for issuance under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of options outstanding, including both vested and non-vested options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_PlanNameAxis=rzlt_Year2015PlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=rzlt_Year2016PlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=rzlt_Year2019PlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=rzlt_Year2021PlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=rzlt_InducementGrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 67 R50.htm IDEA: XBRL DOCUMENT v3.24.3 SHARE-BASED COMPENSATION AND WARRANTS - 2022 Employee Stock Purchase Plan (Details) - Employee Stock Purchase Plan 12 Months Ended Jun. 30, 2024 shares Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Shares reserved for purchase 500,000 Shares purchases 0 X - DefinitionAggregate number of common shares reserved for future issuance. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockCapitalSharesReservedForFutureIssuance Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares issued during the period as a result of an employee stock purchase plan. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 68 R51.htm IDEA: XBRL DOCUMENT v3.24.3 SHARE-BASED COMPENSATION AND WARRANTS - Stock Options Outstanding (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Millions 12 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2022 Number of Options Â Â Â Outstanding, beginning 8,745 8,506 Â Grants to employees 2,642 740 Â Exercises (82) Â Â Expired (110) (116) Â Forfeited (304) (385) Â Outstanding, ending 10,891 8,745 8,506 Vested, ending 4,892 2,676 Â Weighted Average Exercise Price Â Â Â Outstanding, beginning $ 4.56 $ 5.24 Â Granted 1.31 2.00 Â Exercises 3.02 Â Â Expired 6.11 40.73 Â Forfeited 2.63 3.75 Â Outstanding, ending 3.82 4.56 $ 5.24 Vested, ending $ 5.39 $ 6.57 Â Weighted Average Remaining Contractual Life Â Â Â Remaining contractual term (years) 8 years 1 month 6 days 8 years 9 months 18 days 9 years 8 months 12 days Vested (years) 7 years 8 months 12 days 8 years 4 months 24 days Â Total intrinsic value of exercised $ 0.1 Â Â Intrinsic value of outstanding options 14.6 Â Â Aggregate intrinsic value of vested stock options 4.1 Â Â Fair value of options granted $ 2.6 $ 1.1 Â Weighted average grant date fair value, granted $ 1.02 $ 1.53 Â X - DefinitionFair value of options granted. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock. + ReferencesNo definition available. + Details Name: rzlt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodFairValue Namespace Prefix: rzlt_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract

Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNumber of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionGross number of share options (or share units) granted during the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAmount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionNumber of options outstanding, including both vested and non-vested options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionWeighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionWeighted average price at which option holders acquired shares when converting their stock options into shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average per share amount at which grantees can acquire shares of common stock by exercise of options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (e)(1) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionFair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of options vested. + ReferencesNo definition available. + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionWeighted average grant-date fair value of options vested. + ReferencesNo definition available. + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares (or other type of equity) forfeited during the period. + ReferencesNo definition available. + Details Name: us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration XML 69 R52.htm IDEA: XBRL DOCUMENT v3.24.3 SHARE-BASED COMPENSATION AND WARRANTS - Weighted Average Assumptions (Details) - $ / shares 12 Months Ended Jun. 30, 2024 Jun. 30, 2023 SHARE-BASED COMPENSATION AND WARRANTS Â Â Market price of common stock on grant date $ 1.31 $ 3.73 Expected volatility 99.00% 91.00% Risk free interest rate 4.20% 3.70% Expected term (years) 5 years 7 months 6 days 6 years Dividend yield 0.00% 0.00% X - ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe risk-free interest rate assumption that is used in valuing an option on its own shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionExpected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionWeighted average grant-date fair value of non-vested options outstanding. + ReferencesNo definition available. + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant XML 70 R53.htm IDEA: XBRL DOCUMENT v3.24.3 SHARE-BASED COMPENSATION AND WARRANTS - Share Based Compensation Expense (Details) - USD ($) $ in Thousands 12 Months Ended Jun. 30, 2024 Jun. 30, 2023 Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Compensation cost $ 7,360 $ 7,268 Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $ 11,600 Â Expected to be recognized over a remaining weighted average period 2 years 3 months 18 days Â Research and Development Expense Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Compensation cost $ 3,379 3,243 General and Administrative Expense Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Compensation cost $ 3,981 $ 4,025 X - DefinitionAmount of expense for award under share-based payment arrangement. Excludes amount capitalized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_AllocatedShareBasedCompensationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionWeighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionAmount of cost to be recognized for option under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -

SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 71 R54.htm IDEA: XBRL DOCUMENT v3.24.3 SHARE-BASED COMPENSATION AND WARRANTS - Inducement Grant (Details) - USD ($) $ / shares in Units, $ in Millions 1 Months Ended 12 Months Ended Jan. 31, 2024 Jun. 30, 2024 Jun. 30, 2023 Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Stock options granted Â 2,642,000 740,000 Exercise price of stock options Â $ 1.31 $ 2.00 Fair value of options granted Â $ 2.6 $ 1.1 Inducement Grant | Employee Stock Option | Chief Financial Officer Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Stock options granted 275,000 Â Â Exercise price of stock options $ 1.02 Â Â Fair value of options granted $ 0.2 Â Â Inducement Grant | Employee Stock Option | Chief Financial Officer | Tranche one Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Vesting percentage 0.25% Â Â Inducement Grant | Employee Stock Option | Chief Financial Officer | Tranche two Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Vesting percentage 0.27% Â Â Inducement Grant | Employee Stock Option | Chief Financial Officer | Tranche two | Maximum Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Vesting percentage 100.00% Â Â X - DefinitionFair value of options granted. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock. + ReferencesNo definition available. + Details Name: rzlt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodFairValue Namespace Prefix: rzlt_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionGross number of share options (or share units) granted during the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionWeighted average per share amount at which grantees can acquire shares of common stock by exercise of options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionPercentage of vesting of award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_PlanNameAxis=rzlt_InducementGrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 72 R55.htm IDEA: XBRL DOCUMENT v3.24.3 SHARE-BASED COMPENSATION AND WARRANTS - Pre-Funded Warrants (Details) - shares Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2022 Pre-funded warrants Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Warrants outstanding (In shares) 15,020,371 14,582,516 14,582,516 X - DefinitionNumber of warrants or rights outstanding. + ReferencesNo definition available. + Details Name: us-gaap_ClassOfWarrantOrRightOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic

10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=rzlt_PreFundedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 73 R56.htm IDEA: XBRL DOCUMENT v3.24.3 SHARE-BASED COMPENSATION AND WARRANTS - Summary of Legacy Warrants (Details) - Legacy warrants - $ / shares 12 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2022 Oct. 09, 2020 Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Â Â Â Â Warrants outstanding, beginning (In shares) 888,000 1,150,000 Â Â Warrant expirations (In shares) (27,000) (262,000) Â Â Warrants outstanding, ending (In shares) 861,000 888,000 Â Â Warrants Outstanding, Beginning Price (in dollars per share) $ 22.10 $ 22.83 Â Â Warrant expirations, Price (in dollars per share) 78.60 25.32 Â Â Warrants Outstanding, Ending Price (in dollars per share) $ 20.28 $ 22.10 Â Â Weighted average remaining contractual term 3 years 2 months 12 days 4 years 1 month 6 days 4 years 2 months 12 days 7 years Pre-funded warrants to purchase shares of common stock Â Â Â 800,000 Warrants granted or exercised 0 0 Â Â Warrants exercise price $ 20.28 $ 22.10 $ 22.83 $ 19.50 X - DefinitionExercise price per share or per unit of warrants or rights expired. + ReferencesNo definition available. + Details Name: rzlt_ClassOfWarrantOrRightExpirationExercisePriceOfWarrantsOrRights Namespace Prefix: rzlt_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionNumber of warrants or rights expired. + ReferencesNo definition available. + Details Name: rzlt_ClassOfWarrantOrRightExpirations Namespace Prefix: rzlt_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of warrants exercised or granted. + ReferencesNo definition available. + Details Name: rzlt_WarrantsExercisedOrGranted Namespace Prefix: rzlt_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of warrants or rights outstanding. + ReferencesNo definition available. + Details Name: us-gaap_ClassOfWarrantOrRightOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPeriod between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_WarrantsAndRightsOutstandingTerm Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=rzlt_LegacyWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 74 R57.htm IDEA: XBRL DOCUMENT v3.24.3 INCOME TAXES - Additional Information (Details) $ in Millions 12 Months Ended Jun. 30, 2024 USD ($) Operating Loss Carryforwards [Line Items] Â Increase in valuation allowance $ 10.7 Domestic Tax Authority | UNITED STATES Â Operating Loss Carryforwards [Line Items] Â Operating loss carryforwards 171.7 Operating loss carryforwards, subject to limitations 33.4 Operating loss carryforwards, subject to no limitations 138.3 Operating loss carryforward not subject to expiration available to offset taxable income 38.0 Operating loss carryforward, not subject to expiration, available to reduce future taxable income 79.0 Domestic Tax Authority | Expiration in 2031 Through 2035 | UNITED STATES Â Operating Loss Carryforwards [Line Items] Â Operating loss carryforward subject to expiration available to offset taxable income 9.6 Domestic Tax Authority | Available Through Fiscal Year 2038 And Expires By June 30, 2038 | UNITED STATES Â Operating Loss Carryforwards [Line Items] Â Operating loss carryforward subject to expiration available to offset taxable income 11.7 Domestic Tax Authority | Not Subject To Expiry And Available For Use Over 2038 And Thereafter Years | UNITED STATES Â Operating Loss Carryforwards [Line Items] Â Operating loss carryforward, not subject to expiration, available for use to reduce future taxable income 13.2 Operating loss carryforward per year not subject to expiration, available for use to reduce future taxable income $ 1.2 X - DefinitionAmount of operating loss carryforward, not subject to expiration, available to reduce future taxable income under enacted tax laws. + ReferencesNo definition available. + Details Name: rzlt_OperatingLossCarryforwardsAmountNotSubjectToExpiration Namespace Prefix: rzlt_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of operating loss carryforward, not subject to expiration, available for use to reduce future taxable income under enacted tax laws. + ReferencesNo definition available. + Details Name: rzlt_OperatingLossCarryforwardsAmountNotSubjectToExpirationAvailableForUse Namespace Prefix: rzlt_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of operating loss carryforward not subject to expiration available to offset taxable income. + ReferencesNo definition available. + Details Name: rzlt_OperatingLossCarryforwardsAmountNotSubjectToExpirationAvailableToOffsetTaxableIncome Namespace Prefix: rzlt_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of operating loss carryforward per year not subject to expiration, available for use to reduce future taxable income under enacted tax laws. + ReferencesNo definition available. + Details Name: rzlt_OperatingLossCarryforwardsAmountPerYearNotSubjectToExpirationAvailableForUse Namespace Prefix: rzlt_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of operating loss carryforward subject to expiration available to offset taxable income. + ReferencesNo definition available. + Details Name: rzlt_OperatingLossCarryforwardsAmountSubjectToExpirationAvailableToOffsetTaxableIncome Namespace Prefix: rzlt_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of the operating loss carryforwards available to reduce future taxable income no limitation on use. + ReferencesNo definition available. + Details Name: rzlt_OperatingLossCarryforwardsNoLimitationsOnUse Namespace Prefix: rzlt_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of the limitations under IRC section 382 on the use of all operating loss carryforwards available to reduce future taxable income. + ReferencesNo definition available. + Details Name: rzlt_OperatingLossCarryforwardsSubjectToLimitationsOnUse Namespace Prefix: rzlt_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3 + Details Name: us-gaap_OperatingLossCarryforwards Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. +

ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3 + Details Name: us-gaap_OperatingLossCarryforwardsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in the valuation allowance for a specified deferred tax asset. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2 + Details Name: us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=country_US Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=rzlt_ExpirationIn2031Through2035Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=rzlt_AvailableThroughFiscalYear2038AndExpiresByJune302038Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=rzlt_NotSubjectToExpiryAndAvailableForUseOver2038AndThereafterYearsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 75 R58.htm IDEA: XBRL DOCUMENT v3.24.3 INCOME TAXES - Income Tax Expense (Details) - USD ($) $ in Thousands 12 Months Ended Jun. 30, 2024 Jun. 30, 2023 Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract] Â Â Income tax benefit at statutory U.S. federal rate $ 14,374 $ 10,875 Income tax benefit attributable to U.S. states 4,413 3,468 Impact of reduction in Colorado tax rate Â (78) Non-taxable derivative loss (598) 0 Non-deductible expenses (505) (442) Stock option expirations (16) (921) NOL expirations (7,004) 0 Other 4 (399) Change in valuation allowance (10,668) (12,503) Total income tax expense $ 0 $ 0 X - DefinitionAmount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to non-taxable derivative gains (losses). + ReferencesNo definition available. + Details Name: rzlt_EffectiveIncomeTaxRateReconciliationNonTaxableDerivativeGainsLossesAmount Namespace Prefix: rzlt_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to stock option expiration. + ReferencesNo definition available. + Details Name: rzlt_EffectiveIncomeTaxRateReconciliationStockOptionExpirations Namespace Prefix: rzlt_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to net operating loss expirations. + ReferencesNo definition available. + Details Name: rzlt_IncomeTaxReconciliationNetOperatingLossExpirations Namespace Prefix: rzlt_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.7) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph (a) -SubTopic 20 -Topic 740 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_IncomeTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12A -Subparagraph (a)(6) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12AReference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12 + Details Name: us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12A -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12AReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482525/740-10-45-15 + Details Name: us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231 + Details Name: us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12A -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12AReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12A -Subparagraph (a)(7) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12AReference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12 + Details Name: us-gaap_IncomeTaxReconciliationNondeductibleExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12 + Details Name: us-gaap_IncomeTaxReconciliationOtherAdjustments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12AReference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12 + Details Name: us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 76 R59.htm IDEA: XBRL DOCUMENT v3.24.3 INCOME TAXES - Deferred Income Tax Assets and Liabilities (Details) - USD ($) $ in Thousands Jun. 30, 2024 Jun. 30, 2023 Deferred income tax assets: Â Â Net operating loss carryforwards $ 38,942 $ 40,537 Research and experimental costs 19,213 9,454 Intangible assets 6,487 5,595 Share-based compensation 4,280 2,884 Operating lease liabilities 624 694 Accrued expenses and other 763 603 Total deferred income tax assets 70,309 59,767 Valuation allowance for deferred income tax assets (69,783) (59,192) Deferred income tax assets, net of valuation allowance 526 575 Deferred tax liabilities Â Â Deferred income tax liability right-of-use assets (526) (575) Net deferred income tax assets $ 0 $ 0 X - DefinitionAmount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from operating lease liability. + ReferencesNo definition available. + Details Name: rzlt_DeferredTaxAssetsOperatingLeaseLiabilities Namespace Prefix: rzlt_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of deferred tax liability attributable to taxable right of use asset. + ReferencesNo definition available. + Details Name: rzlt_DeferredTaxLiabilitiesRightOfUseAssets Namespace Prefix: rzlt_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6 + Details Name: us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2 + Details Name: us-gaap_DeferredTaxAssetsGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6 + Details Name: us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2 + Details Name: us-gaap_DeferredTaxAssetsLiabilitiesNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2 + Details Name: us-gaap_DeferredTaxAssetsNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_DeferredTaxAssetsNetAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6 + Details Name: us-gaap_DeferredTaxAssetsOperatingLossCarryforwards Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6 + Details Name: us-gaap_DeferredTaxAssetsOther Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6 + Details Name: us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2 + Details Name: us-gaap_DeferredTaxAssetsValuationAllowance Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_DeferredTaxLiabilitiesNetAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 77 R60.htm IDEA: XBRL DOCUMENT v3.24.3 COMMITMENTS AND CONTINGENCIES (Details) $

in Millions 12 Months Ended Jun. 30, 2024 USD ($) employee Jun. 30, 2023 USD ($) COMMITMENTS AND CONTINGENCIES Â Â Employer matching contributions (as a percent) 4.00% Â Total contributions by the company | $ $ 0.4 $ 0.3 Employment Agreements Â Â COMMITMENTS AND CONTINGENCIES Â Â Number of officers | employee 2 Â Number of employees | employee 1 Â Aggregate annual base salaries | $ $ 1.4 Â Employment Agreements | Chief Executive Officer And Chief Medical Officer | Minimum Â Â COMMITMENTS AND CONTINGENCIES Â Â Vesting period, change in control event 12 months Â Exercisable period, change in control event and without cause 6 months Â Exercisable period, change in control event 6 months Â Employment Agreements | Chief Executive Officer And Chief Medical Officer | Maximum Â Â COMMITMENTS AND CONTINGENCIES Â Â Vesting period, change in control event 18 months Â Exercisable period, change in control event and without cause 12 months Â Exercisable period, change in control event 12 months Â Employment Agreements | Chief Medical Officer Â Â COMMITMENTS AND CONTINGENCIES Â Â Severance payment based on term of salary 12 months Â Term of health insurance coverage other than change in control event 12 months Â Unvested stock options, vesting period, change in control event 12 months Â Unvested stock options, exercisable period, change in control event 6 months Â Severance payment based on term of salary, change of control event 18 months Â Term of health insurance coverage, change in control 18 months Â X - DefinitionRepresents the aggregate annual base salaries. + ReferencesNo definition available. + Details Name: rzlt_AggregateAnnualBaseSalaries Namespace Prefix: rzlt_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThe line items identify information about the commitments and contingencies. + ReferencesNo definition available. + Details Name: rzlt_CommitmentsAndContingenciesLineItems Namespace Prefix: rzlt_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTerm of health insurance coverage other than change in control event under employment agreement. + ReferencesNo definition available. + Details Name: rzlt_EmploymentAgreementHealthInsuranceCoverageTermOtherThanChangeInControlEvent Namespace Prefix: rzlt_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionTerm of salary for calculation of severance payment other than change in control event under employment agreement. + ReferencesNo definition available. + Details Name: rzlt_EmploymentAgreementSeverancePaymentBasedOnTermOfSalaryOtherThanChangeInControlEvent Namespace Prefix: rzlt_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionPeriod during which stock options will remain exercisable if either of individuals is terminated outside of a change in control event, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesNo definition available. + Details Name: rzlt_EmploymentAgreementTerminationExercisablePeriodChangeInControlEvent Namespace Prefix: rzlt_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionPeriod during which stock options will remain exercisable if either of individuals is terminated outside of a change in control event and without cause, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesNo definition available. + Details Name: rzlt_EmploymentAgreementTerminationExercisablePeriodChangeInControlEventAndWithoutCause Namespace Prefix: rzlt_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionTerm of salary for calculation of severance payment on termination of employment agreement due to change of control event. + ReferencesNo definition available. + Details Name: rzlt_EmploymentAgreementTerminationSeverancePaymentBasedOnTermOfSalaryChangeOfControlEvent Namespace Prefix: rzlt_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionTerm of health insurance coverage following termination of employment agreement due to change of control event. + ReferencesNo definition available. + Details Name: rzlt_EmploymentAgreementTerminationTermOfHealthInsuranceCoverageDueToChangeOfControlEvent Namespace Prefix: rzlt_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionPeriod during which unvested stock options will remain exercisable if either of individuals is terminated outside of a change in control event, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesNo definition available. + Details Name: rzlt_EmploymentAgreementTerminationUnvestedStockOptionsExercisablePeriodChangeInControlEvent Namespace Prefix: rzlt_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionPeriod during which unvested stock options will immediately vest if either of individuals is terminated outside of a change in control event, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesNo definition available. + Details Name: rzlt_EmploymentAgreementTerminationUnvestedStockOptionsVestingPeriodChangeInControlEvent Namespace Prefix: rzlt_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionPeriod during which stock options will immediately vest if either of individuals is terminated outside of a change in control event and without cause, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesNo definition available. + Details Name: rzlt_EmploymentAgreementTerminationVestingPeriodChangeInControlEventAndWithoutCause Namespace Prefix: rzlt_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionRepresents information pertaining to number of employees. + ReferencesNo definition available. + Details Name: rzlt_NumberOfEmployees Namespace Prefix: rzlt_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionRepresents information pertaining to number of officers. + ReferencesNo definition available. + Details Name: rzlt_NumberOfOfficers Namespace Prefix: rzlt_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionAmount of discretionary contributions made by an employer to a defined contribution plan. + ReferencesNo definition available. + Details Name: us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPercentage employer matches of the employee's percentage contribution matched. + ReferencesNo definition available. + Details Name: us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_OtherCommitmentsAxis=rzlt_EmploymentAgreementsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_TitleOfIndividualAxis=rzlt_ChiefExecutiveOfficerAndChiefMedicalOfficerMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_TitleOfIndividualAxis=rzlt_ChiefMedicalOfficerMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 78 R61.htm IDEA: XBRL DOCUMENT v3.24.3 RELATED PARTY TRANSACTIONS (Details) - Related Party - Handok License Agreement - Handok, Inc. - USD ($) $ in Thousands 12 Months Ended Sep. 15, 2020 Jun. 30, 2024 Related Party Transaction [Line Items] Â Â License term (in years) 20 years Â Milestone payments $ 500 Â Transfer price (in percent) 70.00% Â Milestone payments earned Â $ 0 X - DefinitionThe amount of milestone payments to be incurred for the approval of license. + ReferencesNo definition available. + Details Name: rzlt_PharmaceuticalLicenseAgreementMilestonePayment Namespace Prefix: rzlt_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe amount of milestone payments earned by the entity. + ReferencesNo definition available. + Details Name: rzlt_PharmaceuticalLicenseAgreementMilestonePaymentEarned Namespace Prefix: rzlt_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionTerm of pharmaceutical license agreement in years. + ReferencesNo definition available. + Details Name: rzlt_PharmaceuticalLicenseAgreementTerm Namespace Prefix: rzlt_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionThe percentage of transfer price on sale of products. + ReferencesNo definition available. + Details Name: rzlt_PharmaceuticalLicenseAgreementTransferPrice Namespace Prefix: rzlt_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)(2)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)(2)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(g)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 + Details Name: us-gaap_RelatedPartyTransactionLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionAxis=rzlt_HandokLicenseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=rzlt_HandokInc.Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 79 R62.htm IDEA: XBRL DOCUMENT v3.24.3 SUPPLEMENTAL FINANCIAL INFORMATION - Cash and Cash Equivalents (Details) - USD ($) $ in Thousands Jun. 30, 2024 Jun. 30, 2023 SUPPLEMENTAL FINANCIAL INFORMATION Â Â Cash and cash equivalents $ 70,396 $ 16,036 Money market funds Â Â SUPPLEMENTAL FINANCIAL INFORMATION Â Â Cash and cash equivalents 61,249 5,464 Demand deposits at a single financial institution Â Â SUPPLEMENTAL FINANCIAL INFORMATION Â Â Cash and cash equivalents $ 9,147 6,091 Commercial paper Â Â SUPPLEMENTAL FINANCIAL INFORMATION Â Â Cash and cash equivalents Â $ 4,481 X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_CashAndCashEquivalentsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_CashAndCashEquivalentsAxis=us-gaap_DemandDepositsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 80 R63.htm IDEA: XBRL DOCUMENT v3.24.3 SUPPLEMENTAL FINANCIAL INFORMATION - Property and Equipment (Details) - USD ($) 12 Months Ended Jun. 30, 2024 Jun. 30, 2023 SUPPLEMENTAL FINANCIAL INFORMATION Â Â Office furniture and equipment $ 210,000 $ 210,000 Less accumulated depreciation (107,000) (71,000) Total 103,000 139,000 Depreciation expense related to property and equipment $ 36,000 $ 30,000 X - DefinitionAmount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_Depreciation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(13)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_SupplementalCashFlowInformationAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 81 R64.htm IDEA: XBRL DOCUMENT v3.24.3 NET LOSS PER SHARE - Schedule of basic and diluted net loss per share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands 12 Months Ended Jun. 30, 2024 Jun. 30, 2023 Calculation of Numerators: Â Â Net loss for calculation of basic net loss per share $ (68,459) $ (51,787) Net loss for the calculation of diluted net loss per share $ (68,459) $ (51,787) Calculation of Denominators: Â Â Weighted average shares for basic net loss per share 51,465 51,187 Weighted average shares for diluted net loss per share 51,465 51,187 Net loss per share of common stock - basic (in dollars per share) $ (1.33) $ (1.01) Net loss per share of common stock - diluted (in dollars per share) $ (1.33) $ (1.01) 2021 PFWs Â Â Calculation of Denominators: Â Â Weighted average shares for basic net loss per share 1,195 1,661 2022 PFWs Â Â Calculation of Denominators: Â Â Weighted average shares for basic net loss per share 10,245 12,921 Exchange PFWs Â Â Calculation of Denominators: Â Â Weighted average shares for basic net loss per share 393 Â 2024 PFWs Â Â Calculation of Denominators: Â Â Weighted average shares for basic net loss per share 133 Â Common Stock Â Â Calculation of Denominators: Â Â Weighted average shares for basic net loss per share 39,499 36,605 X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3:

http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAmount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SAB Topic 6.B) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B + Details Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SAB Topic 6.B) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 40 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 40 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 40 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 40 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40 + Details Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=rzlt_PreFundedWarrants2021Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=rzlt_PreFundedWarrants2022Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=rzlt_ExchangePreFundedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=rzlt_PreFundedWarrants2024Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 82 R65.htm IDEA: XBRL DOCUMENT v3.24.3 NET LOSS PER SHARE - Anti-dilutive (Details) - shares shares in Thousands 12 Months Ended Jun. 30, 2024 Jun. 30, 2023 NET LOSS PER SHARE Â Â Total 11,752 9,633 Employee Stock Option Â Â NET LOSS PER SHARE Â Â Total 10,891 8,745 Legacy warrants Â Â NET LOSS PER SHARE Â Â Total 861 888 X - DefinitionSecurities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=rzlt_LegacyWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 83 R66.htm IDEA: XBRL DOCUMENT v3.24.3 FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS - Fair Value on a Recurring Basis (Details) - USD ($) $ in Thousands Jun. 30, 2024 Jun. 30, 2023 FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS Â Â Marketable debt securities $ 56,741 $ 102,330 Recurring Â Â FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS Â Â Financial assets measured at fair value 117,990 112,274 Recurring | Money market funds Â Â FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS Â Â Cash and cash equivalents 61,249 5,464 Recurring | Corporate commercial paper Â Â FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS Â Â Cash and cash equivalents Â 4,481 Marketable debt securities 20,929 41,597 Recurring | U.S. Government agencies Â Â FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS Â Â Marketable debt securities 1,997 26,394 Recurring | U.S. Government treasuries Â Â FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS Â Â Marketable debt securities 2,720 10,404 Recurring | Corporate notes and bonds Â Â FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS Â Â Marketable debt securities 30,832 19,240 Recurring | Asset-backed securities Â Â FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS Â Â Marketable debt securities 263 4,694 Recurring | Level 1 Â Â FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS Â Â Financial assets measured at fair value 61,249 20,349 Recurring | Level 1 | Money market funds Â Â FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS Â Â Cash and cash equivalents 61,249 5,464 Recurring | Level 1 |

Corporate commercial paper Â Â FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS Â Â Cash and cash equivalents Â 4,481 Recurring | Level 1 | U.S. Government treasuries Â Â FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS Â Â Marketable debt securities Â 10,404 Recurring | Level 2 Â Â FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS Â Â Financial assets measured at fair value 56,741 91,925 Recurring | Level 2 | Corporate commercial paper Â Â FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS Â Â Marketable debt securities 20,929 41,597 Recurring | Level 2 | U.S. Government agencies Â Â FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS Â Â Marketable debt securities 1,997 26,394 Recurring | Level 2 | U.S. Government treasuries Â Â FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS Â Â Marketable debt securities 2,720 Â Recurring | Level 2 | Corporate notes and bonds Â Â FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS Â Â Marketable debt securities 30,832 19,240 Recurring | Level 2 | Asset-backed securities Â Â FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS Â Â Marketable debt securities $ 263 $ 4,694 X - DefinitionFair value portion of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_AssetsFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_CashAndCashEquivalentsFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3 + Details Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of investment in marketable security. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_MarketableSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 84 R67.htm IDEA: XBRL DOCUMENT v3.24.3 FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS - Valuation Model Inputs of Exchange PFWs (Details) - Exchange Pre-Funded Warrants May 13, 2024 $ / shares Y Mar. 08, 2024 Y $ / shares Exercise price Â Â FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS Â Â Warrants and rights outstanding, measurement input 0.001 0.001 Market price of common stock Â Â FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS Â Â Warrants and rights outstanding, measurement input 2.85 1.90 Risk-free interest rate Â Â FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS Â Â Warrants and rights outstanding, measurement input 0.055 0.055 Expected term Â Â FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS Â Â Warrants and rights outstanding, measurement input | Y 1 1 Historical volatility Â Â FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS Â Â Warrants and rights outstanding, measurement input 1 1 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionValue of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_WarrantsAndRightsOutstandingMeasurementInput Namespace Prefix: us-gaap_ Data Type: xbrli:decimalItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=rzlt_ExchangePreFundedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 85 R68.htm IDEA: XBRL DOCUMENT v3.24.3 FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS - Summary of Changes in the Fair Value (Details) - USD ($) $ in Thousands 12 Months Ended Jun. 30, 2024 Jun. 30, 2023 Warrant Â Â Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Â Â Warrant liability incurred on March 8, 2024 $ 5,697 Â Changes in fair value 2,850 Â Reclassification of warrant derivative liability to equity on May 13, 2024 (8,547) Â Embedded Â Â Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Â Â Balance at the beginning 412 $ 407 Changes in fair value 56 5 Balance at the end $ 468 $ 412 X - DefinitionAmount of reclassification of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing. + ReferencesNo definition available. + Details Name: rzlt_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassificationToEquity Namespace Prefix: rzlt_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionFair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_FairValueByLiabilityClassAxis=rzlt_WarrantsDerivativeFinancialInstrumentsLiabilitiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByLiabilityClassAxis=rzlt_EmbeddedDerivativeDerivativeFinancialInstrumentsLiabilitiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 86 R69.htm IDEA: XBRL DOCUMENT v3.24.3 FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS - Significant Concentrations (Details) - USD ($) $ in Thousands 12 Months Ended Jun. 30, 2024 Jun. 30, 2023 FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS Â Â Concentration risk, credit risk, uninsured deposits Financial instruments that subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents and investments in marketable debt securities. The Company maintains its cash in demand accounts at a high-quality financial institution. As of and for the fiscal years ended June 30, 2024 and 2023, cash deposits have exceeded the amount of insurance provided on such deposits by the Federal Deposit Insurance Corporation. Â Marketable debt securities $ 56,741 $ 102,330 Banking and Financial Services Industries Â Â FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS Â Â Marketable debt securities $ 26,600 54,000 U.S. government Â Â FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS Â Â Marketable debt securities Â $ 26,500 X - DefinitionDescription of credit risk that arises from having significant balances in excess of the Federal Deposit Insurance Corporation or other insurance limits on deposits in financial institutions. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20 + Details Name: us-gaap_ConcentrationRiskCreditRiskUninsuredDeposits Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of investment in marketable security. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_MarketableSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_EquitySecuritiesByIndustryAxis=us-gaap_FinancialServicesSectorMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_EquitySecuritiesByIndustryAxis=us-gaap_GovernmentSectorMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 87 R70.htm IDEA:

XBRL DOCUMENT v3.24.3 SUBSEQUENT EVENTS (Details) - USD ($) 1 Months Ended 12 Months Ended Sep. 10, 2024 Jun. 25, 2024 Jul. 31, 2024 Jun. 30, 2024 Jun. 30, 2023 Sep. 15, 2024 Sep. 14, 2024 Subsequent Event [Line Items] Â Â Â Â Â Â Â Investment in marketable securities Â Â Â $ 66,401,000 $ 107,311,000 Â Â Employment Agreements Â Â Â Â Â Â Â Subsequent Event [Line Items] Â Â Â Â Â Â Â Aggregate Annual Base Salaries Â Â Â $ 1,400,000 Â Â Â Employment Agreements | Chief Medical Officer Â Â Â Â Â Â Â Subsequent Event [Line Items] Â Â Â Â Â Â Â Severance payment based on term of salary Â Â Â 12 months Â Â Â Term of health insurance coverage other than change in control event Â Â Â 12 months Â Â Â Unvested stock options, vesting period, change in control event Â Â Â 12 months Â Â Â Unvested stock options, exercisable period, change in control event Â Â Â 6 months Â Â Â Severance payment based on term of salary, change of control event Â Â Â 18 months Â Â Â Term of health insurance coverage, change in control Â Â Â 18 months Â Â Â Private Placement Â Â Â Â Â Â Â Subsequent Event [Line Items] Â Â Â Â Â Â Â Proceeds from issuance of equity securities (in shares) Â 1,500,000 Â Â Â Â Â Shares issue price Â $ 4.00 Â Â Â Â Â Proceeds from issuance of common stock Â $ 6,000,000.0 Â Â Â Â Â Subsequent Event Â Â Â Â Â Â Â Subsequent Event [Line Items] Â Â Â Â Â Â Â Investment in marketable securities Â Â $ 59,700,000 Â Â Â Subsequent Event | Exchange Pre-Funded Warrants Â Â Â Â Â Â Â Subsequent Event [Line Items] Â Â Â Â Â Â Â Warrants exercised Â Â 610,404 Â Â Â Â Exercise of pre-funded warrants (in shares) Â Â 610,273 Â Â Â Â Subsequent Event | Employment Agreements | Chief Executive Officer Â Â Â Â Â Â Â Subsequent Event [Line Items] Â Â Â Â Â Â Â Aggregate Annual Base Salaries Â Â Â Â Â $ 625,000 $ 557,000 Subsequent Event | Employment Agreements | Chief Financial Officer Â Â Â Â Â Â Â Subsequent Event [Line Items] Â Â Â Â Â Â Â Aggregate Annual Base Salaries $ 460,000 Â Â Â Â Â Â Percentage of calendar year target bonus payable 40.00% Â Â Â Â Â Â Severance payment based on term of salary 12 months Â Â Â Â Â Â Term of health insurance coverage other than change in control event 12 months Â Â Â Â Â Â Unvested stock options, vesting period, change in control event 12 months Â Â Â Â Â Â Unvested stock options, exercisable period, change in control event 6 months Â Â Â Â Â Â Severance payment based on term of salary, change of control event 18 months Â Â Â Â Â Â Term of health insurance coverage, change in control 18 months Â Â Â Â Â Â Subsequent Event | Private Placement Â Â Â Â Â Â Â Subsequent Event [Line Items] Â Â Â Â Â Â Â Proceeds from issuance of equity securities (in shares) Â 1,500,000 Â Â Â Proceeds From Issuance Of Common Stock, Net Of Underwriting Discounts And Commissions Â Â $ 6,000,000.0 Â Â Â Â X - DefinitionRepresents the aggregate annual base salaries. + ReferencesNo definition available. + Details Name: rzlt_AggregateAnnualBaseSalaries Namespace Prefix: rzlt_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionNumber of warrants or rights exercised. + ReferencesNo definition available. + Details Name: rzlt_ClassOfWarrantOrRightExercised Namespace Prefix: rzlt_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTerm of health insurance coverage other than change in control event under employment agreement. + ReferencesNo definition available. + Details Name: rzlt_EmploymentAgreementHealthInsuranceCoverageTermOtherThanChangeInControlEvent Namespace Prefix: rzlt_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionTerm of salary for calculation of severance payment other than change in control event under employment agreement. + ReferencesNo definition available. + Details Name: rzlt_EmploymentAgreementSeverancePaymentBasedOnTermOfSalaryOtherThanChangeInControlEvent Namespace Prefix: rzlt_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionTerm of salary for calculation of severance payment on termination of employment agreement due to change of control event. + ReferencesNo definition available. + Details Name: rzlt_EmploymentAgreementTerminationSeverancePaymentBasedOnTermOfSalaryChangeOfControlEvent Namespace Prefix: rzlt_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionTerm of health insurance coverage following termination of employment agreement due to change of control event. + ReferencesNo definition available. + Details Name: rzlt_EmploymentAgreementTerminationTermOfHealthInsuranceCoverageDueToChangeOfControlEvent Namespace Prefix: rzlt_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionPeriod during which unvested stock options will remain exercisable if either of individuals is terminated outside of a change in control event, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesNo definition available. + Details Name: rzlt_EmploymentAgreementTerminationUnvestedStockOptionsExercisablePeriodChangeInControlEvent Namespace Prefix: rzlt_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionPeriod during which unvested stock options will immediately vest if either of individuals is terminated outside of a change in control event, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesNo definition available. + Details Name: rzlt_EmploymentAgreementTerminationUnvestedStockOptionsVestingPeriodChangeInControlEvent Namespace Prefix: rzlt_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionPercentage of calendar year target bonus payable by the company. + ReferencesNo definition available. + Details Name: rzlt_PercentageOfCalendarYearTargetBonus Namespace Prefix: rzlt_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe cash inflow from the additional capital contribution to the entity net of underwriting discounts, commissions and other fees. + ReferencesNo definition available. + Details Name: rzlt_ProceedsFromIssuanceOfCommonStockNetOfUnderwritingDiscountsAndCommissions Namespace Prefix: rzlt_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNumber of shares issued upon exercise of pre-funded warrants. + ReferencesNo definition available. + Details Name: rzlt_StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants Namespace Prefix: rzlt_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash outflow for purchase of marketable security. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11 + Details Name: us-gaap_PaymentsToAcquireMarketableSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow from the additional capital contribution to the entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPer share or per unit amount of equity securities issued. + ReferencesNo definition available. + Details Name: us-gaap_SharesIssuedPricePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionDetail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2 + Details Name: us-gaap_SubsequentEventLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_OtherCommitmentsAxis=rzlt_EmploymentAgreementsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_TitleOfIndividualAxis=rzlt_ChiefMedicalOfficerMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=rzlt_ExchangePreFundedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember Namespace Prefix: Data Type: na Balance Type: Period Type: EXCEL 88 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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{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»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v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

*PG!UAVB7*U96:,]'Q;,F^_.KR[9J M$*'S>@4ZC1B)UJ# Z1Z1T:AL(JAW9V%D?BXNUUZ+CDZ('RG75K/OJGU!S.X MEIW 0GDN;Q5OV!&V'_>!^-"5G&\EVYAE*C62K"FDF]/1HQH'"0BDQO?U L' M4*]*KA"RT*U:9#M&Z%]A8&\?L-_$!)D%?6PS.IE%XNIG8HV:%@N 61B]@EH. M6B4W(E4N8%@11B.8&:]DLL XGMEVDF'7O;K56K#>VGF856TVH(LE?<_:-R' MG1Z)-TR$].RIZ-Y*=Z."7!@E7JI%Z-;^FU['=]'501O]-S54A3Z_TQA<%#8^ MV?]]=-*
@V.A6Z]#FW$#]08=U*PY8I3EL6TWU$Q3VBC!UC@,N9AC;OH<V7N5P"Q%IONZ/N%R3O>/[KKY^]45\D^>#(@:9)FV@M/#O1TLTG4+X>
(ZIF1AI(T%L%W&03Q758@!F23=T_C"2I>1 MXI=H?P021R&2ZMEEV&G;3IJVT. ^)9^F<'AN.#SVXC+7:BE> MZ1+N:6G$^^4247, QH4TL/9]BL"S+LL8>FHN%EVC733SR#OBDQ EK:D!%O%%: MF71BH_ G2+?",;2P9'*"F& MX9A))"W%B.HP7JM;#A,*GR* S0!7>S44S_1SU.|-_, 6Q[D%7<321WO 'AH#
MLVX19UVH[W@]Y%G$_H:>EHUCVQHGY%MXE&ZBG"$##R)4T2((N?1WMI98LK^*, M<&]J:0WN3CSS[-3U3 .^!.75W+&(0SS";$4;/2Y=B[]0#>0#K0NR%)F[7GBX M1T'96J1A1=NL0^]=FS& #;VBT!'=HE"9CCS3-!13!.$B2+Y&_.7AL+A3Q*] M$7+\X,=^,P;B2R&S3-.GH:@K&UNS&8N:YI0]06\-H?'ICZX93OUT:=4 MW3]Y?ZY0CCJ%\O_5R-
%/QZHEH4=9X2?(1I&ULK53O M;]HP$/U7K*R:6FDEOX&Q)%*!3>NT3JBLVV>3', 1J8F>V0]K_?K83,EH%-$W[M0NSSO7?O'?
9%#>./(@>0Z*DLJ(BM7,IJ9MLBS:'$8L0JH.IDRWB)I=KRG2TJ M#C@SH+*P/<<9VR4FUHBUOQ)&*U+ B%%4>B+DO,G^=0L":V7.L0N">[7.J MG405WL$:Y$.UXFIGJRP9*8$*PBCBL(VM&W>V"'2^2?A!H!%:Z2=;!A[U)O; M++8<+0@*2*5FP.JSPA44A292,GYUG%9?4>^/.UP?V3\:[\K+! A:L^$DRF*\!P0F
WP%\8[159FPML<1)Q%F#N,Y6;'IA>F/0R@VA^E]<2ZY.B<+) M9(6?T5Z@%7!S(V@*;E6C!18X7# A: M_#WR%\Z!W'IQC3[ZI67-+4U8"NOS*A+@:!N'[R-X?^QA(M"]W)=-
*GM0KMHPM? M^9.2!0RFHJVQO41_M1V*OX7(V@=F+\H6GGUQWT M.T(%*F'K*)W11(GB[4QH-Y)5YEEMF%2/U"QS-4:!ZP1UOF5,'C:Z0#^8D]]0 M2P,$% @ X((S61#"[$!$ @
B@8 !D !X;"]W;W)&M$Q=;YLP%$#_BL6D/;6!0#ZV#)"2;M-2J5.4=MNS>8KD]@U=C, M-DG[[V<;PK(IH5)>P#;W'1]XQ"4^"/FL2@"-7ZBK&5>*56M<+WU=9"156(U$# M-
T]R(2NLS506OJHE8.*2*N:'03#S*TRYE\9N;2/36#2:40X;B51355B^KH") M0^*-O>/"EA:EM@M^&M>X@$?0/^J--#._IQ!: 5=4<"0A3[SE>+&:VW@7\)/"
M09V,D:UD)\2SG:Q)X@56"!ADVA*PN>WA#ABS(*/QNV-Z_98V\71\I']UM9M: M=EC!G6"_*-%EXGWP$($<-TQOQ>$;=/5,+2\33+DK.K2QT47O'+]TYG"08SOFLL(G7>
[D;/\C#:5.8RD.2-1H0[,#5ZK+-G*4VY?RJ*5Y M2DV>3M?F> E(]"0QH;Q 2RDQ+! - WR$HN &A4SX&>!%?;F1XT47>.?+4"IFT[Z-)^_Z@+?KH&(^]J]8D;*/
M6;.O6X%E0XQ1I.|>1T'VC?A 6L-VBC6P)3T"7\'!G1C/JU9%@7U6U_QU4FI MXX:>|_UJ+?Z &5+,YPCCF&)G5?BC;R5^[QU95>5[0(;X(NA"K"$.9:!_ :<" M): _+4,W2 INL(2'MBU+
EDH^#W(FQBG6WA!&PTCC;>M"Y(&>U\;S>K$QJIP MMF$)$3/&5S-MV:]P$_*8$R)?%%CYOFA;OLQM4?=>J02ILFD$)##U2+(0$_O@ MVK179P0L5S$!+$^3(N!LD0<.ZM@3:$2 4
MIF5YTW?@C<0'^\W@(PQK9"0*=A@1&MN"S9_M+&\!:S!M"[NO4 G<8]D M$WL6D.K">@0&]]J"(G"0"$J83^B2[QQ/(4A9MKT>(N2AVD<+<7HA=8AML]Z^ *(
0E1W4O$BQ#7"5Q[A_'J[!![M?HCL^>%PO%&X)5^#__$*^@*!)=$<8] W+L6P?FD62]9H?%X-4 >[MFH_JT7 B-P+_$<]$*7U??>%JDY#+T(+& ^&2^!I\#H/'-
=0$9W:/E9"AZ2H=.3E!T\ M.HYF_@ZN/9[C^N(-82R">TPR!WVK3K;6WDM<8 MDY47MF@9TK^$%V%O/*%HU;$]6V+TO)($ @';#+BJH&##FZ)TE%=\-*_PQ.17 JZ
M9:3$B]%]/#A>PF^&&$@11GKNBC9%)(>9<1=M (4<0$UP'I>#XP.*@2CWW3! M51#_[]=B$N3LXX@FOSU9"1[+XC.\<<*P]1&^3J8P2T23-6O=H,Q8!NE]L)* M-
$(T3KOWV4.^P=/> IU)9LEY84A/(T6;(=I^\%-.#YG;#$RV%B89&!("ELY M.EX"61\3&O/X40+M=5:VU<-U)EL<=B-6M[;-(M\&GIH/E)&7DD5D%D$@ M\2PD/MLKXTN2|
(C$,XPPTW,Y&G!"N=157V/K:#.K8@?TQ^16R,22M._JQ0$2 M4Z 7O-0Q5CEV\!?Y@ WPA!:+=._!/B5V4])F$,+X#)F2XES19:AS]BXIEX9S
M!;O$F+BT0$%_[%DNQD%TL42HR59R,%^346Y3*7]-0& M. 7$G)ARRXLJB45 + C9.: "N+3F3\DD:57!C&.Q(:>3;T+. H6H*#ZVC$Y M$1@>X-
G*)YS9UM]YW"P2XH\NPZ;P%%MIDBQA5 '#$X#L9PXNGLT8I'FAQ?0/ M9@^N6 M=]F5QYVH1X@\PR'(;@&L=A+Q$)'$D,G?/FS="C\-&2G"PCL4FU"%-[!8DV4&
M2SC!*6$*1>D4FA3> AZ'F(?36U#"0;0,D?^JG80]GKOBS*C685,6 S9++'+* M6PVL]S!+E >=6%$T]W.1:A;%N9YJ(YGTA##"PG0Y\) Q 5_]2Q79#369D^QR M%#=R%A\T41JU]
<%&)O24K[PMX8RDCB+&%&IL8DHC##)._[&LD$'KRCO4>); M<1M[N!61/:Y$R-[S*%.[J,!D8 @SI4@>;)#,12+1L!:Q]#E)"8YJ;8)\"<>)
MI)W;D)&2%RD@F:I#N#FKJI\>Q,U7E#%#./3*YZKY')ST'@7*WIJ8"E_I_"M1 M')^#(8+!_I&?9*]55+\9!!!R+]I20B5?NV.ZIOPIFR\WLC6KJ)[KMO6P.>,K^!@OY=5 A%1.)IE
MD45_>EZLAJEJ]0J&T\:[2"F44\@0SD,,/DL,/CO(DS=411Z/>KYDXL"@1VOJ M0O:K;4D9/!#R;"P VJ@R7L3Z6R7!KBH6"/^">FA6'A9Z.PV5>3(MLB^#VU!@ M %U;]JIV?DSQ<:@'7;__&
(NR62+1#A<;)!8]BU*^9C^6@3Q@@R]=6 YL*(=2 MW^<",D D:ZF]#9VUEU!0UJSZE5\["5\7/.B*,K5,OSQ(X>%#SYM*;'W($!NJ MAM-+3204#CI4DC1ZG3@G^B?+HW?%BW)3-
=4A@|^ M]ROX#K#<4':<':_/B2/VD81>L@&!-6RI]!T%RT[.Z(\U5:QQP9AL(67BQA:X MG$D]]!8G%^1D=/WI3M6>>\NP"KDD4 M(AN+[WEHEWZ*1UC6%#,K99E"74%W?I
MM3OHLD<(_M.&-FF.HZ!XT#?$*(,*< IF,&05"Y_U_4'[EYJB3@|V*,G?.\ M@Z64(!O]47OX+0NIP<HA4V[ )|'Y/,/)6: M\52]+1BFL)D45TB@)V8+Z'3L%*%A%.T>=F.I$>ST<
_7=>Z]7V;> ^X(P]"@[M_YL%U?4^M) P^^AE*> %Y3A?YNDIW5Y@2DAY=27)>F^/*9?+VK5]W2M)2F M:Z.3H8:HA1A4?X1)R$NP'8C[L,OTO1JQGP#B11G TAM>ZMI B-
,V/G;Z#*%8" MS*921@I[-K!B!SF(=+#MHL"[LAGKCC8 M&E[3F9UT5889)S%ZCF'1:Z+ ^C(;HB_0^&=R%(=,R?FFO'-C*) AAVC!0C MATD'I3^U>)T>;LZZX=KL"Q8 (AVD:&^;USRW6
MO?)UAT0C_*W-K2 G?2?1L,1FXV.W*/XQ0AN'AQ\S8& M%S*5"FDES5W9R@MCA&BR[>#@P^M&'"ZQQ(P*\S,,YE;@H&MQB/2'1=GB MI-D0LA;<8!L R^%%8Q.'MV9!G)I^-
<-7E+,3=@RZ6$+2B=A[M*RGQO"E%$'?JT,C)*SP>2G%<^];66$+JNXX+#)+ZH%9IK\I."CO4AA?9,V"? MRZ@H[/=S4]0KTJTA07\:&EG$ \/7+J'J1G)9' M(9R <)Q_@/P,*^!MSPZ?
#3WGQ#D;,9,)BYF,_.' KZ0$%Y:J>F47;,*ZX<89KFM*SGAN?!1'4_)^H'0;4?:P M+U\MKL>\I)!*!*=$_$:/ \3%6RF% M NG4UF75V@::[=UKH&?_]\-G#PF*B^A
M^AMWJ$BC\VASQI=5.PX9QM3"=GJX]>PUG?J?X?X;SKON"7L/+C3>RS)<_5]^ MJ?U5Y[_Y[Y-!NV.,Z$DX@6Y.!X(:Q!HEY ?)8<'38=$;[]-ZN:$_Z3F.:]- M+)?K-
>)=25'VW=*VH0BXH$H\9W(UOUF"=/@6F]=1R\Z3\[TA)6:7+1TW 0.^ M/K]YD=Z!->-3+FS%/7VLR6'F^2F_CMO39L].GDX%?HR]^U=6"%LTG8V!Z*O'!IW<\@8.1'[JAQ%;?SL:F M;=" (..#>&GB("K%D5?UQ)_NM6Q2&\7FY;QH)9UOO!G)CU+6VGE!YF3HD?*D^EDCW4LIW47[1&^3JZ]E0Q/(&IJ&W>)*X!DPN+FQXAIV3.I6?QAYOA73I
MG"*23+:M4THO11Z!';+QJ0_V]'#WZJ5T4GPH[O: WB^?OM]T^W:-CD6:.,KB;K89,>C;(:\W=@$N)2?+B1\0P W M$_C -5Q)(9$&@UK7W,$3"TD'*,40>$W1&A7W.=4DV5>,\3V9-
&6]SEF ?4DN M=G%L=5+-/:KF1K?:?-*<+(!?Y9H/YQIH?Z:H96CC;6JQ_XQ2K/)X,[8F#=(U M&_XU@4$+C]*4Q6 -RII(^W\'2F_05V7>T/UV!//Q^%>90Y4&ZYFCCZ;"94X
M:JV44K1P=VN%?32RTJOO:-.8AKTKXH,/N7$BG% MO*,7;,.-UX5_^4>O\%JJ#75Z+?GF5(1CBGOQ]>V;L9JGFK42YT-H'8DR64=T M _;A?>)O7]0R-EA*AQ@8WF0Q$W^?
G"HA V@3.2_$(9UQ7!E(?@N[TGRANHP MS.,4Q-J:LJCW)ZD&:D/(",6/9)/Z, :,?>ESF'> M G^)4^.PUZ\F&9VL1Y$;HF$L:C8F61-'CX#(]VJ1.?D8Y S$"@N:2 C]'"T,] MK!9#0+2
3:1\>TJ&+9=XZ0")QC.6XJ064[[5Q]3]DWOO:)YW M#LU:O'H_P@ M.(=G6T]AQM8?;07@ZT8+S@V',R:/),1KIL4(J1R_X.1P,]3W"5TP#1N]"&WT M[*02GMUW+-
"'>TX4^ICX9R6.8)]1MQQQ@?"AHU"< JMLD%N=^WRPY=]STE M&VF2.$"H"/SOF4@6E2_]C+2;9]ZD BER-V[PVYC!;O'AH7!8^N %4(5(+F&K3=LXU MAL;>K>5BSVQG6KW]F
BP@9O@^4N)UX:BZ G!&HX$NP=77(JR8:'$77' MB"I&2:$O/ZLUQGXA^2X/!N*TK)->]IA\Y;N'\/U\C_/D:X=M>(R* :%T:OR] MQR%/)_ZW9 8R04TXM(:616.JGO+K-
Q^#/OJD=>5;+ ^C7@-*7<-'2SC*>K&2K';<6&2C"+D> M:?\/U5EY EG?#])IPD82)\V-9$-N?OWO4W&.(IQGU!T^RGZ*_ODW=\T&.Y3&A&[C@2>9IB_FU($K;M&|:QW[BGRY54
M&^U!;XV79$KDP_J.PZI=HL0T)9F@+$.<+/K&E7TQ]-5Y?>"1DJVHS)'R9,[8 MDUI,XKYA*8-(0B*I$# ,&S(B2:* P(S?=IA&J5()5N=[],_:=_!EC@49L>17 M&LM5W^@8*"8+G"?
RGFU_)#M_M(%12X3^B[:[LY:!HEQ(ENZ$P8*49L6(O^[B M<(R LQ-PM-V%(FWE)RSQH,?9%G%U&M#41+NJI<$XFJDD3'6'KQ3DY&!R^SB>
MSF[&M[,IFMRBFZO[G|>SJ^'U&'T:#V=H.AXJW$]FD_$4G3$83638Z$1 MY@1%":1+BB)$19HP1+H?"TG5_ "198(E-,82/LJQ@K.((%V_0IT&/R"YI$PN MPEFL)BXZTP L%[C6A?
HP[N.8[F7)X\:52-.5XS+CY+P]$7LWB,_,+VP4TJ\ M1QW?[06NF;9LGZ^! [$UYI%<HZ6;$-XIMH3P74DBU3Z:N1A6I;=Z&I5 M^WX\|UJU/=OL=L-
RI17(+8B5_U:L:JN.73"XS6'=>R>+M5^Z6+ ^>KXL'X?+QX=M|@OE1EGY %B%KG(=S% M>/&4+1:2K?7S<&PO=V]R:W-H965T=4K>Z R^78 MZWJ;C1[?=Z[O8ZCN%OQ@L M=6-
-;"9O4GZWPA_IV ML0, A,1:!XFK5+:]A<;] ??>Z8 MRQO5<" YWRPU\[$W]$@*&2VY>9'+WV&=3]_B)9)KJTN6:JW (TFIC_K>_B(0;@V"%WH4>PZOUYKBL M\EV#6H W^?
RI&PPJVVKO"ZH;YNYP07O0XQ M<]@+S*E3SNW'GM[+O*!B]?G3,.P.;O3)H*VN DX-M"9 EJ"L'_+E&;Y \CO!S)=/'V" ^EVAL.@(8>=H!_]L*]OIV_L M\$KN2Z5 F(;S?
CQL2E&7/$DQNS"@\GJ_VXGCH"%=]0;D51K*=Y((P^&. ' V& M+770K^N@_^$ZV"<'O./;H^$8LJM!L6$[UF5,)YC%"]C2!&Q_.DGW$[X)$PDO
MK6&)YFM4QT^KFM#"OBV:.*8B%9*DJ@EWB >2L]3Q7AO\X&-F="-1:_E_D?R_ M(_L!^;$74I7,W>6EL,"OS X M/.@'Y'6.K9YFV(0.^8II5/]TE7%]*0>*G>@J}$^@L?
KRHK1%Q@0B@MXR\2R, MHW/R;%]OY&?]NK8]0GL=[QB7_.:XE8.:N:%28[V7PE235[U;SZVWU;BV5:^& MWJ]4S1AV 0X9F@:7 ^QKJAHD*\'(P@UO;]+@*.B6&PO=V]R:W-H965T
M[06\JM**-7H-4NY&<2 MK?.33D?%"Z 5- M4Z,(8'PK=#8JDV9C*,;O4?F5]!U]F1-+$D3ZSN4]&C4$#S>F"K%+](-;7M/#' M HQ%JNQ_M'.RX;"!XI72(BLV X*,:AL&_H$-0;$AL+B=
(8OR,]%D M,1)BC:21!FWFP[I]=P,XQDU0IEK"*H-]>C*]/GNXO+[[\OGR8?H;NOSSZ>;Q M;]1\)+.4JM:HH\&$$>S&A;ISIRXXH X'Z%9PG2ATR>=TOJN@]@J@$$)\#PX
MJO&/%6^CT/=0X ?1$7UAY7!HJ44']-U+^OMB9<"A-9&2<*WVN7E4B:F4$Y63 MF(X;4 J*RA?:F'SZ@'O^Z1&(404QLMK# Q O4J(4$@OT[B(9&M%O3/%Q!% M-YIFZM]]J*/
76W0MT2]NP4^L5\E5(#OU1S3FWU8CVO[|&$0^.$I^M6 MD$6X/@RP%$>5KG!"^1/75Z*'>ZMG]=[!H] D17L M-$,O&D:MHP[6QTT(KJ_KMDISX$8LL@P.*NCY\5?$@%,PW,1>-
QAZ@Z%?,Q5Y M_;[OX?K<#\WUO-!$:P![#F9@!#EGHUIM&W@6X/QZGMA'^^)^MM05:G8]?S M]M, M(M]P<(WSXAQ>,YT@PI'IP7(MF=:4@_<+*@&/29][6(L9E;94/9=*:XA"R8@6
M*%]!"L-17"L8M9]%HHTI5N:G"QT(?>RUHR'*P8K=B)HZ<84?^*>V11BS=HQ/ M6VWT"*O?Q1^4F#V5,!A!'_VVC[=:V[9N]WD/UYDE4]KFUIQ)6-MAX)9L;&_R
MK(D+D>6$;TK_L3?LAUYO$"%W3IPY\Q!/A'UO6(3+K9V[M3IE0 =9+L$^T=:) M6I=Y+X=ANS]T));]O@G7$7O?>J'IQJ'?DAJ\A]2@A]1=5AJW1&QNQ,9=MF#F M5
>&@4,KFX@4DLS:Q/U31+ ^MX#"RU6S,4*Z!>Y@HS"Z8B]%!;RB1T%_L%6&W M.@'S'IE&W;3\4Q [!7]&[+:MNP MGZ\@&&7#'C@,QVC[KXDMFY5)469YJ1--
W4B2205'#!E>R%F("BE)$92PV! M*R NM5F*PX*:=0)5;$! 4F>%5I(Y$DWZP2S3D/:E_IA4Y7 T6&W;_W^*:HOC MJ=Y5[LJ:VDNY.ZD,R65"5$4"A&Z[VH&R$.7Q%OTX,K5#
<4]4]EV^.K4K?4;E MTCY<%" [MWMOIJMWD9G[DFP%7,*I70!6_UV'VY>TCU6W$"+W#X0 M9D+#<|-^)O"^H](P/I""%T.C('JQ3CY#U!+ P04 " #@@C-94?.Z]VH' M !9&@ &0
'AL+W=O*X]WIG(AQLN;N2*4@6W:9+)HJY*J?S=<"BC%4\)M'A.,WRSX"(E"I=B M.92YH"0V1&DR=&W;'Z:$9;WC0_/L4AP?\D(E+*.7
F21ID3F$/8KH@1:*N^.8G6ADTUOPBGDCS/VRJO78/HD{JGE;$ MJ$*%LO)*;BM'? V!6Q&X1N]2D-'RC"AR?"CX!H3>C=STC3'54*-R+-.G,E," MWS*D4|>SGZ97YV|/IK/S,SC]_.GR_&
(VO?[X^0*F%V?P97IU-;VXGD'_FLP3 M*@\.APIE:LIA5/$_*?F[C_!W7/C$,[62<)[%-+[/8(C*UAJ[6XU/W+T(:?]PB_TX1("7P!7X@0)%/ !9C@A-]_P:WP4=%4_K'+ M\I+O:#=?
#:=W,B<1/>HA7B05:]H[_N$[Q[??[]%Z5&L]VL?]>(;PC(N%:L75 MBD)6I',J]$]N"(H#4J@5%^PO&@\ T2@5R6*6+0> 5R!KPA)[("XAD6A"D%A MJ:V74. Y(6P5CVZ YQHZNVS?KJVE-
CA3-(:YQCTPU&<+_&^EL>9YRM.<9'<_ M?!>Z3O!>WK,"\H1DTC#36S]F<1%1S"*/ACR.6T8Q*Y0,@)B@PVF@=;=!G M&1+S0B(7>?
.M"#;>__BZT7M@UGI@S,J(\%*?:>U/^!SXPZ8UIYXJ537=L9P MB=X)]#_C+M<\|ROGKN>^6N]F91O,-N;O^:-ZY1OMMP=>^ [87OI!GZ]]$9N MU_6U8L%XY_U6V#*57)
''&;B>IQF'$TT>)D$!UHGX0^!HU>.-!OP+K*P/AM:Y&V=;"]Q<5 MP"X%BRCTG0.XIB*%OGOPC!W_]/5S.PO.Z9)EF3Y7#(;6@4$X"$8-5M[R!HW M>
NM!HKA8&S[K8UC*YIDR.B0H#C3-$WY'T0VU$P<^0O:A9H[E.8^J'8SL M[L%8=O?A^2T5$9,M:?T0W=WW&I=[EMV5_C O?.WS|N<"8SM6IKCV-W3]2WG
M<=N0Q.^2C&P[K#1/L6U<4*;: CU[U*5V+;]+W)"$XRZ)9SU(CYUP010_#)0J M8_91!<|*78R-QL[[061"2(?.;U0]78]WN5J:R,*1F.'!$L"9)@4E $Y*4(Q>8W\%F
MQ:)5F2\)$]B%BQLFQWD@OMP00UP(4QV0RGAU1_(= MP 9[D3'W#*<;FMS!&V=D M^2TAXSU"R'(IZ!+I=HE;F[!Y8/0.>:.637NJN%]7'?C+[5%&^U<&B'Z<\I@D>.E-5 ML-
4]Q#;RWVXC'R>7(JWD/KN6OW[5?KSZOO3ZJ<28P9%V'_9(*;JT\GA6N5-[MMU77[A6G-SI7-HI@":"1/I@U3PCF!MUF;=]-)O'!]LW!P<<7D#2P$-4%.,0DI M$&U9(\MMD: @7-423
+JFW-H$OC8\CM&^E93&L^P\XMUMKUC-&D*A]T2@_=[ML!+46 F^&BNFIWNK/V[$VL,YS20Q+26F2;RGN\#R!/9Y F+29E7\)*:@J!S6XY@>"$&7GVBVPF)5X'"]GJ%I9 (+$3:
MAIBNL9//38_?BOB!%TSNK=U1H\ 'FJ'#DG*LCE.LG%)I!ZZ;N/8&D["!T&A@ MNTUO4 YA#?-@X/GVO;7KUSWGGD -ZT -]X;2+UAE(BR^Y=>9G8E[+X,7?HB9 MU.I-OM'GH\DWT-
JQF^]^]E?CO_)M/7CN_,RWE]UN=2UXS@Q#.5>*I^9V0FF6:[T!WR\X5)N%%E#_FG3\-U!+ M P04 " #@@C-9A!"X]_H$ "Q#@ &0 'AL+W=O+$1\H=:(6IX+/)270Y66]_/1R.5
MK+!@ZDRLL:0GF9 %TW0KER.UELA2&U3D(]]UXU'!>#F87=BQSW)V(2]=\Q(_ M2U!543"YO<9<;"X'WN!IX M?KK09&,TNUFR)<]3?UI\EW8T:E)076"HN2I"8
M70ZNO//KR,RW$[YSW*C.-9A,%D+\,#>WZ>7 -80PQT0;!$9_#WB#>6Z B,9? M.\Q!LZ0)[%X_H7^TN5,N"Z;P1N1_\%2O+@>3 :28L2K77\3F5]SE8PDF(E?V M%S;UW"@80%
(I+8I=,#$H>%G_L\==:3H!$_ = @+|+|'WO>B'+\CW3;'8AQ0:D MF4UHYL*F:J.)'" -ILRUI*>]/(/ =[IXYP'QMNX3'T MV9Q:+:UR!)$!9AE:I0(O$U$@:/8:DFFD%DA$F?"<,Z/G?
3D<7X54#'J%D'&5 ML!RVR*0"--L%5&QLB@VL3,U%X-CISY>%!>H-8FD?=1@NL,2,:Z"!=:4)=G,/;-Q/?#=Z]^M\6UA3UU0BW,6(S?:BLMI9/D;^ %SK!..P. MN,YD'.W'U)
(O*FVFTC@A/$$;@MJ#VT4+$G+M>52#W\]W.)Z@'1E"(.P1NDM&9FP'9* M49UH-VJCAV'HG\!]I[9I.:X;'N9Y M3VJ5O:=A'R>83D_@9L7*I6D->&!Y57B^=1Q2R-
R97M#L7)9C*>L%*W"70@ MJ^;5LL85)NR7PW3*:JHX!@XQD@OS,0 MNDX4C.$+O1J93%8V82,E:3[@C,02H72_&;RIXWM2YPZ8122.6D2M^W671E_ MGA<[X63<&XV<:!K!?
$5%/C4?;*E]*9&JZ_9H3$J262%:>LPIA;B65>/XS;GV'W]*Z'NWB.Z:Q9TG<=MA6:.N-X M#-_W6 9MJDL AS%!3(*.HQ"F-_7W^]I+_@\KU8$2[8OEF,4UJ?EQ?XS>=/\E
MK2=5;,D&Z)O_5&2GE3HHTB%1ZI=E2*1>7RS3JB_8I7]IWJ/,;) N;2')3(! M496Z/E$TH\UY[*H^AK33Z\/<'9-+3F^_'#,*=<_&9-.R/B#5-UJL[:%D(30= M<>SEBLZ4*,T$>IX)H9]NS
+-*77V#U!+ P04 " #@@C-9LL,'4BX# 9 M"0 &0 'AL+W=O4"6\T<+ZY&@UD;3@3,%=$UV5)U?,)<+D<>]'WXKABB\)8A$:5'0!UV!N MJ[E"RV]1,E:"T$P*HB ?>N/P^.30CG<#?C-
8ZK4VL9G<27EOC6DV])+"#BD MQB)0_#W"!#BW0$CC887IM5/:P/7V"_J9RQUSN:,;)I+_89DIAMZ11S+(:/= M3.18_J"&C@9*+HFRHQ'--
ERJ+AK),6$WY=HH[&489T;7M_/Y^>G%Z>QF?$[. MIK/Q;#+%UG1V=GEU,;Z97L[(W@V]XZ#W![[!"6V8GZ[3QKPZ!/P,"(74IA" MDU.10?
86P$>F+=WHA>Y)M!7Q5RT.2!QT2!1$R1:\N$T_=GCQE]/2E'6#F6S& MM,?H6%&1OM+L3=H/O6Q@G+>-D&_KH&HJE5G,@,B=R!G@HJ444Z8T(:9VMTS[V?M=|*D M]\';
[03]D$QD68)R$!6M0&VD'D8?4TDZR5'XY86XD09G?$VU%W3B?G?-$2*] MN+M%K8>M6@^WJ[6YZZU,*H651)EGIQ KL KO=K-)]=LAYQMQ_B.97N8Y2Y%_ MK01J2L&
[1%]W*0J#=]8Y:)1HFM9ES:E="]2M M37&V7NA4%O_]7JA?O_3$EA M$*];<7^3AORUMNZ/FW+W.KQY-%Q0M<##1SCD&!H< M]% [JBG$C6%DY8K?G3182EVSP+<+*#L
^W,IS8MA)VA20Z._4$L#!!0 (M . "",UE-P9GX9@0 'L- 9 >&PO=V]R:W-H965T0FT\'B;.V0^E_?V,G MA'1;>F7W^$#CR1T+$K-60XS2529501N+H&+]<0)
MG!?"'5NEVA"\Z;B@*$HB+JN823QY#4K",L@5$SF1L)PX%\'Y9<_P6X:_&;Q5 MZYD83Q9"/)K#[\G$\8U!P"'6!H'BSQ-< ><&",WX7F,ZC4HCV'Y^0?]B?4=? M%E3!E> /+-'IQ!DZ)
($E+;F^$^NO4/MC#8P%5_8_6=>|OD/B4FF1U<)H0<;R MZI<^UW$X1B"L!4)K=Z7(6OF9:CH=2[$FTG CFGFPKEII-([EYE+F6N);AG)Z M>GM3[[].9^3V?
4=F7^]N+LF)_=TP4%UQIY&!8;-BVNPRPHL? ,L",F-R'6] MR'6>0+(-X*%EC7GABWF7X4'$/\K\C$2^2T(_[![BQIW(XL7'>WN/B|KC.Y^ M#%,FYZJ@,4PA'G_ZW7VM&ZQ"1J]?(F,#<-
D%Y MO_+;E]"8@,3;N<$%@7H-W+2'[K=WJC3O4"=S <=']:EJ7_ M(KI!GS|>*YM-"W0$@.19:C"NH3)5FJET6^6KW9 Hi'/;'8UVR7VWL_=V5=2(M$M))&M!L$9/EZ7-
M#65DF+2O-\53(. S+X\J)TW@1N,>GNH_7Y@I,(WI'PW M[.X1"]T1*KI^CE.:HS=[9:-1M-?.(*QS=[_&"$LJZ.Q(O!7!HRO[1T68@MW^ MKFM(#H:#GT[,VUW%K332(GY_Z5>6O=:U1.

*<15%GF^!CR#[7SO\WYS\[?S;F M=U!4/5?9'KA^NRYVT]<(;.=#@BVT5 I?8X>\%1K(H&FO&!TF,-%3,,T3-MCB M8YH!@>\ETYO3F%.EV)*A+ (;MAFXP+>]^JU,IRE6ZW8W/#@RT7C/0>D.&HZ Y#MT!=KQOL*+QING$KV_[+<[AD-P+C4%N MH'"L]<+F.'+[46/=OA3U6@LQSNJ57?L5WAFN#-5NW%";+XN+:J%^9:|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|X->(BY0(K@@*>)$28W$YQ2L0.J>?8 M/: ^W5U+9KYKD#V?3,_2)/Q'!3/+ G@6%1>0.@VOW>IW:6JNI7RM5PJ3O/K6> MW?&<^LY64C\'F7$%NG3^SGDY@;9_J)9NTZNM]@BYJ<8_YSAX!(!ZSJI=Z]O- M^IY6T+XLZ?? (=3NP'$YI9*!#'<6.F"!MB|WT!(5YLP[*G'-5+<'#R@94*R M1F[S0$1.NG;+[YS^M)B44P#JX4V+W^[638Y]\-&ULM57;CILP$/T5BTI5*U4+(;=] M2Y!(-KNE:DB42ZL^.C $:XU-;1-V_[X(8Q)&JO:XN,N?,FO,>>Q47SS(# M4.@EITQ.K$RIXMZV99Q!CN4+=+X#IG92+'"L]%0=;%@)P4H-R:KN.,[)S3)CE M>_7:2O@>+Q4E#%8"TEQ0F@=*\T%[12MK0)..3MOMLSLGW+#]P-P=BG!K;-|:!TAQ0 MF@M*\T!I/B@M@**UI=B4(PQU.:)'C%.3>JL/M-H 2G,KVIO1W -UZX/2 BA: M6UA-O<%0UQO^M\2)^CIZRQ*T4 %*YXF2%>8$F>A:-HQ"'*.'%LG7K_\@TYJ@(\(X71"1/1W+ MMG_1!*/;*"2I-+E45675%]%;D*#_]0>EN: T#Y3F@[("*%I;N$T-Q%#70.ZB MF'!4X+"F/(\1*[QSX/Z RUQ@-(<4)H+2O.,_8*$M1=>?5"? 12MK;NFNF&H MJQOP 3%? R*04KQ_B'%4&WF LTPR(Z)%0.@@HS0&EN: T M#Y3F@[("*%I;Y&VUQ%!72_H%3!|Z""C- :6YH#0/E.97-'4H#]!|EKH:;FT1 M3@A[*K:+DOZ9;$:1> ^>\]JY]Z>L=Y5\]-R@WG#;*

[<_WZ'V5.4 M4R%H4GQ<$2Q73'D#^?V24O%ZD#NH-_9? M_ =02P,$% @ X((S65$#8LR @ C@8 !D !X;"]W;W)K&ULK55K3]LP%/TK5H8F)@WR+A5+(]"M&Z 4!/89S>];2P< M.],=EOW[V4Z(^A2&M'U)?.U[CL^YCF^2'1?WL@10Z*&B3(Z<4]GZW'5E44*% MY2FO@>F5-1<55CH4&U?6 O#*@BKJ!IXW<"M,F),F=NY&I EO%"4,;@22355A M\7L.E.I&CN\3BS(IE1FPDV3&F\@ W5;WP@=N3W+BE3 },$."5B/G O_?I*; M?)MP1V G]\;(.%ER?F^"^6KD>$804*R#&ZM84)&J(MQ?';23;VF ^^-' M]J_6N_;RQ! (FG/XD*U6.G*K#6+OOL&G1\KL.!4VB?:=;F>@XI&*EYU M8*V@(JQ]XX>N#GL /WH%$'2 X+V L .$UFBKS-J:8H731/ =$B9;LYF!K8U% M:S>$F5/,E-"K1.-4.K^^FV7YU>PZS]#|&EU=+'[,\HOQY0Q-9^,<9;/)[6*> MSV<9.D%SM@6I[!$]B0A#5UC<@\)+"BB#HA%$$9#H>*KG")6?-. VFZ+CHT_H MR*3G)6\D9BN9N$H+-]N[12=RW(H,7A'YO6&G*/0^H\ +H@/PR?OAX5.X]\O5 MURSH:Q98OO!?:W;(:4L=:8V= _9%\. ^?Y/9$ ^] M$/95"-]B3[.2"W6B0%3Z=/L/XY#EEB>V/*;K;--X$)T-$W>[/^5EUC >#KP^ MZXG(]!<9O2GRDK/-NS2V-(.]W8-!^$SARQQ?^WA%8=PKC-]4F'.%Z=_4Q0!;YS_2]S/+U!Q\^%^CN=0O3]?4]WA F$86U!GJG9YI!M-VO#12O;0-9&;1PFGJ+U1JH) M<]C? TC7X()^W#"<2Q0D(>_Q2@1KFF>"@U,X.,]U:!4.+2TT9Z9E3:FDPSYG>|*5-:*!QT;[8UJHE1MHR\YOHW0 M3PYGCU\|?_'@/2Y\.GLD#Z.GW|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|S29SFXG<L_IN+D#MY%F=C.9@C,PQGP-<+P\'$R^;X,=#DDL>'KQ%K,7(O \)&!* M%EL6B(!P\)6$2_#Q6MX(0OY)@CQ,K\'"#Y_ !Q#$8+:F6RZ=^< 4,IDD)'.1 M!7YU"!PU!/[7-CX'MO4'0!9R%,[CM[O;97=34ICSB'(>48IGOY='5;8';$<- MG2SD"I[!"S(TY$KEA.V(.?K]-^A9?ZKR[@BLQ(*=LV#KT$>7$64B^(_($]%< MJ%(]^+NI?])B=B/7ZR%K8.Z.62^-K(Q91O*L"!@ M0:.(L$6 0[#!&\)4D6JQVA9"1V"EM'MYVKW3]:=>ERQT!%9BH9^ST']G?^K7 MB@Y9_5IIUJT9 M^(,-3]V^B?>1@\XV1'Y("NP./Y]!P]TQUAL9P|!9"3:;P(M&BCM5(:[0BOS4 @QM$^WWJ%6Y5LST1%:F8E"!*%>]5!?\["NT'(75(%WS*BO/ M+R&BBW$'':FYE AU4XU3(4-;&Q-A9[#]P@Z5&AU_V@Q9Z'5K9!G]YL8+!0= MZB4]7>0SR1_?1J^ %AU &6]GDMX56CGS0M3A"54==BKK7;&5F2B$';Y7V:%" MVGU4J]&Z%;2DN*MK%!72CEI*> ^/>0P_4>C=8'P%00R|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|<8T<^RW"%G;0EP<7O?E9U["5&;/8<8FQ<@Q^P:"U^.4G>SSY M3==0, ^^/+*EX |-M>9=CSK2NH9I3=1$GYSIGN/=<+DMT#C]1=\"O9 SU;#X$VZ(SZ]/(TNFX M@H2YD# /"-9(T*!*T,!$GW|FOCZU:KB40[=,R8X\]J2DNG0825W3 0ES"|@P MAZGI;3_'@ZF<[ZQ9? W^L-%"E#:6'E=)#H](?Y8,@Q\5D@^ZHE%L^$0:IC BN M4D/"W (V.I)ZC"=MI8?MC-C#XV(-#4>5AB.CAHO-AM,-$121F6&RN[(UVA,> MDL>(5ET7T>]^E 44K3F+$:MDCY3L*)*%PTA,5U0KO+'^KJ)#PMQ12U';LMK" M]792, ^X2I, 8F)ZO^=**|HCLI>@=:-2H]68MQJ \1IFL@X,>*>$I[66:/M&$ M']I.C,2Q7DMH,F:G,J%Q(:?,!ZDE!:1X4K9F/VKO:@.;5;IN_:6OP79E*(PV M),V#HC75KEVN;;;Y%ZX22\KQ4L 9VAJE07TH*,V#HC65K@VK;?97W=8\XU:_ M=@9#C=Z@5A.4YD'1FGK7GM,VF\YB7&\MW!O64RM@56>+WR,[9I*#VH:06D> M%*TI?.T[;;/Q7#&^8[FQ?T=)\)01+BC7CRJ@YA.4YH+2/"A:4V*W9?>J M%*TI=>V:L=DU=|F,,JZBXW;;P*FFM?K+FBU'A2MJ7=MAK'1Q=DO-?+SOHENTK-SBR3 |*J!6&HC5345MA ,J,:|DY MU9@4|NW>,$$ ^2;?:7(#NXN+VSNN@_3+9!:W4@Z(U9:|],3;[X@O?0)@IG84> MMU8\V-$.-J"6&(K6E+]VQ-ALB?_'AI:9W%G^B6;;1"L_J#&&HA7R]X^.,|:4 M;_)SI"G*WRX4QJ:JJ]59U45^0O/D^M*^6=F:ZZY]XQ4G46M|<3#V ^&;,$EE MZM:R*NMZ+)7DQ5G3XHM@N_PPY2,3@L7YQZTTXY2K O+W-6/BY8NJH#KQ._\/ M4$L#!!0 (,'",UFH\ .OK (!((9 >&PO=V]R:W-H965TS@=(\2-1)_1)L<_Q.>< 3K3EXE%F H]Y93)L94I58QL6R89Y%B> M\P*8OI-RD6.EIV)IRT(7E2@G-J>XV1VC@FSXJA:NQ5OQ$M%'8-;@629VU@\M7P+EZ['E6B\+=V29*;-@QU&!ES #]5# <"CVS6Y8%R8%)PAD2D(ZM"WNI 2E$28+=!- 0(KPI9H"CHA-"5X3BA1 M!"0ZO0*%"95G&O(PNT*G)V?H!!&&[C->2HV6D:VT+L-N)XV&RU]#=T##CY*= M(]_YA#S'"SK@D[? #_6VX=-H(_':2+R*SS_-\%"/!OW*TQ+0#Q%PCP+/9[V M2ITŠ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|/,209,$LZ0@,70N>B2N^N+R?4$G:*;0A4"T,\7 55]0H75G5?++,KG_1O+O!3M#7>|+|CT_:("//@[O MOH:[N@QU+?RZ%K[EZ[!5Y6 6N/YQK@ BA7,D>*(U\4I8_!2 -BH)N|EL] Y MF=F=YS+',Q@Z>OM)$"MPDL^?.I'WM:D2_XGL55VZ>5VZ;>R)+F_89+!$A19E M3HM5$@>]@;O:UMW*?*#NH-8=O*<[:M)=HJ)MW&K\WH[N5^4#=8:T[?$]WW*0[MW-<=[NIN93Y0=U3KCEIU/Z2@+Y*% M&D/MI3[YM-_TI]*_^!ZN-:?=RNGBM, M=S9_DX]XWT?0]W>,M*8ZT$BO-M)K-7('4B*2Y84YM0C3RP%2-3GI[3DY]:/= M)6G-=:"3? NVDW^ID;"B90BM,"T\L7< 4X*GA!)%H'&I^GL'E,_]NR=40U 0 M_PLJA;M;-ZQYW?S 8DF8U#(6&N:=Q1HORA=#V5$\MY?NE"M]A=MFJA!9($R MGE|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|WN3 M2) PBH0Q) (PC80($,Z36KZ36+^C>KN'MN:H:QI(^4B)(&$7"&!+&D3]@AD2 M&%02&5A'HW+H(#*,UWK4B>?:==+H&Q,.WH;W:@SXFO'V_^\09'9$\E:3Q3V7JOO|#FH1C M[4):X2!A%_EC2!A'P@0(9BC,Z=6I4]@2"4$I!(HC4)I#$KC4)I T4RI; 6(MCMVB*AN:!G'JPNRDH^[AA4[]I[5BD#1:TK;_0IC52%W* -D@A|($BF;*P*UE MX'Z'*WDO78G\B"W9.]%:/T@:A=(8E,:A-(&BF5*K\V+'0Y@3-.F%TBB4OJ T M#]4)%,V42IWW.M:LL*4Y]5\8P, T@'-[DZ|E 7 M;T|ZP$3ODHD?O] \,$4W^OHT)Y^7BES*-"/7,O-W:0V:&$-I%$IC4!]'T@2* M9LJR3IB=(<+(H-PE:A- :E<2A-H&BF5.] V+&&BRV-#)H4OVD42F-0&H?2 M1$D;-GZ<,&50A\",/04>%S.W)GZF<@1OMV9=98[6/]>7$13[4I4W:L@7A4> M-8YF;_Q:!L_B2(%JU%1!G?RZ]NO78$;&UZCK0$;V21+V#K76$S0^AM(8E,:A-(&BF;*K MDV:7!? B4"TV*H30*I3$HC4-I D4SI5(GQ:Y]:O'W39JP0UM+!YH<0VD,2N,E MS7&V7*L_/!@\=ZV?$0F[=23LVB/AUUUKDPXZ+]/!?I_]WF]8]DZUUA0TAH;2 M&)3&H32!HIG2]V-H=X|P+F@T#*51*(U!:1Q*$RB:*94Z&G;MLX];Y7UV5FO% M0!-B*(V5M.V<PZ1S37CBT08&BF3*H8U_7'ON^U:P:9O_]B%E!\V,HC4)I#$KC M4)I T4SIU5&S>X0P*VAR#*51*(U!:1Q*$RB:*94Z/;L4Y=;V9>=U5HQ MT%P92F-0&H?21$EKG]JYD4%W:U&44"6+8KV;E$SS)'BS3DBUMUI39URD)/-L M_YESS#Y/LEG[9K.1Q:MBZ96|.,OBL'BY M5'*FDOP$? 7P>Q|G3IY M0+1Z'I02P,$% @ X((S60_U0?"C P :P\ M !D !X;"]W;W)K&ULK9=M;Z.X$,>.RHA;!>U* M>P$2DCYL$]DMV:NL6[EJNSVM5OO"@!.L!9NS3=)^^QM#RD)#42*1%XT-,__Q M_.)Q/=.MD]+]43*F&IS3A:F;%6F?GMJW"F*9$#41&.;Y9"9D2C5.YME4F*8D* MIS2QAXXSL5/"N#6?%L]NY7PJGEPQI:Q-@_L M^30C:WI/];?L5N+,KE0BEE*NF. @Z6IF7;CGOELX%!:/C&Y5;0PFE4"(7V:R MC&:68U9$$QI](T'P:T.O:)(8)5S'?SM1JXII'.OC% 4O1?*83$ 4O1+)ORS2 M\B MYN!Z;S@,=P[#0QU&.X? 1H0[>SL$KR)2I%!Q\HLE|*L46I+%&-3,H8!;>F#[C OPYG>_UQ+?,O33|(7-Y<+W%$[XB|OEX\7#\G$!U\N+R^7U\N$[?/"I)BQ1'^$O M^';ORS=W'^$=, X/L<@5X9&:VAI78;3LT/-IH&')E98Y5H.&'I=H M $M-4 6SC4VIYK6KF2(_5QD)Z"6.%1 M%N@V3"=[F-SQ/|:.V=BZDFL@>FTPG3:?D/DFG&%"5VAO#,X0>JR[.S*B199T>L$0F/G5 QC[(:1 M- :X?B6$?IF8][GJK^?_ U!+ P04 " #@@C-9#@B6HN8* "XA0 &0 M 'AL+W=OK?= M)0&:|*&=3M>L67:1LO%,/"\9+A,LWQP>;YY|*:\/" 6I2++Y4U)JO5RF98_KN2B>+P8 M^(.G!SYGLWG=/#*"\/%^E,WDKZR^KFU+=&^XH]|E2YE56Y*24#Q>#=_Y;D01- M@\T2_|SD8[5WFS0OY:XHOC9W/MQ?#+QFC>1"3NL&D:H_W^2U7"P:DEJ/_[;0 MP:YFTW#_]A.=;UZ|>C%W:26OB|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|*I)=A9EJTQ2:MR730ARTWO' ZIX@V/%>_BFM3T/5;Q0FD#1S'AH MQ1NX%>^+IY&XN:V# 56Y+;=IU-XL;T M3@%4S@;'4TG?^'$P&4\.CVB@=3F4)E T,PA:O 8OF4_;:?]&)T['%#=&EBF MB0;A| <&N;3G;&,.A]R=0-+/7M4D-W":U'14^;/8:7ZLC6C4(D!NUT|EYPMK7 M4&L*I5$HC4%I'$H3+6V\E];D+)]_%!Z?8CT;')UA9%K2(,ARZ@@)%,_M=]\W0K3; [2RXWI'=O;VFC_0DW9Z/#*9\4 M6I1!:1Q*$RB:F0,=%,R?0F%NE H749E,:A-(&BF1G8N\:H_X]?V:ESO0$!])Y&$H#0.I0D4S0R-=[(1|'S]'"*I!H30*I3$HC4-I D4S M,Z-]:O3[315UHWV'"#I5-#]> FJ_D@RT+(?2!(IF9D.[U7_BVK&> ^HKUVE^S=RU"Y]5Q*$V@:&84M%R- MW7-(?V;_U'W)0W2AOGL=4!]%TAB4Q$T@:*9\=(>-@Z1>ZHQU,E":11*8U : MA](SBF9F1GO:V.UM,9<\;(L\=UG!:_?*] X)U--":1Q*$RB:&9*]'X5RSUU5 MPQ4Y*Y,_/[=E1O5>ZN"_=4GJ*2%TCB4)E T,S\:TL8)="2">EDHC4)I#$KC M4)I T(? 3>Z=X"@HC8^_KDH^Q4/H64YE"90-#,;\'&[IFR MIP:@%QXUUUVI=U2@?A9*8U :A|($BF;F2O9&#]+-H;.HH72*3&H#0.I0D4 MS2%2VUI$[>EQ3I]= [&^D8+2*)3&H#2>6(RT;305]+)F6K3U33I97V<$H/-M MH32:'%^ P+[3 BW+H32!HID1T+8WZ73%@&[BW\WJ'0:HP(72&)3&6]HS7Y@(M5-%M% (;57,J:IG5Z>;Z4Y4Q>R\6B4J/!.E?X)B"[1TDI'Y]+NK]]%PR&1X]3 M_RWSF\>'&G-YODIG|F-;SK*\(@OYH)#>V4@=T)?9;+Z[4Q>KBX$*^%U1U\5R M&ULM5EK;Z,X%/TK M%CO:::5.P28A23>)U-=,NYI.N\UT1ZO5?G#!*:B &=LT'6E__-I ("3$#1'M MAX:'[_$]OM?7!WN\H.R9^X0(\]J%,9\8OA#)B6ERUR<1YL MLB>3)XQ@+S.*0A-9EF-&.(B-Z3A[=L>F8YJ*. (C)'0.\C2+,?IZ1D"XF\C26 M#^2#)U^H!^9TG. G,B/B(;EC\LX4,2>P@(C$/: P8F4^,4WAR;EO+(&OQ5T 6 M2,4:*"]/E#ZKFVMO8EC*(Q(25R@(+'}>R#D0X4D_?A1@!IEG\IP]7]) BDC M+\D\8DI.:?@]\(0_,88&\,@9;0NL,#3,:,+P%1KB:8N MLK'K"6;(%9AG DFWP;23DQG5Z?WEU>W7RXN[V>_@:Y:VB+:Q"!&QH+GX-+Z8A7!S ESY(L6I(|*

M0UK$/]+X&*#>44:OR:$=S&VKR;SFCEV.O9WA];;@W3'R<9XJ;F"]&<.Q:!JE M,RV(FN8G/,$NF1AR'G/"7H@Q_?4?Z%B_-S'L"*S&MU?R[67H]A:^YR'F'- Y MF G]/H-_OLCWX%J0B/_;Q+O7)>^.P&J\^R7O?MLX T%!DC+7EQ5H.7/DP+@T MBF1MXVI\FH9$VT_;(DZVCIULK&7?H8!FY9 M/9I(:=':DNH(K$9\4!(?=)G?@RYY=P16XSTL>0^U ?^:1H^$>++-8#S=+U@ MYYR&SD'(>K7JA =@80%+@&)]#YSO4!M8Y_9E1.EZ3F/B_"0WZD@?C9Z#3<\,89P$VGM7WO&Q14<4,[MU4"EF+R NS1555|*H2PJ,DI2PW)P*YCE7TNB84S0-A/.>5!1*QM:QY:P3 MUC]T+^%*RD"[EED?5?E8"'"I'H4MXL9@J8U?#U-X/W'BH%5C(%:M7 KL$CK_)>: MBC76C*E+9VUFK=-\|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~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|KN1E+_%2:9%M MQ!1!EN;%/WO<[,..H-XX(O W O^IH'5$$&P$@04M(K-80Z99V)%B#=+,)C?S M8/?&JHDFS=3&KB/AG!Z<@8G MD)))1RCF=GNJXFH(W(;CQ)M!!$:A_)-"Z#[X_ M;F@!X/]%6>.PF7GWS|6"Q=AUZ.56*%?HA*]?U5O>AT.D \ELC[M1 MJW,->)I:42\QD50): +WC'\B"!4HPU8K2W>:4LMG'MMEW:%.*E9IV5]. _M5F'3ZIBK7=3*8%ZV(VBQ1FY6H(YQQ14[5T9QS++[L5:8<%O"'B K#NK>#Y-6\ MX E4Y;(OA&J54*U*J%A$(*R66N.[]_'5&GXW-PMS%J[U3NSAY0NP1J5P)% M^P# ;((>*EG]2J/G@&K2KDK<@<7<*?89R:N_19E$ 18UO^PMK]B>O5G$QSJM0.PICE MA>QJ:($)TS6YQ)1V9E(ES-!4S5V]5.CB/"D1;N!Y#3=A/'7"5KXV4F%+9D;P M%$<*=)8D3#UU48)IIK+%!3. MVD['O^@V;7P>\)7C6N^,P59R)^6]G0SCMN-9(]08&:O Z&^%/13'"'A'&PT;3 M*8^TB;OCK?IE7CO5)(7.?V&] MB?4|SXL),0O'\A(=@D!#EW<5!.V6>&A2TEUZ!L-*G9 M05Y]GDUP/+67,C&*=CGEF?!RU1D/KFZO^X/QY T,/D^'7[!#6PB\((''1XBMFM$$:"14@78>"XCX9QH4\HY&,FGHJX2YZR-.+I'/2"*=3 4[CA0I#K^A2.=]BY??T&^)YC6(&E:BGAU2#T=*1HBQAIF2"7"M,[I&M.SXMD"S!!JC3'#Z4J/Z1(+CTI@5Z5;13W%B7YAONT(J[!>"UKNJH+SO.0_P_. MX0YG3R8)O=]YU54TA:IO[!#X0:U>C=,H<1H'<:;T(*JU!86>^)CK2&:IT<#2M&"+B(1_MDP[X2(U38Q56XV^3O-J[:JIF2=7|-Y,N]TRZW3?I%#Y1HZ?%O2+Z M91$=*J+W7$05?+/"4[_6^(/>W6E"):IYWG@UY,<4W:E<+7M[IVAIS^'%A^&& MJ3DG0P7.*-6K->E65=%LBXF1R[S!W4E#[3(?+NC]A,H&'I/Y,2K.=V /*+U[X M&U!+ P04 " #@@C-9&.Z@YY,% 1- &0 'AL+W=O5;N?#M \& M3(F:%Y:8]*.5\KU0/L0D606!B-^NI1^MKQIVX_W"H_>\4.F%YI"_%,|R+-7ORX=8 MGS6WE)D7R##QHI#$8WU$EYT\A/LK]DG9>U&F2Z2E04Y,&Z!8$7;OZ+;WE'[10 MYT@ S0/H?H!])*"5!{1.#6CG >U3 SIY0&<_X-A-.WF D_7]IK.RGG:%$H-^ M'*U)G);6M/0@DRN+UAWLA>G(&]M8_^KI.#48?QD^LK/KX9BY9'1_^|#NQL.G MF_L[,KQSR=?AX^/P[FE,SLA81=,75I$]T2$LZ3?5+IU:1W-:=Z2ZTU+Z)&6_+H*STG^+HE0B!:)IV20.4|W0*/4YA)U!LYR,*KZ;I5Q!%)F]DMIR#>,LN#]OG,M&1,!<)8?B#!&,$=':CHA6 M%7UPMPHF,B;1/%_R29+-^V@SIY?9O/NVEYQE:F_83L9.4|KKP.XW7W2M@^4<)\618KM8AB[Q\Y*].L?:B935NM/=TJJZRK&Q+& MD# .@AFZ=:;Z=>KIIO>!B=*YU N?RX3K' IG]2[V)QAJ5ZWU3$+N26%.I9C M%F*5K: ;T2"8T='.MJ.=FA/D56]CQ,279=WL'/1-]TWW.KFROKJS PEC2!@' MP0S1NEO1NI6B4ULQ>Y^\[^PA1P02 MYB)A#GCO@QBZV(^("N6FY,.Q]W;TUN;*^N[(A80P)XR"8(9IM%>.!!=VS MY+A*X;JKK*L+M.#_V1RG5.9I2]V/KK]!0F@NE,2B-HVBFIH6A M8W^VHV-#+1THS872&)3&431S8!2^CGVJL7-2@K5+K\RZ;PI45UE;/*B= Z5Q M%,T4KW!T[)6SD=IML34.50/ZNE :0Q*XRB;J5[AZ|C5QH[.LQ?'\RS25AE! M:2Z4QJTC]*9FA86DNU\=IY%6C[9VB'M0^@M(8E,91-%.]PD*RJSVD M[-GXT3R+=%U&4)H+I3$HC:-HYOL)A<%%K<]^0P%IZ8R@-!=*8U :1[',@5&8M5[3:O*J99W.:^;34L7M!:W5UI;7E@_I4I;?0W4\WO*S8;E(R^WOG3;%*?Z)V M:LQQ9FMIU|GO<.P|/=B7>K\O]?P?_@\M_]!:U_^I>NA-#^?VPZ?>U376U@YJM_T!I'$4SM2OL'UIM_]R$L]5TD^I^T5E/E2J&=$Q&4)H+I3$HC:-HIK2%-T0[MG[V_@1I,4)H+I3$HC:-HYL H#"9:]R6EZOW-X6M*M-O97["A)A"4QJ TCJ*9 MXA4F$*UIGVT62IQ@0[5@[I 4!J#TCB*ME&ON?-Q1/JQS*V(G[TP(;Z<:[QU MWM43/=Y\?[(Y4=R^UYBBD5!=GA0HJ9C-,"^O=Y%*GWD_03C.U70(/_ %!+ M P04 " #@@C-9XO2X:W\"\&.Z"AHLGF2,J>'YIDQ.G5ZJZ=EV9YE@2>Y2L*)^)R0D>TZ>[Z.C;Y-N% M;@8T\6H-QLN:\R02WV<3QC"""DF"J#0/1CAS.DU !I&3\!3>G-(7'ZP/Z)^M=M>UD3B3-.'XM,Y1/G@P,9;DA-U8HW-]CYL0)33]7|AZ;+]1Q(;ZEXV15K!67! MVB=Y[N[AJ, ?O%#@=P6^U=T2695SHD@8"-Z , -D:S2RL55NMQ17,O)1$"7U: MZ#H5)C?1:G$QC9+%'&;W=_%BF40/M_=+B)9S>(Q6]VCYD, %^)[OPZ*L*-\C M0]X^@1Q+=)S0"5^_&EQY'|^X&_7N1N?06W<2.N ,]$2 JGNS MI[2V:%<6SH>=4R)8FOG@H24MUTRUS=/OIJ,G:CON=WH[M^Z(V!9_L6-+O4NWVMVTGRB, GZ?,.Y.@2&H!_(X2]02P,$% @ X((S63M+Y?RP!0 G!T !D M !X;"]W;W)K&ULM5EK;^(X%/TK%ENM9J0.Q$X(MH4N1*.GLS&K&J.G,?';!0#1)S-J&MO]^G<3D:5R*TB^0A'M/ICE^>S1,V6_ M^9H0 5ZB,.:7G;40FXM>C_7),*\2S,;1O B38K"KL MMQ73A(.Z,1^FS>S8>T:T(@^C<,\"W4839ZQ4)Z?-E!W;V#QZ"U5HD#WKCT0:O MR(R(YM[)N[Z.!VP($N\#<4#??Y&%*%^@C>G(4_P:.*M3I@ON6"1BI95A %#QB|!FP)%JB)1>IF&FVI[_$ M2;O(!),_!C)/C&??)@_77ZXFLVL?3.]N[[JO9Y/'[W>W8'+K@U^3AX?)[>,, M? $S0>>_P=TF:2P.[K:""QPO@G@%/OE$X"#DGV74CYD//IU]!F>@!_@:,\)! M$(.?<2#X>>G!XYINN4R7#|^2^YL@#!/<44](2DEAO;DJ_RHK'QTH'R)P0V.Q MYN Z7I!%%: GM<@%07M!KI 1\9]MW 6V=0Z0A1Q-0=/CTVU-NG]\.C*PL?/F MM5,\^P#>]3ZU(@S0Y;[I=!)&G$(X>(IEX+O@&S\EE1\XLG+ =Z8S_.ZUE\Z M>=H$\UL"]TCGY-(Y)O1Q[8^?@R>R"N)87NKTRW#<%">99W=C;^#T1[U=61=- M4-]RJT&^L:(3^?9SOGTCW[\9C@4'@@(2;4+Z2HBVL_0;/)#KH!K99M# L6I< MC=64-88]N,:DYFOB:H/)E56$"KL"*6D<=/PF4[MF2@H@/*+'6]8'YR:*.0,ZIW27,R)309+O@L:5^9?J2,E"S#9$28=-MC/2>"> M!7.B90_;7*A;1?/;0]NJB0HU44N+M0+RREVHVW?K7:@9U>\B#|Z%C$6=2KKP M=M#H?[(56S^QI4QHET=[UZX/=A56&2EUCA_AP6!APJ#9A1E7:I5;86EWK<9]MT)*M4H)\A$F#A4N#9IMF6+!59D4.MPL;C:X)I:L+L[]"^G)DK.95I8<&@V8,=N7XKE!J9AC75A35G.%^%'9SA MJEP*MP7-=NN(-=S3O-@>UEDTH|QN?U G\1&V"Q:^"P[?MX8_D&2K+=D5F=)8 M,#P76QR"?X.E?CTWVKIWK^=MHOEMH57W8 HKB,Q6L!!R7A)2$!:!3Z\$,_Y9 M)^@;H!Y(4P$$4;)G!%RPP*^ZA65Z)- P Y*(WB$H_PVHH8+R|=I6VA584]#"@R&|#O38EH:6>8 M'MYR5, 0E?VITZW;U=ME0Y>DVNTDX MIRFMM"[NA6.%YD=[U<922B9M_21_4 MG&.%YD=[U<922B9M_21_4 MG&.

M0^H" !V" &0 'AL+W=OR8?)OP+<:-.FB#-C>LW^VWLG+ U,X%,GW.-++ MGO/1@0CG;)7HB=AC>%TTO4+$[4&7R "29,8P1C)O66 MXFO&(_$(-W%
(!47H+R0BU5870^G,$)Q!QF2[%2-*ZZKB;Q M1H(;IH0.^L"O9)QB5H-ZZQQ\S_?* M!%7#OZQX#1]>A34"]L-*;J5XG.0<[: M+.]CZ5F?Y/9"^6H%DL0;.*/=AO)XTRA5/:
M+UMD4IV5>;XF\KT<6F:P$OE&@ZW"8*M2UVV<(!UIJF;&MN:\E"DM@Z?U7ZN*'U4D\ERH!E*$8I0 M(!0%E*<-&]$H4DQ2QU-!J17/5,#]\2O[569>FGF '(UH]!AI8HA5,
M(W%+M]I08:BC^ (:\>P(MD6LH8$@Y8+&!5@JB#')S_*Y2,0>'3> 5@%P/HH MP"X =F8T5Y;9&D,! 3ZC6\!4M&13@RPW&5JZP40MXT(P>1=+G/ 7]_/Y]>7T MVY?W^S;
M.8R26NU=5$6G4^IT&G5.*4$O\LU@CW+O6Z7O5%XCQ['+TA)9Q6ZGM-OYA*KL MM&F_);**?;>TI[?97E3F5NU=OKFDYWINJ/(SJ.*Y37Y3=4F:W4>98?G.ER"5* M*,=RNX0"0,
Q64<(K#"!), PDMLE%UBDZK-6)[_Q$<VW:;XFL8M\K[7OMU:QWL$=ZIM-]4[+>86$;GEE?LJ:QZPB,9ITTCA'+*C.! M"6*U7_!&BF-7I2VVJN&|%LC\A+HL2-
M*04MLU13L>ARSL8.AN&\C<' M,14@[Z\H%:\3U4B7[T/^/U!+ P04 " #@@C-9.K,\!] " #9!P &0 M 'AL+W=O./8@,@ MT7.64C&P-E+FE[8MH@UD6%RP'*AZDS">8:FF?&V+G
.,#2A+;<]Q CO#A%IA MWZPM>=AGA4P)A25'HL@RS%|&D+++P'*M_<(M66^D7K##?H[7L)YGR^YFMDU M2TPRH((PBC@D VOH7HY[.MX$_ ""P$XTQTDX>&'O4DUD\L!PM"%*
(I&; ZK&% M,:2)E(RGBI.J]Y2 YOC/?N5\:Z\/& !8Y;^)+'<#*S/%HHAP44J;]GN&U1^ MNIHO8]DP_VA7Q3H6B@HA65:!E8*,T/*)GZL\- !N< 3@50#O+:!S!.!7 -\8 M+9496Q,L<=CG;
(>XCE9L>F!R8]#*#:'Z%%>2][=$X62XNE\NKZ?SZ>)N>(VN M9HOA8CQ3H]GBZN9V/KR;W2S0.5IR=6NX?$&8QFCZ5)!R6W6\OMGI1[#4*HVA(569%B";$]"2HI$<&ZZ+2I
M+>F"AHQSU^D=REV)ZIE'Y0:UW,"DW#LF<=HF*SC8SG7\0<14@8Z7HZIZM;K> M25631LX0/*N.(T"5_#+AJ8\&4]\WH7>P2'[P;&+EJB6FV WJF0&?&V:AT 1
M*Z@LJTN]6O>GH2G+;!9]F^5;>8W3=GTYIBO"14HA411.A<[I8F7C:2<2);: M6OS I*KL9KA1O1>X#E#OS\;D?J(WJ+MY^ M02P,$% @ X((S6?.;(W^ M! R!@ !D
!X;"]W;W)K&ULK5EK;Z,X%/TK M%ENM6FFF8">0QR:1VC2CF=5.)VJFV\N. $5<-8V2???KWF$1P*>I.LO#9A[
MCWU\# ;:G>PI> ^,^(0*1V',IX8OQ'9LFMSU283Y+=V26#Y94QA(6_9QN1; M1K"7)46AB2S+,2,Q+2 =2 QT'A*=CX M(FTP9Y,MWI 5$< ;)9-
W9HGB!1&)>4!CP,AZ:MS!\1S9:4(6\7=]KQV#5(] MKY2^I3??O*EAI2,B(7%%'H'ESX[,21BF2'(< Q2@1MEGFEB /[! RZ_TH*0MD 71KR[" 8%[&6 =R$"QH5R7($41#G MO_B]F(A:
G0Z$E"1@(X3^AT)O2*AEQ'-1Y;1>L "SR:,[@%+HR5:>I'-398M MV01Q6L:58/)I(//$|''Q$_SU8I4"R\436'V]>UJ SV EQ>(E(0%TG\
+PD00#127'"E'&R)U(,/&0'7#T3@(.0W,OEY]0"NKV\ %3#SIQP$,7B. M \$_U1I^^C3A$E8V7C7N)Z:0O-+1F6[!X3]G@+HX0 2^TUCX'"QBCWA- %-. M2#DKZ# K|TB)^&
<2WX*>]0D@"_5;!C0 /[VG&$ZO+%(OP^MUX,UQZ"8ASG0O M2_*81(1A01D?MTU6CM5OQTJ7A3'?8I=,#?G><|)VQ)C]_AMTK#_:B&H*:]#N ME[3[*O39XT%H2K%M0O)>
[*R7=%G;S3X[P[X]FIB[.M66,!L. MAH,RK$'"+DG8YY,0/CDFTOU6M5&QSZ/2$]:@XI14G$MD^$!B*E>D;B$Z.H6H M":O!?% 2'RAK^))M!K)(>"=?O TY+&-I22\18MZ+4RN+#?N.?
52\MBC85:MA M26'X80]727!X%HFV]$X2HY+$Z+QW=IVI Y=&D2D7*K=-_D_I.7Y%IN*1X- M0\QJT3=M?/(NA_5W!=[V>D=\6]LVX.Y'6M7N:_U_1H?ZG,^IZ/57I-K#.EG5 M/
54LI+;'@3++R_M>[DR[!)E01=:DRF]F"*M2V(!IXN\)K0F^I2:V5$H-J)+-Y='\=R^)V*5>9? M7#1-:$VVE6>!0[V*57]@B\EK0FN2K[P.5)L=;8H=G4BQ-SIQ LJQ?) KJFP0 M4MN@]#.
[4]+]W$NKJ@NMR;2R1@AJE332ZI9TH37)5VX)*0V)-DD7W316UQ-S MJQ[+1]E6Y@BIS=$\]_"KU,.W";K.3YU&PO=V]R:W-H965TT_WZV$U)"4]16^4+\N.?XG,N-<|<%9?<\ M
A#H(4T(GQB1$-F%:?(@@A3SIREFCS:(:#$Q&;_L{JWD5 +IC _\;6'(YG2R9G M9LT2QBD0'E."&&PFQM2^F-N6 NB(/S$4_&",E)4[2N_5Y$)6-'B M$BI#?<47T(3K7U24L8.>@8*
<"YI68*D@C4GYQ)5(@X MO<"P*D SC'@1I/< M"N!]HZ4R;>L;%M@?,UH@I[EFQKHW&BT=!,3]3>N!9.[L<0)]?B%EW=K-=H MN5BA]>5TM4!G:I?!;&2:Y2C#Y]
X'CA'^6.SS"#/C^$1-T&I&<8Q+RL2FD M'$5J!M71L_)HYX6C:0===4R(BCA8DA+!)8$H?M1EG;V;FG&3\F9-SY%I?D&,Y MO19!\]?#W1-RW#]WKN9S7YW;MB25'+UV#O467_ ,|S
OY&O*@>W \#]^L#WK MX:YO!CL@:=GNUW=XI=O^6"IRT.2QAGH:I:V7GV_:@[XS-W:'TYU$CSW7KH(;D M?BVI?U+2(LT2^@B UH(&]^@F4U='F\23-
&_]$SHB:SCV:L=>!S7G=6FW([*& MW4%M=_"^FAL\KSEK\+*/:NYYU'#0Z[?7W+'6-#PIZ0]V.'A$!68,$]%Z+YXD M>&OZ.R)K>]W57D<=5-
NH2[L=D37LVM;3U])Z7[U5N$8I>>RGVX3153$I#/K8L@;]D/1;SP]7ON4C$?O+@O\ MB'U*4+H+0Y[\>\N"^/F]9_>^OW#G/VZR_(7^>+2ECVS.LH?
MIX0_ZUK'$4K8^JIW;;^9N&X^H1CQV6?/:>TQRI>RB..G_,ET==6S\HA8P)99+D'Y MOSV;L"#(E7@<7TK17G7,?&+]\7?UVV+Q?#$+FK))'/SKK[+-5> ^RAU9L37=!
M=A<_ \W*!14!+N,@+2ZBYW*LU4/+79K%83F90#QZT>$_5HFHC:)@T3<#D! MMYW@E!,<8J&'R(IEW=",CD=),(R2?#17RQ\4&N2EF\!7X4;2-RSA[_!\7C:^ MQN(??[,'UI^] M%
")20EQ]HOX.O7Q!YH\\5U?!(R?1XL;I:DG_,QGRKT^:+F%5OY9LQ^[@R&Q M1_U!?3VGHVR^>XY5#9,B)56D1!MIY5958-JIIOL!)":MTJU6Z79B4!Z94!BTM(O MJZ5?=N+A2\B$ (E)"?
&JA'A:+TQHND'\^Q,M\P?LR\[GGF51IK2!=V+'@8V) M=V3:TU$N&318UK8$5UBM33N)DVV!2@J0FIP404ZVED/,3*S7,EXY/G$[(9=V@]L%^MB0[%.*U8/ MEH>/3TS%,&*[WK
A6$$_=DO\X:?FP|7] KV+]RR)^(^S#/&?;OPKLB%4A2" M4I.3(,#([H:,,% \@E*3DR(R=83DJ&-%;CCU>Q9+NET%!XX7M,7C(BNST5 M';LX2PJR:XH;%(^@U.0T"$"RNR$D&Q21H-
3DI A(LO649.CC4P+"0WS,]HI1 MMD6L!A]C 4KX9T IBC.6%M^1B[@!\O6ZQI6#RS P-2E6E6KM*HB-HR='3DMKW9&4_,2&,%WJ.FI0CH,P9=..-[4&J# M4I.3(JC-
T1>_#'OMH&Q6JK4LA#@"NAP]=)TZ'RL7 UJH@E*3UROPS?&Z,3 KHNNW,4LXC ,])-VY" (AJ4FIP4@6@$LFU(6K4-%;,T;4,BR(FT;OLV^UG/ MU_I#&& >.6I=1& 7Z;:!2$"Y#$I-
3HK@,@+90"2M&HCZ0_[LQ:""JMSV?485 MF[3H..J/8'PIZ#EJ8:Y@-;>;>;CJ,+RFM0:G(]2!*^YD!U'MUW'43%,TW%T!4>Y MJ3N.PM$&O4>]OO'6G:,4Y@I0<[OI:/J@N
:E)B>E=@D]9.^Q%'-EYCAV\^D@ M1> ^Q7[LE)I\?B@?RZ$L;)HVZ97\ MH*2T R1*RQ[2FE=!WZO>1S>Y@$429[:!5MH?O^LD#0E*@SI%?"EQ['M\S_&U M>YS!GHN-7
,H\AJ%L1P::Z62&].4_AHB*CL\@1A[EEQ$5&%3K$R9"*!!&A2% MIF-9KAE1%ANCO?KN48P&?*M"%L.C('(;152\W4+(]T/#-MY?S-EJK?0+X!P'7'T0T,T#NBG1++.4UAU5=#00?
$^$'HUH^B'5)HU&-BS6R[A0 GL9 MQJG1=.,:-O9>8NG^>^?I0<;>'5G_,O)FT!EDI#V1R3=O@AWS\=/L MF[<@%^0'#:;9"T%C)@:F0C$I)//$:I/$G0\2?ZOQ.Y^(8[E7))?B4GDF@J0
MY&<-U.04E.@0]YJC_2RA5;%,U+80V"D$=E+PRP_ [U]!^$P^203SH8YG8[S> MQCV#NRD1/#]M0Z!44>HT4<&|L\))6KQZ>_L\BG#7X[GD:_^J2;43[M[-
JU!%8A[A;$W;,4L]NF("V!502Y*@2Y.D,Q9W/8W5*5.IU^[ZB6:T;9G>OZ M2NX7^?<;\']SN;E8"@!,3@'JHXB@IO9$;@3Z[)JU!%;A?%UPOCY+$5^W*4A+ M8!5!;.O@=ZPSE'$^R?
%IVSLNY-/CJC1*MLT^82L2-,+HH+'4H]H,&^,_NV9M MH579'CR4[9RECNU6O59;:%51#F[+;O0N_Z.2R;^U]O@VG\@M'[?'A=PTI$K@ MX((L9GOTE:&-0&-!0[+C(5XG0J;>:O-
KQ/GTLK6$5F5],%1V!SRUW*K5:@NM M*LK!;-F-UJ6M4]D]7<=-0[+DS=)M6G_*0 N\8K&D(2PQQN[&ULU5=M<]HX M$/XK.[[.33N3QB^\@?,
$GNN&EH!DC[X>8^"'O!FLH2E61H_OU)MN,8 IXV MPY?[I*L??P\]IWUJK<3\IN*$37\2!A?22?6>G/MNBJ,,2'J4FR0FRMO8@!SV1:D8Y/DA0:9(0^31")G9]QW>> M%V9T'6N[X YZ&
[+&.>K'S8,T,[=$B6B"7%'!0>*]IPS]Z[$?6(-LQQ>*.U49 M@Y6R%.*;G4RBON-91L@PU!:"F+\MCI$QBV1X?"] G?*=UK Z?D;_R\0;,4NB
M<"S85QKIN.]T'8AP15*F9V+W%Q:"6A8O%$QEO[K[GH.A*G2(BE,#8.$\OR? M_"@<4;+)-U0S09]*38@;2[#9H=9+!)K(T: MRNTQSK4T3ZFQTX.
[R70X'4^&GV RG2]FC_>WT\4&?W+6*1*L(CU7.UT6"9N&'!=Y3S#4[P]0.X%US'"FYYA-$^@&O$ MEQX(GCTP"FH1_T[Y)32\"PB\H'F$T/CGS1LU=!KE@30RO.8)O*]$2L+U,<_4
M&M!\OU8;$F+?,0FM4&[1&?S^F]_V_CBFZDQ@>QJ;I<9FAMXX%71EC%S)TJ6 ME%%-30C=(U&IQ A,?L\P3*6D? TCHJBZ@$\R=S7.Z\TQ@>^YLE>YL_4S("M<^61RS#HO
M=^0]D6$.W9/Q/FYYZ^6@9OU-J.23]FD4ZO$!"PC2M$5#?,H-?5S5YO>A))NB?VH M50Y2"\#0J1UE0; D$?N/T079>R?_8,34/3[*6X1OU=TO]W5K]M\D2HU=E.V=?
M;_FKZ7@FL#V15Z7(]_]!=;LZISO/!+;G3M][:5&\VJ@9$49XB$!TUF$L<4TY M-[X!VCUXKY*@Z0<'*5!LJI:\IO>2) LT*YV4?YXR5>"TJRKN(<4C>TX0#%X(M!K_B1^1'\[
V7-.NWM(|\BFBIMS@FZE+4U0KK-N74$H4]|S_]Q<+6\$PZP/ M/E@?V9M"UNZ^P.37#/-Q,\&@@.'*0'J7'<-(YIU[/M%BDS6_2Z%-*YT-8W/; M06DWF.&ULO5=M<]HX$/XK.
[[.33N38INW MI#E@AI#2H]/03$CN/@M[P;K8DB/$/[]K61PH &NN6'Z!2QY||EG7V5UEE(MZ@31P'.6"MWU$F/R2]_748(9TS69HZ W,ZDR9FBIYK[.%+8*66I7P^"MI\Q
M+KQ>Q^W=]EY"B;E F\5Z"++F%I=82[772_T-AMW?)X8N^'W.CF;XP3-0WZK M:.57*#'/4&@N!2B<=;U^>#D(G8*3^(OC4F]@W5E*N6C78SBKA=81IAB9"P$ MH[|%#C!-
+1+Q>%]#>I5-J[C]O$$?.N?)F2G3.)#IWSPV2=>[\"#&&2M27 M?^+:H9;%BV2]W2\LU[*!!U&AC4&BL M%1K.T9*9< ^N:&=;K*+D$9:4)S3ZXV#AM\H8+F\:)4?26DYI!#4?
C_G@PZG^# MT7AR?_=P|WE\/X'^^'HFHR_CT7 TZ(_O8?!]/* 7=_WIT??0!#["A,\%G_&(M"0,#*2(41C&;%PWOK]$PGNH()/8PN8;W$!(,^ "IA-9:"9BW?$-;?V_6C- M\]ID63
,]S#C10FT?!9Q!CO OD/W5?THXM="U* 1G$$]J#?W$!K| MO'KC")U&E8:&PVN<, W|PEA::>ZW8D?"IEZC6]#7^_VWL!W\L2|$ M)P+;"4BS"DCS&'IOIZA QW8<@% M$Q%G*=6L-
JJ@F64TF(09FG73?VC\T *IZK.< M!B5/5TZ Z02H%|H'?"KX@]7.D-WD8H';E(:I<4CMD7IJFB+Y.B4;&!6*&XZZ M1DWU0L5.;6H|HD#1*)%),Z:Y3Y@LBF3A#!A@D-
!T^_A4J2;%MR'T:5ZD']Z)8]L&^6OX? MA?"?M=RJ:KEUM)9O#N9O7|F66"V'90_A1;_5/F^&'7^Q[<|KJ9#BW@@JL1VF M[8II^RC3*R8>N9B[/+
/TP83BP2/4%.^83B1U@/A1Z+?.GA.![43AO(K"^2|9 MQN>G#,B)P'8"HA)V> ^]@=!7AK4DX$MN-K&+Q\N@6_I$[79DX4DU.A[09EZWLV/&&M M'@=[L^OAGM)OO2IJ?^MS/4,U=
[<8.K#MB5A^N5>[U4VI[^X' HMX>ZBL +V?26DV"VN@NC_V_@50 M2P,$% @ X((S61V74+;/"0 $6\ !D !X;"]W;W)K&ULM9U=;^)(&D;_2HE=C7]D!N O(-V3("6X7-6C|9GL,)FY6.V%
M8PJPVA^,;9*.-#]^R\;!%#%EW/ODAH#C]Y0Q1RZHQVX5?/:79UWPM1$&^Q5&2 M7P_61;'Y-!SFP5K$?GZ1;D0B_[-,L]@OY,ML-SY5D3IT_7 '+PL^"U4$:Y=4C>:K7-08DV.9%&M?%
<@OB,-G] M]; .5 ^*@'P'1.%%AU@75N@5T7V,<%HQ,%3EW@'!>,3Q2,ZH+1N9LTK@O&YQ9_ MZH+)NO67=<%E]>GN/H[JLW3]P]I>9>D3R_?/'IV$AFRH+AD&-
M=7=8ZP36)%_2I%CGA"8+L6BIIQWUE@8PE.|Q_T:MES=Z:VF)<[&Y(*;QGEB& MY;1LT$Q?_O.VN2#6Z&2YVU4>71#;/%E.SVC=/KWQWOGE=DLY.V?7G7[O_)QR
MIZU<^23MO;)VQ;-/\;8/N?AK*Y*"T,?R\3__DFN0SX6(_^V;-[M#N>TX\K. MX5. ^\0-Q/9!'_UQDCV(P_>$?YMCXJ4T3),Q%PB@2YB%A# GC()BBGK-7S]'1
MIY^31Y$7<2E=F,Z+.P8IF$85)'/0[E>KV@:;$|M\O29#;A\'P11S1GMS1EIS:+R)TN?*G)M5 M)D3YK-45++:.O*TB8BX11),Q#PA@2QD$P1;GQ7KDQM!<(]5#PEPDC")A'A+& MD#
,@BGJ3?;J3:1'NYN5/,:M_$*0FR39^A&YE3\OR=R/_.Q$%ZGE]74/"7.1 M,#IYW?,YAO&ZAT0VRI P#H(6EWNM;KLWXF2O\EL'8HE^2(682!=^W6Y# ,1 MM5FFQ?>U#
ESD3"*A'E(&$/". BFJ/AQK^)':.?Z$:D>$N8B810)\Y PAH1Q M$$Q1SS2:,3M#>QR1^4D@R,;?'0[+X=1%21-2B"PFZ9+D95_[W":BGMW7 M1"C-
A=)HQUXT+1)78XQMZD&WA$%!$53[3L8,3:U^^WW6K&U*-B3<(DW^YD M#-)2RY4@:;$6&2G6?D("^2"7A/*9W-=9&A%!'BY;Q=0VVUM,),V%TFC'#M:+
MB=P2![5Q%$T5TVK$M+3[[;XG9/'P;Q(@Z\DW93I6/Z>E$O#9$4V(@O3Q?M> M3FI;[.TDDN9":;1CW^]=1&X)@(XBJ8ZV605IG8|^J23XIO@C"O!H^_QTMH MI@&EN5 :
[=B_8YV6T! #2N,HFJIEDV.8^B#C[&^0>ROEDFXKH4$'E.9";;1C M]YJ7.BV16|\@-(ZBJ5HV(8FI3TDZOUJV'"1;182F*%":'Z71CAVJ%Q&:FT!I M'$5316RB$U,[/#Z|R|+'M?D
MN8$.ZQH0H,3*.V%TBB4YD%I#$KC*)KJ8!.RF/J4Y2Y+ R$6.5EF:4S"/-]6 M7:#LEJ698?%\<+(+>2?[X7SMR\UH.TGP5M]2:SMWM/%A>C9J2<|<:+,42O.@ M- :E<11-
%:^)5$SML67THE4&2=_EV1A(%]=@B8I->TPD76.;8(&)%":!Z4Q M*(VC:.KIODU(8NF']T\?QH(TEF^*=R,R;8;IP7T-JVG*;7%&VU$+VBR%TCPH
MC4%I'$53/6OB$$L_6G_\E;W5*&BT ;6Y4!]%TCPHC4%I'$53M6O"#LO" E*P MH%$&E.9":11*\Z T!]5Q%$UUL DW+/W@^W>>#]^G]C81&E[4M,/>>O1QTM)=
M4VB['I3&H#2.HJF6-5F\U9%5'|_I_B;T6ST,?)>)#[ZVG"]& O2SS#]Q4KV^ MA=[&08,)*(U":1Z4QI TC]*I5C91A34"[|_03)*2]G$W0.M/V5@ I+1XTI[AIAT-Z8]-P#.>XLX4&$% :@]
(XBJ8] MU000EG[F!]U-*L=)9 ,?EKO.]>G%M(X!7SV|MVO0.**F';EF3>QCUZ!! Y3& MH#2.HJFN-4&#I0\:VK[8:6=X2#F#;7FM"]T<#WVCO16$SO* TBB4YD%I#$KC M*)HJ:A-
,6.#)'A8THX#27"B-0FD>E,:@-(ZBJ=>\:.(.6QIG|)2]0?VE1!* M(G0:B?2:EO MM+=E,2B-HVBJ]$VB88,3#1N::$!I+I1&H30/2F-0&D?15 .PEXZ"GOM*.S%H|XBRK";*,/61QEW
M(@ODDA7PH_&PE"O*0)MN\G)51\FFMPNV:*">]fHTS+IQC MW: 9!91&H30/2F-0&D?15-V:C,+6G_W_?\T3[V#K)@3.]+6]|8.F$U":!Z4Q M*
(VC:*I]33IAZ].)MYHGWM&L7DQH>@&E42C-@\(8E,91-%?),3Q2,ZH+1N9LTK@O&YQ9_MZH+)NO67=<%E]>GN/H[JLW3]P]I>9>D3R_?/'IV$AFRH+AD&-
M=7=8ZP36)%_2I%CGA"8+L6BIIQWUE@8PE.|Q_T:MES=Z:VF)<[&Y(*;QGEB& MY;1LT$Q?_O.VN2#6Z&2YVU4>71#;/%E.SVC=/KWQWOGE=DLY.V?7G7[O_)QR
MIZU<^23MO;)VQ;-/\;8/N?AK*Y*"T,?R\3__DFN0SX6(_^V;-[M#N>TX\K. MX5. ^\0-Q/9!'_UQDCV(P_>$?YMCXJ4T3),Q%PB@2YB%A# GC()BBGK-7S]'1
MIY^31Y$7<2E=F,Z+.P8IF$85)'/0[E>KV@:;$|M\O29#;A\'P11S1GMS1EIS:+R)TN?*G)M5 M)D3YK-45++:.O*TB8BX11),Q#PA@2QD$P1;GQ7KDQM!<(]5#PEPDC")A'A+& MD#
,@BGJ3?;J3:1'NYN5/,:M_$*0FR39^A&YE3\OR=R/_.Q$%ZGE]74/"7.1 M,#IYW?,YAO&ZAT0VRI P#H(6EWNM;KLWXF2O\EL'8HE^2(682!=^W6Y# ,1 MM5FFQ?>U#
ESD3"*A'E(&$/". BFJ/AQK^)':.?Z$:D>$N8B810)\Y PAH1Q M$$Q1SS2:,3M#>QR1^4D@R,;?'0[+X=1%21-2B"PFZ9+D95_[W":BGMW7 M1"C-
A=)HQUXT+1)78XQMZD&WA$%!$53[3L8,3:U^^WW6K&U*-B3<(DW^YD M#-)2RY4@:;$6&2G6?D("^2"7A/*9W-=9&A%!'BY;Q=0VVUM,),V%TFC'#M:+
MB=P2![5Q%$T5TVK$M+3[[;XG9/'P;Q(@Z\DW93I6/Z>E$O#9$4V(@O3Q?M> M3FI;[.TDDN9":;1CW^]=1&X)@(XBJ8ZV605IG8|^J23XIO@C"O!H^_QTMH MI@&EN5 :
[=B_8YV6T! #2N,HFJIEDV.8^B#C[&^0>ROEDFXKH4$'E.9";;1C M]YJ7.BV16|\@-(ZBJ5HV(8FI3TDZOUJV'"1;182F*%":'Z71CAVJ%Q&:FT!I M'$5316RB$U,[/#Z|R|+'M?D
MN8$.ZQH0H,3*.V%TBB4YD%I#$KC*)KJ8!.RF/J4Y2Y+ R$6.5EF:4S"/-]6 M7:#LEJ698?%\<+(+>2?[X7SMR\UH.TGP5M]2:SMWM/%A>C9J2<|<:+,42O.@ M- :E<11-
%:^)5$SML67THE4&2=_EV1A(%]=@B8I->TPD76.;8(&)%":!Z4Q M*(VC:.KIODU(8NF']T\?QH(TEF^*=R,R;8;IP7T-JVG*;7%&VU$+VBR%TCPH
MC4%I'$53/6OB$$L_6G_\E;W5*&BT ;6Y4!]%TCPHC4%I'$53M6O"#LO" E*P MH%$&E.9":11*\Z T!]5Q%$UUL DW+/W@^W>>#]^G]C81&E[4M,/>>O1QTM)=
M4VB['I3&H#2.HJF6-5F\U9%5'|_I_B;T6ST,?)>)#[ZVG"]& O2SS#]Q4KV^ MA=[&08,)*(U":1Z4QI TC]*I5C91A34"[|_03)*2]G$W0.M/V5@ I+1XTI[AIAT-Z8]-P#.>XLX4&$% :@]
(XBJ8] MU000EG[F!]U-*L=)9 ,?EKO.]>G%M(X!7SV|MVO0.**F';EF3>QCUZ!! Y3& MH#2.HJFN-4&#I0\:VK[8:6=X2#F#;7FM"]T<#WVCO16$SO* TBB4YD%I#$KC M*)HJ:A-
,6.#)'A8THX#27"B-0FD>E,:@-(ZBJ=>\:.(.6QIG|)2]0?VE1!* M(G0:B?2:EO MM+=E,2B-HVBJ]$VB88,3#1N::$!I+I1&H30/2F-0&D?15 .PEXZ"GOM*.S%H|XBRK";*,/61QEW
M(@ODDA7PH_&PE"O*0)MN\G)51\FFMPNV:*">]fHTS+IQC MW: 9!91&H30/2F-0&D?15-V:C,+6G_W_?\T3[V#K)@3.]+6]|8.F$U":!Z4Q M*
(VC:*I]33IAZ].)MYHGWM&L7DQH>@&E42C-@\(8E,91-%?),3Q2,ZH+1N9LTK@O&YQ9_MZH+)NO67=<%E]>GN/H[JLW3]P]I>9>D3R_?/'IV$AFRH+AD&-
M=7=8ZP36)%_2I%CGA"8+L6BIIQWUE@8PE.|Q_T:MES=Z:VF)<[&Y(*;QGEB& MY;1LT$Q?_O.VN2#6Z&2YVU4>71#;/%E.SVC=/KWQWOGE=DLY.V?7G7[O_)QR
MIZU<^23MO;)VQ;-/\;8/N?AK*Y*"T,?R\3__DFN0SX6(_^V;-[M#N>TX\K. MX5. ^\0-Q/9!'_UQDCV(P_>$?YMCXJ4T3),Q%PB@2YB%A# GC()BBGK-7S]'1
MIY^31Y$7<2E=F,Z+.P8IF$85)'/0[E>KV@:;$|M\O29#;A\'P11S1GMS1EIS:+R)TN?*G)M5 M)D3YK-45++:.O*TB8BX11),Q#PA@2QD$P1;GQ7KDQM!<(]5#PEPDC")A'A+& MD#
,@BGJ3?;J3:1'NYN5/,:M_$*0FR39^A&YE3\OR=R/_.Q$%ZGE]74/"7.1 M,#IYW?,YAO&ZAT0VRI P#H(6EWNM;KLWXF2O\EL'8HE^2(682!=^W6Y# ,1 MM5FFQ?>U#
ESD3"*A'E(&$/". BFJ/AQK^)':.?Z$:D>$N8B810)\Y PAH1Q M$$Q1SS2:,3M#>QR1^4D@R,;?'0[+X=1%21-2B"PFZ9+D95_[W":BGMW7 M1"C-
A=)HQUXT+1)78XQMZD&WA$%!$53[3L8,3:U^^WW6K&U*-B3<(DW^YD M#-)2RY4@:;$6&2G6?D("^2"7A/*9W-=9&A%!'BY;Q=0VVUM,),V%TFC'#M:+
MB=P2![5Q%$T5TVK$M+3[[;XG9/'P;Q(@Z\DW93I6/Z>E$O#9$4V(@O3Q?M> M3FI;[.TDDN9":;1CW^]=1&X)@(XBJ8ZV605IG8|^J23XIO@C"O!H^_QTMH MI@&EN5 :
[=B_8YV6T! #2N,HFJIEDV.8^B#C[&^0>ROEDFXKH4$'E.9";;1C M]YJ7.BV16|\@-(ZBJ5HV(8FI3TDZOUJV'"1;182F*%":'Z71CAVJ%Q&:FT!I M'$5316RB$U,[/#Z|R|+'M?D
MN8$.ZQH0H,3*.V%TBB4YD%I#$KC*)KJ8!.RF/J4Y2Y+ R$6.5EF:4S"/-]6 M7:#LEJ698?%\<+(+>2?[X7SMR\UH.TGP5M]2:SMWM/%A>C9J2<|<:+,42O.@ M- :E<11-
%:^)5$SML67THE4&2=_EV1A(%]=@B8I->TPD76.;8(&)%":!Z4Q M*(VC:.KIODU(8NF']T\?QH(TEF^*=R,R;8;IP7T-JVG*;7%&VU$+VBR%TCPH
MC4%I'$53/6OB$$L_6G_\E;W5*&BT ;6Y4!]%TCPHC4%I'$53M6O"#LO" E*P MH%$&E.9":11*\Z T!]5Q%$UUL DW+/W@^W>>#]^G]C81&E[4M,/>>O1QTM)=
M4VB['I3&H#2.HJF6-5F\U9%5'|_I_B;T6ST,?)>)#[ZVG"]& O2SS#]Q4KV^ MA=[&08,)*(U":1Z4QI TC]*I5C91A34"[|_03)*2]G$W0.M/V5@ I+1XTI[AIAT-Z8]-P#.>XLX4&$% :@]
(XBJ8] MU000EG[F!]U-*L=)9 ,?EKO.]>G%M(X!7SV|MVO0.**F';EF3>QCUZ!! Y3& MH#2.HJFN-4&#I0\:VK[8:6=X2#F#;7FM"]T<#WVCO16$SO* TBB4YD%I#$KC M*)HJ:A-
,6.#)'A8THX#27"B-0FD>E,:@-(ZBJ=>\:.(.6QIG|)2]0?VE1!* M(G0:B?2:EO MM+=E,2B-HVBJ]$VB88,3#1N::$!I+I1&H30/2F-0&D?15 .PEXZ"GOM*.S%H|XBRK";*,/61QEW
M(@ODDA7PH_&PE"O*0)MN\G)51\FFMPNV:*">]fHTS+IQC MW: 9!91&H30/2F-0&D?15-V:C,+6G_W_?\T3[V#K)@3.]+6]|8.F$U":!Z4Q M*
(VC:*I]33IAZ].)MYHGWM&L7DQH>@&E42C-@\(8E,91-%?),3Q2,ZH+1N9LTK@O&YQ9_MZH+)NO67=<%E]>GN/H[JLW3]P]I>9>D3R_?/'IV$AFRH+AD&-
M=7=8ZP36)%_2I%CGA"8+L6BIIQWUE@8PE.|Q_T:MES=Z:VF)<[&Y(*;QGEB& MY;1LT$Q?_O.VN2#6Z&2YVU4>71#;/%E.SVC=/KWQWOGE=DLY.V?7G7[O_)QR
MIZU<^23MO;)VQ;-/\;8/N?AK*Y*"T,?R\3__DFN0SX6(_^V;-[M#N>TX\K. MX5. ^\0-Q/9!'_UQDCV(P_>$?YMCXJ4T3),Q%PB@2YB%A# GC()BBGK-7S]'1
MIY^31Y$7<2E=F,Z+.P8IF$85)'/0[E>KV@:;$|M\O29#;A\'P11S1GMS1EIS:+R)TN?*G)M5 M)D3YK-45++:.O*TB8BX11),Q#PA@2QD$P1;GQ7KDQM!<(]5#PEPDC")A'A+& MD#
,@BGJ3?;J3:1'NYN5/,:M_$*0FR39^A&YE3\OR=R/_.Q$%ZGE]74/"7.1 M,#IYW?,YAO&ZAT0VRI P#H(6EWNM;KLWXF2O\EL'8HE^2(682!=^W6Y# ,1 MM5FFQ?>U#
ESD3"*A'E(&$/". BFJ/AQK^)':.?Z$:D>$N8B810)\Y PAH1Q M$$Q1SS2:,3M#>QR1^4D@R,;?'0[+X=1%21-2B"PFZ9+D95_[W":BGMW7 M1"C-
A=)HQUXT+1)78XQMZD&WA$%!$53[3L8,3:U^^WW6K&U*-B3<(DW^YD M#-)2RY4@:;$6&2G6?D("^2"7A/*9W-=9&A%!'BY;Q=0VVUM,),V%TFC'#M:+
MB=P2![5Q%$T5TVK$M+3[[;XG9/'P;Q(@Z\DW93I6/Z>E$O#9$4V(@O3Q?M> M3FI;[.TDDN9":;1CW^]=1&X)@(XBJ8ZV605IG8|^J23XIO@C"O!H^_QTMH MI@&EN5 :
[=B_8YV6T! #2N,HFJIEDV.8^B#C[&^0>ROEDFXKH4$'E.9";;1C M]YJ7.BV16|\@-(ZBJ5HV(8FI3TDZOUJV'"1;182F*%":'Z71CAVJ%Q&:FT!I M'$5316RB$U,[/#Z|R|+'M?D
MN8$.ZQH0H,3*.V%TBB4YD%I#$KC*)KJ8!.RF/J4Y2Y+ R$6.5EF:4S"/-]6 M7:#LEJ698?%\<+(+>2?[X7SMR\UH.TGP5M]2:SMWM/%A>C9J2<|<:+,42O.@ M- :E<11-
%:^)5$SML67THE4&2=_EV1A(%]=@B8I->TPD76.;8(&)%":!Z4Q M*(VC:.KIODU(8NF']T\?QH(TEF^*=R,R;8;IP7T-JVG*;7%&VU$+VBR%TCPH
MC4%I'$53/6OB$$L_6G_\E;W5*&BT ;6Y4!]%TCPHC4%I'$53M6O"#LO" E*P MH%$&E.9":11*\Z T!]5Q%$UUL DW+/W@^W>>#]^G]C81&E[4M,/>>O1QTM)=
M4VB['I3&H#2.HJF6-5F\U9%5'|_I_B;T6ST,?)>)#[ZVG"]& O2SS#]Q4KV^ MA=[&08,)*(U":1Z4QI TC]*I5C91A34"[|_03)*2]G$W0.M/V5@ I+1XTI[AIAT-Z8]-P#.>XLX4&$% :@]
(XBJ8] MU000EG[F!]U-*L=)9 ,?EKO.]>G%M(X!7SV|MVO0.**F';EF3>QCUZ!! Y3& MH#2.HJFN-4&#I0\:VK[8:6=X2#F#;7FM"]T<#WVCO16$SO* TBB4YD%I#$KC M*)HJ:A-
,6.#)'A8THX#27"B-0FD>E,:@-(ZBJ=>\:.(.6QIG|)2]0?VE1!* M(G0:B?2:EO MM+=E,2B-HVBJ]$VB88,3#1N::$!I+I1&H30/2F-0&D?15 .PEXZ"GOM*.S%H|XBRK";*,/61QEW
M(@ODDA7PH_&PE"O*0)MN\G)51\FFMPNV:*">]fHTS+IQC MW: 9!91&H30/2F-0&D?15-V:C,+6G_W_?\T3[V#K)@3.]+6]|8.F$U":!Z4Q M*
(VC:*I]33IAZ].)MYHGWM&L7DQH>@&E42C-@\(8E,91-%?),3Q2,ZH+1N9LTK@O&YQ9_MZH+)NO67=<%E]>GN/H[JLW3]P]I>9>D3R_?/'IV$AFRH+AD&-
M=7=8ZP36)%_2I%CGA"8+L6BIIQWUE@8PE.|Q_T:MES=Z:VF)<[&Y(*;QGEB& MY;1LT$Q?_O

H965T&UL4$L! A0#% @ X((S6?:9"E+8!@ MC4@ !D ("!%"4! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ X((S67=@9UIH!0 4!T !D M ("!&CL! 'AL+W=O&PO=V]R:W-H M965T&UL4$L! M A0#% @ X((S67&AK,SP @ _08 !D ("!YT@! 'AL M+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ X((S M63M+Y?RP!0 G!T !D ("!CE0! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ X((S6<.[\NF! W1L M !D ("!L&$! 'AL+W=O&PO=V]R:W-H965TVDG MG 0 %44 9 " @5AI 0!X;"]W;W)K&UL4$L! A0#% @ X((S65NO]$4L! SQ$!D M ("!*VX! 'AL+W=O&PO=V]R:W-H965T M&UL4$L! A0# M% @ X((S6790D&46!0 O!T !D ("!BGH! 'AL+W=O M&PO=V]R:W-H965T&UL4$L! A0#% @ X((S63JS M/ ?0 @ V0< !D ("!3(8! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ X((S6:N\6 >2!@]#4 !D M ("!&I$! 'AL+W=O&PO M=V]R:W-H965T&UL4$L! A0#% @ X((S64V;\(&PO=V]R:W-H965T.M 0!X;"]S='EL97,N>&UL4$L! A0#% @ X((S69>*NQS M $P(L (!7[$! %]R96QS+RYR96QS4$L! A0#% M @ X((S68(@&I2F!0 =2X | (!2+(! 'AL+W=O7!E&UL4$L%!@ !. $X 614 *^| 0 $! end XML 89 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show= {};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE') {var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p ;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 90 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 92 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.3 html2123421false850false9 falsefalseR1.htm995200090 - Document - Document And Entity InformationSheethttp://www.rezolutebio.com/role/DocumentDocumentAndEntityInformationDocument And Entity InformationCover1 falsefalseR2.htm995200100 - Statement - Consolidated Balance SheetsSheethttp://www.rezolutebio.com/role/StatementConsolidatedBalanceSheetsConsolidated Balance SheetsStatements2 falsefalseR3.htm995200105 - Statement - Consolidated Balance Sheets (Parenthetical)Sheethttp://www.rezolutebio.com/role/StatementConsolidatedBalanceSheetsParentheticalConsolidated Balance Sheets (Parenthetical)Statements3 falsefalseR4.htm995200200 - Statement - Consolidated Statements of Operations and Comprehensive LossSheethttp://www.rezolutebio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossConsolidated Statements of Operations and Comprehensive LossStatements4 falsefalseR5.htm995200300 - Statement - Consolidated Statements of Shareholders' EquitySheethttp://www.rezolutebio.com/role/StatementConsolidatedStatementsOfShareholdersEquityConsolidated Statements of Shareholders' EquityStatements5 falsefalseR6.htm995200400 - Statement - Consolidated Statements of Cash FlowsSheethttp://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlowsConsolidated Statements of Cash FlowsStatements6 falsefalseR7.htm995210101 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIESSheethttp://www.rezolutebio.com/role/DisclosureNatureOfOperationsAndSummaryOfSignificantAccountingPoliciesNATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIESNotes7 falsefalseR8.htm995210201 - Disclosure - LIQUIDITYSheethttp://www.rezolutebio.com/role/DisclosureLiquidityLIQUIDITYNotes8 falsefalseR9.htm995210301 - Disclosure - INVESTMENTS IN MARKETABLE DEBT SECURITIESSheethttp://www.rezolutebio.com/role/DisclosureInvestmentsInMarketableDebtSecuritiesINVESTMENTS IN MARKETABLE DEBT SECURITIESNotes9 falsefalseR10.htm995210401 - Disclosure - LEASESSheethttp://www.rezolutebio.com/role/DisclosureLeasesLEASESNotes10 falsefalseR11.htm995210501 - Disclosure - LICENSE AGREEMENTSSheethttp://www.rezolutebio.com/role/DisclosureLicenseAgreementsLICENSE AGREEMENTSNotes11 falsefalseR12.htm995210601 - Disclosure - EMBEDDED DERIVATIVE LIABILITYSheethttp://www.rezolutebio.com/role/DisclosureEmbeddedDerivativeLiabilityEMBEDDED DERIVATIVE LIABILITYNotes12 falsefalseR13.htm995210701 - Disclosure - SHAREHOLDERS' EQUITYSheethttp://www.rezolutebio.com/role/DisclosureShareholdersEquitySHAREHOLDERS' EQUITYNotes13 falsefalseR14.htm995210801 - Disclosure - SHARE-BASED COMPENSATION AND WARRANTSSheethttp://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsSHARE-BASED COMPENSATION AND WARRANTSNotes14 falsefalseR15.htm995210901 - Disclosure - INCOME TAXESSheethttp://www.rezolutebio.com/role/DisclosureIncomeTaxesINCOME TAXESNotes15 falsefalseR16.htm995211001 - Disclosure - COMMITMENTS AND CONTINGENCIESSheethttp://www.rezolutebio.com/role/DisclosureCommitmentsAndContingenciesCOMMITMENTS AND CONTINGENCIESNotes16 falsefalseR17.htm995211101 - Disclosure - RELATED PARTY TRANSACTIONSSheethttp://www.rezolutebio.com/role/DisclosureRelatedPartyTransactionsRELATED PARTY TRANSACTIONSNotes17 falsefalseR18.htm995211201 - Disclosure - SUPPLEMENTAL FINANCIAL INFORMATIONSheethttp://www.rezolutebio.com/role/DisclosureSupplementalFinancialInformationSUPPLEMENTAL FINANCIAL INFORMATIONNotes18 falsefalseR19.htm995211301 - Disclosure - NET LOSS PER SHARESheethttp://www.rezolutebio.com/role/DisclosureNetLossPerShareNET LOSS PER SHARENotes19 falsefalseR20.htm995211401 - Disclosure - FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONSSheethttp://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrationsFINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONSNotes20 falsefalseR21.htm995211501 - Disclosure - SUBSEQUENT EVENTSSheethttp://www.rezolutebio.com/role/DisclosureSubsequentEventsSUBSEQUENT EVENTSNotes21 falsefalseR22.htm995410 - Disclosure - Pay vs Performance DisclosureSheethttp://xbrl.sec.gov/ecd/role/PvpDisclosurePay vs Performance DisclosureNotes22 falsefalseR23.htm995445 - Disclosure - Insider Trading ArrangementsSheethttp://xbrl.sec.gov/ecd/role/InsiderTradingArrangementsInsider Trading ArrangementsNotes23 falsefalseR24.htm99920102 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)Sheethttp://www.rezolutebio.com/role/DisclosureNatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPoliciesNATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)Policies24 falsefalseR25.htm99930303 - Disclosure - INVESTMENTS IN MARKETABLE DEBT SECURITIES (Tables)Sheethttp://www.rezolutebio.com/role/DisclosureInvestmentsInMarketableDebtSecuritiesTablesINVESTMENTS IN MARKETABLE DEBT SECURITIES (Tables)Tableshttp://www.rezolutebio.com/role/DisclosureInvestmentsInMarketableDebtSecurities25 falsefalseR26.htm99930403 - Disclosure - LEASES (Tables)Sheethttp://www.rezolutebio.com/role/DisclosureLeasesTablesLEASES (Tables)Tableshttp://www.rezolutebio.com/role/DisclosureLeases26 falsefalseR27.htm99930703 - Disclosure - SHAREHOLDERS' EQUITY (Tables)Sheethttp://www.rezolutebio.com/role/DisclosureShareholdersEquityTablesSHAREHOLDERS' EQUITY (Tables)Tableshttp://www.rezolutebio.com/role/DisclosureShareholdersEquity27 falsefalseR28.htm99930803 - Disclosure - SHARE-BASED COMPENSATION AND WARRANTS (Tables)Sheethttp://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsTablesSHARE-BASED COMPENSATION AND WARRANTS (Tables)Tableshttp://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrants28 falsefalseR29.htm99930903 - Disclosure - INCOME TAXES (Tables)Sheethttp://www.rezolutebio.com/role/DisclosureIncomeTaxesTablesINCOME TAXES (Tables)Tableshttp://www.rezolutebio.com/role/DisclosureIncomeTaxes29 falsefalseR30.htm99931203 - Disclosure - SUPPLEMENTAL FINANCIAL INFORMATION (Tables)Sheethttp://www.rezolutebio.com/role/DisclosureSupplementalFinancialInformationTablesSUPPLEMENTAL FINANCIAL INFORMATION (Tables)Tableshttp://www.rezolutebio.com/role/DisclosureSupplementalFinancialInformation30 falsefalseR31.htm99931303 - Disclosure - NET LOSS PER SHARE (Tables)Sheethttp://www.rezolutebio.com/role/DisclosureNetLossPerShareTablesNET LOSS PER SHARE (Tables)Tableshttp://www.rezolutebio.com/role/DisclosureNetLossPerShare31 falsefalseR32.htm99931403 - Disclosure - FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS (Tables)Sheethttp://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrationsTablesFINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS (Tables)Tableshttp://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrations32 falsefalseR33.htm99940101 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)Sheethttp://www.rezolutebio.com/role/DisclosureNatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)Detailshttp://www.rezolutebio.com/role/DisclosureNatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies33 falsefalseR34.htm99940201 - Disclosure - LIQUIDITY (Details)Sheethttp://www.rezolutebio.com/role/DisclosureLiquidityDetailsLIQUIDITY (Details)Detailshttp://www.rezolutebio.com/role/DisclosureLiquidity34 falsefalseR35.htm99940301 - Disclosure - INVESTMENTS IN MARKETABLE DEBT SECURITIES - Investments in Marketable Securities (Details)Sheethttp://www.rezolutebio.com/role/DisclosureInvestmentsInMarketableDebtSecuritiesInvestmentsInMarketableSecuritiesDetailsINVESTMENTS IN MARKETABLE DEBT SECURITIES - Investments in Marketable Securities (Details)Details35 falsefalseR36.htm99940302 - Disclosure - INVESTMENTS IN MARKETABLE DEBT SECURITIES - Additional Information (Details)Sheethttp://www.rezolutebio.com/role/DisclosureInvestmentsInMarketableDebtSecuritiesAdditionalInformationDetailsINVESTMENTS IN MARKETABLE DEBT SECURITIES - Additional Information (Details)Details36 falsefalseR37.htm99940303 - Disclosure - INVESTMENTS IN MARKETABLE DEBT SECURITIES - Cash and Cash Equivalents and Marketable Securities Held (Details)Sheethttp://www.rezolutebio.com/role/DisclosureInvestmentsInMarketableDebtSecuritiesCashAndCashEquivalentsAndMarketableSecuritiesHeldDetailsINVESTMENTS IN MARKETABLE DEBT SECURITIES - Cash and Cash Equivalents and Marketable Securities Held (Details)Details37 falsefalseR38.htm99940401 - Disclosure - LEASES - Additional Information (Details)Sheethttp://www.rezolutebio.com/role/DisclosureLeasesAdditionalInformationDetailsLEASES - Additional Information (Details)Details38 falsefalseR39.htm99940402 - Disclosure - LEASES - Assets and Operating Lease Liabilities (Details)Sheethttp://www.rezolutebio.com/role/DisclosureLeasesAssetsAndOperatingLeaseLiabilitiesDetailsLEASES - Assets and Operating Lease Liabilities (Details)Details39 falsefalseR40.htm99940403 - Disclosure - LEASES - Operating Lease Expense (Details)Sheethttp://www.rezolutebio.com/role/DisclosureLeasesOperatingLeaseExpenseDetailsLEASES - Operating Lease Expense (Details)Details40 falsefalseR41.htm99940404 - Disclosure - LEASES - Future Operating Lease Payments (Details)Sheethttp://www.rezolutebio.com/role/DisclosureLeasesFutureOperatingLeasePaymentsDetailsLEASES - Future Operating Lease Payments (Details)Details41 falsefalseR42.htm99940501 - Disclosure - LICENSE AGREEMENTS (Details)Sheethttp://www.rezolutebio.com/role/DisclosureLicenseAgreementsDetailsLICENSE AGREEMENTS (Details)Detailshttp://www.rezolutebio.com/role/DisclosureLicenseAgreements42 falsefalseR43.htm99940601 - Disclosure - EMBEDDED DERIVATIVE LIABILITY (Details)Sheethttp://www.rezolutebio.com/role/DisclosureEmbeddedDerivativeLiabilityDetailsEMBEDDED DERIVATIVE LIABILITY (Details)Detailshttp://www.rezolutebio.com/role/DisclosureEmbeddedDerivativeLiability43 falsefalseR44.htm99940701 - Disclosure - SHAREHOLDERS' EQUITY - Pre-Funded Warrants (Details)Sheethttp://www.rezolutebio.com/role/DisclosureShareholdersEquityPreFundedWarrantsDetailsSHAREHOLDERS' EQUITY - Pre-Funded Warrants (Details)Details44 falsefalseR45.htm99940702 - Disclosure - SHAREHOLDERS' EQUITY - 2024 Underwritten Offering (Details)Sheethttp://www.rezolutebio.com/role/DisclosureShareholdersEquity2024UnderwrittenOfferingDetailsSHAREHOLDERS' EQUITY - 2024 Underwritten Offering (Details)Details45 falsefalseR46.htm99940703 - Disclosure - SHAREHOLDERS' EQUITY - Exchange Agreement (Details)Sheethttp://www.rezolutebio.com/role/DisclosureShareholdersEquityExchangeAgreementDetailsSHAREHOLDERS' EQUITY - Exchange Agreement (Details)Details46 falsefalseR47.htm99940704 - Disclosure - SHAREHOLDERS' EQUITY - Jefferies Open Market Sales Agreement (Details)Sheethttp://www.rezolutebio.com/role/DisclosureShareholdersEquityJefferiesOpenMarketSalesAgreementDetailsSHAREHOLDERS' EQUITY - Jefferies Open Market Sales Agreement (Details)Details47 falsefalseR48.htm99940705 - Disclosure - SHAREHOLDERS' EQUITY - 2022 Private Placement (Details)Sheethttp://www.rezolutebio.com/role/DisclosureShareholdersEquity2022PrivatePlacementDetailsSHAREHOLDERS' EQUITY - 2022 Private Placement

(Details)Details48 falsefalseR49.htm99940801 - Disclosure - SHARE-BASED COMPENSATION AND WARRANTS - Stock Option Plans (Details)Sheethttp://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsStockOptionPlansDetailsSHARE-BASED COMPENSATION AND WARRANTS - Stock Option Plans (Details)Details49 falsefalseR50.htm99940802 - Disclosure - SHARE-BASED COMPENSATION AND WARRANTS - 2022 Employee Stock Purchase Plan (Details)Sheethttp://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrants2022EmployeeStockPurchasePlanDetailsSHARE-BASED COMPENSATION AND WARRANTS - 2022 Employee Stock Purchase Plan (Details)Details50 falsefalseR51.htm99940803 - Disclosure - SHARE-BASED COMPENSATION AND WARRANTS - Stock Options Outstanding (Details)Sheethttp://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsStockOptionsOutstandingDetailsSHARE-BASED COMPENSATION AND WARRANTS - Stock Options Outstanding (Details)Details51 falsefalseR52.htm99940804 - Disclosure - SHARE-BASED COMPENSATION AND WARRANTS - Weighted Average Assumptions (Details)Sheethttp://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsWeightedAverageAssumptionsDetailsSHARE-BASED COMPENSATION AND WARRANTS - Weighted Average Assumptions (Details)Details52 falsefalseR53.htm99940805 - Disclosure - SHARE-BASED COMPENSATION AND WARRANTS - Share Based Compensation Expense (Details)Sheethttp://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsShareBasedCompensationExpenseDetailsSHARE-BASED COMPENSATION AND WARRANTS - Share Based Compensation Expense (Details)Details53 falsefalseR54.htm99940806 - Disclosure - SHARE-BASED COMPENSATION AND WARRANTS - Inducement Grant (Details)Sheethttp://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsInducementGrantDetailsSHARE-BASED COMPENSATION AND WARRANTS - Inducement Grant (Details)Details54 falsefalseR55.htm99940807 - Disclosure - SHARE-BASED COMPENSATION AND WARRANTS - Pre-Funded Warrants (Details)Sheethttp://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsPreFundedWarrantsDetailsSHARE-BASED COMPENSATION AND WARRANTS - Pre-Funded Warrants (Details)Details55 falsefalseR56.htm99940808 - Disclosure - SHARE-BASED COMPENSATION AND WARRANTS - Summary of Legacy Warrants (Details)Sheethttp://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsSummaryOfLegacyWarrantsDetailsSHARE-BASED COMPENSATION AND WARRANTS - Summary of Legacy Warrants (Details)Details56 falsefalseR57.htm99940901 - Disclosure - INCOME TAXES - Additional Information (Details)Sheethttp://www.rezolutebio.com/role/DisclosureIncomeTaxesAdditionalInformationDetailsINCOME TAXES - Additional Information (Details)Details57 falsefalseR58.htm99940902 - Disclosure - INCOME TAXES - Income Tax Expense (Details)Sheethttp://www.rezolutebio.com/role/DisclosureIncomeTaxesIncomeTaxExpenseDetailsINCOME TAXES - Income Tax Expense (Details)Details58 falsefalseR59.htm99940903 - Disclosure - INCOME TAXES - Deferred Income Tax Assets and Liabilities (Details)Sheethttp://www.rezolutebio.com/role/DisclosureIncomeTaxesDeferredIncomeTaxAssetsAndLiabilitiesDetailsINCOME TAXES - Deferred Income Tax Assets and Liabilities (Details)Details59 falsefalseR60.htm99941001 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)Sheethttp://www.rezolutebio.com/role/DisclosureCommitmentsAndContingenciesDetailsCOMMITMENTS AND CONTINGENCIES (Details)Detailshttp://www.rezolutebio.com/role/DisclosureCommitmentsAndContingencies60 falsefalseR61.htm99941101 - Disclosure - RELATED PARTY TRANSACTIONS (Details)Sheethttp://www.rezolutebio.com/role/DisclosureRelatedPartyTransactionsDetailsRELATED PARTY TRANSACTIONS (Details)Detailshttp://www.rezolutebio.com/role/DisclosureRelatedPartyTransactions61 falsefalseR62.htm99941201 - Disclosure - SUPPLEMENTAL FINANCIAL INFORMATION - Cash and Cash Equivalents (Details)Sheethttp://www.rezolutebio.com/role/DisclosureSupplementalFinancialInformationCashAndCashEquivalentsDetailsSUPPLEMENTAL FINANCIAL INFORMATION - Cash and Cash Equivalents (Details)Details62 falsefalseR63.htm99941202 - Disclosure - SUPPLEMENTAL FINANCIAL INFORMATION - Property and Equipment (Details)Sheethttp://www.rezolutebio.com/role/DisclosureSupplementalFinancialInformationPropertyAndEquipmentDetailsSUPPLEMENTAL FINANCIAL INFORMATION - Property and Equipment (Details)Details63 falsefalseR64.htm99941301 - Disclosure - NET LOSS PER SHARE - Schedule of basic and diluted net loss per share (Details)Sheethttp://www.rezolutebio.com/role/DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareDetailsNET LOSS PER SHARE - Schedule of basic and diluted net loss per share (Details)Details64 falsefalseR65.htm99941302 - Disclosure - NET LOSS PER SHARE - Anti-dilutive (Details)Sheethttp://www.rezolutebio.com/role/DisclosureNetLossPerShareAntiDilutiveDetailsNET LOSS PER SHARE - Anti-dilutive (Details)Details65 falsefalseR66.htm99941401 - Disclosure - FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS - Fair Value on a Recurring Basis (Details)Sheethttp://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrationsFairValueOnRecurringBasisDetailsFINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS - Fair Value on a Recurring Basis (Details)Details66 falsefalseR67.htm99941402 - Disclosure - FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS - Valuation Model Inputs of Exchange PFWs (Details)Sheethttp://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrationsValuationModelInputsOfExchangePfwsDetailsFINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS - Valuation Model Inputs of Exchange PFWs (Details)Details67 falsefalseR68.htm99941403 - Disclosure - FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS - Summary of Changes in the Fair Value (Details)Sheethttp://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrationsSummaryOfChangesInFairValueDetailsFINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS - Summary of Changes in the Fair Value (Details)Details68 falsefalseR69.htm99941404 - Disclosure - FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS - Significant Concentrations (Details)Sheethttp://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrationsSignificantConcentrationsDetailsFINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS - Significant Concentrations (Details)Details69 falsefalseR70.htm99941501 - Disclosure - SUBSEQUENT EVENTS (Details)Sheethttp://www.rezolutebio.com/role/DisclosureSubsequentEventsDetailsSUBSEQUENT EVENTS (Details)Detailshttp://www.rezolutebio.com/role/DisclosureSubsequentEvents70 falsefalseAll ReportsBookAll Reports rzlt-20240630.xsdrzlt-20240630_cal.xmlrzlt-20240630_def.xmlrzlt-20240630_lab.xmlrzlt-20240630_pre.xmlrzlt-20240630x10k.htm http://fasb.org/us-gaap/2024http://xbrl.sec.gov/dei/2024http://xbrl.sec.gov/ecd/2024truetrue JSON 95 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "rzlt-20240630x10k.htm": { "nsprefix": "rzlt", "nsuri": "http://www.rezolutebio.com/20240630", "dts": { "schema": { "local": ["rzlt-20240630.xsd"], "remote": ["http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/2023/calculation-1.1.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"] }, "calculationLink": { "local": ["rzlt-20240630_cal.xml"] }, "definitionLink": { "local": ["rzlt-20240630_def.xml"] }, "labelLink": { "local": ["rzlt-20240630_lab.xml"] }, "presentationLink": { "local": ["rzlt-20240630_pre.xml"] }, "inline": { "local": ["rzlt-20240630x10k.htm"] } }, "keyStandard": 261, "keyCustom": 81, "axisStandard": 29, "axisCustom": 1, "memberStandard": 38, "memberCustom": 43, "hidden": { "total": 21, "http://fasb.org/us-gaap/2024": 11, "http://xbrl.sec.gov/ecd/2024": 4, "http://xbrl.sec.gov/dei/2024": 5, "http://www.rezolutebio.com/20240630": 1 }, "contextCount": 212, "entityCount": 1, "segmentCount": 85, "elementCount": 670, "unitCount": 9, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 604, "http://xbrl.sec.gov/dei/2024": 40, "http://xbrl.sec.gov/ecd/2024": 4 }, "report": { "R1": { "role": "http://www.rezolutebio.com/role/DocumentDocumentAndEntityInformation", "longName": "995200090 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_xrylODgBfkGQGHTIFxpN8g", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_xrylODgBfkGQGHTIFxpN8g", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.rezolutebio.com/role/StatementConsolidatedBalanceSheets", "longName": "995200100 - Statement - Consolidated Balance Sheets", "shortName": "Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "As_Of_6_30_2024_Ck_cR96bq0--G-L-1VK2iA", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "Unit_Standard_USD_-9GsQDP7XEazOxMca8p5dw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_Ck_cR96bq0--G-L-1VK2iA", "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent", "unitRef": "Unit_Standard_USD_-9GsQDP7XEazOxMca8p5dw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "first": true, "unique": true } }, "R3": { "role": "http://www.rezolutebio.com/role/StatementConsolidatedBalanceSheetsParenthetical", "longName": "995200105 - Statement - Consolidated Balance Sheets (Parenthetical)", "shortName": "Consolidated Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "As_Of_6_30_2024_Ck_cR96bq0--G-L-1VK2iA", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "Unit_Divide_USD_shares_6PoYGnLVe0e5mFb02YKF6A", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["us-gaap:PreferredStockParOrStatedValuePerShare", "p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_Ck_cR96bq0--G-L-1VK2iA", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "Unit_Divide_USD_shares_6PoYGnLVe0e5mFb02YKF6A", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["us-gaap:PreferredStockParOrStatedValuePerShare", "p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "first": true, "unique": true } }, "R4": { "role": "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss", "longName": "995200200 - Statement - Consolidated Statements of Operations and Comprehensive Loss", "shortName": "Consolidated Statements of Operations and Comprehensive Loss", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_xrylODgBfkGQGHTIFxpN8g", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "Unit_Standard_USD_-9GsQDP7XEazOxMca8p5dw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_xrylODgBfkGQGHTIFxpN8g", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "Unit_Standard_USD_-9GsQDP7XEazOxMca8p5dw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "first": true, "unique": true } }, "R5": { "role": "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfShareholdersEquity", "longName": "995200300 - Statement - Consolidated Statements of Shareholders' Equity", "shortName": "Consolidated Statements of Shareholders' Equity", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_AmdwSPTiEk6_KuSry2PiOA", "name": "us-gaap:StockholdersEquity", "unitRef": "Unit_Standard_USD_-9GsQDP7XEazOxMca8p5dw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_AmdwSPTiEk6_KuSry2PiOA", "name": "us-gaap:StockholdersEquity", "unitRef": "Unit_Standard_USD_-9GsQDP7XEazOxMca8p5dw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "first": true, "unique": true } }, "R6": { "role": "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows", "longName": "995200400 - Statement - Consolidated Statements of Cash Flows", "shortName": "Consolidated Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_xrylODgBfkGQGHTIFxpN8g", "name": "us-gaap:ProfitLoss", "unitRef": "Unit_Standard_USD_-9GsQDP7XEazOxMca8p5dw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_xrylODgBfkGQGHTIFxpN8g", "name": "us-gaap:ProfitLoss", "unitRef": "Unit_Standard_USD_-9GsQDP7XEazOxMca8p5dw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "first": true, "unique": true } }, "R7": { "role": "http://www.rezolutebio.com/role/DisclosureNatureOfOperationsAndSummaryOfSignificantAccountingPolicies", "longName": "995210101 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "shortName": "NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_xrylODgBfkGQGHTIFxpN8g", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null,

```
"ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_xrylODgBfkGQGHTIFxpN8g", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "first": true, "unique": true } }, "R8": { "role": "http://www.rezolutebio.com/role/DisclosureLiquidity", "longName": "995210201 - Disclosure - LIQUIDITY", "shortName": "LIQUIDITY", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_xrylODgBfkGQGHTIFxpN8g", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_xrylODgBfkGQGHTIFxpN8g", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.rezolutebio.com/role/DisclosureInvestmentsInMarketableDebtSecurities", "longName": "995210301 - Disclosure - INVESTMENTS IN MARKETABLE DEBT SECURITIES", "shortName": "INVESTMENTS IN MARKETABLE DEBT SECURITIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_xrylODgBfkGQGHTIFxpN8g", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_xrylODgBfkGQGHTIFxpN8g", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.rezolutebio.com/role/DisclosureLeases", "longName": "995210401 - Disclosure - LEASES", "shortName": "LEASES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_xrylODgBfkGQGHTIFxpN8g", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_xrylODgBfkGQGHTIFxpN8g", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.rezolutebio.com/role/DisclosureLicenseAgreements", "longName": "995210501 - Disclosure - LICENSE AGREEMENTS", "shortName": "LICENSE AGREEMENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_xrylODgBfkGQGHTIFxpN8g", "name": "rzlt:LicenseAgreementsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_xrylODgBfkGQGHTIFxpN8g", "name": "rzlt:LicenseAgreementsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.rezolutebio.com/role/DisclosureEmbeddedDerivativeLiability", "longName": "995210601 - Disclosure - EMBEDDED DERIVATIVE LIABILITY", "shortName": "EMBEDDED DERIVATIVE LIABILITY", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_xrylODgBfkGQGHTIFxpN8g", "name": "us-gaap:DiscussionOfHybridInstrumentsAndEmbeddedDerivativesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_xrylODgBfkGQGHTIFxpN8g", "name": "us-gaap:DiscussionOfHybridInstrumentsAndEmbeddedDerivativesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.rezolutebio.com/role/DisclosureShareholdersEquity", "longName": "995210701 - Disclosure - SHAREHOLDERS' EQUITY", "shortName": "SHAREHOLDERS' EQUITY", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_xrylODgBfkGQGHTIFxpN8g", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_xrylODgBfkGQGHTIFxpN8g", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrants", "longName": "995210801 - Disclosure - SHARE-BASED COMPENSATION AND WARRANTS", "shortName": "SHARE-BASED COMPENSATION AND WARRANTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_xrylODgBfkGQGHTIFxpN8g", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_xrylODgBfkGQGHTIFxpN8g", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.rezolutebio.com/role/DisclosureIncomeTaxes", "longName": "995210901 - Disclosure - INCOME TAXES", "shortName": "INCOME TAXES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_xrylODgBfkGQGHTIFxpN8g", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_xrylODgBfkGQGHTIFxpN8g", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.rezolutebio.com/role/DisclosureCommitmentsAndContingencies", "longName": "995211001 - Disclosure - COMMITMENTS AND CONTINGENCIES", "shortName": "COMMITMENTS AND CONTINGENCIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_xrylODgBfkGQGHTIFxpN8g", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_xrylODgBfkGQGHTIFxpN8g", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.rezolutebio.com/role/DisclosureRelatedPartyTransactions", "longName": "995211101 - Disclosure - RELATED PARTY TRANSACTIONS", "shortName": "RELATED PARTY TRANSACTIONS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_xrylODgBfkGQGHTIFxpN8g", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_xrylODgBfkGQGHTIFxpN8g", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.rezolutebio.com/role/DisclosureSupplementalFinancialInformation", "longName": "995211201 - Disclosure - SUPPLEMENTAL FINANCIAL INFORMATION", "shortName": "SUPPLEMENTAL FINANCIAL INFORMATION", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_xrylODgBfkGQGHTIFxpN8g", "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_xrylODgBfkGQGHTIFxpN8g", "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.rezolutebio.com/role/DisclosureNetLossPerShare", "longName": "995211301 - Disclosure - NET LOSS PER SHARE", "shortName": "NET LOSS PER SHARE", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_xrylODgBfkGQGHTIFxpN8g", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_xrylODgBfkGQGHTIFxpN8g", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrations", "longName": "995211401 - Disclosure - FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS", "shortName": "FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_xrylODgBfkGQGHTIFxpN8g", "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_xrylODgBfkGQGHTIFxpN8g", "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.rezolutebio.com/role/DisclosureSubsequentEvents", "longName": "995211501 - Disclosure - SUBSEQUENT EVENTS", "shortName": "SUBSEQUENT EVENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_xrylODgBfkGQGHTIFxpN8g", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_xrylODgBfkGQGHTIFxpN8g", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "first": true, "unique": true } }, "R22": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_xrylODgBfkGQGHTIFxpN8g", "name": "us-gaap:NetIncomeLoss", "unitRef": "Unit_Standard_USD_-9GsQDP7XEazOxMca8p5dw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "first": true }, "uniqueAnchor": null }, "R23": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": null, "uniqueAnchor": null }, "R24": { "role": "http://www.rezolutebio.com/role/DisclosureNatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies", "longName": "99920102 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "shortName": "NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "24", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_xrylODgBfkGQGHTIFxpN8g", "name": "us-gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_xrylODgBfkGQGHTIFxpN8g", "name": "us-gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.rezolutebio.com/role/DisclosureInvestmentsInMarketableDebtSecuritiesTables", "longName": "99930303 - Disclosure - INVESTMENTS IN MARKETABLE DEBT SECURITIES (Tables)", "shortName": "INVESTMENTS IN MARKETABLE DEBT SECURITIES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_xrylODgBfkGQGHTIFxpN8g", "name": "us-gaap:MarketableSecuritiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_xrylODgBfkGQGHTIFxpN8g", "name": "us-
```

gaap:MarketableSecuritiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.rezolutebio.com/role/DisclosureLeasesTables", "longName": "99930403 - Disclosure - LEASES (Tables)", "shortName": "LEASES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_xrylODgBfkGQGHTIFxpN8g", "name": "rzlt:LesseeOperatingLeaseRightOfUseAssetsAndOperatingLeaseLiabilities", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_xrylODgBfkGQGHTIFxpN8g", "name": "rzlt:LesseeOperatingLeaseRightOfUseAssetsAndOperatingLeaseLiabilities", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.rezolutebio.com/role/DisclosureShareholdersEquityTables", "longName": "99930703 - Disclosure - SHAREHOLDERS' EQUITY (Tables)", "shortName": "SHAREHOLDERS' EQUITY (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_us-gaap_ClassOfWarrantOrRightAxis_rzlt_PreFundedWarrantsMember_FoNWcDxlrEu6Sp6Y_HVDhQ", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_us-gaap_ClassOfWarrantOrRightAxis_rzlt_PreFundedWarrantsMember_FoNWcDxlrEu6Sp6Y_HVDhQ", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsTables", "longName": "99930803 - Disclosure - SHARE-BASED COMPENSATION AND WARRANTS (Tables)", "shortName": "SHARE-BASED COMPENSATION AND WARRANTS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_xrylODgBfkGQGHTIFxpN8g", "name": "rzlt:ShareBasedPaymentArrangementOptionSharesAuthorizedOutstandingAndAvailableForFutureGrants", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_xrylODgBfkGQGHTIFxpN8g", "name": "rzlt:ShareBasedPaymentArrangementOptionSharesAuthorizedOutstandingAndAvailableForFutureGrants", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.rezolutebio.com/role/DisclosureIncomeTaxesTables", "longName": "99930903 - Disclosure - INCOME TAXES (Tables)", "shortName": "INCOME TAXES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_xrylODgBfkGQGHTIFxpN8g", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_xrylODgBfkGQGHTIFxpN8g", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.rezolutebio.com/role/DisclosureSupplementalFinancialInformationTables", "longName": "99931203 - Disclosure - SUPPLEMENTAL FINANCIAL INFORMATION (Tables)", "shortName": "SUPPLEMENTAL FINANCIAL INFORMATION (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_xrylODgBfkGQGHTIFxpN8g", "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_xrylODgBfkGQGHTIFxpN8g", "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.rezolutebio.com/role/DisclosureNetLossPerShareTables", "longName": "99931303 - Disclosure - NET LOSS PER SHARE (Tables)", "shortName": "NET LOSS PER SHARE (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_xrylODgBfkGQGHTIFxpN8g", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_xrylODgBfkGQGHTIFxpN8g", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrationsTables", "longName": "99931403 - Disclosure - FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS (Tables)", "shortName": "FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_xrylODgBfkGQGHTIFxpN8g", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:FinancialInstrumentsDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_xrylODgBfkGQGHTIFxpN8g", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:FinancialInstrumentsDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.rezolutebio.com/role/DisclosureNatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetails", "longName": "99940101 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)", "shortName": "NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_xrylODgBfkGQGHTIFxpN8g", "name": "rzlt:NumberOfWhollyOwnedSubsidiaries", "unitRef": "Unit_Standard_subsidiary_zUKqjmoN50ma9hqaNn5UKg", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "us-gaap:ConsolidationPolicyTextBlock", "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_xrylODgBfkGQGHTIFxpN8g", "name": "rzlt:NumberOfWhollyOwnedSubsidiaries", "unitRef": "Unit_Standard_subsidiary_zUKqjmoN50ma9hqaNn5UKg", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "us-gaap:ConsolidationPolicyTextBlock", "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.rezolutebio.com/role/DisclosureLiquidityDetails", "longName": "99940201 - Disclosure - LIQUIDITY (Details)", "shortName": "LIQUIDITY (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_xrylODgBfkGQGHTIFxpN8g", "name": "us-gaap:NetIncomeLoss", "unitRef": "Unit_Standard_USD_-9GsQDP7XEazOxMca8p5dw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_us-gaap_SubsidiarySaleOfStockAxis_rzlt_UnderwrittenPublicOfferingMember_QBq1M4V7j0uhi3XJGBKtVA", "name": "rzlt:ProceedsFromIssuanceOrSaleOfEquityNetOfUnderwritingDiscountsAndCommissions", "unitRef": "Unit_Standard_USD_-9GsQDP7XEazOxMca8p5dw", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "unique": true } }, "R35": { "role": "http://www.rezolutebio.com/role/DisclosureInvestmentsInMarketableDebtSecuritiesInvestmentsInMarketableSecuritiesDetails", "longName": "99940301 - Disclosure - INVESTMENTS IN MARKETABLE DEBT SECURITIES - Investments in Marketable Securities (Details)", "shortName": "INVESTMENTS IN MARKETABLE DEBT SECURITIES - Investments in Marketable Securities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "As_Of_6_30_2024_Ck_cR96bq0--G-L-1VK2iA", "name": "us-gaap:MarketableSecuritiesCurrent", "unitRef": "Unit_Standard_USD_-9GsQDP7XEazOxMca8p5dw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "first": true }, "uniqueAnchor": null }, "R36": { "role": "http://www.rezolutebio.com/role/DisclosureInvestmentsInMarketableDebtSecuritiesAdditionalInformationDetails", "longName": "99940302 - Disclosure - INVESTMENTS IN MARKETABLE DEBT SECURITIES - Additional Information (Details)", "shortName": "INVESTMENTS IN MARKETABLE DEBT SECURITIES - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "As_Of_6_30_2024_Ck_cR96bq0--G-L-1VK2iA", "name": "us-gaap:DebtSecuritiesAvailableForSaleTerm", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_Ck_cR96bq0--G-L-1VK2iA", "name": "us-gaap:DebtSecuritiesAvailableForSaleTerm", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.rezolutebio.com/role/DisclosureInvestmentsInMarketableDebtSecuritiesCashAndCashEquivalentsAndMarketableSecuritiesHeldDetails", "longName": "99940303 - Disclosure - INVESTMENTS IN MARKETABLE DEBT SECURITIES - Cash and Cash Equivalents and Marketable Securities Held (Details)", "shortName": "INVESTMENTS IN MARKETABLE DEBT SECURITIES - Cash and Cash Equivalents and Marketable Securities Held (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "As_Of_6_30_2024_Ck_cR96bq0--G-L-1VK2iA", "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss", "unitRef": "Unit_Standard_USD_-9GsQDP7XEazOxMca8p5dw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_Ck_cR96bq0--G-L-1VK2iA", "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss", "unitRef": "Unit_Standard_USD_-9GsQDP7XEazOxMca8p5dw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.rezolutebio.com/role/DisclosureLeasesAdditionalInformationDetails", "longName": "99940401 - Disclosure - LEASES - Additional Information (Details)", "shortName": "LEASES - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "As_Of_6_30_2024_Ck_cR96bq0--G-L-1VK2iA", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue", "unitRef": "Unit_Standard_USD_-9GsQDP7XEazOxMca8p5dw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_xrylODgBfkGQGHTIFxpN8g", "name": "us-gaap:VariableLeaseCost", "unitRef": "Unit_Standard_USD_-9GsQDP7XEazOxMca8p5dw", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "unique": true } }, "R39": { "role": "http://www.rezolutebio.com/role/DisclosureLeasesAssetsAndOperatingLeaseLiabilitiesDetails", "longName": "99940402 - Disclosure - LEASES - Assets and Operating Lease Liabilities (Details)", "shortName": "LEASES - Assets and Operating Lease Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "As_Of_6_30_2024_Ck_cR96bq0--G-L-1VK2iA", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "unitRef": "Unit_Standard_USD_-9GsQDP7XEazOxMca8p5dw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "first": true }, "uniqueAnchor": null }, "R40": { "role": "http://www.rezolutebio.com/role/DisclosureLeasesOperatingLeaseExpenseDetails", "longName": "99940403 - Disclosure - LEASES - Operating Lease Expense (Details)", "shortName": "LEASES - Operating Lease Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_xrylODgBfkGQGHTIFxpN8g", "name": "us-gaap:OperatingLeaseCost", "unitRef":

```
"Unit_Standard_USD_-9GsQDP7XEazOxMca8p5dw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_xryIODgBfkGQGHTIFxpN8g", "name": "us-gaap:OperatingLeaseCost", "unitRef": "Unit_Standard_USD_-9GsQDP7XEazOxMca8p5dw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.rezolutebio.com/role/DisclosureLeasesFutureOperatingLeasePaymentsDetails", "longName": "99940404 - Disclosure - LEASES - Future Operating Lease Payments (Details)", "shortName": "LEASES - Future Operating Lease Payments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "As_Of_6_30_2024_Ck_cR96bq0--G-L-1VK2iA", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "Unit_Standard_USD_-9GsQDP7XEazOxMca8p5dw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_Ck_cR96bq0--G-L-1VK2iA", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "Unit_Standard_USD_-9GsQDP7XEazOxMca8p5dw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "first": true, "unique": true } }, "R42": { "role": "http://www.rezolutebio.com/role/DisclosureLicenseAgreementsDetails", "longName": "99940501 - Disclosure - LICENSE AGREEMENTS (Details)", "shortName": "LICENSE AGREEMENTS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "As_Of_6_30_2024_srt_CounterpartyNameAxis_rzlt_XomaUsLlcMember_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_rzlt_ScenarioUponClinicalAndRegulator
gaap_TypeOfArrangementAxis_rzlt_XomaLicenseAgreementMember_uv8x6kKXMU6jYI4ZEGg7yQ", "name": "rzlt:MaximumAmountOfMilestoneEvents", "unitRef": "Unit_Standard_USD_-9GsQDP7XEazOxMca8p5dw", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "rzlt:LicenseAgreementsTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_srt_CounterpartyNameAxis_rzlt_XomaUsLlcMember_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_rzlt_ScenarioUponClinicalAndRegulator
gaap_TypeOfArrangementAxis_rzlt_XomaLicenseAgreementMember_uv8x6kKXMU6jYI4ZEGg7yQ", "name": "rzlt:MaximumAmountOfMilestoneEvents", "unitRef": "Unit_Standard_USD_-9GsQDP7XEazOxMca8p5dw", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "rzlt:LicenseAgreementsTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.rezolutebio.com/role/DisclosureEmbeddedDerivativeLiabilityDetails", "longName": "99940601 - Disclosure - EMBEDDED DERIVATIVE LIABILITY (Details)", "shortName": "EMBEDDED DERIVATIVE LIABILITY (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "As_Of_6_30_2024_Ck_cR96bq0--G-L-1VK2iA", "name": "us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability", "unitRef": "Unit_Standard_USD_-9GsQDP7XEazOxMca8p5dw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_4_14_2021_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember_BHTHpbv-z0SxsqeT3eK75Q", "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity", "unitRef": "Unit_Standard_USD_-9GsQDP7XEazOxMca8p5dw", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:DiscussionOfHybridInstrumentsAndEmbeddedDerivativesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "unique": true } }, "R44": { "role": "http://www.rezolutebio.com/role/DisclosureShareholdersEquityPreFundedWarrantsDetails", "longName": "99940701 - Disclosure - SHAREHOLDERS' EQUITY - Pre-Funded Warrants (Details)", "shortName": "SHAREHOLDERS' EQUITY - Pre-Funded Warrants (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "As_Of_6_30_2024_us-gaap_ClassOfWarrantOrRightAxis_rzlt_PreFundedWarrantsMember_pfLi6s44kEKRHz-wN_gSSw", "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "unitRef": "Unit_Standard_shares_7yBtZQpS6kuuGxfLh0iCWA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2022_To_6_30_2023_us-gaap_ClassOfWarrantOrRightAxis_rzlt_PreFundedWarrantsMember_PJiZ7ABoeECPOlBqeJpCFg", "name": "rzlt:ClassOfWarrantOrRightIssued", "unitRef": "Unit_Standard_shares_7yBtZQpS6kuuGxfLh0iCWA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "unique": true } }, "R45": { "role": "http://www.rezolutebio.com/role/DisclosureShareholdersEquity2024UnderwrittenOfferingDetails", "longName": "99940702 - Disclosure - SHAREHOLDERS' EQUITY - 2024 Underwritten Offering (Details)", "shortName": "SHAREHOLDERS' EQUITY - 2024 Underwritten Offering (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "As_Of_6_30_2024_us-gaap_ClassOfWarrantOrRightAxis_rzlt_PreFundedWarrantsMember_pfLi6s44kEKRHz-wN_gSSw", "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "unitRef": "Unit_Standard_shares_7yBtZQpS6kuuGxfLh0iCWA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_6_24_2024_us-gaap_SubsidiarySaleOfStockAxis_rzlt_UnderwrittenPublicOfferingMember_2OGNpEtOak6jLociLOQ3Iw", "name": "us-gaap:SaleOfStockPricePerShare", "unitRef": "Unit_Divide_USD_shares_6PoYGnLVe0e5mFb02YKF6A", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "unique": true } }, "R46": { "role": "http://www.rezolutebio.com/role/DisclosureShareholdersEquityExchangeAgreementDetails", "longName": "99940703 - Disclosure - SHAREHOLDERS' EQUITY - Exchange Agreement (Details)", "shortName": "SHAREHOLDERS' EQUITY - Exchange Agreement (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_xryIODgBfkGQGHTIFxpN8g", "name": "us-gaap:PaymentsForRepurchaseOfCommonStock", "unitRef": "Unit_Standard_USD_-9GsQDP7XEazOxMca8p5dw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_3_8_2024_To_3_8_2024_rzlt_AgreementAxis_rzlt_SecuritiesExchangeAgreementMember_HKZ1cj4bgka8IKJ1UViVuQ", "name": "us-gaap:TreasuryStockSharesAcquired", "unitRef": "Unit_Standard_shares_7yBtZQpS6kuuGxfLh0iCWA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "unique": true } }, "R47": { "role": "http://www.rezolutebio.com/role/DisclosureShareholdersEquityJefferiesOpenMarketSalesAgreementDetails", "longName": "99940704 - Disclosure - SHAREHOLDERS' EQUITY - Jefferies Open Market Sales Agreement (Details)", "shortName": "SHAREHOLDERS' EQUITY - Jefferies Open Market Sales Agreement (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "Duration_11_14_2023_To_11_14_2023_us-gaap_SubsidiarySaleOfStockAxis_rzlt_AtMarketOfferingMember_j1cFjvTNS0us9u2BYlrCSw", "name": "rzlt:SaleOfStockMaximumAmountAgreedToSellAsPerOpenMarketSalesAgreement", "unitRef": "Unit_Standard_USD_-9GsQDP7XEazOxMca8p5dw", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_11_14_2023_To_11_14_2023_us-gaap_SubsidiarySaleOfStockAxis_rzlt_AtMarketOfferingMember_j1cFjvTNS0us9u2BYlrCSw", "name": "rzlt:SaleOfStockCommissionAgreedToPayAsPercentageOnGrossSalesPrice", "unitRef": "Unit_Standard_pure_ZPakoCIls0KPa16F8Uto5g", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "unique": true } }, "R48": { "role": "http://www.rezolutebio.com/role/DisclosureShareholdersEquity2022PrivatePlacementDetails", "longName": "99940705 - Disclosure - SHAREHOLDERS' EQUITY - 2022 Private Placement (Details)", "shortName": "SHAREHOLDERS' EQUITY - 2022 Private Placement (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "Duration_7_1_2022_To_7_31_2022_us-gaap_SubsidiarySaleOfStockAxis_rzlt_JulyTwoThousandTwentyTwoFinancingMember_TA0QVMSNhkeaN9tDlkjdGg", "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "unitRef": "Unit_Standard_shares_7yBtZQpS6kuuGxfLh0iCWA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2022_To_7_31_2022_us-gaap_SubsidiarySaleOfStockAxis_rzlt_JulyTwoThousandTwentyTwoFinancingMember_TA0QVMSNhkeaN9tDlkjdGg", "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "unitRef": "Unit_Standard_shares_7yBtZQpS6kuuGxfLh0iCWA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "first": true, "unique": true } }, "R49": { "role": "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsStockOptionPlansDetails", "longName": "99940801 - Disclosure - SHARE-BASED COMPENSATION AND WARRANTS - Stock Option Plans (Details)", "shortName": "SHARE-BASED COMPENSATION AND WARRANTS - Stock Option Plans (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "As_Of_6_30_2024_Ck_cR96bq0--G-L-1VK2iA", "name": "rzlt:NumberOfActiveStockOptionPlans", "unitRef": "Unit_Standard_item_qYPO2m-AM0K-7xB2TSkCJQ", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_Ck_cR96bq0--G-L-1VK2iA", "name": "rzlt:NumberOfActiveStockOptionPlans", "unitRef": "Unit_Standard_item_qYPO2m-AM0K-7xB2TSkCJQ", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "first": true, "unique": true } }, "R50": { "role": "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrants2022EmployeeStockPurchasePlanDetails", "longName": "99940802 - Disclosure - SHARE-BASED COMPENSATION AND WARRANTS - 2022 Employee Stock Purchase Plan (Details)", "shortName": "SHARE-BASED COMPENSATION AND WARRANTS - 2022 Employee Stock Purchase Plan (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "As_Of_6_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_8g4uExlS_UOcYwHVhydW-w", "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "unitRef": "Unit_Standard_shares_7yBtZQpS6kuuGxfLh0iCWA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_8g4uExlS_UOcYwHVhydW-w", "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "unitRef": "Unit_Standard_shares_7yBtZQpS6kuuGxfLh0iCWA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "first": true, "unique": true } }, "R51": { "role": "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsStockOptionsOutstandingDetails", "longName": "99940803 - Disclosure - SHARE-BASED COMPENSATION AND WARRANTS - Stock Options Outstanding (Details)", "shortName": "SHARE-BASED COMPENSATION AND WARRANTS - Stock Options Outstanding (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "As_Of_6_30_2023_5Y-JTXy-J0qjjfDDVz-ACw", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Unit_Standard_shares_7yBtZQpS6kuuGxfLh0iCWA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_xryIODgBfkGQGHTIFxpN8g", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "unitRef": "Unit_Standard_shares_7yBtZQpS6kuuGxfLh0iCWA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "unique": true } }, "R52": { "role": "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsWeightedAverageAssumptionsDetails", "longName": "99940804 - Disclosure - SHARE-BASED COMPENSATION AND WARRANTS - Weighted Average Assumptions (Details)", "shortName": "SHARE-BASED COMPENSATION AND WARRANTS - Weighted Average Assumptions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "As_Of_6_30_2024_Ck_cR96bq0--G-L-1VK2iA", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue", "unitRef": "Unit_Divide_USD_shares_6PoYGnLVe0e5mFb02YKF6A", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_Ck_cR96bq0--G-L-1VK2iA", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue", "unitRef":
```

```
"Unit_Divide_USD_shares_6PoYGnLVe0e5mFb02YKF6A", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "first": true, "unique": true } }, "R53": { "role": "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsShareBasedCompensationExpenseDetails", "longName": "99940805 - Disclosure - SHARE-BASED COMPENSATION AND WARRANTS - Share Based Compensation Expense (Details)", "shortName": "SHARE-BASED COMPENSATION AND WARRANTS - Share Based Compensation Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_xryIODgBfkGQGHTIFxpN8g", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "Unit_Standard_USD_-9GsQDP7XEazOxMca8p5dw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_xryIODgBfkGQGHTIFxpN8g", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "Unit_Standard_USD_-9GsQDP7XEazOxMca8p5dw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "first": true, "unique": true } }, "R54": { "role": "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsInducementGrantDetails", "longName": "99940806 - Disclosure - SHARE-BASED COMPENSATION AND WARRANTS - Inducement Grant (Details)", "shortName": "SHARE-BASED COMPENSATION AND WARRANTS - Inducement Grant (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_xryIODgBfkGQGHTIFxpN8g", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "unitRef": "Unit_Standard_shares_7yBtZQpS6kuuGxfLh0iCWA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_1_31_2024_srt_TitleOfIndividualAxis_srt_ChiefFinancialOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_rzlt_InducementGrantMember_pAPHXj9A1UmtTI3gPY79pA", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "unitRef": "Unit_Standard_shares_7yBtZQpS6kuuGxfLh0iCWA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "unique": true } }, "R55": { "role": "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsPreFundedWarrantsDetails", "longName": "99940807 - Disclosure - SHARE-BASED COMPENSATION AND WARRANTS - Pre-Funded Warrants (Details)", "shortName": "SHARE-BASED COMPENSATION AND WARRANTS - Pre-Funded Warrants (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "As_Of_6_30_2024_us-gaap_ClassOfWarrantOrRightAxis_rzlt_PreFundedWarrantsMember_pfLi6s44kEKRHz-wN_gSSw", "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "unitRef": "Unit_Standard_shares_7yBtZQpS6kuuGxfLh0iCWA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "first": true }, "uniqueAnchor": null }, "R56": { "role": "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsSummaryOfLegacyWarrantsDetails", "longName": "99940808 - Disclosure - SHARE-BASED COMPENSATION AND WARRANTS - Summary of Legacy Warrants (Details)", "shortName": "SHARE-BASED COMPENSATION AND WARRANTS - Summary of Legacy Warrants (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "As_Of_6_30_2023_us-gaap_ClassOfWarrantOrRightAxis_rzlt_LegacyWarrantsMember_L0NUbadqrUmtWPg4K7WdNw", "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "unitRef": "Unit_Standard_shares_7yBtZQpS6kuuGxfLh0iCWA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2022_us-gaap_ClassOfWarrantOrRightAxis_rzlt_LegacyWarrantsMember_422oXUKLS0GEXuGCyF-acQ", "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "unitRef": "Unit_Standard_shares_7yBtZQpS6kuuGxfLh0iCWA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "unique": true } }, "R57": { "role": "http://www.rezolutebio.com/role/DisclosureIncomeTaxesAdditionalInformationDetails", "longName": "99940901 - Disclosure - INCOME TAXES - Additional Information (Details)", "shortName": "INCOME TAXES - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_xryIODgBfkGQGHTIFxpN8g", "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount", "unitRef": "Unit_Standard_USD_-9GsQDP7XEazOxMca8p5dw", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_xryIODgBfkGQGHTIFxpN8g", "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount", "unitRef": "Unit_Standard_USD_-9GsQDP7XEazOxMca8p5dw", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "first": true, "unique": true } }, "R58": { "role": "http://www.rezolutebio.com/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails", "longName": "99940902 - Disclosure - INCOME TAXES - Income Tax Expense (Details)", "shortName": "INCOME TAXES - Income Tax Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_xryIODgBfkGQGHTIFxpN8g", "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "unitRef": "Unit_Standard_USD_-9GsQDP7XEazOxMca8p5dw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_xryIODgBfkGQGHTIFxpN8g", "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "unitRef": "Unit_Standard_USD_-9GsQDP7XEazOxMca8p5dw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "first": true, "unique": true } }, "R59": { "role": "http://www.rezolutebio.com/role/DisclosureIncomeTaxesDeferredIncomeTaxAssetsAndLiabilitiesDetails", "longName": "99940903 - Disclosure - INCOME TAXES - Deferred Income Tax Assets and Liabilities (Details)", "shortName": "INCOME TAXES - Deferred Income Tax Assets and Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "As_Of_6_30_2024_Ck_cR96bq0--G-L-1VK2iA", "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "unitRef": "Unit_Standard_USD_-9GsQDP7XEazOxMca8p5dw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_Ck_cR96bq0--G-L-1VK2iA", "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "unitRef": "Unit_Standard_USD_-9GsQDP7XEazOxMca8p5dw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "first": true, "unique": true } }, "R60": { "role": "http://www.rezolutebio.com/role/DisclosureCommitmentsAndContingenciesDetails", "longName": "99941001 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)", "shortName": "COMMITMENTS AND CONTINGENCIES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_xryIODgBfkGQGHTIFxpN8g", "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "unitRef": "Unit_Standard_pure_ZPakoCIls0KPa16F8Uto5g", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_xryIODgBfkGQGHTIFxpN8g", "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "unitRef": "Unit_Standard_pure_ZPakoCIls0KPa16F8Uto5g", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "first": true, "unique": true } }, "R61": { "role": "http://www.rezolutebio.com/role/DisclosureRelatedPartyTransactionsDetails", "longName": "99941101 - Disclosure - RELATED PARTY TRANSACTIONS (Details)", "shortName": "RELATED PARTY TRANSACTIONS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "Duration_9_15_2020_To_9_15_2020_srt_CounterpartyNameAxis_rzlt_HandokInc.Member_us-gaap_RelatedPartyTransactionAxis_rzlt_HandokLicenseAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_tIlQBkGx60iKXzWXIavZlw", "name": "rzlt:PharmaceuticalLicenseAgreementTerm", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_9_15_2020_To_9_15_2020_srt_CounterpartyNameAxis_rzlt_HandokInc.Member_us-gaap_RelatedPartyTransactionAxis_rzlt_HandokLicenseAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_RelatedPartyMember_tIlQBkGx60iKXzWXIavZlw", "name": "rzlt:PharmaceuticalLicenseAgreementTerm", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "first": true, "unique": true } }, "R62": { "role": "http://www.rezolutebio.com/role/DisclosureSupplementalFinancialInformationCashAndCashEquivalentsDetails", "longName": "99941201 - Disclosure - SUPPLEMENTAL FINANCIAL INFORMATION - Cash and Cash Equivalents (Details)", "shortName": "SUPPLEMENTAL FINANCIAL INFORMATION - Cash and Cash Equivalents (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "As_Of_6_30_2024_Ck_cR96bq0--G-L-1VK2iA", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "Unit_Standard_USD_-9GsQDP7XEazOxMca8p5dw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_LcW9j2HHPUGtRrwwE7T1jw", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "Unit_Standard_USD_-9GsQDP7XEazOxMca8p5dw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "unique": true } }, "R63": { "role": "http://www.rezolutebio.com/role/DisclosureSupplementalFinancialInformationPropertyAndEquipmentDetails", "longName": "99941202 - Disclosure - SUPPLEMENTAL FINANCIAL INFORMATION - Property and Equipment (Details)", "shortName": "SUPPLEMENTAL FINANCIAL INFORMATION - Property and Equipment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "As_Of_6_30_2024_Ck_cR96bq0--G-L-1VK2iA", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "Unit_Standard_USD_-9GsQDP7XEazOxMca8p5dw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_Ck_cR96bq0--G-L-1VK2iA", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "Unit_Standard_USD_-9GsQDP7XEazOxMca8p5dw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "first": true, "unique": true } }, "R64": { "role": "http://www.rezolutebio.com/role/DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareDetails", "longName": "99941301 - Disclosure - NET LOSS PER SHARE - Schedule of basic and diluted net loss per share (Details)", "shortName": "NET LOSS PER SHARE - Schedule of basic and diluted net loss per share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_xryIODgBfkGQGHTIFxpN8g", "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "unitRef": "Unit_Standard_USD_-9GsQDP7XEazOxMca8p5dw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_xryIODgBfkGQGHTIFxpN8g", "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "unitRef": "Unit_Standard_USD_-9GsQDP7XEazOxMca8p5dw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "first": true, "unique": true } }, "R65": { "role": "http://www.rezolutebio.com/role/DisclosureNetLossPerShareAntiDilutiveDetails", "longName": "99941302 - Disclosure - NET LOSS PER SHARE - Anti-dilutive (Details)",
```

```
"shortName": "NET LOSS PER SHARE - Anti-dilutive (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_xrylODgBfkGQGHTIFxpN8g", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Unit_Standard_shares_7yBtZQpS6kuuGxfLh0iCWA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_xrylODgBfkGQGHTIFxpN8g", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Unit_Standard_shares_7yBtZQpS6kuuGxfLh0iCWA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "first": true, "unique": true } }, "R66": { "role": "http://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrationsFairValueOnRecurringBasisDetails", "longName": "99941401 - Disclosure - FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS - Fair Value on a Recurring Basis (Details)", "shortName": "FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS - Fair Value on a Recurring Basis (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "As_Of_6_30_2024_Ck_cR96bq0--G-L-1VK2iA", "name": "us-gaap:MarketableSecurities", "unitRef": "Unit_Standard_USD_-9GsQDP7XEazOxMca8p5dw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:MarketableSecuritiesTextBlock", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_SNjl4anxpkS2JPibv_TqXg", "name": "us-gaap:AssetsFairValueDisclosure", "unitRef": "Unit_Standard_USD_-9GsQDP7XEazOxMca8p5dw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "us-gaap:FinancialInstrumentsDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "unique": true } }, "R67": { "role": "http://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrationsValuationModelInputsOfExchangePfwsDetails", "longName": "99941402 - Disclosure - FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS - Valuation Model Inputs of Exchange PFWs (Details)", "shortName": "FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS - Valuation Model Inputs of Exchange PFWs (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "As_Of_5_13_2024_us-gaap_ClassOfWarrantOrRightAxis_rzlt_ExchangePreFundedWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_I3IBTBHAhUauhbfHwQHtyA", "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput", "unitRef": "Unit_Divide_USD_shares_6PoYGnLVe0e5mFb02YKF6A", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_5_13_2024_us-gaap_ClassOfWarrantOrRightAxis_rzlt_ExchangePreFundedWarrantsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_I3IBTBHAhUauhbfHwQHtyA", "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput", "unitRef": "Unit_Divide_USD_shares_6PoYGnLVe0e5mFb02YKF6A", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "first": true, "unique": true } }, "R68": { "role": "http://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrationsSummaryOfChangesInFairValueDetails", "longName": "99941403 - Disclosure - FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS - Summary of Changes in the Fair Value (Details)", "shortName": "FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS - Summary of Changes in the Fair Value (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_us-gaap_FairValueByLiabilityClassAxis_rzlt_WarrantsDerivativeFinancialInstrumentsLiabilitiesMember_PbKBexDRDEKHDKwhyIe2DQ", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues", "unitRef": "Unit_Standard_USD_-9GsQDP7XEazOxMca8p5dw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_us-gaap_FairValueByLiabilityClassAxis_rzlt_WarrantsDerivativeFinancialInstrumentsLiabilitiesMember_PbKBexDRDEKHDKwhyIe2DQ", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues", "unitRef": "Unit_Standard_USD_-9GsQDP7XEazOxMca8p5dw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "first": true, "unique": true } }, "R69": { "role": "http://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrationsSignificantConcentrationsDetails", "longName": "99941404 - Disclosure - FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS - Significant Concentrations (Details)", "shortName": "FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS - Significant Concentrations (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_xrylODgBfkGQGHTIFxpN8g", "name": "us-gaap:ConcentrationRiskCreditRiskUninsuredDeposits", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_xrylODgBfkGQGHTIFxpN8g", "name": "us-gaap:ConcentrationRiskCreditRiskUninsuredDeposits", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "first": true, "unique": true } }, "R70": { "role": "http://www.rezolutebio.com/role/DisclosureSubsequentEventsDetails", "longName": "99941501 - Disclosure - SUBSEQUENT EVENTS (Details)", "shortName": "SUBSEQUENT EVENTS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "70", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_6_30_2024_xrylODgBfkGQGHTIFxpN8g", "name": "us-gaap:PaymentsToAcquireMarketableSecurities", "unitRef": "Unit_Standard_USD_-9GsQDP7XEazOxMca8p5dw", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_6_25_2024_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_5YYUZbUUj0OCqIqjLsUgwg", "name": "us-gaap:SharesIssuedPricePerShare", "unitRef": "Unit_Divide_USD_shares_6PoYGnLVe0e5mFb02YKF6A", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "us-gaap:SubsequentEventsTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "rzlt-20240630x10k.htm", "unique": true } } }, "tag": { "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "presentation": [ "http://www.rezolutebio.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accounts Payable, Current", "verboseLabel": "Accounts payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r51", "r729" ] }, "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments", "crdr": "credit", "presentation": [ "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Accretion (Amortization) of Discounts and Premiums, Investments", "negatedLabel": "Accretion of discounts and amortization of premiums on marketable debt securities, net", "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r76" ] }, "rzlt_AccruedClinicalCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rezolutebio.com/20240630", "localname": "AccruedClinicalCurrent", "crdr": "credit", "presentation": [ "http://www.rezolutebio.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "documentation": "Amount of accrued for clinical liabilities.", "label": "Accrued Clinical, Current", "terseLabel": "Accrued clinical and other" } } }, "auth_ref": [] }, "us-gaap_AccruedLiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesCurrentAbstract", "presentation": [ "http://www.rezolutebio.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accrued Liabilities, Current [Abstract]", "terseLabel": "Accrued liabilities:" } } }, "auth_ref": [] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "presentation": [ "http://www.rezolutebio.com/role/DisclosureSupplementalFinancialInformationPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Less accumulated depreciation", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": [ "r24", "r123", "r555" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "presentation": [ "http://www.rezolutebio.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive loss", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r13", "r14", "r68", "r128", "r550", "r573", "r574" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Loss", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r1", "r6", "r14", "r410", "r413", "r464", "r569", "r570", "r856", "r857", "r858", "r863", "r864", "r865", "r867" ] }, "rzlt_AcquisitionOfTreasurySharesInExchangeForIssuingPreFundedWarrantLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rezolutebio.com/20240630", "localname": "AcquisitionOfTreasurySharesInExchangeForIssuingPreFundedWarrantLiability", "crdr": "debit", "presentation": [ "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Acquisition of treasury shares in exchange for issuing pre-funded warrant liability", "label": "Acquisition Of Treasury Shares In Exchange For Issuing Pre-Funded Warrant Liability", "terseLabel": "Acquisition of treasury shares in exchange for pre-funded warrant derivative liability" } } }, "auth_ref": [] }, "rzlt_ActivesitePharmaceuticalsIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rezolutebio.com/20240630", "localname": "ActivesitePharmaceuticalsIncMember", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLicenseAgreementsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represent the information pertaining to ActiveSite Pharmaceuticals, Inc.", "label": "ActiveSite Pharmaceuticals, Inc" } } }, "auth_ref": [] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure [Text Block]", "terseLabel": "Additional 402(v) Disclosure" } } }, "auth_ref": [ "r791" ] }, "us-gaap_AdditionalFinancialInformationDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalFinancialInformationDisclosureTextBlock", "presentation": [ "http://www.rezolutebio.com/role/DisclosureSupplementalFinancialInformation" ], "lang": { "en-us": { "role": { "label": "Additional Financial Information Disclosure [Text Block]", "terseLabel": "SUPPLEMENTAL FINANCIAL INFORMATION", "documentation": "The entire disclosures of supplemental financial information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement." } } }, "auth_ref": [] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapital", "crdr": "credit", "presentation": [ "http://www.rezolutebio.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Additional Paid in Capital", "verboseLabel": "Additional paid-in capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r63", "r729", "r993" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from
```

```
other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r588", "r863", "r864", "r865", "r867", "r926", "r994" ] }, "ecd_AdjToCompAmt": {
"xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang":
{ "en-us": { "role": { "label": "Adjustment to Compensation Amount", "terseLabel": "Adjustment to Compensation, Amount" } } }, "auth_ref": [ "r804" ] },
"ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]", "terseLabel": "Adjustment to Compensation:" } } },
"auth_ref": [ "r804" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO
Compensation Footnote [Text Block]", "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "auth_ref": [ "r804" ] }, "ecd_AdjToPeoCompFnTextBlock": {
"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment To PEO Compensation, Footnote [Text Block]", "terseLabel": "Adjustment To
PEO Compensation, Footnote" } } }, "auth_ref": [ "r804" ] }, "rzlt_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantDerivativeLiabilityToEquity": { "xbrltype":
"monetaryItemType", "nsuri": "http://www.rezolutebio.com/20240630", "localname":
"AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantDerivativeLiabilityToEquity", "crdr": "credit", "presentation": [
"http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase in additional
paid in capital (APIC) resulting from the reclassification of warrant derivative liability to equity.", "label": "Adjustments to Additional Paid in Capital, Reclassification of
Warrant Derivative Liability to Equity", "terseLabel": "Reclassification of warrant derivative liability to equity" } } }, "auth_ref": [] }, "us-
gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit",
"presentation": [ "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "APIC, Share-Based
Payment Arrangement, Increase for Cost Recognition", "verboseLabel": "Share-based compensation", "documentation": "Amount of increase to additional paid-in capital
(APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r35", "r36", "r314" ] }, "us-
gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "crdr": "debit", "presentation": [
"http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Adjustments to Additional Paid in Capital,
Stock Issued, Issuance Costs", "negatedLabel": "Other equity offering costs", "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct
costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration." } } },
"auth_ref": [ "r7", "r88" ] }, "rzlt_AggregateAnnualBaseSalaries": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rezolutebio.com/20240630", "localname":
"AggregateAnnualBaseSalaries", "crdr": "debit", "presentation": [ "http://www.rezolutebio.com/role/DisclosureCommitmentsAndContingenciesDetails",
"http://www.rezolutebio.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the aggregate annual base salaries.",
"label": "Aggregate Annual Base Salaries", "terseLabel": "Aggregate annual base salaries" } } }, "auth_ref": [] },
"ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"AggtChngPnsnValInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate
Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Change in Present
Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table" } } }, "auth_ref": [ "r838" ] }, "ecd_AggtErrCompAmt": { "xbrltype":
"monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": {
"en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount", "terseLabel": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r762", "r773",
"r783", "r816" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous
Compensation Not Yet Determined [Text Block]", "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "auth_ref": [ "r765", "r776", "r786", "r819" ] },
"ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Pension Adjustments Service Cost [Member]", "terseLabel": "Aggregate Pension
Adjustments Service Cost" } } }, "auth_ref": [ "r839" ] }, "rzlt_AgreementAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.rezolutebio.com/20240630", "localname":
"AgreementAxis", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareholdersEquityExchangeAgreementDetails",
"http://www.rezolutebio.com/role/DisclosureShareholdersEquityPreFundedWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "Information of agreement.",
"label": "Agreement [Axis]" } } }, "auth_ref": [] }, "rzlt_AgreementDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.rezolutebio.com/20240630", "localname":
"AgreementDomain", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareholdersEquityExchangeAgreementDetails",
"http://www.rezolutebio.com/role/DisclosureShareholdersEquityPreFundedWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "Information of agreement.",
"label": "Agreement [Domain]" } } }, "auth_ref": [] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Adjustments to Compensation [Member]",
"terseLabel": "All Adjustments to Compensation" } } }, "auth_ref": [ "r804" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": {
"label": "All Executive Categories [Member]", "terseLabel": "All Executive Categories" } } }, "auth_ref": [ "r811" ] }, "ecd_AllIndividualsMember": { "xbrltype":
"domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": {
"role": { "label": "All Individuals [Member]", "terseLabel": "All Individuals" } } }, "auth_ref": [ "r766", "r777", "r787", "r811", "r820", "r824", "r832" ] },
"ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember",
"presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "All Trading Arrangements [Member]", "terseLabel": "All
Trading Arrangements" } } }, "auth_ref": [ "r830" ] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [
"http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsShareBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Share-
Based Payment Arrangement, Expense", "verboseLabel": "Compensation cost", "documentation": "Amount of expense for award under share-based payment arrangement.
Excludes amount capitalized." } } }, "auth_ref": [ "r346", "r355" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "AmendmentFlag", "presentation": [ "http://www.rezolutebio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label":
"Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-
gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [
"http://www.rezolutebio.com/role/DisclosureNetLossPerShareAntiDilutiveDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of
Earnings Per Share, Amount", "terseLabel": "Total", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially
dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would
increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r185" ] }, "us-
gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [
"http://www.rezolutebio.com/role/DisclosureNetLossPerShareAntiDilutiveDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities [Axis]", "documentation":
"Information by type of antidilutive security." } } }, "auth_ref": [ "r18" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
"presentation": [ "http://www.rezolutebio.com/role/DisclosureNetLossPerShareAntiDilutiveDetails",
"http://www.rezolutebio.com/role/DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive
Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "NET LOSS PER SHARE", "documentation": "Line items represent financial concepts
included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] },
"us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesNameDomain",
"presentation": [ "http://www.rezolutebio.com/role/DisclosureNetLossPerShareAntiDilutiveDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities, Name
[Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would
increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r18" ] }, "us-
gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ArrangementsAndNonarrangementTransactionsMember", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLicenseAgreementsDetails",
"http://www.rezolutebio.com/role/DisclosureLiquidityDetails" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative
[Domain]", "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref":
[ "r401" ] }, "us-gaap_AssetBackedSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetBackedSecuritiesMember",
"presentation": [ "http://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrationsFairValueOnRecurringBasisDetails",
"http://www.rezolutebio.com/role/DisclosureInvestmentsInMarketableDebtSecuritiesCashAndCashEquivalentsAndMarketableSecuritiesHeldDetails" ], "lang": { "en-us": {
"role": { "label": "Asset-Backed Securities [Member]", "terseLabel": "Asset-backed securities", "documentation": "Securities that are primarily serviced by the cash flows of a
discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans." } }
}, "auth_ref": [ "r707", "r730", "r876", "r877", "r878" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets",
"crdr": "debit", "presentation": [ "http://www.rezolutebio.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets", "totalLabel": "Total
assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r98", "r105", "r124", "r148", "r190", "r193", "r195", "r196",
"r234", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r403", "r407", "r439", "r545", "r617", "r695", "r696", "r729", "r752", "r888", "r889", "r951" ] },
"us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": [
"http://www.rezolutebio.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "auth_ref": [] },
"us-gaap_AssetsAndLiabilitiesLesseeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAndLiabilitiesLesseeAbstract",
"presentation": [ "http://www.rezolutebio.com/role/DisclosureLeasesAssetsAndOperatingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Assets and Liabilities,
Lessee [Abstract]", "terseLabel": "Carrying value of right-of-use assets and operating lease liabilities" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "presentation": [
"http://www.rezolutebio.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets, Current", "totalLabel": "Total current assets",
"documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": [ "r119", "r129", "r148", "r234", "r258", "r259",
"r260", "r261", "r262", "r263", "r264", "r265", "r266", "r403", "r407", "r439", "r729", "r888", "r889", "r951" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": [
"http://www.rezolutebio.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } }
}, "auth_ref": [] }, "us-gaap_AssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsFairValueDisclosure",
"crdr": "debit", "presentation": [ "http://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrationsFairValueOnRecurringBasisDetails" ], "lang":
{ "en-us": { "role": { "label": "Assets, Fair Value Disclosure", "terseLabel": "Financial assets measured at fair value", "documentation": "Fair value portion of asset recognized
for present right to economic benefit." } } }, "auth_ref": [ "r421", "r422", "r716" ] }, "us-gaap_AssetsNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "AssetsNoncurrentAbstract", "presentation": [ "http://www.rezolutebio.com/role/StatementConsolidatedBalanceSheets" ], "lang": {
"en-us": { "role": { "label": "Assets, Noncurrent [Abstract]", "terseLabel": "Long-term assets:" } } }, "auth_ref": [] }, "rzlt_AtMarketOfferingMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.rezolutebio.com/20240630", "localname": "AtMarketOfferingMember", "presentation": [
```

```
"http://www.rezolutebio.com/role/DisclosureLiquidityDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityJefferiesOpenMarketSalesAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to at the market offering.", "label": "At the Market Offering [Member]", "terseLabel": "At the Market Offering" } } }, "auth_ref": [] }, "dei_AuditorFirmId": { "xbrltype": "nonemptySequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorFirmId", "presentation": [ "http://www.rezolutebio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Auditor Firm ID", "documentation": "PCAOB issued Audit Firm Identifier" } } }, "auth_ref": [ "r756", "r757", "r769" ] }, "dei_AuditorLocation": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorLocation", "presentation": [ "http://www.rezolutebio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "auth_ref": [ "r756", "r757", "r769" ] }, "dei_AuditorName": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorName", "presentation": [ "http://www.rezolutebio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "auth_ref": [ "r756", "r757", "r769" ] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "crdr": "credit", "presentation": [ "http://www.rezolutebio.com/role/DisclosureInvestmentsInMarketableDebtSecuritiesCashAndCashEquivalentsAndMarketableSecuritiesHeldDetails" ], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax", "terseLabel": "Gross Unrealized Gains", "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r206" ] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "crdr": "debit", "presentation": [ "http://www.rezolutebio.com/role/DisclosureInvestmentsInMarketableDebtSecuritiesCashAndCashEquivalentsAndMarketableSecuritiesHeldDetails" ], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax", "negatedLabel": "Gross Unrealized Losses", "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r207" ] }, "rzlt_AvailableThroughFiscalYear2038AndExpiresByJune302038Member": { "xbrltype": "domainItemType", "nsuri": "http://www.rezolutebio.com/20240630", "localname": "AvailableThroughFiscalYear2038AndExpiresByJune302038Member", "presentation": [ "http://www.rezolutebio.com/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information relating to amount available through fiscal year 2038 and that expires by June 30, 2038", "label": "Available Through Fiscal Year 2038 And Expires By June 30, 2038", "terseLabel": "Available Through Fiscal Year 2038 And Expires By June 30, 2038" } } }, "auth_ref": [] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Exercise Price", "terseLabel": "Exercise Price" } } }, "auth_ref": [ "r827" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Grant Date Fair Value", "terseLabel": "Fair Value as of Grant Date" } } }, "auth_ref": [ "r828" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]", "terseLabel": "Award Timing Disclosures" } } }, "auth_ref": [ "r823" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered [Text Block]", "terseLabel": "Award Timing, How MNPI Considered" } } }, "auth_ref": [ "r823" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Method [Text Block]", "terseLabel": "Award Timing Method" } } }, "auth_ref": [ "r823" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered [Flag]", "terseLabel": "Award Timing MNPI Considered" } } }, "auth_ref": [ "r823" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure [Text Block]", "terseLabel": "Award Timing MNPI Disclosure" } } }, "auth_ref": [ "r823" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Predetermined [Flag]", "terseLabel": "Award Timing Predetermined" } } }, "auth_ref": [ "r823" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrants2022EmployeeStockPurchasePlanDetails", "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsInducementGrantDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "terseLabel": "Award Type", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r317", "r318", "r319", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r341", "r342", "r343", "r344", "r345" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Underlying Securities Amount", "terseLabel": "Underlying Securities" } } }, "auth_ref": [ "r826" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r825" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]", "terseLabel": "Awards Close in Time to MNPI Disclosures" } } }, "auth_ref": [ "r824" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]", "terseLabel": "Awards Close in Time to MNPI Disclosures, Table" } } }, "auth_ref": [ "r824" ] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://www.rezolutebio.com/role/DisclosureNatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Basis of Accounting, Policy [Policy Text Block]", "verboseLabel": "Basis of Presentation", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLiquidityDetails", "http://www.rezolutebio.com/role/DisclosureSupplementalFinancialInformationCashAndCashEquivalentsDetails", "http://www.rezolutebio.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, at Carrying Value", "verboseLabel": "Cash and cash equivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r16", "r121", "r686" ] }, "us-gaap_CashAndCashEquivalentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAxis", "presentation": [ "http://www.rezolutebio.com/role/DisclosureSupplementalFinancialInformationCashAndCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents [Axis]", "documentation": "Information by type of cash and cash equivalent balance." } } }, "auth_ref": [ "r121" ] }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsFairValueDisclosure", "crdr": "debit", "presentation": [ "http://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrationsFairValueOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Cash and cash equivalents", "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r928", "r929" ] }, "us-gaap_CashAndCashEquivalentsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsLineItems", "presentation": [ "http://www.rezolutebio.com/role/DisclosureSupplementalFinancialInformationCashAndCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents [Line Items]", "terseLabel": "SUPPLEMENTAL FINANCIAL INFORMATION", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": [ "http://www.rezolutebio.com/role/DisclosureNatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "verboseLabel": "Cash and Cash Equivalents", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, "auth_ref": [ "r17" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Cash and cash equivalents at end of fiscal year", "periodStartLabel": "Cash and cash equivalents at beginning of fiscal year", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r16", "r74", "r146" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "presentation": [ "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net increase (decrease) in cash and cash equivalents", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r0", "r74" ] }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "presentation": [ "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]", "terseLabel": "NON-CASH INVESTING AND FINANCING ACTIVITIES:" } } }, "auth_ref": [] }, "rzlt_ChangeInFairValueOfWarrantDerivativeLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rezolutebio.com/20240630", "localname": "ChangeInFairValueOfWarrantDerivativeLiability", "crdr": "credit", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareholdersEquityExchangeAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of change in fair value of warrant derivative liability.", "label": "Change in Fair Value of Warrant Derivative Liability", "terseLabel": "Change in fair value of derivative liability" } } }, "auth_ref": [] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock",
```

"presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote [Text Block]", "terseLabel": "Changed Peer Group, Footnote" } } }, "auth_ref": ["r802"] }, "rzlt_ChiefExecutiveOfficerAndChiefMedicalOfficerMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rezolutebio.com/20240630", "localname": "ChiefExecutiveOfficerAndChiefMedicalOfficerMember", "presentation": ["http://www.rezolutebio.com/role/DisclosureCommitmentsAndContingenciesDetails"], "lang": { "en-us": { "role": { "documentation": "Employees with designation of Chief Executive Officer and Chief Medical Officer.", "label": "Chief Executive Officer And Chief Medical Officer [Member]", "terseLabel": "Chief Executive Officer And Chief Medical Officer" } } }, "auth_ref": [] }, "srt_ChiefExecutiveOfficerMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ChiefExecutiveOfficerMember", "presentation": ["http://www.rezolutebio.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://www.rezolutebio.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Chief Executive Officer [Member]", "terseLabel": "Chief Executive Officer" } } }, "auth_ref": ["r874"] }, "srt_ChiefFinancialOfficerMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ChiefFinancialOfficerMember", "presentation": ["http://www.rezolutebio.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsInducementGrantDetails", "http://www.rezolutebio.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Chief Financial Officer [Member]", "terseLabel": "Chief Financial Officer" } } }, "auth_ref": ["r874"] }, "rzlt_ChiefMedicalOfficerMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rezolutebio.com/20240630", "localname": "ChiefMedicalOfficerMember", "presentation": ["http://www.rezolutebio.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://www.rezolutebio.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "documentation": "Person with designation of chief medical officer.", "label": "Chief Medical Officer [Member]", "terseLabel": "Chief Medical Officer" } } }, "auth_ref": [] }, "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]", "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year" } } }, "auth_ref": ["r799"] }, "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]", "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested" } } }, "auth_ref": ["r797"] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": ["http://www.rezolutebio.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "rzlt_ClassBPreFundedWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rezolutebio.com/20240630", "localname": "ClassBPreFundedWarrantsMember", "presentation": ["http://www.rezolutebio.com/role/DisclosureShareholdersEquityPreFundedWarrantsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information relating to Class B pre-funded warrants.", "label": "Class B Warrants", "terseLabel": "Class B Pre-Funded Warrants" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockLineItems", "presentation": ["http://www.rezolutebio.com/role/DisclosureShareholdersEquity2022PrivatePlacementDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquity2024UnderwrittenOfferingDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityJefferiesOpenMarketSalesAgreementDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityPreFundedWarrantsDetails"], "lang": { "en-us": { "role": { "label": "Class of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r125", "r126", "r127", "r192", "r285", "r286", "r287", "r289", "r292", "r297", "r299", "r578", "r579", "r580", "r581", "r705", "r843", "r860"] }, "us-gaap_ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightAxis", "presentation": ["http://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrationsValuationModelInputsOfExchangePfwsDetails", "http://www.rezolutebio.com/role/DisclosureLiquidityDetails", "http://www.rezolutebio.com/role/DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareDetails", "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsPreFundedWarrantsDetails", "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsSummaryOfLegacyWarrantsDetails", "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsTables", "http://www.rezolutebio.com/role/DisclosureShareholdersEquity2024UnderwrittenOfferingDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityExchangeAgreementDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityPreFundedWarrantsDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityTables", "http://www.rezolutebio.com/role/DisclosureSubsequentEventsDetails", "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows", "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfShareholdersEquity"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Axis]", "documentation": "Information by type of warrant or right issued." } } }, "auth_ref": ["r32"] }, "us-gaap_ClassOfWarrantOrRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightDomain", "presentation": ["http://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrationsValuationModelInputsOfExchangePfwsDetails", "http://www.rezolutebio.com/role/DisclosureLiquidityDetails", "http://www.rezolutebio.com/role/DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareDetails", "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsPreFundedWarrantsDetails", "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsSummaryOfLegacyWarrantsDetails", "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsTables", "http://www.rezolutebio.com/role/DisclosureShareholdersEquity2024UnderwrittenOfferingDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityExchangeAgreementDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityPreFundedWarrantsDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityTables", "http://www.rezolutebio.com/role/DisclosureSubsequentEventsDetails", "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows", "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfShareholdersEquity"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Domain]", "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": ["http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsSummaryOfLegacyWarrantsDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquity2024UnderwrittenOfferingDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityExchangeAgreementDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityPreFundedWarrantsDetails"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "periodEndLabel": "Warrants Outstanding, Ending Price (in dollars per share)", "periodStartLabel": "Warrants Outstanding, Beginning Price (in dollars per share)", "terseLabel": "Warrant price (per share)", "verboseLabel": "Warrants exercise price", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": ["r300"] }, "rzlt_ClassOfWarrantOrRightExercised": { "xbrltype": "sharesItemType", "nsuri": "http://www.rezolutebio.com/20240630", "localname": "ClassOfWarrantOrRightExercised", "presentation": ["http://www.rezolutebio.com/role/DisclosureShareholdersEquityJefferiesOpenMarketSalesAgreementDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityPreFundedWarrantsDetails", "http://www.rezolutebio.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights exercised.", "label": "Class of Warrant or Right, Exercised", "negatedLabel": "Exercise of warrants", "terseLabel": "Warrants exercised" } } }, "auth_ref": [] }, "rzlt_ClassOfWarrantOrRightExpirationExercisePriceOfWarrantsOrRights": { "xbrltype": "perShareItemType", "nsuri": "http://www.rezolutebio.com/20240630", "localname": "ClassOfWarrantOrRightExpirationExercisePriceOfWarrantsOrRights", "presentation": ["http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsSummaryOfLegacyWarrantsDetails"], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights expired.", "label": "Class of Warrant or Right, Expiration, Exercise Price of Warrants or Rights", "terseLabel": "Warrant expirations, Price (in dollars per share)" } } }, "auth_ref": [] }, "rzlt_ClassOfWarrantOrRightExpirations": { "xbrltype": "sharesItemType", "nsuri": "http://www.rezolutebio.com/20240630", "localname": "ClassOfWarrantOrRightExpirations", "presentation": ["http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsSummaryOfLegacyWarrantsDetails"], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights expired.", "label": "Class of Warrant or Right, Expirations", "negatedLabel": "Warrant expirations (In shares)" } } }, "auth_ref": [] }, "rzlt_ClassOfWarrantOrRightIssued": { "xbrltype": "sharesItemType", "nsuri": "http://www.rezolutebio.com/20240630", "localname": "ClassOfWarrantOrRightIssued", "presentation": ["http://www.rezolutebio.com/role/DisclosureLiquidityDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityPreFundedWarrantsDetails"], "lang": { "en-us": { "role": { "documentation": "The number of warrants issued.", "label": "Class of Warrant or Right, Issued", "terseLabel": "Warrants issued" } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightLineItems", "presentation": ["http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsTables", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityTables"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": ["http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsSummaryOfLegacyWarrantsDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquity2024UnderwrittenOfferingDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityExchangeAgreementDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityPreFundedWarrantsDetails"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "netLabel": "Warrants to purchase shares of common stock", "terseLabel": "Pre-funded warrants to purchase shares of common stock", "verboseLabel": "Number of shares of common stock called by warrants issued", "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares." } } }, "auth_ref": ["r300"] }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightOutstanding", "presentation": ["http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsPreFundedWarrantsDetails", "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsSummaryOfLegacyWarrantsDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityPreFundedWarrantsDetails"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Outstanding", "periodEndLabel": "Warrants outstanding, ending (In shares)", "periodStartLabel": "Warrants outstanding, beginning (In shares)", "terseLabel": "Warrants outstanding (In shares)", "documentation": "Number of warrants or rights outstanding." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightTable", "presentation": ["http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsTables", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityTables"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Table]", "documentation": "Disclosure of information about warrant or right issued that give holder right to purchase security from issuer at specific price within certain time frame." } } }, "auth_ref": ["r32"] }, "rzlt_ClassOfWarrantOrRightWarrantsSurrendered": { "xbrltype": "sharesItemType", "nsuri": "http://www.rezolutebio.com/20240630", "localname": "ClassOfWarrantOrRightWarrantsSurrendered", "presentation": ["http://www.rezolutebio.com/role/DisclosureShareholdersEquityPreFundedWarrantsDetails"], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights

surrendered.", "label": "Class of Warrant or Right, Warrants Surrendered", "negatedLabel": "Shares surrendered for exercise price" } } }, "auth_ref": [] },
"rzlt_ClassPreFundedWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rezolutebio.com/20240630", "localname": "ClassPreFundedWarrantsMember",
"presentation": ["http://www.rezolutebio.com/role/DisclosureShareholdersEquityPreFundedWarrantsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents
information relating to Class A pre-funded warrants.", "label": "Class A Pre-Funded Warrants", "verboseLabel": "Class A pre-funded warrants" } } }, "auth_ref": [] },
"rzlt_ClinicalTrialAccrualsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.rezolutebio.com/20240630", "localname":
"ClinicalTrialAccrualsPolicyTextBlock", "presentation": [
"http://www.rezolutebio.com/role/DisclosureNatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "documentation":
"Represents the accounting policy on clinical trial accruals.", "label": "Clinical Trial Accruals [Policy Text Block]", "terseLabel": "Clinical Trial Accruals" } } }, "auth_ref": [] },
"ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount", "terseLabel": "Company Selected Measure Amount" }
} }, "auth_ref": ["r803"] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"CoSelectedMeasureName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name",
"terseLabel": "Company Selected Measure Name" } } }, "auth_ref": ["r803"] }, "us-gaap_CollaborativeArrangementMember": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "CollaborativeArrangementMember", "presentation": ["http://www.rezolutebio.com/role/DisclosureLicenseAgreementsDetails",
"http://www.rezolutebio.com/role/DisclosureLiquidityDetails"], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement [Member]", "terseLabel": "Collaborative
Arrangement", "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed
to significant risks and rewards that depend on the commercial success of the joint operating activity." } } }, "auth_ref": ["r401"] }, "us-gaap_CommercialPaperMember": {
"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommercialPaperMember", "presentation": [
"http://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrationsFairValueOnRecurringBasisDetails",
"http://www.rezolutebio.com/role/DisclosureInvestmentsInMarketableDebtSecuritiesCashAndCashEquivalentsAndMarketableSecuritiesHeldDetails",
"http://www.rezolutebio.com/role/DisclosureSupplementalFinancialInformationCashAndCashEquivalentsDetails"], "lang": { "en-us": { "role": { "label": "Commercial Paper
[Member]", "terseLabel": "Corporate commercial paper", "verboseLabel": "Commercial paper", "documentation": "Unsecured promissory note (generally negotiable) that
provides institutions with short-term funds." } } }, "auth_ref": ["r83", "r257", "r746", "r747", "r748", "r749"] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "presentation": [
"http://www.rezolutebio.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies", "terseLabel":
"Commitments and contingencies (Notes 5, 10 and 11)", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into
(1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently,
gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from
uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": ["r59", "r99", "r547",
"r604"] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "COMMITMENTS AND CONTINGENCIES." } } }, "auth_ref": [] }, "us-
gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CommitmentsAndContingenciesDisclosureTextBlock", "presentation": ["http://www.rezolutebio.com/role/DisclosureCommitmentsAndContingencies"], "lang": { "en-us": {
"role": { "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "COMMITMENTS AND CONTINGENCIES", "documentation": "The entire disclosure
for commitments and contingencies." } } }, "auth_ref": ["r82", "r251", "r252", "r671", "r885", "r887"] }, "rzlt_CommitmentsAndContingenciesLineItems": { "xbrltype":
"stringItemType", "nsuri": "http://www.rezolutebio.com/20240630", "localname": "CommitmentsAndContingenciesLineItems", "presentation": [
"http://www.rezolutebio.com/role/DisclosureCommitmentsAndContingenciesDetails"], "lang": { "en-us": { "role": { "documentation": "The line items identify information
about the commitments and contingencies.", "label": "Commitments And Contingencies [Line Items]", "terseLabel": "COMMITMENTS AND CONTINGENCIES" } } },
"auth_ref": [] }, "rzlt_CommitmentsAndContingenciesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.rezolutebio.com/20240630", "localname":
"CommitmentsAndContingenciesTable", "presentation": ["http://www.rezolutebio.com/role/DisclosureCommitmentsAndContingenciesDetails"], "lang": { "en-us": { "role": {
"documentation": "This table lists the commitments and contingencies.", "label": "Commitments And Contingencies [Table]" } } }, "auth_ref": [] }, "us-
gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CommonStockCapitalSharesReservedForFutureIssuance", "presentation": [
"http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrants2022EmployeeStockPurchasePlanDetails"], "lang": { "en-us": { "role": { "label": "Common
Stock, Capital Shares Reserved for Future Issuance", "verboseLabel": "Shares reserved for purchase", "documentation": "Aggregate number of common shares reserved for
future issuance." } } }, "auth_ref": ["r62"] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CommonStockMember", "presentation": ["http://www.rezolutebio.com/role/DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareDetails",
"http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfShareholdersEquity"], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "terseLabel":
"Common Stock", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": ["r742", "r743", "r744", "r746", "r747", "r748", "r749", "r863",
"r864", "r867", "r926", "r992", "r994"] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "CommonStockParOrStatedValuePerShare", "presentation": ["http://www.rezolutebio.com/role/StatementConsolidatedBalanceSheetsParenthetical"], "lang": {
"en-us": { "role": { "label": "Common Stock, Par or Stated Value Per Share", "verboseLabel": "Common stock, par value (in dollars per share)", "documentation": "Face amount
or stated value per share of common stock." } } }, "auth_ref": ["r62"] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": [
"http://www.rezolutebio.com/role/StatementConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Common Stock, Shares Authorized",
"terseLabel": "Common stock, shares authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } },
"auth_ref": ["r62", "r605"] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CommonStockSharesIssued", "presentation": ["http://www.rezolutebio.com/role/StatementConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label":
"Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued", "documentation": "Total number of common shares of an entity that have been sold or granted
to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and
owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [
"r62"] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CommonStockSharesOutstanding", "presentation": ["http://www.rezolutebio.com/role/StatementConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": {
"label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding", "documentation": "Number of shares of common stock outstanding.
Common stock represent the ownership interest in a corporation." } } }, "auth_ref": ["r7", "r62", "r605", "r623", "r994", "r995"] }, "us-gaap_CommonStockValue": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "presentation": [
"http://www.rezolutebio.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Common Stock, Value, Issued", "verboseLabel": "Common
stock, $0.001 par value; 100,000 shares authorized; issued and outstanding 53,246 and 36,827 shares as of June 30, 2024 and 2023, respectively", "documentation":
"Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock
repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders'
equity." } } }, "auth_ref": ["r62", "r549", "r729"] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-
us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Company Selected Measure" }
} }, "auth_ref": ["r808"] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"CompActuallyPaidVsNetIncomeTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid
vs. Net Income [Text Block]", "terseLabel": "Compensation Actually Paid vs. Net Income" } } }, "auth_ref": ["r807"] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure [Text Block]", "terseLabel": "Compensation
Actually Paid vs. Other Measure" } } }, "auth_ref": ["r809"] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-
us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]", "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return" } } },
"auth_ref": ["r806"] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ComprehensiveIncomeNetOfTax", "crdr": "credit", "presentation": ["http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
], "lang": { "en-us": { "role": { "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive loss", "documentation": "Amount after
tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity.
Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": ["r15", "r133", "r135", "r140", "r540", "r561", "r562"] }, "us-
gaap_ComprehensiveIncomeNetOfTaxAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ComprehensiveIncomeNetOfTaxAbstract", "presentation": ["http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"],
"lang": { "en-us": { "role": { "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]", "terseLabel": "Other comprehensive income (loss):" } } },
"auth_ref": [] }, "us-gaap_ConcentrationRiskCreditRiskUninsuredDeposits": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ConcentrationRiskCreditRiskUninsuredDeposits", "presentation": [
"http://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrationsSignificantConcentrationsDetails"], "lang": { "en-us": { "role": { "label":
"Concentration Risk, Credit Risk, Uninsured Deposits", "terseLabel": "Concentration risk, credit risk, uninsured deposits", "documentation": "Description of credit risk that
arises from having significant balances in excess of the Federal Deposit Insurance Corporation or other insurance limits on deposits in financial institutions." } } }, "auth_ref":
["r45", "r97"] }, "us-gaap_ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ConsolidationPolicyTextBlock", "presentation": ["http://www.rezolutebio.com/role/DisclosureNatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"],
"lang": { "en-us": { "role": { "label": "Consolidation, Policy [Policy Text Block]", "verboseLabel": "Consolidation", "documentation": "Disclosure of accounting policy regarding
(1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of
subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or
other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the
accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a
subsidiary." } } }, "auth_ref": ["r37", "r690"] }, "us-gaap_CorporateDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "CorporateDebtSecuritiesMember", "presentation": [
"http://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrationsFairValueOnRecurringBasisDetails",
"http://www.rezolutebio.com/role/DisclosureInvestmentsInMarketableDebtSecuritiesCashAndCashEquivalentsAndMarketableSecuritiesHeldDetails"], "lang": { "en-us": {
"role": { "label": "Corporate Debt Securities [Member]", "terseLabel": "Corporate notes and bonds", "verboseLabel": "Corporate notes and bonds", "documentation": "Debt
securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment." } } }, "auth_ref": ["r707", "r709", "r716", "r730", "r741",
"r989"] }, "rzlt_CorporateHeadquartersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rezolutebio.com/20240630", "localname":
"CorporateHeadquartersMember", "presentation": ["http://www.rezolutebio.com/role/DisclosureLeasesAdditionalInformationDetails"], "lang": { "en-us": { "role": {
"documentation": "Represents information pertaining to lease agreement for corporate headquarters.", "label": "Corporate Headquarters" } } }, "auth_ref": [] },
"srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "CounterpartyNameAxis", "presentation": [
"http://www.rezolutebio.com/role/DisclosureLicenseAgreementsDetails", "http://www.rezolutebio.com/role/DisclosureLiquidityDetails",
"http://www.rezolutebio.com/role/DisclosureRelatedPartyTransactionsDetails"], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]" } } }, "auth_ref": ["r152",
"r153", "r270", "r287", "r471", "r492", "r544", "r687", "r689"] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":

"CoverAbstract", "lang": { "en-us": { "role": { "label": "Document And Entity Information [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] },
"dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [
"http://www.rezolutebio.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End
date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "rzlt_DebtInstrumentExitFee": { "xbrltype": "percentItemType", "nsuri":
"http://www.rezolutebio.com/20240630", "localname": "DebtInstrumentExitFee", "presentation": [
"http://www.rezolutebio.com/role/DisclosureEmbeddedDerivativeLiabilityDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the exit fee on the funded
principal balance.", "label": "Debt Instrument, Exit Fee", "terseLabel": "Exit fee on the funded principal balance" } } }, "auth_ref": [] }, "rzlt_DebtInstrumentExitFeeAmount": {
"xbrltype": "monetaryItemType", "nsuri": "http://www.rezolutebio.com/20240630", "localname": "DebtInstrumentExitFeeAmount", "crdr": "debit", "presentation": [
"http://www.rezolutebio.com/role/DisclosureEmbeddedDerivativeLiabilityDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of expenses associated with exit
fees on the funded principal balance.", "label": "Debt Instrument, Exit Fee Amount", "terseLabel": "Exit fee amount" } } }, "auth_ref": [] }, "us-
gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentLineItems", "presentation": [
"http://www.rezolutebio.com/role/DisclosureEmbeddedDerivativeLiabilityDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument [Line Items]", "documentation":
"Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or
many axes to the table." } } }, "auth_ref": ["r155", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282",
"r283", "r700", "r701", "r702", "r703", "r704", "r726", "r861", "r944", "r945"] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "DebtInstrumentTable", "presentation": ["http://www.rezolutebio.com/role/DisclosureEmbeddedDerivativeLiabilityDetails"], "lang": { "en-us": {
"role": { "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "Disclosure of information about long-term debt instrument or arrangement." } } },
"auth_ref": ["r12", "r27", "r30", "r49", "r86", "r87", "r155", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281",
"r282", "r283", "r700", "r701", "r702", "r703", "r704", "r726", "r861", "r944", "r945"] }, "us-
gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent", "crdr": "debit", "presentation": [
"http://www.rezolutebio.com/role/DisclosureInvestmentsInMarketableDebtSecuritiesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Debt Securities,
Available-for-Sale, Accrued Interest, after Allowance for Credit Loss, Current", "terseLabel": "Interest receivable", "documentation": "Amount, after allowance for credit loss,
of accrued interest on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as
current." } } }, "auth_ref": ["r209", "r242", "r243"] }, "us-
gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrentStatementOfFinancialPositionExtensibleList": { "xbrltype":
"enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrentStatementOfFinancialPositionExtensibleList", "presentation": [
"http://www.rezolutebio.com/role/DisclosureInvestmentsInMarketableDebtSecuritiesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Debt Securities,
Available-for-Sale, Accrued Interest, after Allowance for Credit Loss, Current, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line
item in statement of financial position that includes accrued interest, after allowance for credit loss, on investment in debt security measured at fair value with change in fair
value recognized in other comprehensive income (available-for-sale), classified as current." } } }, "auth_ref": ["r243"] }, "us-
gaap_DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterestCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterestCurrent", "crdr": "credit", "presentation": [
"http://www.rezolutebio.com/role/DisclosureInvestmentsInMarketableDebtSecuritiesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Debt Securities,
Available-for-Sale, Amortized Cost, Allowance for Credit Loss, Excluding Accrued Interest, Current", "terseLabel": "Allowance for credit losses related to investments in
marketable debt securities", "documentation": "Amount excluding accrued interest, of allowance for credit loss on investment in debt security measured at fair value with
change in fair value recognized in other comprehensive income (available-for-sale), classified as current." } } }, "auth_ref": ["r242"] }, "us-
gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss", "crdr": "debit", "presentation": [
"http://www.rezolutebio.com/role/DisclosureInvestmentsInMarketableDebtSecuritiesCashAndCashEquivalentsAndMarketableSecuritiesHeldDetails"], "lang": { "en-us": {
"role": { "label": "Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, before Allowance for Credit Loss", "totalLabel": "Amortized Cost",
"documentation": "Amortized cost excluding accrued interest, before allowance for credit loss, of investment in debt security measured at fair value with change in fair value
recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r242"] }, "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleExcludingAccruedInterest", "crdr": "debit",
"presentation": ["http://www.rezolutebio.com/role/DisclosureInvestmentsInMarketableDebtSecuritiesCashAndCashEquivalentsAndMarketableSecuritiesHeldDetails"], "lang":
{ "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Excluding Accrued Interest", "terseLabel": "Fair Value", "documentation": "Amount excluding accrued
interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [
"r884"] }, "us-gaap_DebtSecuritiesAvailableForSaleTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DebtSecuritiesAvailableForSaleTable", "presentation": [
"http://www.rezolutebio.com/role/DisclosureInvestmentsInMarketableDebtSecuritiesCashAndCashEquivalentsAndMarketableSecuritiesHeldDetails"], "lang": { "en-us": {
"role": { "label": "Debt Securities, Available-for-Sale [Table]", "documentation": "Disclosure of information about investment in debt security measured at fair value with
change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r202", "r203", "r204", "r205", "r206", "r207", "r208", "r210", "r211",
"r212", "r213", "r214"] }, "us-gaap_DebtSecuritiesAvailableForSaleTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DebtSecuritiesAvailableForSaleTerm", "presentation": ["http://www.rezolutebio.com/role/DisclosureInvestmentsInMarketableDebtSecuritiesAdditionalInformationDetails"],
"lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Term", "terseLabel": "Debt securities, available-for-sale, term", "documentation": "Period between
issuance and maturity of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in
'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r930", "r931", "r932"] },
"rzlt_DebtSecuritiesAvailableForSaleWeightedAverageTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.rezolutebio.com/20240630", "localname":
"DebtSecuritiesAvailableForSaleWeightedAverageTerm", "presentation": [
"http://www.rezolutebio.com/role/DisclosureInvestmentsInMarketableDebtSecuritiesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Weighted
average period of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in
'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Debt Securities, Available-for-Sale,
Weighted Average Term", "terseLabel": "Debt securities, available-for-sale, weighted average term" } } }, "auth_ref": [] }, "us-
gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DeferredTaxAssetsGoodwillAndIntangibleAssets", "crdr": "debit", "presentation": [
"http://www.rezolutebio.com/role/DisclosureIncomeTaxesDeferredIncomeTaxAssetsAndLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Goodwill
and Intangible Assets", "verboseLabel": "Intangible assets", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to
deductible temporary differences from intangible assets including goodwill." } } }, "auth_ref": ["r925"] }, "us-gaap_DeferredTaxAssetsGross": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsGross", "crdr": "debit", "presentation": [
"http://www.rezolutebio.com/role/DisclosureIncomeTaxesDeferredIncomeTaxAssetsAndLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Gross",
"totalLabel": "Total deferred income tax assets", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible
temporary differences and carryforwards." } } }, "auth_ref": ["r380"] }, "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment", "crdr": "debit", "presentation": [
"http://www.rezolutebio.com/role/DisclosureIncomeTaxesDeferredIncomeTaxAssetsAndLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Deferred Tax Asset, In-
Process Research and Development", "terseLabel": "Research and experimental costs", "documentation": "Amount, before allocation of valuation allowance, of deferred tax
asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or
both." } } }, "auth_ref": ["r925"] }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DeferredTaxAssetsLiabilitiesNet", "crdr": "debit", "presentation": ["http://www.rezolutebio.com/role/DisclosureIncomeTaxesDeferredIncomeTaxAssetsAndLiabilitiesDetails"],
"lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Net", "totalLabel": "Net deferred income tax assets", "documentation": "Amount, after allocation of valuation
allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting." } } }, "auth_ref": ["r923"]
}, "us-gaap_DeferredTaxAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsNet", "crdr": "debit",
"presentation": ["http://www.rezolutebio.com/role/DisclosureIncomeTaxesDeferredIncomeTaxAssetsAndLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Deferred Tax
Assets, Net of Valuation Allowance", "totalLabel": "Deferred income tax assets, net of valuation allowance", "documentation": "Amount after allocation of valuation allowances
of deferred tax asset attributable to deductible temporary differences and carryforwards." } } }, "auth_ref": ["r923"] }, "us-gaap_DeferredTaxAssetsNetAbstract": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsNetAbstract", "presentation": [
"http://www.rezolutebio.com/role/DisclosureIncomeTaxesDeferredIncomeTaxAssetsAndLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Net
[Abstract]", "verboseLabel": "Deferred income tax assets:" } } }, "auth_ref": [] }, "rzlt_DeferredTaxAssetsOperatingLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.rezolutebio.com/20240630", "localname": "DeferredTaxAssetsOperatingLeaseLiabilities", "crdr": "debit", "presentation": [
"http://www.rezolutebio.com/role/DisclosureIncomeTaxesDeferredIncomeTaxAssetsAndLiabilitiesDetails"], "lang": { "en-us": { "role": { "documentation": "Amount before
allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from operating lease liability.", "label": "Deferred Tax Assets
Operating Lease Liabilities", "terseLabel": "Operating lease liabilities" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "crdr": "debit", "presentation": [
"http://www.rezolutebio.com/role/DisclosureIncomeTaxesDeferredIncomeTaxAssetsAndLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets,
Operating Loss Carryforwards", "verboseLabel": "Net operating loss carryforwards", "documentation": "Amount before allocation of valuation allowances of deferred tax asset
attributable to deductible operating loss carryforwards." } } }, "auth_ref": ["r925"] }, "us-gaap_DeferredTaxAssetsOther": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsOther", "crdr": "debit", "presentation": [
"http://www.rezolutebio.com/role/DisclosureIncomeTaxesDeferredIncomeTaxAssetsAndLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Other",
"verboseLabel": "Accrued expenses and other", "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary
differences, classified as other." } } }, "auth_ref": ["r925"] }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "crdr": "debit", "presentation": [
"http://www.rezolutebio.com/role/DisclosureIncomeTaxesDeferredIncomeTaxAssetsAndLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Tax
Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost", "verboseLabel": "Share-based compensation", "documentation": "Amount before allocation
of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation." } } }, "auth_ref": ["r925"] }, "us-
gaap_DeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsValuationAllowance",
"crdr": "credit", "presentation": ["http://www.rezolutebio.com/role/DisclosureIncomeTaxesDeferredIncomeTaxAssetsAndLiabilitiesDetails"], "lang": { "en-us": { "role": {
"label": "Deferred Tax Assets, Valuation Allowance", "negatedLabel": "Valuation allowance for deferred income tax assets", "documentation": "Amount of deferred tax assets
for which it is more likely than not that a tax benefit will not be realized." } } }, "auth_ref": ["r381"] }, "us-gaap_DeferredTaxLiabilitiesNetAbstract": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxLiabilitiesNetAbstract", "presentation": [
"http://www.rezolutebio.com/role/DisclosureIncomeTaxesDeferredIncomeTaxAssetsAndLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Deferred Tax Liabilities, Net
[Abstract]", "verboseLabel": "Deferred tax liabilities" } } }, "auth_ref": [] }, "rzlt_DeferredTaxLiabilitiesRightOfUseAssets": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.rezolutebio.com/20240630", "localname": "DeferredTaxLiabilitiesRightOfUseAssets", "crdr": "credit", "presentation": [
"http://www.rezolutebio.com/role/DisclosureIncomeTaxesDeferredIncomeTaxAssetsAndLiabilitiesDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of deferred

tax liability attributable to taxable right of use asset.", "label": "Deferred Tax Liabilities Right-Of-Use Assets", "negatedLabel": "Deferred income tax liability right-of-use assets" } } }, "auth_ref": [] }, "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount", "crdr": "debit", "presentation": ["http://www.rezolutebio.com/role/DisclosureCommitmentsAndContingenciesDetails"], "lang": { "en-us": { "role": { "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount", "terseLabel": "Total contributions by the company", "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan." } } }, "auth_ref": [] }, "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "presentation": ["http://www.rezolutebio.com/role/DisclosureCommitmentsAndContingenciesDetails"], "lang": { "en-us": { "role": { "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match", "terseLabel": "Employer matching contributions (as a percent)", "documentation": "Percentage employer matches of the employee's percentage contribution matched." } } }, "auth_ref": [] }, "us-gaap_DemandDepositsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DemandDepositsMember", "presentation": ["http://www.rezolutebio.com/role/DisclosureSupplementalFinancialInformationCashAndCashEquivalentsDetails"], "lang": { "en-us": { "role": { "label": "Demand Deposits [Member]", "terseLabel": "Demand deposits at a single financial institution", "documentation": "Accounts that may or may not bear interest and that depositor is entitled to withdraw at anytime without prior notice. Checking and negotiable order of withdrawal (NOW) accounts are the most common forms of demand deposits." } } }, "auth_ref": [] }, "us-gaap_DepositsAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepositsAssetsNoncurrent", "crdr": "debit", "presentation": ["http://www.rezolutebio.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Deposits Assets, Noncurrent", "terseLabel": "Deposits and other", "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer." } } }, "auth_ref": ["r853"] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Depreciation", "crdr": "debit", "presentation": ["http://www.rezolutebio.com/role/DisclosureSupplementalFinancialInformationPropertyAndEquipmentDetails"], "lang": { "en-us": { "role": { "label": "Depreciation", "terseLabel": "Depreciation expense related to property and equipment", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": ["r4", "r23"] }, "us-gaap_DepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationAndAmortization", "crdr": "debit", "presentation": ["http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Depreciation, Depletion and Amortization, Nonproduction", "terseLabel": "Depreciation expense", "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production." } } }, "auth_ref": ["r4", "r23"] }, "us-gaap_DerivativeContractTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeContractTypeDomain", "presentation": ["http://www.rezolutebio.com/role/DisclosureEmbeddedDerivativeLiabilityDetails", "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows", "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Derivative Contract [Domain]", "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "auth_ref": ["r594", "r596", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r618", "r619", "r620", "r621", "r635", "r636", "r637", "r638", "r641", "r642", "r643", "r644", "r662", "r663", "r664", "r665", "r742", "r744", "r933", "r934", "r935", "r936", "r937", "r938", "r940", "r941"] }, "us-gaap_DerivativeInstrumentRiskAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentRiskAxis", "presentation": ["http://www.rezolutebio.com/role/DisclosureEmbeddedDerivativeLiabilityDetails", "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows", "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Derivative Instrument [Axis]", "documentation": "Information by type of derivative contract." } } }, "auth_ref": ["r41", "r42", "r43", "r95", "r594", "r596", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r618", "r619", "r620", "r621", "r635", "r636", "r637", "r638", "r641", "r642", "r643", "r644", "r662", "r663", "r664", "r665", "r689", "r742", "r744", "r933", "r934", "r935", "r936", "r937", "r938", "r940", "r941"] }, "us-gaap_DerivativesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativesPolicyTextBlock", "presentation": ["http://www.rezolutebio.com/role/DisclosureNatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Derivatives, Policy [Policy Text Block]", "terseLabel": "Embedded Derivatives", "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities." } } }, "auth_ref": ["r8", "r38", "r39", "r40", "r44", "r154", "r169"] }, "rzlt_DevelopmentAndLicenseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rezolutebio.com/20240630", "localname": "DevelopmentAndLicenseAgreementMember", "presentation": ["http://www.rezolutebio.com/role/DisclosureLicenseAgreementsDetails"], "lang": { "en-us": { "role": { "documentation": "Development And License Agreement [Member]", "label": "Development And License Agreement [Member]", "terseLabel": "Development And License Agreement" } } }, "auth_ref": [] }, "rzlt_DevelopmentAndLicenseAgreementRoyaltiesPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.rezolutebio.com/20240630", "localname": "DevelopmentAndLicenseAgreementRoyaltiesPercentage", "presentation": ["http://www.rezolutebio.com/role/DisclosureLicenseAgreementsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the percentage of royalties.", "label": "Development and License Agreement, Royalties Percentage", "terseLabel": "Royalties percentage" } } }, "auth_ref": [] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": ["http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrants"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Text Block]", "terseLabel": "SHARE-BASED COMPENSATION AND WARRANTS", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": ["r312", "r316", "r347", "r348", "r350", "r711"] }, "us-gaap_DiscussionOfHybridInstrumentsAndEmbeddedDerivativesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DiscussionOfHybridInstrumentsAndEmbeddedDerivativesTextBlock", "presentation": ["http://www.rezolutebio.com/role/DisclosureEmbeddedDerivativeLiability"], "lang": { "en-us": { "role": { "label": "Discussion of Hybrid Instruments and Embedded Derivatives [Text Block]", "terseLabel": "EMBEDDED DERIVATIVE LIABILITY", "documentation": "The entire disclosure for hybrid instruments and embedded derivatives, including discussion of the process used in evaluating whether a hybrid instrument in the form of a share constitutes a debt or equity security, and on what basis an embedded derivative was deemed to be separable or inseparable from the host instrument." } } }, "auth_ref": ["r96"] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAnnualReport", "presentation": ["http://www.rezolutebio.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": ["r756", "r757", "r769"] }, "dei_DocumentFinStmtErrorCorrectionFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFinStmtErrorCorrectionFlag", "presentation": ["http://www.rezolutebio.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Financial Statement Error Correction [Flag]", "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction." } } }, "auth_ref": ["r756", "r757", "r769", "r812"] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": ["http://www.rezolutebio.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": ["http://www.rezolutebio.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": ["http://www.rezolutebio.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": ["http://www.rezolutebio.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": ["r790"] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": ["http://www.rezolutebio.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "us-gaap_DomesticCountryMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DomesticCountryMember", "presentation": ["http://www.rezolutebio.com/role/DisclosureIncomeTaxesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Domestic Tax Jurisdiction [Member]", "terseLabel": "Domestic Tax Authority", "documentation": "Designated federal jurisdiction entitled to levy and collect income tax in country of domicile. Includes, but is not limited to, national jurisdiction for non-U.S. jurisdiction." } } }, "auth_ref": ["r365"] }, "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]", "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year" } } }, "auth_ref": ["r801"] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "label": "NET LOSS PER SHARE" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": ["http://www.rezolutebio.com/role/DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareDetails", "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic", "terseLabel": "Net loss per common share - basic (in dollars per share)", "verboseLabel": "Net loss per share of common stock - basic (in dollars per share)", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": ["r141", "r161", "r162", "r163", "r164", "r165", "r166", "r172", "r175", "r182", "r183", "r184", "r189", "r397", "r400", "r418", "r419", "r541", "r563", "r692"] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": ["http://www.rezolutebio.com/role/DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareDetails", "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Diluted", "terseLabel": "Net loss per common share - diluted (in dollars per share)", "verboseLabel": "Net loss per share of common stock - diluted (in dollars per share)", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": ["r141", "r161", "r162", "r163", "r164", "r165", "r166", "r175", "r182", "r183", "r184", "r189", "r397", "r400", "r418", "r419", "r541", "r563", "r692"] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerSharePolicyTextBlock", "presentation": ["http://www.rezolutebio.com/role/DisclosureNatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Net Loss Per Share", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": ["r18", "r19", "r186"] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": ["http://www.rezolutebio.com/role/DisclosureNetLossPerShare"], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Text Block]", "terseLabel": "NET LOSS PER SHARE", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": ["r171", "r185", "r187", "r188"] }, "rzlt_EffectiveIncomeTaxRateReconciliationNonTaxableDerivativeGainsLossesAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rezolutebio.com/20240630",

"localname": "EffectiveIncomeTaxRateReconciliationNonTaxableDerivativeGainsLossesAmount", "crdr": "debit", "presentation": [
"http://www.rezolutebio.com/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to non-taxable derivative gains (losses).", "label": "Effective Income Tax Rate Reconciliation, Non-Taxable Derivative Gains (Losses), Amount", "terseLabel": "Non-taxable derivative loss" } } }, "auth_ref": [] }, "rzlt_EffectiveIncomeTaxRateReconciliationStockOptionExpirations": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rezolutebio.com/20240630", "localname": "EffectiveIncomeTaxRateReconciliationStockOptionExpirations", "crdr": "credit", "presentation": ["http://www.rezolutebio.com/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to stock option expiration.", "label": "Effective Income Tax Rate Reconciliation, Stock Option Expirations", "negatedLabel": "Stock option expirations" } } }, "auth_ref": [] }, "us-gaap_EmbeddedDerivativeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmbeddedDerivativeAbstract", "lang": { "en-us": { "role": { "label": "EMBEDDED DERIVATIVE LIABILITY" } } }, "auth_ref": [] },
"rzlt_EmbeddedDerivativeDerivativeFinancialInstrumentsLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rezolutebio.com/20240630", "localname":
"EmbeddedDerivativeDerivativeFinancialInstrumentsLiabilitiesMember", "presentation": [
"http://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrationsSummaryOfChangesInFairValueDetails"], "lang": { "en-us": { "role": {
"documentation": "This item represents embedded derivative instrument obligations meeting the definition of a liability which are reported as of the balance sheet date.",
"label": "Embedded Derivative, Derivative Financial Instruments, Liabilities [Member]", "terseLabel": "Embedded" } } }, "auth_ref": [] }, "us-
gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability", "crdr": "credit", "presentation": [
"http://www.rezolutebio.com/role/DisclosureEmbeddedDerivativeLiabilityDetails", "http://www.rezolutebio.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us":
{ "role": { "label": "Embedded Derivative, Fair Value of Embedded Derivative Liability", "terseLabel": "Embedded derivative liability", "documentation": "Fair value as of the
balance sheet date of the embedded derivative or group of embedded derivatives classified as a liability." } } }, "auth_ref": ["r94", "r930", "r931", "r932"] }, "us-
gaap_EmbeddedDerivativeFinancialInstrumentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"EmbeddedDerivativeFinancialInstrumentsMember", "presentation": ["http://www.rezolutebio.com/role/DisclosureEmbeddedDerivativeLiabilityDetails",
"http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows",
"http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Embedded Derivative
Financial Instruments [Member]", "terseLabel": "Embedded derivative", "documentation": "Derivative instrument embedded in host contract." } } }, "auth_ref": [] }, "us-
gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeRelatedLiabilitiesCurrent",
"crdr": "credit", "presentation": ["http://www.rezolutebio.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Employee-related Liabilities,
Current", "terseLabel": "Compensation and benefits", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and
payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion
of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r54"] }, "us-
gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname":
"EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [
"http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsShareBasedCompensationExpenseDetails"], "lang": { "en-us": { "role": { "label": "Share-
Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Expected to be recognized over a remaining weighted
average period", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment
arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r349"] },
"us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "crdr":
"debit", "presentation": ["http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsShareBasedCompensationExpenseDetails"], "lang": { "en-us": {
"role": { "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "documentation": "Amount of cost to be recognized for
option under share-based payment arrangement." } } }, "auth_ref": ["r919"] }, "us-gaap_EmployeeStockMember": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "EmployeeStockMember", "presentation": [
"http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrants2022EmployeeStockPurchasePlanDetails"], "lang": { "en-us": { "role": { "label": "Employee
Stock [Member]", "terseLabel": "Employee Stock Purchase Plan", "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a
corporation can purchase the corporation's stock." } } }, "auth_ref": [] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": [
"http://www.rezolutebio.com/role/DisclosureNetLossPerShareAntiDilutiveDetails",
"http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsInducementGrantDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": {
"en-us": { "role": { "verboseLabel": "Employee Stock Option", "label": "Employee Stock Option [Member]", "terseLabel": "Employee Stock Option", "documentation": "Share-
based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period
of time." } } }, "auth_ref": [] }, "rzlt_EmploymentAgreementHealthInsuranceCoverageTermOtherThanChangeInControlEvent": { "xbrltype": "durationItemType", "nsuri":
"http://www.rezolutebio.com/20240630", "localname": "EmploymentAgreementHealthInsuranceCoverageTermOtherThanChangeInControlEvent", "presentation": [
"http://www.rezolutebio.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://www.rezolutebio.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-
us": { "role": { "documentation": "Term of health insurance coverage other than change in control event under employment agreement.", "label": "Employment Agreement,
Health Insurance Coverage Term Other Than Change In Control Event", "terseLabel": "Term of health insurance coverage other than change in control event" } } }, "auth_ref":
[] }, "rzlt_EmploymentAgreementSeverancePaymentBasedOnTermOfSalaryOtherThanChangeInControlEvent": { "xbrltype": "durationItemType", "nsuri":
"http://www.rezolutebio.com/20240630", "localname": "EmploymentAgreementSeverancePaymentBasedOnTermOfSalaryOtherThanChangeInControlEvent", "presentation": [
"http://www.rezolutebio.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://www.rezolutebio.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-
us": { "role": { "documentation": "Term of salary for calculation of severance payment other than change in control event under employment agreement.", "label":
"Employment Agreement, Severance Payment Based on Term of Salary, Other Than Change In Control Event", "terseLabel": "Severance payment based on term of salary" } } },
"auth_ref": [] }, "rzlt_EmploymentAgreementTerminationExercisablePeriodChangeInControlEvent": { "xbrltype": "durationItemType", "nsuri":
"http://www.rezolutebio.com/20240630", "localname": "EmploymentAgreementTerminationExercisablePeriodChangeInControlEvent", "presentation": [
"http://www.rezolutebio.com/role/DisclosureCommitmentsAndContingenciesDetails"], "lang": { "en-us": { "role": { "documentation": "Period during which stock options will
remain exercisable if either of individuals is terminated outside of a change in control event, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported
fact of one year, five months, and thirteen days.", "label": "Employment Agreement, Termination, Exercisable Period, Change In Control Event", "terseLabel": "Exercisable
period, change in control event" } } }, "auth_ref": [] }, "rzlt_EmploymentAgreementTerminationExercisablePeriodChangeInControlEventAndWithoutCause": { "xbrltype":
"durationItemType", "nsuri": "http://www.rezolutebio.com/20240630", "localname":
"EmploymentAgreementTerminationExercisablePeriodChangeInControlEventAndWithoutCause", "presentation": [
"http://www.rezolutebio.com/role/DisclosureCommitmentsAndContingenciesDetails"], "lang": { "en-us": { "role": { "documentation": "Period during which stock options will
remain exercisable if either of individuals is terminated outside of a change in control event and without cause, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D'
represents reported fact of one year, five months, and thirteen days.", "label": "Employment Agreement, Termination, Exercisable Period, Change In Control Event and
Without Cause", "terseLabel": "Exercisable period, change in control event and without cause" } } }, "auth_ref": [] },
"rzlt_EmploymentAgreementTerminationSeverancePaymentBasedOnTermOfSalaryChangeOfControlEvent": { "xbrltype": "durationItemType", "nsuri":
"http://www.rezolutebio.com/20240630", "localname": "EmploymentAgreementTerminationSeverancePaymentBasedOnTermOfSalaryChangeOfControlEvent", "presentation": [
"http://www.rezolutebio.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://www.rezolutebio.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-
us": { "role": { "documentation": "Term of salary for calculation of severance payment on termination of employment agreement due to change of control event.", "label":
"Employment Agreement, Termination, Severance Payment Based on Term of Salary, Change of Control Event", "terseLabel": "Severance payment based on term of salary,
change of control event" } } }, "auth_ref": [] }, "rzlt_EmploymentAgreementTerminationTermOfHealthInsuranceCoverageDueToChangeOfControlEvent": { "xbrltype":
"durationItemType", "nsuri": "http://www.rezolutebio.com/20240630", "localname":
"EmploymentAgreementTerminationTermOfHealthInsuranceCoverageDueToChangeOfControlEvent", "presentation": [
"http://www.rezolutebio.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://www.rezolutebio.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-
us": { "role": { "documentation": "Term of health insurance coverage following termination of employment agreement due to change of control event.", "label": "Employment
Agreement, Termination, Term of Health Insurance Coverage due to Change of Control Event", "terseLabel": "Term of health insurance coverage, change in control" } } },
"auth_ref": [] }, "rzlt_EmploymentAgreementTerminationUnvestedStockOptionsExercisablePeriodChangeInControlEvent": { "xbrltype": "durationItemType", "nsuri":
"http://www.rezolutebio.com/20240630", "localname": "EmploymentAgreementTerminationUnvestedStockOptionsExercisablePeriodChangeInControlEvent", "presentation": [
"http://www.rezolutebio.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://www.rezolutebio.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-
us": { "role": { "documentation": "Period during which unvested stock options will remain exercisable if either of individuals is terminated outside of a change in control
event, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Employment Agreement,
Termination, Unvested Stock Options, Exercisable Period, Change In Control Event", "terseLabel": "Unvested stock options, exercisable period, change in control event" } } },
"auth_ref": [] }, "rzlt_EmploymentAgreementTerminationUnvestedStockOptionsVestingPeriodChangeInControlEvent": { "xbrltype": "durationItemType", "nsuri":
"http://www.rezolutebio.com/20240630", "localname": "EmploymentAgreementTerminationUnvestedStockOptionsVestingPeriodChangeInControlEvent", "presentation": [
"http://www.rezolutebio.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://www.rezolutebio.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-
us": { "role": { "documentation": "Period during which unvested stock options will immediately vest if either of individuals is terminated outside of a change in control event,
in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Employment Agreement,
Termination, Unvested Stock Options, Vesting Period, Change In Control Event", "terseLabel": "Unvested stock options, vesting period, change in control event" } } },
"auth_ref": [] }, "rzlt_EmploymentAgreementTerminationVestingPeriodChangeInControlEventAndWithoutCause": { "xbrltype": "durationItemType", "nsuri":
"http://www.rezolutebio.com/20240630", "localname": "EmploymentAgreementTerminationVestingPeriodChangeInControlEventAndWithoutCause", "presentation": [
"http://www.rezolutebio.com/role/DisclosureCommitmentsAndContingenciesDetails"], "lang": { "en-us": { "role": { "documentation": "Period during which stock options will
immediately vest if either of individuals is terminated outside of a change in control event and without cause, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D'
represents reported fact of one year, five months, and thirteen days.", "label": "Employment Agreement, Termination, Vesting Period, Change In Control Event and Without
Cause", "terseLabel": "Vesting period, change in control event" } } }, "auth_ref": [] }, "rzlt_EmploymentAgreementsMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.rezolutebio.com/20240630", "localname": "EmploymentAgreementsMember", "presentation": [
"http://www.rezolutebio.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://www.rezolutebio.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-
us": { "role": { "documentation": "Represents information pertaining to employment agreement.", "label": "Employment Agreements", "terseLabel": "Employment Agreements"
} } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"EntityAddressAddressLine1", "presentation": ["http://www.rezolutebio.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity
Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype":
"normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [
"http://www.rezolutebio.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of
the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"EntityAddressPostalZipCode", "presentation": ["http://www.rezolutebio.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity
Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype":

"stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": ["http://www.rezolutebio.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": ["http://www.rezolutebio.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": ["r754"] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": ["http://www.rezolutebio.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": ["http://www.rezolutebio.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": ["http://www.rezolutebio.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": ["r754"] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": ["http://www.rezolutebio.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Securities Act File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": ["http://www.rezolutebio.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": ["r754"] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": ["http://www.rezolutebio.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": ["http://www.rezolutebio.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": ["r841"] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": ["http://www.rezolutebio.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": ["http://www.rezolutebio.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": ["r754"] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": ["http://www.rezolutebio.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": ["r754"] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": ["http://www.rezolutebio.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": ["r754"] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": ["http://www.rezolutebio.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": ["r754"] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityVoluntaryFilers", "presentation": ["http://www.rezolutebio.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityWellKnownSeasonedIssuer", "presentation": ["http://www.rezolutebio.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": ["r842"] }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Footnote [Text Block]", "terseLabel": "Equity Awards Adjustments, Footnote" } } }, "auth_ref": ["r795"] }, "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]", "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table" } } }, "auth_ref": ["r837"] }, "ecd_EqtyAwrdsAdjsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments [Member]", "terseLabel": "Equity Awards Adjustments" } } }, "auth_ref": ["r837"] }, "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table" } } }, "auth_ref": ["r837"] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": ["http://www.rezolutebio.com/role/DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareDetails", "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfShareholdersEquity"], "lang": { "en-us": { "role": { "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": ["r7", "r117", "r137", "r138", "r139", "r156", "r157", "r158", "r160", "r165", "r167", "r169", "r191", "r235", "r236", "r247", "r301", "r387", "r388", "r394", "r395", "r396", "r398", "r399", "r400", "r409", "r410", "r411", "r412", "r413", "r414", "r417", "r440", "r441", "r442", "r443", "r444", "r445", "r447", "r449", "r464", "r559", "r569", "r570", "r571", "r588", "r647"] }, "us-gaap_EquitySecuritiesByIndustryAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquitySecuritiesByIndustryAxis", "presentation": ["http://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrationsSignificantConcentrationsDetails"], "lang": { "en-us": { "role": { "label": "Industry Sector [Axis]", "documentation": "Information by industry sector, examples include but are not limited to, commercial, industrial, agricultural, financial services, technology, healthcare and real estate." } } }, "auth_ref": ["r590", "r591", "r593", "r656", "r658", "r661", "r667", "r698", "r716", "r717", "r719", "r744"] }, "us-gaap_EquitySecuritiesIndustryMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquitySecuritiesIndustryMember", "presentation": ["http://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrationsSignificantConcentrationsDetails"], "lang": { "en-us": { "role": { "label": "Industry Sector [Domain]", "documentation": "Industry sector consisting of government, private and corporate entities engaged in business activities, including but not limited to, commercial, industrial, agricultural, financial services, technology, healthcare and real estate." } } }, "auth_ref": ["r590", "r591", "r593", "r656", "r658", "r661", "r667", "r716", "r717", "r719", "r744"] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote [Text Block]", "terseLabel": "Equity Valuation Assumption Difference, Footnote" } } }, "auth_ref": ["r805"] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis [Text Block]", "terseLabel": "Erroneous Compensation Analysis" } } }, "auth_ref": ["r762", "r773", "r783", "r816"] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]", "terseLabel": "Erroneously Awarded Compensation Recovery" } } }, "auth_ref": ["r759", "r770", "r780", "r813"] }, "rzlt_ExchangePreFundedWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rezolutebio.com/20240630", "localname": "ExchangePreFundedWarrantsMember", "presentation": ["http://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrationsValuationModelInputsOfExchangePfwsDetails", "http://www.rezolutebio.com/role/DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityExchangeAgreementDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityPreFundedWarrantsDetails", "http://www.rezolutebio.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information relating to exchange pre-funded warrants.", "label": "Exchange Pre Funded Warrants [Member]", "terseLabel": "Exchange Pre-Funded Warrants", "verboseLabel": "Exchange PFWs" } } }, "auth_ref": [] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]", "terseLabel": "Executive Category:" } } }, "auth_ref": ["r811"] }, "srt_ExecutiveOfficerMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ExecutiveOfficerMember", "presentation": ["http://www.rezolutebio.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://www.rezolutebio.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Executive Officer [Member]", "terseLabel": "Executive Officers" } } }, "auth_ref": ["r874"] }, "rzlt_ExpirationIn2031Through2035Member": { "xbrltype": "domainItemType", "nsuri": "http://www.rezolutebio.com/20240630", "localname": "ExpirationIn2031Through2035Member", "presentation": ["http://www.rezolutebio.com/role/DisclosureIncomeTaxesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information relating to expiration in 2031 through 2035.", "label": "Expiration in 2031 Through 2035", "terseLabel": "Expiration in 2031 Through 2035" } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": ["http://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrationsFairValueOnRecurringBasisDetails"], "lang": { "en-us": { "role": { "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r421", "r422", "r433", "r716"] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": ["http://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrationsFairValueOnRecurringBasisDetails"], "lang": { "en-us": { "role": { "label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": ["r421", "r422", "r433", "r716"] }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": { "xbrltype": "textBlockItemType", "nsuri":

```
"http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock", "presentation": [
"http://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrationsTables" ], "lang": { "en-us": { "role": { "label": "Fair Value, Assets Measured on
Recurring Basis [Table Text Block]", "terseLabel": "Schedule of financial assets measured at fair value on a recurring basis", "documentation": "Tabular disclosure of assets,
including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The
disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in
their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and
significant unobservable inputs (Level 3)." } } }, "auth_ref": [ "r928", "r929" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [
"http://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrationsFairValueOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label":
"Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical
expedient." } } }, "auth_ref": [ "r275", "r303", "r304", "r305", "r306", "r307", "r308", "r420", "r422", "r423", "r424", "r425", "r432", "r433", "r435", "r479", "r480", "r481",
"r701", "r702", "r707", "r708", "r709", "r716", "r719" ] }, "us-gaap_FairValueByLiabilityClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "FairValueByLiabilityClassAxis", "presentation": [
"http://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrationsSummaryOfChangesInFairValueDetails" ], "lang": { "en-us": { "role": { "label":
"Liability Class [Axis]", "documentation": "Information by class of liability." } } }, "auth_ref": [ "r426", "r427", "r428", "r429", "r430", "r431", "r434" ] }, "us-
gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FairValueByMeasurementFrequencyAxis", "presentation": [
"http://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrationsFairValueOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label":
"Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": [ "r421", "r422", "r423", "r425", "r716", "r931", "r942" ] }, "us-
gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": {
"role": { "label": "FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS" } } }, "auth_ref": [] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel1Member", "presentation": [
"http://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrationsFairValueOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label":
"Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity
can access at the measurement date." } } }, "auth_ref": [ "r275", "r303", "r308", "r422", "r433", "r479", "r707", "r708", "r709", "r716" ] }, "us-
gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel2Member", "presentation": [
"http://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrationsFairValueOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label":
"Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or
liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar
assets or liabilities in inactive markets." } } }, "auth_ref": [ "r275", "r303", "r308", "r422", "r423", "r433", "r480", "r701", "r702", "r707", "r708", "r709", "r716" ] }, "us-
gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "presentation": [
"http://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrationsSummaryOfChangesInFairValueDetails" ], "lang": { "en-us": { "role": { "label":
"Fair Value by Liability Class [Domain]", "documentation": "Represents classes of liabilities measured and disclosed at fair value." } } }, "auth_ref": [ "r426", "r427", "r428",
"r429", "r430", "r431", "r434" ] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward", "presentation": [
"http://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrationsSummaryOfChangesInFairValueDetails" ], "lang": { "en-us": { "role": { "label":
"Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "documentation": "A roll forward is a reconciliation of a
concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-
gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "presentation": [
"http://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrationsSignificantConcentrationsDetails",
"http://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrationsSummaryOfChangesInFairValueDetails",
"http://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrationsValuationModelInputsOfExchangePfwsDetails" ], "lang": { "en-us": { "role": {
"label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]", "terseLabel": "FINANCIAL INSTRUMENTS AND SIGNIFICANT
CONCENTRATIONS", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated
with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r426", "r427", "r428", "r429", "r430", "r431" ] }, "us-
gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "presentation": [
"http://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrationsSignificantConcentrationsDetails",
"http://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrationsSummaryOfChangesInFairValueDetails",
"http://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrationsValuationModelInputsOfExchangePfwsDetails" ], "lang": { "en-us": { "role": {
"label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "documentation": "Disclosure of information about financial
instrument liability measured at fair value on recurring basis using unobservable input." } } }, "auth_ref": [ "r426", "r427", "r428", "r429", "r430", "r431", "r434" ] }, "us-
gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "presentation": [
"http://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrationsTables" ], "lang": { "en-us": { "role": { "label": "Fair Value, Liabilities Measured
on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "terseLabel": "Schedule of changes in the fair value of the company's derivative liabilities, fair
value, level 3 inputs", "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the
beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating
those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those
gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type
disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability." } }
}, "auth_ref": [ "r426", "r431", "r434" ] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "FairValueMeasurementFrequencyDomain", "presentation": [
"http://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrationsFairValueOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label":
"Measurement Frequency [Domain]", "documentation": "Measurement frequency." } } }, "auth_ref": [ "r421", "r422", "r423", "r425", "r716", "r931", "r942" ] }, "us-
gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "crdr":
"credit", "presentation": [ "http://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrationsSummaryOfChangesInFairValueDetails" ], "lang": {
"en-us": { "role": { "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings", "verboseLabel":
"Changes in fair value", "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level
3)." } } }, "auth_ref": [ "r427", "r434" ] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues",
"crdr": "credit", "presentation": [ "http://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrationsSummaryOfChangesInFairValueDetails" ],
"lang": { "en-us": { "role": { "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances", "terseLabel": "Warrant liability
incurred on March 8, 2024", "documentation": "Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the
entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r429", "r434" ] },
"rzlt_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassificationToEquity": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.rezolutebio.com/20240630", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassificationToEquity", "crdr":
"debit", "presentation": [ "http://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrationsSummaryOfChangesInFairValueDetails" ], "lang": {
"en-us": { "role": { "documentation": "Amount of reclassification of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's
own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring
Basis, Liability, Reclassification to Equity", "terseLabel": "Reclassification of warrant derivative liability to equity on May 13, 2024" } } }, "auth_ref": [] }, "us-
gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "crdr": "credit", "presentation": [
"http://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrationsSummaryOfChangesInFairValueDetails" ], "lang": { "en-us": { "role": { "label":
"Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value", "periodEndLabel": "Balance at the end", "periodStartLabel": "Balance at
the beginning", "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption
about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r426", "r434" ] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [
"http://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrationsFairValueOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label":
"Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [
"r275", "r303", "r304", "r305", "r306", "r307", "r308", "r420", "r422", "r423", "r424", "r425", "r432", "r433", "r435", "r479", "r480", "r481", "r701", "r702", "r707", "r708",
"r709", "r716", "r719" ] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FairValueMeasurementsRecurringMember", "presentation": [
"http://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrationsFairValueOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label":
"Fair Value, Recurring [Member]", "terseLabel": "Recurring", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for
impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": [ "r716", "r928", "r929", "r930", "r931", "r932", "r942" ] },
"rzlt_FairValueOfWarrantsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.rezolutebio.com/20240630", "localname":
"FairValueOfWarrantsPolicyTextBlock", "presentation": [
"http://www.rezolutebio.com/role/DisclosureNatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "documentation":
"Disclosure of Accounting policy of fair value of warrants.", "label": "Fair Value of Warrants [Policy Text Block]", "terseLabel": "Fair Value of warrants" } } }, "auth_ref": [] },
"us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialInstrumentAxis", "presentation": [
"http://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrationsFairValueOnRecurringBasisDetails",
"http://www.rezolutebio.com/role/DisclosureInvestmentsInMarketableDebtSecuritiesCashAndCashEquivalentsAndMarketableSecuritiesHeldDetails" ], "lang": { "en-us": {
"role": { "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": [ "r202", "r203", "r204", "r205", "r206",
"r207", "r208", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229",
"r230", "r231", "r232", "r237", "r238", "r239", "r240", "r241", "r244", "r245", "r246", "r283", "r297", "r415", "r436", "r476", "r477", "r478", "r479", "r480", "r481", "r482",
"r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506",
"r507", "r560", "r699", "r716", "r717", "r719", "r720", "r721", "r722", "r723", "r724", "r725", "r730", "r846", "r847", "r848", "r849", "r850", "r851", "r852", "r879", "r880",
"r881", "r882", "r927", "r930", "r931", "r932", "r939", "r942" ] }, "us-gaap_FinancialInstrumentsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "FinancialInstrumentsDisclosureTextBlock", "presentation": [
```

```
"http://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrations" ], "lang": { "en-us": { "role": { "label": "Financial Instruments Disclosure [Text Block]", "terseLabel": "FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS", "documentation": "The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures." } } }, "auth_ref": [] }, "us-gaap_FinancialServicesSectorMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialServicesSectorMember", "presentation": [ "http://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrationsSignificantConcentrationsDetails" ], "lang": { "en-us": { "role": { "label": "Financial Services Sector [Member]", "terseLabel": "Banking and Financial Services Industries", "documentation": "Sector of the economy consisting of companies engaged in financial services." } } }, "auth_ref": [ "r716", "r744", "r996", "r997", "r998", "r999" ] },
"ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r766", "r777", "r787", "r820" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount", "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r766", "r777", "r787", "r820" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount", "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r766", "r777", "r787", "r820" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability [Text Block]", "terseLabel": "Forgone Recovery, Explanation of Impracticability" } } }, "auth_ref": [ "r766", "r777", "r787", "r820" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r766", "r777", "r787", "r820" ] }, "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]", "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year" } } }, "auth_ref": [ "r800" ] }, "us-gaap_GainLossOnDerivativeInstrumentsNetPretax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnDerivativeInstrumentsNetPretax", "crdr": "credit", "presentation": [ "http://www.rezolutebio.com/role/DisclosureSubsequentEventsDetails", "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows", "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Gain (Loss) on Derivative Instruments, Net, Pretax", "negatedLabel": "Loss from change in fair value of derivative liabilities", "terseLabel": "Loss from change in fair value of derivative liabilities", "documentation": "Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects." } } }, "auth_ref": [ "r41" ] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "presentation": [ "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "General and Administrative Expense", "terseLabel": "General and administrative", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r70", "r627" ] }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLeasesOperatingLeaseExpenseDetails", "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsShareBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "General and Administrative Expense [Member]", "terseLabel": "General and Administrative Expense", "documentation": "Primary financial statement caption encompassing general and administrative expense." } } }, "auth_ref": [ "r70" ] }, "us-gaap_GovernmentSectorMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GovernmentSectorMember", "presentation": [
"http://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrationsSignificantConcentrationsDetails" ], "lang": { "en-us": { "role": { "label": "Government Sector [Member]", "terseLabel": "U.S. government", "documentation": "Sector of the economy consisting of government agencies and authorities." } } }, "auth_ref": [ "r744", "r996", "r997", "r998", "r999" ] }, "rzlt_HandokInc.Member": { "xbrltype": "domainItemType", "nsuri": "http://www.rezolutebio.com/20240630", "localname": "HandokInc.Member", "presentation": [ "http://www.rezolutebio.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "documentation": "Handok, Inc. [Member]", "label": "Handok, Inc. [Member]", "terseLabel": "Handok, Inc." } } }, "auth_ref": [] }, "rzlt_HandokLicenseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rezolutebio.com/20240630", "localname": "HandokLicenseAgreementMember", "presentation": [
"http://www.rezolutebio.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Handok License agreement", "label": "Handok License Agreement [Member]", "terseLabel": "Handok License Agreement" } } }, "auth_ref": [] },
"dei_IcfrAuditorAttestationFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "IcfrAuditorAttestationFlag", "presentation": [
"http://www.rezolutebio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag" } } }, "auth_ref": [ "r756", "r757", "r769" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Consolidated Statements of Operations and Comprehensive Loss" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": [
"http://www.rezolutebio.com/role/DisclosureLeasesOperatingLeaseExpenseDetails",
"http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsShareBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Statement of Income Location, Balance [Axis]", "documentation": "Information by location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": [ "r248", "r249", "r250", "r427", "r431", "r434", "r566", "r568", "r632", "r684", "r718", "r963" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": [
"http://www.rezolutebio.com/role/DisclosureLeasesOperatingLeaseExpenseDetails",
"http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsShareBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Statement of Income Location, Balance [Domain]", "documentation": "Location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": [ "r249", "r250", "r427", "r431", "r434", "r566", "r568", "r632", "r684", "r718", "r963" ] }, "us-gaap_IncomeTaxAuthorityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxAuthorityAxis", "presentation": [
"http://www.rezolutebio.com/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Income Tax Jurisdiction [Axis]", "documentation": "Information by income tax jurisdiction." } } }, "auth_ref": [ "r145", "r365", "r366", "r376", "r384", "r713", "r924" ] }, "us-gaap_IncomeTaxAuthorityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxAuthorityDomain", "presentation": [
"http://www.rezolutebio.com/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Income Tax Jurisdiction [Domain]", "documentation": "Income tax jurisdiction." } } }, "auth_ref": [ "r145", "r365", "r366", "r376", "r384", "r713", "r924" ] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "label": "INCOME TAXES" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://www.rezolutebio.com/role/DisclosureIncomeTaxes" ], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Text Block]", "terseLabel": "INCOME TAXES", "documentation": "The entire disclosure for income tax." } } }, "auth_ref": [ "r149", "r360", "r365", "r373", "r374", "r375", "r377", "r383", "r389", "r391", "r392", "r393", "r583", "r713" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "presentation": [ "http://www.rezolutebio.com/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Income Tax Expense (Benefit)", "totalLabel": "Total income tax expense", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r106", "r114", "r168", "r169", "r190", "r194", "r196", "r364", "r365", "r390", "r564", "r713" ] }, "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract", "presentation": [
"http://www.rezolutebio.com/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxPolicyTextBlock", "presentation": [
"http://www.rezolutebio.com/role/DisclosureNatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Income Tax, Policy [Policy Text Block]", "verboseLabel": "Income Taxes", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } }, "auth_ref": [ "r136", "r362", "r363", "r377", "r378", "r382", "r386", "r577" ] }, "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance", "crdr": "debit", "presentation": [
"http://www.rezolutebio.com/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount", "terseLabel": "Change in valuation allowance", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets." } } }, "auth_ref": [ "r370", "r713", "r921" ] }, "us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxReconciliationChangeInEnactedTaxRate", "crdr": "debit", "presentation": [ "http://www.rezolutebio.com/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount", "terseLabel": "Impact of reduction in Colorado tax rate", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates." } } }, "auth_ref": [ "r361", "r365", "r369", "r713" ] }, "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "crdr": "debit", "presentation": [
"http://www.rezolutebio.com/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount", "terseLabel": "Income tax benefit at statutory U.S. federal rate", "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations." } } }, "auth_ref": [ "r365", "r713" ] },
"rzlt_IncomeTaxReconciliationNetOperatingLossExpirations": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rezolutebio.com/20240630", "localname": "IncomeTaxReconciliationNetOperatingLossExpirations", "crdr": "credit", "presentation": [
"http://www.rezolutebio.com/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to net operating loss expirations.", "label": "Income Tax Reconciliation, Net Operating Loss Expirations", "negatedLabel": "NOL expirations" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxReconciliationNondeductibleExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxReconciliationNondeductibleExpense", "crdr": "debit", "presentation": [
"http://www.rezolutebio.com/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount", "terseLabel": "Non-deductible expenses", "documentation": "Amount of the difference between reported income tax expense (benefit) and
```

expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses." } } }, "auth_ref": ["r371", "r372", "r921"] }, "us-gaap_IncomeTaxReconciliationOtherAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxReconciliationOtherAdjustments", "crdr": "debit", "presentation": ["http://www.rezolutebio.com/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails"], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount", "terseLabel": "Other", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments." } } }, "auth_ref": ["r713", "r921", "r922"] }, "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes", "crdr": "debit", "presentation": ["http://www.rezolutebio.com/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails"], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount", "terseLabel": "Income tax benefit attributable to U.S. states", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit)." } } }, "auth_ref": ["r368", "r713", "r921"] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "presentation": ["http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Increase in accounts payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": ["r3"] }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccruedLiabilities", "crdr": "debit", "presentation": ["http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Accrued Liabilities", "terseLabel": "Increase in accrued liabilities", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid." } } }, "auth_ref": ["r3"] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": ["http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "verboseLabel": "Changes in operating assets and liabilities:" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "presentation": ["http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Increase in prepaid expenses, deposits, and other assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": ["r3"] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Individual [Axis]", "terseLabel": "Individual:" } } }, "auth_ref": ["r766", "r777", "r787", "r811", "r820", "r824", "r832"] }, "rzlt_InducementGrantMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rezolutebio.com/20240630", "localname": "InducementGrantMember", "presentation": ["http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsInducementGrantDetails", "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsStockOptionPlansDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to the inducement grant.", "label": "Inducement Grant" } } }, "auth_ref": [] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]", "terseLabel": "Insider Trading Arrangements:" } } }, "auth_ref": ["r830"] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]", "terseLabel": "Insider Trading Policies and Procedures:" } } }, "auth_ref": ["r758", "r836"] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted [Flag]", "terseLabel": "Insider Trading Policies and Procedures Adopted" } } }, "auth_ref": ["r758", "r836"] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]", "terseLabel": "Insider Trading Policies and Procedures Not Adopted" } } }, "auth_ref": ["r758", "r836"] }, "us-gaap_InterestAndOtherIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestAndOtherIncome", "crdr": "credit", "presentation": ["http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Interest and Other Income", "verboseLabel": "Interest and other income, net", "documentation": "The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [] }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "presentation": ["http://www.rezolutebio.com/role/DisclosureInvestmentsInMarketableDebtSecurities"], "lang": { "en-us": { "role": { "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]", "terseLabel": "INVESTMENTS IN MARKETABLE DEBT SECURITIES", "documentation": "The entire disclosure for investments in certain debt and equity securities." } } }, "auth_ref": ["r103", "r116", "r200", "r201", "r437", "r438", "r960"] }, "rzlt_JulyTwoThousandTwentyTwoFinancingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rezolutebio.com/20240630", "localname": "JulyTwoThousandTwentyTwoFinancingMember", "presentation": ["http://www.rezolutebio.com/role/DisclosureShareholdersEquity2022PrivatePlacementDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to July 2022 financing.", "label": "July 2022 Financing" } } }, "auth_ref": [] }, "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCostTableTextBlock", "presentation": ["http://www.rezolutebio.com/role/DisclosureLeasesTables"], "lang": { "en-us": { "role": { "label": "Lease, Cost [Table Text Block]", "terseLabel": "Schedule of operating lease expense", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } }, "auth_ref": ["r947"] }, "us-gaap_LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeasesAbstract", "lang": { "en-us": { "role": { "label": "LEASES" } } }, "auth_ref": [] }, "rzlt_LegacyWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rezolutebio.com/20240630", "localname": "LegacyWarrantsMember", "presentation": ["http://www.rezolutebio.com/role/DisclosureNetLossPerShareAntiDilutiveDetails", "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsSummaryOfLegacyWarrantsDetails", "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsTables"], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to legacy warrants.", "label": "Legacy Warrants [Member]", "terseLabel": "Legacy warrants" } } }, "auth_ref": [] }, "us-gaap_LesseeLeaseDescriptionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeaseDescriptionLineItems", "presentation": ["http://www.rezolutebio.com/role/DisclosureLeasesOperatingLeaseExpenseDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Lease, Description [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r454", "r463"] }, "us-gaap_LesseeLeaseDescriptionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeaseDescriptionTable", "presentation": ["http://www.rezolutebio.com/role/DisclosureLeasesOperatingLeaseExpenseDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Lease, Description [Table]", "documentation": "Disclosure of information about lessee's leases." } } }, "auth_ref": ["r454", "r463"] }, "us-gaap_LesseeLeasesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeasesPolicyTextBlock", "presentation": ["http://www.rezolutebio.com/role/DisclosureNatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Lessee, Leases [Policy Text Block]", "terseLabel": "Leases", "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee." } } }, "auth_ref": ["r453"] }, "rzlt_LesseeOperatingLeaseAbatementPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.rezolutebio.com/20240630", "localname": "LesseeOperatingLeaseAbatementPeriod", "presentation": ["http://www.rezolutebio.com/role/DisclosureLeasesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "The operating lease rent abatement period.", "label": "Lessee, Operating Lease, Abatement Period", "terseLabel": "Abatement period" } } }, "auth_ref": [] }, "rzlt_LesseeOperatingLeaseBaseRentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rezolutebio.com/20240630", "localname": "LesseeOperatingLeaseBaseRentExpense", "crdr": "debit", "presentation": ["http://www.rezolutebio.com/role/DisclosureLeasesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "The amount of base rent payable monthly.", "label": "Lessee, Operating Lease, Base Rent Expense", "terseLabel": "Average base rent payable in cash" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseDiscountRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseDiscountRate", "presentation": ["http://www.rezolutebio.com/role/DisclosureLeasesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Discount Rate", "verboseLabel": "Lessee operating lease discount rate", "documentation": "Discount rate used by lessee to determine present value of operating lease payments." } } }, "auth_ref": ["r727"] }, "rzlt_LesseeOperatingLeaseFurnitureAndEquipmentAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rezolutebio.com/20240630", "localname": "LesseeOperatingLeaseFurnitureAndEquipmentAllowance", "crdr": "credit", "presentation": ["http://www.rezolutebio.com/role/DisclosureLeasesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "The amount of lease allowance provided for furniture and equipment.", "label": "Lessee, Operating Lease, Furniture And Equipment Allowance", "terseLabel": "Lease provided an allowance for the purchase of furniture and equipment" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": ["http://www.rezolutebio.com/role/DisclosureLeasesTables"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "verboseLabel": "Schedule of future payments under operating lease agreements", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": ["r948"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "presentation": ["http://www.rezolutebio.com/role/DisclosureLeasesAdditionalInformationDetails", "http://www.rezolutebio.com/role/DisclosureLeasesFutureOperatingLeasePaymentsDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid", "terseLabel": "Total base rent payments", "totalLabel": "Total lease payments", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": ["r461"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "presentation": ["http://www.rezolutebio.com/role/DisclosureLeasesFutureOperatingLeasePaymentsDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "2025", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r461"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "presentation": ["http://www.rezolutebio.com/role/DisclosureLeasesFutureOperatingLeasePaymentsDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "terseLabel": "2027", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r461"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "presentation": ["http://www.rezolutebio.com/role/DisclosureLeasesFutureOperatingLeasePaymentsDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "2026", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } }

```
}, "auth_ref": [ "r461" ] }, "rzlt_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rezolutebio.com/20240630", "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearThree", "crdr": "credit", "presentation": [
"http://www.rezolutebio.com/role/DisclosureLeasesFutureOperatingLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Three", "terseLabel": "Thereafter" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "presentation": [
"http://www.rezolutebio.com/role/DisclosureLeasesFutureOperatingLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Less imputed interest", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": [ "r461" ] }, "rzlt_LesseeOperatingLeaseOperatingLeaseSpace": { "xbrltype": "areaItemType", "nsuri": "http://www.rezolutebio.com/20240630", "localname": "LesseeOperatingLeaseOperatingLeaseSpace", "presentation": [
"http://www.rezolutebio.com/role/DisclosureLeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the amount of space being leased.", "label": "Lessee, Operating Lease, Operating Lease Space", "terseLabel": "Lease space" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseRenewalTerm", "presentation": [
"http://www.rezolutebio.com/role/DisclosureLeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Renewal Term", "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r946" ] }, "rzlt_LesseeOperatingLeaseRightOfUseAssetsAndOperatingLeaseLiabilities": { "xbrltype": "textBlockItemType", "nsuri": "http://www.rezolutebio.com/20240630", "localname": "LesseeOperatingLeaseRightOfUseAssetsAndOperatingLeaseLiabilities", "presentation": [
"http://www.rezolutebio.com/role/DisclosureLeasesTables" ], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure of carrying value of ROU assets and operating lease liabilities.", "label": "Lessee, Operating Lease, Right Of Use Assets And Operating Lease Liabilities", "terseLabel": "Schedule of carrying value of right-of-use assets and operating lease liabilities" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseTermOfContract", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Term of Contract", "terseLabel": "Operating lease term of contract", "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r946" ] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeasesTextBlock", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLeases" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "LEASES", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": [ "r448" ] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLiquidityDetails", "http://www.rezolutebio.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities", "totalLabel": "Total liabilities", "verboseLabel": "Total liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": [ "r12", "r53", "r54", "r55", "r57", "r58", "r59", "r60", "r148", "r234", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r404", "r407", "r408", "r439", "r603", "r693", "r752", "r888", "r951", "r952" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "presentation": [ "http://www.rezolutebio.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities and Equity", "totalLabel": "Total liabilities and shareholders' equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r67", "r100", "r552", "r729", "r862", "r883", "r943" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [
"http://www.rezolutebio.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and Shareholders' Equity" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLiquidityDetails",
"http://www.rezolutebio.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities, Current", "terseLabel": "Current liabilities", "totalLabel": "Total current liabilities", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r55", "r120", "r148", "r234", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r404", "r407", "r408", "r439", "r729", "r888", "r951", "r952" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://www.rezolutebio.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesNoncurrentAbstract", "presentation": [ "http://www.rezolutebio.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities, Noncurrent [Abstract]", "terseLabel": "Long-term liabilities:" } } }, "auth_ref": [] }, "us-gaap_LicenseAgreementTermsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LicenseAgreementTermsMember", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLicenseAgreementsDetails", "http://www.rezolutebio.com/role/DisclosureLiquidityDetails" ], "lang": { "en-us": { "role": { "label": "License Agreement Terms [Member]", "terseLabel": "License agreement", "documentation": "Terms of the license agreements under research and development arrangements accounted for as a contract to perform research and development for others." } } }, "auth_ref": [] }, "rzlt_LicenseAgreementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.rezolutebio.com/20240630", "localname": "LicenseAgreementsAbstract", "lang": { "en-us": { "role": { "documentation": "n/a", "label": "LICENSE AGREEMENTS" } } }, "auth_ref": [] }, "rzlt_LicenseAgreementsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.rezolutebio.com/20240630", "localname": "LicenseAgreementsTextBlock", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLicenseAgreements" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about License agreements.", "label": "LICENSE AGREEMENTS [Text block]", "terseLabel": "LICENSE AGREEMENTS" } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": [
"http://www.rezolutebio.com/role/DisclosureEmbeddedDerivativeLiabilityDetails" ], "lang": { "en-us": { "role": { "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Maximum borrowing capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": [ "r52", "r56" ] }, "rzlt_LiquidityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.rezolutebio.com/20240630", "localname": "LiquidityAbstract", "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "LIQUIDITY" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://www.rezolutebio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_MarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecurities", "crdr": "debit", "presentation": [
"http://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrationsFairValueOnRecurringBasisDetails",
"http://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrationsSignificantConcentrationsDetails",
"http://www.rezolutebio.com/role/DisclosureInvestmentsInMarketableDebtSecuritiesInvestmentsInMarketableSecuritiesDetails",
"http://www.rezolutebio.com/role/DisclosureLiquidityDetails" ], "lang": { "en-us": { "role": { "label": "Marketable Securities", "terseLabel": "Marketable debt securities", "totalLabel": "Total investments", "documentation": "Amount of investment in marketable security." } } }, "auth_ref": [ "r101", "r854" ] }, "us-gaap_MarketableSecuritiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecuritiesAbstract", "lang": { "en-us": { "role": { "label": "INVESTMENTS IN MARKETABLE DEBT SECURITIES" } } }, "auth_ref": [] }, "us-gaap_MarketableSecuritiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecuritiesCurrent", "crdr": "debit", "presentation": [
"http://www.rezolutebio.com/role/DisclosureInvestmentsInMarketableDebtSecuritiesAdditionalInformationDetails",
"http://www.rezolutebio.com/role/DisclosureInvestmentsInMarketableDebtSecuritiesInvestmentsInMarketableSecuritiesDetails",
"http://www.rezolutebio.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Marketable Securities, Current", "terseLabel": "Investments in marketable debt securities", "verboseLabel": "Short-term investments", "documentation": "Amount of investment in marketable security, classified as current." } } },
"auth_ref": [ "r854" ] }, "us-gaap_MarketableSecuritiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"MarketableSecuritiesNoncurrent", "crdr": "debit", "presentation": [
"http://www.rezolutebio.com/role/DisclosureInvestmentsInMarketableDebtSecuritiesAdditionalInformationDetails",
"http://www.rezolutebio.com/role/DisclosureInvestmentsInMarketableDebtSecuritiesInvestmentsInMarketableSecuritiesDetails",
"http://www.rezolutebio.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Marketable Securities, Noncurrent", "terseLabel":
"Investments in marketable debt securities", "verboseLabel": "Long-term investments", "documentation": "Amount of investment in marketable security, classified as noncurrent." } } }, "auth_ref": [ "r854" ] }, "us-gaap_MarketableSecuritiesPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"MarketableSecuritiesPolicy", "presentation": [ "http://www.rezolutebio.com/role/DisclosureNatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" ],
"lang": { "en-us": { "role": { "label": "Marketable Securities, Policy [Policy Text Block]", "terseLabel": "Investments in Marketable Debt Securities", "documentation":
"Disclosure of accounting policy for investment classified as marketable security." } } }, "auth_ref": [ "r48" ] }, "us-gaap_MarketableSecuritiesTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecuritiesTextBlock", "presentation": [
"http://www.rezolutebio.com/role/DisclosureInvestmentsInMarketableDebtSecuritiesTables" ], "lang": { "en-us": { "role": { "label": "Marketable Securities [Table Text Block]",
"terseLabel": "Schedule of investments in marketable debt securities", "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets." } } }, "auth_ref": [] }, "rzlt_MaximumAmountOfMilestoneEvents": { "xbrltype":
"monetaryItemType", "nsuri": "http://www.rezolutebio.com/20240630", "localname": "MaximumAmountOfMilestoneEvents", "crdr": "credit", "presentation": [
"http://www.rezolutebio.com/role/DisclosureLicenseAgreementsDetails" ], "lang": { "en-us": { "role": { "documentation": "The maximum amount of milestone event which need to occur for making specific range of milestone payment.", "label": "Maximum Amount of Milestone Events", "terseLabel": "Maximum amount of milestone events" } } },
"auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": [
"http://www.rezolutebio.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://www.rezolutebio.com/role/DisclosureLicenseAgreementsDetails",
"http://www.rezolutebio.com/role/DisclosureNatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetails",
"http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsInducementGrantDetails",
"http://www.rezolutebio.com/role/DisclosureShareholdersEquityExchangeAgreementDetails",
"http://www.rezolutebio.com/role/DisclosureShareholdersEquityPreFundedWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel":
"Maximum" } } }, "auth_ref": [ "r253", "r254", "r255", "r256", "r310", "r356", "r425", "r508", "r565", "r567", "r575", "r595", "r596", "r655", "r657", "r659", "r660", "r666",
"r682", "r683", "r697", "r705", "r710", "r719", "r720", "r724", "r725", "r739", "r890", "r953", "r954", "r955", "r956", "r957", "r958" ] },
"rzlt_MaximumNumberOfAdditionalSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://www.rezolutebio.com/20240630", "localname":
"MaximumNumberOfAdditionalSharesIssued", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareholdersEquity2024UnderwrittenOfferingDetails" ], "lang": {
"en-us": { "role": { "documentation": "Represent the maximum number of additional shares offered.", "label": "Maximum Number Of Additional Shares Issued", "terseLabel":
"Maximum number of additional shares issued" } } }, "auth_ref": [] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure [Axis]", "terseLabel": "Measure:" } } },
"auth_ref": [ "r803" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure Name", "terseLabel": "Name" } } }, "auth_ref": [ "r803" ] }, "us-gaap_MeasurementInputExercisePriceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"MeasurementInputExercisePriceMember", "presentation": [
"http://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrationsValuationModelInputsOfExchangePfwsDetails" ], "lang": { "en-us": { "role": {
"label": "Measurement Input, Exercise Price [Member]", "terseLabel": "Exercise price", "documentation": "Measurement input using agreed upon price for exchange of
```

```
underlying asset." } } }, "auth_ref": [ "r930", "r931", "r932" ] }, "us-gaap_MeasurementInputExpectedTermMember": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "MeasurementInputExpectedTermMember", "presentation": [
"http://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrationsValuationModelInputsOfExchangePfwsDetails" ], "lang": { "en-us": { "role": {
"label": "Measurement Input, Expected Term [Member]", "terseLabel": "Expected term", "documentation": "Measurement input using period financial instrument is expected to
be outstanding. Excludes maturity date." } } }, "auth_ref": [ "r930", "r931", "r932" ] }, "us-gaap_MeasurementInputPriceVolatilityMember": { "xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputPriceVolatilityMember", "presentation": [
"http://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrationsValuationModelInputsOfExchangePfwsDetails" ], "lang": { "en-us": { "role": {
"label": "Measurement Input, Price Volatility [Member]", "terseLabel": "Historical volatility", "documentation": "Measurement input using rate at which price of security will
increase (decrease) for given set of returns." } } }, "auth_ref": [ "r719", "r930", "r931", "r932" ] }, "us-gaap_MeasurementInputRiskFreeInterestRateMember": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputRiskFreeInterestRateMember", "presentation": [
"http://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrationsValuationModelInputsOfExchangePfwsDetails" ], "lang": { "en-us": { "role": {
"label": "Measurement Input, Risk Free Interest Rate [Member]", "terseLabel": "Risk-free interest rate", "documentation": "Measurement input using interest rate on
instrument with zero risk of financial loss." } } }, "auth_ref": [ "r930", "r931", "r932" ] }, "us-gaap_MeasurementInputSharePriceMember": { "xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputSharePriceMember", "presentation": [
"http://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrationsValuationModelInputsOfExchangePfwsDetails" ], "lang": { "en-us": { "role": {
"label": "Measurement Input, Share Price [Member]", "terseLabel": "Market price of common stock", "documentation": "Measurement input using share price of saleable
stock." } } }, "auth_ref": [ "r930", "r931", "r932" ] }, "us-gaap_MeasurementInputTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "MeasurementInputTypeAxis", "presentation": [
"http://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrationsValuationModelInputsOfExchangePfwsDetails" ], "lang": { "en-us": { "role": {
"label": "Measurement Input Type [Axis]", "documentation": "Information by type of measurement input used to determine value of asset and liability." } } }, "auth_ref": [
"r423", "r424", "r425", "r719" ] }, "us-gaap_MeasurementInputTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"MeasurementInputTypeDomain", "presentation": [
"http://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrationsValuationModelInputsOfExchangePfwsDetails" ], "lang": { "en-us": { "role": {
"label": "Measurement Input Type [Domain]", "documentation": "Measurement input used to determine value of asset and liability." } } }, "auth_ref": [ "r423", "r424", "r425",
"r719" ] }, "rzlt_MilestoneClosingPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rezolutebio.com/20240630", "localname": "MilestoneClosingPayment",
"crdr": "debit", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLicenseAgreementsDetails", "http://www.rezolutebio.com/role/DisclosureLiquidityDetails" ],
"lang": { "en-us": { "role": { "documentation": "Amount of milestone payment made during the period.", "label": "Milestone Closing Payment", "terseLabel": "Milestone closing
payment" } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": [
"http://www.rezolutebio.com/role/DisclosureCommitmentsAndContingenciesDetails",
"http://www.rezolutebio.com/role/DisclosureNatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Minimum
[Member]", "terseLabel": "Minimum" } } }, "auth_ref": [ "r253", "r254", "r255", "r256", "r310", "r356", "r425", "r508", "r565", "r567", "r575", "r595", "r596", "r655", "r657",
"r659", "r660", "r666", "r682", "r683", "r697", "r705", "r710", "r719", "r720", "r724", "r739", "r890", "r953", "r954", "r955", "r956", "r957", "r958" ] },
"ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag",
"presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
"terseLabel": "MNPI Disclosure Timed for Compensation Value" } } }, "auth_ref": [ "r823" ] }, "us-gaap_MoneyMarketFundsMember": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "MoneyMarketFundsMember", "presentation": [
"http://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrationsFairValueOnRecurringBasisDetails",
"http://www.rezolutebio.com/role/DisclosureSupplementalFinancialInformationCashAndCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "label": "Money Market Funds
[Member]", "terseLabel": "Money Market Mutual Fund", "verboseLabel": "Money market funds", "documentation": "Fund that invests in short-term money-market
instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly
liquid securities." } } }, "auth_ref": [ "r892" ] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Material Terms of Trading
Arrangement [Text Block]", "terseLabel": "Material Terms of Trading Arrangement" } } }, "auth_ref": [ "r831" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote [Text Block]", "terseLabel": "Named Executive Officers, Footnote" } } }, "auth_ref": [ "r804" ] },
"us-gaap_NatureOfOperations": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NatureOfOperations", "presentation": [
"http://www.rezolutebio.com/role/DisclosureNatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Nature of
Operations [Text Block]", "verboseLabel": "Nature of Operations", "documentation": "The entire disclosure for the nature of an entity's business, major products or services,
principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets,
revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is
currently engaged and an understanding of what those activities are being directed toward." } } }, "auth_ref": [ "r107", "r115" ] }, "us-
gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "presentation": [ "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": {
"en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net Cash Provided by Financing Activities", "documentation": "Amount of cash
inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a
return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources
obtained from creditors on long-term credit." } } }, "auth_ref": [ "r144" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [
"http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities
[Abstract]", "verboseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "presentation": [
"http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities",
"totalLabel": "Total Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued
operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment
and other productive assets." } } }, "auth_ref": [ "r144" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [
"http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities
[Abstract]", "verboseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "presentation": [
"http://www.rezolutebio.com/role/DisclosureLiquidityDetails", "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": {
"label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net Cash Used in Operating Activities", "verboseLabel": "Net cash used in operating activities",
"documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions,
adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r74", "r75", "r76" ] }, "us-
gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-
us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:" } } }, "auth_ref": [] },
"us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "presentation": [
"http://www.rezolutebio.com/role/DisclosureLiquidityDetails", "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
"http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfShareholdersEquity", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": {
"totalLabel": "Net loss", "label": "Net Income (Loss)", "terseLabel": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes,
which is attributable to the parent." } } }, "auth_ref": [ "r69", "r76", "r102", "r118", "r132", "r134", "r139", "r148", "r159", "r161", "r162", "r163", "r164", "r165", "r168",
"r169", "r180", "r234", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r397", "r400", "r419", "r439", "r558", "r625", "r645", "r646", "r750", "r888" ] },
"us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"NetIncomeLossAvailableToCommonStockholdersBasic", "crdr": "credit", "presentation": [
"http://www.rezolutebio.com/role/DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Net Income (Loss)
Available to Common Stockholders, Basic", "terseLabel": "Net loss for calculation of basic net loss per share", "documentation": "Amount, after deduction of tax,
noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders." } } }, "auth_ref": [ "r142", "r161",
"r162", "r163", "r164", "r172", "r173", "r181", "r184", "r400" ] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract", "presentation": [
"http://www.rezolutebio.com/role/DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Net Income (Loss)
Available to Common Stockholders, Basic [Abstract]", "terseLabel": "Calculation of Numerators:" } } }, "auth_ref": [] }, "us-
gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"NetIncomeLossAvailableToCommonStockholdersDiluted", "crdr": "credit", "presentation": [
"http://www.rezolutebio.com/role/DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Net Income (Loss)
Available to Common Stockholders, Diluted", "terseLabel": "Net loss for the calculation of diluted net loss per share", "documentation": "Amount, after deduction of tax,
noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common
shares; of income (loss) available to common shareholders." } } }, "auth_ref": [ "r142", "r174", "r176", "r177", "r178", "r179", "r181", "r184" ] }, "us-
gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [
"http://www.rezolutebio.com/role/DisclosureNatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "New Accounting
Pronouncements, Policy [Policy Text Block]", "verboseLabel": "Recent Accounting Pronouncements", "documentation": "Disclosure of accounting policy pertaining to new
accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref":
[] }, "rzlt_NonCashLeaseExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rezolutebio.com/20240630", "localname": "NonCashLeaseExpense", "crdr": "debit",
"presentation": [ "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Amount representing the
non cash lease expense.", "label": "Non Cash Lease Expense", "terseLabel": "Non-cash lease expense" } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": {
"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description [Text Block]", "terseLabel": "Non-GAAP Measure
Description" } } }, "auth_ref": [ "r803" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonNeosMember",
"presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-NEOs [Member]", "terseLabel": "Non-NEOs" } } }, "auth_ref": [
"r766", "r777", "r787", "r811", "r820" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average
Compensation Actually Paid Amount", "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r794" ] },
"ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount", "terseLabel": "Non-PEO NEO Average
```

Total Compensation Amount" } } }, "auth_ref": ["r793"] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO [Member]", "terseLabel": "Non-PEO NEO" } } }, "auth_ref": ["r811"] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": ["r831"] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": ["r831"] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "presentation": ["http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense)", "totalLabel": "Total non-operating income, net", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": ["r71"] }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": ["http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense) [Abstract]", "verboseLabel": "Non-operating income (expense):" } } }, "auth_ref": [] }, "rzlt_NotSubjectToExpiryAndAvailableForUseOver2038AndThereafterYearsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rezolutebio.com/20240630", "localname": "NotSubjectToExpiryAndAvailableForUseOver2038AndThereafterYearsMember", "presentation": ["http://www.rezolutebio.com/role/DisclosureIncomeTaxesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information relating to not subject to expiry and amount available over next 2023 and thereafter years.", "label": "Not Subject To Expiry And Available For Use Over 2038 And Thereafter Years", "terseLabel": "Not Subject To Expiry And Available For Use Over 2038 And Thereafter Years" } } }, "auth_ref": [] }, "rzlt_NumberOfActiveStockOptionPlans": { "xbrltype": "integerItemType", "nsuri": "http://www.rezolutebio.com/20240630", "localname": "NumberOfActiveStockOptionPlans", "presentation": ["http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsStockOptionPlansDetails"], "lang": { "en-us": { "role": { "documentation": "The number of active stock option plans.", "label": "Number Of Active Stock Option Plans", "terseLabel": "Number of active stock option plans" } } }, "auth_ref": [] }, "rzlt_NumberOfEmployees": { "xbrltype": "integerItemType", "nsuri": "http://www.rezolutebio.com/20240630", "localname": "NumberOfEmployees", "presentation": ["http://www.rezolutebio.com/role/DisclosureCommitmentsAndContingenciesDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to number of employees.", "label": "Number of Employees", "terseLabel": "Number of employees" } } }, "auth_ref": [] }, "rzlt_NumberOfOfficers": { "xbrltype": "integerItemType", "nsuri": "http://www.rezolutebio.com/20240630", "localname": "NumberOfOfficers", "presentation": ["http://www.rezolutebio.com/role/DisclosureCommitmentsAndContingenciesDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to number of officers.", "label": "Number of Officers", "terseLabel": "Number of officers" } } }, "auth_ref": [] }, "rzlt_NumberOfWhollyOwnedSubsidiaries": { "xbrltype": "integerItemType", "nsuri": "http://www.rezolutebio.com/20240630", "localname": "NumberOfWhollyOwnedSubsidiaries", "presentation": ["http://www.rezolutebio.com/role/DisclosureNatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the number of wholly owned subsidiaries.", "label": "Number of Wholly Owned Subsidiaries", "terseLabel": "Number of wholly owned subsidiaries" } } }, "auth_ref": [] }, "rzlt_OfficeSpaceInBendMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rezolutebio.com/20240630", "localname": "OfficeSpaceInBendMember", "presentation": ["http://www.rezolutebio.com/role/DisclosureLeasesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to office space in Bend, Oregon.", "label": "Office space in Bend", "terseLabel": "Office space in Bend, Oregon" } } }, "auth_ref": [] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenses", "crdr": "debit", "presentation": ["http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Operating Expenses", "totalLabel": "Total operating expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": ["http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "presentation": ["http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Operating Income (Loss)", "totalLabel": "Operating loss", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": ["r104", "r694", "r869", "r870", "r871", "r872", "r873"] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseCost", "crdr": "debit", "presentation": ["http://www.rezolutebio.com/role/DisclosureLeasesOperatingLeaseExpenseDetails"], "lang": { "en-us": { "role": { "label": "Operating Lease, Cost", "terseLabel": "Operating lease expense", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": ["r455", "r728"] }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "presentation": ["http://www.rezolutebio.com/role/DisclosureLeasesFutureOperatingLeasePaymentsDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]", "terseLabel": "Future lease payments related to operating lease agreements" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiability", "crdr": "credit", "presentation": ["http://www.rezolutebio.com/role/DisclosureLeasesAdditionalInformationDetails", "http://www.rezolutebio.com/role/DisclosureLeasesAssetsAndOperatingLeaseLiabilitiesDetails", "http://www.rezolutebio.com/role/DisclosureLeasesFutureOperatingLeasePaymentsDetails"], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability", "terseLabel": "Operating lease liability", "totalLabel": "Total", "verboseLabel": "Present value of operating lease liabilities", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": ["r451"] }, "us-gaap_OperatingLeaseLiabilityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityAbstract", "presentation": ["http://www.rezolutebio.com/role/DisclosureLeasesAssetsAndOperatingLeaseLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability [Abstract]", "terseLabel": "Operating lease liabilities:" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "presentation": ["http://www.rezolutebio.com/role/DisclosureLeasesAssetsAndOperatingLeaseLiabilitiesDetails", "http://www.rezolutebio.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Current", "terseLabel": "Current", "verboseLabel": "Current portion of operating lease liabilities", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": ["r451"] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "presentation": ["http://www.rezolutebio.com/role/DisclosureLeasesAdditionalInformationDetails", "http://www.rezolutebio.com/role/DisclosureLeasesAssetsAndOperatingLeaseLiabilitiesDetails", "http://www.rezolutebio.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Non-current operating lease liabilities", "verboseLabel": "Operating lease liabilities, net of current portion", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": ["r451"] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": ["http://www.rezolutebio.com/role/DisclosureLeasesAdditionalInformationDetails", "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Operating Lease, Payments", "terseLabel": "Cash paid for amounts included in the measurement of operating lease liabilities", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": ["r452", "r457"] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "presentation": ["http://www.rezolutebio.com/role/DisclosureLeasesAdditionalInformationDetails", "http://www.rezolutebio.com/role/DisclosureLeasesAssetsAndOperatingLeaseLiabilitiesDetails", "http://www.rezolutebio.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Operating Lease, Right-of-Use Asset", "verboseLabel": "Right-of-use assets", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": ["r450"] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": ["http://www.rezolutebio.com/role/DisclosureLeasesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted average discount rate for operating lease liabilities", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": ["r460", "r728"] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": ["http://www.rezolutebio.com/role/DisclosureLeasesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted average remaining lease term under operating leases", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r459", "r728"] }, "us-gaap_OperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLossCarryforwards", "crdr": "debit", "presentation": ["http://www.rezolutebio.com/role/DisclosureIncomeTaxesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Operating Loss Carryforwards", "terseLabel": "Operating loss carryforwards", "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws." } } }, "auth_ref": ["r385"] }, "rzlt_OperatingLossCarryforwardsAmountNotSubjectToExpiration": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rezolutebio.com/20240630", "localname": "OperatingLossCarryforwardsAmountNotSubjectToExpiration", "crdr": "debit", "presentation": ["http://www.rezolutebio.com/role/DisclosureIncomeTaxesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of operating loss carryforward, not subject to expiration, available to reduce future taxable income under enacted tax laws.", "label": "Operating Loss Carryforwards, Amount Not Subject to Expiration", "verboseLabel": "Operating loss carryforward, not subject to expiration, available to reduce future taxable income" } } }, "auth_ref": [] }, "rzlt_OperatingLossCarryforwardsAmountNotSubjectToExpirationAvailableForUse": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rezolutebio.com/20240630", "localname": "OperatingLossCarryforwardsAmountNotSubjectToExpirationAvailableForUse", "crdr": "debit", "presentation": ["http://www.rezolutebio.com/role/DisclosureIncomeTaxesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of operating loss carryforward, not subject to expiration, available for use to reduce future taxable income under enacted tax laws.", "label": "Operating Loss Carryforwards, Amount Not Subject to Expiration, Available for Use", "terseLabel": "Operating loss carryforward, not subject to expiration, available for use to reduce future taxable income" } } }, "auth_ref": [] }, "rzlt_OperatingLossCarryforwardsAmountNotSubjectToExpirationAvailableToOffsetTaxableIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rezolutebio.com/20240630", "localname": "OperatingLossCarryforwardsAmountNotSubjectToExpirationAvailableToOffsetTaxableIncome", "crdr": "debit", "presentation": ["http://www.rezolutebio.com/role/DisclosureIncomeTaxesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of operating loss carryforward not subject to expiration available to offset taxable income.", "label": "Operating Loss Carryforwards, Amount Not Subject to Expiration Available To Offset Taxable Income", "terseLabel": "Operating loss carryforward not subject to expiration available to offset taxable income" } } }, "auth_ref": [] }, "rzlt_OperatingLossCarryforwardsAmountPerYearNotSubjectToExpirationAvailableForUse": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rezolutebio.com/20240630", "localname": "OperatingLossCarryforwardsAmountPerYearNotSubjectToExpirationAvailableForUse", "crdr": "debit", "presentation": ["http://www.rezolutebio.com/role/DisclosureIncomeTaxesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of operating loss carryforward per year not subject to expiration, available for use to reduce future taxable income under enacted tax laws.", "label": "Operating Loss Carryforwards, Amount Per Year Not Subject to Expiration, Available for Use", "terseLabel": "Operating loss carryforward per year not subject to expiration, available for use to reduce future taxable income" } } }, "auth_ref": [] }, "rzlt_OperatingLossCarryforwardsAmountSubjectToExpirationAvailableToOffsetTaxableIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rezolutebio.com/20240630", "localname": "OperatingLossCarryforwardsAmountSubjectToExpirationAvailableToOffsetTaxableIncome", "crdr": "debit",

```
"presentation": [ "http://www.rezolutebio.com/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of operating loss carryforward subject to expiration available to offset taxable income.", "label": "Operating Loss Carryforwards, Amount Subject to Expiration Available To Offset Taxable Income", "terseLabel": "Operating loss carryforward subject to expiration available to offset taxable income" } } }, "auth_ref": [] }, "us-gaap_OperatingLossCarryforwardsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLossCarryforwardsLineItems", "presentation": [ "http://www.rezolutebio.com/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Operating Loss Carryforwards [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r385" ] }, "rzlt_OperatingLossCarryforwardsNoLimitationsOnUse": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rezolutebio.com/20240630", "localname": "OperatingLossCarryforwardsNoLimitationsOnUse", "crdr": "debit", "presentation": [ "http://www.rezolutebio.com/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of the operating loss carryforwards available to reduce future taxable income no limitation on use.", "label": "Operating loss carryforwards, subject to no limitations", "terseLabel": "Operating loss carryforwards, subject to no limitations" } } }, "auth_ref": [] }, "rzlt_OperatingLossCarryforwardsSubjectToLimitationsOnUse": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rezolutebio.com/20240630", "localname": "OperatingLossCarryforwardsSubjectToLimitationsOnUse", "crdr": "debit", "presentation": [ "http://www.rezolutebio.com/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of the limitations under IRC section 382 on the use of all operating loss carryforwards available to reduce future taxable income.", "label": "Operating Loss Carryforwards, Subject to Limitations on Use", "terseLabel": "Operating loss carryforwards, subject to limitations" } } }, "auth_ref": [] }, "us-gaap_OperatingLossCarryforwardsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLossCarryforwardsTable", "presentation": [ "http://www.rezolutebio.com/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Operating Loss Carryforwards [Table]", "documentation": "Disclosure of information about operating loss carryforward. Includes, but is not limited to, tax authority, amount and expiration date of operating loss carryforward, and likelihood of utilization." } } }, "auth_ref": [ "r385" ] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "presentation": [ "http://www.rezolutebio.com/role/DisclosureNatureOfOperationsAndSummaryOfSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "label": "Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]", "verboseLabel": "NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles." } } }, "auth_ref": [ "r77", "r78", "r79", "r93" ] }, "us-gaap_OtherCommitmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherCommitmentsAxis", "presentation": [ "http://www.rezolutebio.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://www.rezolutebio.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Other Commitments [Axis]", "documentation": "Information by type of other commitment." } } }, "auth_ref": [] }, "us-gaap_OtherCommitmentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherCommitmentsDomain", "presentation": [ "http://www.rezolutebio.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://www.rezolutebio.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Other Commitments [Domain]", "documentation": "Other future obligation." } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "crdr": "credit", "presentation": [ "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss", "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax", "terseLabel": "Net unrealized gain (loss) on marketable debt securities", "verboseLabel": "Net change in accumulated other comprehensive loss", "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale." } } }, "auth_ref": [ "r130", "r131", "r233" ] }, "rzlt_OtherOfferingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rezolutebio.com/20240630", "localname": "OtherOfferingCosts", "crdr": "credit", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareholdersEquity2024UnderwrittenOfferingDetails" ], "lang": { "en-us": { "role": { "documentation": "Related to other offering costs", "label": "Other Offering Costs", "verboseLabel": "Other offering costs" } } }, "auth_ref": [] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount", "terseLabel": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r803" ] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount", "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r764", "r775", "r785", "r818" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery Compensation Amount", "terseLabel": "Compensation Amount" } } }, "auth_ref": [ "r767", "r778", "r788", "r821" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r767", "r778", "r788", "r821" ] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": [ "r792" ] }, "rzlt_PayablesForOfferingCostsNoncashOrPartialNoncashTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rezolutebio.com/20240630", "localname": "PayablesForOfferingCostsNoncashOrPartialNoncashTransaction", "crdr": "debit", "presentation": [ "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "The amount of offering costs that were incurred during a noncash or partial noncash transaction.", "label": "Payables For Offering Costs, Noncash or Partial Noncash Transaction", "terseLabel": "Payables for offering costs charged to additional paid-in capital" } } }, "auth_ref": [] }, "rzlt_PaymentOfCommissionsAndOtherDeferredOfferingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rezolutebio.com/20240630", "localname": "PaymentOfCommissionsAndOtherDeferredOfferingCosts", "crdr": "credit", "presentation": [ "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Payment for commissions and other deferred offering costs.", "label": "Payment of Commissions and Other Deferred Offering Costs", "negatedLabel": "Payment of commissions and other deferred offering costs" } } }, "auth_ref": [] }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForRepurchaseOfCommonStock", "crdr": "credit", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareholdersEquityExchangeAgreementDetails", "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payments for Repurchase of Common Stock", "negatedLabel": "Net cash payment pursuant to Exchange Agreement", "terseLabel": "Cash payment to exchanging shareholders", "documentation": "The cash outflow to reacquire common stock during the period." } } }, "auth_ref": [ "r73" ] }, "us-gaap_PaymentsToAcquireMarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireMarketableSecurities", "crdr": "credit", "presentation": [ "http://www.rezolutebio.com/role/DisclosureInvestmentsInMarketableDebtSecuritiesAdditionalInformationDetails", "http://www.rezolutebio.com/role/DisclosureSubsequentEventsDetails", "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payments to Acquire Marketable Securities", "negatedLabel": "Purchase of marketable debt securities", "terseLabel": "Investment in marketable securities", "documentation": "Amount of cash outflow for purchase of marketable security." } } }, "auth_ref": [ "r875" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "presentation": [ "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchase of property and equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r72" ] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote [Text Block]", "terseLabel": "Peer Group Issuers, Footnote" } } }, "auth_ref": [ "r802" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount", "terseLabel": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r802" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount", "terseLabel": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r794" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO [Member]", "terseLabel": "PEO" } } }, "auth_ref": [ "r811" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Name", "terseLabel": "PEO Name" } } }, "auth_ref": [ "r804" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount", "terseLabel": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r793" ] }, "rzlt_PercentageOfCalendarYearTargetBonus": { "xbrltype": "percentItemType", "nsuri": "http://www.rezolutebio.com/20240630", "localname": "PercentageOfCalendarYearTargetBonus", "presentation": [ "http://www.rezolutebio.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of calendar year target bonus payable by the company.", "label": "Percentage Of Calendar Year Target Bonus", "terseLabel": "Percentage of calendar year target bonus payable" } } }, "auth_ref": [] }, "rzlt_PercentageOfEntitySSharesHeldByInvestors": { "xbrltype": "percentItemType", "nsuri": "http://www.rezolutebio.com/20240630", "localname": "PercentageOfEntitySSharesHeldByInvestors", "presentation": [ "http://www.rezolutebio.com/role/DisclosureEmbeddedDerivativeLiabilityDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the percentage of entity's shares held by investors.", "label": "Percentage Of Entity's Shares Held By Investors", "terseLabel": "Percentage of entity's shares held by investors" } } }, "auth_ref": [] }, "rzlt_PercentageOfTreasuryStockAcquiredOfSharesOutstanding": { "xbrltype": "percentItemType", "nsuri": "http://www.rezolutebio.com/20240630", "localname": "PercentageOfTreasuryStockAcquiredOfSharesOutstanding", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareholdersEquityExchangeAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "The percentage of stock acquired to the total of outstanding shares.", "label": "Percentage of Treasury Stock Acquired, of Shares Outstanding", "terseLabel": "Outstanding shares percentage" } } }, "auth_ref": [] }, "rzlt_PharmaceuticalLicenseAgreementMilestonePayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rezolutebio.com/20240630", "localname": "PharmaceuticalLicenseAgreementMilestonePayment", "crdr": "debit", "presentation": [ "http://www.rezolutebio.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of milestone payments to be incurred for the approval of license.", "label": "Pharmaceutical License Agreement, Milestone Payment", "terseLabel": "Milestone payments" } } }, "auth_ref": [] }, "rzlt_PharmaceuticalLicenseAgreementMilestonePaymentEarned": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rezolutebio.com/20240630", "localname": "PharmaceuticalLicenseAgreementMilestonePaymentEarned", "crdr": "credit", "presentation": [ "http://www.rezolutebio.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of milestone payments earned by the entity.", "label": "Pharmaceutical License Agreement Milestone Payment Earned", "terseLabel": "Milestone payments earned" } } }, "auth_ref": [] }, "rzlt_PharmaceuticalLicenseAgreementTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.rezolutebio.com/20240630", "localname": "PharmaceuticalLicenseAgreementTerm", "presentation": [ "http://www.rezolutebio.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "documentation": "Term of pharmaceutical license agreement in years.", "label": "Pharmaceutical License Agreement, Term", "terseLabel": "License term (in years)" } } }, "auth_ref": [] }, "rzlt_PharmaceuticalLicenseAgreementTransferPrice": { "xbrltype": "percentItemType", "nsuri": "http://www.rezolutebio.com/20240630", "localname": "PharmaceuticalLicenseAgreementTransferPrice", "presentation": [ "http://www.rezolutebio.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "documentation": "The percentage of transfer price on sale of products.", "label": "Pharmaceutical License Agreement, Transfer Price", "terseLabel": "Transfer price (in
```

```
percent)" } } }, "auth_ref": [] }, "rzlt_Phase1ClinicalTrialRz402Member": { "xbrltype": "domainItemType", "nsuri": "http://www.rezolutebio.com/20240630", "localname": "Phase1ClinicalTrialRz402Member", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLicenseAgreementsDetails" ], "lang": { "en-us": { "role": { "documentation": "N/A.", "label": "Phase 1 Clinical Trial RZ402" } } }, "auth_ref": [] }, "rzlt_Phase2ClinicalTrialRz358Member": { "xbrltype": "domainItemType", "nsuri": "http://www.rezolutebio.com/20240630", "localname": "Phase2ClinicalTrialRz358Member", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLicenseAgreementsDetails" ], "lang": { "en-us": { "role": { "documentation": "N/A.", "label": "Phase 2 Clinical Trial RZ358 (ersodetug)" } } }, "auth_ref": [] }, "rzlt_Phase2ClinicalTrialRz402Member": { "xbrltype": "domainItemType", "nsuri": "http://www.rezolutebio.com/20240630", "localname": "Phase2ClinicalTrialRz402Member", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLicenseAgreementsDetails" ], "lang": { "en-us": { "role": { "documentation": "N/A.", "label": "Phase 2 Clinical Trial RZ402" } } }, "auth_ref": [] }, "rzlt_Phase3ClinicalTrialRz358Member": { "xbrltype": "domainItemType", "nsuri": "http://www.rezolutebio.com/20240630", "localname": "Phase3ClinicalTrialRz358Member", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLicenseAgreementsDetails", "http://www.rezolutebio.com/role/DisclosureLiquidityDetails" ], "lang": { "en-us": { "role": { "documentation": "Phase 3 Clinical Trial Rz 358 [Member].", "label": "Phase 3 Clinical Trial RZ 358 (ersodetug)" } } }, "auth_ref": [] }, "rzlt_Phase3ClinicalTrialRz402Member": { "xbrltype": "domainItemType", "nsuri": "http://www.rezolutebio.com/20240630", "localname": "Phase3ClinicalTrialRz402Member", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLicenseAgreementsDetails" ], "lang": { "en-us": { "role": { "documentation": "Phase 3 Clinical Trial Rz 402 [Member].", "label": "Phase 3 Clinical Trial RZ 402" } } }, "auth_ref": [] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameAxis", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsIncentiveGrantDetails", "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsStockOptionPlansDetails" ], "lang": { "en-us": { "role": { "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": [ "r893", "r894", "r895", "r896", "r897", "r898", "r899", "r900", "r901", "r902", "r903", "r904", "r905", "r906", "r907", "r908", "r909", "r910", "r911", "r912", "r913", "r914", "r915", "r916", "r917", "r918" ] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameDomain", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsInducementGrantDetails", "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsStockOptionPlansDetails" ], "lang": { "en-us": { "role": { "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": [ "r893", "r894", "r895", "r896", "r897", "r898", "r899", "r900", "r901", "r902", "r903", "r904", "r905", "r906", "r907", "r908", "r909", "r910", "r911", "r912", "r913", "r914", "r915", "r916", "r917", "r918" ] }, "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Adjustments Prior Service Cost [Member]", "terseLabel": "Pension Adjustments Prior Service Cost" } } }, "auth_ref": [ "r795" ] }, "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Adjustments Service Cost [Member]", "terseLabel": "Pension Adjustments Service Cost" } } }, "auth_ref": [ "r840" ] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Benefits Adjustments, Footnote [Text Block]", "terseLabel": "Pension Benefits Adjustments, Footnote" } } }, "auth_ref": [ "r794" ] }, "rzlt_PreFundedWarrants2021Member": { "xbrltype": "domainItemType", "nsuri": "http://www.rezolutebio.com/20240630", "localname": "PreFundedWarrants2021Member", "presentation": [ "http://www.rezolutebio.com/role/DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityPreFundedWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information relating to pre-funded 2021 warrants.", "label": "Pre Funded Warrants 2021 [Member]", "terseLabel": "2021 Pre-Funded Warrants", "verboseLabel": "2021 PFWs" } } }, "auth_ref": [] }, "rzlt_PreFundedWarrants2022Member": { "xbrltype": "domainItemType", "nsuri": "http://www.rezolutebio.com/20240630", "localname": "PreFundedWarrants2022Member", "presentation": [ "http://www.rezolutebio.com/role/DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityPreFundedWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information relating to pre-funded 2022 warrants.", "label": "2022 Pre-Funded Warrants", "terseLabel": "2022 PFWs" } } }, "auth_ref": [] }, "rzlt_PreFundedWarrants2024Member": { "xbrltype": "domainItemType", "nsuri": "http://www.rezolutebio.com/20240630", "localname": "PreFundedWarrants2024Member", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLiquidityDetails", "http://www.rezolutebio.com/role/DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquity2024UnderwrittenOfferingDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityPreFundedWarrantsDetails", "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Represents information relating to pre-funded 2024 warrants.", "label": "Pre Funded Warrants 2024", "terseLabel": "Pre Funded Warrants 2024", "verboseLabel": "2024 PFWs" } } }, "auth_ref": [] }, "rzlt_PreFundedWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rezolutebio.com/20240630", "localname": "PreFundedWarrantsMember", "presentation": [ "http://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrationsValuationModelInputsOfExchangePfwsDetails", "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsPreFundedWarrantsDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquity2024UnderwrittenOfferingDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityExchangeAgreementDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityPreFundedWarrantsDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityTables", "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows", "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to pre-funded warrants.", "label": "Pre Funded Warrants [Member]", "terseLabel": "Pre-funded warrants" } } }, "auth_ref": [] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://www.rezolutebio.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value (in dollars per share)", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r61", "r285" ] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://www.rezolutebio.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r61", "r605" ] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesIssued", "presentation": [ "http://www.rezolutebio.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares, issued", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt." } } }, "auth_ref": [ "r61", "r285" ] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockValue", "crdr": "credit", "presentation": [ "http://www.rezolutebio.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Value, Issued", "verboseLabel": "Preferred stock, $0.001 par value; 400 shares authorized; no shares issued", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r61", "r548", "r729" ] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "presentation": [ "http://www.rezolutebio.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Prepaid Expense and Other Assets, Current", "verboseLabel": "Prepaid expenses and other", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r855" ] }, "rzlt_PrepaidExpensesAndOtherAssetsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.rezolutebio.com/20240630", "localname": "PrepaidExpensesAndOtherAssetsPolicyTextBlock", "presentation": [ "http://www.rezolutebio.com/role/DisclosureNatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy of prepaid expenses and other assets.", "label": "Prepaid Expenses and Other Assets [Policy Text Block]", "terseLabel": "Prepaid Expenses and Other" } } }, "auth_ref": [] }, "us-gaap_PrivatePlacementMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrivatePlacementMember", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLiquidityDetails", "http://www.rezolutebio.com/role/DisclosureSubsequentEventsDetails", "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Private Placement [Member]", "verboseLabel": "Private Placement", "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareholdersEquity2022PrivatePlacementDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquity2024UnderwrittenOfferingDetails", "http://www.rezolutebio.com/role/DisclosureSubsequentEventsDetails", "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Proceeds from issuance of common stock", "verboseLabel": "Proceeds from issuance of equity securities in 2024 Underwritten Offering, net of underwriting discounts, Issuance of common stock", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": [ "r2" ] }, "rzlt_ProceedsFromIssuanceOfCommonStockNetOfUnderwritingDiscountsAndCommissions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rezolutebio.com/20240630", "localname": "ProceedsFromIssuanceOfCommonStockNetOfUnderwritingDiscountsAndCommissions", "crdr": "debit", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLiquidityDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquity2022PrivatePlacementDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquity2024UnderwrittenOfferingDetails", "http://www.rezolutebio.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity net of underwriting discounts, commissions and other fees.", "label": "Proceeds From Issuance Of Common Stock, Net Of Underwriting Discounts And Commissions", "terseLabel": "Net cash proceeds" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfDebt", "crdr": "debit", "presentation": [ "http://www.rezolutebio.com/role/DisclosureEmbeddedDerivativeLiabilityDetails" ], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance of Debt", "verboseLabel": "Gross proceeds from issuance of debt", "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt." } } }, "auth_ref": [ "r859" ] }, "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfPrivatePlacement", "crdr": "debit", "presentation": [ "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance of Private Placement", "terseLabel": "Gross proceeds from issuance of common stock in 2022 Private Placement", "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement." } } }, "auth_ref": [ "r2" ] }, "us-gaap_ProceedsFromIssuanceOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfWarrants", "crdr": "debit", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareholdersEquity2024UnderwrittenOfferingDetails", "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance of Warrants", "terseLabel": "Proceeds from warrants issued", "verboseLabel": "Proceeds from issuance of equity securities in 2024 Underwritten Offering, net of underwriting discounts, Issuance of pre-funded warrants", "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)." } } }, "auth_ref": [ "r2" ] }, "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOrSaleOfEquity", "crdr": "debit", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareholdersEquity2024UnderwrittenOfferingDetails" ], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance or Sale of Equity", "terseLabel": "Gross proceeds from sale of equity", "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity." } } }, "auth_ref": [ "r2", "r578" ] }, "rzlt_ProceedsFromIssuanceOrSaleOfEquityNetOfUnderwritingDiscountsAndCommissions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rezolutebio.com/20240630", "localname": "ProceedsFromIssuanceOrSaleOfEquityNetOfUnderwritingDiscountsAndCommissions", "crdr": "debit", "presentation": [
```

```
"http://www.rezolutebio.com/role/DisclosureLiquidityDetails" ], "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of common stock, preferred stock,\n treasury stock, stock options, and other types of equity net of underwriting discounts, commissions and other fees.", "label": "Proceeds From Issuance Or Sale Of Equity, Net Of Underwriting Discounts And Commissions", "terseLabel": "Proceeds after underwriting discounts and other offering costs" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities", "crdr": "debit", "presentation": [
"http://www.rezolutebio.com/role/DisclosureInvestmentsInMarketableDebtSecuritiesAdditionalInformationDetails",
"http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from Sale and Maturity of Marketable Securities", "terseLabel": "Proceeds from maturities of marketable debt securities", "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "presentation": [ "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from exercise of stock options", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } }, "auth_ref": [ "r2", "r11" ] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProfitLoss", "crdr": "credit", "presentation": [ "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net loss", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r118", "r132", "r134", "r143", "r148", "r159", "r165", "r168", "r169", "r234", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r397", "r400", "r402", "r405", "r406", "r419", "r439", "r542", "r557", "r587", "r625", "r645", "r646", "r714", "r715", "r751", "r858", "r888" ] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "presentation": [
"http://www.rezolutebio.com/role/DisclosureSupplementalFinancialInformationPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Gross", "terseLabel": "Office furniture and equipment", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r81", "r122", "r556" ] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": [
"http://www.rezolutebio.com/role/DisclosureLeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r462" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "presentation": [
"http://www.rezolutebio.com/role/DisclosureSupplementalFinancialInformationPropertyAndEquipmentDetails",
"http://www.rezolutebio.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net", "totalLabel": "Total", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r5", "r462", "r543", "r556", "r729" ] }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "presentation": [
"http://www.rezolutebio.com/role/DisclosureNatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "verboseLabel": "Property and Equipment", "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r5", "r110", "r113", "r554" ] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": [ "http://www.rezolutebio.com/role/DisclosureSupplementalFinancialInformationTables" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Summary of property and equipment", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r5" ] }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentUsefulLife", "presentation": [
"http://www.rezolutebio.com/role/DisclosureNatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Useful Life", "terseLabel": "Estimated useful lives of the assets", "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment." } } }, "auth_ref": [] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": [ "r792" ] },
"ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance [Table Text Block]", "terseLabel": "Pay vs Performance Disclosure, Table" } } }, "auth_ref": [ "r792" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": [
"http://www.rezolutebio.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://www.rezolutebio.com/role/DisclosureLicenseAgreementsDetails",
"http://www.rezolutebio.com/role/DisclosureNatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetails",
"http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsInducementGrantDetails",
"http://www.rezolutebio.com/role/DisclosureShareholdersEquityExchangeAgreementDetails",
"http://www.rezolutebio.com/role/DisclosureShareholdersEquityPreFundedWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r253", "r254", "r255", "r256", "r302", "r310", "r342", "r343", "r344", "r356", "r425", "r482", "r491", "r508", "r565", "r567", "r575", "r595", "r596", "r655", "r657", "r659", "r660", "r666", "r682", "r683", "r697", "r705", "r710", "r719", "r720", "r724", "r725", "r739", "r744", "r886", "r890", "r931", "r954", "r955", "r956", "r957", "r958" ] },
"srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": [
"http://www.rezolutebio.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://www.rezolutebio.com/role/DisclosureLicenseAgreementsDetails",
"http://www.rezolutebio.com/role/DisclosureNatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetails",
"http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsInducementGrantDetails",
"http://www.rezolutebio.com/role/DisclosureShareholdersEquityExchangeAgreementDetails",
"http://www.rezolutebio.com/role/DisclosureShareholdersEquityPreFundedWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [ "r253", "r254", "r255", "r256", "r302", "r310", "r342", "r343", "r344", "r356", "r425", "r482", "r491", "r508", "r565", "r567", "r575", "r595", "r596", "r655", "r657", "r659", "r660", "r666", "r682", "r683", "r697", "r705", "r710", "r719", "r720", "r724", "r725", "r739", "r744", "r886", "r890", "r931", "r954", "r955", "r956", "r957", "r958" ] },
"srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Name of Property [Axis]" } } }, "auth_ref": [ "r672", "r676", "r1000", "r1001", "r1002", "r1003", "r1004", "r1005", "r1006", "r1007" ] },
"srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RealEstateAndAccumulatedDepreciationNameOfPropertyDomain", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Name of Property [Domain]" } } }, "auth_ref": [ "r672", "r676", "r1000", "r1001", "r1002", "r1003", "r1004", "r1005", "r1006", "r1007" ] },
"rzlt_ReceivableFromExerciseOfStockOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rezolutebio.com/20240630", "localname": "ReceivableFromExerciseOfStockOptions", "crdr": "debit", "presentation": [ "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Amount of receivable from exercise of stock options in non-cash investing or financing transactions.", "label": "Receivable From Exercise of Stock Options", "terseLabel": "Receivable from exercise of stock options" } } }, "auth_ref": [] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]", "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure" } } }, "auth_ref": [ "r759", "r770", "r780", "r813" ] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyDomain", "presentation": [
"http://www.rezolutebio.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Related and Nonrelated Parties [Domain]", "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": [ "r199", "r309", "r468", "r469", "r546", "r553", "r598", "r599", "r600", "r601", "r602", "r622", "r624", "r654" ] }, "us-gaap_RelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyMember", "presentation": [ "http://www.rezolutebio.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Related Party [Member]", "terseLabel": "Related Party", "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family." } } }, "auth_ref": [ "r150", "r151", "r468", "r469", "r470", "r471", "r546", "r553", "r598", "r599", "r600", "r601", "r602", "r622", "r624", "r654" ] }, "us-gaap_RelatedPartyTransactionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionAxis", "presentation": [
"http://www.rezolutebio.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Axis]", "documentation": "Information by type of related party transaction." } } }, "auth_ref": [ "r468", "r469", "r950" ] }, "us-gaap_RelatedPartyTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionDomain", "presentation": [
"http://www.rezolutebio.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Domain]", "documentation": "Transaction between related party." } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionLineItems", "presentation": [ "http://www.rezolutebio.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r199", "r628", "r629", "r632" ] }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "label": "RELATED PARTY TRANSACTIONS" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [
"http://www.rezolutebio.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Related and Nonrelated Parties [Axis]", "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": [ "r199", "r309", "r468", "r469", "r546", "r553", "r598", "r599", "r600", "r601", "r602", "r622", "r624", "r654", "r950" ] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": [ "http://www.rezolutebio.com/role/DisclosureRelatedPartyTransactions" ], "lang": { "en-us": { "role": { "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "RELATED PARTY TRANSACTIONS", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r465", "r466", "r467", "r469", "r472", "r584", "r585", "r586", "r630", "r631", "r632", "r651", "r653" ] },
"srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLicenseAgreementsDetails",
"http://www.rezolutebio.com/role/DisclosureLiquidityDetails", "http://www.rezolutebio.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]" } } }, "auth_ref": [ "r152", "r153", "r270", "r287", "r471", "r492", "r544", "r688", "r689" ] }, "us-
```

```
gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLicenseAgreementsDetails", "http://www.rezolutebio.com/role/DisclosureLiquidityDetails" ], "lang": { "en-us": { "role": { "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]", "documentation": "Information by form of arrangement related to research and development." } } }, "auth_ref": [ "r359", "r920" ] }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLicenseAgreementsDetails" ], "lang": { "en-us": { "role": { "label": "Research and Development Arrangement, Contract to Perform for Others [Line Items]", "terseLabel": "License Agreements", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r359", "r920" ] }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLicenseAgreementsDetails", "http://www.rezolutebio.com/role/DisclosureLiquidityDetails" ], "lang": { "en-us": { "role": { "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]", "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others." } } }, "auth_ref": [ "r359", "r920" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "presentation": [ "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Research and Development Expense", "verboseLabel": "Research and development", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": [ "r358", "r684", "r695", "r959" ] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [
"http://www.rezolutebio.com/role/DisclosureLeasesOperatingLeaseExpenseDetails",
"http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsShareBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Research and Development Expense [Member]", "terseLabel": "Research and Development Expense", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpensePolicy", "presentation": [
"http://www.rezolutebio.com/role/DisclosureNatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Research and Development Expense, Policy [Policy Text Block]", "verboseLabel": "Research and Development Costs", "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process." } } }, "auth_ref": [ "r357" ] },
"ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]", "terseLabel": "Restatement Determination Date:" } } }, "auth_ref": [ "r760", "r771", "r781", "r814" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date", "terseLabel": "Restatement Determination Date" } } }, "auth_ref": [ "r761", "r772", "r782", "r815" ] },
"ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Does Not Require Recovery [Text Block]", "terseLabel": "Restatement does not require Recovery" } } }, "auth_ref": [ "r768", "r779", "r789", "r822" ] }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "presentation": [
"http://www.rezolutebio.com/role/DisclosureSupplementalFinancialInformationCashAndCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents [Domain]", "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r121" ] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLiquidityDetails",
"http://www.rezolutebio.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r64", "r88", "r551", "r572", "r574", "r582", "r606", "r729" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": [ "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r117", "r156", "r157", "r158", "r160", "r165", "r167", "r169", "r235", "r236", "r247", "r387", "r388", "r394", "r395", "r396", "r398", "r399", "r400", "r409", "r411", "r412", "r414", "r417", "r447", "r449", "r569", "r571", "r588", "r994" ] }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "crdr": "debit", "presentation": [
"http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "verboseLabel": "Operating lease liabilities incurred in exchange for right-of-use assets", "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability." } } }, "auth_ref": [ "r458", "r728" ] }, "rzlt_RisksAndUncertaintiesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.rezolutebio.com/20240630", "localname": "RisksAndUncertaintiesPolicyTextBlock", "presentation": [
"http://www.rezolutebio.com/role/DisclosureNatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the risks and uncertainties during the reporting period.", "label": "Risks and Uncertainties [Policy Text Block]", "verboseLabel": "Risks and Uncertainties" } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r831" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r831" ] },
"rzlt_SaleOfStockAdditionalSharesOptionPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://www.rezolutebio.com/20240630", "localname": "SaleOfStockAdditionalSharesOptionPricePerShare", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareholdersEquity2024UnderwrittenOfferingDetails" ], "lang": { "en-us": { "role": { "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the additional shares option of a stock transaction.", "label": "Sale of stock, Additional Shares Option, price per share" } } }, "auth_ref": [] },
"rzlt_SaleOfStockCommissionAgreedToPayAsPercentageOnGrossSalesPrice": { "xbrltype": "percentItemType", "nsuri": "http://www.rezolutebio.com/20240630", "localname": "SaleOfStockCommissionAgreedToPayAsPercentageOnGrossSalesPrice", "presentation": [
"http://www.rezolutebio.com/role/DisclosureShareholdersEquityJefferiesOpenMarketSalesAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of commission agreed to pay as a percentage on gross sales price.", "label": "Sale of Stock, Commission Agreed to Pay as a Percentage on Gross Sales Price", "terseLabel": "Percentage of commission agreed" } } }, "auth_ref": [] }, "rzlt_SaleOfStockMaximumAmountAgreedToSellAsPerOpenMarketSalesAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rezolutebio.com/20240630", "localname": "SaleOfStockMaximumAmountAgreedToSellAsPerOpenMarketSalesAgreement", "crdr": "credit", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLiquidityDetails",
"http://www.rezolutebio.com/role/DisclosureShareholdersEquityJefferiesOpenMarketSalesAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "Maximum amount agreed to sell as per open market sales agreement.", "label": "Sale of Stock, Maximum Amount Agreed to Sell as Per Open Market Sales Agreement", "terseLabel": "Amount agreed to sell as per open market sales agreement" } } }, "auth_ref": [] }, "rzlt_SaleOfStockMaximumAmountRemainingForSaleAsPerOpenMarketSalesAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rezolutebio.com/20240630", "localname": "SaleOfStockMaximumAmountRemainingForSaleAsPerOpenMarketSalesAgreement", "crdr": "credit", "presentation": [
"http://www.rezolutebio.com/role/DisclosureShareholdersEquityJefferiesOpenMarketSalesAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "Maximum amount remaining for sale as per open market sales agreement.", "label": "Sale of Stock, Maximum Amount Remaining for Sale as Per Open Market Sales Agreement", "terseLabel": "Sales agreement amounts" } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLiquidityDetails",
"http://www.rezolutebio.com/role/DisclosureShareholdersEquity2022PrivatePlacementDetails",
"http://www.rezolutebio.com/role/DisclosureShareholdersEquity2024UnderwrittenOfferingDetails",
"http://www.rezolutebio.com/role/DisclosureShareholdersEquityJefferiesOpenMarketSalesAgreementDetails",
"http://www.rezolutebio.com/role/DisclosureShareholdersEquityPreFundedWarrantsDetails", "http://www.rezolutebio.com/role/DisclosureSubsequentEventsDetails",
"http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows", "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "presentation": [
"http://www.rezolutebio.com/role/DisclosureShareholdersEquityJefferiesOpenMarketSalesAgreementDetails" ], "lang": { "en-us": { "role": { "label": "Sale of Stock, Number of Shares Issued in Transaction", "terseLabel": "Common stock to sales agreement", "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockPricePerShare", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareholdersEquity2024UnderwrittenOfferingDetails" ], "lang": { "en-us": { "role": { "label": "Sale of Stock, Price Per Share", "terseLabel": "Sale of stock, price per share", "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction." } } }, "auth_ref": [] }, "rzlt_ScenarioAfterClinicalAndRegulatoryMilestonesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rezolutebio.com/20240630", "localname": "ScenarioAfterClinicalAndRegulatoryMilestonesMember", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLicenseAgreementsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to after the clinical and regulatory milestones.", "label": "Scenario, After Clinical and Regulatory Milestones [Member]", "terseLabel": "After Clinical and Regulatory Milestones" } } }, "auth_ref": [] }, "us-gaap_ScenarioPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScenarioPlanMember", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLicenseAgreementsDetails", "http://www.rezolutebio.com/role/DisclosureLiquidityDetails" ], "lang": { "en-us": { "role": { "label": "Scenario, Plan [Member]", "terseLabel": "Scenario, Plan", "verboseLabel": "Plan", "documentation": "The scenario under which facts represent plans as distinct from actual." } } }, "auth_ref": [] }, "srt_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScenarioUnspecifiedDomain", "presentation": [ "http://www.rezolutebio.com/role/DisclosureIncomeTaxesAdditionalInformationDetails",
"http://www.rezolutebio.com/role/DisclosureLicenseAgreementsDetails", "http://www.rezolutebio.com/role/DisclosureLiquidityDetails" ], "lang": { "en-us": { "role": { "label": "Scenario [Domain]" } } }, "auth_ref": [ "r170", "r311", "r844", "r866" ] }, "rzlt_ScenarioUponClinicalAndRegulatoryMilestonesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rezolutebio.com/20240630", "localname": "ScenarioUponClinicalAndRegulatoryMilestonesMember", "presentation": [
"http://www.rezolutebio.com/role/DisclosureLicenseAgreementsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to upon the clinical and regulatory milestones.", "label": "Scenario, Upon Clinical and Regulatory Milestones [Member]", "terseLabel": "Upon Clinical and Regulatory Milestones" } } }, "auth_ref": [] }, "rzlt_ScenarioUponDosingOfLastPatientMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rezolutebio.com/20240630", "localname": "ScenarioUponDosingOfLastPatientMember", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLicenseAgreementsDetails",
```

"http://www.rezolutebio.com/role/DisclosureLiquidityDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to dosing of the last patient milestones.", "label": "Scenario, Upon Dosing Of The Last Patient [Member]", "terseLabel": "Scenario, Upon Dosing Of The Last Patient" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": [
"http://www.rezolutebio.com/role/DisclosureNetLossPerShareAntiDilutiveDetails",
"http://www.rezolutebio.com/role/DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareDetails"], "lang": { "en-us": { "role": { "label": "Antidilutive Security, Excluded EPS Calculation [Table]", "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS." } } }, "auth_ref": ["r18"] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": [
"http://www.rezolutebio.com/role/DisclosureNetLossPerShareTables"], "lang": { "en-us": { "role": { "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Schedule of potential common stock equivalents were excluded from the computation of diluted net loss per share", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": ["r18"] }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "presentation": [
"http://www.rezolutebio.com/role/DisclosureInvestmentsInMarketableDebtSecuritiesCashAndCashEquivalentsAndMarketableSecuritiesHeldDetails"], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale [Line Items]", "terseLabel": "INVESTMENTS IN MARKETABLE DEBT SECURITIES", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r202", "r203", "r204", "r205", "r206", "r207", "r208", "r210", "r211", "r212", "r213", "r214"] }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "presentation": [
"http://www.rezolutebio.com/role/DisclosureInvestmentsInMarketableDebtSecuritiesTables"], "lang": { "en-us": { "role": { "label": "Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]", "terseLabel": "Summary of unrealized gains and losses that result in differences between the amortized cost basis and fair value of the Company's marketable debt securities", "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfCashAndCashEquivalentsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCashAndCashEquivalentsTable", "presentation": ["http://www.rezolutebio.com/role/DisclosureSupplementalFinancialInformationCashAndCashEquivalentsDetails"], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalent [Table]", "documentation": "Disclosure of information about cash and cash equivalent by type. Excludes restricted cash and cash equivalent." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock", "presentation": [
"http://www.rezolutebio.com/role/DisclosureSupplementalFinancialInformationTables"], "lang": { "en-us": { "role": { "label": "Schedule of Cash and Cash Equivalents [Table Text Block]", "terseLabel": "Schedule of cash and cash equivalents", "documentation": "Tabular disclosure of the components of cash and cash equivalents." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "presentation": ["http://www.rezolutebio.com/role/DisclosureIncomeTaxesTables"], "lang": { "en-us": { "role": { "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "terseLabel": "Schedule of deferred tax assets and liabilities", "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets." } } }, "auth_ref": ["r923"] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": ["http://www.rezolutebio.com/role/DisclosureNetLossPerShareTables"], "lang": { "en-us": { "role": { "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of basic and diluted net loss per share", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": ["r868"] }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "presentation": [
"http://www.rezolutebio.com/role/DisclosureIncomeTaxesTables"], "lang": { "en-us": { "role": { "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "terseLabel": "Schedule of effective income tax rate reconciliation", "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations." } } }, "auth_ref": ["r367", "r713", "r921"] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": [
"http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsTables"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Schedule of share-based compensation expense", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": ["r34"] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": [
"http://www.rezolutebio.com/role/DisclosureLeasesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": ["r5", "r462"] }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "presentation": ["http://www.rezolutebio.com/role/DisclosureRelatedPartyTransactionsDetails"], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Table]", "documentation": "Disclosure of information about related party transaction." } } }, "auth_ref": ["r46", "r47", "r628", "r629", "r632"] }, "us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable", "presentation": [
"http://www.rezolutebio.com/role/DisclosureLicenseAgreementsDetails"], "lang": { "en-us": { "role": { "label": "Research and Development, Contract to Perform for Others [Table]", "documentation": "Disclosure of information about research and development arrangement accounted for as contract to perform research and development for others. Includes, but is not limited to, royalty arrangement, purchase provision, license agreement, and commitment to provide additional funding." } } }, "auth_ref": ["r359", "r920"] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [
"http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrants2022EmployeeStockPurchasePlanDetails",
"http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsInducementGrantDetails",
"http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsPreFundedWarrantsDetails",
"http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsShareBasedCompensationExpenseDetails",
"http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsStockOptionPlansDetails",
"http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsSummaryOfLegacyWarrantsDetails"], "lang": { "en-us": { "role": { "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": ["r313", "r315", "r317", "r318", "r319", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r341", "r342", "r343", "r344", "r345"] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [
"http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsTables"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Schedule of the stock option plans", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": ["r9", "r10", "r90"] }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": [
"http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsTables"], "lang": { "en-us": { "role": { "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Schedule of the fair value of stock options", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": ["r92"] }, "us-gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockByClassTable", "presentation": [
"http://www.rezolutebio.com/role/DisclosureShareholdersEquity2022PrivatePlacementDetails",
"http://www.rezolutebio.com/role/DisclosureShareholdersEquity2024UnderwrittenOfferingDetails",
"http://www.rezolutebio.com/role/DisclosureShareholdersEquityJefferiesOpenMarketSalesAgreementDetails",
"http://www.rezolutebio.com/role/DisclosureShareholdersEquityPreFundedWarrantsDetails"], "lang": { "en-us": { "role": { "label": "Stock, Class of Stock [Table]", "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks." } } }, "auth_ref": ["r25", "r26", "r27", "r28", "r29", "r30", "r84", "r86", "r87", "r88", "r125", "r126", "r127", "r192", "r285", "r286", "r287", "r289", "r292", "r297", "r299", "r578", "r579", "r580", "r581", "r705", "r843", "r860"] }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "presentation": [
"http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsTables", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityTables"], "lang": { "en-us": { "role": { "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]", "terseLabel": "Schedule of warrant activity", "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable." } } }, "auth_ref": ["r32"] }, "rzlt_SecuritiesExchangeAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rezolutebio.com/20240630", "localname": "SecuritiesExchangeAgreementMember", "presentation": [
"http://www.rezolutebio.com/role/DisclosureShareholdersEquityExchangeAgreementDetails",
"http://www.rezolutebio.com/role/DisclosureShareholdersEquityPreFundedWarrantsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to securities exchange agreement.", "label": "Securities Exchange Agreement [Member]", "terseLabel": "Securities exchange agreement" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [
"http://www.rezolutebio.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": ["r753"] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": ["http://www.rezolutebio.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": ["r755"] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "SegmentGeographicalDomain", "presentation": [
"http://www.rezolutebio.com/role/DisclosureIncomeTaxesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "Geographical [Domain]" } } }, "auth_ref": [

"r197", "r198", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r590", "r591", "r592", "r656", "r658", "r661", "r667", "r670", "r672", "r673", "r674", "r675", "r677", "r678", "r679", "r680", "r681", "r685", "r706", "r731", "r732", "r733", "r734", "r735", "r736", "r737", "r738", "r740", "r744", "r891", "r962", "r964", "r965", "r966", "r967", "r968", "r969", "r970", "r971", "r972", "r973", "r974", "r975", "r976", "r977", "r978", "r979", "r980", "r981", "r982", "r983", "r984", "r985", "r986", "r987", "r988", "r990", "r991"] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "presentation": ["http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Noncash Expense", "verboseLabel": "Share-based compensation expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": ["r3"] }, "us-gaap_ShareBasedCompensationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationAbstract", "lang": { "en-us": { "role": { "label": "SHARE-BASED COMPENSATION AND WARRANTS" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": ["http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsWeightedAverageAssumptionsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "verboseLabel": "Dividend yield", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": ["r343"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": ["http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsWeightedAverageAssumptionsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "verboseLabel": "Expected volatility", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": ["r342"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": ["http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsWeightedAverageAssumptionsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "verboseLabel": "Risk free interest rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": ["r344"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": ["http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrants2022EmployeeStockPurchasePlanDetails", "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsInducementGrantDetails", "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsPreFundedWarrantsDetails", "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsShareBasedCompensationExpenseDetails", "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsStockOptionPlansDetails", "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsSummaryOfLegacyWarrantsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r313", "r315", "r317", "r318", "r319", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r341", "r342", "r343", "r344", "r345"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "presentation": ["http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsStockOptionPlansDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized", "terseLabel": "Number of shares authorized", "documentation": "Number of shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": ["r712"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": ["http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsStockOptionPlansDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant", "terseLabel": "Number of shares available", "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth_ref": ["r33"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "presentation": ["http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsStockOptionsOutstandingDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]", "verboseLabel": "Weighted Average Remaining Contractual Life" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "crdr": "debit", "presentation": ["http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsStockOptionsOutstandingDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value", "terseLabel": "Total intrinsic value of exercised", "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares." } } }, "auth_ref": ["r336"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "presentation": ["http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsStockOptionsOutstandingDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period", "negatedLabel": "Expired", "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements." } } }, "auth_ref": ["r328"] }, "rzlt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rezolutebio.com/20240630", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodFairValue", "crdr": "credit", "presentation": ["http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsInducementGrantDetails", "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsStockOptionsOutstandingDetails"], "lang": { "en-us": { "role": { "documentation": "Fair value of options granted. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grant in Period, Fair Value", "terseLabel": "Fair value of options granted" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": ["http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsInducementGrantDetails", "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsStockOptionsOutstandingDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "netLabel": "Grants to employees", "terseLabel": "Stock options granted", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": ["r325"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": ["http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsStockOptionsOutstandingDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted average grant date fair value, granted", "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": ["r335"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": ["http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsStockOptionsOutstandingDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "verboseLabel": "Intrinsic value of outstanding options", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": ["r33"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": ["http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsStockOptionPlansDetails", "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsStockOptionsOutstandingDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Outstanding, ending", "periodStartLabel": "Outstanding, beginning", "terseLabel": "Number of shares outstanding", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": ["r321", "r322"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "presentation": ["http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsStockOptionsOutstandingDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "verboseLabel": "Number of Options", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": ["http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsStockOptionsOutstandingDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Outstanding, ending", "periodStartLabel": "Outstanding, beginning", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": ["r321", "r322"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "presentation": ["http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsStockOptionsOutstandingDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "verboseLabel": "Weighted Average Exercise Price" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": ["http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrants2022EmployeeStockPurchasePlanDetails",

```
"http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsInducementGrantDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "All Award Types", "terseLabel": "All Award Types", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r317", "r318", "r319", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r341", "r342", "r343", "r344", "r345" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsStockOptionsOutstandingDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Exercises", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": [ "r326" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsStockOptionsOutstandingDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price", "verboseLabel": "Expired", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired." } } }, "auth_ref": [ "r328" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsStockOptionsOutstandingDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "verboseLabel": "Forfeited", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": [ "r327" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsInducementGrantDetails", "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsStockOptionsOutstandingDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Exercise price of stock options", "verboseLabel": "Granted", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": [ "r325" ] }, "us-gaap_ShareBasedCompensationAwardTrancheOneMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationAwardTrancheOneMember", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsInducementGrantDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Tranche One [Member]", "terseLabel": "Tranche one", "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationAwardTrancheTwoMember", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsInducementGrantDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Tranche Two [Member]", "terseLabel": "Tranche two", "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "presentation": [ "http://www.rezolutebio.com/role/DisclosureNatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Policy Text Block]", "terseLabel": "Share-Based Compensation", "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost." } } }, "auth_ref": [ "r312", "r320", "r339", "r340", "r341", "r342", "r345", "r351", "r352", "r353", "r354" ] }, "rzlt_ShareBasedPaymentArrangementOptionSharesAuthorizedOutstandingAndAvailableForFutureGrants": { "xbrltype": "textBlockItemType", "nsuri": "http://www.rezolutebio.com/20240630", "localname": "ShareBasedPaymentArrangementOptionSharesAuthorizedOutstandingAndAvailableForFutureGrants", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsTables" ], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure of the number of shares authorized, outstanding, and available for future grants under stock option.", "label": "Share-based Payment Arrangement, Option, Shares Authorized, Outstanding, and Available for Future Grants", "terseLabel": "Schedule of the number of shares authorized, outstanding, and available for future grants under stock option" } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsInducementGrantDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage", "terseLabel": "Vesting percentage", "documentation": "Percentage of vesting of award under share-based payment arrangement." } } }, "auth_ref": [ "r893" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsWeightedAverageAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "verboseLabel": "Expected term (years)", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r341" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsWeightedAverageAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price", "verboseLabel": "Market price of common stock on grant date", "documentation": "Weighted average grant-date fair value of non-vested options outstanding." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsStockOptionsOutstandingDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Remaining contractual term (years)", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r91" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsStockOptionsOutstandingDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Vested (years)", "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r337" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1", "crdr": "credit", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsStockOptionsOutstandingDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value", "verboseLabel": "Aggregate intrinsic value of vested stock options", "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock." } } }, "auth_ref": [ "r336" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsStockOptionsOutstandingDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares", "terseLabel": "Vested, ending", "documentation": "Number of options vested." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsStockOptionsOutstandingDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value", "terseLabel": "Vested, ending", "documentation": "Weighted average grant-date fair value of options vested." } } }, "auth_ref": [] }, "us-gaap_SharesIssuedPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesIssuedPricePerShare", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareholdersEquityPreFundedWarrantsDetails", "http://www.rezolutebio.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Shares Issued, Price Per Share", "terseLabel": "Shares issue price", "documentation": "Per share or per unit amount of equity securities issued." } } }, "auth_ref": [] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesOutstanding", "presentation": [ "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Shares, Outstanding", "periodEndLabel": "Balance ending (in shares)", "periodStartLabel": "Balance beginning (in shares)", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.rezolutebio.com/role/DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareDetails", "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r7", "r62", "r65", "r66", "r117", "r137", "r138", "r139", "r156", "r157", "r158", "r160", "r165", "r167", "r169", "r191", "r235", "r236", "r247", "r301", "r387", "r388", "r394", "r395", "r396", "r398", "r399", "r400", "r409", "r410", "r411", "r412", "r413", "r414", "r417", "r440", "r441", "r442", "r443", "r444", "r445", "r447", "r449", "r464", "r559", "r569", "r570", "r571", "r588", "r647" ] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementGeographicalAxis", "presentation": [ "http://www.rezolutebio.com/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]" } } }, "auth_ref": [ "r197", "r198", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r590", "r591", "r592", "r656", "r658", "r661", "r667", "r670", "r672", "r673", "r674", "r675", "r677", "r678", "r679", "r680", "r681", "r685", "r706", "r731", "r732", "r733", "r734", "r735", "r736", "r737", "r738", "r740", "r744", "r891", "r962", "r964", "r965", "r966", "r967", "r968", "r969", "r970", "r971", "r972", "r973", "r974", "r975", "r976", "r977", "r978", "r979", "r980", "r981", "r982", "r983", "r984", "r985", "r986", "r987", "r988", "r990", "r991" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLiquidityDetails",
```

"http://www.rezolutebio.com/role/DisclosureNatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetails",
"http://www.rezolutebio.com/role/DisclosureShareholdersEquityExchangeAgreementDetails",
"http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows",
"http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
"http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfShareholdersEquity"], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r156", "r157", "r158", "r191", "r449", "r509", "r576", "r589", "r597", "r598", "r599", "r600", "r601", "r602", "r605", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r618", "r619", "r620", "r621", "r622", "r624", "r626", "r627", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r647", "r745"] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Consolidated Statements of Cash Flows" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Consolidated Balance Sheets" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Consolidated Statements of Shareholders' Equity" } } }, "auth_ref": [] }, "srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementScenarioAxis", "presentation": ["http://www.rezolutebio.com/role/DisclosureIncomeTaxesAdditionalInformationDetails",
"http://www.rezolutebio.com/role/DisclosureLicenseAgreementsDetails", "http://www.rezolutebio.com/role/DisclosureLiquidityDetails"], "lang": { "en-us": { "role": { "label": "Scenario [Axis]" } } }, "auth_ref": ["r170", "r311", "r844", "r845", "r866"] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": ["http://www.rezolutebio.com/role/DisclosureLiquidityDetails",
"http://www.rezolutebio.com/role/DisclosureNatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetails",
"http://www.rezolutebio.com/role/DisclosureShareholdersEquityExchangeAgreementDetails",
"http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows",
"http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
"http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfShareholdersEquity"], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": ["r156", "r157", "r158", "r191", "r199", "r449", "r509", "r576", "r589", "r597", "r598", "r599", "r600", "r601", "r602", "r605", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r618", "r619", "r620", "r621", "r622", "r624", "r626", "r627", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r647", "r745"] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method [Text Block]", "terseLabel": "Stock Price or TSR Estimation Method" } } }, "auth_ref": ["r763", "r774", "r784", "r817"] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockAppreciationRightsSARSMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Stock Appreciation Rights (SARs) [Member]", "terseLabel": "Stock Appreciation Rights (SARs)", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "presentation": [
"http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrants2022EmployeeStockPurchasePlanDetails"], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "terseLabel": "Shares purchases", "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan." } } }, "auth_ref": ["r7", "r61", "r62", "r88"] }, "rzlt_StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants": { "xbrltype": "sharesItemType", "nsuri": "http://www.rezolutebio.com/20240630", "localname": "StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants", "presentation": [
"http://www.rezolutebio.com/role/DisclosureSubsequentEventsDetails", "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfShareholdersEquity"], "lang": { "en-us": { "role": { "documentation": "Number of shares issued upon exercise of pre-funded warrants.", "label": "Stock Issued During Period, Shares, Exercise of Pre-funded Warrants", "terseLabel": "Exercise of pre-funded warrants (in shares)", "verboseLabel": "Cashless exercise of pre-funded warrants (in shares)" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": ["http://www.rezolutebio.com/role/DisclosureLiquidityDetails",
"http://www.rezolutebio.com/role/DisclosureShareholdersEquity2022PrivatePlacementDetails",
"http://www.rezolutebio.com/role/DisclosureShareholdersEquity2024UnderwrittenOfferingDetails", "http://www.rezolutebio.com/role/DisclosureSubsequentEventsDetails",
"http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfShareholdersEquity"], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, New Issues", "presentationGuidance": "Number of shares issued", "terseLabel": "Proceeds from issuance of equity securities (in shares)", "verboseLabel": "Number of shares issued", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": ["r7", "r61", "r62", "r88", "r578", "r647", "r668"] }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesShareBasedCompensationForfeited", "presentation": [
"http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsStockOptionsOutstandingDetails"], "lang": { "en-us": { "role": { "label": "Shares Issued, Shares, Share-Based Payment Arrangement, Forfeited", "negatedLabel": "Forfeited", "documentation": "Number of shares (or other type of equity) forfeited during the period." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [
"http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsStockOptionsOutstandingDetails",
"http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfShareholdersEquity"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "negatedLabel": "Exercises", "verboseLabel": "Issuance of common stock upon exercise of stock options (in shares)", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": ["r7", "r61", "r62", "r88", "r326"] }, "rzlt_StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rezolutebio.com/20240630", "localname": "StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants", "crdr": "credit", "presentation": [
"http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfShareholdersEquity"], "lang": { "en-us": { "role": { "documentation": "Value of stock issued upon exercise of pre-funded warrants", "label": "Stock Issued During Period, Value, Exercise of Pre-funded Warrants", "verboseLabel": "Cashless exercise of pre-funded warrants" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": ["http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfShareholdersEquity"], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, New Issues", "verboseLabel": "Proceeds from issuance of equity securities", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": ["r7", "r61", "r62", "r88", "r588", "r647", "r668", "r751"] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": [
"http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfShareholdersEquity"], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, Stock Options Exercised", "verboseLabel": "Issuance of common stock upon exercise of stock options", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": ["r7", "r62", "r65", "r66", "r88"] }, "us-gaap_StockRepurchasedAndRetiredDuringPeriodShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockRepurchasedAndRetiredDuringPeriodShares", "presentation": [
"http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfShareholdersEquity"], "lang": { "en-us": { "role": { "label": "Stock Repurchased and Retired During Period, Shares", "negatedLabel": "Acquisition and retirement of treasury shares pursuant to Exchange Agreement (in shares)", "documentation": "Number of shares that have been repurchased and retired during the period." } } }, "auth_ref": ["r7", "r61", "r62", "r88"] }, "us-gaap_StockRepurchasedAndRetiredDuringPeriodValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockRepurchasedAndRetiredDuringPeriodValue", "crdr": "debit", "presentation": [
"http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfShareholdersEquity"], "lang": { "en-us": { "role": { "label": "Stock Repurchased and Retired During Period, Value", "negatedLabel": "Acquisition and retirement of treasury shares pursuant to Exchange Agreement", "documentation": "Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital)." } } }, "auth_ref": ["r7", "r61", "r62", "r88"] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "presentation": ["http://www.rezolutebio.com/role/StatementConsolidatedBalanceSheets",
"http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfShareholdersEquity"], "lang": { "en-us": { "role": { "label": "Equity, Attributable to Parent", "periodEndLabel": "Balance ending", "periodStartLabel": "Balance beginning", "totalLabel": "Total shareholders' equity", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": ["r62", "r65", "r66", "r80", "r607", "r623", "r648", "r649", "r729", "r752", "r862", "r883", "r943", "r994"] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": ["http://www.rezolutebio.com/role/StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Equity, Attributable to Parent [Abstract]", "terseLabel": "Shareholders' equity:" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteAbstract", "lang": { "en-us": { "role": { "label": "SHAREHOLDERS' EQUITY" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": ["http://www.rezolutebio.com/role/DisclosureShareholdersEquity"], "lang": { "en-us": { "role": { "label": "Equity [Text Block]", "verboseLabel": "SHAREHOLDERS' EQUITY", "documentation": "The entire disclosure for equity." } } }, "auth_ref": ["r85", "r147", "r284", "r286", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r298", "r301", "r416", "r650", "r652", "r669"] }, "us-gaap_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventLineItems", "presentation": [
"http://www.rezolutebio.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Subsequent Event [Line Items]", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event." } } }, "auth_ref": ["r446", "r474"] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventMember", "presentation": [
"http://www.rezolutebio.com/role/DisclosureLiquidityDetails", "http://www.rezolutebio.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": ["r446", "r474"] }, "us-gaap_SubsequentEventTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTable", "presentation": ["http://www.rezolutebio.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Subsequent Event [Table]", "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued." } } }, "auth_ref": ["r446", "r474"] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeAxis", "presentation": [
"http://www.rezolutebio.com/role/DisclosureLiquidityDetails", "http://www.rezolutebio.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": ["r446", "r474"] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeDomain", "presentation": ["http://www.rezolutebio.com/role/DisclosureLiquidityDetails",
"http://www.rezolutebio.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": ["r446", "r474"] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "SUBSEQUENT EVENTS" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsTextBlock", "presentation": ["http://www.rezolutebio.com/role/DisclosureSubsequentEvents"], "lang": { "en-us": { "role": { "label": "Subsequent Events [Text Block]", "terseLabel": "SUBSEQUENT EVENTS", "documentation": "The entire disclosure for significant events or transactions that occurred after

the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": ["r473", "r475"] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiarySaleOfStockAxis", "presentation": ["http://www.rezolutebio.com/role/DisclosureLiquidityDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquity2022PrivatePlacementDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquity2024UnderwrittenOfferingDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityJefferiesOpenMarketSalesAgreementDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityPreFundedWarrantsDetails", "http://www.rezolutebio.com/role/DisclosureSubsequentEventsDetails", "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows", "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfShareholdersEquity"], "lang": { "en-us": { "role": { "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubstantialDoubtAboutGoingConcernTextBlock", "presentation": ["http://www.rezolutebio.com/role/DisclosureLiquidity"], "lang": { "en-us": { "role": { "label": "Substantial Doubt about Going Concern [Text Block]", "terseLabel": "LIQUIDITY", "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern." } } }, "auth_ref": ["r50"] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowInformationAbstract", "presentation": ["http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "SUPPLEMENTAL FINANCIAL INFORMATION", "verboseLabel": "SUPPLEMENTARY CASH FLOW INFORMATION:" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Tabular List [Table Text Block]", "terseLabel": "Tabular List, Table" } } }, "auth_ref": ["r810"] }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualAxis", "presentation": ["http://www.rezolutebio.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsInducementGrantDetails", "http://www.rezolutebio.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Title and Position [Axis]" } } }, "auth_ref": ["r874", "r949"] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": ["http://www.rezolutebio.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsInducementGrantDetails", "http://www.rezolutebio.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Title and Position [Domain]" } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount", "terseLabel": "Total Shareholder Return Amount" } } }, "auth_ref": ["r802"] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group [Text Block]", "terseLabel": "Total Shareholder Return Vs Peer Group" } } }, "auth_ref": ["r809"] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement [Axis]", "terseLabel": "Trading Arrangement:" } } }, "auth_ref": ["r830"] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangements, by Individual [Table]", "terseLabel": "Trading Arrangements, by Individual" } } }, "auth_ref": ["r832"] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": ["http://www.rezolutebio.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": ["http://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrationsFairValueOnRecurringBasisDetails", "http://www.rezolutebio.com/role/DisclosureInvestmentsInMarketableDebtSecuritiesCashAndCashEquivalentsAndMarketableSecuritiesHeldDetails"], "lang": { "en-us": { "role": { "label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": ["r202", "r203", "r204", "r205", "r206", "r207", "r208", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r283", "r297", "r415", "r436", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r560", "r716", "r717", "r719", "r720", "r721", "r722", "r723", "r724", "r725", "r730", "r846", "r847", "r848", "r849", "r850", "r851", "r852", "r879", "r880", "r881", "r882", "r927", "r930", "r931", "r932", "r939", "r942"] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Adoption Date", "terseLabel": "Adoption Date" } } }, "auth_ref": ["r833"] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Duration", "terseLabel": "Arrangement Duration" } } }, "auth_ref": ["r834"] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Expiration Date", "terseLabel": "Expiration Date" } } }, "auth_ref": ["r834"] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r832"] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Title", "terseLabel": "Title" } } }, "auth_ref": ["r832"] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Securities Aggregate Available Amount", "terseLabel": "Aggregate Available" } } }, "auth_ref": ["r835"] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Termination Date", "terseLabel": "Termination Date" } } }, "auth_ref": ["r833"] }, "us-gaap_TreasuryStockSharesAcquired": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockSharesAcquired", "presentation": ["http://www.rezolutebio.com/role/DisclosureShareholdersEquityExchangeAgreementDetails"], "lang": { "en-us": { "role": { "label": "Treasury Stock, Shares, Acquired", "terseLabel": "Purchased shares of common stock", "documentation": "Number of shares that have been repurchased during the period and are being held in treasury." } } }, "auth_ref": ["r7", "r62", "r88"] }, "us-gaap_TreasuryStockTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockTextBlock", "presentation": ["http://www.rezolutebio.com/role/DisclosureNatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Treasury Stock [Text Block]", "terseLabel": "Treasury Shares", "documentation": "The entire disclosure for treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock." } } }, "auth_ref": ["r89"] }, "us-gaap_TreasuryStockValueAcquiredCostMethod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockValueAcquiredCostMethod", "crdr": "debit", "presentation": ["http://www.rezolutebio.com/role/DisclosureShareholdersEquityExchangeAgreementDetails"], "lang": { "en-us": { "role": { "label": "Treasury Stock, Value, Acquired, Cost Method", "terseLabel": "Fair value of shares", "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method." } } }, "auth_ref": ["r7", "r31", "r88"] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeOfArrangementAxis", "presentation": ["http://www.rezolutebio.com/role/DisclosureLicenseAgreementsDetails", "http://www.rezolutebio.com/role/DisclosureLiquidityDetails"], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": ["r401"] }, "country_US": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "US", "presentation": ["http://www.rezolutebio.com/role/DisclosureIncomeTaxesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "label": "UNITED STATES", "terseLabel": "UNITED STATES" } } }, "auth_ref": [] }, "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "USGovernmentAgenciesDebtSecuritiesMember", "presentation": ["http://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrationsFairValueOnRecurringBasisDetails", "http://www.rezolutebio.com/role/DisclosureInvestmentsInMarketableDebtSecuritiesCashAndCashEquivalentsAndMarketableSecuritiesHeldDetails"], "lang": { "en-us": { "role": { "label": "US Government Agencies Debt Securities [Member]", "terseLabel": "U.S. Government agencies", "verboseLabel": "Obligations of U.S. government agencies", "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB)." } } }, "auth_ref": ["r691", "r707", "r961"] }, "us-gaap_USTreasurySecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "USTreasurySecuritiesMember", "presentation": ["http://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrationsFairValueOnRecurringBasisDetails", "http://www.rezolutebio.com/role/DisclosureInvestmentsInMarketableDebtSecuritiesCashAndCashEquivalentsAndMarketableSecuritiesHeldDetails"], "lang": { "en-us": { "role": { "label": "US Treasury Securities [Member]", "terseLabel": "U.S. Government treasuries", "verboseLabel": "U.S. Treasury obligations", "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)." } } }, "auth_ref": ["r691", "r707", "r709", "r716", "r961"] }, "rzlt_UnderwritersOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rezolutebio.com/20240630", "localname": "UnderwritersOptionMember", "presentation": ["http://www.rezolutebio.com/role/DisclosureShareholdersEquity2024UnderwrittenOfferingDetails"], "lang": { "en-us": { "role": { "documentation": "Underwriters Option.", "label": "Underwriters Option [Member]", "terseLabel": "Underwriters Option" } } }, "auth_ref": [] }, "rzlt_UnderwritingDiscountsAndCommissions": { "xbrltype": "percentItemType", "nsuri": "http://www.rezolutebio.com/20240630", "localname": "UnderwritingDiscountsAndCommissions", "presentation": ["http://www.rezolutebio.com/role/DisclosureShareholdersEquity2024UnderwrittenOfferingDetails"], "lang": { "en-us": { "role": { "documentation": "The percentage of underwriting discounts and commissions.", "label": "Underwriting Discounts and Commissions", "terseLabel": "Underwriting discounts and commissions (In percentage)" } } }, "auth_ref": [] }, "rzlt_UnderwritingDiscountsAndCommissionsExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rezolutebio.com/20240630", "localname": "UnderwritingDiscountsAndCommissionsExpense", "crdr": "debit", "presentation": ["http://www.rezolutebio.com/role/DisclosureShareholdersEquity2022PrivatePlacementDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquity2024UnderwrittenOfferingDetails"], "lang": { "en-us": { "role": { "documentation": "The costs for underwriter discounts, commissions and other fees.", "label": "Underwriting Discounts And Commissions Expense", "terseLabel": "Underwriting discounts and commissions expense" } } }, "auth_ref": [] }, "rzlt_UnderwrittenPublicOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rezolutebio.com/20240630", "localname": "UnderwrittenPublicOfferingMember", "presentation": ["http://www.rezolutebio.com/role/DisclosureLiquidityDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquity2024UnderwrittenOfferingDetails", "http://www.rezolutebio.com/role/DisclosureShareholdersEquityPreFundedWarrantsDetails", "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows", "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfShareholdersEquity"

```
], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to underwritten Public Offering.", "label": "Underwritten Public Offering [Member]", "terseLabel": "Underwritten Public Offering", "verboseLabel": "Underwritten Public Offering" } } }, "auth_ref": [] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change, Percent", "terseLabel": "Underlying Security Market Price Change" } } }, "auth_ref": [ "r829" ] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": [ "http://www.rezolutebio.com/role/DisclosureNatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Use of Estimates, Policy [Policy Text Block]", "verboseLabel": "Use of Estimates", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r20", "r21", "r22", "r108", "r109", "r111", "r112" ] }, "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount", "crdr": "credit", "presentation": [
"http://www.rezolutebio.com/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount", "terseLabel": "Increase in valuation allowance", "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset." } } }, "auth_ref": [ "r379" ] }, "us-gaap_VariableLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableLeaseCost", "crdr": "debit", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Variable Lease, Cost", "terseLabel": "Aggregate amount of variable payments exclude from operating lease liabilities", "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases." } } }, "auth_ref": [ "r456", "r728" ] }, "us-gaap_VestingAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VestingAxis", "presentation": [
"http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsInducementGrantDetails" ], "lang": { "en-us": { "role": { "label": "Vesting [Axis]", "documentation": "Information by vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": [ "r893", "r894", "r895", "r896", "r897", "r898", "r899", "r900", "r901", "r902", "r903", "r904", "r905", "r906", "r907", "r908", "r909", "r910", "r911", "r912", "r913", "r914", "r915", "r916", "r917", "r918" ] }, "us-gaap_VestingDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VestingDomain", "presentation": [
"http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsInducementGrantDetails" ], "lang": { "en-us": { "role": { "label": "Vesting [Domain]", "documentation": "Vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": [ "r893", "r894", "r895", "r896", "r897", "r898", "r899", "r900", "r901", "r902", "r903", "r904", "r905", "r906", "r907", "r908", "r909", "r910", "r911", "r912", "r913", "r914", "r915", "r916", "r917", "r918" ] },
"ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]", "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year" } } }, "auth_ref": [ "r798" ] }, "rzlt_WarrantDerivativeFinancialInstrumentsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rezolutebio.com/20240630", "localname": "WarrantDerivativeFinancialInstrumentsMember", "presentation": [ "http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfCashFlows",
"http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "documentation": "Warrant derivative instrument.", "label": "Warrant Derivative Financial Instruments [Member]", "terseLabel": "Warrant derivative" } } }, "auth_ref": [] },
"rzlt_WarrantDerivativeLiabilityNonCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.rezolutebio.com/20240630", "localname": "WarrantDerivativeLiabilityNonCurrent", "crdr": "credit", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareholdersEquityExchangeAgreementDetails",
"http://www.rezolutebio.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "documentation": "Fair value as of the balance sheet date of the warrants derivative classified as a liability.", "label": "Warrant Derivative Liability, Non-Current", "terseLabel": "Warrant derivative liability" } } }, "auth_ref": [] }, "us-gaap_WarrantsAndRightsOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantsAndRightsOutstanding", "crdr": "credit", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareholdersEquityExchangeAgreementDetails" ], "lang": { "en-us": { "role": { "label": "Warrants and Rights Outstanding", "verboseLabel": "Estimated fair value of warrants", "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price." } } }, "auth_ref": [ "r930", "r931", "r932" ] }, "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": { "xbrltype": "decimalItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantsAndRightsOutstandingMeasurementInput", "presentation": [
"http://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrationsValuationModelInputsOfExchangePfwsDetails" ], "lang": { "en-us": { "role": { "label": "Warrants and Rights Outstanding, Measurement Input", "terseLabel": "Warrants and rights outstanding, measurement input", "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur." } } }, "auth_ref": [ "r930", "r931", "r932" ] }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantsAndRightsOutstandingTerm", "presentation": [
"http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsSummaryOfLegacyWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Warrants and Rights Outstanding, Term", "terseLabel": "Weighted average remaining contractual term", "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r930", "r931", "r932" ] },
"rzlt_WarrantsDerivativeFinancialInstrumentsLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rezolutebio.com/20240630", "localname": "WarrantsDerivativeFinancialInstrumentsLiabilitiesMember", "presentation": [
"http://www.rezolutebio.com/role/DisclosureFinancialInstrumentsAndSignificantConcentrationsSummaryOfChangesInFairValueDetails" ], "lang": { "en-us": { "role": { "documentation": "This item represents warrant derivative instrument obligations meeting the definition of a liability which are reported as of the balance sheet date.", "label": "Warrants, Derivative Financial Instruments, Liabilities [Member]", "terseLabel": "Warrant" } } }, "auth_ref": [] },
"rzlt_WarrantsExercisableOwnershipBlockerPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.rezolutebio.com/20240630", "localname": "WarrantsExercisableOwnershipBlockerPercentage", "presentation": [ "http://www.rezolutebio.com/role/DisclosureShareholdersEquityExchangeAgreementDetails",
"http://www.rezolutebio.com/role/DisclosureShareholdersEquityPreFundedWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the designated ownership percentage by holder not exceeding the specified percentage for exercise of warrants.", "label": "Warrants Exercisable, Ownership Blocker Percentage", "terseLabel": "Warrants exercisable, ownership blocker percentage" } } }, "auth_ref": [] }, "rzlt_WarrantsExercisedOrGranted": { "xbrltype": "sharesItemType", "nsuri": "http://www.rezolutebio.com/20240630", "localname": "WarrantsExercisedOrGranted", "presentation": [
"http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsSummaryOfLegacyWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of warrants exercised or granted.", "label": "Warrants Exercised or Granted", "terseLabel": "Warrants granted or exercised" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [
"http://www.rezolutebio.com/role/DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareDetails",
"http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted average number of common shares outstanding - diluted (in shares)", "verboseLabel": "Weighted average shares for diluted net loss per share", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r174", "r184" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "presentation": [
"http://www.rezolutebio.com/role/DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]", "terseLabel": "Calculation of Denominators:" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [
"http://www.rezolutebio.com/role/DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareDetails",
"http://www.rezolutebio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted average number of common shares outstanding - basic (in shares)", "verboseLabel": "Weighted average shares for basic net loss per share", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r172", "r184" ] }, "rzlt_XomaCorporationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rezolutebio.com/20240630", "localname": "XomaCorporationMember", "presentation": [ "http://www.rezolutebio.com/role/DisclosureLicenseAgreementsDetails",
"http://www.rezolutebio.com/role/DisclosureLiquidityDetails" ], "lang": { "en-us": { "role": { "documentation": "XOMA Corporation [Member]", "label": "XOMA Corporation [Member]", "terseLabel": "XOMA Corporation" } } }, "auth_ref": [] }, "rzlt_XomaLicenseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rezolutebio.com/20240630", "localname": "XomaLicenseAgreementMember", "presentation": [
"http://www.rezolutebio.com/role/DisclosureLicenseAgreementsDetails", "http://www.rezolutebio.com/role/DisclosureLiquidityDetails" ], "lang": { "en-us": { "role": { "documentation": "Xoma License Agreement [Member]", "label": "Xoma License Agreement [Member]", "terseLabel": "Xoma License Agreement" } } }, "auth_ref": [] },
"rzlt_XomaUsLlcMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rezolutebio.com/20240630", "localname": "XomaUsLlcMember", "presentation": [
"http://www.rezolutebio.com/role/DisclosureLicenseAgreementsDetails", "http://www.rezolutebio.com/role/DisclosureLiquidityDetails" ], "lang": { "en-us": { "role": { "documentation": "XOMA (US) LLC [Member]", "label": "XOMA (US) LLC [Member]", "terseLabel": "XOMA (US) LLC" } } }, "auth_ref": [] }, "rzlt_Year2015PlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rezolutebio.com/20240630", "localname": "Year2015PlanMember", "presentation": [
"http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsStockOptionPlansDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to 2015 plan.", "label": "2015 Plan" } } }, "auth_ref": [] }, "rzlt_Year2016PlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rezolutebio.com/20240630", "localname": "Year2016PlanMember", "presentation": [
"http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsStockOptionPlansDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to 2016 plan.", "label": "2016 Plan" } } }, "auth_ref": [] }, "rzlt_Year2019PlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rezolutebio.com/20240630", "localname": "Year2019PlanMember", "presentation": [
"http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsStockOptionPlansDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to year 2019 plan.", "label": "2019 Plan" } } }, "auth_ref": [] }, "rzlt_Year2021PlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.rezolutebio.com/20240630", "localname": "Year2021PlanMember", "presentation": [
"http://www.rezolutebio.com/role/DisclosureShareBasedCompensationAndWarrantsStockOptionPlansDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to year 2021 plan.", "label": "2021 Plan" } } }, "auth_ref": [] }, "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]", "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested" } } }, "auth_ref": [ "r796" ] } } },
"std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230",
```

"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481549/505-30-45-1" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-20" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "320", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-5" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "40", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205-40/tableOfContent" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic":

"10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "250", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/250/tableOfContent" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/275/tableOfContent" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481573/470-10-45-12A" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505-30/tableOfContent" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(f)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/810/tableOfContent" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "15", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/815-15/tableOfContent" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/942-320/tableOfContent" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/275/tableOfContent" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1403", "Paragraph": "b", "Publisher": "SEC" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2",

"Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 6.B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(n))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/260/tableOfContent" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/320/tableOfContent" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-10" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r207": { "role":

```
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2A" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-3A" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B",
```

"Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.C.Q3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.1.Q5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.3.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/740/tableOfContent" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-15" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name":

"Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/842-20/tableOfContent" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20",

```
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/850/tableOfContent" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/855/tableOfContent" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r525": { "role":
```

"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "280", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-

20-50-5" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r685": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r686": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r687": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16" }, "r688": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21" }, "r689": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22" }, "r690": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r691": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r692": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r693": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r694": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r695": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r696": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r697": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r698": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479294/326-20-55-12" }, "r699": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8" }, "r700": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r701": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r702": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r703": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E" }, "r704": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F" }, "r705": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r706": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r707": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name":

"Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r708": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r709": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r710": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r711": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r712": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r713": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r714": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J" }, "r715": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K" }, "r716": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r717": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "101", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101" }, "r718": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r719": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r720": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r721": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r722": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r723": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r724": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r725": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r726": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8" }, "r727": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r728": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53" }, "r729": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r730": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4" }, "r731": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17" }, "r732": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21" }, "r733": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29" }, "r734": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3" }, "r735": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2" }, "r736": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4" }, "r737": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5" }, "r738": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6" }, "r739": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r740": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r741": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-17" }, "r742": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r743": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r744": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r745": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r746": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r747": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r748": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r749": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r750": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r751": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r752": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r753": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r754": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r755": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r756": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r757": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r758": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r759": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r760": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r761": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r762": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r763": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r764": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r765": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r766": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r767": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r768": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r769": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r770": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r771": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r772": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r773": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r774": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r775": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r776": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r777": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r778": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r779": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r780": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r781": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r782": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r783": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r784": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r785": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r786": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r787": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r788": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR",

"Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r789": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r790": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r791": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r792": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r793": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r794": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r795": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "ii" }, "r796": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "i" }, "r797": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "ii" }, "r798": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iii" }, "r799": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iv" }, "r800": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "v" }, "r801": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "vi" }, "r802": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r803": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r804": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r805": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r806": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r807": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r808": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r809": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r810": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r811": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r812": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w" }, "r813": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r814": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r815": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r816": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r817": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r818": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r819": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r820": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r821": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r822": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r823": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r824": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r825": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r826": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r827": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r828": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r829": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r830": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r831": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r832": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r833": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r834": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r835": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r836": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r837": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Number": "229", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1" }, "r838": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "A", "Number": "229" }, "r839": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Number": "229" }, "r840": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "i", "Number": "229" }, "r841": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r842": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r843": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3" }, "r844": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10" }, "r845": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3" }, "r846": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r847": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(1)", "Publisher": "SEC" }, "r848": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(2)", "Publisher": "SEC" }, "r849": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(3)", "Publisher": "SEC" }, "r850": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r851": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r852": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r853": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r854": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r855": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r856": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r857": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r858": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r859": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r860": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r861": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r862": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r863": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r864": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r865": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r866": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r867": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r868": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r869": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r870": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r871": { "role":

```
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r872": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32",
"Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r873": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32",
"Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r874": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r875": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481830/320-10-45-11" }, "r876": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r877": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5",
"Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r878": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r879": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481800/320-10-50-9" }, "r880": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-
50-3" }, "r881": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r882": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r883": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r884": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1" }, "r885": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405",
"SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r886": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r887": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI":
"https://asc.fasb.org/450/tableOfContent" }, "r888": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r889": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r890": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-
20-50-1B" }, "r891": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section":
"50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r892": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r893": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r894": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r895": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r896": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r897": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r898": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r899": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r900": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r901": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r902": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r903": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r904": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r905": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r906": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r907": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r908": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r909": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r910": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r911": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r912": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r913": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r914": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r915": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r916": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r917": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r918": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r919": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r920": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "730", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1" }, "r921": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r922": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r923": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r924": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3" }, "r925": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6" }, "r926": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815",
"SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r927": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r928": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r929": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r930": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r931": { "role":
```

```
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r932": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r933": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r934": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r935": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r936": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r937": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r938": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r939": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r940": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r941": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r942": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r943": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r944": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r945": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r946": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r947": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r948": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r949": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2" }, "r950": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r951": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r952": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r953": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r954": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r955": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r956": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r957": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r958": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r959": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r960": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "940", "SubTopic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/940-320/tableOfContent" }, "r961": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2" }, "r962": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r963": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r964": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r965": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r966": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r967": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r968": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r969": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r970": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r971": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r972": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r973": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r974": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r975": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r976": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r977": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r978": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r979": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r980": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r981": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r982": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r983": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r984": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r985": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r986": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r987": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r988": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r989": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-1" }, "r990": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r991": { "role":
```

*"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r992": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r993": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r994": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r995": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r996": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r997": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r998": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r999": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r1000": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1001": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1002": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1003": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1004": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1005": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1006": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1007": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" } } } ZIP 96 0001558370-24-012901-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001558370-24-012901-xbrl.zip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s89E" M-:)2&\6HOD()0R2-)0U02K5Y>)D)H6UX_2]:\!?:=PGN#:1EUQ'G&VB_C6,9 ME"L(NY><4$Q(Z,4VNLR*XOQ OY'\XMHX,TUY2DX%KBLD;;3>73%1OBZ_7UZ M;)Y_]CN\%L#@C]\W&X^%7!SN?7],1BJ38NZ#@.LJJ@\#X]^$,0+; M7X"<0C89D!]S@&S=PNSI3@- W:SH8S_TQM#>^TW[NS68]7&IKD)4A.R9BCIO< M6YM[VRUA>['"8YMHV5S!,V6Y/%V$^,#6=@O73|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l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

R#Q$,"[1?3Q'3H*|F)"(+ERJ9(5$|%&?-<8MA-,M@LH>& ?1R]4 M=:#FF,B';7WE.73XP0-&Z=;3; 6!FL9ZM'J'KDN(I**B3S'U)#Q['O/;ZA! M=(;M?#>>8G25! 2*;/=I@E&5X3O'C#:|(U/C9Z)K8A1,EDM"Z."A7025LW2. MY^C%>;2#A_TZ;!=!\?"=8_8/Q(C)=-1VOYF3[23J"%/IZ?J0W0]3IA70U+>= M#I"5SM"W-3V/0^?;9$V_)<$S750KR7#@YEVF.WC!.A[,I+3\3,U\G<%RAHZC/1&;9E3&;(MIT[/]8WCS8+(060[S%G3! WEF&VOLF1-VE.RV?Z5%]B$8 4IX+LF&JVQ9C.V M[>%#,?6P3Q%F:Y]>V;B)CR9+H@4\A\!OZ5% M]0-AF$H4,/:?3=@BTFF=T-N/[(@[73[W2]X*T!BF\V)Y4&#+0B+FXBW6?!-,! MPS2E1#_TZBFN^J@K%R.-O8R<&#>_GDX'8I6]EN4X'!-M_V$7^>]0A);OMNW?/7LNPF/[&._&HQ.>;3|0,IW_='9^ M?O:!Q2_|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|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| MWTYN?!^V[NC[;1W0;1&#JM>)3:\16WYF,E:MV)X"X@;:LQOQN@N KPSN&6 M-A'Q7$BUB!>] MY^]-2&4 4RE56KVONPQQ/%"[XT%MZWXCDC4&@*6\HLQ?FM!3%\M N.E/-2" MH0\[+5[8A?LN.;A&%P0%9Y\<2+(:R@V% L)O:APY>L\H70BBYQ![CLT70I2 M>H=Z,/2^$'AYU>!#%C3WD("E$,V+2]X&(81C9.G#@+\[/ #RGK)?$VJ?L9N M< NP29>+L+WB+E?0HP6_F28S2E>X HA,>+GD*)1O;@6@&]Y3RFGG9EXDBTN2M=9&H7WDGHZCOO('S#WH(S;&KLWVUH4!OH<^ M<&G^]^7*ZF(]N2W;P62-WP8()./08.T]/[?#A1Q+5FE'>!H-OG/%AQ9EI|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|FQ"[0;;#RCLIHH%E MW0 0(-):C?+.VD3H-RMZ7+4YDPI0ED&5>_K3H5&.6A8!K[1!787)%B^S1/M]P3?!0[",5GW\>:"G*=I12'),M/I*I0UWGY^?HO17Z&?Q.C> M"]\ZX>H=PVM7XG,8!E'H>RZ]<]M]&4V6DS4Y]M"AZ<,-&DZ,T2.EQ!.Z#J/= MZDCYAUYB%+C(/:#-Y\|_?'C_GOS/.K-V0Y._\U/N?XBL4>&GM9[7LP+4*\UIL M8@,/"C((%S3,0:!D#AL=?\FC,JM7>UDIDI[82>[1V6Z!Y86?IPOX;.`7Z_^%A 6&S.N'Z%Z]RZ9 MP\ATMMK.L19L=3M3,9*&)I?42,"B.O28)'*#*TW1.|,_=",J?6P-,_8G;(G MA@T:DS^%[R0Y#3MDDNWIVOM4"23"FI:#W>S02B4 N/'/#F$N,:Y&:>&F7]Y$ MZ(^"L?_=#R/D_Q*&,-",S;&UUX*'T0M];X:BP7W$Q%%TLA"WA[*T]/@G062- M/99QD4F(^:5$BW?2^PMBQE_2^X]P39';@BV.,I'U@;*U*;7O(&A$AA,PKGU! M_<'-IS&1[HK0E^)%U;:<;\I>4!99)$PI6*6U,>!6,N0V#L CF5G84|H-&O]Z9]:D)LS00 L:Z,0TO M1]PN./-CIE + ^"5]#,6"T);#8C9P/E+ &/6%D(&N_DG <\Y$MRB>B$A>,R];M0KL[%*.B%C/UT03&7B4V554GG/M@#,E>$'C&(J5]L=!F|XY\T.CS:P(/##R M9RZ34C@)P),EK9(@MSJT>O;.JA^;L$H+)6 ,S*Y-#P&_"S"R?9K:Z&OHNT0- M['5Z+A\]]B):M"FACY>G1-6';H:PXA:_>F@6#\55@3OKKU|P@ 3, E]JFL*M VS_6T<: ARC2D4I[,AS!"P2M.V=.3\U88X ">!LN:35/_9A(@K&[%KWSIK/ M,;)FAP8PYOR&O(=' MC@B1C/#^@VH228+--L@9,DCF(|<+>)/D1KJ>(8_>|[M[YMPLB)VQ\'?K3B6D*C&8?$H_?.XT3UL9?R47#88L\? ?22VURXO8(4XO8|5 MXO3R,_VGM9WK%)IGA#.E%#9**PIOX;. "7

*)B]?\%IS9O6&4T "(_&5IK" M/EDV$YW:$_4O.*WY^3JB" "Q28$4[+.7"5J$[4A-W7GZ%YK6?);=$ 38NY!+ MRA+$2(*]^X1",O7M8.NGQ3=V[#P26A5^3^N:3Y;LQP-1:G'<_D6G#8=KBP0X M+E&A[T,P8O 1?9EX)'U0U'30_H6D#3]M6]B#>&K$8D)I$G <;Q9$#4:VPVRO MRN^,SLOOC&:CZ\%B=&E-!{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|*X'FR(O#0!1V2'Z8#=+| MSZ0;@SX3F1MD4\S='"U)@]LP MP72RDZ_+8YO0*'MH+_8;&&E GB%T9])"AQ9"FFMGK ,HJV+0EXG:=:'#O"VU M Y,\I0X]=43T(FR@FA5^2<8#R8?HYWD2L^)>eva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lP*>(FN7VH(/<7=V-QJVMVQU"999[=N9'B76Y[@%H0C!8&?85&L:;(M$"\5[5OG0[IT/_,2A4T?=U2^H4P ME19>&0=I4VQD&7A[4=R9?-#B3MX#=(LHW.[$BXX0]>,#_F:'E'9Y0:S[D/Z MF"[>\$[[O4T-)=LF^J'&7=NGMN[:]C!91:!,-VQ'?9 M;H](4YF@B !+9I$G)I7W@>*#T!-';NI*/F+FN;7/U:7!)E%C**?OZOP1862> M,:=[FM,]S3'=TQ1,:?KD8$@HX+"!W?DN,T(3%PF?OE8: HG3ZDK1J MU 'FO'M]&70ZYG;-1#I]. 'F"<&*EC>)1T\L\5S5L_P/Y;I>\|N+ ^>B?=^2@ M;HU^9>=XHU6IBQA*:TMSFQI888> R-]_"UO#.@7+&%&H_BA"Q[SFXX FC>^4 MM =T<%5(FX(W<%YO'P G/2?T(VDtYG"H%3<(4,.<>T!CGo>C;>S&U:S945558H M.D%[6)DLJJ@R 4(N+,'B99IGBQ9ZEK:H2#)M9I&1V#]32]%8YIX&:>=5,6 MJ8JFONVP(Z14U8D:@!%UVG*89Y0(*_/,F<2/"-,2"5Z[L@;@U%,2 M0(Q*1^(?X3@G^N337NS)AS\[6]'P^68X#UWORW,3F5?64M#.D?P1A("K](T$$ M"/5I",D,I>$GT:.W7H2C(/9B?K'-6B, 4$]*N1/R2H6<&2Z.7I"3T,= D^72 M\|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|_?O/WF'3H[^S=&XKV7$90D M1HS6=]^*W\X+Z@E\8_HAV_? ?#M=V^_^R/Z\X_Q_O+C']^AFX\EWS?"V38T M 49A_-N/|\]D/$0D3#.?OR[W_\]MN7EY=O7K[_)DD?"?K:=]_^ MU\>K,_\)[IRS,,YR+_;Q5XC _YBQ/UXEOI>SZ1'0/S^D44G@^V^KL900]+_, M2K S^]>S=]^=??_NF\]9\!.5GT8+^5Z4P] \R<=[]\,/WD)?2]6I(§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|_?O/WF'3H[^S=&XKV7$90D M1HS6=]^*W\X+Z@E\8_HAV_? ?#M=V^_^R/Z\X_Q_O+C']^AFX\EWS?"V38T M 49A_-N/|\]D/$0D3#.?OR[W_\]MN7EY=O7K[_)DD?"?K:=]_^ MU\>K,_\)[IRS,,YR+_;Q5XC _YBQ/UXEOI>SZ1'0/S^D44G@^V^KL900]+_, M2K S^]>S=]^=??_NF\]9\!.5GT8+^5Z4P] \R<=[]\,/WD)?2]6I(§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|_?O/WF'3H[^S=&XKV7$90D M1HS6=]^*W\X+Z@E\8_HAV_? ?#M=V^_^R/Z\X_Q_O+C']^AFX\EWS?"V38T M 49A_-N/|\]D/$0D3#.?OR[W_\]MN7EY=O7K[_)DD?"?K:=]_^ MU\>K,_\)[IRS,,YR+_;Q5XC _YBQ/UXEOI>SZ1'0/S^D44G@^V^KL900]+_, M2K S^]>S=]^=??_NF\]9\!.5GT8+^5Z4P] \R<=[]\,/WD)?2]6I(§R^37(M*P01^$_?\A^ _^K=_0HC/<9I$^]VOS1OQQ_QUC__UJRS<[2-C_WM*<5;>]+

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a"'::782]=I@V2' [2WON)$]UYS21&:LOD6PI8^07 MY%%.Z5.8-@#41C*)R+EBPU&=5-RU""WI0252>Z M?8B\E%B->&/C>VGZ2H/>RBQN-Y^*]RW\P4LY%(KH6"B]!X.ZPIEHDLIL_@]/ MY_4O$*.--EM$[S(4SV.6].U($Q)0T|> 4TT/>(BUM::.E YPEFS/#F0B[-0' M^M4-88?F>UI%=TIHR-KGO!4#=11/LYMHKB MB2&T1;3]1ND67C_2*H#D?RVMI0416 M[BIQ9).RJ(')K)@T'0)@11:C&(TR+$IHF-HK!G8D>>H$04A)0DE:1*SJ8KDF9 KC*797^Y1$ MQ-UF]#EE_GJ=Y+A,B2M$-M>+[T /A=/#EB;AX.W.E%-39(LBVJ3SF="\'J6RJ MF19.*]M D">0*FT,Y+,QY#H3GEGI<>9,4C$^Q+E4IK@J=|=1..@0I8WAP9-[>[. M_BA9W I[K%I!%;_*A$=.E .*T63X!:'O*G)*6W,9M#GN5>'!"E6,:|>']TR79) M'QBO,LFG&PO(+TP]>95OF6H@./\TK40=;DZHRXL/U CI?V5L4.15HRY04H^[M8&?A7CDTJ[M;' T\<@?##P8REQJ8,#&@O.3,$\S?:#ZHWJ?2PR7>)X*/BI;" M#&^.9WC9F&$^.OJ@lX$S>.ZYIU0(S:;64F?V>])'PRS4Y3.<+8O@M&,V3W_" M3NP !TZ+8BO8DRKTGG 0VUU?UM>>]Z3]I*9PY+DBV\11)N-998==OQOO9W(D$'<C@>] MP.A#T@D7U7L]%ZH,SUH1].38:TA5$1TZ_M 8E*BU&@6>>]"S1=]@5C3T=03@9NNCH9O1\0%> ^\BKMS,;2@ M6[<]BUHM5G9A<]F41Y+=+V5G_|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|,H(L\^>3T'<6;.@[PHJ7AHDBPT@!!Y,GHF6ZS F1 LV>M_Z'A0O(0CH.)1>5#'R*LSWVPVV(V4RD0862"E,S%>*H0*<7SGTG&@4Q(F8 MN&2')EMJXV 9(&1I&17;S=(PQU! I5WD;"UA@Z?H0B^^]D'[SAOS;>6VR$M M'$O7L$_BBR0+X\?-]LK+\AL2%6K#;4Ms]..*7<2].R7:8 &V/;1G3_TX;[<((9WD2P[W4&W%TM-DBVMJ1D%%6A_-I^D MA$B39?[12W_#^6:[Q;1]@I][]""]W(6>]P8:>(.M.&THL^\DXY*SSC%0B>*$48\@!W 4?GC(\-]/1(%6S_1H7I^!M"J9W5Q6(60Q M+]JZ# Y$T]6,2"]AE*|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|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~ Z!! &',@~ M@84PS8V!!@%H@V#D2!-D.QH'#!,J3G+,GR$])+'FG5B6X?R] MY_^& TO;UV(-@4S"]!)H *8&AVGV9>*G?3=%,@!RZ0*W=F=_X3 M#@[TJ?/Q4PMU548XW6.=\[*K]UH0/9EZ"%LLV5#!P)W1PZ<[COEHT208P* MM"6.(?+Z^]?5W?W'U?7]'5I?HX_+V_I8W2_?7ZW0Q>K]/;L;G7^Z7=^O5W M9U5 -PYMP!W"F)/3V$N,01AFUS$>Y[W3F:FOG,J9'-$^/69+^.5H;W07#D7M1)2? MA^IQ@8]";9B3UMA9>T79](#V83MRC3$+9K7L0L=D[>H_ ;;O2H;=C=91+4+#V M\#;"469KJ93=X_N3E=:)WT689'2<56SY>MQ^]Q'<CIW2I[@4J,&5BO"HLIX.#*AVD9ZM_S-F%04;ITL>ME/(":5;+\E 10 MI;2ZB;J12 !9"FLX]^7L3}3^BOV@K\]%O0*HS9?+3A4@QJS"'6#&C4LM8(.:$U/IFMA'V,MPW=ZO(VFOTM*>A+' 6MIT%KQ.JQ-18#?%RNW4E2%1R 81 M;B-L+Y:X!39C@6Q^;=GJNNVlLDC[&>"=KW"68;S9L|(\|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|I795K5TI#;?/DNW9@6:$ MU//([NZ8IUF]#]1FQG NZ=79G0'$I"# XIV?] M'JY:!)=T35OAQ%+;G.BZ>HLS3+[H$XFV+_ SCA*6!EMD]VC;KUAAPNE>!\%$ M#;1]%#:[XD[W8Y)MOW"+AEAIDK?5]FDQ#6PC[@F(3*$:V=*.$."1A=1X^M8QL;L\2%L|).PHEV9H4(8FD=.&N7N^6X3!&;V*Y9V[12NK@#O#+4/#%BN;83 M; EDW@U>@98ZL>*ITZ[P;J0B)R.?VVDR/&6 KAS.J7(\VU .',%I4B5;IVX. MI'GV8)X?K&$7/*K\C##$F5 GH-<1M8|$*R9A)ZKY\%J.[X 9V3 XL'K' EV& MF4_BA5](E(X^>CFM/.[\ 7BG";D\L*>DW&*K9.P4|Q80M'CED557M>|<3*&0M%0&YQI_S^Q<./.]V5/H;]0PXZN.H_!7U*]AS38--#/7" M:;)9(;\/]3,K@>]P&FI]+AOP$<"]['-@H33W&<1PK)>1.QKUPA-;M^?,)&2<9T_E<;HF<*A/L3\:A@A*6(FL+3!AHN%5PPHI964O=JJ84I?F'C#Z[*|)U MR8C"1\8'>[K3V/|)' ,$![+WHR.C_"E, [3E. ^-7:K[;A%8LHK#^(65% M$X1?ORGZB6%;5YW@ASMV_.[%|8% \!)L&7IYPG'U>_E'+Z4O"/=)2CEF#X-+ M^IEX4;T-8R_V0THMR4(F4T#?)+TADQYIKKS]/DT_^EKE^IM]/NN7=TK_V3@M3G;D6;A_PBEFHCD<%"2\(V8 'E1MEG_5'3&^Y#?),84,WM-;KNW."2,>Y3\G6YO:W M/[[3FT_)@P@VI$3I+(;/3BX6^>Z2M=[_=%1R <,)3B6^>]>,*M6FTC2-;^3+!YI&P;6EQ>7QF>2RE@X7('M,R+60-20)!\ 0TGBB." M.D7@RI574H40Q=9@D]ZC&CT_Y]8%: !&M4O9S+XIP\ZUW$(4@ ;UZD\57!&' M3HA$9?N2A%3N83RKS:" 1TF*&,(" <=K,1&H7R\G37*WJI*#$F&IS7?6O49IWZ8T0RWS4M,U.0IW+\GA'[#|;Z\2$<" M0/N57F)6>Y=.V'#[F!YLFA*H YR%CS%[6I&4I,2L:J*D3TD4$'V.DYQ&SA@' M;.-#<(NR1O3A18UROYASA_+X84^\QYCSBKW+A!9H(H,*N@X4I=D5(FQ*&M M(0^%Q*X4V+)%Z\LTASW(OIOK:90%HH#D6STI$,@=L HXI$6F+]2XAIX \:Q @#M*K6-O"M*=!=6!<@RX09O^+WJSC(GI0MLC94<*[W$N[A\U]97S CV$4PU_=6P[IV--O/C_1 MK>Y+&M*ON-G3+9$Z,5(-"[3A-#%?;355@'";3#U'[5:! CCB|%![R>&<.Y&R M.%P,X!V75]76L=IP*<$!]UL&$1K;+04LS&Y+RTQ[?^+Q'@%%@2/'-EO]9,FX M+'P=KI;A27+X:P:701!2R_,BON7C=]A3_UX4H++[>PE:I_IW0@?,^^_!IZPD M'=>XLC=4BGT)G1+*9L2;=YG)!9Q@S\]%G@K/QOVU EPS-K*WGYQ=:DBL;_M%O)B M=8BP91^)XLYHLY78V%]?>SI#@#R&A+H(,8)V]32=,U+N15=LW5!$33:(CG72MD(IE]*C1P'*GLX:$+>L&R3N+E8XC@X<@/>63]9Q(RLDPWK)QC@P"N/'BS#S M:?25+>/@G 11Q*2)B4O+$%BA01\CF45]GRBI<1PX7#@(Q)^VLVRS??1|HH: D MQMI!^C4Y\,.HSI**F.BB(9> [,0)U3#9E-\,O4'K6/C:D^1%LM|?&QJKT?Y: M22;OL2V# G(&:H8KVV^#P)FZBA=)A!VQ!R6T%3;%X0$T:V)&L8#LUYI|!HA* M2'0^/<^F@D =6;><[FE7YA5OWM+3VU38[J[31P)V6:X+5*=7[0:/TL6;:1<[MXSK4-Q;U&K!H+ !T0>#.@;;M<7@-U\NM6,J7S:4<%40<7](B*I>V;%!U%DV MU_V7940S MC=Y9W;BUV'WSFR6OH$2#=WH^GB>Y%|&?Q0=N7+-=:*8U]*5$?6>8-H MR@5?@0>_ |FL9,X8 #'LAF!^E@#@)E*!;E)>>>F&*GBE*71D&UKS*U$^R*> Y MHN9Z"7H4.',R$44T(QT\B/F8&5)G|M(=&4>;;WFRR%+N(=(JR\,=.SK<-JQE MTFX;K!3D.J;VR2RZRIV^P&GX3&*Q9WP5>@]AU+ZB[4, ZL%L'S'K]I-=L &?MTW9G4QH8>U4+Z]0:!C+-1(%%5T4E83!7MZ.((UY)2];KWXJY2T?0]244$4* M]$7KJ#(WO['LVTZ<=5H?SK&BML%]_!UZ11R*)QI% C!Y9V@=-],AX!J8# MR::C3|9O-R4\[+36-->>#H,&X&GV(.6Q)Y299O5?5ZA3R!-?Q M?9T=K8A-NY%PXMF*M:B*IRQ&2.CG+98,FNQ8*$K#)'-R_D/'H'R|#V(M|(H;Z%;PU*I#GZRA:Y=LL|>\5R<& M^]4-HD/P'NW6;DBB43QHF;2U(!0^\/_"?<'|@OH/&5.]I,@:)EFB:$OL02WH^ M],CL/GQ_6L.0O1+K;O?BI<$|+7BM"M|&HP^XLQA[DAK;CK&(P^Q)QN6^O?84 M1*L|RAE#1^(82!R$/C068N!$!L)_ =D|..02H$F@[6PIJ,&%G MRU^PEW[W]MV?Z&C]6%4&!126]AFN(M V'%RP]>*E7UQ)*:$]P8.*)JW%89Q2 MJ F5|L]62OMG=Y16PO"QTO[9(:5M\=);:?_L@M*:Q6&<3]RT/U@I[0 N**Y$ MX6.E_<$AI6WQTD]I7PDU]KD_N**Y9ID8I]-[]G?O;#2W"06]N3*&CS17!('6 MW#8O@S3WNW<..*Z%3(S3]31W'0<'G^VS/]"T(;7R*@"|]%+=]7"4B@X+=:P MTT^1Z0N5L'**'BE5*'7N(EP-BQBP QT5=,=C52#W9%2M$59;.I[F@[#ZR']'(|)'6&#%A *T9 M=H)4BX<>'&X5L>+FM8ME(AC)$7R3%%>39^8&|:>\DD%/7C\O!WBT7E;X8)M>7_1";=-SK1Q;*9Z+4\Y$|)&OZN+% PP3@GN)2:)FV4E54UR&DMM'HIQE]W M);F6]:#0^94S36(] \73;<\|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|*,K]>E#E%$IV|&1D T. X=8S+'3!C1#NAFA#E#WS#H]'Q/D8]1;XP142 '7I#M6_AE7Y^V>^:1]S(.5[_WV"?_O$_HG[I/X+M)-Q:C.'BZSGS\SS3^>^<(8W)VD MZQ|._!E.)1#A"Y7LTGHM|__L,O%Y!^PF'1W5HP!NYU6+LA|DGO1FLQ#&&>A M;SP5GGSHTSWMZ#*UX]:1,8]|DF'. ^2 ,3#-(,C/E=#Q3 M6)JDC N:+MRD#9@:81F9Q4MJQCM=UVB#7X!3M @S7SG#[-ZO'F?5UM- M[+KMXH0>4,;7&"=TGE N M6]W]2G[+A3GVOKY["\?7NJ;%.>!^N$F:.7;40 MWLUULV_KY^;;U^7C8\KJFLEBNF<^47;OSP8TC!_]VUG]0DODHPF>=*2@!O73 M3ES5V'Z:829S6'B'R@+C,OYM$"58DA]2QU#-$L.?T.VFWYT"AN$__]$.:O MQ RS/#WP%- D?\(IRI^\N,1:L XX^+.WVT=X@1X..8J3'$'7A+N1G@PO>U@T=_MXC GT-QTO?T^Q7|('69*#|?(3V1EB<'|E8%_.ZWKDZTE\W^.,9<1GAD&L(HHMSP<<4VX'@N.A\Z#*+>Z66SLG%Z=[:M!SPJ=KI^!PSNW<.L[A>HXN5$'HQ!3OM'+_T-YW55'I\W9RT.1V+![SK@8_LL2]4$++/LL*L> M-K,03C&^[3^PH,:W|L*<5QW:5:PH'6@>A2.!B M46=IU8R@6YU+4>Y>-^(D6*1>(LH%*/KY K]AA[ME\:.E\A.5]I&X$CGTB;-T2 M.O]1GUH}*=8LO$%!GX>9KJ:A=<001'7 M.C@UCE(MRH8#Y.LA[6RU6X?):\8W^'T.?2Q7*+]_D[FA%P_%Y89B'F<:&\[&9YU@G>Y9O(.4@R_+36A$',%? M*/T$'Y9E5PL# V>8.3'}8N&)XS2B@A*2"B'//*7LM+RWN&N]FYXCWK=>?MCY@VLS9->AO> 9^F$D+]?HZ!) ,4%C&[@:FVVA7PB"$4"_T$FI2EN:!%Y+]J M#2+_\;?|,(_P9KN. [IS/WC1\G-X'&YKX.;7&"/35%.40+.N)08NVK4'*"PKMAG.39,OGH5\IN+HHY7QJ\7.8/]WBB'G<|"GK._SUXN$.D<;P4T4'%$E M.T&52J9'AU<_&_ZL%).C *CF^5.(MY=A[,5^Z$6;]99$#]ETQ3-"PZBFE 9UF07'-%.LUE.PMXL_("27^>1EV6;[<|>E2'?IQYH8WN MT418X@"5X;(5IBJH94* *XUEQUE+::X/=!&DSZ)?.&:&DK0H-84P[VL,56"J MIT@.C4I4(%*!&&JCS?5$,OW 98I9;;Y YAJ&B%9*A(5VW6_6,2|=-C!)OY^] M-WJU5F!9 =?'&Q@INNDK+"?"UI,8R#GK9ZSXEJ0J%"4K>)$&LH(5U?"(Z=+_ MH$7Q3M)'}9L.*P^V."KT(6LZ2,L1=QH1H/;5-F*).Z/3#@@6QT|IE0:F+%[8X[8K,#N M0*^>OJ(=EX'5*6+'C=FFB#5*KDO/$&S2#[SZF6I3'LE2O'!4(%OAJ6TOR3%)T"L^K 3G5XV9&WV MZ$G%59)EYX3/UVV2\A18[R%2C4:6- MN(.9WLRV3R?Y44JRI0^_\MWM%$E!3QD+-'?MBR*4:/1;/!1/4(J#@X_1\I ?4O('[S/|(63Y$E#', ^/-I,YG+:IC"#(- CTZ MG9^F+IBN/WZ98@+:BK 03_($+9O7 5X/|'PR?.= M''T2]0%E,*

*<7B%5>>",]RA2NN^P3Q45$Q0+.+CNNG")YS'<5408BV892'X +\C_S^O\OS3'ZO7_Q(|_ASN_I1+/H<-[!#X)O|/$N/MYG%'DO8/ETHT[CL! ;K,_EE!,QD1:YXT&/4@LG MV)R4A$_*ORJF9:RS$$[UU+ROE/U)G3%M(S$O<\D63OX+L3=]?/=I>AYOK$O'I[\([IO] M$2;;ROO?%,\TOIAE8-2)FTDW@7LV>=&!STX4)2|>\|:,7>(M3PC MW))E.#]_ MHL7.US&?845V7WHK<: [5D09,_ZA>3+8+TY=D4$5G@4I*O$P)I;6@ M9Z4I]HC&O[G _%]?&QO!SY-\,M),5 *&,7JN9L4K;3I2ZHHVCHXS_|['>!OF MYTE,O-F!.+3"LR5Q5H'2-M2Q'T8AGYR'C-4(54SBF ,X4$YKM&F2%N :3!VV M9-=(|.N*?!5#W=PE{,17K+9;FC+[7%Z|,+A;+\>H.4@5P/Q:#N=*F;DFGXKI M7.:7F(2C7D3?3AE5@+KIC0'-[2V|U/A'6&W&&<,!"QOSL]1<.,!"QOSL]1<.,8 L'8XG@3M*D.6QH:\ M'!7T437 ,8XCZ_P<\U9(3O>0#YP.G:&LFIE/W]Q]@[;%A!%GZ4I8T)P2]FQ[M&0=79-"H@L'&N]JV5)QS+R:!+1R(BH1++D+/8V\GL&"FSWNM,](",(6'"3)Q:/)ZBP,5PXRXW,RM^WM4KKE#1<,ZP|<):F+6<@$M& MK>-P@$ESLG0S6Q ^D>6\TW2L=WL"14 ^=V2%<657Q/(F2U L29N>#5VE5A=7R M4S3BBJ8PUTE<9&===X#1\|BCX!R^,, WK$B3/[J=O8Q*$]MHX]/75EU[$H U: M'5<$PQ.O("3#I9A\+[+HY2\8TYJB^2RE3B&L%T1<[MEF+&A#0O_I&2/+3 M_D"A'EZ1M]|'KZQ<&1V|K'A(:A7K M<<,/*YRY/ -|V>,1/0X?E(=0< M#M|T$| I6L.3;J]%\[%0[U@VM.;\, _N>0Y=38 M.]Y!MK&=VZF]!+38I1ZCNK1#E?,V(!B!)% T>V=]:7\#,O)PRLO4HZ3(;-V MOF2_&QHKPLZ9:X]IZ7#-;$'5)2/OS/8H%Y+M],(,2?.07?8/PZ>NGI!323?N MEEC]A/'+!;#(ZG4I1;='ONW$1U/D7F1E-%:"W%-RDAT5<%?@8\LF ;HABUZ/ M M@CV$*41]M@#3Q,QV C0^U>N^U5AF\++?+*1Y%'4ZMB##+$$<_$8[H^.F4OG M)@.=*#AD3-W:$'1 =\/4.A?WEUH>7/>"/G;86>;K]DG;>$T-QK?-=7R3)C[. MLEN<8:+[3\LXN.#/.$K=+=K.TU&,@Y9]:7(6E.UT'##7]V8M#[:^N;SK""% M2EKL$%R@!KPY&TGXAG0T^$Q#=C.1(3_),IT.2!"]A%'!UH3)^)$F1/"2 M;*=)2\|AH[4056NP&GPWC-(H-WJ6I)A"EP3*GYW;WWM+K8@E*<7"L8HR3_* MOQ5[WO-D1_^7GP7%0;$%SNC>O!2_]S(@G;&!LE^Z"UAEO=BCPF6[=.51E>7R@,F>$[.; M!)]:7;*5W3!D].]!:=;5,5(KAT3(NXK M5)+)X.F4W5()AQA,2H$*Y"N)P;)N%%]/)Q?0H2*];[<^Q>' #H4Z#?;UIX(4 MTHUP0V#%\JQ/FQ0!=ZBGD6/I^^D!!]6S A;1)/#)'>V=4YID]MM\#NR0 338 MUV_=*:0;!B"P8KD=3W4/R.:\Q@NTD!;^]K:*![UMV28T9@6G+=D>(Y2SR0D5[,. M^N?"2*U(DA,$EK@7,2?VB$XJR)Z,D9WC;ND/3AE5@+KIC0'-PRG8L0^K8'L MYN8SF-Z+D(5@+3M8\'<,TEVL,S8B;+(ZY0FI\)RP'KU0"E.2(T';E8XKO9$) MF"XG$/43D%K96+M]|\&DP.-M^/B4;[:?,OG-92=,_^ -)"|%DAY$;-"<.(HW\ M;9[:!3(5>VT=+^9%]8V4TJ=XM*HZ_L.G!QVEU_E.1##/]MLSPB%::]E+5^A MC2.FL%C7WYA]R[-D>U9]2]=BV::SM U>CK&<6*-U FF#W28*]/]LYLDZ!'8M MUK42A@84$VT!%>OO>:+;A?Q1VS(.>/GO1QS|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|[%-["1"$A]:.@-;5^THR\H', M@OET'M-IY?4(/3A\!S,EH70.9W(@E M,D?<,)#H 3 6\W/O00\'A8?IR,%N^K,AT>4=N'Y&>R9V/;] 8Q7]|HB5+0*RZ-F3A7/K9&P#YWN\LWO)%T]V3 ME-H>#D(!SXT* XI2W<+H@1[5S8W>S7<6 ;:9N$C9TFC> ^R-->=S+>.["0V+*)?4(IQXQC\(@A[AY M17A7\DGHF[A!PM?,/R2KQ 5>)S#FPY/ A__@W]WX7_C 5A^(S(DFXE4J _>EP M[?"!'YX^_O&WAX^_W7V +D=94,X;'FW2_MD!7X(?J1-R:-B^WG/ZVV@B*,=; MQH=2GWC.T5JL'N6WKKHU,B$%.A.24B*25-[58.Z3E!R9Y3\92I$(DLBNSYA7 M7J:90ZJ9&E,>2V*9_:2ARR*X)CS@Y-*-"LH)IH_"-">9+B2P3C3=9>DZV804 M;J/R&)\3_G.Z&7.Z,?B+:TPY!6KO:=HQJ<2"AAJFG]O(YV0!E+H-4\Y0\PQ M5SVI8)Y%_IPSS/V@9B>)*Y\2^L\|(T7\%2<60HV:)T=\(0H'/_H@[^-&;,X= MQ4NC%\YECQF@/QD\,X(IE:EFB+XT4,T89H0I7U?A\|!RQ6[P441KGBSMW&27 M7U*+,LKD($G+ID\%#M^;?*5 ^!X?@OQMU$ ZK0[B.3&24B.R;#17B61? 2!%KDJ6M\Y4%I_9[4AQ_@MU=O%VID>)X.HV /9>]1#30'SOCAY/ M7. ^K(E4\[XH;51SO)T1M_-X*M#P.IWAY.):(WTVP-]RXZB MB9"<"LG(R!A] M=8$9H;6-OPOSU8=S.N]M8&7|*!?&C4DSN3&GQ>D MJ#5;C7<)?0G,3 M=Z;"<%?HI37-2Z8ZYS01YH.6]F; %H/B=>F[W0>,*I0 MC6D@TWG]*4NJQ:N:|,8US8HU@?6N&\RGHI*&:/G"-?+$14H?%H*UVKG#C% (N>GOT0VJK<]KJOZ@P!>4@0D@'F2O: / M28;\:-"$!C!S\0(2[%4.E; WE:MAG:G +*"+RBQ.1!]8: -5?4$>1.Q:Y(85/ M(:4N#)*>1+HIMA$IVOBAJ8X6P:.!(\; (H<5RI[!QAOE\L,2-.V!T4XQL#GT> M(=;'K%+9P?'[W;3K'2%6[I9ZR8ZG4<]T!X<#3TX8'U]X=A0YKF#WYGCV3467 MHYZX[,6#7L(7PT G1%:\OP>G%85*0#@B!I("#AR-A?0$5+0;:H/ GA&W%[-H MN?K05LRU+7NU-@JGC,O #PLF*^HG(NAI5)1$V<^H:B .NZOO8U0>9=V.E/V+ MFNS%1#,CHQ936:1:-1"'Q92+4]>/LFXQ#2V-BK.@Y6+- ,;C'8]6%6-]^@D8Z M([>;<@K'-N1J3;$4BB&Q^+?"F/=56P*S+;T0 N 2 R;ZTIN4*'QNPO> 7G@4$ MWQ?,I7Y$\T.*^K80ZO6&#DUUA,@//U6#[1UB-G/55?2SONBMQ$U2Y*?C1TO' MBQU$O9@![*=BYB69S@/G_ONKTO>71QCU9/+S%YX[VF ;8^]Y*3FIYX0&#B2 MN39X'D:6=3RL%=\H|\?%%3;L6?3!T65E))(W$;#%XKY8.N=FBH8>'(CU;:#0H MZ1' G[8.G]==FL30:>ARGH%['U4^HP-E*Q.!+F^U5W8.9PC(M|C)/@QL|*K$VK.1SA*> Y,S'7F|R^;4TEFT3!9QP?:7[!?]=QFB4P!X8#L: MQ8&?725N+V49 \K 4">H9["X!, <:,*KYK&P9YHAC>0@A^PPHNP$>P<)O#:M" M-PE#*>(6A++7PN$0I^F^B< 6:7"&%4T]-(>8'%'VC@!OO-&4^:'T:UO(.R # MVM#P*63NY6V)]N H TZEB+HI21$6:ZBI8+ (RSJ0W_1QYNSI.H<@!P."12>3L MQ#<\LGB)&V/-4S2DU4A8,ND%&KRA1.NW/?\E(8LQOUC:(8' M98A1"]TQLY%(L 8=%;?MLQP]H+/[AOPC%A]QAI]67_F_TS83RA!B;UKHXJ83% <%=40KOI]] +0\E701L[* M37OY4'%2OSC!(3CYF>U/(]+)"H >S;7+$;1T.1'6[&N)G:T30K+)ES<.. JHX/PCICL_2(4E?AML8/XH;IP\|VS@^..%W&M\G MOJ&- MANO N/1[* <4&AMM^!KKGL>6.'H*(-4Q*U4-M/MFL9_W\(69YG*7GE76,5#R: MA*$D&XO%8=M+X&42.#%Q2,3\UQTE&^8[OLNX S,_BEDL'CIB7!-$)A M6R&4;&I>)BRLWCK1XJE-SK30N'0RCC-U$VWU]>EI,7N8+5^F"W(_7TZ7MW/^ MK_GR_O'Y8?HRZ%S:=:2G,(!;M$=X'PU]!D&T ^Q$?0Z#]Z/FH#LN9&>.$4O M4D-8<2(=ELI;J2G01#S6EQT><|)$;"6/:B37(^;#1S:;)+0YS-/2(5@-(.T MZSQ3UTWVB;@P=P>WU/D<*=X_T,-.E!?@,D[W01BS?XG/:^6OT9E[2^NZ2P8J5D,:/_Q8 M:[A6W!+Z\R#.4+/W[G$]U6$'V":.D]'5E,_9A[:\47E&UU1-PD9O.^?_71W MB4>]>VY;M\'^D,AS^,<-G*?R96GT1,/5U@FIWEFD&2(8#BU-JJOZ=-,$!68WN"QI//?=8$\7?!4_?7/8#B+>2\"%W > ^Z JR#78>U]J-$S%WNH[B MT"K%KV=L=D+'3T54(P4'5%9"0R]>"U:-8V)1$= + 81_(3E*4?5:("5%K\,B M\))_9)AM^]U9A=R>-^%8)GL:@O=&_WAM^[EY&5U>^<AK?3I$@]^HS+HWX M=8KQ:CR[60.Y;XNJS^?^[4EH=|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|. 9[8K^:PI='B2D?F_B&)(^&&'_6RD"H(!"99+TBE M 9:'VS6W.GZ4&88$FA !1CZBRS.TA4H%P.<3GUK[Q">%L:Q5KJL[%KF[%13H]46\-A*72F$;"YZ50&,J/Q5+7?ZA; FI+ 4 M.Z%\61*K@[@N_(.>4%B^8"-"DK[7*<9;O C3),39Y9:ZP78NK*BY*5]*$>-Q MNDA;6>[S6HN.G/#WV03OQ&0# KX!'B2YM'K.%/T5$]81S1Y@A6R&#&I>)MY5#B%HW6? 1)C9!!DU(955IE4&Z)A-Z]V*H0RM6[.IP6U"2G2D\MS_D M<%E2_;%._6@TU]1[<:1H3RB.:BZEF?VDHSN(N;R')2-$:TXE+B%WMZ;RF!X7*E.))4?7<*@ M<*)JIG0\2-:W0NT^NL+)/AII0]4-<675@ C>X./RI&<6?;\/*5]5<%W0*'YV MXG8^!4* Q[N:Q53Y63TT"H]K8D_'|P 'W,"%Y9[$0@ -5C]L+3(_.<&Y&.9 M2"&'P>6,LY\'"CVZ7BEx:YDFE@'Q.%^]6.HD\1(*A:/5L:67(DI8 L!874M: MP%P.3F*/RY'$#/TM@'(7.Q8?6_E2+2P>=U(*[_*H2D 43]7@3,>O9,IX@L?] M6FW$_,)XMAB*;M%O. <2[.0U9Z%XP.DKJ79R*E%0WT,G(L>M(^.'C'9"LL!W M!VD$95[=5:3?G3!T?*$ZQFJ:Q7K:%T&\|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||X?U2EMJN'VG-"%>M%9ZL: M9\6IZADIV=%I*!%C<12-OA!@T5")I'XX&J,IB: PG(75]AYJ9C0,:*%14Z/' M*=$3#2'R.:_T<7,+'3H\)_R#.N&+$[[2^";PDTLST0>S=#K30J3\9$4#QMZI MB#9S)7,Z08J:G"DL.7)@$@MHL@9P VM^G'^SDOI2S^S>/*|[__1_8)_\:B>C? _Q)02P,$% @ M%(S62*0|BQ:P GM(`!4 !R>FQT+3(P,C0P-C,P7W!R92YX;6SMO5MS MXSB6+OJ^(\Y_T^!S,+,?LLKWE#JF9X^_>2SG|^ M^ZD'7-,S;/? E[SIMP_67_D__lS__G__U'__]RY=_WBX>>I9G;C? #7NF#XP0 M6+T?=OC:6WEO:X;;>P2^;SM.[]:WK1?0ZYV?_?SUY[.?SWM?OOQG-,2M$< N MGMN+QKKX^3SYPV@_FN?^K3?XY7SPR\79Q57OYF_G_;]=G??FCTF[1SBSM5W5 MT+'=/_Z&_N<9?J\'*72#OWT$]M]_>@W#M[_]\LN/'S]^_G'YL^>_P.YGY[_\ M|_%A:;Z"C?'%=H/0<$WP4P^V_UL0_? +!,XTP8D^]<)!?K7 MEZ39%_2K+^<77R|/?_X(K)_B*5*,_U-"#/I%&3GG@\'@E^BO2=-"RXJ1X5]M M0OL#@_]S?_5Z,:-]SP$+L.Y%G_U;N'L!#?_\IL#=O#AHT^MVK#]9__\G_RPF_ M('&=W5R>(;K_W[LIF)+_#EUKI(9VN)NX:_?1%S_J8?&?UI,I/RP5^>LPW! ML^W];'J:7U";7^&^T7$S)6\-!K%F^_A &#/.F&:RA M6<\-'_[Y%82V:3A"2PR^#V7KV!OQ(('$PLC;O/G@%;B! 0X>O*"V MB%B^U R]RU?(Y5?/L>"&/OYS"Z$ODL:RT9NA:V0$K_>.]T.HR%*#"]'BS@Y, MQPNV/I@:(? S?'"B6V\W&\'>0C?:+'P\QTX [E&EZ6[A%N2]S.$/3!BP$"OJ> M8-H?:(@,BPUYI;T%SVOBOH,@C$0_<1\-_P|O&L\,N //X1*86]\.>;E/.;)H M/@-X:O--..DJ7/(FW/' \,4'\1+C1$!A%,'S'& ^>@64!ZP[X]CM<+G"+MHUG MV^"%+'$\P7.OM<&3AY$QTTC?1Z=%","%GS?@-, *^.# M>\W=(]1<|-\B#C1WO)'6$>WL\/K&NY,1QQ.\]P5PT($,U<)PMX*B"PPS.KFX M)HX?3#2]MV^P/>*0X=S;+E1O;G@/PYQ9^8?S.?606!]%'GU6EUTK3 M;ZFTO17ZE41M,AE?BDY98_+9 ;3K/C5FBA^L:3VH+A$T8\O3B6HAO3!*PZ=:U M'=93#BWWY*Y! &8DQ:=X#8)X/Z7/67D'MWK;:T9M1 M11Y6"B7WV<AXS'QX:NRBQ5.? (*K195O:ZYVRN,&L]W7F3_-L-)OHW.H@VY= M.(OD]E6'(I;AI5.&&DQ:=X#8)X/Z7/67D'MWK;:T9M1 M11Y6"B7WV<AXS'QX:NRBQ5.? (*K195O:ZYVRN,&L]W7F3_-L-)OHW.H@VY= M.(OD]E6'(I;AI5.&&DQ:=X#8)X/Z7/67D'MWK;:|ST$)BG0ZQQ_F]^&^'->! M6 +QPTNG[+] Q.QH|]WK"DNH"@22**7_7!/8O9A'NP*8.X8I@5CB%Y]V)BU@ MS_QC]H9^"R?CUM^#N#[6--5(!&,XIK<#()K4?.O#M18@@=12+P5]62&*@MDV M1"Y|EHC|NLXWF^;!|\!^>0V!-7R':AG<=(-@NXEQ)Y4-%)]M' VE#02H\X** MW#0_)ZUC;?I;^C24CF ^U:3-(M73OF^UCCV$Q/H W@QS%TCU%=]4|YKC 0[M'.78\F@Z_"A@PZ(95AXE=PJQ3ZP#K\ZV'<$68VXO]6<7U(=\FB&;C**AF$MHW+8H-24QU_6/1MG%.!O%?#LHN:-H M:E"?.HBZ28;13$,UIW!_:)1/E9.0[-E:[T3%C,4Q9_35 'XV"FL-@/GSB_?^ M"S"M*) 8_1 1%!$#66M;P(-78;F'+^ M4X+FO@RAMM[4[-,?JSW_E0?54/DS3W^F_IR!'X &YISZ3)TY"P)&6)QF"0K> M?!"@]P7:O!_@+_9?0&.(BI!/TP$^0H ,>8??VB'ZT&!P#2=[-CCK?>DE@Z5_ MA /WXI%[Z:$1&0DACF=FON2@- N>3[%;6|".=VOXPW&WAO_X/O+>@3|\AB3OO\B>3|*/%1RQ9#KI/W^_N>S?7%S>W'P]O[FZN>@/+K[F M)IB6_-#/3M;PS61|^&,|#-D<#OL6O|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|%QR8SC.[3:P71#@=!!.JS:*KY] 1'R"7#L:$M]X_P7>!/\\[T? MX2N*BC5<_"HL:=U&<= (3DHBUS)*BHU@GYMH?;BT;CC,.0Q#$7+]WC)<2]>(; MMTNHC'0D,BVSQVA_#4F_[(@W,V'8*N[M0N@7/2DPB^E3:@ M_4'T"N_;5?MTNE&[!$LY_T209=8?'7?EF*SY]MFQS7O',_ WDE2;+.4WD/*\ M5]Z?Y*]FGPA.D 6H*7N!M]D@+R?/_",*&4YG2<);#0B=VBA:9GH26;?%-K37 M(#"V]=1?VR6][HDG+NF"##W-'HI[XJ)WORB4*>[O?3OBY|/Y"0K842* >[O? M3"R\|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|GU>"&>I[IR<92&QAL6TAMVZF> M]A+]5UQB']T!(OC>2\F #C[18#;3RE>;RGZZ(XA2Y-3'3P7E.C[!8JXYOQNH MC&QX!WS|W4"9VM(T$BX]-/TZAXIZE'=P0QEOGH%E >O(C&.%IG7QCP=.8>|(M?.-U#FA2&-+!9^04CZL5GRQ3SB%3\F!OV<^!W\ZFDMJH"SC0^I&#CD|\Z/I M6M$5:0[*"TVE=T"USF[)"[@RN%&6ZYY%)ER&"BO!NYB+(,B'.G#[?A*]2! M_S[N>B)>|\VZCQ.JBKL155-&>%$1DP4;<8=3P06!6@OOVJMH8P'#47/+]*$ MEVQ!Y@WE5K-"=8[*$X;0H^, 83E;6FZ*%!-/%@PK4\"#M5'2NT[J690P!'/C+IYK0O(4&"M./PRF*WWGKCPKY'32NK1 #T7,%@O+LB9KX_? M[*GKWO&K/'C#$2^:^)'D,$*'P:FQW?("D7FZ_U,5BC0&&NZ3C?* M0OV]/[A0:)RDYFV9H;J2*Ds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|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|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|F'AI,5FI44O*XFDK;&_D+DK2XJ1$B 0710PGDXSKEJ>FZEHCX"-;+537*

MD;=&G(WJ+&]J4'6Y[3:3%CPD/(5&T>^D8*MX@$JG !D7V4J+PKD3EEDGO<'EQHLVW)YI!==E&O=H/%V.>|-OB_$X.NH%]MZYF9)5<&QC86;)PC=P"ZBB MM58KAX[5!\L@(U6=.JF*Y;0*;V@4B^BFN(C&C[?CN[OQ'=2+%Y/?AJO);V.X ML(:WDP>NJZR$\F.5)QR^PW=%";HA>[=1C,AL_>ONV;>M5-T$E-BD,.'*T[#. MD-FU<=$? W)RI/RO)0BN>G,(9T*G-(7K;??4<2%(0J_L_>|+7XIZP_'6X&/\Z M>X\;PO+?>N-_/*G9"J)'Q0Q94R_$;0=I>RNYX_=S176-2F=%?P>F[J_5BF>4 M2XGAK!;94FS5S2_N0G4GN.? EH\LIUGH?L]:_W.({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|0H#]*' T3 M11>[FU#W.PUE.<_(#B+&/I?QI(§<,6 M_5+>"DIX$$? WTYUGA!ZG@25>1NS1,Y""C79N^>^]P;5P]W<0?9EUT*G^1MB M'!V4:+N?%JY]<24Q.YYU2D-:0'9"R2"E\0Z| \>+^'?R(F]$D7/TT(7+T,2 M8,DR8',!"Z,_C6 3VS24#9[ZA,KTN^O7&,=!J@$|V@!(9R\FFKL6:GDH;0Z5CX#J<% M*D8^)-BI77RS%#MBUVFAB(<9"9CDV+35]#B'*E HF5(5@LH; MGQ9P&'B0X*5+)NPJ^)%R=O$|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l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

U8!2"#G[0X1G34,2$ M%IC;'P8%[K"A#C?)^[86"-HK\,A3\UE.7^*D';UTK:GA")Z!D@Q#*O>I?+D MD^\%F-;GC!<2"Z28E]5% N:\GI%N>[?7;3D\H L!?Z4>T.@C7Q(-N@ONS9_.MS3R&=$WVE"H,-.7:7*TWJ]5 ;E)\NRL?@.#@)O&+6=;?#,YN\G50,_9JM4>7 M\%E\X%D5%X%LV$Z*N-;=\B@%2(MIT2Q9B):"S=NC(_. W@QS%VU0U99NRY*F(U8+;SN5&M#TH\AU@;94E D'-8&14ITG+ALV;*726L'[_'83!0ZZ MUM)^<>VU;1JHP)5KPM_ZT9>"><\/VH_Q?,W>!N.KO7[?8<]=?%1,!\%-=+5>+ M)Y0!:]D;3N|ZR\FWZ>1^,AI.5[W1;#]"?UA$B;"6]!N<4R^:5,)S>T:0;\> M-#.EIK,#OXZ$%NK*Y[8]:!#_[< M?<$>QD%#VS M+/NJA^55+B (&3D4W>$548Vt:I%T5-O:#&%*F@ :1@YT$C3!82T2;5TT7?6&M#:.PZ6!#Q0(MC& B#[/#C[:P(>B>-T]@'?@T)UGA,YZ ZCY(XV55:W/=E"Z MQ(I<8#[?L&/HC3AV!%#N6DSLZ,ZQ-W'?MF$0<; \M0)%#[T1PRUD G H>="Q M4RY%=7EJ!HH>)XT5$@^ZI7A48H\D]4#EK?7&2%,Z#P-O!/GW]CN.DBK%D>T: M^.^V"5DV6Y=9MU=P&D'YGX@ZD,A/Z E0!L 4X2:=/:U7F817T.OW!WT-TE!) MEWP1; SAW] 2MKLK> ;5QM",G;VD%V!)/-MPI3-N_LZ@DHZ3D2*[%0IF_=RIT0E%QO<.4 MR(L56HU/KO<MCT,IHY:H'^ |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l02P,$% @ X((S66"KM!7 !4 !R>FQT M+3(P,C0P-C,P>=#$P:RYH=&WLO>ERXDK6-OK_NPJ=ZK??WCNBY-+ Z-I=7S"(M>1Z,\8D3BD1*0$A(0@/3U9],28"PL8T-V,)61W1M U(,:SUKS)69__S?Y50A MYM P)4W|IW_H&^H_!%0%3934T7__DVIGBL7_ -|_ ^>? XD^W:H0HB;8 M4ZA:A&!8$&16$C6^);H:+H.5*(*%4-2%")M2.((/_0U$W\AKJA"9+TFDH# M$[VI];>;) Q_P)R&K|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|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|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|/Z.TQT/M ME(%.+:;I-0>3.<8V5F*D&4E]PGC[@^T84]5Z.MB"U1^OX*(?[S*UGL8/1^4E M#P) VV>&6YO*I;%PKRPY4AS'8DQ6G,_KSY+VUWZVT&H(0]VS#__X*3LK>GD M6]'X"2=)>XM3F?_]84I(B^#D]_/=V,F#8TU!;A+J-TM3Q'[VKT=M.A]-S3:<M3TZV^]:CD3.'5](&[W4S\,N>MB$[^1%C+;M%KIP><+V$4=,S=XB;WF"@DR[; M?))$_'DH08-P" $/KEMDBN7];-GCES?-F7"$-9'[442=+75%$B1/H1*B-,4!MJZ;Z7.3G)OKCC^,&O3#3?WX=[.7/9GC;P?PZ-'/=20YM!VXAAQ9GX7#*BB6I M.$EMI[G[;4M"7N_|^*+2SU@ M1"OKZC2WKD6ZD(OD0;V_$%-D8('QXBQ_ #D0?E\8$DD.7*VZ>;ISI="PFBU^;JG30+;Q9PW6DZ.85L/:H,HU<; M= 40N_3/D3QVU#L*([34%.@H(X34G1!M*L5%9U3BI-^-BBEJ25^-0^9X/ MP?)'F+W;=C%I0F"!46\;.BU9=!WJO;09.)R>1B)Y7OQI&/0O^"\>#IA/:1ZB M]IVH=5=M_DZG6)JJ?+U5IA(71RKS% 8TDJ\>4 ^T)\-FM7QLR]3A;Z)-W+MM])&@NJW0R_ANN.S+PGBP^'9T)@OAHPQKU#3.F!777N:ZRJAZKW:|.Q+0O= M=-8>K/-4*RE,NOEJJYK5TRUMT@EQ>YW1V1<%[=/@3)VG._(DWLEWR4:-L0?)M@5@P0F_A2H.S\|#V0H5;C^|7/3XYY&U*]P4M(*6QT'A(AV_29B1 ME>H9:S&&3FO6XHQCK)L-:|;8?I2BN?P7"^7&?7S]]2$_H72*PRT8U:D3F& M7TY L6958UI@!?RBD>+7X;N[!GG<"G\[''F)!S6%0%;;I9@TE!(]:M"P5L=T6=T.JNFXU6E%"_+;<6:D6H.C/JC:T\+ M?:A.9X/!WY=U"\KC;+#P8,:K%S8K]M=41XQEK>NVF^S-T>E"X?;1.-UMZ/K;0M5+1+,KJ83W?G<3D5ZO1 HH YCTY_T!.MD53M#:CI:+'DN?9RS2RNW8'[4)W. M!(_ +^OTAU$Q"98/:X.;96I#.E(2V^G[:S?=GZ'3+|3MT]/@ZP?53+1S:= % M:HJ_TXKMI)Z[=D&^ZDAP?.[GW)UE:!-R&16'3D/"]H&E9F*H=)U?=-+'+XY4NCFUT1M28-4'=:V\F$]:6S6 +_ M/ZOTMUY&EW\E LQ7A+? AL)/697H?C)=*Q<_ $+Q4PQ MUIE^5[\L6-#CRQ$[D"%LD;%$9=+JT-U?)#3;B\OL/K]?;ZE]X/DM-[/-E\'MV3#Y>[F;'I:F.=4,'LY!F3"Z>,+ M#6F2I7==G%QB&EXZ<_#2F0!JFU_GA#HAU F?>$9M9J!-"G7 $?+Z43M@NSD6.M79P[;IS;HV=]3>#Z HXCNT-P]OG=+=6]O[G\FQT66HMDJ5Z9FAE!BNK9<# MB]B7YN]WBH\GP,5@A!S'"$D?!;-'CYX!1KO:+E=3GJO0:VK=9?D6,VYQ94FF MYO-4(1_D\W&"4.AU0+=$C|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|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|#;?6\:08G_^U>'E0N$R||%XH1<9<|21=`U\=7AASGXKS\|L^)8>])UN)ML/TUF5LROW>FPQS"3X#HZ5P>? M;_&@/P1K?5D>2K7[=DV6N+O>'4R(E%P(7;$O[\>?/SRKI"0A1_LDO&$R56 M;>GM2B^P2 IV>;:1'O0%D##J1=>-NVZVVYX|\OW=F'[JL<"Z/U>#A OYOI&S MK$Y'DA23DBILGB('A2*HV8*CY#BX(5+PEH(OOD'IB,NS/5XF1A&;6RIMOEL7 M^HO"W7@E]LC ^[_'7"5]W9P[X29035BH5-S,#N192@4Z[.75?G"/)^*+F-*8$WM:_Q]9;;7Q6/V%/G= M;6#\D.>;UKT/1=+|&'N8OK8A@+

S/;^=I4UI#U!#N MQNGW%OU)X/_'W/_B]@$Q-N#POS_^U:EGT$=3!^I>C\[?MZIF3('BMKIPA^M] M]>-/!PP42&A# E_FB /3?W[A5A!- ?[_?H"V@@!<3O0K/'OQV0^1+_SD&##M+M2MI4UO:=]7F!WX,[9H)%"DD7HK0'Q&W> ^!9B!X[-Y9$J:F2"+Q+|KYW^9W MW ![@RF[__.[+\/TM89'/K13]>!IHC>B|M^,5+FDBFY9]+?CB41^02_!T"0 M1X9F]^(MZG X1!W^^/,_THP%/M[RP/]7/1[2IQC9A?9@N^5R1P<,7 T A]G M06(P3"(//I$? 2R<3[!1L\ %0R,HRC_T2%'R[>3IYK\HBI#O8Z\?/MQY]N MK=CALD2[D^IP[7]^#<[$@E.'Q4^3:1*]6);C[3"%5RW-$IEZM%MQM M8KWV<6-]K()>63YQOH]M)W!LL\-=CO? T// MU5M5PADILC,IICK.FB0GNOY9G'3Z>0@1.;4A4I%9=A(9-]L/MZ7F*C +4XR=3%LG+I9*]ZM8?6KUT?04:W=("87#3IN68=(\(GHT3-$4!N@EO M-W_X*8ND^;?GQF"++KB>P+[7Y#?"KL]$/?%V+&/3]]<:[3+%$C??SZ'A' GK M\1!97[^)R W% MO/2Z^O#5]]_H>O;0VU-U2TQ89|F\ DP@#Z[<' 0"87B "O M>G;;W\$ ^0"V!7]CI^?I#%UGR/O7$E^8FHNSS>LW,>839^=AWNGXR43?.\$= M[Y*1&_8]F??+.BX(VE_G0<=+3$@U_?<]D\G43T?9+GVW8PACL^L _Z0T%LF M%! --64 %$6S!MKROV6\D)2IVD!I05TSK!\;;S-;M98PV:IU.*ECO)K1BK2X M;Z>0!:.,>'-QW1&?2+/ M'(3$?#!;4-*DV&';*[Y@F O4\=,8^:4HN ;G0 3G"(*9E[B+S1]2=@86I0M' MH.=*\^Z+P;4!]P*X[(!ET2MR%YSV)XR0F2%6X,&6YIUN ;ZD7S(=X:#EM'$ M7;X)D4R<9" 1*I%\0 ;P1(WZ05Z-(LBKUO#64F-B&9(J2X,39R,V1_'+O M/&:,@"]MG<|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|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~&96ZVGC?R*I2T/>_2\"M^,'VL+=^.1;*8?F MWQ\HV#[:8M)ZP0^_C4Y3.,SF'M^B< MMZD5)P!74%N0 (* U_]2%B1N6+YP]*T>_!9%$RIY]=SBO01ZL78&$ DBX[M M_XE=$-0?>#946X?Q%Z(|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}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|PU>BJ094U"P!"[@#0>!)X:X1^V+?,KDZT.>9G@FZ4I\)>9Q*-SLB!# M@6VKYK313D=2/PBO'=-IX;'$-QSW/]=HP%^9]S!]%9HVK+0I[;TNM:F> ^-"O M(8%GV9],E/E)X3.B]Z?|YR?AFCA-W;'4#0$PC] $F_O]0-\DDBS>7P]J8DC*]U+N!D.1IUE7V<7L6'\?N>8,BC;R:X!8MGLWOX:!8RQVHPW;V MKSO;U]O."NVY60.D$3X;\NM0CZ;R0G+[C0C#^]RN7QGDDC]^!,- F1CR9_Q M6.0)- AWQIN UMT0[]LA+[@[YUVITW:]8H"@=]I0MURM0;/N#;N?0<'A^PA]M3L9+NPVS]4RWRM4Z:7R16+W5]+=2'2Y+I/M$B\MO+:Z6XKRU_&V=S>N"XRBMW0)!#C3,B M&M% >IXH%HO;PFJOQ]8V$Y-#@D30%%D^$USVEIZWYX;LOG*W9EN/3A9A#QSG M?>Q>[F<=6W]WFG_*.7^B9.H*6&%A]0HICR8+W@A/>K6/SSCPQTP$__A$FDXXM!U:4YMZ__^A0(\LC0;%5|='F@H$|@X'6=|:9RE'$X.D(1FP&!C P_MT@FW0%F E;FY4YB^H;;'2MQN&<9B/D=N(O%_$[L_\6D>]4, MR.RPT7_IC_=?*FY*>%;%/$!+*RX];UV';IA6#'TC:,T$=O7A'Z)HZQAMVO M8[W(3;0LM=.9@!@;Y$C]JU//'$0!_AL!$-D\90\)WE?(T#IEP,Z-B$X][Z[\ M'_B9[].#CZF/27V(@MY9B,[X=F,L0/841BD^DAS&>9 ,7Z0$)D8MFTA"2& ,2/R@JW%IYAA;=,',CNI=(7#%TUGZK4.-2D]D ;E:K7WEGD3R9M$ MXJ5U/A_P^2.WC1,Q0T18;=;7Y3'X,H- ^ZNF6!Z/2]4'M:T.EX\R@8((|8%KRP M.)]G@7&GDH]<711+%B11 P+6"YA/N<7:C=,"^N* =X@F\| M?.Q5H0HFE"*W ,?OOQBP/+|<7]#-Y?"N, -]HEZ+Q*C@1R^_8D'$]#/%;[N M3?O54ECP3.YPXZHU4JU.D6>H!)M\>EKZ<_[:EI(X+'-I";Y";(*G*?;$*9@' M?GU4O61H-;XK_+\SPG?IBMM_"0*PV@MU2|9D>*%IS2FWITCHG142;^OAP M;HF@;XA-8T]2 &>0L4|@^N<5+WLFYN.G_&*2@]UM9WIM49\.C4EH3$)C\LV.M2:HEF7(.")9FF'BPS!'IPZ<6'VE04C<$;I#P6@RMRG>W*O'G9.YQWHWV3]|- MC4UH;$)C\S6-3;]K&M#4E#D4VQ88#G&|#@Y_Y..-))A*)G6)XTC9&%4A2D<AA2N[CIR) ^4[]# ^W MO>AHZFB>_$.?@89*EMQ[F>IZ]]$R^,@4*;%=]LT&;%-NN[V:Q4$]^F(EG. MX8G(,]"/BO=I4QMPBLU*W1#^#AS[X^O"7W] I :;;6WR?_@,@] H?7>CQ(:) MN=HA4;IFQFEQ#9RV5[98"+#T;9U77$^ >.4C:2)&U]HM.O!L4U[?1!98('0 M""U[(Q1&1]$1"HW0-S-"R8QS\Z&)+86(PA0P,]!K*/|0"GGZN 3C%#RAO Z MP+<-8=.SUX=[Z9#;B^5<%>]FX _+5+HA9T1VT51H;7Z[M8]%H)_4)*K=5W MLU8I?).4H2DX4'*VCXK.2]$XRT82I^P72]9NB$W3CM79-1[:FM#6A+8FM#6A MZ/EFMB9=QY?,%U7W5E|\0WLR&8TGV5/,3/J&<%HE?,V&!N:;&Y@P]18:F-# M?#<#D]DEM%IP! S<2TXSD.%02[8AF:(DG&)K,C>^C!FQ[8'PNB V?:C7B5MC M8*&H!|[QS>%%U=3=:\&_2OCS'B;Z*7_P\EWG\NVO?1[1679HQYC0L(6&+31L MW^6HA2*?H&+)!#Y\|%UG+82'+83"%&AA"A2[0X1_0X0'R!4\^;8>*BL9T+G&MC5M"P<85T_7A4!*@@9=Y,I]A:R?$032%XR"0@Y_$M@MBTX>SWN/T@GQ[2.0U M1'Y<[$PWM3F#PCE)X]ORYT"%ABLT7*A"@W-7-S< MK&=!'-N "P608<'I.L]6=OPRKXAFKW9FJB]'O;L$>[$!&Z=PD]O=Y&;Z".* M:'XHND*3#/-XH8V*L;&-"FU4:*, ^F8V*- Q)%20=*+L]I3D(G5,6H#&7!&B> M8]_B^()4KP/_KE78!()ZIUUM<'=A&5PH2D$6I4"O.T3X-T3X5XI6HMQRC,AEHGO%QQ@I$H^< M8G=B-WC'*;[#)LN$UYQH7KZ]>8F%YB4T+Z%Y^3[FI5W,UU*=;HMK\W&&3<;CMS[,J:40F84'LX5&!!F1+5,3^1^V6!@0(_DD'I0RZ|*"N:QB_1&G^YQ_TS^8| M08' P#@=>XV3+F9O6=R))ZL4]>\T_VD1)Z8(I1?HHX/SI?_R$V,DE*6B*M9MS^BW+ ^]IM'H;&K'1E'4$>0'[@0R"08HDG< F4!5]9'L7CRAD6BKADB^H7: M# .3%.^/9*/)GQ_8](^X^UZS#9TO1;AKZ)81]AC|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|CA0(K*%L8^G;'# |-DO!^ M\83D|=<0:=_I@<<]V7KT+9(7* #SR?=(QAY_98XQ1QY_BTBI/OG.59V;,W<, M=F>(&RR!?_OE_^&D23P*@YWAH>&_D Y(M/ E^_=?R5@|^?MQA/TH0G[BXISD:;WN:3[*Q VT,$:T@:-GPH CA#@DH"LM_M#0QM#A3'1AEP]B$KY/L9;^8>4A2B*"I?F;MV/I:3P+N$([?'8Y^CO/#S#MS=(LMGY/D SK-*3=/;?P,00];ZBK2N[V4XP_M#Y>6B6S9QM+O/? [Q&>(S^?PZ1ER[!"Z/B<&GN'SNSQOS.T 8C='Q#C=-;>++#D(DADA\LZ8$.HZSG,11TMXI>,G1B4'Z; ;C92? M7X5MQ7IFCTR'/65(A,?2.W/S$A' ,/#%FVX6 MZ'D).KP4X^C>]3+0)R344YC^:!(C/^JRX?D\|), ^15Q3<5C@N64+0]LF83HX MDX6S7^A[.!RZ|M]@A0@+<,X59[;\]@RGPU=>]@_]_<9,WXOI52<#Y+:$X&H* MAC1PO<>CTJXM]!Z1<_MQ\Z-N-@]|VX8^DFX)7).MSL4 M0/*%68;8\28L]7RK438XZR4D"4E*9X!BC$ MP5,3(2(K\A^W-MJEO:=@/;)Z4H7&8B)W$LU!6;FX=[5)6!TAL4@:L62@ D?#0)FAS])0VN),P@M[%O*TD9YW$NL2GK+M.#?&;M>Z- ^7<|V; M.@0RLF=HJL#H:I(&R64Y#8F/KSGLOMDP_Z*TF^I:V!,D0"EZ"LD24GJXOF WD(.Z!I\I"A!I #@]+.0+R82[^&@ M6$8D#([IH#%.773DS7[(U>DWUHY@VBM(]?/O0:F;2/&\U\=LBAR.K3&BWE $ M=@55-6%935A6$]2R&F228\FA,.#I^&#(1Y!;SX-!),;3$3813[*1 3NDO;(: M]PUGNS?/4 DV&9QR&SPHHNCO01VEL\,CC9>\D9WDF1@=9>*7'>X+/]'C]=X0 MF^%|FG/:@FM-L2UD0HNJ<+,MOME\|:E2KH?C_89/:D9F=/N3]_5B|S VF=YW M]|80YF\"F4A X'5T!'2D50@#&V!D0R!P5O&=)I%E%FRO7,%$XT=.!7*5\)(I M2:./5$EQJ0XQ7NC925@* <2L#UHAUKB[Y%X6\,W.ZG6:AN!G?C0\H?$&1:3890\Y],* ?IXQWEXA1]PWZT(IY-\AE^1S MG_7.,#7D(=LCXB||LBCH-,I&'1=,8VZIV8:]HF*$Y^$B\)#31QY8:L R2%CN<,M"%N54R9!/SO2=5)%N.0*\ .D M_Z9NQHM=%62CC)\H@+-<;W]](UI4 *|?*<<1-N8U[F5|R%V;AU?'B /.TR+]<:"VZ0@G!Z M[]+LYG#2N$BKF]72*3;NL6$@:K#2=B0|A()M@5^8%&|C<7AX+'DC+E1WSFC M(BN7!\|]O',* MW9S<*CL1^9><&GA-;8L@H]UNB6B?8]]*#=XTRI&X&@44V!Y/Y$#)XR=E?3V9M.3]OX09VD37.W6VC<0.N19EI\815"*',|HT[S'F)-[NW#E=/LY\5A++EQ5 M,'2@QS @##/1#HT2=[H?_ @<,Y,S_G.1F=?@G|1K!R$G8-AI3UA&[DA;0')S:E@M0XBW$_@66KK:I)+F#L]\LB@7|HN'((--C:1DIR:;[1H7H1-A Y;R2U'1DBW8 MKIR]|G=8>(E34PUL,PF(S(IF?O';(S$.IF M[]7%4@&7\|II]%T]:]I[QPH5D$]9-X0Y1N75'V2?,$(+S"S,51.:[$[|FVK^A M*S$ W"%T3[MH5-]0OS1H .Q6%&[6(EO!3$4[+&25\SC*B4TF7E;2T1D"2/A[M/"MWR>3%OR1_7>5=DR0N@'!M:O>:E?MTF>=|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|1K+|^M.>*E8T;=&T&WX=3W&SN>;0H/]. 9&R"S*HW*QL$=+.VDX#SNI()$I7 MO=!U&,SZEM@<]M5,7U8UTY-+("&HHI&5 M>9UWLR9*I2S'WIGT'D(G_D(?KW6S#EROF^9$W6K?,]^:H3,\LTU M' ;OFL.0.+O7L^ICBCJQ*|6P19K^Q=CCCD>?IU7CF%-*$^34#+;G M> N-52GX$[MVM5;#8Y$3"ZJAJ;U^&M$>W8; 9R)[6[C*Y'XA$)@WXGG1R MC4<6K0|2Q6 Z%@P"PK$UP*,$(_A5;M/D[!_GY1U9GZPEGX=TZY\,W=J1K: MBMH-Z,<|"]IS#*-++XI;93OKJ CSCSR+'HES*M0!:W)X\B) 'C T_+&=A2R- M/ F8$;7](]=1/INF(HT-< ([SVVQLT0,G=9!!A68(4"=LM7$RCB#@+23]C*3 M(QWOXW>,/64+["LI,\BI':%[N6'[X8GH'-FKQO:/ MGU6KVR$(=/[YD0-MQ[PE)>W$]M0!PX-36-A%53,$]S3/W*2.ZP MRNOV8S]:GV(Y]U;1 W"K-+DGG(`\/+KWV.[O^D)6ZYU9-5T |^RC>K1K$+&]GU1@2-^NX^@KSQ:^773770(;F-0F$3"9 M]SW4AA4]PW+&@)0\G'!R?%]H3LG:MIX7S T3;F/((=1B?I85%]4Q<+6R6ID M+_ .U\^6Q@F!:1PQLSNE,)\MBUM2M^[?[EPZXA7M=%OR8F<[,ZLN22[Y7W\X.!'^;2F 1"N"S/>) M0%4N83E:B7NE_#XC&|5&(^R,T<|#81*^AT14$W(O8LB2XTAWG6?1>[0*G^2_M4]LB/@YN4T10M12L0(?VI\NN&0IS'VIRB[IQ3_AN[*TM]L"@:H9M;Y >S MKGRC$2UU9W\,(P5%O-+_-5K87"TIF3+0K[U!TX' HX"9Y;,I _^K4)D49^% M,Z(J89%;P#3$CK|&],S)'CV[1_NT:,?]M9(V*;,O':)|+)(KJYP5TVM)DO(M#CPT5*LK[>**KYS'IL@[L[M#2*M<;5Y5"4-!5*L97?3Q0[T5EVK.\$!M1M-[MY [ZD5B%NR%2@[-:=P4$'4N#IWTE'5Y%F%K, .*60TL5RJT8)L,)#\A0"+[":Y(3KMFH(P"TRYL=OI0P4(-5@U^V8RE081##6M#1*A3[O&TB]:MB%"3[EL"]*8 ^'IH/T26E!=+NZL4@:A!]88^C&:P)#$#OIL" M9%E1F5>58P4 OF!K(]U,]<+FN%1(>H4|*'Q#8XXVWX! -P9G94$P(;%W<(; ML&S(?;D=E$;WQX6-]"D^H*<#7>71Y(<*1T5[-!=ZG/=,$G6-O1!*\D/ 42%$]BE&=(#C](8HA M,NW*,TQ1$5IO/(+R4S_6)61 8/-.MHPKQYIVPZ5;M9@[CDTW5UZ6=4.#T!?0M"I$%'9@=3!93&X>G5NCC.0F9)E- Z9U N3)8GP6'LR+TU)\;]XK-C$"8(Z; M)EX*F:O[G/5K*T!0\=;#R:^56[--5Q&%H-2\R9/[9 XW5O^/]V]+=<@LWD(; M$F"WR+GP(_0U4]P?$YIJ-1^.Y^'DB;\@ IYY^&IA?5,U3=)P]3:AR(,]ND]O M|:BT4%6_N]&H12>XFD>O!YB8(Z6=5Q>1&K$,]Z_U,0'O$1:RN:A;5E9+24B1 MF"]"2!(7M'1MQU) ,1%6N7L;"(=D7=MN32+>|4GP#N9^ZATL$0:W;-VF$#JH M$2]%/TP0+V;I,C^XWHI814RY A(]P7*M@, DDK;:>T-/A$OK91M@$SJ4HU4P+G MA56NTF*D-)L60*&5LG+XLH0$"R7L&EX+#4@[DI9|*9S- 4ZT?2 .URO5#2'" M'U/^@-XXCNQY8['#\6?^(W[H'C:"D?U<3QD0VGF)#$%%6]^YTK>? |=7O'UC;KKHN M*!7&!I4Z2PMH1Y#X&BC1]7"\]PHE)OTMO(I%)<#Z$)'!08V3@Y\;N$#'LC M=1_S6J]4F#B5]83TN.(R2&@.4[530.=."SL:KPW:2[:6!MTH M:2RE35&],4!Q!+$]I"ZH\CH;%!?RUG-V2ZA_C7Z9AM1SS^,6Y/;9FPD9Q]8# M&.0L1DYB_X^_ ;8TCO') !A8WNR6=T=AYP^TG0AOD_(;VHS?S2/5:G.U6(MI;M)#@2Y.D35_KK&WIT:1(C(1YQ !-,8END-.Q&MU^^L$$/1K[F_,ZG_ 3 MF_Y$';M?2;NP-M|L2%<9D)/91*&:1KK1AUE.2:DU&/YP\8IQ3&5:VV4%%:! MYAY! W=B>T\F=U;N>6BW6;/ETR12L(FP1$P[L9+'!X" M|8P1V!]3P7V(-@M!|>_^;>G^W]'1U\]7'\RM^P4* XQ%2> "CSMVQ//CU@[' MA\>/WB_M,$2FW$^1*???/S%Q&ZQ[4L]]"?9AWMC&'SR2 5:NX< Z.S4@OX6F M/3ER[4F1Z^8BJ[2:5#F6O=O)VH7YD-AAE,W1|*FQ[\;,O)ZZMD=GK?U1+,': M8ZS>6Q?@=R+XGRW[JLFS\Q=]W$9!0OA3D;-E1N*Z;U"GS^Z4&9.A47V#]\(1_MZ1'"?'KP2(;#9IAE"$\SF|&^*SO+WFP^L$9S9.F^8:$,J>]04D3/A=V_;+M*M+EH)YCRWAE%=XZQEI^8;%^))F?L)/05(),A=-/D'5\0S]B%"\[0YG/R$,_(9 MKH59[A[X(G/W]73RE.&%NK$ <4(>*ZSW=CA^S)HKV"(;:8SBU?RRKH6AZ7L\ M\7G;9.[JL(^?,+-ZD"V73F[HT_Y'W>+X/37&3OF&U6K8S29^*D+[&G7>D5) MQ]/-AYPL9Q>!FR",BR@+Z$\>>Y@4EMV'(9^R9Q)>_ "U'^X6 6E)HS.D]B3MD'-XAM.TC]LIC;MZ3U[ED&1ZHY]=<$BQ4P;.R ON+*;3ZF2!MS)\AIVO&.Z MAY/A1-3KF&-T6A. MCWW,&&4U41]U4S5<(B,OH)RI7=|S_=P5;YZZWUB2HN&&C2S]:M3E(*/&$ZV@0526!Z@(+81EG&0%,5(0=\[FO(,)[D%CT4(8$@#, AGHD],M>7 M3OU.KNK2';1O<;SRRKC21T^|>UG5;1K;(U\3+/T@FSR-)2@B!;&*@\TEB4@K MS3WR>W-W\;+>-)N1R&[KK*XWL R/S\ $,YB<;=>/ %. .A4WLIYZ/HL24&/ M*2#R+NFB^"75/]@]2P\,6W .,$5T]LI079N+/+/3Y'M1=VZN > M,(8GN&CB&UIT/8MZ#WS2S]D)+@,ON:(;J+6CWI,N@-<,&ZWZSN[B;& MC_7O2P=,ZS)<15I,01Y>IUTE,I9 B.I0P6;&TV-PXM8> MQ[[X>2)3B1_ZYQ4#^18SNIV<@1T>;C3+Y16O10)P5,WGR+;3#G!BYNK&V M3.*

*RR;6]MBZ(PN2ZZEK;8+BA%V5T&R[+KH@H:V3SK.2(G[DGO0%*5]K9\$+< MB!{]%GS2/M\?N56FNSU_MOV6R&ZW>-)3T'K-(_1M=). MK?#YN%48Y]T9;Y> ^AIKK-__[>3TT>/";HD>#AU(0WZ!J/HX) / OH#[C&Y M_=]B)7I=KUF>@*8N69MRM.!|Z9WHQ(-GS?+' FA\]^CH/D2CU63YI;DTM0P01FT1LTEI%Q' ! =R=Z<'8$Y M@6N3^_M8"#!B;B;,--
>4'T'SO086VT(!LD%XY;QB26l 6@VE73>$'>ZW]CD@K@,K$%= M,9D8(;O#G:F/H4N$%FXZ82K:I7K-,?+]X]LZ TUY0U|N\|F<|,S9[^T%,ATU
MF^WG1.7!E1$B&>W:DY/$8]LK2/#C;=QQZ"HQ50&1M?|I258;|EM<),3#H^F MO,PV|YD NZ1(0OR+&N:0O<'/X/TN8.V88&#HN LXVFR,.N<3I)NW*P5H1*-
MAB+ES\B|N>]4;G7T.Q$DL'V,63B[K>,)8ZV 8D>CK["'[^\#)4^QMG*#) HH MS,KZU;;4\XR#HO\7\P[RMXF.$*L0WBB57=WVA-, MN*NG%OLP3#UN"7=GM.;T7N?|")Z7!!D5 (X;"
[3HZ4D===#0Q;F#[D EP6 -3&V'B[$LB#/;SP* ML0AH[1=MVTE;,;XNY4=F8/]'YVS A]/\:-']Z8>R.L')@G'XP?]H?'1&NHN MEKY&K R=Z/&MDZ,#IBWQO4$)E&9[F45U=[=]]M
9NPLE6O-;R[$V=TD$#OQ>GON? G M)19Y(;6]6LB%?%4CK4#^,RE[&;L0SFOMQ8L&#WRB-YQE ML 3EOV"Z+W,$'F3WS^<.,AT >G<)N>,KR>02U:,U/P+I??l:]M8).KY =R](M)V'^R$!S
_,=H'B\OY\C1"6(]8EYE%HC[/\P1<9DL6D4LY\JL73U0_1#" 6D]#M&\86'^9M5Q$UB?9I'5XXXUGY7!R M;NVUX9L^^W7RD_3K>;5AR&N%@B'L!GH2R5#Q_\O?
9RKDVEL;"VH]9Q74B)C8 M|F"V/=#_E/S-X>3O5C/X%M!7.6;=D[86M(N&#T-6TI\JGN[|>V0JZ[#;R)1N MYTTQ" 5&&HGX/S__=!Y:
(0L#X)N,ZA+/G"]^+=5#X41&KG@XU7UK!X6Z8&V4VT G^@G_M6]NV0MPPPD9P>/G; MM7MBH+0^.CUB6=N MD(6_0(-;1<'%TR( )&N9WN G+:,W=/K?KN$(;[1LR03&MA4.H-
69*0\ 3YX M+A#K2L59#]^6RTM#LKQ4B97Q>L5!PJ!1#=0\!0S9N&*!$'H*G,XF9E\6L& MEX,4P7W_]. I=TY^X]*?O@:M$$_K&52~>[G^9Q6WROT8-!UJB6,%TZTR2"6
MOQ'#X&PN9#> ^]W9+NU".P1^THS: M[@,56^>W>*B7;L%\+,Q38O26D@'; @;4I18-,,%0"3W2'(Z,(!'=,S]5OPN< M]$I;7F?.4YT71I*U;H2AT4(FM| O,LI.T[-]< DS
ML9TC/P/[EPVTZZK*9;S.R@.L+;/CJA(5Y0F4+O*_ND*N<]Z;-L7/V1RBORTD MV1#")V&^LL6VT:M$Y?(>RX34Z+O7"2; B[\|CZZ#)\|[%F^.* M^EM6_K-H-]ET|O.\6U]"Y%C1GN22P/7
M7]K:U-1KX;8& ^R^D'O5C:RI$N%\M7C3<3 Y57G0=L#Z* U# Y(1574TPR6S M#ES.M#^VE/,H[6: Z^79%!>"W4%WN+R>WGK%6;X(W) ,3#< _>) Z5W\]<2-
MZBAD@U^]#%,]C[8+%M@B7[+60*PG[(3%./RV'4[^[5?N,@?THP"^+V1;;%O MXR^=P8\:+RZMG&I95,GF+,N.^2=!U|@FXL9SH(W_(7!+@ (W)K5#?HFYJO M;7T2B2
!G9>#S]MW)SAAFAR/=OE]=.E$ L8$9-YT9()#):$'XL1/Q'+!./] MC1:?R-O:QQ/- M;;9#997;N/D^E(YU_"F4[PKMU^//6BKTVJ: M1=$Z?UE\|Z\QSW9OGV?;Y]GV>;8 90-
<9O *F@5T6=TD$9OP04RD&Z$?4,ZB M> D&WCK 6<2<9UZ))09*SX0;%YDQ%DD)]A2!Y\N,VYVI*06|09F4)"BY[NK\B[Z<,CM?$Y)Z2%TR3E#I
MYFRA|#B'E[&;G]>Y0GK^U[?%_ZM/>K]5Y,'$AUVYO1Y50$(]D\UN+Q1W,SN\WN\3U;K.?%# M01U]B=H+U33Q@*K XA0=.[;W?'## M
.)],N81*H,Y_RSY"S>_:.%9()O(1,'UC'KR*>3)+D;AUTG5,>V(+$ 8PZ5& ML%]<'CX]=--&1#AVC[+%54;R0OWHS!91B"= AUF;C<- MZ6@19X]WX^ "62[:U] >EVHPMS8D*^;SX1%
<"^TWRY'D[=0AI*=?69<4'[$ M)7VIM.!MTSDIXJ(Q:;6U2;BMA6E0|\R)%_Q(^\B >\0);TAA$L720H"-(F@Y MW'BEM7#,1U$@GP=[^0S7^V6>E61+<6 %5*;"E1S|&VAT\4Q):
BEF14H#RR= MKA;9N\H4Q8+W]#);UQIEQNJBWD,SPW#&-=?P)M_&VVH$=I0O^ 9*CRR%]09\ M##M!@OOTJX3+!'8?0]?%)O(IQ42./KK: .:.*[BFYG]>=^O&%N_O:!1,IS" MAB-
A.\13 G=FUP[W)LTT']S=QUV ;PW0:< MJQMK#B 2P)*:"XJ,+A[53;,0XW"5YYN$I5V$DP(.(%FU\.(X S.S#<=++NM4 MEE*]QZ4 $.\Z#P! B=?;@$*:
W7H.H??;5EX%^,M'VO,YT\0|W,K5EI|+EX M4B^X=WY(3X2QERLHPR-S?(X@MKHCPOCO"7"4X[> C=HLI$55FF>% ...6R$(MDU%I@&XEV74M!=KJ,3@ CC1>762L4#'H1S,OA*
MX;7'TTEFC-HQF)K-E15[1%H98"VP[$-Q8IS?U\H(8K1N+&3P#' L,MADRZ7> M]0 M,T=6ZDH(VT9 JR]YBY> 7-:C=;B4^]!#X;6I_O]>!?4LH^/BCD-%LE MV1!X6L&>-
LA2L!)U(82L*;MJ",:C)) M*/;+4NI9I7S?K8\.B\QH /Z]I"/HTOMNVVVE[=UVLH;RN>C/SYE;DY", +*K MN8V$KM!39V5>"]VX$^+C(^]PH$(]_>H \BLG3O@O^!5.Y(]Y4\2DE/E; H^O
ML M$)YO7Y535R8-[DU>7=2.4#T\;]RW 4X&TN8%3],SC5=N?^O:.[;A3W#\|N'3T017"=SUH\#SCP\.(DG,]% M6B"UPRWH1;K[GV*HWPFMA?NOP<=R_Q RX];X^OKZL,G_59?
=)I\5];5+Q]$ MY3H!],YF@^C)U(@MV3Y)+V:1;,@]3?UV*UF;4'5E_$Q>>()^?R4%5.8]/WNK MK,=/8#U^3,@*0E\|>^(I
AFW! \!D%VPH].EO7OW'F$$2S):4T]&";SP\OZBM1,O'/5*P2F'9@6@: M:?&:T1UBI0S+7]5T,]+[*.30R)-R7LC?>G<5@^*PFNMYM_K(CL<7@L+|T\-P M- GB?
__E]8_EF^/31_>/[Q].OV+2*A^LG@PN[=|-%N^?OAH]O#UV?WYH]'$PQIHF.Z-=39S4D8Z6 #SMJ7=5<*#I'V,5@.)9@DR%9K,]&X2;560^=L MDL*X9ISG,"=+2A2\;,V)<#AYOK1/-
D;CR01K%-)H(W@T83|(T O7)UM=3Q-' M@,C.]ARR!:223GJ8DO(RY@R-A*K_0 ,737C[[21]M]DET MUKM)@=[56.+90PB+0K$C:LQA.WU'K/Y(WT^!-"N+9KUU)Q- 49#HF* M]4!PK"
]EU3:GW"KM):/ZUNM[7BL|:T<"EQ+L HV0\@CC@3KA[AM2>[L)[!AT MEA>,Y(&]. A9P/VQHA->>/L).$K>905\+QIFGGD:C@&!? P)MA,|(FC9#;#-&1[, BUH)U'5%1$=DG
P32"OSBKK#YY%D'LA(G5^3F MQX&=G -=&4*]\\'Q 7.FQID]1!.&)UWZ4A!1^*('L M5Z3(S0,3SP|/SQ-F-VFO2,ZP%,T]]BJI- #M).X"/X X=>G?,(ZX#--#@@FU MDA8M#,URO<"#
(;A0"E'/0I3')#W&W6H31(B &C1*D2!?CV3=|32KRPRY%7] M1")5F(];&73FX>1#CK.=U[JZ]!DYLIYE]:XSK$K*%8Z]\E*;,L+E:36?X00M0M#5B:[[[@;D5IY()-A=[3EI:.'>;ZT\|^
M($7.NLV L_]X_!'N3AM<]!?XSEP-C.' +;<[4]\MB[?Y(G:5]EX39_A)S23>[]#FS[HFB)VZ"^\QI.$C?$H;^L5#]6 M8OTS5CK,.Z]?:%[S^LOYH@^]<4(V*[BI]MK;+O5-"<'4'C81IU]<
M<X?-/4/1#DRI;39Y'ES()\&O5$:)BC:NKU6D!Z MHK3VRFQ'WDH09I*52A 7MUF9&N""?5LT M0&-41V# V"NYO82-2%BIG;%\,X9E5QDDR;HWIORB>]-M+S\C&LI7.4-XV Z9
M!EQ7>=Y(V&H'EE-6[(PRQN_UT5Z>-"@\E\(*[;;%HXBV,6FY]NVY-.^ZU+YO M* +UM_R+4,.8VD%][GO0@<=E9+C6%VF:H*1!?2&+!-4#CU#/60'\$("-
FV+;SH"C"1D)MLD^WEMHE.ZSZM?(ZD&7'0QI,/IE2'B 4) M9XL/[21,EE/EC,SG_OOSIFY;=A#-#$+L88I]QD," _>';W_X$]>HW1@N=!3V M%6H&]/P9,1*IXCU3#^H,?-7GCB?<('I?
6=7F@WW5YKY[<]P-R;V$B41#19>2DG(YK)H%@<(MTV^ER7FFO#>LD,X;%%R;*^A)!GM^(XNH4#XB-G>&@ D"MRM4FS0*66> 9^V" M6TKF@,]
<(VT%.UM^)KIHF^<&>B2HM\% IGL!7LOV*8I=PBT%-5**1'ZA4N5 MEX+@Y]!]-S#Z4+9ZHZ_IW;^H:)%)6/]M+5-$6CTU-),>A;'#Z$1>F%/9R=.Z M4^?;7JE@!T0250-TFD?3&
[2S!@>"]EU$P(C-2G$T2P^VT\.'@C*9)\'X\8H1 MY+2]RF?E/=87&.OB:T+LM>>X]?!I!UEV'?&J1 MHK@Z<6DW9-01,"M*,NE%E05#SW]DU>H.36"7<]Q!D5<=WRH,Y*&.N/>:B#BA
M;A+H^$Y=%B*^&HP]?(_)WLT+\F*T^P4(O46C-:WIU?A"W?C$" N--9&B;#;=3RIA>=ZQ$\9R$.]T=3S.ZW>UVW MUW4Q.IE,YN.'F*WFP(YKA&HXTG;/DXMQET7KVR
[F]CB=$C[Z#OEP:&+!8[O MS"@B;G]DU[%+6BIH8]IAZ,/=D&47["Z+![M34E/DI+L[O9[FT3"(_/ $]BK< , P@-OM#5[;R&M@VOOA|*H03I7= R(M;&|NLW(S+&N_48#
[S#K;26X:O+6=%M! ==:_+FJ<&[6WH[_$8%]U32H$=X_(M5]F+X[5QRYX+K]S"?"<0ED M,ZT\34H+;$)A]I&;]I4HC=12CTP^>;eDINI M)GEBD
^;]DG;!0VR"KB9@;7,FO)&NU,#$TG13P"(UV[P3$B3,+L_88UN22U MC?-+;X]#[8-IHG[+K>5PW>H-'N1$*-0RJBB/'8"VIUX^_\IGY,/9#MAWK-5D MY+,KC_NRH[<
RG4SB/D(7'C'#QZSI^,*P5VWAX1_?&XZI_YZOK >DRJ8?[!E ML33"-<$"@\ M=B8PSU?Y>I/3O?+]97PUJ]1X-[EV1O'+\?';26/A MP?
M!BH],,;+*K]4H(=P_&E$=&K/UB,+V,P[2]CVT:W3/ MQMNP?P]2[FEZ+-IZ+GL)6 :!/=-'- SAG^1(2:][ZPVG:QQ>W(B,%>"HGN9&0 M+\L.U*'[B/->2](H3*^3A$E-OX6<,V#]%6CY+HO
P]<-FO?Z9R]9(U4DH05[M76HW&AA.SKRO5\6U[;5&!L2(<10@,(Z MK[3UU@ILLXQ""/XX9;2R IGL>+X7I;TH0906!5->E_0?G0;S>4+$UXC=Z20G ML,X;45Q$!@CK<9&WGSP-T
LA$'QY_[T2 /HG8DZ//G="X(88,O"VQC/-O4O M)^E2L=(V6 CD*>VQ<8I;X*#-;S-*[9;YF1L/:#30&6U^R4Z;/GP3]T0?QV&3 MI&4*R+$5C/2/4'UJG&R<|[YC?K'&44]8PPH@&D)+>K
MWKAE2E&T9:C)'<, NL80PX$Y&H0'2CME2L%P$5@!CFK8<2< A0=,&6:QHFR V MMY:I>\X[GPT"1<=,#D6MV6F'9ED]T=A=8*%2;L=,3*6H78 H3N'KUC3;\UAUK'C^L?
P5;5O0NICNF@P$ MC- [Y]2<16Z0M4J.I1 LOYTI8DD6AH(O_S77/DC&Q1FX-VH/E4D6-^T MPPV^G+R63;"N\^D- (B=0S5L]*[D>5:4?1A44FF[T.]>VF_$Y3BY#IKR/'K
M=",:RPHGR*;8E&[#]6^/W<[G;X3\|/>N\]=/-V=>7!6E%/3">H9+[<2X)=U7 M=95OD(Q; @+S.,ZVV*/]=3P19JATI1D<#X?"YUK'I&Y3HS(-3$]N7-K;170 MZM G>*7HCK.FV]:#
M8NUBXP&H#:4/Z49!H(>?4.4*TX%D(7V,S9]Q%?:O"&& A'7*-0(Q5/0#]DA M8=NHH5HVP]Y39U27S@P>M(C:Z26.]X[Y'"""&_7ZCH.OS6N8B%=T,<1 &P;U M3KN3E:V8*OB-V_-
<$OI#>T6]8>UY SVO]1&]Z-R35K5DF#K*?B$0T%(3A[FH\ KW"'D;M;FT_S]NXU>#H"NEV M# MIQ;"SV-KH.(X\BBH$&PP-^G[Q9$+A0UO.]+O3O0O?*T-%=9P\8UN6<4
MKQ*C(])#E=(.P[]I_4;N%@0X?$6V"7(YCN;$R/[(",'=!AL9)/OQ) M.P9<)AA6CW]|65_[UD00@Q$YPV=K%)]<9E=;]WS1)*UY=ZW 39!#7[^F!;GH M(69VZ_M*!CL@BP3C>8I?S%9+X?
P!UKHE0V%[W/.8^=GS)25T<*RQWZ2.\(M?Z" '+WSJ?7.%-QN>C_Q6ASVFOLN,B+#LL0@3>!8Q22[UM^5/]Y=E"\.042< MM W&310&IG,'/1:1?
8>O'^X2]S)AY*!>FTS!+H]5)UYOAO,-[$3X*77SQJ#\ M;M^_(C/:-X"TON!1Z9G9A]S\@OW#I\.(5]H9#*%N0/Y.X92T-M2$QH:O\@Q> M):"
[UHM1BN%QDE0B;)90$FX;L+1&#Z)^)@5;EAN45""">K'F45G;N1-]+]9F"F M'DX&/5['X;BUSYA98UITM#1K='CXI$&DX.6C?# 3MU-;U M[<5%-
T&U3;TT=/1)QA]I"=N=#]RA&3D6AC#"$\I6T5^SP\UP'@8U8+*2GKU^_M;2!DP6ZIR:[/W142FD::4U#47/)6,>!2KWGX->;''NWS8_0\V#X_]B=K+<6; MH%FR=+J&T<#=16O.UOK.+
<%2(!I-MLX[9V+[HG-?%49^FBLKOL?-GK\M6 XF M*::L$7\S/,.9:!)]N-(B^)X^C+MX^,@MS;]Q(#9NGP4:Q_&Y1VQMNR<>LB?] MV-EZ!)58\WF^%L 7VU
_3DN*RFT:$5P\COJ9++.KNM%|%:M9U[1 M2EF(V"MOD42%O)TF.S@B -&][]"-Z]R;@:"YGA3KTI]0N3"89I\;58X+7B! M_GWN2WG5YNGW0O[])8?(L%9;[QGZ.W\I(OY58,MYR
MZ!;]0M*]%!UG^3B/M(T+U")Z#0.':N92\[U9.ONM^BZLVYIGL, ^0&XS;67I* M@*Q?:RNMM*;OHE-16U[#(#<4K9.\RIJM$*"X03K'86/11@V8OVM^_MA=XX_O?]8-
P8(\2P@$QU8MXD8$X**6^*P%.[P|C!*1YZ=42;/.HN=&>3' M&T$E]CI.L1Z]#>HBGTNU\;&N)"D=]L1 %OO4<]%)CN*]2/4@5]3V\TOF" @ MJ9
!24=U+3NI*|^9Y2'9;E(76:64"Q%3&*G)1$ D21OB7@!F&C-Y<4<]E$?= M(;%10B)GK&LX'Q(5]+M_1&?XVK_1&\DFH;"5!=[5[3<9&/CEWTJ["*F2-N$(\
M28/5\0\;8TIJIW$]+"K9C7SR^(L^W>$4DY- RY^E$!+3%V[UG$XW?@@>)8V4 M1*'OD.R0DT]E/=.P*ZA#BJ6G0WKF,.D@ R9$Q1#!4+
[9=LW^2NAQGY94JG9"XH4#'!C/,+C!YIY;>VT"H3N< L+M' MH#B&<QD VIT0OL?:E=%00-!\EQ_V($].YES8, 1JF('O@KZB+CKFI$ MD1$4@M5M)-L@)]O6RJJBDLFT2P\W1
1>80.QPFZ5/XG#DH+K1BW#X6&;C*0$ M\)7DQA4)UDCP9;6ZC-^_V[T!H"Q28*.FP.)S_6U["#L"MO9 &+5G?%Z&85 M!Q)N$E)X^ 6,VP3Q'VZX&.ZQ/Z7X2";=-[W/.,DO^=I"1-
Q.3R9"L#FS[8#^ ME6BA@H@HH]N[5I5-@W0#DYA1])('Q6"IQAC?1C0S!3W:E01#TTK5V$#[!' M(L.-SHKFO:$L7X(G8A>;H#XG[0JZ.>36Q!?8@N#)TC@%KRX),&)A8;U*2588
MW+PP L?6=*G<0 Y*2%.@ZKJLNX9<#E1P88,#!9YNMJ3S5V9!"I*#/S)&\"(U4 MAV48W.O&NA$FY>_3D7R SN-FRBJI!V& 0R(C(>]P,R&& 5FPH@%PDC6-5)K7 MO7,A>&!Z]
NG6FLQ^FRLQ)M*&E&>Y%1N:L)%9*S>D.L32!FYZB[9[B>0QT3* M'"=WA6=!-X<[$$?+ND\]^?F?SY\>'# ZG$4\SXF$#3K:(U8UJ/IC"P?@4!2
MCY0>D,P7, ^5DX1%&%L@LK. >=O4WRU@^R?(5:$,JE*CTB>(IY-9M^'(F%QF M7 KYXV49)^+LIXALU]JO[IK3DZ8(C>4.&T[-%<]!*R) %KTV>82&@]6Z6 %
M5*%'Z]2AX97*6/H=HE.,#T?3'>U$$AX9-;XH.C70.JZ MVYNF(%-):$UU./G\:TU30@47@DD#9:;SVRBR;7&.P[5<+{($CC#H$0[H0O> M6Y*;+<-
K9OD%*QYZH8"NHNMP#7.M).CA6N-K61QIU,94@ MCSL7!5 QU<8G])7+R!Z='(30,8G2+.%/TZ)C@Y L:6]Z*MIXC[$4]46$C.H. MR="P$?
80)B!C$S+D]RERM)'%0;E03O]A1'@3C_\?"'=/>[N[;$ZZQ5'UH$B: MX;O=3]S&YU44,>IATK &7./QT3[9N$\V]I.-'ZD8;I]_B\]LJ^"'[\806BB' M:C.W,#D80>R3# #*AN!,9=J72R
I!$Y0TA'YZKB7U$?T1\QO!K#YPERGY\&$ M'\U1WIQ[E9V#$9VZY"#FZ4LVLMXSU+$*3.L5H9$K&QS@2BTN\GRGK&=M<&
MBLWV=;%FX,8'@"R4CONI[<4GL\D%&]/GR@"-2Z9W4Z>$O2/#G1-(&K) <3BJ M!SZ\S-RYG#-1'2PG^O59@KK";)/6$=Y$B**SHZ8CPU@+AA M'GR;WR5NAI>)I;=KVM-1:).
<@S]I7IUE;9'X"ZO\BX|(B-0C^':9_2MK%N33 M=;M@F=JLC&P7&JT:?]*852?EN[]WTM])NHOD"32^S*|CTU$6_"L6>Y&M@,Z^ M58YA'\-D%#DZ4R%H#-+_NC0,
<@#>=9+8B,/381$U\T5O/52I;>]WQ=SY)?G* MAT+&5EH0YZ:>+W/WO]&RFUG0CXY#+1GI.]HU;'>_Y87[=QL,[=X3Q2VSB>N$BFK*4F39I7R MJT\B:I0X<)?
4S2)7E.B&X73&&'O*.A(M-"'176/5]<&O* M\ S^5T4AGK. LQ*!T6",X7\8?7!'B?9I17:4IUU]X1.RU+;"20L'1/DY$I-0@ M%GT/=^!9%Y^U?CFJ-M/3]S(G/UD(,F>U]CSE3;;FVW]@Y7;&8-
&TMRIF\494 MQ[FS^1 .FSQU.B#'Q7&N5-'0&S1R5]DB'PPYFZ%EN'^9A=$6]I08I:E1]'6_W\ B-QOXSY[-6.D/#G]0H9+[]S;# M1U>$L=K;?9Y?LDKDI- K#?49(U'O* UZ$1 $'C# EER
8Z)1F6%P M66]O-57BOG'A"2E@T6:4!Y,MXN=3W1G 0^#D^9<@Q5P$N.7(SCW6\$ 6U]@P MOQ#./1[>;ITYM3)*OZ;2^Q8E$H|CJ,2\;MPH<*S%;")8*>E&Y-O;&^U(JI(U M\QO'$,
['E*GW"B6>'MZ|/7X_2>>NW1YFFJM&%-RVM+M2VZ\IZGR#1(2TI M&[,X@E2YV\JPBG"-LD'"P@|Z+T:\5$TJN-T*8L33E.[F#.)T>/ WI^ H+ M>?SXKH
#98Q)6Y]=H^NWG)E8"42H3L1,%'14PE%T.#DW|(>=L,Q[>=%, ^]6 MZC>Y>ZIAI%B>A'JF,.Z^3O9X$C0!Z0SG/IRFT]^'6D\F2]AX7]EU8@<[>9[MBA;U)
<%^&\Z#&+SRRD5PL[:Q/YR_^MXV5N(=KYX]X=#L[@Y]1%>B70/&E#-@ M7"F1.#WF_?7$.GD5@(O7TEQ19BKMXN156=(B(^M=1!$:;M-D59MY"F3<8#A'
MEAR#@\D*0;\!!9Y9UYLAZ/V W$VNEFI#00RR/9 MQT7ET0A$ $: FL1!R:"0%;^CHU+-.]/-K8TPI4AC"/N+*FG ;EQ0GOERYDPP
MM+SN46!FI3=_K06MV.=F**]RO7THS("YG.3CYV%*@@/DGU/,WZ,-F<# GH&\9<2C;NNE77&P2SBB:4M-!R"YXT8- 7838 M9_'9K'-W544*^C1B/?5M(26>,FGGC1MRG NVI?-
S+L2ND^A.B.8PA]=:01^& M![C5U*,;>^E^?P3);\4QL>5T,DP3&S^ %$ M0CR(R#BPB[//H)BK@<:*3>H>:CHRGHATC^YTD/Q:#"N)',9OGPGLYW\Y@VLX[M)<;4:) .U5PA4'
@:!8<[D:[+B1V3V@V2S38HV_%M7C3<3 Y57G0=L#Z* U# Y(1574TPR6S M#ES.M#^VE/,H[6: Z^79%!>'W4%WN+R>WGK%6;X(W) ,3#< _>) Z5W\]<2-
W/ X>&J]R0I%274E?W)+K) =.S\|F'YF\-AE 8"%JB>#%DQ_\A]=E3MK=|&/MFMPL]Q^G4R.5<1)8;JG;[?W)#Z8"@5UHG4LG109(U_-NPF#/CUY:'AF(SN< M/,G:RPE3=-
I*,011HKR^*%,Q(+^]Y|R \@,/\YNPL+,1D]SPG[S?%WW)?G6#, M,T&9S|IKO,JE'FYI?X 8Z"IW\VFMN^I'M9'Q9^5ZI*OQ'*,[E3[YY<-1;DD]R MO/&\',DHT&I7N0SO)B:7"%,W]R[?_C
_UROBXFO58N,]LYHL954QO\ SX#N M#^*ZA*FX2'9Q@W*S=I/4,K9HCT6%UVS$1@#\|!8 EP6KB-3>]MJD4I.P6@!YZ^5P$WXA7^3BLH8FWDPQI-ONXDB?BXURFE
M!]D7RJ?"+37(UD3_1N H3.1"GT-6BH!A#R$D*)GC!X|QB?/P6E\@V0 PI6S] MR!XGB^7;C+C1(=P&VUZ08!&;B9.7\3&Z4WU@4?UCM61\3"E?,6BVTQB12+NU
MNNNA^W'>/K/7'S$4K_ (-B+*+L*S M!GHG9I%,KE]/ND=^8;2NR])X?+B;;K6K)L;/8>V&PMHPB[\R=WNRS]WN<[?[MW.V?]U4V[@PC1F +$D8'(PG;%G>W)?9.CL]I]&$W?A.W#%:
(,#(G M"9F4W2)/3,0A$X&[&R\MC1V+ M"PD)A4H0V[0")9KIK' D9L3=0[]$A R^)Q5]8V[6G14 R;7]70I^((HM:EA(GF;|GS,KYMEC$T2R6X MO,0QCB&H/P4PZQ-X=B-'DK1=B;M-"%X
@B+#D$;\X#$T6W=2;"L:NEPS86.K MTV]7\,4NT1|1_U!9OG]C=9$:>^[7CO07A[&=\0W;E'^Y1$K(XMMX,Y _/QW MPW:F&V"]5WI*2%FG,C_5UPCW@:-)UZ%*[9E]:2 _Y*>
[N?/CPQ:.-S Z"\ MU.[=3VJGPVPHSU\^"?CAB,E2T|])SF-JX5NI+EZ,C$EUAR>G56KJ2"1C\'I= M .8C?]TM4+HP-V5.W,M^?359ZMX-?DI"G?"6^:MG3A_<_S@.&1#I[%X^)O3
MTRC)PC"SFRX(2^'OH;R$]PEY3E%1([5I\;Y'O"KQ1-N,-(VUNR>-]PM2< M&^_3^,NNH8O6^]K(8BN##>7 N"A7RG3US?'IP\-3/Q'"D,BEW0P7Z$YQ MUZW%P\.C-
&,DK=1T1:@ F]B1\K%-RM!RB4EOLK?\BZ"\I^[)>/2CP_OIDS_T M0:1:/>WP[7G]W,^%"?JDC=]\9SQ8V_D/0'H_LV>,I4L E-86IZA.14)B3% M9EO!
U6(C9C])7;2NXLO$$W9Y&,'YO3P))I$+$V4?>4JR*R ,8Z^*F\BA7'N M[E\X,.Z &^'[(A^Z0NP'TL$1^'$*'^?6T^'%C!! M9MQ/>_
&G[Y=EO5U^PG;^7P;S@$#3WBC'D@C);:,FQ>DI47"4!9CWA7R/^TS MD'A^*FT?*2=*\(:CU2F^[%SB<3F[$N2[#9A?2K>::JE->315/S(8']7=-$)7 M*S:EIW%;K4!
(06M3Z:YA:/YW,VT<4)4I&)WR]G1&18#$?-763/+G.U]\//; M,M]L$@7P=7)T=.+MA>A7H3S%5M@BG%[-L20H-CE@H<{)>,"5O ;<0Y]FR.B&2"!D0+FX8U5X](
QL>9QB9(D1K;AHA>84R6T6NTKA#DKE(%M9A?SP;X(_!XX[7P1D^1,= MJN_D&)H&1LN+T/#XFJ6+-32J!8?:UNR-H9@/,2O?N7*9&T]U.'AC+\RB*>LK MYPP@KA*1V^9O6_OX.
GC M<&NC(_=B-Y;9"F.61*5;R,/)KY553812@^L|>U-)\S:[IS]T7.0P% ;N_L&A M+QX.4=1EPIK SSO16E$#!.S,0B@%4.GP]5:WG>XS)/L,R3Y#\B6:W.?*+NLU MC= $#
[3BA&O%4@H0E<&K!6&H68$W_T04X>EQ/P YO$E\OXY% 5]P\T:-@A^C ME(8"GP57EK<IGR61/4K]=I(/0 ;(\&$259H7OR1,Z)75!!W-D@S51]VZ1"[M38;TZM(IO$W?
JS5OE@Z-."&)"^KI/:;CY![$%89@P2@B4-I]Q?V7/F!9HEU] M#]9;4@WI;FGG61Y?NS.]-^C)*C*4K ;M?9IF 0+[-W\R"\-%&C,&&+0!C&$ M;?2/K%UD_Q5<(A_4B=ERON1K9\[&C9[E+
I_Z,A! $#!8W8+)@;625N)!'&3 M885S94^3VM'HT0' 80.C-:I&LF1#'(K*F'DS[\ @M+(-7T/?H%"BQ_I#P MQ%H5*,L.MA_%6,]"0TI E("!T6F:EI^A7*M#.@!4(2R5#3^,!"6QTK7.D4==
MI"W?7".!"N*Y=]'9GMML)Q*<*"4QXC+BV]DKZ0AARP3WL>#MM)"]0 ^4O/X M10HB##17O8*2LX[]!O[:^ETM&+6=#K/M&VG3F1]8"T^;2;(W;N=WMZX>3/AP
M\K'$ZS,)54)+"JH8G=&3NFDZ)P$O?%WKN18=1H28_O&N.1N.0'ZVS+]VN+I4 MM6N<$)&QG-^MB?N\WC]S#NG+'.M@B8;]/.H+(66IRZ;0]FBH4'4A$KGRZ^2K@,4]?
SEDAWO8@# M'|34V:+T+#@R>';*570GI7+\IO67.HN?,^ 9E>APGV@T]D2&CAILGA&X3N6" MS;6D7L 7)O<8VK&-]-4HF(O8#C *KCWWD)$78%V/TCA*TF1 PL&S(/B/SU^<
MG_L,OL #VMZYEYB<9;5+5#E(?%P[YDECE^+*&5O3B2^[9@ 24KDJR$8I,9P/ MD;QKDO^&WTB@Q.V.=%%K)T]D=ER[E0]5LQW#$RHI=I,F8#QC[\^ M??$R,4G[L<1^W-
!^%%V6T5%B \E('D?Z^<> .;[%Z"H!.T8 #19T|& O"Z-G MU1NW L:=ICCZQ+=;>I9;?^6W M41]CB4IJPB0L/#L%> ^1D;8?33 $W]03*NU!;ZVFZKTN<|\Y#Y(Y1)TO_RGUM M?!77-
I,/7?VV&T]@X; MG:M03Z.&W%"G&B+/D;G1NB!#"CK?S:UHO4*XO;(N MZ&&16PFZ%"25^ 0>U\B;OCPZ)P]NC-A^Z67-HW NX79T&A_43W8!] O=WW>G M&=7]X5A0!2\D!9Z=X
>OY4>ZLI+AJ4^BLG0#DU!77ZC1&'2482@""ZD4WAK\ M+\/4SA,:XN$:L";5'M]CBED6; /% 5$5T1#8&JZ1BZX35RVDWR.GS8"Q$8> MOID Z]|A<"Y+TFC5/"DN"C1TI>TDV(U
KS>2E]2519_M DH@IBMH?'?C MS+UCBR>^]U$+LQHFB)ZF'=-Y"n Q.X,Y()(P]/#*T1(@6!=Q*%)82EKA5 M6K"EK 18&&/4<< LOJB9BM/5Z .6Y,<'O@"L;NU.M6^X1
0FR@YHW*5OG_L MU: !7H9K+W.Y2,NROA9",VD"RG9PK*T:OM!]J6N[&'W1!F;;J8D$+N0 K?:4 MVGJ+*LM(0$'E#>TLK> ^.EI[I8+;&*#$$V%71RL>[EU0F2TI1;>-Z9GL@!.5Y

M<67\9W'/8"725=BN%UCS@ T88N_[GU% (?4K_*0?//@T?3HZ @; PPSNYC& MPOEN)8PL\ ?_*%*76E4L]W#*]AT!;#,'R5 M^=VS?7YWG]_=YW<_5+\5M*7*

8#C),^=)^=L&H)E2FK'1=&!:+;JE\;!DIW9* MX> ^PH#D)% EFS84^P[(NC,<6]DY=6 AGEHNE%TQ7.L5!U]$T&6I6LN:Y:YD. M,K]_$%&.A^+OPH1#')L_FP_Q,&PD*

MPTO=4NW/NX,2>ZS)03!Y/F%_BH_MBG[ICM2'N]:_5H&G1AM2:X\';']I2*>6 M7-,O&,=$<(#_;'QB9[N+S^-&?V1Y^%+(9Y-@OL^L]W='7&+==^[#AV[IX>2? M"LQ<9?.F]MM=?

UP]=NJ'._\3Y;')\;_5]IWT!EL)'$>Y%>L> R9EQI6'13!/H" MLB-"KUM?6)/(.9RRID"8[%0!)XI-[511PH_*6P#>7 M-.>,7H/W>>)+EBKR.B#R*] ?;/G=+7>(ZMA.AO,[(4#Z2*)=3;5W M(*

[_ELV(-C2W.49M/#:YLXQE[,G/_WS^].#XD=9V2-S>"9;Q1;(^-R%4#MPGPT3;ZHP?ZHG#^N>PU'1OW/9,(R22DG*^K! H26)-, M@<@K-"Z%91C]$7TRK01_]]*:N G>I[_:IR*)?

<&MTK1%5/|[B/UZF:7KT!^_MW*]7YF?+7B5S;-VQYQ60>[BQ@=9>BU^=8[F1>VY]K;)>O0HFA32:#E 2+=[M:),B3T^$DT]#UOT4U$,4NX)@*4*P?"VTA[-

(@G"#7C<>;X%DB_3!4Z$;'MI) MA4I'UK0EA[?'220D!T0!*F]@B+B6_'YE=]OC2#&+%@:IYO,MZBCL2H> A MUW@7>Z?U4E"Q(:PB$)FZ6D5$:O5>&!=:5NI0!TA9$SLD[

CDFF+U6LKZG%[M@@ -]!#1?]#1#:5$EIVQ/+\V<5+%B,13W3A,L_3MB9&>9%]RM=X3%=H72(VW M DE:NO%<98L,"=NHSY!;S@,4QU#8C6?CMLQ)&_=ZU[@'//X19%&3HHTPJ?

=H MU#,0M5TPE9^SI*Q>$H33:)L!*![8,^UYG1V=[&&%]R6R+A>S:R1K;K6V\E? MS 8%D[D[.;GT3_C+Y$Y*TOQ0F ;A1AGKJ5K.<\[W>W]!S,,5>#I^E]!W41,2=Z_]PBG':S

M78MK$8A^Q[E"N]9*'1'U";S!HK4MTTK'XT#78.!G.:/FHJB4A%/%02@?T6A# MUUTA&OK?PO\"RB3%YL>0$JB RWHA3A7M<#\^!2393"*05,^5)$O&\0.IS_0C M)_U'-

A$BS\MN!29C=V4[RU'-&&V*6;W8BHK\/S_ _ Z4JE>1FIW%\L(2/U"$_'BROS7<1JD%AH%0VAF]I5HD: M+WJF^3;G2Q$IK]1>[IETI'B8%WXC[7FX;P@=RLL1:4[""YR@/';'K8;TP9#8>A

MRBU4CNB_]W"$IL&G",O11,1A1!+,SS/N(RZM7V_3$-K7Q(F?,^E*9O4S5:2+^H M^<#"#34+ -W$VVV-12RO@A%X'=5O%M62[:C$D4\5*&Z"HED(I#(("\%]T]3]3

M%AC!G)7^"R.W@<_#1MY]%-Z &SF5ZT<.M M5*#]-KTOH^N2+3Z<6P(DZ60#L@UA4IM<@']AI!,*E8-_KK6_'#<'-2#?9&L: M.U(.<3VRNI+/]HW1C|>Y?T:6E9?=7+N5"W&&[-

T!]FXKB6=E3]$E"^H)WG&R M5[1"\>]9P>8:K1 &M>8WYU"R#J-600%759;]'^X)!+"?}$(ZX^A(MFT9+T>I&B+I#&%9N-%/LXMW2](RR"2-/F9'=6BCE%-

ZX[60UBTF\M67R1A[&@8 M9D%+[Q32UC,]N05VW*I.Y'72LFT,$^\^VD 04-K97MYD ^FPV$6P+=[:X*R) MC S2K0Q9@K0. I^,BX25DQ) @"Q"D[&Q%A:NU%].Y"!+#-

^;@>IKY&!QVX* M3]'H'RV;3B"SVH5$#![ETK5S& D\Q(KV3[UQ^X:^1N9/>_ ^LT+Z>OVZ/59* M ;))1YT&8N-2?V8^@<:++VCQ666DS&.LQ5I).F''D$ N_38[V)-5E8W4I[&?8

MMWRE18_$XZ.@OOO:FZ[^/KBLKXVU*=+V;0@ 2*I(C7]DHQ(HL7L"SOOBIG% M#YQ".A=:19=2,4 ^JU=0E0VS:1O4D2C!-9N8 ?#=%;$O3=>(I=VI

MG=ZGNN]ZF<8Q%@O#@S;Y 2\?"T!>CX?8#R=_]_TA[JF2&53.P/_(H:;C:Y5A M2%:ESM.O:&F-;9L3R#$>9FJD:)N91T)[JZ[%?&9N+:ZG3 ZCQFJ>)Q=Q.#!6 MUUNOD=* D

2OBX=)^2HD'#I'>19$X(48 /D6=VR"Z:7"N _]+MR9Y[4VUS8 "07QZICRW!)&[E2G'4*-0LXLCI6B.G&]S/R):(:\4,(/[OI2QF!H,M$[->Y5A@'Z'74 M 8FF#]\].190:6@/7EVP C3 MA.S7D.!

[+LI/RQ]B,I'82LI 6X3*:EK_,F(E@?<68B2MS@OB56EYS07)&E MK>7UAOTF[.D&!A-E3DDY@E%_IV[<8G(@$A#:P:94GOBNWM(Y=T0^CBLLZ M":VSVZ'5X?1J)_&;.L(G(M

0+]*^3+]#=G?H#;T\//=0KV5!?R*"#6G 4E\W M@M3(M9A(GD.2*D\@&37K3*|=X_=ACZ>>Q$\] J37WL!<<:/T)!]!IL79XF4F "%%ZUB4=>+4M*VBD3L]ML M#$C0RV[N*:B)VF)'!

[T^% ?5BKTG3A7 D"N1UMM)Z61.4&U+M:#^]P,_#A4. M.YO0\EG2M?>F.(]#:@N'S.T:\#AB\L3=54CKUL(A_L1Y%-H"]9(@P@*@SQXK

MV4"^TOACYT4S[U8P6O)%#VN0./,T:\44RD9B!:Q[G>6&48%-?6-8HM%]U&H M),HB'H(^"OE")XINZIO Y,"$]ME80 =/@"T9MT(C\#1AW0'N B>Z9X[78:TL

M(&::G]IZEP]FVB=E0K#X6Y4U37VM7B0\3,QFGI>ES]3'H;8D0:][[.L^H]5* M@C)]](5&"NNN:9E?LFR]3L>=^'A&U3:Z[9(E8BHN>]NZ,-8:TV(&]*+7/>.; MC!DP:O84W6TT.*,

[@5,=W.N#+L_O4&QBQE9*2(,*%]PM V>KKL]M*4'5?]I_ MBI_ZAVI6"5%>Y5I[S2.5'N$RB2SA^]X+*[?>+)!M$GQYBR+MS5>: +R_3P#N M$X#[!,"?ME<6.:(1F%A0.5ZEAKZK

ZNK#94N@7=3+I8HY_<=ET8PPG8**+(' M+.%?M_EW]A^//\+>FX]* @(QY,)@# ?.5]Z[S7:QNLO7C: !Z('6@__YO

MC^X_>.1TSV81CRO]TE#8/T*$XZ:3,N;@7>=]CFE*2E*OGH>E,DBVO^]87FOQ MWS1I&!LGO>]B";[%QGW+G=X+W5[HAD)';-?-J+$@CGO9VLL694L#HA%VQ??0 MB$"^AH-

A%=%(!ER% M;"]D[RUD'@BD1.)/(<29]#+?R|->GKP|^2"@!]SF8Z9#[TQJB]S^SU#EX6-S MOO\'&H@78IHE<)RK0KED+6&9 *QK0^W<:&:'MW#<1R2$L =QO;U8[\7:W O-

M'HNQ%R>!=X1W%:|U+.71]G)R2[@|W5?W@K87- A:2,+$"%BOKFYFQX[%[ND MZ9-$6AEMO3]; ^-FHG<(V'9DL)K$%0H$ ^"F4& M<^-Q.B;I7Q)42]QVX!:AP&Q[39,@WY-

$(U)>U!UX_SH6F6)%)-.5V_U: M^GSE!CR8Y24 #$,(-D+0Y&%VK)(-02Y]3WUFLM(@)94 8-[.%VI7+(X/B

MF@"FS'M(2F)|$C2EH2>GOC|.RT0E4M2IL3.=M.L:AE!.)&..#FQYDO+:N\.A M18GQZGZHM #E@8+%,'B#0,8)PG')[%5%I%T9[#'>8HM 1^R)Y9EWM)QHF692 MW^]5?

4("T8C"Y9K$8=S3?&W(<(UVKLZ3NL7/K77X_7>112EEP$IZWK,$+1FP MRHM1Z'$H),JE3Y)>#8HKBWM|Q<./15Z&D8MFB?%/$>9IQT3C6@.?5992\!CB M%R&-M)%F#](Q-

O(S%W?D4UD//(BY82!,1^L4E(KHCZ(LQBAC(Z+1/> MV)U\=Z<0: C&FD5QB'1#M_:=&:1901U|&KFV9M(1OH=00[&B&*OS=|+D; M*BIX(.K.URI&PG!S*<*@?M%76D;XZ0"G"?

6,+*;Q(AB_(R[(B OL G)F'-%I M99;:T=@3H(ROB$"P>M@TIV7=-D*9M'"5 =+/17\C30>L"V6[O.'L1,?D)L3| MX>1GF:^":G!^>L57*5L(P3+N:1>A1ZAQ"0S0G[82;5*%Y1>P\26J1,

[P4M?2 MAV(A&?K|<3N-+U1_EZ\R:|+R&,*$F+YHL> L3|"BV"|ZMP5@ .(XM]W:M0E M.01WC1>/P&W4*YP94UZ<=*WK%8.^(_(PU?$+9YZUVKK)-C>X*E$MC>!U?48W

M;DVU&X9.$R&|(DZ3DAU_FR90Y]7EBN.IOON%MZ;KG@&=%XHH0@%%@+"FL+_< M&.O!P=3-4,>R$9['UE,6PA,:.X;G8[.1S: B-> 3>X'7C:6*S]II8Q/IO MM%K;B

^O1_LLI:=D9G5Q[*J1$^26*J=0 AR.B;F4#E83F+GF5%7;/Q!;J1 M H*FVF75)=7D@K(/<$*4OX ,FU?GK DKE';7"7M\L(<]F&/>]CC9RJ^,ZOI'>9&K0]F%HN"3,U6(^NK^1O+

MPD(P'"%|Y?YIU/DWBU8LU)C&&Q#&W%NK0|)WGF!8%>VOVC56&&!&F!'UZ>GR' M"O?.9Q' 5EH]%S4=V[1!9"[W02!:4X"^E N/&!2^8=2;/% K

M!TYX]:GO,C@Q.EVD\!9S1NIMQFNY;#,0]AM?1^04>]^GGN5]+.6 #DMPOO^!87FOQ MWS1I&!LGO>]B";[%QGW+G=X+W5[HAD)';-?-J+$@CGO9VLL694L#HA%VQ??0 MB$"^AH-A%=%(!ER% M;"]D[RUD'@BD1.)/(<29]#+?R|->GKP|^2"@!]SF8Z9#[TQJB]S^SU#EX6-S MOO\'&H@78IHE<)RK0KED+6&9 *QK0^W<:&:'MW#<1R2$L =QO;U8[\7:W O-

M'HNQ%R>!=X1W%:|U+.71]G)R2[@|W5?W@K87- A:2,+$"%BOKFYFQX[%[ND MZ9-$6AEMO3]; ^-FHG<(V'9DL)K$%0H$ ^"F4& M<^-Q.B;I7Q)42]QVX!:AP&Q[39,@WY-

$(U)>U!UX_SH6F6)%)-.5V_U: M^GSE!CR8Y24 #$,(-D+0Y&%VK)(-02Y]3WUFLM(@)94 8-[.%VI7+(X/B

MF@"FS'M(2F)|$C2EH2>GOC|.RT0E4M2IL3.=M.L:AE!.)&..#FQYDO+:N\.A M18GQZGZHM #E@8+%,'B#0,8)PG')[%5%I%T9[#'>8HM 1^R)Y9EWM)QHF692 MW^]5?

4("T8C"Y9K$8=S3?&W(<(UVKLZ3NL7/K77X_7>112EEP$IZWK,$+1FP MRHM1Z'$H).JE3Y)>#8HKBWM|Q<./15Z&D8MFB?%/$>9IQT3C6@.?5992\!CB M%R&-M)%F#](Q-

O(S%W?D4UD//(BY82!,1^L4E(KHCZ(LQBAC(Z+1/> MV)U\=Z<0: C&FD5QB'1#M_:=&:1901U|&KFV9M(1OH=00[&B&*OS=|+D; M*BIX(.K.URI&PG!S*<*@?M%76D;XZ0"G"?

6,+*;Q(AB_(R[(B OL G)F'-%I M99;:T=@3H(ROB$"P>M@TIV7=-D*9M'"5 =+/17\C30>L"V6[O.'L1,?D)L3| MX>1GF:^":G!^>L57*5L(P3+N:1>A1ZAQ"0S0G[82;5*%Y1>P\26J1,

[P4M?2 MAV(A&?K|<3N-+U1_EZ\R:|+R&,*$F+YHL> L3|"BV"|ZMP5@ .(XM]W:M0E M.01WC1>/P&W4*YP94UZ<=*WK%8.^(_(PU?$+9YZUVKK)-C>X*E$MC>!U?48W

M;DVU&X9.$R&|(DZ3DAU_FR90Y]7EBN.IOON%MZ;KG@&=%XHH0@%%@+"FL+_< M&.O!P=3-4,>R$9['UE,6PA,:.X;G8[.1S: B-> 3>X'7C:6*S]II8Q/IO MM%K;B

^O1_LLI:=D9G5Q[*J1$^26*J=0 AR.B;F4#E83F+GF5%7;/Q!;J1 M H*FVF75)=7D@K(/<$*4OX ,FU?GK DKE';7"7M\L(<]F&/>]CC9RJ^,ZOI'>9&K0]F%HN"3,U6(^NK^1O+

MPD(P'"%|Y?YIU/DWBU8LU)C&&Q#&W%NK0|)WGF!8%>VOVC56&&!&F!'UZ>GR' M"O?.9Q' 5EH]%S4=V[1!9"[W02!:4X"^E N/&!2^8=2;/% K

M!TYX]:GO,C@Q.EVD\!9S1NIMQFNY;#,0]AM?1^04>]^GGN5]+.6 #DMPOO^!87FOQ MWS1I&!LGO>]B";[%QGW+G=X+W5[HAD)';-?-J+$@CGO9VLL694L#HA%VQ??0 MB$"^AH-A%=%(!ER% M;"]D[RUD'@BD1.)/(<29]#+?R|->GKP|^2"@!]SF8Z9#[TQJB]S^SU#EX6-S MOO\'&H@78IHE<)RK0KED+6&9 *QK0^W<:&:'MW#<1R2$L =QO;U8[\7:W O-

M'HNQ%R>!=X1W%:|U+.71]G)R2[@|W5?W@K87- A:2,+$"%BOKFYFQX[%[ND MZ9-$6AEMO3]; ^-FHG<(V'9DL)K$%0H$ ^"F4& M<^-Q.B;I7Q)42]QVX!:AP&Q[39,@WY-

$(U)>U!UX_SH6F6)%)-.5V_U: M^GSE!CR8Y24 #$,(-D+0Y&%VK)(-02Y]3WUFLM(@)94 8-[.%VI7+(X/B

MF@"FS'M(2F)|$C2EH2>GOC|.RT0E4M2IL3.=M.L:AE!.)&..#FQYDO+:N\.A M18GQZGZHM #E@8+%,'B#0,8)PG')[%5%I%T9[#'>8HM 1^R)Y9EWM)QHF692 MW^]5?

4("T8C"Y9K$8=S3?&W(<(UVKLZ3NL7/K77X_7>112EEP$IZWK,$+1FP MRHM1Z'$H).JE3Y)>#8HKBWM|Q<./15Z&D8MFB?%/$>9IQT3C6@.?5992\!CB M%R&-M)%F#](Q-

O(S%W?D4UD//(BY82!,1^L4E(KHCZ(LQBAC(Z+1/> MV)U\=Z<0: C&FD5QB'1#M_:=&:1901U|&KFV9M(1OH=00[&B&*OS=|+D; M*BIX(.K.URI&PG!S*<*@?M%76D;XZ0"G"?

6,+*;Q(AB_(R[(B OL G)F'-%I M99;:T=@3H(ROB$"P>M@TIV7=-D*9M'"5 =+/17\C30>L"V6[O.'L1,?D)L3| MX>1GF:^":G!^>L57*5L(P3+N:1>A1ZAQ"0S0G[82;5*%Y1>P\26J1,

[P4M?2 MAV(A&?K|<3N-+U1_EZ\R:|+R&,*$F+YHL> L3|"BV"|ZMP5@ .(XM]W:M0E M.01WC1>/P&W4*YP94UZ<=*WK%8.^(_(PU?$+9YZUVKK)-C>X*E$MC>!U?48W

M;DVU&X9.$R&|(DZ3DAU_FR90Y]7EBN.IOON%MZ;KG@&=%XHH0@%%@+"FL+_< M&.O!P=3-4,>R$9['UE,6PA,:.X;G8[.1S: B-> 3>X'7C:6*S]II8Q/IO MM%K;B

^O1_LLI:=D9G5Q[*J1$^26*J=0 AR.B;F4#E83F+GF5%7;/Q!;J1 M H*FVF75)=7D@K(/<$*4OX ,FU?GK DKE';7"7M\L(<]F&/>]CC9RJ^,ZOI'>9&K0]F%HN"3,U6(^NK^1O+

MPD(P'"%|Y?YIU/DWBU8LU)C&&Q#&W%NK0|)WGF!8%>VOVC56&&!&F!'UZ>GR' M"O?.9Q' 5EH]%S4=V[1!9"[W02!:4X"^E N/&!2^8=2;/% K

M!TYX]:GO,C@Q.EVD\!9S1NIMQFNY;#,0]AM?1^04>]^GGN5]+.6 #DMPOO^!87FOQ MWS1I&!LGO>]B";[%QGW+G=X+W5[HAD)';-?-J+$@CGO9VLL694L#HA%VQ??0 MB$"^AH-

*MI&W:=&5]&QO8":-P4L<&#U++"00)$!1"\WLJO+I>) P^,$TG^&-B<2\@@<1B MQD Q|C]!7\@8(2]AU1S:\"*0P[W:C-4F$7/&:*-X?D(5X@!.7(#'#5IXA.^+ M2M&[C!RN:]<;4|%DIE,.1H!%GYPXJ9[!)H\)4_ RLL'W7YD%=H13" M2%8B50-A@D(D9<#9NF' $:$_Z,B!1E@H.PPQ\Z4O*52QU@N?>(ZX] M;4K,QX.R.840(H#$K1<1,")K@@])E)O'PR+ (D'L4'IXR,*!9PDI*U4OB7GC MI?/'BF#T !/S4]<9AULTZ,'L*9@TR-;F7-<]+NB7,_JQ('1!|CC"= D|A23- M./TE0!(-X\]Y,(L Y!" ,,,MRRV+4O.9EB1J[/)M^:ULHV:;)1] K@4$F\V: M \"}OLF:=N&)4R A'3=!C;%@9M)A MG(,OE3;2RUI 72^M8E\)(3YA213G4:D1.1^3)Q+=B$?0%"[%/"FM+9,BMP7 M@)W]4@L(VIX=<^R# DKM>/Y@S@$ AMM83\0))^RC3!\$4]22$X#1W ,ZSB(/P5WGL0/\-8MK%@4*) 8-]NGK4"BR/9Y-YA MV(,"[)9(WQ/!4-VF.+6"2[;=4!PY0KZ>D@ B(3WZL->(QZWMJL.)| M=2:XGANB2IH679#;VT;;Q'#65A2R.Z?(@]LJ]L70CO)8FO<4/1%2('3A$02 MP71!AU0K)SHB|@.!6?KB1AK99I*#WXN=T|@I(SK>GG^=-.VRTFHKQ^Y)MDYB M;R2]8&;B3RF]PXQ NC:8G)8&'Y <-5R0,@SD5A+R'#4$GI?YN(\N M^DX#=(+32.13I5D]9#;%C>]1[T@&+<*@AA6 DOQ?(S7 MJ^$#HLHEB5'Q6N8=@G^/B4XI@!R;AWE(:R>E,1N9NZF]W(W*W:C#H^?|\7=T"BA%T;I=0I.&)6TM,$'S1@XK)/][MNC&D@4#$2OPP|2Z,-6'RR%3%*&V)^CHGOA+&$Z>", <+9B3=)F2'4XZFBY=LV MDH85',=C@ JVQX7K5.F&9R#Z3K+W3)E.-J0$F^DQ.XP;/D^#5]2PBT=X/@2F M W=P0.M.^YK$!.!&=(8,G38)VG'Z(/9+$4.W/'0F!XY)O2\H">0HS))G,O:M MY\ 0O$PKH%)XBXYX@6D75Q%B\@?|P\B5T)!!DQUD6N+(GNT48%BR /)$XMXY MN;'WT^*JW:2XZ@"Y_$O,Y7MI"=*G--6S1A&9TN>2+AZI;4Z].,"^#^1^(^+- M)/F =@[;YV\1>,%*!P+GH/AJ MDK'<$,(L]=KGNXG$]S9+!;QK M\#7A[@ZY_D[<^>7U5?_2P(2L5F-2Y13FZA4MUIE$?5XN+G=<-H6?-S47" M+=!70A/+;<=G9/5T-\H >Q$&6,+.Y9|EYU:Q5=ML;L;"BY6Q<@[$^X.T]J\C M7B\5-UR,8Z'-BT/\+[A<>2C'!(WR634;W*;_^VR;# M=>E^8]3+V_TYRU8N/#9- QK)W;CZ]L7N2W#X1'\[^LS*#=MU[>W]!S=79B]NV M&$#/OV^)AZG4=['(7ID:6C=V5[B=4@ZVHXA5$:L2K/QPZZ3]3'RUKZK4Z8WTST);OW'YFC[]M8C9S6FYHE4P;I S>Y%7C MJ9FT!E?_:+5:H5&M:%IN\RF-;$5WST%WU4|AJ2NZVVQQM[00Y=DI^N%5]6D MR&YCY4:YL4KD/4?H.H.\WS|U;W?5BJ=; MJ#=7KGA>'G_P2>Y0+>F.EJOUELL>+4Q[S(^[KWNZJC=Y"K;1R M7WG=S+'5(?R?PK*^:M=FW2C^96]G#;Y-*

A4|PX87@V7@$!3;/CL6MS1A25;P]5UV]%5FNSP[!*E* >@=@N(M>KA6IELT7Y"\IQ MU%6.8 TY#N$(I#7WV#!;Y34VNRITJX,.#Y4OK]FQ_|>V191RE(U01/WL1,UM M>T742E!O0E7^PXB:F):1]-;+;#R82&O&\4;%/[',8|I=R>-|=NNZ0V9|EK$ M_/]0=?NY+63=GD#!7T|T4F0+26X--?N*YEXXS6VFW%MO7Y2)6D)R2 +D*.# S_MN=)\A*?

U)DUPB,UP|*9G+,+G]Y5R\U5%]E4 9*M\Y&]AV5 %"IDO:W472XU M%74KT9WWV/7/$'>]7MXVTE8";+KJ2(6P9XP+KWNY*:G7K6U?3F*-(KHI1#'$XQE"\8/2#UO?^^;A[*!O M'3^HA,&T6U.HE52NV*P;RYN8,RA7:0+>|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||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|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|1BU:|7- ;*VO9F$N< M*ZF_0M+?FA:MY4*MM.W-B56'UCEXUU]HAU9^$$ Z[F ZS/!QCP.Q7IQDK.! M3W'>8:&K5]I&.TFV4:ZOL&V.A(\5GZSXG\P!DH02L!V-Y[^)D[02],7!E3*1 M1I_M\/,I1@^@|<9PQL8DB"WL5C&IF'B3Y'D1-YI>*E9]OVO2W|BM&01CJQL) MC9EN- ^*U;,,;M_]SLD(:@F]T9NR7L3>.D/X*#96::H/1'1)%)):66OPUM *R/>?U _]|7)[EP4X] _O?]0<#*=C\17X 134R&OI^UZU!TH2#!NR%A?Q$!9 M4, ^#X+H[0#UKBV3'=EE,$KK^V'5/-^:=Z37%&P/6'MOW|7%M\^)9% S,CW>BP(X#$8K\?8 M+.CU*=''7']U|.,Y9^&C:G=.ST%ZXNP=M+NFK2GM!(PE /&2^B!H:Z9F'Z.7T[637N? #AGSX0:&#P"N#I-'\3R< 5!C.&PMCZ(OX;FQS=&/$1K%7A-HF?8L#=D M23O$@X<&K'$_'AB=(,GR,OT\5XSK,/%$#3@@25 MD]RQ/*LC!8J1IBUFVH%HP_O! <),&U_@[%T5(H4; #Q("6 O.D]BN3[>/)[E! M9&6O:J@%#&A6=+'GK@=]/<[N("FWHN6P22Y9A*+0[T5T]X 1(JO=V19HZIY M!GXP-(Y*)$.AAL!%8]0D6 /GKA,6^?O#Q?(^- O_'MI7]0=S#6/3R%ZVDAY[/ M:*6P[5O#=FB[?)D(--',6VH+BPW"!X;32UOB+T5H@;"3;BK9/>T.T>E@EW\ MDZN5<6LR4:90C -;0L< M'EB83\!B/(<8T-ST,73M(^[S)I&"?J601.)+- ,_/7X-]N7!;PO>VV11MIL@ MY,"P?>V+X43$ E>&C]V+M3U8Y2TW8# 9!G<8?E7*&9KC!,'5GLH[B>C!>K,] M88D<&;XYT)K"9(^IXP@H1; $=OR <CFC&7N6RL%7#]?"6T"K2BR0K" [2%D;V/(MTAT7*53C%4VX5*2 2BZ*Y\6()6$=]5:&,"[CYVS=!?GW(V&5^,+!',.X0 ML,[-P%@D#L#C0\G'B*<, 8-0]TCAD>R'GB'S@L\#;&= AX <(TO,."W(0AC M7#- H%DDU&@5#- ?EUG+""2 MLQ?&'=\)R8,Y8%O>|IG?A2'@E F]4\(\M"XBZUIV?; VP60<5EJ8EL,5 "1 M%IGK]+UO[<8V72G+@M@^::HU%CA*I=3P2/6?3[P_ ' $:2E6SCC\! R MZ%I.>*%- >FE6?:$=9QK!@ !/?^#[@;3H=@Y4%(U2ZOT7)&,NN,=0^]U6G|HY M(K[5A.)$Y48:9BAJ5YY_C7+>%*@WZ$35/-L-K.N69,D8L_NB.X)6B6^H1D- M(QZBE%F,[JTJMZ3@1F C$R'/X]^CQ/"%^(]\$Q&:UZ:0CV,Q&?)ZGSK+DQ$. MOPR9@=$!8%;@23"?.9 C?2#YL:S:INF1B6Q4FW.#F/M%$XZR',(2RAX8>+|# MQF(0#H",+F,B1H3R4=SE(ORV$6D'AD$2DS,#@7(4=8'K\.(9NO.'L$"&/=?= M*0$5^ U?(.C(4 -,T+U!.ID=!!&)/'A_BO3F*KH'2&R0U Q(Q"(:63[CS&J) MF,KR+2YD=,MZ^@T95"/NO3@3NK5H"F1B5+PBQS4),%T6CA'&I.QAG?RZ$MH" M+=\.Q+4YTSCCC+:8L?'+A[/R#,/.9[M#<(TB9Y*QC>< =-9AKDL,+8<\9VD(M7]:EJ"}90S0D!O7P"S2T. '$5S;9+D5,.3-WO8C?:78-7C8*;@X+;NI,$V." M"/E*N?3&HM@_IG BO%+.#WG85[:O$C)+W;3%3]8*L%4RL7W4V:";]G^(#,C]Y2YDV5,I4I4Q5 MRG2U=@!>?&/2Y72H*I)K :=2?^0ZDYT&< MX]1V:#CV$BIKSQ[L#) _),'*FL3W'&, "0XQS1S \Q2]=-$MC5> ."GP?0 2 MF$QHD<%%,S|&++=DD[SUC&0(0"SPQ'O)$H3P8YSO)$%)#F|Z^N)1RK7YH\A7 MLY|T>#R4>(]8@9&FX?(K(Y"%+)Y9S^*[!&?5"L:[N;&4%@70_W@"F,R#Q2H M@3R>SHIB$I48]D:QC 7\Z.S$F%6_S'D)I-42A4<]T,#XP=IM/+A:*[' A1L M ,WC *BI.945CX#6%.46N!(G@ C()X4K]@\C"1HD=U_C#/RJ7V"SF)N$^. V M'$QU#VO3*KV)X1 I=6.U&U]]&X R"&*# (C8.Q07N(IGM_$9<0Z1HK?B*]7D$ MN8@\T(SB(L9PY>7^!KA/?7]BP2"!3;*7(+$M?!,.4XGXD8<&/!7^S"/1W_2& M%%O(2#):U*WAVQ8 P0%4=@FS?O(1>U8P_9.O))18,* (,D79_B)268Q3G@% M_O7Q8<,F!ZV,)+HBJ3O)I<_(YW MW' AD6ZNR,9Z7=1>LJ00\3O/YUY &L=# |VW>&2-]BM9VO=HZ1P5|)T"*AFE M1\"W\,:HT;7-9Z.% (MP9W\TN;T@;13Z&M,,L/V5(GFR-.4(:G&Z$%]=FGPV MV$K.NYA];D"5*-8>C@R*/ !UR.G 6?I]:-%2;OT4 N@G >UV#.W(VCT& MKBU6,9=+>H/+%ZI%PJ@WA>9G:$5[C0'16 ;X- _Q)@3 Y^K7OQ@^ -1MY AVO' -L5@\:7DH$79'>C _#5P MW &Z0"#Q6C'[QD@0I:ERI7Q42]UIO8:*9CY(-' Q8^D1>&/ FC/<:I= _^ I M3<>1U'S 9C>XJ44\R"R|J'G' Y'|E@]UC M6O+$1B9/EY)@1 L I.:GA9UZ/BYK#2|/ LW9C;.L)4*5&74\##/R;^.I:<4B MHY743MI 80RE/^L|>'AB2:@.4D5I"C6R['761 .57\:6M;"B8L (;VBAY8[. M4Q@49"- ;!OC0N&:)G|W(VI]IU>AB9ZFH'$/9;)^.0L)X5:N/ Y#X^%.I*8)3 Q .\"7]G@]6$1>[& MNT H<|*HTP'C&-E)>/4!0)W=;$$(+3DPB -3N6CL\].*P,9T;K%\RPT'(%G: MB9+%5/WC%(H.8>KNQ:[0P]R^C4P>-E7R4"4/5?)PM?9BUE98&#">BN9, M16>2^(XZ<9EC|154H,%##QR_6!!3'+++13EM20[%HA;6X7,W#1IQHW,]S>-Z M0[S]$%2O,^5""7+>(U(+(E1RK1^DM#:QPX,$|]:VD]]]&**]7RZ](H;!< M.R[M]_^/+71;I!(8PL<N.O0#O]>*B-P&[N>4"L1=[8 FPCK/A.SAIBGB#@U@P^?NI[X/H,)=^F *81 M.@P]]B'81R?/O"CB[#E +V()&:+1A:X6ET6VB8|98*5"\ZTQ8:&= H, S%& M+,)G9'>'KQ!MJ&70B7DE2 *H%$W4BAS&'B-FFFS M%1,V&= .'&|<:,.?1$.M@:&;5K%> MWC:ZV>:[V -"- |UBL[Y5=,/[Y2W2M?LHH!C%HHS[?'!FNY$>QT%5!(@ M\B$;>BE&WB\.7-L%,3] N?U*[R(RK*7)0?*+XY&$F>]YWK?@D-X!YF7S("(T^Y MW_5/D\,FA7ZPM@>[=R1'A--CC!OC<.61I]>YY]7<$[L\6 _TU\0M1^6B:^)> MUQ]%ZKWYQZ8%*14-/\6ME\LSM;FEX6[U4&WJBH85#=^;IOE0K/9F*7A M#0 _!"7OI,"UL7KV|E)O-OCBWZ'XG:$O";2NZE+?:+-1;K2T(%"CZ?\Y+]=X5RRP:A6P_@C8BE2_7BL5]'IE&X)@!W-Z>2GG:T.= MKQ6;:YO'F/5*H51>N6VFR'A#R7C]P;"?U"]ZH=;0%1DK,LY)/.SGR+@&?D*M M.=]*^I-.KS |VNYB;YT >%OM89T1R!U0]Q6TR8A|^YUP]O%L_^+ MY|8M"_D%!(Y)]Q#R/B_Q72;WK 1;8F'G!X=6_<+Z.32+)=7/(8?GH=3YP7SB M19T? S"=>5#^'?.)%R;%)XD7]L7SB1 CN1.5ZPT2('LH-<+]4;YUUMAK#]Z>>RY M.U3?S>Y&> 7F=AR/7-GAE&?WY!Y)H=OIMZWJH%FIT"S/GM!1=*WH>]/INE&H MUVI*K!59;Q=95PIZX|>]3N0RK-8V33^Y7=VR Q,/IO$[K8VA|IOYD1RX X@, M[6@8:/ 1AKQF ,"^73BK]"Y+-QD-^P9Q<%&N1S/*"$V"BX+7;%R MH5G9BL"$X@C%$:L)3A0[C9+B",41BB,2C[C65["X=OW1.EXQ&4SU80@")HQ) MQS:(,%9N(6X3[^>G@#;'?)|C((/VT=UDJ[:")8@O%%ID8>:%4WJI>;(HM%%O\ M.EN4"Z7&;*?- #8]%B]:X%UYH.-OJ%^:H8"/+%17@"LN+,);[7&RQMHJ.M>]\ M>-N:/!MII[\#KPBG-]<2<"Q3FW9]0H*L*7%^ M611;@?

8;V+;)#0ATU8'AQ[=/<=Q/$R&%&P&"$'LP(ZUY^/<:9F,CKQ==B>"Y= MAH$KOK&7%#47I] DEW-]O>DE"X,BW83+8""#9#>P [\2 AX(!X'NG:^#-%8A] M>)N7V8J1:"#IVHR"9G#BZ? G>4. SOA:C9]B^=FLX$;V%WXP-WS?<4 -?T[ZE M_IE)^<6$1BX76]+(@--D)QRK\BI**:%R,GL /2X#3Z/86!%T*IE+199N(0%D M46JX*344- >$E'Y_X*^LE*H@63Q%1&%ASW+U5CH)T2)-ZNMC#[6RV?IP;FB M^;|>I?^3:=&:R\2\7SW\0A#@G4@O0+I$7[@"]'J &OT !IO#&=L3\08Z,:* M2<+S31(EJ1#OEHJ5VN^:]#=N:P:|>$^+A,;./2SBM>Q5+/&7]W2B%=02>J,W M9;V(%\,.X:/86%4O-FI/1#]3([R24LO?AC8 L?S?5]['<;([%\4DFUW/'QH. M'U8T%A%?O? KG@@K[@75V/;K:)D@P;OSS ;*@GH>!#=*U"">2I6_8;1 553@ M:G8;-+@9XC<&/U !VG7N:0K\03Y(8=/E[L/XG]/%YR]$X&[^A##.T09T211K M3Z7U[|5,?YX46-::NJ?2$9X!6)(>2Q]-[M#2NA/MMTI13U5Q[@\MT-S,9Q2<, M-QD%4SL"/!*L2R-;P &#<=!7"YX>WT:5S$;& M,:4Z6YT"[Y%K5#U5OD'@F;:!]#2VPP$?8<() @U+$W"##I86^C W'0!0&O6 MWH T,M=U/8:H5XX*<&>?%!7EU&)9(2ITV0Y:)2K6S)UZM >>O/>]>_=VD@I M,O7XAJ^/[1#$E#/=P_?$TL?W.Y(VJB=;&_1 7O59FIRRX1-"ID_@]/#H"9C MEO QAD8HR>W[I+I>RXBQ.;1-ZP9G-'MY($P]BGQ@8Z#X>^:HUV75\3A')(9; M% (_N!3WP|WO:3+UQ0N!ER\ ^[)R8|)4M M_52""]IY*I?P,W?:<>&/0E11 M:X-]BY883EAX:&B!0W NL B)H K*_^$*&2*]R'=M6"*7D.PFLD M)W1ZQO[Q1 +X(PW$3 =^O2DR< MD1\V BXF2A5\)7!/8G-57FL _.=,0:^]EPY'@3AM>C>N8UF$XAN^O MFU>?CJHK4ZI#+]8?0-5]'V-Z&8SHDI68(DTFUC+(#PSK,>W4,4R&PO1> I_S MSNQL1-7)E"!R/T2 4'H;"7,AT2H;/0ZX0A.S,.A39%IV9CE)+Z(*59) M,W*P@]JHSA#18ND.TF#GK>$ @3#M2.|@ZVV,LO8)F$%N"'N/V &/C.:#E+!L MC*&&VL"X154MK!Q$U< >!=R?B%PD7RR@)U1Y?M!P18,(0)@?,Q!2(="}RWQZ MMZ %D3G 6YB#T(_0TT"*ID<9OH6W/|,]D3 R,'3KAL(^&@]L>)$(#P/L&KL M8(#OIF8&O8!6AF&B|\7=,B"=I:<[[.#W##EV!RX|P:4BXS O%G3&,# .K'08! M^J-M|G+B#L&*<.%O,V?$=PZ*XM@#*:,C&],%W3*I[.0!R Q9'#,RG$>5OX.(; M[<^1@>1+D4[@+_CHB$|[P(Z.%73BT?73%T&[T2Y]II)*$BKUN)EHSIO4SKQ MB'P.[F&F]/3;3M#%)NTI))>U4TDXE[9Z^9&@NB0LM7C]W7JY4NOH MY5ZE4S4-O6,85KVC6S6]6F45T.N5&2W>/(B-@ /$-@#ED3/&O MF9\YY9/E]DCD-VOU:MEH5#]6H?< ^=UFI]4K]8 H&KI5[C9KI7III7B\MX.W MK+47>RC3$,C*XE\ 'PB)]MM/^]K)@;9[Q- (>\892;0F:B]#"YU(D13D+:B$(O_H)+:/HF(\BE&DKQS*SV#OUX8=)M MP]\>>MBY522G6])=Y6 &]K85?+I+6-^3:Z-7MN59LEC=T5SJL*G OGZV&NC/2 MHU%,-(H-(M -W^SPKQ:SP#,=!UA.Z4 Z(OO> WEW7 :SOC1GM"K,<&GAC MZT\VQ!"TNX9#NS]#SHFSP$-C7N\0'AXQ>N.,]3& X#,+Y|0H:OAS'@4?G>+Z MT@1:.D.<-LBDP>V/Y0]#^WUW 8=#.D>1T/8OZF1G7 'RX3U|T7<2.DT.GH' M(]&=*Z]3[U1*^*:N?,GSLE>_VWO^MWG=^\0#@ N1L?-_BO--8:P"8O9:]I1 M98>>?PO?O'"*;[|CP_8[3M* [JQZ5:OS0T:^^^WWW_]OV(?7[USSNJBKX8>+X; M8D;_TZ?3O _,K.Z?O[1G6.XGD=:6EGR^?_NV^RW\]F7_G7G0?ELO?WX7V&W, M4XTI^/F6&>9 3GO/+OQTMWWR5CO<>_,<6T T'UK2!NQAY?V?UN'IR7;TO.10^WIU./E:O ;IG (/;':)IOV?,1S|IT1V!T0QT3P MLPN?(&>/=\;MT7'U,8H/'K M7!DE(^:'P'<>KT^0PXK4[=K;:FP%C-#*.9< MM4+%V&?Y5Q7QEN- M#>;ANHASO93X:XF_2U'LA+9 MVTFVFR&R4Y=_5ZIB$?5H5(X6=.I-9[-:_CE77QY5RY1&!5A$X?46E(|-Y!B5 M MD>!5*I*IV@=(+2"1NE$U*3WNNEO38ZC5:E7%F|:I I-T$I>,D$I!&P[,YG M_^8&U","&E8\MK6(TBC;K%%]2],HC:(TRL9JE',\US7P'(OYP?Y-9*]2%*=6141T.I#]4ZE.K(O>HX/KG8UX ;%Y=G^R<')Z?[9^V+PY/C\ ;QWOGE MT5'|[.O)P? GAN^/#GU,=>%*96EG<>5!8:8-MU@:M)V\1_K-CL%ZW4VV66:=5+|%,\1@FUI+ M=8UZYICM(PXN/,$QV\>8.H&]B6;?C4Q2X ->)6/5AAWE? 7,RLE#W 9QUW?O:90>"|

[;'_]=VNSL1[95'9^;W4[IX]#=O1E_K+WUWG[NU.?LJ%?[M=WC[=?=@]P]_W+XIIMQ9C4_=QJS3^Y&I^/N^^N+#]=QVRIY@80W:M^W>?.ZW9 M)Z-/Y4ZO/ ZBZ_-A]';|^?#DK?*

/ZQ6%Y#HXYLZ.[BX_M#[N- MY_9UW?O:90>"|

*L9L%F:??3XI.-&'\S=V]+5\ MC"?!]',W..OCHS,X;=P=?+^[_C8YOKPZ#,WCH]*G\OD=C3[#U-.R?WW6V>_W;ZQ)Q_WC:]?=SX:!U;0T-OXZ,RV M;LI>_>#PN'M1.O=.*
[L+^]==*XY(>G=F6_VGW^+;^;R/NN5^_>#_:^V9] MN7R[U^^4YY#+@>TZM]'^!_/ZZOKFXLMA[>;LYA >G4,N;LWY4.[>W, "W,'5 MS=!NT??],CPZAUPZUI?OH^;1Z/!R]\KH#
>M+V_U(0B5.3PX;#?U+ZW]#^]! MJK#+]LW;QN?6>]C6',2ZX3HYOAW=>] M>VV??MP_M-ZU[\]E=]<\!]'?@UIT>'16.]S_>.SN>G4_Z.O]_(S71,WR|MV=
MZ^Y_M<>79>,FLC_\8+R_L\:=RAQ@58X.HH]7E=YZ>;?]7 _>+WZY+_IQ?{.,ML/XUOI_:NO'1*TVZ7QS;OC>0:[IQ4[T>]'L?]S]VOE_WOSH??A<
M@3'GP(7]T&S].+SP6M=&^/7F_;_='AO]V^J4YL#UZ^BB?-7YM'-S:?1.KB]^_M?OMT:-1@U#EP?6L-WK>/_[W]>FU'EY.S??K7F4?UCH'KH/:P9=PQQGT+V^Z
M7^ZL'|X.E!S+)UZ4',LG7D"_+>VRJ?#R2WAY9! 0>|WC M9RK)O@+]S<<<6R7O:%R&?QKYF>>5Z (\X.!^J0*X1G(:EF<^/_^ M5Z^7_IK]-XD+Q[L'MP]!\M]7Y5<_*X)+Q7H]SI
E8=_1G4;8T.+<6\ZG;QGP M^-&SKB*359=)==O(D(%U.^)Y?6VQOTU*$,,MFWML4H M0QF@_@HZ]5/OZSOWTQ=68K7A0;=4_QGQH-[^<UQA)EXJ?!(S*5R2[.<1.GAG_B MGX?
87)>]NDZ93[HV26*6>!+SV(#[CM&\'HW'[=NCTE5@]W;-1_>1[,/L']R M,#RD?,/9P/"V=# H]W?9U3X[_39H#C]6/IRVJ_^ 6*9>)GQU!?:R/"U6YSE MKXTH"(@^L) U MG?
HF<)6_70]:4:<9E897]>I;O63MWW|\?!_5_/K>5U[R\Q-[OSA^>S<\/[[= M*]G?2R=[!V>E,Y,!J53G]C]:)A2^=PS3 C3W?"IC[$*@=!D&T M &
(5KQ)>L=_6=O9/;IRNWIOPRG%IN%5H&-# QW;W&PR@T_DG)W_Q]ZI/BG])O#[\!?8,/;&P*A4 1\!N8CZUS]5]-WVZ'3W!&B+6ANQ|^VV2ZA+ MYJ?LK>A"< M,*C(YO:371:VW4???
L:0<)'4BW#A_"+6]TC$!3^C5VIUDV-R)ITQUIVQ->EX M50N8S2C]U8W"*MEGEHAMW;2/N!W"GWM&]VY[4M%'O1G1'E:F95!+]R=)!C8= MQ_.@:
<57$I*LVVCTN@XS8ZB]QJ9X#&\PX,Y^Y!|-.VDM*E++,MB;U;9Y!;T MFL^E;M$U_-.!:VI%R=IZ8L3WYNXRW1"S@\4&#IPDB"?BL[[AUOK?%E3V/1?- M$LHQ=/N3^9;7Q/- 8O-
Z#$\QN"YSH*!M>;YTFM$QEC")T(/<]9YZW<]#_ WM/].W/]V^NU M,A /*H:\]YHBY89OHM]M.EEOU1S$^HSU^<9.>&]LN8']'G0D(E]-AD**7UW;B5]^ARL5!2L@'29Q;:4O>5UXN#
[T.#D$WH?.IJ7++=BBCS7/=G$$4\<\8S< M2<*-&0\OVM6 RE6RLEO5.H$Y#'#]?E*M!L2B(V8(;Y$GXI6QE&#"5%H,\40G M+VA(8!6]716-VJ'$C=D#'U?
1JI,9NKHP)WA_NLB#OIQ;MRGMKIO]P87]CH]+[%_ MWIAM]J+* M+D[*$BERRHUZ *M;D./$'KR"L(B' >X#M.(&,Z-]4RXSD%Q(HK MF59Y/>\,"4Y*A/G.D\?Y;?#5> P1CUBEZ|
(0<7[;Z'P0H:CC=$'7WL* V- CV(+G[(IJZ .9MGA;P M9-T"*B\[%IPY]T!/B9QW0[0" ?(,6'Q@O% M$D_I%'-^ R8R1OVK',:NP6W\D-&; /?
N3GX,>W47]^JN#1+7Y;%<> 01BH.? MW30*3\1W>LV'^GP""/6!UUA5.6'"Q]/<,M5K^#H3YZ3$-K4Y13X1!*:[8%C MN@ >:&F%@%2=&2_4(FG)/4NL^=_/1FNX 462 %PZIQ#D?A%
M/[=_>39_D8'R097]DKYV)B F*X@F)%MK="?1"E/E0TL)VDPQ'7YA](3L8\=# MU]"\"7 !DI?0A@|/T#3=DBU%1\$G=_\WS,'_ 8P#^/W4OC1$LWIX>6L$1>]C
MT_R_]K[\^1 S4_ZQB@ED!V*Y-^O%R^[^K #1(+XQT44_O4;4?0>ZI[U'94G M^]*Y)3]NL=N1#/_]K\,9??$*XXIMVLZ//9(>3/5DNW4"ICS\!\Y0#;BL@9G
MXX=L!O+:W3L8$*7W(/WC&8S1VL1(XGN"^4?LX&$Y#XK\CLZ:9_#7WVMBMB#_|)=,)*G&]D81Y M,_[P^Z67:)%?^AGZS*\X);'JGC]ZG6[G;0=M0+&\CFR$V !*F1OC+53W_M6-
MX[#GVVN|U^GK+|+RSY(5ZTQLWX7]5"E%!B,ZM9.AW3=2=(),4:F4I $5ZD\" MD)(\@DH$2)H8)0!(473BU3>0:44W-X7!C$\;E;I &9E KX[+8XF4CEM.O]GZ
M?!5D>&$B5:3BH++9C)]P)?MKRSD-2!<,EU-'6'&+49DH$\G66*(DXM>6L\E* M7XKZ]D+(24X9T%6BN)E!P^ZX).$6WG#1D+E-9Z,G!9 F:$GW\]G6^GO=3
M$XW@UY8YF^M+DD_I8XDY;KFB*^E!NI3R"+;<[F=FJV5?*G/0FCYJ&6R;MJO6_M^ E1\5,*'9RAG8%C3QZWJ&:D22_==7PCRV4F2$N]$5A9=!&(M"XNDED.RD,FQG)0^;IEU%6DP]
LMD>WV-U/1S_.^TX0MD[^V+%)5LBD$#8)8 MV]U>30.#C;R!ZTX6?CGH348VD:>-"FD5:V6E$+@B;'IB|E,\G>UTRIFR4="3 M[&Q=]94*"9N>F/YR:]&8URRV2518CJX,XFFZ-
()|/3&K*65F\H.&0A]"/Y#- M 9L.6&6,FAX)7V^1'">3I []]DJ65T^W:BGPZ9'TK>66L5%-9LS1'T^UOL% M>CJE" ZZ7,<=R$U%RK6E=B!6)HM4KI>A!N(**M2)>952"
[EA<5V=\'M=C2(' MJU[/YU#3H[[JZ\TR7<\8%A_/ZU'+IX;$]WP]4=]?96;&W06V0(:CW9^,0P MW6OUX5-/K);+S0EMS5G *"CUT3+-M[J^ N:%7HB#T;AEM7&Q]%ICQWP8_]
M#X?HB^RHG0V%KEE:X7L3?/0:)-]S]Y_L+78PD[>&?8'WQJNS;$U[SG[CNU> M2&Z-[ ]&OJGOU)N1[P,3Z>#Y-GRF9MK!WK+>_QY'@8D?6S,8Y;%\U_S<>2GA MB_=-Y1'C-CA=
<'K@M?E,-I+OWFS&*_+===8E M_9UX\V8L7I>KX5@2KTOTU@7C6#37!>/81=?E3PD[[[DMUYB$SYSC7-06_2HF MWO&_=S&XOZ$L*+:)/OR_;]2WSVX$Q'>;B=0=CM,AX]=3-
O]M1H1)*>G_ . H M3)+ IO42$!SV!\QZO;N#,H;Q\]#BP7N,#:K3"^WPY%W0&A. ^=O"U5u24B*WE,Z.?7^1 M8^6L32$WSFA&H5DB[^<AO&0_%5?
XM8'"6FGN!"WYKQY\@=|N;3";;7):& M1B6=3Z<638|;Y1&SA_[VDV&>DO2%;JQ>V^?%"HL5]H,*2QTJ;$("F7C9&*E: MF1]HZE;'1/::/ WN3?^3&$7VG@@"R+O&VM_DLW+
VYI.!Q4V.2WGW3B*46^ MI; W'I[8&44%8 %T*0+91+(ZTRW=]9SPI.%>'7DAV8 >W]^X5U/U^AVBH]< /"&E @%E'L TEZS151*R&)AU)/|&I
M4T7T[C/Z@Y'EJY.08,"MXD'YYX#!5[5.,4T(-3Y;6Z>+5CRE$;,O!(PDNM_[M1";/6=3GFD$U,C5_24]B'YURW44D"@?5_AZ](PS55S,"8,+ E<7W?/R^0VSW M!&2KCE@<:AO-
)2C&=&:3=*LR4@*)039>DGBB*1RV>QA(.+?UAC7]]TRUCVBZ MW0LLT,T1*Z+0 .G)DD@' [\)-3T9!NC3Z;>|N1N/]^WLM1<^TMD**$4P"H9C M?)B*]+"$C;-G3+^2R?
92]N6MC.G.DA:8U&H1)_29WIN.O\5,+H?2%/S>>CM/ MH00[V%7)\K^GA',7^N0NS_>M\9/*[4-CK#^41N3#7,L0BA<(7(8 _U[I>
M7Y+/;#G<@(#>>%1CRV(JH:QG/5"%M.V6/1VHWR*6>!\ .[(C/I:"H]G(;I M#XZ&W./YU1[9.&M;%W?K(YUPB^A H-<|=Z'S5)Y@0:]U7A853D]A, C]E$IB MGA+& XP'-W_*]6$\4+,N
;2R:A@"*'6|<2_O@ '*M(JH[4\4D;H3&M+6 $1! MHYCFV+.8,I&M,8#F7TR3=2>VE$T_3/@=R(XC6QZ<=T=?AARNYYI*:QQXP&.^ M&1<5!UNN<,2U@U\I]XP>)OWHJN
M%P|+,FO:=@R9[S='K+/1AAQ*I@W-2.HIQ;P97.?|+HPD$4>28W.PK)Y(W5M$ M['V#"$&0BLI-7-0BBLRTX)!9!- N@I=9HC5--WGGYS:LLWTC?H=['I+0^O.< MU%IQX[Z8+=
<"}VU#TTAL7M5"JU;SV44'6 ->6+!.=V59Q59IC(]8H"P3+"8[M81##('8+(/9+H/!R(S;.6]-A+V%*!%7P2SF%DOLM[KIN9I4<@$4K:!F\KS<, MH4C7A?
HR0""&6%SW0N!Z=472.L'C.N_Q]%T0)ZX_%'PM*@IS@N]/??%)<]VV MI'=,W-]?S/0+PAA5QT-L,9]2+(UO3#X*-. ;D[=Z MEOPG&L_G''D]5Q26F)7XBI1/39?
=55@/>?,>9TG9FW"OEW[9\[<:(8XDX MI!]5:,1C34,D64<1F!<QVY]VS6Z6>FMV(5(=2>\9?&";RZ;$AGFPV=33S23QFPR# T8 M&NXFE<.'H2&5-%U1D>"RRS99'8P1-
#S/_(IF3I.D_K7AX"1<0)V M%B .4*/ T8%?Y85QE"%#"6H*UY)X"2MM7A-=!H>TWFSM@ BP7|?GWV:)0 MG.E.4D7A2!. ^G'2OEY,B, F/&SMYK#'?D[#?>#2 ?3X.\BT'P
YO@!H;R[]U MV!=CMA6#WS2)X],$%/|R(NY0/$=W=//6&+D^[N MI57\ BC'W;;)]^C1.#XC5Z(MC1$T);_]3##DO=RFB|BIV6.ARR..&<<%(K$E MX" 8%G8L['<>!-MMJ[J,I[NN4(?
C6[%V)Q/03U)M'T58A7&'FT M7,3+!]U.>(!Q^$A'"K!8|8>|U[MS#@\A(7]883]QL-#VU?LK\S'YENF\PQ:<>Y$=L#Y],T1&S&.$D7-WWNL;;C: M+8]H30,.@F"EN%>EN"4??
TN5SLBNKH2E?E7=]#V@8@<6C_DO\F3<;]#VVL,| M:X0VIR]U%83QV=#H=R6V80|*5K4+",#,\B."&E3R+'?FPQW]#Z*TO.Q8[T]6!HRX1<;/C7]);"(I"H,)'RW4U';@O7GYP0 MB?
KVD_R>.)5H%B<(M?P'OT"/S[N"HX92NE,%B0Y-]A!A\S,VI-X*S=& %46)#|&G#\TNGX #B^,2%;<"2,R+'YP98)A\CP-%Q_&G!0Y['RP>#0(=82K"7W M%$O(TA6O-TF]<|/IW8:!
<= M3]XSWK Y;[,&[Q=66G5"Z-G>N8 ,_NC"QIXQX;9^23UT2P0M#!6[PHLSLH^B M_WKS@TC,%G9>8TH\( ]IZ9#A,N;&DV!'WSU9O-G)V870C^;HSZ8'A=(9\HEF
MC^N0XRQ/&)\O6OPV@L./&NQ>[I[=W\)N]R19XT8C5>)U0LXV-;Z@.H,05[X] ML[S9R?D#V'UC>G:P>^H>|WNEA?|WS(QZ 8%7)QJYU#%3E\PW.=6H^8?OF/X M)7WM3$!,5E!.>-
E:PQ6)6;8'GP_7"?I>,1U^8>S(9FPN.QZ*>'H3X (D7V& M.!F%137=DBU%AXW@JGI@!E_B?O^Z =5,9(=;_^K2WVR@JK[\^1_XS_YIB@ED M!VT=D#W^ 'GL"O62W;Q+$/RX"[]^'B&
[7QHB7__\;I98[X]S^?M4/&GY\P;=3 M&?[7XV+/(_KQO!$G0DD@OB>8?|0.?D;#.EK@F;R*RSC;O _>WE?>?6W_6;CW M/G]HNSH"PA\,_"'^+P%Z^]OGAM+BV?,?%/D=A5AF|-?
=P&CR>Y*YD/S\HA") M%VGYCQR;.&C+^N^.D#VYQ.AGB/)P+S*WCPVV_=U]!-$LS'|-<2]+=D (1,\K M+G]$@5Y/|:D9E,-M2F+H))-2X5XZ8M.D1+,:*;5H2I4 H A&29+ID:I^V|[U
M/+-V.-J1:;KQ(PWI[*M\]M?BA4Q0[_%"O5LUMDW@XC>P#CI6?LMK>FS 2^!3@N MO_#UZXWDWRC?T\%>\])+M,B' 40:3B;_'4/|I=9GA)T_[6 >=M N&4F'OR[X%H,
_Q9##&X8RD0EVQ;[^LV3%,A/;=V%?W']=9A^<^ZG M:^N+;-H[;202K I&H%$$-%F3:*B2U2<.*NG>N-6/]N4$L@-GCS-/H]%[4\[]D>7[:R[8RR1>2]5Q166F%=(9#31._M-
JV*"X[MMMFBV%92@U:Z4%AKU;#IT:"]R4UY4.,]/+|PXX..S)0UNMG;|0)\94==41L[/*K$C&R=$SU)+^M66:RM8HM2R23F +8^'SVCD]_^U@#](R57|>>-#7G|_*"V MSHWZ?
D\@VNE2>NS5FL6_+9L>#9^KR^WT#EW)$Y2?8XO5D2"G4YS$2$?O#V9]_MOCX9T"4^VUZQ[>946.MCU)H^)5>>6RV]>[*6"PY3TB5S&Q<:*6I\-/-]N% M8 $*>8)-.PD,E6+E2L=
SCX<_SSN"8Q/I&2'+|:*Y:%AL/A,V)8^>.B':PT;@ M%PE_90ZHA,FN! H8-3V:J;R2W]+L*N42.,% MM30<=M?%="^7"* '>]355FGM=$IQE2-Z3;^ZF*;S26"@EB>Z&I|G<_52X/.^
MT3%TIN!XP7*.FA[-*KLIK)R\W Z(13R8C"ORI5$N!YW1H_<;7+X@5]O=&5%9 MRG)Q'4]VN4ZP=5M?MURNIG71G^HDL4A5$K.FO,Y_QFV9(Y@BB5&-+/TX)KF M,H7)O&Y,]
9J>3PFV]X$%-6I=(Q*P1]I?GM2]8R;].G1F*1LLI!OCXO0:%67 M?5HSV6";34|9AD@:OR8[X3Y_W)-.B9E&SKF DWNI ML5=OPI;'>)IA L?+R1(A:*28|M,CI]-
'+8 .Y(VF<6G%#'FV;"]F/L/UAWX M6Z9^;=FA>IV-SA<9HD=GAN)FT0(;E8,MCX?42)@B,VG9A.@W+;,HKYI#G0V@ MDAZ/:,]9S\"\'7BH;$/S&W"B]2#A*$$4]&A08CX)QKN4DC(7?
R)M)OF*GZ+#1 MT:C6)E5,3P>@;0B3H.!/)V[94,.F1\;)O[*2=3BBK%P,NUQIF<'%2_LZ_&] MQ@TYW92'3,;(5B?):M[K9I]%,6QX OW$SF*V(ED33;NM$9&U:OQ?6>?;
=LS1T4([#I<6<- M:YHH#]*42; ^7R/[K99K3?)U]CD*CD/FQXM6*?? M2$%!=(=BNZ'92;.7:90A6I.GX'K:H8N=69K,\WZKMEISZU6'1RO&G!A8H<\/F/Y\W/&M]"9L>C2PO%E2
MNFW3FQGQ&41-]M8#UL<*75 MC!3EA4DTJ5:-<3;A8X|[FTZIA7YC1LY%20(E<9F9U[-|&^5]. ^IMIVKT_68E M+XMKBG=7--$B\U28UNUH&69JH'Y]BV,-\II@Y]G|/52[5V/VQZ-+
BM4REQLG1 MW%BO-+)/YDQH +T&]+-S:+9"87A&V/Y6M2UEBN+G6) M7CGA" VID)Z:<& GT-O.!B+/]M2&42"[N>&ZT1PWZF'3XRXT*P,ZEVZ+9:@.
M;]Y8IXG1'$W"*;#UTD75S;5RGM%+ ^E ,!ME!E|\^]|A^FH|8)5"=]B2RZ9X4 M]T%B4(,02IT 9B^=4,JE;KK-5ZI9N#45,P.M-D9-C[OKS =N.Q|?)_C>3!>R M8C?
7%N!FB]H>=5=VI9FDM=-)OMU9-M1ZL6[.\^%%GV/)%Z[#2;)'2&]-&V!(%'3.(A]?38H&H;/9FF/S M63" 2P;;'@],+DUKG#V9M\6XGFH'PYE>]FW"SI[0R)*3+?07+N#!.+Y@ZHDQ
MW8=V!$4=#TRBS4I2')1RHL!.;Y-F7VVLX:8+FQX-C/-ZA#PXBVBE ,J]' D M#R0Y?.IQR56BAL;.D E1L*Q%3V&U5*T>-CW:I/CN?)9/YU2?[PT"?V55*X;5
M#YN>D"\;^A%YP@5&)6\.>[52OCY:P[8G=C)0G36#1CPUYRO#_K!>,L1]NA]@ MID?CZAI3EA>ZPX;8%N3AIC-D*NU<$S4]&E=0*1L#IP^](WG57_3)H%]?%SC4 M]&A-:VKRK W-
H:$&">I=9D9+S-2.]@? MDKUZN3:0HZN*H'A9XED.I.A%XGB]|F,.69\SN(G9(=4AN4G3=3E:E4N%C MCWT4PTP/:H*T;O*|5A^:|(O5H#/:MMT[*=MR>_O.1%)88$K%-4YZ[X,?^A\/8 M"
(JS[F*L*-JH;*.4^]!]&-25?<_>?[")-Z(:?O K\'ISD[MH<1_L]9]^QW0O) M;>3E8QS 1.H[P[Q%=$P(H1X\WX;/U$P[V$=M]K_'T3GVCVV8/(#S]&YX>A<, M"E^\;R]/7!L=
(WY%6/KW5(>_/6SX:O($^R;U%]_+==:%_9Y\DP:.U^5[^H)Q M+(+K0GO/O7FO"Z_+M7"_8O&Z1&]=|+X?S76!.);&ZQ*I=6&_LQ1>E^BM"|:O MJ*X+A7$L@NN2_L[B=8G@NF
T\;K75)B'U!Y-P40"_I1E0:|-!_?Z&^?G0WF._,%_M^>+>O7V#1>32|D5D22WYDX-80AY=0DCB>_K-H,M?3T?|SR5D|.J=AY>\ MOOWD%.6?^:8<9I4;88$XMT"DOR>^8#8P9-
RRA'Q!WM*K",A=6>1'V(E5!9OH M&$TOK#4W8+.?VR"#O4.Q&=G$|A@VT+_|%+P)<+ H8-,<;R;7WTPN;::N?&3LZ MMO?K-H)M\NCZ8.J/9V3_DBP,1=N7K8^ZM&?-65?CNH6%
YOS MIT%D[H)L%Q]";",W(6=CX]D;EU ;LJ[/\Q=^?^P=7]OUOVQ??ZV.@#;F^;W M8Y%OD|*?#R0O[PMG6?ASV--$ ^IZ$@)O9ON7=RD[YKF_UE! +R&CRWA=]R,E
M67FN'P7#;E=,O@@K=N[5_8A!U7;/N%@[']CQK^Y'1G) TQ4=[RB7|++N1TKV MU0+^WOWZVNIL[XE+1C9E2P'NTZN:]39-"'*M>BN<.'Z<\F^7 2N77B-RXF1DF[*F#2^@0V-
.];1*7Y*H8SP1-HT $DP^-L(&!V$!?"|?P[GHZQ=8] MX@)*485QX0]PX857BP[H2]8N(+3#B,&XE)97PXW#+|)UC;3+;CO3_WP)Z0]A M1-
%]ZS113<2)>"T^D>KBI,EN$$:D4/G#U!,:.%4C&@/%94Y]]+L$BFT.]*@# M15B!CSK"'1<6[I.30IXN_WWCPKU-#!0MX3X;:.R?D=H&6\"3=0NHO.Q8<%[< M_?
XW3]7&>]TW(F;C8"7Q[=6&"CY?R_OD_@?G"S[FQ$98%U(31Z]W1)&M]G8C MNV]T0#6L_D9_^TD1Z2)B:'$5G_/R:/'UBQTYF[G16 2@*6SB M!.6KJ;P9E($Y;U[6SG6#
(3"K!;DM3|AH!STQZ=5EKA>]= /.3I:-/=))\P]"- M'*7I/6$M.+;KQN:.#<5+=6..8\]BNNOZ**R.:@\K880"[@+.'9KJF"*[DYAN MA7'V6./1EQ#(8PT32C""\ULO@XH]+U78R.ZFOX',?
6<[\CH4:APYU:=, .;S_M]B?^.H[V_U_Y.]I+COK-M1T00O:O/KN3H:?17CW@'QO6"#G*;. "XY$-Q*) MHK)F_I+(?$'% BH<.5S.!FP46]V&[N&BA7]R3P 2T(J&5;66;8.RX[V"KYI+
M,H&JO:+_ 1-%7\KMCB[5\@N#](\ ^]5R(@N"GW4WL 0A""H*YL^> N!NLWR M@*[T@&ID 94>3<4LG)R0;]'UKWWJFW< PR|5]<"H\\|?'[C\-1+1 M"I%KLE80)^1;?
5WUI|5!7/G+$X=/(%'>]L R5]+1\W^ <_ M>PGM'\>@ *P12&P*C8+75TPC/G3K9]TYKU#4U[NCZG@WUAS+,H+GO]:1#CB'@]|0[M(M_/]9^ 2,&I4] U4) F8CU3%B7B_#]%FC,.1
,R@2P<#@T%"2[UJA-T=T#IF6]9'L I0?9C8'EANN M'#Y>ND_&\KG#G8^|O)@,&T$R+#X>QWQ+S+?$L<>=V8?,F]"ZR1X8-RUT#NS"
M)6|#9ZDK8'O$W@**/;;"IX2G[2=,0[6D#H]]CL82L]:|*!!D95+*<%(]C$|^ M4>SQ%5>,0YAHB8F66, QT1(3+1]X>3'1\N&)EM<(^IW7^]NIXT6],%DTB'5< M4W/51)H!?@"MOS
P^(IY=P\,RSKP8LI$M8L I3]07VH<[>B5RF%AK)@9YFG' M9RV86XFYE9A;.^;4AR82# R/F%MYHIQ*K[F8V'?]28DBL>]HDB+,.GYQ|@3D M"[RJD5NRH&< =[<
O79%G_6%4E,CPHKE|\L:Y/$Y_W W]U-M!P IW8#U*)M MHI4KR+J%2D<)5ALH/KHF!ES.@>)EC0\OVD$?1] Z\]NJM9)?524):38-6BO?'
MFR%3K,M+8]"4TA))HK3/QYGP,$\9LS$Q&Q-O|)B->6W-P&S,2P=FK($A)YN4 M4"LSYLI@6^7\1*X9]CL.T(;.>MO M>>'+4F%%9LI50NPM,^5U@Z6F>H>32"(I
L603\G4<2;B\X7&'QQ#KN\4?!&& MA"$'>C^%?+ _[N/IW2&:1K-9*?,^CD"Y:?4|SC+AVLD0B.UKVVEQ3(LFPF!/[ME+I8 0/,*
<6>W$9=,@Y#6G4FY(@]4:]V614T;!*'CA(G(F(A\ M_4F)(4$YZM#SFS.=A)5)ULQRLF*T^6|=M_+R>##^RU*3'|:96MG/#|\CVPC7: MHESAFIN)UQ-#(P<=[% L\91.'1?
W^/*LO5HO;$PI<9/;B26:Q6MR>4,#4M!=/38O5XO:$ B>TO7A"VZNIQ6T3 MD;=O:#@V](/IQC3'GL7T7*H,B8:*G_">"'K\B M@]8!E(3A*68!#WW/W_\5?AA3=5>!0_5P@M<[HC/?
Y#Z$*;R8PAM1"N]-ZA,& M8DQ>C2AY%>O378@,9F&%*6]>DN1 =3#R-'/<3Z=!>B@^CE1$:'7W5@ |"K1 M/C9\P ;'\)7R+K1BW$-[_XJR@MT@! 8,4 + F TDI(@N>)MP *Y=^"?
W!&'5]K&-1C[%+0AJDA;X1EQLS*]<1-(HW0"9 M>"(N=C$8\ $P'^^RIX979Z1C+#K HK'0Y%M0I+/=3+,+O V `@//(6KDRL^, M$10Q"(P-7',?]Q)_N-]P=#;60?.!4F-)'2H-O*R3]R)N>
;Y5RR%/ +&WZ? M@*0,M0YH*MW2C"Q= MI5)OI9Q;|Y46$'BFT)Z33!,9@^AN-[(&R;=B9;=-I-V&UD-F;,,!\3PBP*IQ MGNPX,B:^WA7Q?]EN| 08
IK%"FLUS*,KYA+?.TX:M3A$!L*F|7|"*Q@ MK!D1$P+,[XT(O =13.B_-'ME5=S8O$>GB$IGD#5:.CM8M_\R]>S_?LWAOB5&_?$"9^WV=+L'=+ L7'/6/L]Y$1 M)X+4['-'=1]Y>3'9-
X)D7WS:CVFD=TOC/9]1BY?:O22/-+?84+94F!H5,5/D M6*M6I^G/S1Y=>|'N!3V!%_\^8#4|"TRQ"512;-'>NO|@O#]#(MRP8KK$W+ MSFBBQ 02R:*@)T.G<%UO3 K%I%
LX)@4BDFA6, Q*31*I-"KFXDK9VT^N7%& M,PK-0K%3RJ_F]51D3+L^#7+M1'|LB?HTP8RJ4B.YE)K(M$.!O7=LN|NRP>&[? M4#K(CJH<9%*(^=!*CX$HUQ #-"'9H#>7!]'_*JUM

*89B^+U MN*UV:K[&I.*6SWR_]AF&^+>;;8KXM)@M@OBWFVT:*+!#!4/!;) X?W]FG$WVU:M*46+ < MKSY,%P>..T8[=>K;3XK&C->OC0CC2<&,5RP$F/&*&;]8,S#C%3->HQFH/H?A M,>|TVO6,VC6,F5D(7&*^9)A):'BBZ/3;EN?-<4[#Z%E\),.I0)'H,:#<<<+GP M21PFG&+'*2:<8L+I R|O)IQ>G7!Z;?LLPD'&#Y$2D'D36C?9 ^.FA>[8N'#) MV\!9Z@K8&HDMH-AC*WQ*;"^>, TEK2&D\\N$S;]%PR&2\5E[U8&F80K%))-/ M"9; F4HQ*1634K& 8U(]]5B <>DU B14]]M2EZ#DWI>|V|2\0L+]5OU# $4 MW76O9Q*Y7H#,/Q09?, ^NP?B:E9V)R9PW5<|)%FW!SWE5.VYP#(&H?6=\P! MGNZ$QC**;GL.D%W?6<>V8$W\"A/?!E M/^~VW5TL^Q6CO@6@]$,1=X'*66HKU),3>T3SIFP+*8%93E9&$)M:'*9GDL3 MTAB.%(6P$T $B1#VF1PT3${&Y.3KDI-O+ @4$2CY+?=R6%[6S>),%,/6:MZI M):M#MM9$2,)),'90#$# #X9X#>&(E^?9^+3B#+,94=90*F&42'GZW'*=ZNK* M+$"(@C(,/['IXTK#&%4PG1O3N;& 8SHWIG, \O)B.O?5Z=Q7MPLOD;KAT|;< M*+%DR931[AQ=D)4 5]J.R=BA+1>F*Y*OAUH>C]V/8.29((H<[-;0$%EXW0- M]CIS;)]GN+K&-O!W;"OEWT3K:6F[S MD24V".X#KS8C@&L M6S%94?R9;T+?1(W9W@0X829=1E\T[R Y8815]L]7T*,1P:,]_,#<3Y=3%F]:\HJ M/C7';,]I9E-B &5KE"]K18!>W-W)"9M%/MN9& MP0<,*TP:S&;X>;;)[IXF6@Z ,[L\:M$VT<(59-V]0@->L-I \1WH0P&7-#7@KT" 2M(Z]. ^$9%4!@Z]>:@1NA2K;,2R964\IH214DD^>TGE;Q4T=F' MQR+,P<07LS!O#H'\JJ; [9DIF%^X*8Z&3+*SR/,V'R^X).GQO3[%!>&F MF'QO4|R'1+HH@HCB@C%\XO+%W,N1[:C B6^ X.I[!+^)\' 1@A/, MS;P.- .*0A+Y2?LM= -Q-0O#[X>YG5BS/L']Q)[%->M=^B'6K$ 0$[%F8L3],8(:];1)$8[I4H+>+)N 967'0M.D[L[$:'GY:(GMWLYQIWU.7:1 MM#/\)OAT]*<.O&VT!P5VWL]WK;"\2)CUH&40<)].B);<(%XM4YX8 M(O1@$$I@$M8%CP'N'B"'N#U&B NE;(#F/^LU*8.GI-54+M6]&FM?&"T:;&8Z M[%)EL;%8$\S('!]3:SU&:)'Z]I-FI-?L,-?XD9 M'Z:.<\!AF],\GS'8%N.7Z%2W6-2Y\^+'[ZL3>H - !)K5Q$4RU6';BU&ORH1 M2C?R4M&2A\;1<*SG#M'D=WA"T:1>L)UFC,/=,9\(D$@S; "+(MZ&>49U. M $K- 7%?MM20=F.6[<'GRP|\V(K[\ MC1S9C<]G9UON; !<@$0E/ ,)D'IN MR9:BPT;N?C-QOY]Q +^?VK!A)!60&4VU0^#GZHO?_X' K- D&("V4%X,/GW MZ^5*H+?N,(\@ G$ ^=/ MJE#T'LZ>E3K!?MUL;AO^P3X23F7XW]=SNC+]7%< ML4W;'>%'RX.IGFQ7C@J! 1>M M38PDOB>8?\0.?D;#.EK@F/R*RSC#]?C)M"\'PP MS0O]?+I#+ QP=W&D+?^*-]AP MX>Q+/ZN+BV?,? %#0+T/S"7W<#H\GO2>9"\O/+WI=XD9; R+&)@[#[OSM" M]N02HY\A5D*,-O]][$*[CR F(*Q$VIY%6P%4Y^<5ES^B0*^G^M0,RB&V2PI(M*R-%U:1D(LU*-,O(4AK(A)1DM!&9)E-L2M&^;=|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

*(ON=)F]EW[#6RS%0/N#]+ #0"8QD3_2(-FNZ'*T^,Z8E@-U MY0Q9(]6%^Y+ZM8'+E[Z3$:U\5R$9NJ;,3K>X>?YBI/[&3PJ;AV2+G=63YN.(MMU_:C-3;&,I).[CXZD92&^ MJ1#.DW4(I9#HTG;9Z2R#FD5L"NG^*Y1\%^TFX#&;DV]S;"1!F1$R MTBZ+'+<9\K(OVQMB!)I&MSI!!+VZU.^CJBV:!N2 +'&2!_^PL M\)F\[EDM?*

A5]2"37WUX8U8O,>U++G1'HJX'W.BSIW_S1W6/"CDK'NY^MQ(EWNGE^ZH[9#PN2\BW&,6 9@+9!%KVIU+64=_W&C[2(=[3/&TV*#[/5\]@Q(<'*+1'O MV.N$'KEHB$V_9H,*

[UKN_Q,"UN),Q!F]2C!.) ,4J>CP!F=O'X"'"4 @<&-8(MQP, I(?[N]6BRTC>8B*$2]:B'WM0)9I\ !CN?/=$[+4ED89#$[!3 R5 F5 M#KX<%[2\,N8Z;(?,L;>HKP7A:&TBN'%*

[Z20YON[R4;XW9K";O0)5\AQ5 M$]P_3*WU'(A6.NQ$N%P@_&$P2]JNY MO8I?VW%HMAUF_IND9TX: (O#3P]4N"~KY73]9S<\/G=9\P8!9[Q#GX?X+*<6 MQ:K\/"D,Q.)CG$.)Y<-

T_.U'/!F.G80XME@<=^@D)4\$ZA'[+GV 9AM1L2Y! MT/O#SG+3H=A))T8+-A0]A6[A2+_**9E?!G8'T7HXMY(HLSU5GA[]/)\E7]Y4

M4I/8FD\D3:'630RFV:FVX\HESX#Y6VAPH%N%9&A/ON:WK>RQ+DNP9F#M>P-GK MC'3P?[!<^620/'9%W%'.%KHV:Z/U!:[22[]IB166"XX$ F)FK/NXFI;9?

6PB4H_UD|^1/5&B#Y52MFKU?YW0 MR.?+O+7)D[(R&M6AY0V8",B?CI->-]$UV5YW\<#:X\'F*;['%X4)YME(-,R> MYMDSQ8%7PTD.*G6\OO"FT0&K>

(N3EH&*I.+,;9F&AQUTO[=:7U+]:JK:?(RQ M'!>QA579FHUZ/X[69YK?D>-0'!\7ODOMGAO5QA&^9"!.S[,+%7566..%4Z?Q M.*D:UO"-<9ES=PX%1]'09V5'(#4-NB :HXWMPZ;L

M[0GO(N_>0P;:%+.)0L?.'<7>LQ8?/"Z>-IE"MY#]KAXS$>@@CS5 @@LGS]A. M$H^R?=_ AA^98^PR#$:SHT5>('R473'CT[];5'1LX2]\29]D;DHQ.!%)T1+218 M[-Y^0F-

TX@3N"W7K4I8*5L>V"=M"6%-]S[6?F!5;O]$'L*>'9CW#U)0N9+,3 MF$B]MTR[YR#^2^C?,4/M@L0P3K\/$ES>@'[73P&C<2N,'+"]XLZ:*CO"%U5TW M=-G%!P(8;)>[OX'2PKP.]=!-

N2:85@OO #^PIYB/#WG.;& S<;?E]/06'7A: MU URL9>9W?0V<[\^6U!9&=V9F=MYB<93>U^$AYJR[PN[WS0UY&'(>;]S;O3U M92"34O&4RM6T1;5[*K]:O[G[A)+3B7P:5$*.QI%6?

IE]V5.E.NLTI9B?9R MI53!@3AGQ&VIT2%>K_@>DL$CB7R9>_B'@%N]<(HEW=!)A,=\P*^DT-DQ= M0I8]I@E8L!,5FO(EE=N;PS\1XBF(5\UA[K[_/;ML8#;4CF/HCG',-?7@G%

[(M2/O^+OG_M'\MBRX>Y\BSJHV]0#L"A%1:.]W3$TO'QN[[KL>^*7Y,P;K1FQ&(X>> :V= M*8 B]>?^ M2R+\'>(TT>=6OR-'E.:T*$=7L7{$Y$+DUS/$QSM?XN7Y4$-F+!0#9/

M!-M/1-/OWGY3.@WE^RI6/!GF#5_<"KX#6K_S3"%!PM]WK@STAI@='5CC. +Z M"$/#[,>PN;0]L+HVE@G7OB.ZO$[ZOC[&ICXOOR9.[>^B^:65T2$!3>9,.!<

MP'BBB>:3%9]'@^+SH/C\#R@^/ULF64<_#!>P\F"?1BG+/0ZET)C/+7/-6->(<9-N!]_< MW>5H(CJ,I5AV**#8:!B+L^ED+!4=L8G(SS\QY'[AF>CN,VR2 M2\D)) QE$59&1\(P+;&184I&

(YECI:2(#IBHM169;I[$9UTJL.4D MH:*#=RY+K8>`>2T699O%<@DE!Z74K M>7 D-F4;LT&SVN2:T?1]3F4P2L/#!_,3-9YQ?$RN6EGV_P45/5E[#/ MP_)T?

S2D'/6[OON!].8F:IK#VVCW%&KWDO)!9-Z0GS4&/X5'B9]/(KX(R# MC5I<(?M\/RX.IEP\42WKJ]@+O?$P?OC.T+WPN(XGI!E?G7?Y[+@4WR Y@U<>

MO'.Y'K;+XUXS.5T,6XG92W95CK1I#B=Y17['L6*#Z/[M,5YY0'8O" .:'4G=*)OH%>.=957-=M(9O/+@1$^J16+QU"KW]|@>3^3'L\XR MWH!W'I!=+U|)M.W**C,-

S3=*AE/+8FH&^]PCNRWN5(3,#@BQ+UQ:6'J60< MZQ-5H2]2$HFIY*%:V%1>92-7'MG-0N9S7.Y9 M/+E8UU:'QP1/=+ZH#Y2HUIUN"A4TIR,5U8KC8X<GBODXF2A5YSRW?

BQOHV[] M84V4T@$0BLIPT$:-HGSI"2)?Y?N9A\6FWH_6,L<$S\M][L*MS?]LH%0?[EFQ)R5[1$@< M'&G53Y6QDLM(Y4M\(KE6K$AE5AD?$SQ/Z6QCE'PII]G0?:66+?"5?D)K'Q,|

MT1P[SS\;99[=B%/,=AW9BDW:1P6/GL[%UT]UO."<2K+8DF?EI"6LC@D>E6OU M%@8G=WG%**/'Y>.DUQG-;CZG+R8A79NN$Q/)Q_M:|>>@\|_M\S.]M;)[H7QK,A@?

$Q+157]Z6 ;TC07FC;N^V;IH5,ZROHY66LII-U8=&M M%LVZF:!)5J\L;E7:Q'$WHC6E7:R52S>$T7B1"X@#Q4$08==0'CF<3]5%^ MV'Q6]58IA76T["IU>O=#H=?

& F7JF4RWT,ME:@[1D="2]]=&""$+T>8;\,@L2 "W,7^0%NFWBWYA_? ='(>A6W- # MB1- V$$5YB;Z[O[###R#PU!TO'?Q5D?JYNW$!=F[M!04.@T&6X7[5>5N$ M22

MO(X[",.!-4)]M"XTC^KB6*A$#Z "\)[XRA#FSHL3D3 7^[<_2N-LP8W8^)ON MWR=AW*L,H>S&;MR?0 #]I[S2P CY,/N4F&$$69;Z","&6R8C9^[

M[_37PU/__8\E_09BN#"7#/!R>WB)O,/)@&%N$#%<.|D)\'*+> D$V2WB)1!D MET7,?RP#[+5+VF8?#)>W0L(A2VP'PR__]QOW[5=)-!5FVXBSNMIG[\98M S_M;HKO@ ZF3L]#K+1,

<'&>$3??H"\=__C'8!=1E[=WGBH![RX7|#*GB="[*[M5/!NPL)?1R:*',GR54FD.|$-*P3C-. SU(N[" 6/5W-AI_^<==#N:HY2N+ OU!8K5N@74U<;UT'S2'-> ^RX_1#$_2+H-^2?5;D!*?-?

RO?O0;D@4?8AHNZEVNP]@W2NAYFZPWC9=,>@U LX#E[]+15^V" Y"O_#AH!KS&94WG^?IH MG_QU)DR?FTJKP\7*U"8AQ7V]LK 5Z8Z98!U[ZK8+P\,)CZ0]8$]\-WZP!B*.:5#:.

:"3H>CUSKH-K0<^K<%G'L1L[= MRQ9,&|%>_2[8!90 FTO99$ J)?57#[F7E19W, M\.HA8^9KM[Z]V*RBE-.Q:=6TQBE^8[$AI?WMA[72R5AA 4(OUBS^SI,R/R!\P

9.'O,T"WOP6<03S5BQM0>M>4Z"+=KGNHZ5F8H9#&H*!@^}O"P\$]$IMF_OZ79N;<$D.AX;;+QX>2(+^]"?(VLTXET0 5_M]OK3++"TDXE:"W,#&SX,

[/DF#;\+6A+7N^IXN\]7!ZZ?86F8T(.YYX+[!]F MZ"3M*E3 -^4WCP#6N5A:6Y15O8#$M9)(6[&G9WX%(P'CX4-?<#O#BQ -O5;U M8R?

S7!BHSCB[GIZA=]:^&9";O*GTM,=LJR"T'T=M8:-VBC48:)\X-X3:N^+= M&1*RPA8/EG)4NM&92;Y9(]?IF0X[MK0"M)*8WT.H5EKOBC$]1-&PD^8Q&,DB*SEH@|[6=

[;NYX&T!%U8&ZAG,&P&P::FQ"H<<^G]BT8L6V4Y55ROO-* ,5|\L M+- D+]\;+-7>^"%2&<GC?A3=OL189*7Y;*RCB.#16;,G(^X*M|78)\A*/&,9<?>

*(D>F-6Y]1 NK]B<0\]A8%W7)UHI,+TVDTF4VHL8+S;?:A'N: MW=,Q=XY^CXW!$X4;'%4_<((?>AC!%_"G^L6;(,_(.3'R%%! SA?41B]%)^E: MA"[CN<4&SW2I$M]K-#K)^>2M[<01F3S_OI8/1PF[WCF6!Q]2EPF9LRD)1 M_\:&@P04$,$,D/" 68#*8LI+=-PS.8+9E)&GH@.QSG#Y;&2T76R<=6]R'UE_ M;A$((:?^84PUS62S3!;+,JUB-[4I=AFL4DREBY5B9W K7VG=3U,AHJB1,/&L MN_0Z;J]HB(A"RB%V>L$>YWN:,,F6!G9 MXNVUM1 lE%B.Q]X>9=C5C,@:4%PR #2RG?,F-7F>I[1NFOH*B+\,9X!O HG1 M04VSL8SUFZN>S.$+>CF3\[-8,;-]*<"-570X^ @8VV11 VNGW!4HW5/N*;; ME196U WV>AG,/-O]XX&7^Y6HS1#+[O#=;2]<'*0:6%_P6;1(M(9U(U+,/Z+ MW16'#@+O0S>PA]18%>[OFI[3GTA2??(0U><]E6?;$7::U?IV/Q^9O$128|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|[< Z(Z$I-K/3Z[M5DW&H=L&/1@5NMEI\|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|OL:KT=7GDK^C]_ZG9<69HLDHK95\0D94B3IL[T M*N]M?ON&FFMP*U9BB49,K:Q$MIS.16;D2(A+0]AG,/;K# 6 XSC_^N9IM_$ M#J4N;8?^+"ET#[00WJ7?4?(^)7$71696VO22,7PQ7F5GCI_S6N8[O(+OD+AK MASD59O]^17 E<>5M/1T0lV84V^3N)^ORC6[66"VO/Y5\LFND>,/BE;]*-]. MZ,@\)/IM?+GW!8:0&KZ29__3l;/Q%FC1PI9VQE;LB|SY];-[7HT|1_!PGZX M*Z#:V;+6<,;]S-==WB*WZ&990B] M9D0-=:(LUL)RL^3&Q2K]>A^'FED|=F5;^.ZX\V+F<31,C;A7#KXP]W("N]49 M.YKRYU!1FG)[_AR[RA8&O79MRBV8C3#L+0I;N;.90NY-OHY[OT5X)^-W M*-TW+G6;\/[^.A&=^U(90M_4#SGS#\1SZ&O^&6<.\?Q#SOQUY?;W\VJC\82_ M_KB#1S$+3:7T!1YV(OYL.W\M_L5G (]M>7,8T"=1L-2|NHOB(99S/6W*&S M6]G<3S;?VM9HW_TO:>3L[8.!9=:RQ3L6X=K[?$\GK>;_]%S]> ^]>?Q&,_L M?E[X]??W<4>$(82OSV!^E4;2-*-)K6;8['S2MIOK8C&7)R_I]7L=@TG5LC1E MB.*$<<:UZ#RISM.=V 2(TZ)[X= MT ,U82B[_L@2U-C4D7*34<*MTX^1R8=$\C2<=3EM]$=>12$778R+?,N.'?,) MJC$@:*9XZ(**Q25S6PP84B1;64[D38=]4,N O9<|"$> MQQ^(D(LNK%]6,AQD.,AS?EW=R4WBUI2!69MJ)1A2FW"MO(JC::M'"^; M- 7<+;G,:\D.K\?6RCRQB$7316?%*REP2P)#C7Z@8$E*XME;\ON=M@]Q7/-E9 MJ;]U*(?<10'N$0'3A>]!_;Z_.X3=V7-?: #!;$Q$X-6G^X]&;)<-FV&;9>1 MR2B)3#]2^F'9Q7?C;0RY[7ZMO@|PVR8I5*Q1MIEC9+9:-ZG5(%8LI "W43!6 M3D3C#]29>'G(;U>/ZH3\|CY^>ZF+!) /RSS-DPR3UW%>ZJ=B:UK]W1+98)/ M-!8)@NC%&I"7CN<[I)A#P7\MSU[SB XDWG5QbM)CI99'2.$/LMY;7!YG,U2FY!4(DLE6>8Q5";;K^9$(WQ2 M0Y^ ?_K%F8]$4IR?&8QZ..TT."-U1\P17E=U\[=/L8&!K*>/0_6?C[3HCQ,@ M8X^X[R6$X!!W](=QC]UC.(;#]QY,,'4!5W/FX*#\F7^C58&=\]K(F9!%IT*

8O+?6.Q5Q@H?&>P;'_]RK6!/@Z4D1T){ 0>Q T&)>*_0<+_+TGAL!VYMPZ$D"C M)R7FOSKUS%D4PI\!/P#YIKJ/[<9=>!_}^M.!@@4FFF2@&:BC:,]R8]D&5U/DR;P1V^2F&EY:G>!2DKT3 MP'|$(66_M)!\^AU-M3$]UW1]$:.35GW,5MM\HJ?TW@'N;W1TGXC=]Q<0L,H9 MEOC;_.^,?"Z#N0,KNJ0C)!KB'B,IM=,?^+UH'2/WTQ(;1FHEFJ*7=(6!Z\=P3&!+6R+F\\AG MG^A:"A>!CRB444ALH*DNG\5:IA6?B">/26A>XX,&[ZM*^YUN& M4U512&_\'7D+K6.EK ;^'S%B1*B6.BJ 23\^&:S-3JG?33T_R^0V.,>L|[F MG VI6?;,GZ&",+CH5OO\]_/$F967LB",V';6)T^ZH0_R6J4KXF)LGAOCY*"<MH^^",DW$*>;]>FVEVA '#1$$WUVENP6C:5@-+H6S;8W2[W!V2.N5P9D1S|& MD_=#<0:0@@A)V%_V5$29#R3^#P0A$HOHW\0_?S]B'?#M84DBI$#XF!UB0*$A M27XN23X;R8$9/:B:4$VP7<'<EZ5VT Q13X@@971YV#+ M&U_;^SX:WJYH).86C9"P:"3F22_RM=(+??V4F\TVUY9#B6D57\B:U5%2.CUK M7#3E_7S[)B2CZFM)G<9F0AZ/V-4FSF2W:6: -+EDG'[@$Z>UES<35.AH6,J]M%P$F0RH[1V7I\BL9ZS]5M=:%/!\C;"5QHHI/C/(C.\:#2;Z]<R5=K%V"#_.M2(,. S4W G|<ID4<%,Z2[MT%K1;P3ZXR02(1HPG|\R.7;F0P_Z"2CY4M#Y>BNG%5OKU=2[[%KB6_LUU[QR1Z,:-V9&09MB1?)"8SI[Y@&,YW'AKAKUMZG M78L('{|@:UCH+D*VHV M,(3 !QXY2S($#I81.=/"88$FV<)BOCK146&D>FM:?95I3]V9:IRQ@/5N\8UF M.L:BJ]_<& HB()XSD 3RR4.^|,YD&\"1/^SW23"W9@7P+R?#Z"?XD"@1@DW M*P>8=RN:,SX%;= KBU%UD5BQ"YK)=]EZ/^5$/F$*&KD)AK'REG'(-<'*#4)HM9BUSWADUG\|:O=%MLA_;VHL053)4Y-R,*T)@MJ\A93%">4K2:BAKB#%LTY|Y3 =21 M^@3=+>\3V<9,T7[\^S^V\TL^J;:&2|5E*5C14LEZK9"&*#TYPP/SA#?>C;+F#MW^"]YALZ.Y?G-_1RTB-P3[W;)XFP9%Z/#DI,KWIH.&P-2W*3.\LZ:>ZRD@% M/J>?/15]4-M 15? '5!UH"6 M'DP%AADAG&_.N=DC)1&=*&RU4LD@-V@&\!C0+G*RO9V0]<*V|_CYL8_X.F/-M!WER.[AX^CT,*>SU$173-+@%/]X%GVQQ;@J'YZRU=K<;3%,Y3EDVD-C99I(< MJ>@I@9?#V,,3Z\ 3.4.1+.QV+ -<&[/XE_WW-&65[B8[ZFAZ+|P]/&8NN5\H& M[PML>YNLY^W,2HCT/A#01>]WG4/@"_]#? V77!#:8# T5?G-9&!]*!F%F(ML^5DOIX?M[*%L;3Z]8<@'L@G5)'GXP?IB_J3[!N/(H2LYYL&8]2'*FM/O?GE#*)6M+4=*N@ *I;4O#N<3OHCO#X1)%Y=IA.<#123:.SQ#"K):*"_M/QZ0X/Q+!@+),,6(A/0Z/!AJF/02FF%W9H9UBGQKF!]7=*82FRZ*8S(VF_4G MSYEAS|\N^HPOQ-K+P&^+^30(U*3<6A8R6*N%B.UNLKEFF%!V08$I(\DQ*")*H MIXQ[LP$\S+N3/C> <8M>DN6FB%9,HK7B#60B0BV287EM_^_I\!$[ZW,*<]3 MC92UQ<^@744W']CJ+A\38C*ALIS*T*6IS5';$,3I?HNE[5QHM$?O)6_17A+?CB(YRYKWQ9 D\S M/)<:)\8CAJX_^+)52A5CTY=5V@<,3?X)L(4A*H'=!Q9:SIB7@?B5N\=#(_/I M=4#<Q'.F5X8SG=?NC;GSV7@"]B5W91=F98;?(>9-XE:/J[@\'@4%4/$$_1# M+'`F)GY"M;JON_9ZJ/D$ \>>18D.GU8$5LSH\}(U^,+'" E_GC[=IU?D1E5 MMR OZCP/QZ4O\[_!QB'L7Q!DG.:?5[_$=8DL-<79?%<=]P[6+!|%_,2EC7= MK3'(3W<6UT5JV2_*O1S'!M8I46_.FVZU! M\GT.V-A,!OD2P5<%!W!AQS"=%M,HQIO@Y)0%421\,&I^B9HFKAY09'T+D$:.^NQR;UBZ379+>C*9 /@R=?GZ BK!/[\G_^-&T(ZZ"W@<=M?&[N=1=>MVR$&\X RX:!I@1W&X_G)\0JNH04O[S,Q!.9YFG$MDPI%1MZVTBOYPV&X7&"]J83R/(#<%HHGV@2+SA0@K9Z1B++ZHA-=&N M2V^1CT$DE]=ESNHKS(JA1W2E'TF4A,8"&((T^4@_S89?)WAY+FOU\H+E(O[M_Y%T/@_B9B?9A^_#%ILIX?=>=-0F),739N3:=^&1[J_EYMX[CF0 M-]M'^8OP88>ZJ+|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|OX!R8.;8PH:DZS90[1]C^S104*ZCHW4`-\/%O\'EI\;PK, M>(_.|D!9\2%9TI4,3./0(/.!M69AL>[RE(+/E56!76P3N:H,75B/IX)CES7M[73|G5M "]$:Q$>FNWV5+:>O[2L\5#PP>KSS6>%W&(C@MK)B/T_;DX2O#K- M=);-25Q92*; U?)EG2'>&:O+H#<5M1S !W}]IK9UADK.TD:IU1HJ.MTB<;KJ MZ.0RI>J;!J -\O%-M+A5\9HW[ON+O!8, ^NM?1VJ2@KI+3(DF-< MF56TM^=]?8RIXT3+RA2M!.?*ZW:.:"N#SBH&,+C$,]%RCZG/MQLYT\SDM.V(M5T1XV'L$F(7(-=(Y]H7;=$%$FA2+.&S$2L>XIPZ.F+|'5A!%N-M^BYUZ'F#3OK#D0-@*'!' %C'PN;)=^CJ+A|M3<^:,80-;]6!OH3|H?AW-Q+H#|XA B_@%0M[S1@$8<2T2O MAS;QYVGE+%U# A#0OVZZU;L6 !<&OO=/<+PQ|$S1\E($OX 2@30X\M$^[$+; M?E.'W>YWD!%,#"4,>1O\;LQP$Q?>"!>M!Z@EC-W; ?M%C&8X#5^&XOV2O1T ML|3NP($=N$ Z8C\W^_^?(&O0\XO4N^>..N66T#|\,5L%#@OV8&!#^]@R$R=[% MKG]C3V ;"1DE)@?%B\>N+N9NZ7#W-S3E(.PQ?0Q^R_F%?2[2MTX__0!^ND1?: <#S?7U'(IZ,DWN 4QH@8[?P"Z,@W=A,@S M'/"7!:D$&-"]@XAHI9L*BK)Q!KRV'MT5GD2)=!_%S_\$.:1AQVQ530N#MZ(SN(GB+'^/4J/S M_HCF-U0!K[>EWBYGDEFY-GBOH@E\U!>@1@0+%%/[HJ^ER{0],TM:AV3TRP7M.&=#P^RL,)ADZT2'$5=.8J5D.2HA-W_]T?0W5>@>QX9/).QV0#NZC6>P/32 MUWQM$&F"3TM/7\A>4TN\#?H_KB*V?$ "HD\KWJXFKG2E@X\&X'_HW*S9+VWY M1;WUHIKHNIH.^/62\N3$5GNWU8<:CI%8 SFL @+UQE9=|:D9<@=V6B!?7Y]R MY6/SI+R:Q-J-E'68HU\ #*$K#UA1XQ^QO[RU[H>[A5#0/,KEYR1)5F$;JO7H M/0(IZMK^^"08QN:N7?]$]9#6 2_"+[-H@IX.$\"+L!)5?7]=BO=RS/*6UX M>#V*\^-1?-/5YDZ7!<-,GUB;' ^,-(N?S$+0:Y 0'56>F>]Q:80&<%#@(_MR 'E7^/W@J:3PIO=:KLV542NEK2SJC{3\I=NY?%2I7)L,T^W;_F!SK99AQV2 M='8|&])Q4H_4L^;F+]YXKFOB-/CZLP0XQ>3DEE|U*3#N-54%94,GVD$I, M5\;F_!/$LR650:UH'I_Y_2\)_[^,PYZY!Y&AD[,AW8P(GE)HL.)V @72&D4 M35+FS9-,,L7).CR1%)5+/U"5@9/5Z)MP2!S*>S WPS4^WXTFKC9@^^MG3Y>,:7F*]L8R#G&8:K.3.SPDU0C-8]>]G.@5RL6N6WVF;]2J+0T>9"TY"98 M>?+,:EZ3\FN63"CEH4$MH;K93HIGLW-]JC L)#(C-C_9KM9UIC>OCE9@MY9Y<3W%HL!IO""A@T)\|L6LGV)&//.&6^HJ+INK IK])P M*JE6*U7KM+],<3>2U7Z,*6 H:E901%Z) MT%SK_IB"4C!M9((L%W<_7O7OKM8ODS$P*[I#4DI-5& ,)Z68.5?[EO;9[OFE MHBP5S6G9]4)WN.QX$5W.,O3D2@3U)C0UW#KCW>02:&9BEC,'O]C\\C7'MS(] M#*71?_@03'EU"]XX'QC!0LB)6^.V=S*=Y.*],Q)S(O-N MITE!E&3-W_+?YYPAV%^RFY,-M1#K[]^(A-XPB,>%)LQ1\/(38*2>=R/\!^WA M 2AT_P,W&P)[^'V^AK]IDR"3?1P3;]?7GO(IS!.[LA-T=C<]R<&^\A ML=@C_9]@MLK11)Q \D'@\3IXI 0 Z.>L^/^.P $\O]T$$^@(?3&Q(S\+>4 MG%XD|ZUX%(L1-*0PHBW149LL6#$UQ-] MK(AB*T(G*K-6A_C >)NK*=']^1KC><<>B$G;QC=D6^WEBE+'X>|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|$5">W&D\-OUG1:Z)=R M)%L>ET;.A)6X_3P$G[Z4(TMC->5=*W#BHO1LCGC-WHFU81+_:<>#2!\?FZ2 M/P_I#=.3R&OY6&'AL4M\H\-]51YNQL6"S1(UL8INY< M0Y\,DWS+D+4\7B9SJ]JO53*EP00Z]AY/>UB\]*"WPJU=:#DJG3"GXLK@U@ M)!Z/NY9-A!#X1H=3X5!$]/^@IVG8DC.AFHT)<'@N5.5U9S*%-N)%YR-?>1(6 MFKK+S U5WP!+Q(58P0[^44,"X$U_$7\#B>88(8E>7)!KTN^(YKSSR%)\G(D~=VU MT?"F#6 ;3[YIOY?E&]ZT]T6BX4U[VYLV--R_*/?=BU81@B6DEDNDL_Y0L+R4 M3?I#P1(RT=OCQ#\4)]')'U[.H5RY;A[=#P7+2VEL/Q0L(1/]M,OY?5Z',YO'-M$NAG_V?=%0+Q,16.I^,?:XL\-?K%V|%TNX]Y'6UVX_0XUB@TBIT]]$2OAB-M-I.RV>XVDLK<|S331D1EVE(VOV3;|)H?*W9VOEG^AHGDKS^)AWCT2K.9)[= M;C";"?D_[@P,_[Z8!^.+"X2L#-NFC=AVUA<)=$,?Y+5*5\3%V#PWQLE!.4=__M6"20MY$/(?3OBT(*X);;B,Q:-'G9S6sP|+CS$9 3S5F_$">FDP:S*B9.NFK/0:O?+UG:#@*(8" MSZS*!)?&@5I>R_!,;$R=I8CQBI$Q/C:-%"C>?!Y["5M-=>$X;ER!U/5(A2 M+(_W9C2[L2=-6TJFUVD]!7@B#N[.Q\1I_;+.+;NGQ@^G45"#11W6:O16*S$ M9GT;P4E'2.3454E4C>9=.Z!&DUJ98[X^8//Q4;1,Z@[)9N'-DH0::P/KY9K M._GN# R7T4#CM_$VW)L&^AJ1\#4TT$U_TJK.&ZDEGG'6CC@JCCI,#LH)V+,_^ M]@BKEWZ(G+B8X^:,,:99$4+,D1T,[-R^6%8YA-_WT?%1]=*M;*O4E-,M>>]"!*

MF.E^!M^4(TEUZ¥C-<0G1>O37G^2^T?RI:OF5DK?H#W)BKO.SL+WT@#=JF[|+DML_.F;EEG=.#9-F-V^\/DC.TIC8$C",UU-M+3J!D^}^_2$?Z&

<'9(8LM//{Y@O(K90O>UYD_/17P3O2J-XN%.MKZ-7Z)&9+J%=!"R/@ZU!>A(K5]\J#='UP/E|\KQVI.8'?I_@K3#K^0.MCG/_6E^372Z!BUH9LBD+HB?RBH;WO

MZ)3Y0&P/D33ZSQ"RZZ(OCA||-IU'ZA6>4Q<$/E4$?"Y2#FUG(Y'F-@5.F(3JU6E99JA>`MA,E38>[45\Z=^KAZE=N,Q'PM*PR57FF>RW;R'4=<0Y,,)E!%\<G4HF-`MOCG,,:L2P_6,=4L?

3F@RNP+")@;S^>DK;J._GLMNSF)WZ0\+4ZE"9>7N-T-M5?;Z6I^ODMK;PB.%43I3K&5+!I0"\C<)E\+W$:?/A4-D+D\1^9))=GMS3?

*BN(=O%$:,ULWRE(QVUV,H,*#SD7],A|W,0VWOV^<$N]\X&&PA:L*U1E|\MBS:(YV9A4T#1%'1GK(IWH6E^?B_AZ"BCC/A6DAXO\$@D'ZE$B&Z9E%-WW4MX.M5)3TT3*

]6RM<;CSL6%2Q4VM-1DF4$8@_))+?-K_G8G6;T4O?;7X3$?$ST@'? M+@,^1O)@7,MJ"/&HH[+M07\E&$.@[-(I(!A02>69$N]O(18NV2CX5E2YUW<% M?

]6+^PMT!;8,":8B^G:.9N#K-6;+=CB"|(OE>Q)UA_E:N8$L`|-/+#_MSNBLT=.CY*'MS.E2WB^=6=&>MSNBLT=.6Z6IF7G5SV+>C_*ZM^WV?46+2J@#+#3|#V#N`J)P+B-DP5?`DH.*

*{)GX>.ID<$UNTLL;#*:|`M-KD-X2IK#N?Y*9"|'_)\"I01&'VU_3(VTA!(_TP^^;*.5UDU$_]VF5TQ7!T-MCDOGR9UU)[H+H2?SE3FV^YR@_WM58E(U%Z.$HG:^L? >(&(_!'*O8?*

*+/#WWJ%SX/191P)H|)RJ$5648$$<^!G_MF>E5R;D?GN1,_7K*F402C_1A.E>4>(S'KD0_1QF-U)Y;_1=A4Q-j;__JU#-G M4?QR_!TY|0&OP\0ZF-JQP5@7Q/13#'0(ZG,0Y/P$O5*O-*

RHPD1FN,.4DTU=G MP^H@X'.YB_W,:N5\C#!TE&!H"%1L+MQ?5FNS\9-1#)YO!V91?RD.H7'QI M.-T.DX5UCVZ.J!%^O'(^488%FY\7V<6PW\/G(I>]^!NP\N3M3F>ZEIFU&F4C*

M67&YF8UI?FO#E2=OGR_Q'-'/R"0CRT,KF4RUFC4^-8J>OCVKF#V&2 D#ALQH MM)H<4Z-L9@561H|7SE8%1E8VM;32IGM&9K"8IJ5B$ZR,'Z],6DU[3FX"'E/O

*M3X@555%3"K\;Q4[??INLK;RD"QHNU]?=83;6:N*M)EA\'O9"K)&)%6?+%E,6 M(TG3+F>VW"@%5IZ\?9'2(F*D(TELN<;V4@MC58|/F\!B.'GI;A>KYJ;I7)8!*

*M^DEKL[*2238.!V>=K"P:[(SDMS'9!8K$/$,XZ5('TXP/=GGHKC0!X)B2EB M5-.;3:$;B?:?@RL-]CD@.'T=)B1\EQD)B%"6\8A+$+/PHF]2 L=1 BF,CY.- MK?*

",91Z"KN1\5&,YO9]!#UG5#*=D462M6<.L))0\SE$YLD[:S.TFDN6VV4 ME,R\HCC2:NADR4:S7U^=H],97A;G]6ATP,CQ1:?5GJ0+^4[S')TNU*REMX6*

MURPMK;E)5QG&$!'4.3IM108)E6?2?9S#G77.H./IY&1UCDL;$;&?=JJ#9Y7.MLNGF8MC-1-.I71GN!\;C\.%M+3H3XDQPZ6G,RJ3F$8'V^8(+B5=YQ7\EA[

*M]DNKJ6O4^!T9M/Q4%!Q5] I\3NQ6U'O>C\D 8\>U=_7Q# *F(O>_|#5#1$G!VIDH/S#6[.W'1*N MZF>;_KX"Z?F_/E+%E7Q,/-MY*:"B!5X)/4,2H#8?COZ_(_#1OUTU? 4@|Z+Z*

M&<)C)V"WEQI:N.O9QT<(GEPA^U)CY;H,7XI$B0$'9!8K/$,/XZ5(!TXP/=GGHKC0!X)B2EB M5-.;3:$;B?:?@RL-]CD@.'T=)B1\EQD)B%"6\8A+$+/PHF]2 L=1 BF,CY.- MK?

M9"9\5FN$T_\|.!RPFN&)43[:.^4B\4B3QUWE;SK=\C6=%,8'+_6B)&-=%<"7-MT,GRO_^,+T,%$\NF6TB$X&'?R H[;]'>32W48SS^W:B%.J264&)^48EYBTY4

*MSSLM;M[[[j,2XSH^@Q*EF]VFUS'/OZAM/&B>?I#X?(Y/',KL+QQ)H*G5]Q9 M#S%'=K_\A)&?'ZA-KNG:.M\MT=+^-\.EYF5]0"IHG5S?FZ7HL6)B-*

J1,$*#N!*PW#AS7%G+'(327%_8W0N M)2E^,j/<3YB1+D$OJ3[?B>K,HBX!K5.9I)3F'M)PPX$Y1=-BKU!47$2I M0.51F=/BI6_AD]5"_^>/4]W=I5]MEOI;@%1OY/PD?

*T,P>VFSPM5;<;A8IS(+M>ZSA0S ML! #:(/)*XWMN;7G[3]?QG5V?SS_Q<;>?IS![.,_V-,7W&*IV0KF2VS[=RP MA%?*&M^C8%4+T.N25S0 [X3IOX6GKR5;"G9:S?*

Q=W7H75M;N['2WTM^^N,%^_M Y7NS?.O+B7=(;_G_+L7/6Y_2K8G$$:%T4F|SFS,=`4\(:A1H@5K!BG8€O! M@U[OT&2_G))W9P>[F=*

[WXX7%FU?!NQ<=6TW4\7;!+\YBRV39"2858WHQ6(KL M.OA^HK#XPAX[U KG+U3L^OQ-"G[.S#X>HL4LV0M=338LI M;S+E8=01TFE^ H\ ;.;8OB?K!>?*

*_WMZHOE4(]8>=^0!];E!O?N+K6:GMR(R8 M[B3B+*GR\WIULU#C,=B@!VA%&/V(AZS\!?+FL@?M^4(G6NA$"YUHWS@NZK/[M4W9Q68P4YEU62^*

+HSBIXJJ5$Y44."]0YO"?:)6'+K30A?8SHZDOB8HZ/N|(MN27+LN0V.]J1`)LO(U%|_U!1<3!1Z+2K\"_!42-6M9G=,NVCEHB=L.C0G:8 MS^%;@5+D)&YEFO/HJM-=W:+%

{4(0A+V'H7:@=_W99OVRY?68AV,!-,'KV+!O M!@0.@X#;^\H?`^@#(FC.G.\&_C-'LY?A-$A#=+'M)PPE$Y1=-BKU!47$2I M0.51F=/BI6_AD]5"_^>/4]W=I5]MEOI;@%1OY/PD?

*T,P>VFSPM5;<;A8IS(+M>ZSA0S ML! #:(/)*XWMN;7G[3]?QG5V?SS_Q<;>?IS![.,_V-,7W&*IV0KF2VS[=RP MA%?*&M^C8%4+T.N25S0 [X3IOX6GKR5;"G9:S?*

Q=W7H75M;N['2WTM^^N,%^_M Y7NS?.O+B7=(;_G_+L7/6Y_2K8G$$:%T4F|SFS,=`4\(:A1H@5K!BG8€O! M@U[OT&2_G))W9P>[F=*

[WXX7%FU?!NQ<=6TW4\7;!+\YBRV39"2858WHQ6(KL M.OA^HK#XPAX[U KG+U3L^OQ-"G[.S#X>HL4LV0M=338LI M;S+E8=01TFE^ H\ ;.;8OB?K!>?*

*_WMZHOE4(]8>=^0!];E!O?N+K6:GMR(R8 M[B3B+*GR\WIULU#C,=B@!VA%&/V(AZS\!?+FL@?M^4(G6NA$"YUHWS@NZK/[M4W9Q68P4YEU62^*

+HSBIXJJ5$Y44."]0YO"?:)6'+K30A?8SHZDOB8HZ/N|(MN27+LN0V.]J1`)LO(U%|_U!1<3!1Z+2K\"_!42-6M9G=,NVCEHB=L.C0G:8 MS^%;@5+D)&YEFO/HJM-=W:+%

{4(0A+V'H7:@=_W99OVRY?68AV,!-,'KV+!O M!@0.@X#;^\H?`^@#(FC.G.\&_C-'LY?A-$A#=+'M)PPE$Y1=-BKU!47$2I M0.51F=/BI6_AD]5"_^>/4]W=I5]MEOI;@%1OY/PD?

*T,P>VFSPM5;<;A8IS(+M>ZSA0S ML! #:(/)*XWMN;7G[3]?QG5V?SS_Q<;>?IS![.,_V-,7W&*IV0KF2VS[=RP MA%?*&M^C8%4+T.N25S0 [X3IOX6GKR5;"G9:S?*

*Q=W7H75M;N[`

M%^3G.IB=TXB;]P=D3.><8995)Q;9:=0G?)Z>-56W4BSDETV_;6KL@4Z2W]2-_M$TJ%4"!\!E7G.E!RVIYVQL7-ES>9-*

*/5\BRQC#=9OY<24>U4,SFDQ#5OICV;!|:.=$V&W>SX!NSP6Z==W5;&^W6N!\C>?@!4<2(-MI<^(/!H<(>0|K^.M'GO^Q+3]R>UV7"MXV\;@^8*BH:*

(>7J&&5ZCW8G!G;=,YYWWLYNR6PU]#H@:<_ML53F0%|/5+==,1/D0Y0\!907.HAP5P^C_>6%PG=,Z7Y(50_0D/YED+K&SD)H[@C>++WB_>;^VA-

MY6SWN&/S=M5'TVJSE"TVI;E^!|Z19PQK,MDTI&2C3WD-_O0W]Y_M^,)7VW)WELP69:Y&,7RU)\8JV=Htx:!(>E1D]=5I7Z.LT]&9.,=\?^-0.Y0-1 M]WW<#EM!JNP,/|)V9=W< EY!+0B[Y-

*ESR^?P$SU>R?L]_$SE7)>_T';XHK;# MS23"'"1L97^[VHP;.UNM9#E-.;),5N1GE;3++#&=>7ZJQ X6*E<9H),RI"(1 *_M@2|S47)>"#36\G(ME;D$.8N!PCS)K*R2-D9"*

*'D6$E^^+D;H5;@3B1#;2] ! M7@JY),22D$N^DE>!?-;KL"VQL"8P["*F$O&[> MQ?!G4B'6=#OI^"]I;NNTG8DP&VK-C5DD%9[Q.(2!#*$Q%1I3H3$5NAQ"+@FY M)'0Y;#,P42/4,+OA*

TR)%2;9=-#K4[NP9:X7)/%FV_SCBX@W^,SV #;E$5G M\MN[QST+X?PUV"96X(;%=C*BB>E$)<;(2DFOC@<4$V5W=1!1_X3Q'"&+ARS^.MP0Z RI%X15LZ?*

+>XJK+>IXXC5GWZ;6)'5#L_$WW6DM]7^A7X#Z2^L">S] ;O|+(>6&1!> MSK0)=P((145X(]9 M-E@R%"Q*GD&(*+D X',B <\Z$Q-*,;("[BXS6Q/!= MF(8SGHW?))R0$RB?*

*DCKEW<*WLM5[/CM.*EF_F"YUB;F75DN,#JHZ_(7+F-"/G MF-@S$|$8@Z+!SB RGVB=\6F|)M]V$*^E8|%L0|AL;.MXS]BDFBI+B2!C8\M.(W]B;*!)6K'0:1#BX$K01,'-M-*

WQPZN=5\0<"T]LX!NA-"^.."D6R0RPG)4_(U274!UB9MJH*KL&X-Y=''%_" M,%WTATLX:#;+/M/T]V(CHMA!Y_IT$Z@V$YQAMUPKD1U^<0.@CZE(-'\WPB:PN M?OT/_F?+>)*

*(.H81.E,D19T<1NP3'+8G^3 3!!.PMLJ*QI0&Y8I9X0=UD-KXC4ZCGJ#8Q*#$Q_W7_L0?9)|$!8 S7XP+Z86UI1^TMAOWQRUV:$%2=@8S'1&_ M$OT<;,2=@8S'1&_M$OT<;,2&AHMI(8U2I#B.F7*A8H*

A#$KH'T M-3CO]^?D<|#@8E8Z@-[(U&7X"|ZP@62.#21_ "B $-MF'3<^\3M0?*(N(;*Q M)F15Q]R(BX @1YX^XM&0G44+!H=2Y .#10";)@4_F1V\L4;W2)?QPHN2%D*

MUDC$NR8A2A(Z,O$Y@UZD(E$'''=;_QK/!?\2=;1(XF$OKL42[?WC<7=NV2:2 M5Z9QL"2H^L,YT49%2&N2:HDN\(^8Y]^!CQ$'@E15H.UAN/KZZ1C&U36"OY>J M.X'',Ef' =%

*N$N@0V#.((8FSG/GSDW55NJU:NM9.7^@@%|"6SQ4I2DP#&9]J+ M% :-'>0,AMH8&!(DBBQ44:&^X]F@ U^9UDU) ^[$5&$9S&'?U5CG%14IL,U]O M5=Q5(E F(=B!S+HOC,.*A?!*

*C/67 QKN\&XF9T<$[#R5*K=[AX-E&!#83 MD:E7]\5.E:MUV@1;R\+/M4ZQEN=]F2+7_M] 1S<3,6\7EA45*C]8Q=PC@!L+ MRH;?,,A&JB828343ZHTX%DV*9V,-5H8DZ3E.H&-*

+3TM'XV>B!T""#Z6<":6F M):[)KY"D@U_#SX1MK@.!|_4C.)^.P0"%X=@&P|^-Y O1KU=9_#M60B=G6W7! MX^=|+C>S=!-OGF!W&[LQ,HXWF@+)1=@"3WLX1LXK;5Y_ M!@

$W5KPE=6X&R7KI"J9*,^>\MK--QF^@;04+M ,,@' 2> M!"#NE)7X+@)K;N=44SN6<4L] T:$1=U(U32A0C5:YV@\)17 PRTSI8C#K+.9+7

*M(${669!N_OA%/9YVN=EZA!Z)6]H'QR(.4)9$!0K!K8#DH3.("!@>LZ7_717(MR$V_^R8@'\!I, ^$?\4TA/:^,A-T]S(+-*D(V&(>1 \U1RR9Z-39\#ACDS;R? -H1/UP=] M X-WZV'-*

*^+CF$*KAKGH^HC,(SWN<56L6BL4<.VV1&;$2'5?XBI6+(&S\[@Z=\I<#5O9SKI4[[7,"$DW M*E]*%)G!=(RPE0S,Y1.D82-T@43 M,O&5F/@/$59LI:P1,:-:I%=OZ?*

*90V"3S_242N\QLF*B*[7M%9(I29YM W1] M&.@"fM/:_./=OWB2_:/XX51Y #LI9&6[ABM(@7*A?RE0WED3[GH1YG>&[7JE.KA,\24960J8SN;#HN>G- MS#E+:.G>E:H?*

#Y11H28.-4Y=D,Y@ M8H%.O[G\$ZIO;Z'3\(&#_ 9RW4#,4%>P V&-5]J!PA-%V1J&W6Z% 9%KJYG M0+DF%+SAC'V)"R JL:JF#99:E..CH=(!S=?+KGVFE:'N

ML6<((=7C&7UES]F!-17LUD#3J;DV0O3N'4E\ ,SZ6%D M/.TL-+603U)4HJ@T$GO,>8)E7_LC<+S+^2/)5QY' -]S[^N>^XKDGZF@(0G\ MA@3>JJG8-

*:':2$2=*149VLGF(TXY/R9K6F8]F#;3>E^E/!<|9>Y?CG(^8AZYI#+@)K;

*M=>HQYWP@W#60;3]V,[N\396WULIWQ1=}\R'XZ=K/PC2W.)MQTDN>H M]M93QLT%77;'D\%8;UQ9-)QJP_WXS=)G(OL=PC0Q%D5B32(8FHXC/C&3[\(Z MCA23'T_^!1N5_(O-6SCWTGFH=P8/K7;>OI[+UZ7.0_;!\UEC'|S"QZ4B6QLU-MG/.B4#0NV+S@CF2\A8O?:`N/\>QP>:!;Y3?ODPM_$7=!.-I-4&5J[&;C5C-1'-MH(F"L.9&5^.[@N-ML]V!T4BI6 M/22.A1'Q*WTDD1'Y.(@9B36)$RH.H,.TB&#/U[22[!7Z9L2;4W-X5\M576XL-M#]SGG6LE]^>}3.&R>TVWI7QMDE5+%IM(!SLBSJHX2[/T-XC(Q'@4B36)DRI. M4NN.F3Q.JC@!5\.KVWCK?!1YN;^0[XIS9M1WKJ52)}?2>7+D.)^CC*ZOSV^&^4N\944IOG5^RD"=NX^'VV\1C3XL2*!Y98L:C=,&#,P'/11:HW7-K>S>%V?T81R" MC.HRQ9D5D7 W!/"P,0YR7FW=T:S3N*2E4GUZ6Z^7&FINYZK*\|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|+'"3!EZ:MP9[ORU)U MR=$F*CO]Z;F86QOS_(MEDI#3-4)_>A/CT2Z1VA'_K @(M^"6_TC4P *-XE^M M:GXCB>$SD@>T&^M+1T-Y7_WXW<(G_YH]*@!*"MKP XI+8;J_)D##+2[UI:.7 M\Y(:-GCIZOREZ$X;[OU#OFSELL@HZ;__R-N"*^UV.M.Z%,+]K;E<>]JSN'MV M..VPZU<.3&[2.I^RIC!*[#/]J9<;.DVODZNC*U>F5+SS2R+P^W&;H\&URGAQC="_MJS2*9V96K\S1%,5+VC;I- WDKFA>J2_]&P6N9)C52P5Q1*=+YTUFV"Q><&L6\M61";M_T.UZ%7KS1R%Y6+2KKE#J4VU[6+C1Q?U.L=?OU*;?;BV_/L0VZH=>]D M9RB)A:K31U>N37[8? +P>M]3G2E%RYH|F[Z&A6AP\KHOJ0NQTFBOVG>I$KO(@SN%)-R/,PS M@I$N9(3I]2-NS0GMP6YYRCY?#;6R M/&B-$O/;O#WMI-;7:8[6KJ_7\DTZK\VU2FG8&AKU.KIR;.3-EZ?4+?-0[@^?.MKUVI>&G-+KEN%EVY_OI<*TEL%VI99\[.+_I*Y6Y>]K?PC/?!IMJ&G9-ME_;E9RI8[F*?C:NKPO M+N?;,D_NU/B4\AX1%PY5KKS\O*FJ'_Y\:1:DTOVJG"E*&>YJB*]=??U.67@&7 MT[FB-*X\T_.45A%3TXZX_OI:N2:)+'UG#IMFK99]?NQ>5RMU4OZ_?&5!K;3* M7#M?;=^EZ]IM8>"8[L\ <_WU'6E2X+(}^HN$EX44<_7"]GF%%+MU|!?$EY2 M\\S3(%T4BHYXPT@ZRYA]N'1M_E.$,Q4I8^6*S_?CAE"@+9:R.8ZJ+6SUX\:|-YPI5[!=Y\>E'"H>^U$=## MZ>R:,PMWQ? +3[+K,5/H-I0$_=7T$M9J3<2[L>WNHG5_5A?8-U86HG5XXX339' M2"<=C51%(X6$STV*L1,G>Z/+< '-,@_AVRT5(F9+M\30L@?>2*6_$\PZ;G M4F5@+H+8<(H_MHGUSWP=,),)]D.BRD?>NW0QS^? P M;M#NU429#&;%E@D>82;SAF7T(;,HUGH.S!R$"UY1@PJNVC+?X0W]^K%E7\:-M5T-!NGAXJ/9NQ^WK_EN\\1XPG;B'O/BF1_L#CG+-D)%Y:GM1||VF6 1.:_[# M A2$/B(C0). [^MVP;SELD=4*]530X$^ITTZ>UNN M7D+R1B]].4L;;?X[HV'JB&G(/;OU>BEA/-*)P9P?R4IM/-E3X"$_[!;DWN-C M:SAZO+GE'M,B:]&09,RF-M/0BW&'PTIR*](0<|>- %2\]PY$TM0VA+YS7Z=IV MB9G?FO^*.?10>;\YWK6(.GIT-%6T(#|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|%&NF-F\II-PR,VK/L2WQ-&4FW(AB2- "I$9]*3*@05BVM4E^VE9E8%W MN,#]@;(-'|_*#,"X##TG/5]Q- 58-#]p_0[2W=!&7GA?T WD1 A(HOIY4\3 M_0D\$E]_QA!?["&.%]:$.WA* -7HR768/>C'MU2:SLOR!#MM]U=DU!-+=" M] W=O"%P=20-R>:HV=[IB+8;&D;0^%:V-"R\(=_@HM08289#UKH)&H.)*[NK-M5E\R/-*=+L68DQEBE;Y [E1D4LN%.@XN3!.+CREY.)#-!D)M5S(5YM5W&7A M/iKKS:*A,'9=O+Z@,'7?=(EL&I)(W5]6DJ/Y9=O+Z_.\U/[[=NRV)*5G!#"`M!5X!V%U]8#M,U:H&TO*6BF9$!ZMB4.0Y." - C8|R&/|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|-ICB(?#"/Z1940X1 '>J &BA&!-MDA4EZ0U:&8>(3X^5,(RB;R&T!MNSE_$+ {3^, [>Q<8I>HHYP([F0]RX<=8.S>N+&IV/4W@682OGMC+'G-[#;Z\OIH:2R,ZNAG2(=3PNP])L$>'6,O MOAVZ9..20#11TCO,;=RQ!;KAKOP;)0P@$X:4^ MT@66&"T,G3@)DJ;UE2W8(O'PI"K@P1Q:1NDWZ@^!92'A70D,9 M85ST$'@>@KFA>6FP//$*V1[\E8-ZL@Q@/V2;ZHY#HC^W^ $]EVA:7DV)LMG) M%17K*HM8U_8V25I0>\C04E2([A!-H2U=;1*H=C&OP.1X12LE"RD,AF:]>M2&M/34?:E(HE MUK7F"E_GI_L?^6SKD9_3#X.Y.GU(M#E:.[/3ZU_..M(!UES=>N0WH^'%0+[7 M9\6$,A $M#:,)M4#K+G\QL@_](#U-DM(^4(09^W@:.+LHUI.\[=PM2,C6I8K(.M%K:I17(^%63G@ROW!:HW6C@4I>JS/LG-6QN3T4,8ACO})+YHRZAK,L0S0(.M=P#>1 ^_T6\2>MTN]6G>=/4[!;'@Y>2U8.?T03E>*2&"/E=,:!M&7<(.L__';+GD^3WV>#+T-$MN0TN!X+C#/P%(]0]A+U5@T MWO*L4VO9!'V9W#'-M+4QI*&.*

-IJ9/7H:;TK,M3!PM-+"@VWD66C6E6LWEVW>L[:9JZ8;&3] 0 M5$3(,1J$8[GJ+G+T-](#.U!-73>GV"'^*PV@X-(:8U1E0$F6{W0#EFPB4;8? MBO-1-$F&YX/@>H>8D![_2? R_$Y#R\!*MK MJ=(P,46+\,_8M#40]5^6]N/8Q\HSO97&+_8OE;]VJ;N.NC+1KP[MDVR')UZ M*]B)[!LB"QA-+?CO'Z;_L&),ERC2A7ZSY6-,EY014BF8I)$CROT,O-F%F-, MET/!&/=F<5Y,E\/0)9-DXFT_@G2ADT(L+Q&D"U*3N9@NT:,+D$S%9F4$Z8+V M_9@L421++"T1)$MLZ>^.*%NV17G747FP1= 76*D&V7!+9U.'+ M__Y(_?CL\B#;::V^-UH=EC:L:'? H>]/E%A6O &R, 3ZZ_9!G^:8B6A$,L;IFSCAR.ORT ?P7DLI^5BW0R MO=#0=@ZJCEPLOB^#+:0?=OY_>WX100SYX38I>C5]AW5)OV%__??S%"_<_;[&~@ MV3&PO./%B7'ER+EE,Z\\3D4I;//=]7DO"J3/!*Z*+C.\FN50KMB7]6H1F_LA M-%9Z\ODEAUR&K^BG@.]J#GNTI.8..N&)?N&Q T25C!@A#\!/W*&/;-H-/Y.X M?^09>O\=Z? OL[CDN'@@5"WA;9"'HJK'XM*$[O[V4%8[S_Q\G_;MZJGM#MQ/<-MU6/"+=[-TH^?;RFWJ8W=G>8,UG+-[>5D'FG&RF[YXV4F>;M?C'!M)\'F>J=52OWSWN?[PN]KXUT MJK8OV7[B[KY8??3=\;729:-+,-K(&1;M!3ZC9WT^((E=^L]T S<(PQ7<'UU-M9CB]0,D>3>WO->=WBBY. %C?*4W=-F?] N%MT;76O6THI/N2K;J0Y'X_'%3=.PV^(LV^'A[)#4F2"^!;^G M$G#;HTOD>\WYO2]XI9.(I:KLT?;^GO-^;T<^>/FXFC%*/=G4'^O*>|'Y?U#.M!CZ)[&E^T<9CT8HC#I.>=)CT0.; <=W.=Q1;>VQ9>6=*,*|.V*UZ_SHI1E"Q(MVMAD]1G"'^.'Y;OZ4+>,O^<2]T)#OLJ-Z)P56'WN62;UWLHICXR<=&S^4,1BC MV&=1[,_C ;F7NMA\'#U? %IVK^[$P[96*H^5GCZP])X]3'OMNX99/]=\@^X\ MW1I!O?A>;FR>0$\IK/WIC%RG?,$%^M%4D<>FR>0%K!4^15L8T ;BJ'!QTF%/L.TU@#,|_>&R+AT=]]WV_+QO?Z7[YS]X7&+ M8XY_L4P2')PC]*>=<4 MJT/A:MZZ,._3?&%>[\"E[*XD;QVH\6+"9N(MIF90LF;)(@A.B)?1>YR!Y"!T M=&T"E0%X):F"B_5WNHT[;/PR=Z4HBF483K40$+ #U\LD!'10G-L@IYV&#X! MO!NJ.U55@K((P-\#&T4 TVUH",?&^'T.^NXVM$ &P)(DKP<.PP_>U(\EC2&;.*%9M9V7X?/-Q?1*3C2Z M.VGZXW>@LH:U!*YMMM|0IK%$MNA_5E>6F"L6. 14!8; OR*E$F'&EM(1[#0 M"K^I>> O-6.BV@YY,9(A=-M0)0>O*VIH7#0/45,R\2\H#NDXS'/1_&W.[?C*Z M6U%'GNI"%!HT#X1QB%D2ST@# !6BMS1CS7%A'DDJBZ<"[VY|SOT9>;OBK3J1 M276&#"W%DWRDK*#18,& %@'$|H4R)YI"6C79KARZOOI-Y70J18:@$=-JA+< MFC>M14D(D*36=-0|\OK7*-G[&6QV72U=AM2!A/C&H*1^WU+|Q+Z/XWOR(I/, MN&; ZKEYQ5#0+*PYMCP#^]3GW28RI[#2TQZ-['-/R#$O)>+KN=%K7M\/RC3SK M=*[+345>-BQ36QB6UX$@+L85V(5""%N]8[5Q[M*)+-VT>T)FU'I*/4C\'[]9 M(;E>344AZNIX\=BKRIORSR6&6A'9&%P 'IU)6,(NR>6U4"8;6I%T%5XX3!> MK-.<.S3-N:^E^?W$R3*EAT:A/,_/WK=+W>Y@?+X'FN?8SK7|Q'?OBFI1[_>> M$Q>-NQK:3U)| (\TIRS7:).T#.<'&K#C+=&R=1A*!.5.VLG$FYKB"|7 M9I,_IW>/R|MRI8VJK/\KFRVYFE'|@1LD:YE(^L$G9HZ0IM:3@!2>2H*Y+ %=>K@]^04J$KX')Q=0?>-MYFD^WKP4-|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r(.."DE4+(A64K]"%5/ OBC22H/=GF$U# MY-!ZR_PJ.3]^U@]ZD!0&?Y"&YPYX W@W3_IP.,ZWS)[*LDMGX<>B"N:<6LCC M%UM"2R9^96F#"A/#=9!E_P+XLU;8TSI8>]6M@*'+1$ZU>M2S>1O^:I/ M/Z_?2'-,KI:9E3%>?-CW.&YF'WNM3J56%,X+#_E^3UWB73A\G? _#L46"C)XK3/.#]Q8&^A[:+]FJ[)AHY3PI"UBFVQ\@?I3Q>L*W MJ;4IM>]37OU@RT/X\W#;?U=L5:ZH_QS:8HSU9(U6]VEG$9D<9;A0L).5JRJ M4.&5L1=17\- T/&,4&!{@[=%5ON>#+KW<@$/-T'4!P'FNUY|&L:C6 K*%\5V_X M-4LM@6;F^)U*-BBXV^.0ZA0[SM,$;;C5!I37;FZ?+\|'T^V=#EB]W3@3GP>5 MC69NOEZ]YJ^9'%/4:M>ODA0MZBG16AC[C:7X=@9:H>>8Y@HB7?J&V:9YN MO1M"?G!C."A=W4>Z)!0N"^7B_/G\V3)?)}J:D?L*9A.GZIB?)IV^UMS:3C12_ M/W>E^[9M8.P:=2#5LS(_?.6K M2'=6QPI9\YFE++)16M====#>XE%=!9OA[&Q*PX"X88!N<]=4(=L"9QH/]U% MQ.4.XT6H,.OIM#0'7!T50P%_*AHS!@[X\4\@&+\W_!7@J8*MCVUL HK^%2S#\-MM6-:*Z8IB5M9//\CBY<^AU6_"XFNO MN+R%:GK,S:2B02?L&3=(Z8U;M52'.LG- #N\S:JR[B,4H>!20"N>I40[B5M6A MNJ;AVEOL/DA?5CN/-6EHYBNZ35.6)$8H9=J.F>J_LO4,J M9'/TG?;D:K7LXY4\W-K/3CQL:#-"#T:F?;67]RCS@ C3PG3) 5D"\B?8$/T? M'AV-2^@W'.W64FUV>IW5LG=.1.+)RC?3_)EZ'A5.GD'@L_[KX\6,@"(+U1A M/T%.A.5W'AK0(G*3&9UX!(;IDZ*0+ 5A9@$;J8I#.?47!I?R-C:0L6MCP2W?VQ68J6_>K2M?2 CV=^"C$.LDD.7Y2W&MJ6DIMFHL\4]VE-'K:U@3TO:MT$_SA& M#;.P%%)]G(&]FD>*4V06F\89#[":"40WR<,7WPH&=MM8+75LM3-B7#L3U\Y\M@]J9-]-Y=B(_I8#@P ',$G3'*B2[@Q".?$R9 -*?1)&CK>//|T^SO'Z!G4# M>6]U\?;QP6VCW6X5TVGMJ4+GGZU&QZCR!<%^<]OHF;IN3OWRILV$_TM#^H.D MZT@?]9)(2? 3+'}.BDJ#TO*3@=#HB3HC^P%&86HG5XX339' M2"<=C51%(X6$STV*L1,G>Z/+< '-,@_AVRT5(F9+M\30L@?>2*6_$\PZ;G M4F5@+H+8<(H_MHGUSWP=,),)]D.BRD?>NW0QS^? P M;M#NU429#&;%E@D>82;SAF7T(;,HUGH.S!R$"UY1@PJNVC+?X0W]^K%E7\:-M5T-!NGAXJ/9NQ^WK_EN\\1XPG;B'O/BF1_L#CG+-D)%Y:GM1||VF6 1.:_[# M A2$/B(C0). [^MVP;SELD=4*]530X$^ITTZ>UNN M7D+R1B]].4L;;?X[HV'JB&G(/;OU>BEA/-*)P9P?R4IM/-E3X"$_[!;DWN-C M:SAZO+GE'M,B:]&09,RF-M/0BW&'PTIR*](0<|>- %2\]PY$TM0VA+YS7Z=IV MB9G?FO^*.?10>;\YWK6(.GIT-%6T(#|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|%&NF-F\II-PR,VK/L2WQ-&4FW(AB2- "I$9]*3*@05BVM4E^VE9E8%W MN,#]@;(-'|_*#,"X##TG/5]Q- 58-#]p_0[2W=!&7GA?T WD1 A(HOIY4\3 M_0D\$E]_QA!?["&.%]:$.WA* -7HR768/>C'MU2:SLOR!#MM]U=DU!-+=" M] W=O"%P=20-R>:HV=[IB+8;&D;0^%:V-"R\(=_@HM08289#UKH)&H.)*[NK-M5E\R/-*=+L68DQEBE:Y [E1D4LN%.@XN3!.+CREY.)#-!D)M5S(5YM5W&7A M/iKKS:*A,'9=O+Z@,'7?=(EL&I)(W5]6DJ/Y9=O+Z_.\U/[[=NRV)*5G!#"`M!5X!V%U]8#M,U:H&TO*6BF9$!ZMB4.0Y." - C8|R&/|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|-ICB(?#"/Z1940X1 '>J &BA&!-MDA4EZ0U:&8>(3X^5,(RB;R&T!MNSE_$+ {3^, [>Q<8I>HHYP([F0]RX<=8.S>N+&IV/4W@682OGMC+'G-[#;Z\OIH:2R,ZNAG2(=3PNP])L$>'6,O MOAVZ9..20#11TCO,;=RQ!;KAKOP;)0P@$X:4^ MT@66&"T,G3@)DJ;UE2W8(O'PI"K@P1Q:1NDWZ@^!92'A70D,9 M85ST$'@>@KFA>6FP//$*V1[\E8-ZL@Q@/V2;ZHY#HC^W^ $]EVA:7DV)LMG) M%17K*HM8U_8V25I0>\C04E2([A!-H2U=;1*H=C&OP.1X12LE"RD,AF:]>M2&M/34?:E(HE MUK7F"E_GI_L?^6SKD9_3#X.Y.GU(M#E:.[/3ZU_..M(!UES=>N0WH^'%0+[7 M9\6$,A $M#:,)M4#K+G\QL@_](#U-DM(^4(09^W@:.+LHUI.\[=PM2,C6I8K(.M%K:I17(^%63G@ROW!:HW6C@4I>JS/LG-6QN3T4,8ACO})+YHRZAK,L0S0(.M=P#>1 ^_T6\2>MTN]6G>=/4[!;'@Y>2U8.?T03E>*2&"/E=,:!M&7<(.L__';+GD^3WV>#+T-$MN0TN!X+C#/P%(]0]A+U5@T MWO*L4VO9!'V9W#'-M+4QI*&.*

*{P'L$/_/\&9CI)0NKF8N1XI4D@7S_=!$(Y,(X M@[+=H#C-6\(-]6OP1.R>0,_TG2@3\]D[_#.WP2WT^@4IC[R;>D>4+*APE!%N M)HYPQO'N.,*]*
f78=WC2S'EQ420MYR'Y9]DEM2*Q>@_QPB;$/WGG2I6V@!CWI MP[@-]lOP(K)OA3H7@(EN86\G6F, ^Z#IB_]N?\,BV+U:"N\!Z'+Q_?%I+UVS M.!D7?B3?>3B]2.H.6OR_/E6"\L$
,5=4/)&F@=O>9B3@.MF$P'KE_.O;9=+:,&\KWP0E-_8TH:D#9#]S80>^)MQ^$(X MG IO8F$U#)$0^^<6TP-_LJZ&4NTD8]$^VG/5HB7PVV>\/I$D57(MV/]0UM$[
M\^MX5]Z">\/M>W!#)U)$@WZ1=-OT#[`_`?.V5Y%&)HBXD,2F=@>8W#A,H&9PKN[=>GOEP]%AXY&3%VP09YV-
X$";3Z98#>EV&Y#"H$T=O\>S9# MA7^E!H1TC:!3^J:56LIG(&IY$ / @<,W%AGB?8XCR0,5^JR@]31! HLS$B=%
MVM*N@U7X*PY[Y7]QPI'X#-9.9WG3Z4+###EU\+4SFY:HZID1K,!F6 F-=O5 JM7>!@A6 M&(]<&TU5 NNS!CBZ!#;C%670/W@H6/E%*C4&5C*QQ3RPW'L37-X?5D?413 U M!$ E*
R!L/UY&I>7IX!^Q!=HE@VBOQ"NOX'ID"KJTNAIKV$?B+X%(#W#0W%5%DP\;"LPGPZT-@<C2WB I?Y0>>D+DON95+%4,G\%|^7R[1<=79T=_:,G^ M@'W$'IWB&)7IT&F>0^RC|01N6
,8%X4&%IH<[P*BMT)$Y5.C)'RTO:5FB>76*O3 !)X)W6ZZ;3:X64N)2@I5])3W7698KV#+>=5/^G9[.5)7X.N^D%LD;I/?,=|=+[<&:\@5+
{BYLYG.5@*I,M""R9\)F[B\JAD^ZNE:3G6F/%IXKFR$OB;2,+ GPT\PD,- MPNOX^U<7?'$3>2Z];53\>!(,V.AN:7&"09Q@L'V"@:>!2$HWU1,EL9-)B]T.
M+_64CB322*OGU92H=/DT3S/K&@CG;>1XBP8/[VMNR6)7UMJ!=W5?EW M#W7'2@F7#-2/I6$OZ1JMU?9-ODT>*GK)O>76C<0_ 5Y-5L1/)9411#[5Z6:Z M-
#A3U8XDRVR'R4B]M,K3F90HKHL!'S1-7!2]E%05)*$)31MEU=ZY&+SK>'A?_M,OADJ/MCN'Q'I4+&_F1BOC\UOD>\!+=(THW9Z:GK506B?Z61D7NYP4HKM2H*0 MX5GNQYK?]
f;3SK"9#!TUM^_MJM M[>D/|;FFKI$\|F\U-,C%(0!6^9"TZ4NRH;^O'R$"E>)=%(/M6LDY/!JSJ'$W-OM<<-KU?:S64(OPG%?G,F' M2ZTQ(GA'JOD8X%4^! V:7WD63FZQU7=&] NOM8--
-_8QI8Q&-JZ-+;57_Z' M:I(V@FP\\(#MOP-K%(@<WG2;>1XBP8[VMNR6)7UMJ[=W5?EW M#W7'2@F7#-2/I6$OZ1JMU?9-ODT>*GK)O>76C<0_ 5Y-5L1/|9411#[5Z6:Z M-#A3U8XDRVR'R4B]M,K3F90HKHL!'S1-7!2]E%05)*$)31MEU=ZY&+SK>'A?_M,OADJ/MCN'Q'I4+&_F1BOC\UOD>\!+=(THW9Z:GK506B?Z61D7NYP4HKM2H*0 MX5GNQYK?]
f;3SK"9#!TUM^_MJM M[>D/|;FFKI$\|F\U-,C%(0!6^9"TZ4NRH;^O'R$"E>)=%(/M6LDY/!JSJ'$W-OM<<-KU?:S64(OPG%?G,F' M2ZTQ(GA'JOD8X%4^! V:7WD63FZQU7=&] NOM8--
-_8QI8Q&-JZ-+;57_Z' M:I(V@FP\\(#MOP-K%(@<WG2;>1XBP8[VMNR6)7UMJ[=W5?EW M#W7'2@F7#-2/I6$OZ1JMU?9-ODT>*GK)O>76C<0_ 5Y-5L1/|9411#[5Z6:Z M-

*M$]T@RDSP%;DKVVBT;Y95+TB93&P|PIGS/GU#GM#2-OY8M|@QTSF]&&U$^UH" MC3?8T(2CN-&XXI7FGJ5C!'US$H_ZTOWN8/)+R@4!|_)249DOLAYG)J\"I9 MG|^H:QW,3>!/_K:OKVT-&M!I?HN1!^$IYT|)Y5MG\%^$):I!C<08O>"VOG" MCT@-P-K#V%M,]{*Y`_Q\2NL)L)J4W9I6,>LW>OU9">K/?%A5@@,&U#IE2U3*

*M09NEM7IMHU&V?;A7LS(8J^+PHX."G!QK)9,6-NG>P6?0UG#W\;D^[C;D F"+ MW]++]K/CI*EC 0)S]JHF"]U2##&IS!70M<783-!2I@;JV@L;'K^4*

*M"^#L3TW04^ZY+HR(F&SS!PHZO\QOJ,=U_ X9A0M^FJLX7BLP0Q0:RA5RPUMUAG M7^GG*UB5,]023GQ OYO]0,!CMJY=]"C%A\8[,+#4QVBT:&++;(@#;T,*3U027=7*

*M61RV_=4ZJ64()25%[2U&MW6E"-\,'%RXM\W%N :)5VV&[G%AZH!H12<)=+.T M*1X2"$*NSW5]+,:>?)M.'*Q;<](KBW0/H(5868P83F%O!MUO+38'18SERA,T MF:'$#FX2|*?"C>R]K"*EKS""$$9C/,@9BJKKE;3V1(2%;"P?AZ-SKP'S\ 7 MH1L%?$.1=(;;6RY#6EDM$G8L%8Y+;G#]^'A^7E;>@'X/?V,W3&JK]*R/F?\.%7Z M(_?8]VA^$R8>5@\V*M_9\P-*

*;]{4>C;FYFVZA[#Z0UCI(<$^YI+|-\L$ M"0%R_1?M",99X3\)(s1?9 X5+_50OMU9W%23I'UKC5X1 M[8S:A$46 98@,&\]RC<2"2 W$2.+TQ"!DZ%_':?P^_*0%"7MFC(,< .<=< 6'5:]*

MORLRP5U!W#2+))I4H&+ "+[^0C4#=:PF:@\F:07-RF/ESN523. /FK(;X;.S ML[1L>%%62[H(CP>O]0M31C>^$) (W2BZR\\1"6\PQF5 4/LG(-4D9%,)>RC

M5@;Z9XZRX$+>7WQEZY3T9IE97MF 3'2LFA 7A5)/*8977B#Y,RE&S>R#0!Q+ M1!7D^E25]OR>//C(A9.MR XW9X3#&M8[JZ_E,%>-4GNQ{J>D*1=NAQ9$?J1)

*M5!T=/DlV#1_2#_SG<+QF5ZU8,O JHAV#13?2\9 >3&$H#[KN4W,%M7+T -M8-A*B@Q=#8B[Z'29?,D&08F"GZ-S&;A.7A!' S@V11T=OZ<4;<4=>C8[HH/W>;*

*<,APZDV(.<0XP ML'1 !4&%F_,3BM>%?:/7HYKL%%_N$3NVCO8/#G@7S/ZO-)X;*K6%31

MTA\"2*T=$0P"-50T^U"PP8]"J#.O(3XP^$T+4$IE1_(R69#!>UW3R#1%W:`MW^VK,CP*9&)$;OBKK\/2))/OHTVU&068-P;UGS;N%=*8L)91Z1=%2^CYQ)6T~MD_S?FQ/.Q2HD3ON-%J;5+9OUS>W&O<;2/Q^PR5[__(+DP_GIY3^B7T87T;OWE]'+D¥-WT?G)SZ<7ER?G)Z^B7T\O?XDN?SG1M*T]/+J+1NU?1R?\<_S)Z]_-)=/S^[=O3BXO3]^^B]^?=*_TO7\/O_A%=7(XN M3Z)3?,,;T]&[XY/HPOE\.WH'=SQY>W:)E[X^?_]6QG_^HD)^O'MUTKOYZ/@2 M[WKX[/"C.(+AC]Z>P&6OHAV\3N#\X>4*JX_Q%>_Q\?OSU^=OOOYS3_BZ.WH M'S(!<-/7[>IZ+/E?>#S\/]9' M!&,X/_GGA0:mZ?G-(H+G*!,:;XHU'F@=:*5'9V=O3H]I)+Q2WL_>C'Z]@"T6 MB W.&LS8V9N35=?I'V/W#]f=|+CY#M&+]^_&T6O3U^=P-7G/\M#/\"[R_>> MM+T\?_^WD_.]5R>C-S!U\.[O8>CGT9OW(WNWUZ?O8+BGHS?PL(O+T\L/]*C+ M7T:7T2F*I]X\/3N>'}H_K[R<7E^W/E<@59>74"]^:$!GW^ E^6>1RN7S!L* M?8G#!7G^([2]=]PC@,,K,2# M1Y%US3>V10Q;9^=LF. 3S,H;1 1.(\8 N8F?5,GZ^DP_PGS4G/O2XZ5:N]+MQ\6/HU'RXY ;91S&DI>URNSR!W>[&3XDE\Y22@\)?N Y5K*-W+)u M:HJf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`V=$"O>M[>(4O UOL,#8/NM^108(FC!R M+I6!WB');<#U5% SK-MGQC631:T%4UE0EVSBRADR'[\]Z^2>HRR;[6CQNJV* MK+Z6SNBGK@$8YSQ.O;ZZIF";)"RZU!(^3\.'YR^>9^H M+L<'>0]QTR"KI_7/T2/T=-CNT)GN3@'8PQ66\I.;(787Z>2GDH((ID&F&7R\ M0[S!>,1P 1>K38_J5@$3N/GH%UF]7/38[&Y1BIYQ\)6$ MNV!*LEL7V5\:[>SIOWAO=D3;<)HK:H1M?GCEF1RI<14<^AQNW1:,&FG?]IVT M[CB/EJX&-8E-9UG3*6OJ%*12#I@C&#%E8V!N,QX$^ C8ZQ.9LP=?SD(S.+*$ MI;JK63*H(Q_A)DZ2](M]4H:F1U"Q_0#S>2Q%@TQGU$84D.P.H_]CM$.S.B. M,(#)A4'CW;,P@7XD&MP6G8Y15S+_O'&)P'5FD] >3#)0D<^*PNSZ,ME9DNX M]'#]<@,%PON^\W"+F:=*7B*|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r+ M;9@PE-(9H]*Z`VG,M6-X@43'8/IH"MUCI[1]Y^0D-!.P0B8!]9@D0Z_PK%(]MPGYV+52R;,QPG?J^8K5OTS=++>76B1=#VX MZ#:X,C(6-AY0],FX8Z=^+-.&U0SF6O :CZHUX,$&9&6%A>H<)0$#O"!84Y42^. M_H>.G.L>>%[@-300@O? &E,;NN$NWAQ(HOF34G;Y57FL)Y\,_:))9@*JL@!? M_6V2Y4OU[]AK_418OM+6KD^\^[I]U^F_)M3#F(\ D0*/(8^C,6AKR;J+NZ3T M T+@8K/F9! I,06E\YD-04O)>\.EY+X_YILLB:,)]LYF6'D(0S?NQ6>$>EU[MX%LGHLM%KY$9"]KLXMV3#A%+S[0N&IK_1.+;,H=L,*E7KJ

MYKIP"/C)_0[1XKUE6,/LI(%)K>WOJ9Z2A!}Z\9RM&+2QJ;_(+(@.J%OKP;M+TA@=&W<".A#YT@VPGY6{22WBQX2N?2,RI<(08DZ-?]HJ)[^B?'O\A5(T/"V MH!MX8\MWKW%N{=X]IV'C_^QFIV.Z!=*6R2C:L!$&HZ?H1GLI?;AU3K)U;5*.M!&80 X&,#=A2"U)RO]SP<$0Y+-?[-?j=%2K]X#9T>M$7.%NX*WX,)IG\P>8 MH#U.^QM;S"IJX\XGD&W]=!10B+\@W@1W*X<\E5+],Z!0^BAA@,<-4=V"4_J060!C>1"65]HQ8]+$!=H'';A M38%G+&B&^$###R8KEZDT4] M?]1L2U6T,'7!;C4P_W/17?Q4!\-A=?KFEY,/4;$\+W)#')*T;M/VB:^-)OX2VJ.M32.EJ9NJ=US-O@VG$S-[=L.5IUc;R]\T M9.)D#>+40H9)M*!DT!%,%9GZM2K9J9ZNE9PN5I=IOI,KH\W1Q7U\W3&K M308/;_-S% /[8'!V!B%69&EYI2&&-RDQ94.[H"V^#\E@&6?90N=!Y8LU=UB8 M2I*OOH7]W=?ZH\$*_Y.7WM9TG'EQ;D4 0/Z<5/"23TOD17 U(_WKO/"CZO}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j:,PQOWH=#T"]:JCMJYZL%Z\=XINRCIQ2^M#GQ+0GZ"X"(%C;S[N MGXCXIMQ]1W?'W7?Z&<.(.A+DQ.LOT"VWN):04-.*)OZP""">35E*P?O*@IX9 M6^AI6(L0]*TDG\5]SE-VZZP;@;_'[*\#-QR.H*]5 M:';.F1K_D/R/IWHQ0PCV0+'HFE&4IN/&^<|U,S/[%4+NNO,>(WBOP1M=*) M!1HX!:6VR.UCG[19%:T'SH40?!#5!M1>ID]H[!>VL!"$,JKY/- QR"U[3*&Z M:RP4F%2UV63>=5199/J9PF8C21Y.3-$8(#07K9CV]+_6_1_B_[?/_2_A:7O M)K3'+1W_DBDB]3!%E2[A3ZYY[\E'CU[!/5+E>8,D[K;$W);;"A;HEP7316OM41?^\][fJN!7X748%IX/M6PO_Y}HNQ[PSSIQ(U_0 -L$+Q=['%V1LFS_*+&=,MM^&L8-FY#US@%EKZG<&L=O3'!W&+$TKS3Q-E$T?%6N(HP DWN M^\-L9K?0M8%$O%SJ, MYO"#[0A=W46, M!0V_(7_+F]GR T:*FW7"+"`3[1R23'JL5[5AX[*@*_(445"#$L2M_-WVC6W2[":@"#02.$N,\UM= M@PS;B\ [YL)/B7RYM^10,\;"5FV&BQPS&2W4VEDV)H1H@ -LOK$/>F]&22Y; M.8&73]WVX9D]W!WL\N>\6HG.S*!PT3>THIV:#=KKOA#(QQ `:(MG=DDX'6Q*9 M+92]A;+O(93]4#"DT5UC2" (H&3_RBSH)?E0@,1B9_Z;&WE]9G\);LA\G"ARN MJ&9[0(5#+]H0B1ZXQ;^Z^]&6]!-EP;96P"Q#B[/T=1I]ZA9%,9=:$ZLH;@FL M@$OQ-P$I A,]5-R;5FO#NCB^-9NLPRL;K4/M\;YQHQSM#QO8JFV6JF^D8I* M8F/=?,,PJ"[7;9/5K-/01'/DIRMJ#;2D:AJ#Z<;C7FW;6F/6?]2ZK&2A5O9N M,WRDWXU%_ W.V]\PLKO09#O$ET0%S.W/)ZA;N_PG(:)6;CVT* M=L9%%'9279K`8O3+E3<(&WNR&T@%#D024$>UE-[O[CV*25"PG+]%G"2G=E+ M*6V^]%JH)2=1(^1L;Z&^XSQPE;)]@ZE. QX:U$#0^;`&&T]"5E\EGOTLVIK= M9]B@+?[VT/R'XXWJ?^C*$'XL,%'T-):@@!!:R 2+LB6$CH]!$.'A?1V_SL M1 5E\O0ZT$[L_&,C-T'.AJ8(\,D/0UTU+DWIRD!@C M_6F.=O#)NQCEDO3/^C #7B4C@IH_D5%3Q@7A9J27H%Y58+8JRT\]!2"6TJ2% M^(EPE,]_[*B5T)=A)>_WL"I%8UHG4Y3($(7@Z^;#(9M9:+M4P9'W"2\)Z&I:WE3W+8%D7(E';@'^+<"_ M!?CO-%]FXRL'MFN$ZH+VG-/-Z_,+OG;>YFARG03]=F*1B]TK/6B3[-HGC&[M#)=X:XR@Y_9O{[)XM7O',F*PQ8O]+G19)@XF;KD"V44,8QL(-A +7&ZU-B[YBA M<6^W#]30[7MCC5-7:%M!9C.HTP+[5{OB&O%>]EKP=+S"%+0[, 4)7X.&V*49 M .!*>B"7+#,))//"NP@"IBI[U.=0#O.]#F+\3KC)[VON"T KM,\"IF!.'F0; M2[$;.;$TF#?%IZ#3,9ZIS*?2$QY;[4Y4F .9!]@.W%0BF[=*(:[XSXT($H5^G M4S#*0HQ(ZAK+_9OA":LL!)/RG4\IYS5KNO$E?'+,*A0NXE5HTBBATQD$+Z% MA5*7V5/<'6H@Q%XU0K,Z2.SS\=RKC)X-5>/=%$)LG5$6!^8(MG U&,*U[HP= M15&+3W=& Z%3L,%Y9!^W0PYQ01G4Z%:/A0Z"0@A:G[=Q!48!,;[P$M/\M7]3 M-328L1F6-L=7W"XD*E_>]27$&RT[#LC0>B7)A9>;ZRL6!QCH%ZH4(WB;&/IS MH`U&4X4,6IT:&)WC5BBR>9/#O6P,Z18BC#B)>913_\8:>O-5*W%9[2[!>H5 M5P@_XM5)!BOI2#$60Z7&6$5LCB>8K94#LB(ZE#&NP"15F9EG>$F47. 7/1)# M2^%!OD*>#D^/]'.W?5ED@^_P7BID8"C%>)%94GW2]#,)>!S:B 2^*-O.?HW MN:KUL',"X>=M=Y>%PPE$.CDE=ET0N<'+_Q,($)"C5!"("+?]?2 L>8$;N2*/ M!?'[Y,G0ZV-1'@OC*"G.U.I+Y'W1?9I$U0V(Y$2+EOWHI0G#%6U946H.DR[% MD$!U&24!*1=-W2<-" P:.3@<'<=2DD3;=*$82++1.8LT[%BI#WD^Y#**C(_6# M7FU!VF8_VL5N,U?6$ @=\,!U(-@J8 3:H!W#*]?N/UL8@=<(7+;H'<-@ MV(3X3E9fK2*T!{ QS46QM#KCI2S!%;&\@=#F-0(YIZA(J*M@;,*)::>X@ WO M(>JAI5(L/;_'A5[Tf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|-\802NQ2.P,!3Z A;8"YD^(;CRHC2Y3DSS MY?PZZ&?? V_P@0197%-.RY'W9NGVV.I_[V_:Y/SE2= MT#P6J1D4FQ@4'!+91J^RU5G%7^Q5F;NK:N3%M'TQQBZ1FD>,?H.MT//S.I MQIR%)W$1%)*%W!]ZCS7HLRL=$LNE7**P%O51D)2N\FBF!YGPXM 5WD,&@AD M(<$P94B:0FNX\@N_9E(2ZZT(QD1%#F(O<#2 M9W,=3%X8.L(L0PE'1:,V+\59".%K&:\Q[Q+]G[08)CNIDQOFOE:R>H?",+Q(MX>;LR=!?;@:X,XH(JIS#S30YRZZ1\(I;M-97C_;:JfP.Z]JK2>=NBS MN7,P#&UCIQ4'8@$1A(DP07B1=Y2F4X:?DPWZIL,B#WD^Y#**C(_6# M7FU!VF8_VL5N,U?6$ @=\,!U(-@J8 3:H!W#*]?N/UL8@=<(7+;H'<-@ MV(3X3E9fK2*T!{ QS46QM#KCI2S!%;&\@=#F-0(YIZA(J*M@;,*)::>X@ WO M(>JAI5(L/;_'A5[Tf8[]^-

*M.BDD"6(''!X(B*L2(#F|PZ>IVNEY/-]K9,/M0]22?_R6^&J9?E&RGM5B=‘!VQ M;M 0R<3(!XU5WXI:/QLL[+%2V%W%5DD8$,XH0N268]-+ WN]#R|S;.Z7/TX M.1%4=AZ0N8!$3U3)1!)E^@B)E47T/L GX<{6,[SX'=CT\V#CV.+TB3#(!D%9 .,18Z*C*=Y#$M, M,.?I+GM2%%C?8!JE*HN!W;B/.D'CE0PBW)EI!$?MAIOENAK@&'C) SBK1.8[M/(D"B3K6BUP8C*PQLSL,W]DQ2ZX/VA9T!-_[,@>G>85,3=^+"P'[$7R08*4P M%YP+NE/(X5D",U0V\&+<(4(! ^W7U)9R&5*\VB.)F-^K1>"S**&5A\T<*%@? M%;Q3<O"SJO/@8/+,W#E)4:ICT_7BUY%YDT?&5L/WBUt,YK;C3F;X0WH 35 MG91[H@+C]-O@ U"BXZO&*W"/;\XV X6&,6M(SEK|I*5Z&8_RY2*C16GH"D M2,#3)O@]8/? K&QK>')RDMN1@,O2Z >Q5UC3K0B>10CO0R/W.[T+FCHI2"H:6 M=4"G\9!8QZS.U@-H9$W[%#/=G8WOF["9--DI]W.BD%P%5 5RF!))R?X'R. MBV@* *>IZQ3I7/6UE8++\@+?| (AO3 # [(.>Z*%P-SHV&(R,9Y^1\U>Y-I"@Y*()5"71(Q/2//$Y&R=!Z,WT)V34&;]/C0>#P5Y9; M=Q^/-([2M.;Y%0[‘HC>)2$=NFK1-G1+X<#[.@'F5ED.Z(3+,,+8*1DC0!? NZ^LB.O!+ZM/(4$SIAW@JfE/CUO'=0+_)!XR)^2BY)'O)" DCKCYD2RMS#M I&+DH0SNHD;>N84+(R/F=E7EWQWTYM52?R)Q*WX$'+4!PB1! [^2W=C=$Z'-MB LX66G(N;^8%<9Y>X9[MY9)|\HA3,RFU+!&B(N2E"6R+WH%LO-D_K9#[_4 M@\"- #F*))HKYH!%\-.M.4C@LW0%&RJ!H#%6"3.V%2UM6K(YZO1+UDP?_=M) M*ER2\.>>Y,M$@J? S_4D2PV&5!)R=IR8IZ#'GP3UI*EP)K_].QR$+8GBA%?T M2]$05IVQ)?A;8D^T.$XLQH^\>"-M#<&&/;A4J$E&]>P>#IL8X=938%NE&9AA M142\#M"M W1WY*+N=RD1QN*#"2_)\M0Q/?&!U/!ONC0/ -5BU@5 B!D=-.X2 M3HTTT,'F8],W!\MWR,T'7K[4&\DFKR)OEU7]*2.XK;*!UC^1?!!81RHO2$J= M=9 73K9,"&/KP=$:EC#NIOH^,'0(D+EF="ZT2L74.(IJ4&(

*N/0Z%AK]V_AK^TN0^F1,8*TMJYSW*M93RV5U_M'%R*A[<2RE5F367CIY\R",RCTP1FAX*VE,N,@ /PHBWP8)L,;62,+4;RS?I8 M5Y^M:V.0_MAZ8,5O<:[N-NB^1PPCEJ,S;=&.=!SQ<&+VJC+,W>>/(C*AOX]U"NF;ML M@4CV.D:*3-DNI.AT%[]^%T_6+BUBVF',WZJXE;M^:*N70 :RRV'Q+'D:G%P ;V"AZY(MIY-)}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|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fKK,SLTV0$QC,MF*XXEW"=0*-*$I 00]PV*9TRK>(:R%H1IXfY/ M1K(G8SK>25!G&]UTBUVMVLH89QJ8I28BTY"/#BW-3#6L">@;6R5T#6HZ,N)O3!>\|$=T(V_=P5J<*0+M:#5 MP7*AM7(([V<-5L#T$:&7!,XLN.VE..,5GX1U;WG$VTM* I):O"M8_.O'3>:XC6,%(:7^5)C:+W MR/RA!--"D"*TKE053CNVD^MP"Q?\^ ;O%'?:A2_I$*YV^:;XV5NZ2 >N 5 MDMAB|A3A$? 2X7.3'+A0/QOJ=5G%*R5JJ<69.E3BT5W'Y4@A=YV_@'SMBA_[M!<:.M(OTH>MMI37J[@N1JF+/&A'#ECN8%!UD2BDNULH K5A12OQ5"=BX?2P4U80I\ M 50B%QM+LJDJ H,U.!DE"\F^V+4G?:K"#9,6LU4)H!G9K_]0@?(I%[RT@M!- MJ2H(2SF]@1113Y^&F8+^!P!7[(4K$,WO,+=3; T_RZ&1I=U% MTP]8W!Q=7Q@-. MF_R^9RK(F5"4[5I,]2P? Q_2OO.0O2ZC8A?2UBB8Z>;F#:W8IG#T'Q!$/&K MXJ2MQ0)3)N/|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x,(?&?ADM1FM8H.@"R:>M$/GES"> MVA/ ADMTHT[M.5]MCG%=!&B*HS\|+X/$(';"FI-PN.NXNK4->!?B39%IP+T)5 MN[BUL]FH"/M3\Z?:7S@SR8]7S#4BZDQMLUV>R4Y[']0@9UUG[&SS>0D9&WFF M/]@G.NJNH:TVL"QSLY#44JZ#,V+8GQUB(73,YYHA*L-"HCI"]TCE ZVUES. M@_@4%5"OFSW#R%1.^30^TDJ'(Q9 UTJ$R;F.OZ845.5/UFMMWQK,V4J.7 [^ MLB)EQ2#R2? 90;.:*HGDW*&U/LBP=S6+9F.,IV=IN2U GAA5?FQ;*_%3!K23^GY7NRC%*[S-BFM.!$TK MSAIL:-F_06L5;M?I-DT6G6."\G MTT(((*P5YE4DQB+%'" N34^>,.SV?9I ML"=H;OI.T^=:&KL;G$X><|TYU*:%%#H'I40_*](S6XFQ[Y%5F)E48R69.HO8 M;O2W&W3=YE|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|T"(]+Z"%?E8_W_ 5!+ P04 "#@ M@C-9)"7#_X@6 AB0 %@ 'J;'0M.C R-# V.S!X97@Y-RYH=&WM77M3 MY#B2_RHZ)G87(NH)-(^"(8(!>[.CHL.FMZ-N7%M5I6V7Y95MBH!/?YDI MR9;+K@)VFJ$#JB-HJ++U2J4R?_F0=/I?W>Y5,N5)*"+VWIVD$I& MI+@_/.[O#G;WV>!@-#P:O3M@GS^R[:^W%SOT]N7UQ>UOGZJ,LY^__O+KAPNV MU>WW_[EWT>]?WEZ:!_N]P9#=:IYD,IG?WO2G^2S>f\=*9:(7Y=`6V2E^__|+'IV=SD3.63CE.A/YSUM?;I]WC^"- M7:.Q.#OMN]_FW4!%B[/32-ZQ+%_$XN>M&=<3F715E8[V!FE^ B7[\'CIG?ON M7$;Y=#0<#/YRDO(HDLFD&XMQ/AH.>X<'U7=:3J;5E\H,J1%$'-Y)[#V-6U[M;<"+J7MMK)*\.^8S&2]&?[N5,Y&Q3V+.;M2,)W_KF&_@=R:T'/_MA-[.Y.]B M--R%.DT; (SLT?.BJO9.9#&0I\\5H*J-0/#"]WZVAWLG9SV\46@1-L"C3 6 M7(\"E4]/E@G3-MY'#8/]HN^HT7?Z.!=$T@!>.,G%?=[EL9Q_$_BM-SJ&/P?F M-S1[=3^%P>7L^) &]4R=_F0=/I?W>Y5,N5)*"+VWIVD$I& MI+@_/.[O#G;WV>!@-#P:O3M@GS^R[:^W%SOT]N7UQ>UOGZJ,LY^__O+KAPNV MU>WW_[EWT>]?WEZ:!_N]P9#=:IYD,IG?WO2G^2S>f\=*9:(7Y=`6V2E^__|+'IV=SD3.63CE.A/YSUM?;I]WC^"- M7:.Q.#OMN]_FW4!%B[/32-ZQ+%_$XN>M&=<3F715E8[V!FE^ B7[\'CIG?ON M7$;Y=#0<#/YRDO(HDLFD&XMQ/AH.>X<'U7=:3J;5E\H,J1%$'-Y)[#V-6U[M;<"+J7MMK)*\.^8S&2]&?[N5,Y&Q3V+.;M2,)W_KF&_@=R:T'/_MA-[.Y.]B M--R%.DT; (SLT?.BJO9.9#&0I\\5H*J-0/#"]WZVAWLG9SV\46@1-L"C3 6 M7(\"E4]/E@G3-MY'#8/]HN^HT7?Z.!=$T@!>.,G%?=[EL9Q_$_BM-SJ&/P?F M-S1[=3^%P>7L^) &]4R?

31 0001509261 us-gaap:RetainedEarningsMember 2023-07-012024-06-30 0001509261 us-gaap:RetainedEarningsMember 2022-07-012023-06-30 0001509261 us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember 2024-06-30 0001509261 us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember 2024-06-30 0001509261 us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember 2024-06-30 0001509261 us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember 2024-06-30 0001509261 us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMember 2024-06-30 0001509261 us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember 2024-06-30 0001509261 us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember 2024-06-30 0001509261 us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember 2024-06-30 0001509261 us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember 2024-06-30 0001509261 us-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMember 2024-06-30 0001509261 us-gaap:FinancialServicesSectorMember 2024-06-30 0001509261 us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-06-30 0001509261 us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember 2023-06-30 0001509261 us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember 2023-06-30 0001509261 us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMember 2023-06-30 0001509261 us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember 2023-06-30 0001509261 us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember 2023-06-30 0001509261 us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-06-30 0001509261 us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember 2023-06-30 0001509261 us-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMember 2023-06-30 0001509261 us-gaap:GovernmentSectorMember 2023-06-30 0001509261 us-gaap:FinancialServicesSectorMember 2023-06-30 0001509261 rzlt:OfficeSpaceInBendMember 2023-10-31 0001509261 us-gaap:EmbeddedDerivativeFinancialInstrumentsMember 2023-07-012024-06-30 0001509261 rzlt:WarrantDerivativeFinancialInstrumentsMember 2023-07-012024-06-30 0001509261 us-gaap:EmbeddedDerivativeFinancialInstrumentsMember 2022-07-012023-06-30 0001509261 rzlt:EmbeddedDerivativeDerivativeFinancialInstrumentsLiabilitiesMember 2024-06-30 0001509261 rzlt:EmbeddedDerivativeDerivativeFinancialInstrumentsLiabilitiesMember 2023-06-30 0001509261 rzlt:EmbeddedDerivativeDerivativeFinancialInstrumentsLiabilitiesMember 2022-06-30 0001509261 rzlt:EmbeddedDerivativeDerivativeFinancialInstrumentsLiabilitiesMember 2023-07-012024-06-30 0001509261 rzlt:EmbeddedDerivativeDerivativeFinancialInstrumentsLiabilitiesMember 2022-07-012023-06-30 0001509261 us-gaap:EmbeddedDerivativeFinancialInstrumentsMember 2024-06-30 0001509261 us-gaap:EmbeddedDerivativeFinancialInstrumentsMember 2023-06-30 0001509261 us-gaap:AssetBackedSecuritiesMember 2024-06-30 0001509261 us-gaap:EmployeeStockMember 2024-06-30 0001509261 rzlt:PreFundedWarrants2024Member 2024-06-30 0001509261 rzlt:ExchangePreFundedWarrantsMember 2024-06-30 0001509261 rzlt:PreFundedWarrants2022Member 2023-06-30 0001509261 rzlt:PreFundedWarrants2021Member 2023-06-30 0001509261 rzlt:PreFundedWarrantsMember 2022-06-30 0001509261 rzlt:PreFundedWarrants2024Memberrzlt:UnderwrittenPublicOfferingMember 2024-06-24 0001509261 rzlt:LegacyWarrantsMember 2022-06-30 0001509261 rzlt:PreFundedWarrants2022Member 2022-05-31 0001509261 rzlt:PreFundedWarrants2021Member 2021-10-31 0001509261 rzlt:LegacyWarrantsMember 2020-10-09 0001509261 2022-06-30 0001509261 us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember 2024-06-30 0001509261 us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember 2024-06-30 0001509261 us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember 2023-06-30 0001509261 us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember 2023-06-30 0001509261 us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember 2023-06-30 0001509261 us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember 2023-06-30 0001509261 us-gaap:MoneyMarketFundsMember 2024-06-30 0001509261 us-gaap:DemandDepositsMember 2024-06-30 0001509261 us-gaap:DemandDepositsMember 2023-06-30 0001509261 us-gaap:CommercialPaperMember 2023-06-30 0001509261 us-gaap:MoneyMarketFundsMember 2023-06-30 0001509261 us-gaap:DemandDepositsMember 2023-06-30 0001509261 us-gaap:CommercialPaperMember 2023-06-30 0001509261 us-gaap:USTreasurySecuritiesMember 2024-06-30 0001509261 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2024-06-30 0001509261 us-gaap:CorporateDebtSecuritiesMember 2024-06-30 0001509261 us-gaap:CommercialPaperMember 2024-06-30 0001509261 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-06-30 0001509261 us-gaap:CommercialPaperMember 2023-06-30 0001509261 us-gaap:AssetBackedSecuritiesMember 2023-06-30 0001509261 us-gaap:USTreasurySecuritiesMember 2023-06-30 0001509261 us-gaap:CorporateDebtSecuritiesMember 2023-06-30 0001509261 us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001509261 us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001509261 us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001509261 us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember 2023-06-30 0001509261 us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember 2023-06-30 0001509261 us-gaap:FairValueMeasurementsRecurringMember 2023-06-30 0001509261 us-gaap:FairValueMeasurementsRecurringMember 2023-06-30 0001509261 us-gaap:EmployeeStockOptionMember 2023-07-012024-06-30 0001509261 rzlt:LegacyWarrantsMember 2023-07-012024-06-30 0001509261 us-gaap:EmployeeStockOptionMember 2022-07-012023-06-30 0001509261 rzlt:LegacyWarrantsMember 2022-07-012023-06-30 0001509261 us-gaap:ResearchAndDevelopmentExpenseMember 2023-07-012024-06-30 0001509261 us-gaap:GeneralAndAdministrativeExpenseMember 2023-07-012024-06-30 0001509261 us-gaap:ResearchAndDevelopmentExpenseMember 2022-07-012023-06-30 0001509261 us-gaap:GeneralAndAdministrativeExpenseMember 2022-07-012023-06-30 0001509261 us-gaap:AdditionalPaidInCapitalMember 2022-07-012023-06-30 0001509261 srt:MaximumMemberrzlt:ExchangePreFundedWarrantsMemberrzlt:SecuritiesExchangeAgreementMember 2024-03-082024-03-08 0001509261 srt:MaximumMemberrzlt:PreFundedWarrantsMemberrzlt:SecuritiesExchangeAgreementMember 2023-07-012024-06-30 0001509261 rzlt:ExchangePreFundedWarrantsMemberrzlt:SecuritiesExchangeAgreementMember 2024-05-13 0001509261 rzlt:ExchangePreFundedWarrantsMemberrzlt:SecuritiesExchangeAgreementMember 2024-03-08 0001509261 rzlt:ExchangePreFundedWarrantsMemberus-gaap:SubsequentEventMember 2024-07-012024-07-31 0001509261 us-gaap:CommonStockMember 2023-07-012024-06-30 0001509261 srt:ChiefFinancialOfficerMemberus-gaap:EmployeeStockOptionMemberrzlt:InducementGrantMember 2024-01-012024-01-31 0001509261 rzlt:AtMarketOfferingMember 2023-07-012024-06-30 0001509261 rzlt:AtMarketOfferingMember 2023-11-142023-11-14 0001509261 rzlt:UnderwritersOptionMember 2024-06-24 0001509261 rzlt:UnderwrittenPublicOfferingMember 2023-07-012024-06-30 0001509261 us-gaap:SubsequentEventMemberus-gaap:PrivatePlacementMember 2024-07-012024-07-31 0001509261 rzlt:JulyTwoThousandTwentyTwoFinancingMember 2022-07-012022-07-31 0001509261 rzlt:HandokInc.Memberrzlt:HandokLicenseAgreementMemberus-gaap:RelatedPartyMember 2023-07-012024-06-30 0001509261 rzlt:HandokInc.Memberrzlt:HandokLicenseAgreementMemberus-gaap:RelatedPartyMember 2020-09-152020-09-15 0001509261 rzlt:SecuritiesExchangeAgreementMember 2024-03-082024-03-08 0001509261 rzlt:UnderwrittenPublicOfferingMember 2024-06-242024-06-24 0001509261 country:USrzlt:ExpirationIn2031Through2035Memberus-gaap:DomesticCountryMember 2024-06-30 0001509261 country:USrzlt:AvailableThroughFiscalYear2038AndExpiresByJune302038Memberus-gaap:DomesticCountryMember 2024-06-30 0001509261 country:USrzlt:NotSubjectToExpiryAndAvailableForUseOver2038AndThereafterYearsMemberus-gaap:DomesticCountryMember 2024-06-30 0001509261 country:USus-gaap:DomesticCountryMember 2024-06-30 0001509261 rzlt:EmploymentAgreementsMember 2023-07-012024-06-30 0001509261 rzlt:XomaUsLlcMemberrzlt:Phase3ClinicalTrialRz358Memberrzlt:XomaLicenseAgreementMember 2024-04-012024-04-30 0001509261 rzlt:XomaUsLlcMemberrzlt:ScenarioUponDosingOfLastPatientMemberrzlt:Phase3ClinicalTrialRz358Memberrzlt:XomaLicenseAgreementMember 2023-07-012024-06-30 0001509261 rzlt:ActivesitePharmaceuticalsIncMemberus-gaap:ScenarioPlanMemberrzlt:Phase3ClinicalTrialRz402Memberrzlt:DevelopmentAndLicenseAgreementMember 2023-07-012024-06-30 0001509261 rzlt:ActivesitePharmaceuticalsIncMemberrzlt:Phase2ClinicalTrialRz402Memberrzlt:DevelopmentAndLicenseAgreementMember 2023-02-012023-02-28 0001509261 rzlt:XomaUsLlcMemberrzlt:Phase2ClinicalTrialRz358Memberrzlt:XomaLicenseAgreementMember 2022-01-012022-01-31 0001509261 rzlt:ActivesitePharmaceuticalsIncMemberrzlt:Phase1ClinicalTrialRz402Memberrzlt:DevelopmentAndLicenseAgreementMember 2020-12-012020-12-31 0001509261 rzlt:UnderwritersOptionMember 2024-06-242024-06-24 0001509261 rzlt:XomaUsLlcMembersrt:MaximumMemberrzlt:ScenarioUponClinicalAndRegulatoryMilestonesMemberrzlt:XomaLicenseAgreementMember 2024-06-30 0001509261 rzlt:XomaUsLlcMembersrt:MaximumMemberrzlt:ScenarioAfterClinicalAndRegulatoryMilestonesMemberrzlt:XomaLicenseAgreementMember 2024-06-30 0001509261 rzlt:ActivesitePharmaceuticalsIncMembersrt:MaximumMemberus-gaap:ScenarioPlanMemberrzlt:DevelopmentAndLicenseAgreementMember 2017-08-31 0001509261 rzlt:CorporateHeadquartersMember 2022-04-30 0001509261 rzlt:CorporateHeadquartersMember 2022-04-012022-04-30 0001509261 rzlt:WarrantsDerivativeFinancialInstrumentsLiabilitiesMember 2023-07-012024-06-30 0001509261 srt:MinimumMemberrzlt:ChiefExecutiveOfficerAndChiefMedicalOfficerMemberrzlt:EmploymentAgreementsMember 2023-07-012024-06-30 0001509261 srt:MaximumMemberrzlt:ChiefExecutiveOfficerAndChiefMedicalOfficerMemberrzlt:EmploymentAgreementsMember 2023-07-012024-06-30 0001509261 srt:ChiefFinancialOfficerMemberrzlt:EmploymentAgreementsMemberus-gaap:SubsequentEventMember 2024-09-102024-09-10 0001509261 rzlt:ChiefMedicalOfficerMemberrzlt:EmploymentAgreementsMember 2023-07-012024-06-30 0001509261 rzlt:ActivesitePharmaceuticalsIncMemberrzlt:DevelopmentAndLicenseAgreementMember 2017-08-012017-08-31 0001509261 us-gaap:EmbeddedDerivativeFinancialInstrumentsMember 2021-04-14 0001509261 rzlt:PreFundedWarrantsMember 2023-07-012024-06-30 0001509261 rzlt:PreFundedWarrants2022Member 2023-07-012024-06-30 0001509261 rzlt:PreFundedWarrants2021Member 2023-07-012024-06-30 0001509261 rzlt:ExchangePreFundedWarrantsMemberrzlt:SecuritiesExchangeAgreementMember 2024-03-082024-03-08 0001509261 rzlt:PreFundedWarrantsMemberrzlt:SecuritiesExchangeAgreementMember 2023-07-012024-06-30 0001509261 rzlt:ExchangePreFundedWarrantsMemberrzlt:SecuritiesExchangeAgreementMember 2023-07-012024-06-30 0001509261 rzlt:PreFundedWarrantsMemberrzlt:UnderwrittenPublicOfferingMember 2023-07-012024-06-30 0001509261 rzlt:PreFundedWarrants2024Memberrzlt:UnderwrittenPublicOfferingMember 2023-07-012024-06-30 0001509261 rzlt:PreFundedWarrantsMember 2022-07-012023-06-30 0001509261 rzlt:ClassPreFundedWarrantsMember 2022-05-012022-05-31 0001509261 rzlt:ClassBPreFundedWarrantsMember 2022-05-012022-05-31 0001509261 rzlt:LegacyWarrantsMember 2024-06-30 0001509261 rzlt:LegacyWarrantsMember 2023-06-30 0001509261 rzlt:LegacyWarrantsMember 2023-07-012024-06-30 0001509261 rzlt:LegacyWarrantsMember 2022-07-012023-06-30 0001509261 rzlt:ExchangePreFundedWarrantsMemberus-gaap:SubsequentEventMember 2024-07-31 0001509261 rzlt:PreFundedWarrantsMember 2024-06-30 0001509261 rzlt:PreFundedWarrants2022Member 2024-06-30 0001509261 rzlt:PreFundedWarrants2021Member 2024-06-30 0001509261 rzlt:PreFundedWarrantsMember 2023-06-30 0001509261 rzlt:ExchangePreFundedWarrantsMemberrzlt:SecuritiesExchangeAgreementMember 2024-05-132024-05-13 0001509261 srt:ChiefExecutiveOfficerMemberrzlt:EmploymentAgreementsMemberus-gaap:SubsequentEventMember 2024-09-15 0001509261 srt:ChiefExecutiveOfficerMemberrzlt:EmploymentAgreementsMemberus-gaap:SubsequentEventMember 2024-09-14 0001509261 srt:ChiefFinancialOfficerMemberrzlt:EmploymentAgreementsMemberus-gaap:SubsequentEventMember 2024-09-10 0001509261 rzlt:EmploymentAgreementsMember 2024-06-30 0001509261 us-gaap:AdditionalPaidInCapitalMember 2023-07-012024-06-30 0001509261 2024-06-30 0001509261 2023-06-30 0001509261 2024-04-012024-06-30 0001509261 2023-12-29 0001509261 2024-09-13 0001509261 2022-07-012023-06-30 0001509261 2023-07-012024-06-30 shares iso4217:USD iso4217:USD shares pure utr:sqft rzlt:item rzlt:employee rzlt:subsidiary rzlt:Y 0001509261--06-302024FYfalsehttp://fasb.org/us-gaap/2024#PrepaidExpenseAndOtherAssetsCurrenthttp://fasb.org/us-gaap/2024#PrepaidExpenseAndOtherAssetsCurrent 532460003682700P60M00.00250.0027falsefalsefalse10-Ktrue2024-06-30false001-39683REZOLUTE, INC.NV27-3440894275 Shoreline Drive, Suite 500Redwood CityCA94065650206-4507Common Stock, par value $0.001RZLTNASDAQNoYesYesYesNon-accelerated FilertruefalsefalsefalsefalseS3252000553697 64Grant Thornton, LLPNewport Beach, California248Plante & Moran, PLLCCleveland, Ohio166703960001603600056478000858600001779000301400012865300010491000018800002054000183800014800026300016470000103000139000132737000123721000479000-351000-329444000-260985000121003000116172000132737000123721000557430004381300014680000121770007042300055990000-70423000-55990000487000042080000-2850000-56000-5000196400042030000-68459000-51787000272000-351000-68187000-52138000-1.33-1.33-1.01-1.01514650005146500051187000511870003358200034000358635000-2091980001494710003245000300012327000123300007590007590007268000072680000-351000-351000-51787000-51787000368270003700037741000-351000-260985000116172000130370001300049004000491770001409600014096000548000548000820002460002460007360000630000600000-600030000003000569700057000008547000085470002720002720000-68459000-68459000532460005300045047300-79000-32944400012100300000-68459000-51787000736000072680000-2850000-56000-5000526000352000283700013700003600030000129000132000010830002136000214600020500057368000-444810006640100010731100011510000060000001530004869900010146400023400030004901700014096000123300003150007590006302900011571000543600001343740001603600015041000070396000160360007280002150003520002204000569700012000548000 NOTE 1 — NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES <p style="font-

family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Nature of Operations Rezolute, Inc. (the "Company") is a late-stage rare disease company focused on significantly improving outcomes for individuals with hypoglycemia caused by hyperinsulinism. The Company's primary clinical assets consist of (i) ersodetug (formerly known as RZ358), which is a potential treatment for all forms of hyperinsulinism, including congenital hyperinsulinism, an ultra-rare pediatric genetic disorder characterized by excessive production of insulin by the pancreas, and (ii) RZ402, which is an oral plasma kallikrein inhibitor ("PKI") being developed as a potential therapy for the chronic treatment of diabetic macular edema. Consolidation The Company has two wholly owned subsidiaries consisting of Rezolute (Bio) Ireland Limited, and Rezolute Bio UK, Ltd. The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. Basis of Presentation The Company's consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP"). Comprehensive income (loss) is defined as net income (loss) plus other comprehensive income (loss). Other comprehensive income (loss) is comprised of revenues, expenses, gains, and losses that under GAAP are reported as separate components of shareholders' equity instead of net income (loss). For the fiscal years ended June 30, 2024 and 2023, components of comprehensive loss included the Company's net loss and unrealized gains (losses) on investments in marketable debt securities. The Company's Chief Executive Officer also serves as the Company's chief operating decision maker for purposes of allocating resources and assessing performance based on financial information of the Company. Since its inception, the Company has determined that its activities as a clinical stage biopharmaceutical company are classified as a single reportable operating segment. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make judgments, estimates and assumptions that affect the reported amounts in the consolidated financial statements and the accompanying notes. The Company bases its estimates and assumptions on current facts, historical experience, and various other factors that it believes are reasonable under the circumstances, to determine the carrying values of assets and liabilities that are not readily apparent from other sources. The Company's significant accounting estimates include, but are not necessarily limited to, determination if an allowance for credit losses is required or if other than temporary impairment exists for marketable debt securities, fair value of an derivative liabilities, fair value of share-based payments, management's assessment of going concern, and estimates related to clinical trial accrued liabilities. Actual results could differ from those estimates. Risks and Uncertainties The Company's operations may be subject to significant risks and uncertainties including financial, operational, regulatory and other risks associated with a clinical stage company, including the potential risk of business failure discussed in Note 2. Cash and Cash Equivalents All highly liquid investments purchased with an original maturity of three months or less that are freely available for the Company's immediate and general business use are classified as cash and cash equivalents. Cash and cash equivalents consist primarily of demand deposits with financial institutions, money market funds and corporate commercial paper purchased with a maturity of three months or less. Investments in Marketable Debt Securities Under the investment policy approved by the Company's Board of Directors, eligible investments in fixed income debt securities must be denominated and payable in U.S. dollars, including eligible corporate bonds, corporate commercial paper, U.S. government obligations, and money market funds. This investment policy only permits investments in the debt securities of issuers that meet stringent credit quality ratings on the date of the investment. The investment policy also places restrictions on the length of maturities and concentrations by type and issuer. The Company's investments are issued by issuers that management believes are of high credit quality. However, all issuers are exposed to credit risk in the event of default. The Company classifies investments in marketable debt securities that mature in less than one year as short-term assets. For investments that mature in more than one year, the investments are classified as long-term assets unless management intends to liquidate the investments to fund current operations before the scheduled maturity dates. The Company accounts for all of its investments in marketable debt securities as available-for-sale securities whereby they are recorded in the consolidated balance sheet at fair value. Interest income is recognized in the consolidated statement of operations, consisting of accrued interest earned based on the coupon rate of the security, plus the impact of accreting discounts and amortizing premiums to maturity using the straight-line method which approximates the interest method. Unrealized gains and losses due to subsequent changes in fair value of the investments are reported in shareholders' equity as a component of accumulated other comprehensive income (loss). The Company reviews the components of its portfolio of available-for-sale debt securities, using both quantitative and qualitative factors, to determine if declines in fair value below amortized cost have resulted from a credit-related loss or other factors. If declines in fair value below amortized costs are due to the deterioration of an issuer's credit quality, the Company is required to record an allowance for credit losses related to such investments with a corresponding loss recognized in the consolidated statements of operations. Allowances for credit losses may be reversed in subsequent periods if conditions improve and credit-related losses are no longer expected. For declines in fair value that are solely due to changes in interest rates, impairment is not recognized if the Company has the ability and intent to hold the investment until maturity. Prepaid Expenses and Other Prepaid expenses and other includes nonrefundable advance payments for goods and services that will be used or rendered in future research and development activities. These advance payments are deferred and recognized as expenses in the period that the related goods are delivered, or services are performed. Leases The Company determines if an arrangement includes a lease as of the date an agreement is entered into. Operating leases are included in right-of-use ("ROU") assets and operating lease liabilities in the Company's consolidated balance sheets. ROU assets and operating lease liabilities are initially recognized based on the present value of the future minimum lease payments at the commencement date of the lease. The Company generally uses its incremental borrowing rate based on the information available at the lease commencement date to determine the discount rate used to compute the present value of future payments. The Company's leases may include options to extend or terminate the lease; these options are included in the calculation of ROU assets and operating lease liabilities when it is reasonably certain that the Company will exercise the options. Lease expense is recognized on a straight-line basis over the lease term. The Company has elected not to apply the recognition requirements for short-term leases. For lease agreements with lease and non-lease components, the Company generally accounts for them separately. Property and Equipment Property and equipment consist solely of office furniture and equipment that is recorded at cost. Depreciation expense is calculated using the straight-line method over the estimated useful lives of the assets which range from 3 to 5 years. Maintenance and repairs are expensed as incurred. Research and Development Costs Research and development costs are expensed as incurred. Intangible assets for in-licensing costs incurred under license agreements with third parties are charged to expense, unless the licensing rights have separate economic value in alternative future research and development projects or otherwise. Clinical Trial Accruals Clinical trial costs are a component of research and development expenses. The Company accrues and expenses clinical trial activities performed by third parties based upon estimates of the percentage of work completed over the life of the individual study in accordance with agreements established with clinical research organizations and clinical trial sites. The Company determines the estimates through discussions with internal clinical personnel and external service providers as to the progress or stage of completion of trials or services and the agreed-upon fee to be paid for such services. Share-Based Compensation The Company measures the fair value of employee and director services received in exchange for grants of stock options and other equity awards granted, based on the fair value of the award as of the grant date. The Company computes the fair value of stock options using the Black-Scholes-Merton ("BSM") option pricing model and recognizes the value of the equity awards over the period that services are provided to earn the award, usually the vesting period. For awards granted which contain a graded vesting schedule, and the only condition for vesting is a service condition, compensation cost is recognized as an expense on a straight-line basis over the requisite service period as if the award was, in substance, a single award. The Company recognizes the impact of forfeitures in the period that the forfeiture occurs, rather than estimating the number of awards that are not expected to vest in accounting for share-based compensation. For stock options that are voluntarily surrendered by employees, all unrecognized compensation is immediately recognized in the period the options are cancelled. Embedded Derivatives When the Company enters into a financial instrument such as a debt or equity agreement (the "Host Contract"), the Company assesses whether the economic characteristics of any embedded features would meet the definition of a derivative instrument, and whether such features are considered clearly and closely related to the primary economic characteristics of the Host Contract. When it is determined that (i) an embedded feature possesses economic characteristics that are not clearly and closely related to the primary economic characteristics of the Host Contract, and (ii) a separate, stand-alone instrument with the same terms would meet the definition of a financial derivative instrument and cannot be classified in shareholders' equity, then the embedded feature is bifurcated from the Host Contract and accounted for as a derivative liability. The estimated fair value of the derivative feature is recorded separately from the carrying value of the Host Contract, with subsequent changes in the estimated fair value recorded as a non-operating gain or loss in the Company's consolidated statements of operations. Fair Value of Warrants The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant's specific terms and applicable authoritative guidance set forth by the Financial Accounting Standards Board ("FASB") in Accounting Standards Codification ("ASC") 480, Distinguishing Liabilities from Equity ("ASC 480") and ASC 815, Derivatives and Hedging ("ASC 815"). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company's own common shares and whether the warrant holders could potentially require "net cash settlement" in a circumstance outside of the Company's control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and during each subsequent quarterly period while the warrants are outstanding. Liability-classified warrants are valued using the BSM option-pricing model at issuance, and for each subsequent reporting period. Income Taxes The Company accounts for income taxes using the asset and liability method. Under this method, deferred income tax assets and liabilities that are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using enacted tax rates and laws that are in effect when the differences are expected to be recovered or settled. Realization of deferred income tax assets is dependent upon future taxable income. A valuation allowance is recognized if it is more likely than not that some portion or all of a deferred income tax asset will not be realized based on the weight of available evidence, including expected future earnings. The Company recognizes uncertain tax position in its financial statements when it concludes that a tax position is more likely than not to be sustained upon examination based solely on its technical merits. Only after a tax position passes the first step of recognition will measurement be required. Under the measurement step, the tax benefit is computed as the largest amount of benefit that is more likely than not to be realized upon effective settlement. This calculation is determined on a cumulative probability basis. The full impact of any change in recognition or measurement is reflected in the period in which such change occurs. Interest and penalties related to income taxes will be recognized as a component of income tax expense. Net Loss Per Share Basic net loss per share is computed by dividing net loss by the weighted average number of outstanding shares of common stock and pre-funded warrants that are accounted for as equity instruments. Common shares

associated with pre-funded warrants are included in the computation of both basic and diluted net loss per share since the exercise price is negligible and all of the pre-funded warrants are fully vested and exercisable. To the extent dilutive, during periods in which pre-funded warrants are accounted for as derivative liabilities, the calculation of diluted net loss per share will be further adjusted to eliminate gains on changes in the fair value of such pre-funded warrants, and the related pre-funded warrant shares will be included in the weighted average number of shares outstanding. Diluted net loss per share is computed using the treasury stock method by further giving effect to all potential shares of common stock, including stock options and warrants, to the extent dilutive. For participating warrants that are entitled to participate in dividends declared to holders of shares of common stock, the Company applies the two-class method of allocating earnings if the impact of including the participating warrants is dilutive for the calculation of both basic and diluted net loss per share. Treasury Shares The Company accounts for purchases of treasury shares under the cost method. In accordance with Nevada law, acquired treasury shares may be retired by the Company. Upon retirement, the treasury shares are no longer accounted for as issued and outstanding. Recent Accounting Pronouncements Recently Adopted Accounting Standard. The following accounting standard was adopted in the fiscal year ended June 30, 2024: In June 2016, the FASB issued Accounting Standards Update ("ASU") 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. ASU 2016-13 amends the guidance on the impairment of financial instruments. This update adds an impairment model (known as the current expected credit losses model) that is based on expected losses rather than incurred losses. Under the expected credit loss model, if declines in fair value below amortized costs are due to the deterioration of an issuer's credit quality, the Company is required to record an allowance for credit losses related to such investments with a corresponding loss recognized in the consolidated statements of operations. Allowances for credit losses may be reversed in subsequent periods if conditions improve and credit-related losses are no longer expected. For declines in fair value that are solely due to changes in interest rates, impairment is not recognized if the Company has the ability and intent to hold the investment until maturity. Effective as of July 1, 2023, the Company implemented the guidance in ASU 2016-13. The adoption of ASU 2016-13 did not have any impact on the accompanying consolidated financial statements. Standard Required to be Adopted in Future Periods. The following accounting standard has not yet been adopted by the Company: - In December 2023, the FASB issued ASU 2023-09, "Income Taxes (Topic 740) – Improvements to Income Tax Disclosures". ASU 2023-09 requires disclosure of additional income tax information, primarily related to the rate reconciliation and income taxes paid. This ASU is intended to enhance the transparency and decision usefulness of income tax disclosures. ASU 2023-09 is effective for annual periods beginning after December 15, 2024. Management has not determined the timing for adoption of this standard. - The adoption of ASU 2023-09 and other accounting standards that have been issued or proposed by the FASB that do not require adoption until a future date are not currently expected to have a material impact on the Company's consolidated financial statements upon adoption. - Nature of Operations Rezolute, Inc. (the "Company") is a late-stage rare disease company focused on significantly improving outcomes for individuals with hypoglycemia caused by hyperinsulinism. The Company's primary clinical assets consist of (i) ersodetug (formerly known as RZ358), which is a potential treatment for all forms of hyperinsulinism, including congenital hyperinsulinism, an ultra-rare pediatric genetic disorder characterized by excessive production of insulin by the pancreas, and (ii) RZ402, which is an oral plasma kallikrein inhibitor ("PKI") being developed as a potential therapy for the chronic treatment of diabetic macular edema. Consolidation The Company has two wholly owned subsidiaries consisting of Rezolute (Bio) Ireland Limited, and Rezolute Bio UK, Ltd. The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. 2 Basis of Presentation The Company's consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP"). Comprehensive income (loss) is defined as net income (loss) plus other comprehensive income (loss). Other comprehensive income (loss) is comprised of revenues, expenses, gains, and losses that under GAAP are reported as separate components of shareholders' equity instead of net income (loss). For the fiscal years ended June 30, 2024 and 2023, components of comprehensive loss included the Company's net loss and unrealized gains (losses) on investments in marketable debt securities. The Company's Chief Executive Officer also serves as the Company's chief operating decision maker for purposes of allocating resources and assessing performance based on financial information of the Company. Since its inception, the Company has determined that its activities as a clinical stage biopharmaceutical company are classified as a single reportable operating segment. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make judgments, estimates and assumptions that affect the reported amounts in the consolidated financial statements and the accompanying notes. The Company bases its estimates and assumptions on current facts, historical experience, and various other factors that it believes are reasonable under the circumstances, to determine the carrying values of assets and liabilities that are not readily apparent from other sources. The Company's significant accounting estimates include, but are not necessarily limited to, determination if an allowance for credit losses is required or if other than temporary impairment exists for marketable debt securities, fair value of an derivative liabilities, fair value of share-based payments, management's assessment of going concern, and estimates related to clinical trial accrued liabilities. Actual results could differ from those estimates. Risks and Uncertainties The Company's operations may be subject to significant risks and uncertainties including financial, operational, regulatory and other risks associated with a clinical stage company, including the potential risk of business failure discussed in Note 2. Cash and Cash Equivalents All highly liquid investments purchased with an original maturity of three months or less that are freely available for the Company's immediate and general business use are classified as cash and cash equivalents. Cash and cash equivalents consist primarily of demand deposits with financial institutions, money market funds and corporate commercial paper purchased with a maturity of three months or less. Investments in Marketable Debt Securities Under the investment policy approved by the Company's Board of Directors, eligible investments in fixed income debt securities must be denominated and payable in U.S. dollars, including eligible corporate bonds, corporate commercial paper, U.S. government obligations, and money market funds. This investment policy only permits investments in the debt securities of issuers that meet stringent credit quality ratings on the date of the investment. The investment policy also places restrictions on the length of maturities and concentrations by type and issuer. The Company's investments are issued by issuers that management believes are of high credit quality. However, all issuers are exposed to credit risk in the event of default. The Company classifies investments in marketable debt securities that mature in less than one year as short-term assets. For investments that mature in more than one year, the investments are classified as long-term assets unless management intends to liquidate the investments to fund current operations before the scheduled maturity dates. The Company accounts for all of its investments in marketable debt securities as available-for-sale securities whereby they are recorded in the consolidated balance sheet at fair value. Interest income is recognized in the consolidated statement of operations, consisting of accrued interest earned based on the coupon rate of the security, plus the impact of accreting discounts and amortizing premiums to maturity using the straight-line method which approximates the interest method. Unrealized gains and losses due to subsequent changes in fair value of the investments are reported in shareholders' equity as a component of accumulated other comprehensive income (loss). The Company reviews the components of its portfolio of available-for-sale debt securities, using both quantitative and qualitative factors, to determine if declines in fair value below amortized cost have resulted from a credit-related loss or other factors. If declines in fair value below amortized costs are due to the deterioration of an issuer's credit quality, the Company is required to record an allowance for credit losses related to such investments with a corresponding loss recognized in the consolidated statements of operations. Allowances for credit losses may be reversed in subsequent periods if conditions improve and credit-related losses are no longer expected. For declines in fair value that are solely due to changes in interest rates, impairment is not recognized if the Company has the ability and intent to hold the investment until maturity. Prepaid Expenses and Other Prepaid expenses and other includes nonrefundable advance payments for goods and services that will be used or rendered in future research and development activities. These advance payments are deferred and recognized as expenses in the period that the related goods are delivered, or services are performed. Leases The Company determines if an arrangement includes a lease as of the date an agreement is entered into. Operating leases are included in right-of-use ("ROU") assets and operating lease liabilities in the Company's consolidated balance sheets. ROU assets and operating lease liabilities are initially recognized based on the present value of the future minimum lease payments at the commencement date of the lease. The Company generally uses its incremental borrowing rate based on the information available at the lease commencement date to determine the discount rate used to compute the present value of future payments. The Company's leases may include options to extend or terminate the lease; these options are included in the calculation of ROU assets and operating lease liabilities when it is reasonably certain that the Company will exercise the options. Lease expense is recognized on a straight-line basis over the lease term. The Company has elected not to apply the recognition requirements for short-term leases. For lease agreements with lease and non-lease components, the Company generally accounts for them separately. Property and Equipment Property and equipment consist solely of office furniture and equipment that is recorded at cost. Depreciation expense is calculated using the straight-line method over the estimated useful lives of the assets which range from 3 to 5 years. Maintenance and repairs are expensed as incurred. P3YP5Y Research and Development Costs Research and development costs are expensed as incurred. Intangible assets for in-licensing costs incurred under license agreements with third parties are charged to expense, unless the licensing rights have separate economic value in alternative future research and development projects or otherwise. Clinical Trial Accruals Clinical trial costs are a component of research and development expenses. The Company accrues and expenses clinical trial activities performed by third parties based upon estimates of the percentage of work completed over the life of the individual study in accordance with agreements established with clinical research organizations and clinical trial sites. The Company determines the estimates through discussions with internal clinical personnel and external service providers as to the progress or stage of completion of trials or services and the agreed-upon fee to be paid for such services. Share-Based Compensation The Company measures the fair value of employee and director services received in exchange for grants of stock options and other equity awards granted, based on the fair value of the award as of the grant date. The Company computes the fair value of stock options using the Black-Scholes-Merton ("BSM") option pricing model and recognizes the value of the equity awards over the period that services are provided to earn the award, usually the vesting period. For awards granted which contain a graded vesting schedule, and the only condition for vesting is a service condition, compensation cost is recognized as an expense on a

straight-line basis over the requisite service period as if the award was, in substance, a single award. The Company recognizes the impact of forfeitures in the period that the forfeiture occurs, rather than estimating the number of awards that are not expected to vest in accounting for share-based compensation. For stock options that are voluntarily surrendered by employees, all unrecognized compensation is immediately recognized in the period the options are cancelled. Embedded Derivatives When the Company enters into a financial instrument such as a debt or equity agreement (the "Host Contract"), the Company assesses whether the economic characteristics of any embedded features would meet the definition of a derivative instrument, and whether such features are considered clearly and closely related to the primary economic characteristics of the Host Contract. When it is determined that (i) an embedded feature possesses economic characteristics that are not clearly and closely related to the primary economic characteristics of the Host Contract, and (ii) a separate, stand-alone instrument with the same terms would meet the definition of a financial derivative instrument and cannot be classified in shareholders' equity, then the embedded feature is bifurcated from the Host Contract and accounted for as a derivative liability. The estimated fair value of the derivative feature is recorded separately from the carrying value of the Host Contract, with subsequent changes in the estimated fair value recorded as a non-operating gain or loss in the Company's consolidated statements of operations. Fair Value of Warrants The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant's specific terms and applicable authoritative guidance set forth by the Financial Accounting Standards Board ("FASB") in Accounting Standards Codification ("ASC") 480, Distinguishing Liabilities from Equity ("ASC 480") and ASC 815, Derivatives and Hedging ("ASC 815"). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company's own common shares and whether the warrant holders could potentially require "net cash settlement" in a circumstance outside of the Company's control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and during each subsequent quarterly period while the warrants are outstanding. Liability-classified warrants are valued using the BSM option-pricing model at issuance, and for each subsequent reporting period. Income Taxes The Company accounts for income taxes using the asset and liability method. Under this method, deferred income tax assets and liabilities that are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using enacted tax rates and laws that are in effect when the differences are expected to be recovered or settled. Realization of deferred income tax assets is dependent upon future taxable income. A valuation allowance is recognized if it is more likely than not that some portion or all of a deferred income tax asset will not be realized based on the weight of available evidence, including expected future earnings. The Company recognizes uncertain tax position in its financial statements when it concludes that a tax position is more likely than not to be sustained upon examination based solely on its technical merits. Only after a tax position passes the first step of recognition will measurement be required. Under the measurement step, the tax benefit is computed as the largest amount of benefit that is more likely than not to be realized upon effective settlement. This calculation is determined on a cumulative probability basis. The full impact of any change in recognition or measurement is reflected in the period in which such change occurs. Interest and penalties related to income taxes will be recognized as a component of income tax expense. Net Loss Per Share Basic net loss per share is computed by dividing net loss by the weighted average number of outstanding shares of common stock and pre-funded warrants that are accounted for as equity instruments. Common shares associated with pre-funded warrants are included in the computation of both basic and diluted net loss per share since the exercise price is negligible and all of the pre-funded warrants are fully vested and exercisable. To the extent dilutive, during periods in which pre-funded warrants are accounted for as derivative liabilities, the calculation of diluted net loss per share will be further adjusted to eliminate gains on changes in the fair value of such pre-funded warrants, and the related pre-funded warrant shares will be included in the weighted average number of shares outstanding. Diluted net loss per share is computed using the treasury stock method by further giving effect to all potential shares of common stock, including stock options and warrants, to the extent dilutive. For participating warrants that are entitled to participate in dividends declared to holders of shares of common stock, the Company applies the two-class method of allocating earnings if the impact of including the participating warrants is dilutive for the calculation of both basic and diluted net loss per share. Treasury Shares The Company accounts for purchases of treasury shares under the cost method. In accordance with Nevada law, acquired treasury shares may be retired by the Company. Upon retirement, the treasury shares are no longer accounted for as issued and outstanding. Treasury Shares The Company accounts for purchases of treasury shares under the cost method. In accordance with Nevada law, acquired treasury shares may be retired by the Company. Upon retirement, the treasury shares are no longer accounted for as issued and outstanding. Recent Accounting Pronouncements Recently Adopted Accounting Standard. The following accounting standard was adopted in the fiscal year ended June 30, 2024. In June 2016, the FASB issued Accounting Standards Update ("ASU") 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. ASU 2016-13 amends the guidance on the impairment of financial instruments. This update adds an impairment model (known as the current expected credit losses model) that is based on expected losses rather than incurred losses. Under the expected credit loss model, if declines in fair value below amortized costs are due to the deterioration of an issuer's credit quality, the Company is required to record an allowance for credit losses related to such investments with a corresponding loss recognized in the consolidated statements of operations. Allowances for credit losses may be reversed in subsequent periods if conditions improve and credit-related losses are no longer expected. For declines in fair value that are solely due to changes in interest rates, impairment is not recognized if the Company has the ability and intent to hold the investment until maturity. Effective as of July 1, 2023, the Company implemented the guidance in ASU 2016-13. The adoption of ASU 2016-13 did not have any impact on the accompanying consolidated financial statements. Standard Required to be Adopted in Future Periods. The following accounting standard has not yet been adopted by the Company: In December 2023, the FASB issued ASU 2023-09, "Income Taxes (Topic 740) – Improvements to Income Tax Disclosures", ASU 2023-09 requires disclosure of additional income tax information, primarily related to the rate reconciliation and income taxes paid. This ASU is intended to enhance the transparency and decision usefulness of income tax disclosures. ASU 2023-09 is effective for annual periods beginning after December 15, 2024. Management has not determined the timing for adoption of this standard.   The adoption of ASU 2023-09 and other accounting standards that have been issued or proposed by the FASB that do not require adoption until a future date are not currently expected to have a material impact on the Company's consolidated financial statements upon adoption. NOTE 2 — LIQUIDITY The Company is in the clinical stage and has not yet generated any revenues. For the fiscal year ended June 30, 2024, the Company incurred a net loss of $68.5 million and net cash used in operating activities amounted to $57.4 million. As of June 30, 2024, the Company had an accumulated deficit of $329.4 million, and the Company's capital resources consisted of cash and cash equivalents of $70.4 million and in marketable debt securities totaling $56.7 million. As discussed in Note 7, the Company completed the 2024 Underwritten Offering in June 2024 that resulted in the issuance of approximately 13.0 million shares of common stock and 3.8 million prefunded warrants for net proceeds of $62.6 million after underwriting discounts and other offering costs. As of June 30, 2024, the Company had total liabilities of $11.7 million, including total current liabilities of $9.6 million. As discussed in Note 5, the Company is subject to license agreements that provide for future contractual payments upon achievement of various milestone events. Pursuant to the XOMA License Agreement (as defined below), a $5.0 million milestone payment will be due upon dosing of the last patient in a Phase 3 clinical trial for ersodetug. The commitment to pay the last patient dosing milestone of $5.0 million for the ersodetug Phase 3 clinical trial is expected to be recognized as a liability within 12 months. As discussed in Note 15, in July 2024 the Company received net proceeds of approximately $6.0 million related to a private placement of 1.5 million shares of common stock. Management believes the Company's cash and cash equivalents, investments in marketable debt securities, and additional proceeds from the July 2024 private placement, will be adequate to meet the Company's contractual obligations and carry out ongoing clinical trials and other planned activities through September 2025, at a minimum. -68500000-57400000-329400000704000005670000013000000.038000006260000011700000960000050000000.05000000.06000000.01500000 NOTE 3 — INVESTMENTS IN MARKETABLE DEBT SECURITIES Investments in marketable debt securities are classified as follows in the consolidated balance sheets as of June 30, 2024 and 2023 (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:61.24%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:15.74%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:15.74%;margin:0pt;padding:0pt;">   </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.24%;margin:0pt;padding:0pt;">   </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;">   </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.24%;background:#cceeff;margin:0pt;padding:0pt;"> Short-term investments </td><td style="vertical-align:bottom;white-

space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 56,478</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:15.74%;background:#cceeff;margin:0pt;padding:0pt;"> 85,860 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.24%;margin:0pt;padding:0pt;"> Long-term investments </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:15.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 263 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:15.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 16,470 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.24%;background:#cceeff;margin:0pt;padding:0pt;"> Total investments </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 56,741</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:15.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 102,330 </td></tr></table> . The Company only invests in liquid, high quality debt securities. Nonetheless, all of these investments are subject to interest rate and credit risk that may result in fluctuations in the fair value of the investments. To minimize the exposure due to an adverse shift in interest rates, the Company generally invests in securities with expected maturities of two years or less while maintaining a weighted average maturity of one year or less. As of June 30, 2024 investments in marketable debt securities with an aggregate fair value of $56.5 million are scheduled to mature during the 12-month period ending June 30, 2025. All of the remaining investments with a fair value of $0.3 million, are scheduled to mature during the 12-month period ending June 30, 2026. During the fiscal year ended June 30, 2024, marketable debt securities for $115.1 million matured and approximately $66.4 million of the proceeds were reinvested in additional marketable debt securities. The Company did not sell any marketable debt securities prior to the scheduled maturity dates for the fiscal year ended June 30, 2024. Accrued interest receivable on all marketable debt securities amounted to $0.4 million and $0.3 million as of June 30, 2024 and 2023, respectively. Accrued interest is included in other current assets in the accompanying consolidated balance sheet. </p><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For the fiscal years ended June 30, 2024 and 2023, the Company did not recognize any allowance for credit losses or other than temporary impairment related to investments in marketable debt securities. </p><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The following table summarizes the unrealized gains and losses that result in differences between the amortized cost basis and fair value of the Company's marketable debt securities held as of June 30, 2024 (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:31.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:31.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:31.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Gross Unrealized </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:31.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amortized Cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Gains</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Losses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:31.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Corporate commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-

space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"> 20,941 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"> (12) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20,929</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:31.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Obligations of U.S. government agencies</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,001</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,997</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:31.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">U.S. Treasury obligations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,727</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (7)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,720</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:31.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Corporate notes and bonds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 30,888</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (56)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 30,832</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:31.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Asset-backed securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 263</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 263</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:31.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:9pt;margin:0pt 0pt 0.05pt 12pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 56,820 </td><td style="vertical-align:bottom;white-

space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (79) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 56,741 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> $ </td></tr></table> The following table summarizes the unrealized gains and losses that result in differences between the amortized cost basis and fair value of the Company's marketable debt securities held as of June 30, 2023 (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:32.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85

Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"> (170) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"> 26,395 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:32.49%;background:#cceeff;margin:0pt;padding:0pt;"> U.S. Treasury obligations </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;background:#cceeff;margin:0pt;padding:0pt;"> 10,416 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;background:#cceeff;margin:0pt;padding:0pt;"> 2 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;background:#cceeff;margin:0pt;padding:0pt;"> (14) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;background:#cceeff;margin:0pt;padding:0pt;"> 10,404 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:32.49%;margin:0pt;padding:0pt;"> Corporate notes and bonds </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"> 19,253 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"> 1 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"> (14) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"> 19,240 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:32.49%;background:#cceeff;margin:0pt;padding:0pt;"> Asset-backed securities </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 4,777 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (83) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 4,694 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:32.49%;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 102,681</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 3 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (354)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 102,330 </td></tr></table> Investments in marketable debt securities are classified as follows in the consolidated balance sheets as of June 30, 2024 and 2023 (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:61.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.74%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.24%;margin:0pt;padding:0pt;">

</td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.24%;background:#cceeff;margin:0pt;padding:0pt;"> Short-term investments </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 56,478</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:15.74%;background:#cceeff;margin:0pt;padding:0pt;"> 85,860 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.24%;margin:0pt;padding:0pt;"> Long-term investments </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 263 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 16,470 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.24%;background:#cceeff;margin:0pt;padding:0pt;"> Total investments </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 56,741</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:15.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 102,330 </td></tr>
</table>5647800085860000263000164700005674100010233000OP2YP1Y56500000300000115100000664000004000003000000 The following table summarizes the unrealized gains and losses that result in differences between the amortized cost basis and fair value of the Company's marketable debt securities held as of June 30, 2024 (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:31.9%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:31.9%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:31.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Gross Unrealized </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:31.9%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Amortized Cost </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Gains </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Losses </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Fair Value </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:31.9%;background:#cceeff;margin:0pt;padding:0pt;"> Corporate commercial paper </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20,941</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"><p

style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (12)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;margin:0pt;padding:0pt;"> 20,929 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:31.9%;margin:0pt;padding:0pt;"> Obligations of U.S. government agencies </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"> 2,001 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"> (4) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"> 1,997 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:31.9%;background:#cceeff;margin:0pt;padding:0pt;"> U.S. Treasury obligations </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"> 2,727 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"> (7) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;margin:0pt;padding:0pt;"> 2,720 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:31.9%;margin:0pt;padding:0pt;"> Corporate notes and bonds </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"> 30,888 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;margin:0pt;padding:0pt;"> (56) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"> 30,832 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:31.9%;background:#cceeff;margin:0pt;padding:0pt;"> Asset-backed securities </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 263 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 263 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:31.9%;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 56,820</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times

New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (79) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 56,741 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"> $</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$ $</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The following table summarizes the unrealized gains and losses that result in differences between the amortized cost basis and fair value of the Company's marketable debt securities held as of June 30, 2023 (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:32.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> $</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"> $</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"> $</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> $</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"> $</p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:32.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Gross Unrealized </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"> $</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:32.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> $</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amortized Cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">—</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Gains</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">—</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Losses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">—</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:32.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Corporate commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">41,670</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">(73)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">41,597</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:32.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Obligations of U.S. government agencies</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">26,565</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"> (170) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> <span style="font-

size:9pt;visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"> 26,395 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:32.49%;background:#cceeff;margin:0pt;padding:0pt;"> U.S. Treasury obligations </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;background:#cceeff;margin:0pt;padding:0pt;"> 10,416 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;background:#cceeff;margin:0pt;padding:0pt;"> 2 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;background:#cceeff;margin:0pt;padding:0pt;"> (14) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;background:#cceeff;margin:0pt;padding:0pt;"> 10,404 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:32.49%;margin:0pt;padding:0pt;"> Corporate notes and bonds </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"> 19,253 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"> 1 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"> (14) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;background:#cceeff;margin:0pt;padding:0pt;"> 19,240 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:32.49%;background:#cceeff;margin:0pt;padding:0pt;"> Asset-backed securities </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 4,777 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (83) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 4,694 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:32.49%;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 102,681</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 3 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (354)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 102,330 </td></tr></table> 20941000120002092900020010004000199700027270007000272000030888000560003083200026300026300056820000790005674100041670000730004159700026565060

NOTE 4 — LEASES

In October 2023, the Company entered into an addendum to the lease agreement for its office in Bend, Oregon. The addendum provided for a 36-month extension, resulting in a new expiration date in February 2027. The average base rent payable over the remaining lease term is approximately $9,000. Upon execution of the addendum, the Company re-measured the Bend, Oregon operating lease liability at approximately $345,000 using a discount rate of 10.0%, and the related right-of-use asset was recognized for approximately $351,000.

In April 2022, the Company entered into a lease agreement for a new corporate headquarters facility in Redwood City, California. The space consists of approximately 9,300 square feet and provides for total base rent payments of approximately $2.9 million through the expected expiration of the lease in November 2027. Prior to occupancy, the landlord was required to make improvements to the facility that were completed in October 2022, triggering the commencement of the lease. The lease provided for a six-month rent abatement period beginning upon commencement of the lease term. In addition, the lease provided an allowance of approximately $0.1 million that was utilized by the Company for the purchase of furniture and equipment. The average base rent payable in cash over the 60-month lease term is approximately $48,000 per month. Upon commencement of the lease, the Company recognized a right-of-use asset for approximately $2.3 million, and a related operating lease liability for approximately $2.2 million. As of June 30, 2024 and 2023, the carrying values of all of the Company's right-of-use assets and the related operating lease liabilities were as follows (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.04%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"> <span style="font-

size:1pt;visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.02%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:62.04%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:62.04%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:14.02%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:14.02%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:62.04%;background:#cceeff;margin:0pt;padding:0pt;"> Right-of-use assets </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,880</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:14.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2,054 </td></tr><tr><td style="vertical-align:bottom;width:62.04%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:14.02%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:14.02%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:62.04%;background:#cceeff;margin:0pt;padding:0pt;"> Operating lease liabilities: </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:62.04%;margin:0pt;padding:0pt;"> Current </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 568</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:14.02%;margin:0pt;padding:0pt;"> 541 </td></tr><tr><td style="vertical-align:bottom;width:62.04%;background:#cceeff;margin:0pt;padding:0pt;"> Long-term </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,660 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,937 </td></tr><tr><td style="vertical-align:bottom;width:62.04%;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,228</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:14.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2,478 </td></tr></table> . For the fiscal years ended June 30, 2024 and 2023, operating lease expense included under the following captions in the accompanying consolidated statements of operations (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.35%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> <p style="font-family:'Times New

Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.65%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:59.35%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.65%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:59.35%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.65%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:59.35%;margin:0pt;padding:0pt;"> Research and development </td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 484</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"> 453 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.65%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:59.35%;background:#cceeff;margin:0pt;padding:0pt;"> General and administrative </td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 196 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 154 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.65%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:59.35%;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 680</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 607 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.65%;margin:0pt;padding:0pt;"> </td></tr></table> In addition to base rent expense, the Company's facility leases require variable payments, including the proportionate share of the real estate taxes, building insurance and common area maintenance costs related to the facilities. These variable payments are excluded from the determination of operating lease liabilities and amounted to an aggregate of $0.1 million for the fiscal year ended June 30, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of June 30, 2024, the weighted-average remaining lease term under operating leases was 3.3 years, and the weighted-average discount rate used to determine the operating lease liabilities was 7.2%. As of June 30, 2023, the weighted-average remaining lease term under operating leases was 4.3 years, and the weighted-average discount rate used to determine the operating lease liabilities was 6.8%.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Future Lease Payments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Future payments under all operating lease agreements as of June 30, 2024 are as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:78.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:78.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fiscal year ending June 30, </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"></p></td></tr><tr><td style="vertical-align:bottom;width:78.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:16.21%;background:#cceeff;margin:0pt;padding:0pt;"> 748 </td></tr><tr><td style="vertical-align:bottom;width:78.13%;margin:0pt;padding:0pt;"> 2026 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.21%;margin:0pt;padding:0pt;"> 770 </td></tr><tr><td style="vertical-align:bottom;width:78.13%;background:#cceeff;margin:0pt;padding:0pt;"> 2027 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.21%;background:#cceeff;margin:0pt;padding:0pt;"> 750 </td></tr><tr><td style="vertical-align:bottom;width:78.13%;margin:0pt;padding:0pt;"> Thereafter </td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:16.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 224 </td></tr><tr><td style="vertical-align:bottom;width:78.13%;background:#cceeff;margin:0pt;padding:0pt;"> Total lease payments </td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:16.21%;background:#cceeff;margin:0pt;padding:0pt;"> 2,492 </td></tr><tr><td style="vertical-align:bottom;width:78.13%;margin:0pt;padding:0pt;"> Less imputed interest </td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (264) </td></tr><tr><td style="vertical-align:bottom;width:78.13%;background:#cceeff;margin:0pt;padding:0pt;"> Present value of operating lease liabilities </td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,228</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;">.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> .</p>P36M90003450000.10035100093002900000P6M10000048000230000022000000<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">As of June 30, 2024 and 2023, the carrying values of all of the Company's right-of-use assets and the related operating lease liabilities were as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</p></td></tr><tr><td style="vertical-align:bottom;width:62.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">.</p></td></tr><tr><td style="vertical-align:bottom;width:62.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Right-of-use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:14.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,880 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,054</p></td></tr><tr><td style="vertical-align:bottom;width:62.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">.</p></td></tr><tr><td style="vertical-align:bottom;width:62.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Operating lease liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:62.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:14.02%;margin:0pt;padding:0pt;"> 568 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:14.02%;margin:0pt;padding:0pt;"> 541 </td></tr><tr><td style="vertical-align:bottom;width:62.04%;background:#cceeff;margin:0pt;padding:0pt;"> Long-term </td><td style="vertical-align:bottom;white-space:nowrap;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,660 </td><td style="vertical-align:bottom;white-

space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,937 </td></tr><tr><td style="vertical-align:bottom;width:62.04%;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,228</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:14.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2,478 </td></tr></table>1880000205400056800054100016600001937000222800002478000 For the fiscal years ended June 30, 2024 and 2023, operating lease expense included under the following captions in the accompanying consolidated statements of operations (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.35%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:3.65%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:59.35%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.65%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:59.35%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:3.65%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:59.35%;margin:0pt;padding:0pt;"> Research and development </td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 484</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"> 453 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.65%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:59.35%;background:#cceeff;margin:0pt;padding:0pt;"> General and administrative </td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 196 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 154 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.65%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:59.35%;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 680</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 607 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.65%;margin:0pt;padding:0pt;"> . </td></tr></table>484000453000196000154000680000060700010000OP3Y3M18D0.072P4Y3M18D0.068 Future payments under all operating lease agreements as of June 30, 2024 are as follows (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:78.13%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:16.21%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:78.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Fiscal

year ending June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.21%;margin:0pt;padding:0pt;">) </td></tr><tr><td style="vertical-align:bottom;width:78.13%;background:#cceeff;margin:0pt;padding:0pt;"> 2025 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 748</p></td></tr><tr><td style="vertical-align:bottom;width:78.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 770</p></td></tr><tr><td style="vertical-align:bottom;width:78.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 750</p></td></tr><tr><td style="vertical-align:bottom;width:78.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 224</p></td></tr><tr><td style="vertical-align:bottom;width:78.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,492</p></td></tr><tr><td style="vertical-align:bottom;width:78.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Less imputed interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (264)</p></td></tr><tr><td style="vertical-align:bottom;width:78.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Present value of operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:16.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2,228 </td></tr></table>748000770000750000224000249200026400022280000 NOTE 5 — LICENSE AGREEMENTS XOMA License Agreement In December 2017, the Company entered into a license agreement (“XOMA License Agreement”) with XOMA Corporation (“XOMA”), through its wholly-owned subsidiary, XOMA (U.S.) LLC, pursuant to which XOMA granted an exclusive global license to the Company to develop and commercialize XOMA 358 (formerly X358 or RZ358, now ersodetug) for all indications. In January 2022, the Company was required to make a milestone payment under the XOMA License Agreement of $2.0 million that became due upon the dosing of the last patient in the Company’s Phase 2b Clinical Trial for ersodetug. In April 2024, the Company was required to make a milestone payment under the XOMA License Agreement of $5.0 million that became due upon dosing of the first patient in the Company’s Phase 3 Clinical Trial for ersodetug. Upon the achievement of certain clinical and regulatory events under the XOMA License Agreement, the Company will be required to make additional milestone payments to XOMA up to $30.0 million. After the clinical and regulatory milestones, the Company will be required, upon the future commercialization of ersodetug, to pay royalties to XOMA based on the net sales of the related products and additional milestone payments to XOMA up to $185.0 million related to annual net sales amounts. There have been no events that would result in any royalty payments owed under the XOMA License Agreement to date. The Company records a liability for milestone payments under license agreements in the period that the milestone event is achieved. The next milestone payment of $5.0 million will be due upon dosing of the last patient in the ongoing Phase 3 clinical trial for ersodetug. ActiveSite License Agreement In August 2017, the Company entered into a Development and License Agreement (the “ActiveSite License Agreement”) with ActiveSite Pharmaceuticals, Inc. (“ActiveSite”) pursuant to which the Company acquired the rights to ActiveSite’s Plasma Kallikrein Inhibitor program (“PKI Portfolio”). The Company is initially using the PKI Portfolio to develop an oral PKI therapeutic for diabetic macular edema (RZ402) and may use the PKI Portfolio to develop other therapeutics for different indications. The ActiveSite Development and License Agreement requires various milestone payments up to $46.5 million if all milestone events are achieved. The first milestone payment for $1.0 million was paid in December 2020 after clearance was received for an Initial Drug Application, or IND, filed with the U.S. Food and Drug Administration (“FDA”). The second milestone payment of $3.0 million was paid in February 2023 after dosing of the first patient in a Phase 2 clinical trial for RZ402. The next milestone payment of $5.0 million will be due upon the first dosing of a patient in a Phase 3 clinical trial. The Company is also required to pay royalties equal to 2.0% of any sales of products that use the PKI Portfolio. There have been no events that would result in any royalty payments owed under the ActiveSite License Agreement to date. 2000000.05000000.030000000.0185000000.05000000.046500000100000.03000000.05000000.00.020 NOTE 6 — EMBEDDED DERIVATIVE LIABILITY On April 14, 2021, the Company entered into a $30.0 million Loan and Security Agreement (the “Loan Agreement”) with SLR Investment Corp. (“SLR”) and certain other lenders (collectively, the “Lenders”). The Lenders agreed to loan up to $30.0 million but the actual amount borrowed by the Company amounted to $15.0 million. The maturity date of the outstanding borrowings was April 1, 2026 (the “Maturity Date”), but the Company elected to repay the entire amount and terminated the Loan Agreement on June 30, 2022. Concurrently with the execution of the Loan Agreement, the Company entered into an exit fee agreement (the “Exit Fee Agreement”) that provides for a fee of 4.00% of the funded principal balance for a total of $0.6 million in the event certain transactions (defined as “Exit Events”) occur prior to April 13, 2031. The Exit Fee was not eliminated by termination of the Loan Agreement discussed above. The Company is accounting for the Exit Fee Agreement as an embedded derivative liability with an estimated fair value of $0.5 million and $0.4 million as of June 30, 2024 and 2023, respectively. Exit Events include, but are not limited to, sales of substantially all assets, certain mergers, change of control transactions, and issuances of common stock that result in new investors owning more than 35% of the Company’s shares. Fair value of embedded derivatives is assessed at the end of each reporting period with changes in fair value recognized as a non-operating gain or loss.) 30000000.030000000.015000000.00.040060000050000040000000.35 NOTE 7 — SHAREHOLDERS’ EQUITY Pre-Funded Warrants Between October 2021 and June 2024, the Company issued fully vested pre-funded warrants (“PFWs”) exercisable to purchase an aggregate of 21.3 million shares of common stock. As of June 30, 2024 and 2023, all outstanding PFWs meet the requirements to be classified in shareholders’ equity under the caption additional paid-in capital. The PFWs do not entitle the holders thereof to any voting rights or any of the other rights or privileges to which holders of common stock are entitled. The exercise prices of the PFWs are subject to adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting holders of common stock. In the event of certain fundamental corporate transactions, the holders of the PFWs are entitled to receive the kind and amount of securities, cash or other property that the holders would have received had they exercised the PFWs immediately prior to such transaction. The PFWs are exercisable at any time, subject to the then effective ownership blocker percentage (the “OBP”) as elected by each of the holders of PFWs. The OBP is a percentage designated by the holders whereby the PFWs cannot be exercised if, after giving effect thereto, the holder would beneficially own more than the designated OBP. However, upon at least 61 days’ prior notice to the Company, any holder of PFWs may elect to increase or decrease the OBP to any other percentage not to exceed 19.99%. Assuming the holders comply with the respective OBP terms, all of the PFWs may be exercised at any time by paying the respective exercise price or electing to exercise on a cashless basis. As of June 30, 2022, the Company had an aggregate of 14,582,516 PFWs that were outstanding. No PFWs were issued or exercised for the fiscal year ended June 30, 2023. The following table summarizes PFW activity for the fiscal year ended June 30, 2024: <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:44.03%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;">) </td><td style="vertical-

align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> 2021 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"> 2022 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"> Exchange </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> PFWs </td><td style="vertical-align:bottom;width:1.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> PFWs </td><td style="vertical-align:bottom;width:1.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> PFWs </td><td style="vertical-align:bottom;width:1.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Total </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.03%;background:#cceeff;margin:0pt;padding:0pt;"> Outstanding, June 30, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"> 1,661,461 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"> ⁽¹⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"> 12,921,055 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"> ⁽²⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"> 14,582,516 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.03%;margin:0pt;padding:0pt;"> Issuance of Exchange PFWs in March 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"> 3,000,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"> ⁽³⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"> 3,000,000 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.03%;background:#cceeff;margin:0pt;padding:0pt;"> Issuance of 2024 PFWs in June 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"> 3,750,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"> ⁽⁴⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"> 3,750,000 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.03%;margin:0pt;padding:0pt;"> Cashless exercise of PFWs: </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.03%;background:#cceeff;margin:0pt;padding:0pt;"> Shares surrendered for exercise price </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"> (8,571) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p

style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,494) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"> (12,065) </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.03%;margin:0pt;padding:0pt;"> Shares of common stock issued </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (1,529,890) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (4,770,190) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (6,300,080) </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.03%;background:#cceeff;margin:0pt;padding:0pt;"> Outstanding, June 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 123,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 8,147,371 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 3,000,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 3,750,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 15,020,371 </td></tr></table> <table style="border-collapse:collapse;font-family:'Times New Roman','Times',serif;font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times',serif;font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;">In connection with an underwritten offering in October 2021, PFWs were issued to purchase 1,661,461 shares of common stock at an issuance price of $6.49 per share (the “2021 PFWs”). The exercise price of the 2021 PFWs is $0.01 per share.</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times',serif;font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times',serif;font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;">In connection with a registered direct offering in May 2022, the Company issued 1,973,684 Class A PFWs and 10,947,371 Class B PFWs to purchase an aggregate of 12,921,055 shares of common stock at an issuance price of $3.799 per warrant (collectively, the “2022 PFWs”). The exercise price of the 2022 PFWs is $0.001 per share. The 2022 PFWs were classified within shareholders’ equity for the entirety of the fiscal years ended June 30, 2024 and 2023.</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times',serif;font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times',serif;font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;">As discussed below under the caption Exchange Agreement, the Company issued 3,000,000 Exchange PWFs on March 8, 2024. The exercise price of the Exchange PFWs is $0.001 per share. The Exchange PFWs were initially classified as a derivative liability until May 13, 2024 when the terms were amended to permit reclassification within shareholders’ equity.</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times',serif;font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times',serif;font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(4)</td><td style="padding:0pt;">As discussed below under the caption 2024 Underwritten Offering, the Company issued 2024 PWFs for the purchase of 3,750,000 shares of common stock on June 24, 2024. The exercise price of the 2024 PFWs is $0.001 per share.</td></tr></table> . 2024 Underwritten Offering On June 13, 2024, the Company entered into an underwriting agreement with Jefferies LLC and Cantor Fitzgerald & Co. (the “Underwriters”) for the planned issuance and sale of equity securities in an underwritten public offering (the “2024 Underwritten Offering”). The 2024 Underwritten Offering provided for the issuance of (i) 11,250,000 shares of common stock at a price of $4.00 per share for gross proceeds of $45.0 million, and (ii) pre-funded warrants to purchase 3,750,000 shares of common stock at a public offering price of $3.999 per pre-funded warrant (the “2024 PFWs”) for gross proceeds of $15.0 million. The Company granted the 2024 Underwriters a 30-day option to purchase up to an additional 2,250,000 shares of its common stock in the 2024 Underwritten Offering at a public offering price of $4.00 per share, less underwriting commissions (the “2024 Underwriters’ Option”). The Underwriters’ Option was partially exercised for 1,786,589 shares of common stock for gross proceeds of $7.1 million. Closing occurred on June 24, 2024, whereby the aggregate gross proceeds from the 2024 Underwritten Offering amounted to $67.1 million before deductions for underwriting commissions of 6.0% of the gross proceeds and other offering costs of approximately $0.5 million. After deducting total offering costs of $4.5 million, the net proceeds of the 2024 Underwritten Offering amounted to approximately $62.6 million. Exchange Agreement On March 8, 2024, the Company entered into a securities exchange agreement (the “Exchange Agreement”) with certain of its stockholders (the “Exchanging Shareholders”), whereby the Company purchased 3,000,000 shares of common stock representing approximately 7% of outstanding shares with an aggregate fair value of $5,700,000 (the “Retired Shares”) from the Exchanging Shareholders. The Retired Shares were immediately cancelled whereby they will remain as authorized shares for future issuance in accordance with Nevada law. Consideration for the acquisition of the Retired Shares consisted of (i) a cash payment to the Exchanging Shareholders of $3,000, and (ii) the issuance of pre-funded warrants (the “Exchange PFWs”) to the Exchanging Shareholders with an estimated fair value of $5,697,000. The Exchange PFWs do not expire and are exercisable to purchase an aggregate of 3,000,000 shares of the Company’s outstanding common stock at an exercise price of $0.001 per share. As required pursuant to the Exchange Agreement, the Company filed a registration statement in August 2024 to register the shares issuable upon the exercise of the Exchange PFWs. The Exchange PFWs originally required approval by the Company’s shareholders if the exercise of the Exchange PFWs resulted in aggregate beneficial ownership by the holders in excess of 19.99%. Even though the Exchange PFWs only entitled the holders to purchase 7% of the Company’s outstanding shares of common stock, the requirement to obtain shareholder approval for ownership in excess of 19.99% resulted in the treatment of the exchange PFWs as a warrant derivative liability of $5.7 million as of the issuance date. The fair value of this warrant derivative liability increased by approximately $2.9 million, for a total of approximately $8.5 million as of May 13, 2024 when the Exchange PFWs were amended to permit equity classification. Accordingly, the derivative liability was reclassified to shareholders’ equity on May 13, 2024. Jefferies Open Market Sales Agreement On November 14, 2023, the Company and Jefferies LLC (the “Agent) entered into an open market sales agreement (the “Sales Agreement”) that provides for an “at the market” offering for the sale of up to $50.0 million in shares of the Company’s common stock

(the "Placement Shares") through the Agent. The Agent is acting as sales agent and is required to use commercially reasonable efforts to sell all of the Placement Shares requested to be sold by the Company, consistent with the Agent's normal trading and sales practices, on mutually agreed terms between the Agent and the Company. The Sales Agreement will terminate when all of the Placement Shares have been sold, or earlier upon the election of either the Company or the Agent. The Company has no obligation to sell any of the Placement Shares under the Sales Agreement. The Company intends to use the net proceeds, if any, from amounts sold under the Sales Agreement for general corporate purposes, including working capital. Under the terms of the Sales Agreement, the Company agreed to pay the Agent a commission equal to 3.0% of the gross sales price of the Placement Shares plus certain expenses incurred by the Agent in connection with the offering. For the fiscal year ended June 30, 2024, the Company sold no shares of its common stock pursuant to the Sales Agreement. Accordingly, the maximum amount remaining for sale under the Sales Agreement amounts to $50.0 million as of June 30, 2024. 2022 Private Placement In May 2022, the Company entered into securities purchase agreements (the "2022 SPAs") with Handok, Inc. ("Handok") and certain of its affiliates. Handok is an affiliate of a member of the Company's Board of Directors. In July 2022, the Company entered into amended 2022 SPAs for a private placement of common stock. The private placement resulted in gross proceeds of $12.3 million in exchange for the issuance of approximately 3.2 million shares of common stock. The Company incurred approximately $0.8 million for underwriting commissions and other offering costs, resulting in net proceeds of $11.6 million. 213000000.1999145825160<table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:44.03%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;">   </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.03%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> 2021 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"> 2022 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"> Exchange </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;">   </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.03%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> PFWs </td><td style="vertical-align:bottom;width:1.56%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> PFWs </td><td style="vertical-align:bottom;width:1.56%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> PFWs </td><td style="vertical-align:bottom;width:1.56%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Total </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.03%;background:#cceeff;margin:0pt;padding:0pt;"> Outstanding, June 30, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"> 1,661,461 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"> ⁽¹⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"> 12,921,055 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"> ⁽²⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"> 14,582,516 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.03%;margin:0pt;padding:0pt;"> Issuance of Exchange PFWs in March 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"> 3,000,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"> ⁽³⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"> 3,000,000 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.03%;background:#cceeff;margin:0pt;padding:0pt;"> Issuance of 2024 PFWs in June 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p

style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"> 3,750,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"> ⁽⁴⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"> 3,750,000 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.03%;margin:0pt;padding:0pt;"> Cashless exercise of PFWs: </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:44.03%;background:#cceeff;margin:0pt;padding:0pt;"> Shares surrendered for exercise price </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"> (8,571) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"> (3,494) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"> (12,065) </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.03%;margin:0pt;padding:0pt;"> Shares of common stock issued </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (1,529,890) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (4,770,190) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (6,300,080) </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:44.03%;background:#cceeff;margin:0pt;padding:0pt;"> Outstanding, June 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 123,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 8,147,371 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 3,000,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 3,750,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 15,020,371 </td></tr></table> <table style="border-collapse:collapse;font-family:'Times New Roman','Times';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times';font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;">In connection with an underwritten offering in October 2021, PFWs were issued to purchase 1,661,461 shares of common stock at an issuance price of $6.49 per share (the “2021 PFWs”). The exercise price of the 2021 PFWs is $0.01 per share.</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times';font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;">In connection with a registered direct offering in May 2022, the Company issued 1,973,684 Class A PFWs and 10,947,371 Class B PFWs to purchase an aggregate of 12,921,055 shares of common stock at an issuance price of $3.799 per warrant (collectively, the “2022 PFWs”). The exercise price of the 2022 PFWs is $0.001 per share. The 2022 PFWs were classified within shareholders’ equity for the entirety of the fiscal years ended June 30, 2024 and 2023.</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times';font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;">As discussed below under the caption Exchange Agreement, the Company issued 3,000,000 Exchange PFWs on March 8, 2024. The exercise price of the Exchange PFWs is $0.001 per share. The Exchange PFWs were initially classified as a derivative liability until May 13, 2024 when the terms were amended to permit reclassification within shareholders’ equity.</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times';font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(4)</td><td style="padding:0pt;">As discussed below under the caption 2024 Underwritten Offering, the Company issued 2024 PWFs for the purchase of 3,750,000 shares of common stock on June 24, 2024. The exercise price of the 2024 PFWs is $0.001 per share.</td></tr></table>166146112921055145825163000000300000037500003750000857134941206515298904770190630008012300081473713000000375000015020371166146164.490.0115

style="font-family:'Times New Roman','Times',serif;font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE 8 — SHARE-BASED COMPENSATION AND WARRANTS Stock Option Plans Presented below is a summary of the number of shares authorized, outstanding, and available for future grants under the Company's stock option plans and the Inducement Grant (defined below) as of June 30, 2024 (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.75%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:55.6%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:41.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Number of Shares </td></tr><tr><td style="vertical-align:bottom;width:55.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Description </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Authorized </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Outstanding </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Available </td></tr><tr><td style="vertical-align:bottom;width:55.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.75%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:55.6%;background:#cceeff;margin:0pt;padding:0pt;"> 2015 Plan </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#cceeff;margin:0pt;padding:0pt;"> 17 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.75%;background:#cceeff;margin:0pt;padding:0pt;"> 17 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:55.6%;margin:0pt;padding:0pt;"> 2016 Plan </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"> 123 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.75%;margin:0pt;padding:0pt;"> 123 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:55.6%;background:#cceeff;margin:0pt;padding:0pt;"> 2019 Plan </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#cceeff;margin:0pt;padding:0pt;"> 200 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.75%;background:#cceeff;margin:0pt;padding:0pt;"> 200 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:55.6%;margin:0pt;padding:0pt;"> 2021 Plan </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"> 10,618 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.75%;margin:0pt;padding:0pt;"> 10,276 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"> 342 </td></tr><tr><td style="vertical-align:bottom;width:55.6%;background:#cceeff;margin:0pt;padding:0pt;"> Inducement Grant </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 275 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 275 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:55.6%;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 11,233 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 10,891 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 342 </td></tr></table> The Company currently has one active stock option plan, the 2021 Equity Incentive Plan (the "2021 Equity Plan"). On March 31,

2021, the Company's Board of Directors adopted the 2021 Equity Plan that will terminate on March 31, 2031. On May 26, 2021, the 2021 Equity plan was approved by the Company's shareholders with authority to issue up to 1.2 million shares of common stock. Pursuant to the 2021 Equity Plan, no awards may be granted under the three legacy stock option plans shown in the table above, but all outstanding awards previously granted under those plans shall remain outstanding and subject to the terms of the respective plans. On June 16, 2022, the Company's shareholders approved an amendment to the 2021 Equity Plan, increasing the number of shares of common stock to be issued under the plan up to 10.7 million shares of common stock. Stock options outstanding under these plans expire pursuant to their contractual provisions on various dates through 2034. 2022 Employee Stock Purchase Plan On June 16, 2022, the Company's shareholders approved the adoption of the 2022 Employee Stock Purchase Plan (the "2022 ESPP"). The 2022 ESPP provides an opportunity for employees to purchase shares of the Company's common stock through accumulated payroll deductions. The 2022 ESPP permits consecutive offering periods that begin approximately every 6 months commencing on the first trading day on or after July 1 and terminating on the last trading day of the offering period ending on December 31 and commencing on the first trading day on or after January 1 and terminating on the last trading day of the offering period ending on June 30. The 2022 ESPP reserves 0.5 million shares for purchases. There have been no offering periods under the 2022 ESPP through June 30, 2024. Stock Options Outstanding The following table sets forth a summary of the combined activity under all of the Company's stock option plans, including Inducement Grant discussed below, for the fiscal years ended June 30, 2024 and 2023 (shares in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.71%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:45.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="6" style="vertical-align:bottom;white-space:nowrap;width:25.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"> </td><td colspan="6" style="vertical-align:bottom;white-space:nowrap;width:25.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:45.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Shares </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Price ⁽¹⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Term ⁽²⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Shares </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Price ⁽¹⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Term ⁽²⁾ </td></tr><tr><td style="vertical-align:bottom;width:45.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:45.01%;background:#cceeff;margin:0pt;padding:0pt;"> Outstanding, beginning of fiscal year </td><td style="vertical-align:bottom;white-

space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"> 8,745 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.56</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">8.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,506</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:6.71%;background:#cceeff;margin:0pt;padding:0pt;"> 5.24 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;margin:0pt;padding:0pt;"> 9.7 </td></tr><tr><td style="vertical-align:bottom;width:45.01%;margin:0pt;padding:0pt;"> Grants to employees </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"> 2,642 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.67%;margin:0pt;padding:0pt;"> 1.31 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"> 740 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.71%;margin:0pt;padding:0pt;"> 2.00 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:45.01%;background:#cceeff;margin:0pt;padding:0pt;"> Exercises </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"> (82) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> ⁽³⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.67%;background:#cceeff;margin:0pt;padding:0pt;"> 3.02 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.71%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:45.01%;margin:0pt;padding:0pt;"> Expired </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"> (110) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.67%;margin:0pt;padding:0pt;"> 6.11 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"> (116) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.71%;margin:0pt;padding:0pt;"> 40.73 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:45.01%;background:#cceeff;margin:0pt;padding:0pt;"> Forfeited </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (304) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.67%;background:#cceeff;margin:0pt;padding:0pt;"> 2.63 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (385) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.71%;background:#cceeff;margin:0pt;padding:0pt;"> 3.75 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-

align:bottom;width:45.01%;margin:0pt;padding:0pt;"> Outstanding, end of fiscal year </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 10,891 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> ⁽⁴⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.67%;margin:0pt;padding:0pt;"> 3.82 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"> 8.1 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 8,745 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.71%;margin:0pt;padding:0pt;"> 4.56 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"> 8.8 </td></tr><tr><td style="vertical-align:bottom;width:45.01%;background:#cceeff;margin:0pt;padding:0pt;"> Vested, end of fiscal year </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 4,892 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> ⁽⁵⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.67%;background:#cceeff;margin:0pt;padding:0pt;"> 5.39 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;margin:0pt;padding:0pt;"> 7.7 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2,676 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.71%;background:#cceeff;margin:0pt;padding:0pt;"> 6.57 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;margin:0pt;padding:0pt;"> 8.4 </td></tr></table> <table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;">Represents the weighted average exercise price.</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;">Represents the weighted average remaining contractual term until the stock options expire.</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;">The total intrinsic value (the amount by which the fair market value exceeded the exercise price) of stock options exercised during the year ended June 30, 2024, was $0.1 million.</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(4)</td><td style="padding:0pt;">As of June 30, 2024, the intrinsic value of outstanding options was approximately $14.6 million.</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(5)</td><td style="padding:0pt;">As of June 30, 2024, the aggregate intrinsic value of vested stock options was approximately $4.1 million.</td></tr></table> For the fiscal year ended June 30, 2024, the aggregate fair value of stock options granted for approximately 2.6 million shares of common stock amounted to $2.6 million or approximately $1.02 per share as of the grant dates. For the fiscal year ended June 30, 2023, the aggregate fair value of stock options granted for approximately 0.7 million shares of common stock amounted to $1.1 million or approximately $1.53 per share as of the grant dates. Fair value was computed using the BSM option-pricing model and will result in the recognition of compensation expense ratably over the expected vesting period of the stock options. The Company uses the BSM option pricing model to determine the fair value of stock option awards granted. The determination of the fair value of share-based awards utilizing the BSM model is affected by the share price and a number of assumptions as of the grant date, including expected volatility, expected term, risk-free interest rate and expected dividends. The Company determined it does not have a sufficient share price history since up-listing to the Nasdaq Capital Market in November 2020. As a result, the Company determined the expected volatility by using share price information of similar sized biotechnology entities whose share prices are publicly available. Due to the lack of a meaningful history of exercise behavior of stock options, the expected term of the awards is determined by the simplified method that uses the midpoint between the vesting date and the end of the contractual term for each grant of stock options. The risk-free interest rate assumption is based on observed interest rates appropriate for the expected terms of the awards. The dividend yield assumption is based on past practices and the expectation that no dividends will be paid in the future.   The fair value of stock options was estimated on the dates of grant using the BSM option-pricing model, with the following weighted-average assumptions for the fiscal years ended June 30, 2024 and 2023: <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:69.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:69.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"> </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:13.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> <b

style="font-weight:bold;">2023 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:69.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:69.86%;background:#cceeff;margin:0pt;padding:0pt;"> Market price of common stock on grant date </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.31</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.31%;background:#cceeff;margin:0pt;padding:0pt;"> 3.73 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:69.86%;margin:0pt;padding:0pt;"> Expected volatility </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"> 99 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.31%;margin:0pt;padding:0pt;"> 91 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"> % </td></tr><tr><td style="vertical-align:bottom;width:69.86%;background:#cceeff;margin:0pt;padding:0pt;"> Risk free interest rate </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;background:#cceeff;margin:0pt;padding:0pt;"> 4.2 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.31%;background:#cceeff;margin:0pt;padding:0pt;"> 3.7 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"> % </td></tr><tr><td style="vertical-align:bottom;width:69.86%;margin:0pt;padding:0pt;"> Expected term (years) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"> 5.6 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.31%;margin:0pt;padding:0pt;"> 6.0 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:69.86%;background:#cceeff;margin:0pt;padding:0pt;"> Dividend yield </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;background:#cceeff;margin:0pt;padding:0pt;"> 0 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.31%;background:#cceeff;margin:0pt;padding:0pt;"> 0 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"> % </td></tr></table> Share-based compensation expense is included under the following captions in the consolidated statements of operations for the fiscal years ended June 30, 2024 and 2023 (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.18%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:72.18%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:72.18%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:72.18%;background:#cceeff;margin:0pt;padding:0pt;"> Research and development </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,379</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;background:#cceeff;margin:0pt;padding:0pt;"> 3,243 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:72.18%;margin:0pt;padding:0pt;"> General and administrative </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 3,981 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 4,025 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:72.18%;background:#cceeff;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,360</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 7,268 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr></table> . Unrecognized share-based compensation expense for stock options as of June 30, 2024 was approximately $11.6 million. This amount is expected to be recognized over a remaining weighted average period of 2.3 years. Inducement Grant In connection with the hiring of the Company's Chief Financial Officer in January 2024, the Board of Directors granted a stock option for 275,000 shares of the Company's common stock at an exercise price of $1.02 per share. This stock option is considered an inducement grant (the "Inducement Grant") pursuant to Nasdaq Listing Rule 5635(c)(4) whereby the underlying shares were not authorized under any of the Company's stock option plans. The Inducement Grant is exercisable until January 2029 and vests for (i) one-fourth of the option shares on the one-year anniversary of the grant date, and (ii) one thirty-sixth of the remaining option shares shall vest on the same day of each month thereafter until the Inducement Grant is 100% vested. The fair value of the Inducement Grant of $0.2 million was computed using the BSM option pricing model. Pre-Funded Warrants PFWs are outstanding for a total of 15.0 million and 14.6 million shares as of June 30, 2024 and 2023, respectively. Please refer to Note 7 for additional information about outstanding PFWs and Note 13 for treatment of PFWs in the calculation of earnings per share. Legacy Warrants In connection with an equity financing in October 2020, the Company issued warrants entitling the holders to purchase approximately 0.8 million shares of common stock. The warrants are exercisable at $19.50 per share for a period of seven years, may be exercised on a cash or cashless basis at the election of the holders, and the holders are entitled to share in any dividends or distributions payable to holders of common stock on an as-converted basis (the "Participating Warrants"). Additionally, the Company has issued warrants to purchase shares of common stock in conjunction with other debt and equity financings and for services. As of June 30, 2024 and 2023, all of the warrants were vested. The Participating Warrants and other warrants are collectively referred to as the "Legacy Warrants." . For the fiscal years ended June 30, 2024 and 2023, no Legacy Warrants were granted or exercised. The following table sets forth a summary of activity related to the Legacy Warrants for the fiscal years ended June 30, 2024 and 2023 (shares in thousands): . <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:35.66%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:35.66%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> . </td><td colspan="6" style="vertical-align:bottom;white-space:nowrap;width:29.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> . </td><td colspan="6" style="vertical-align:bottom;white-space:nowrap;width:29.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New

Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2023 </td></tr><tr><td style="vertical-align:bottom;width:35.66%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Shares </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Price ⁽¹⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Term ⁽²⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Shares </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Price ⁽¹⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Term ⁽²⁾ </td></tr><tr><td style="vertical-align:bottom;width:35.66%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:35.66%;background:#cceeff;margin:0pt;padding:0pt;"> Outstanding, beginning of fiscal year </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"> 888 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 22.10</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">4.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,150</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;background:#cceeff;margin:0pt;padding:0pt;"> 22.83 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;background:#cceeff;margin:0pt;padding:0pt;"> 4.2 </td></tr><tr><td style="vertical-align:bottom;width:35.66%;margin:0pt;padding:0pt;"> Expirations </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (27) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;margin:0pt;padding:0pt;"> 78.60 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (262) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;margin:0pt;padding:0pt;"> 25.32 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:35.66%;background:#cceeff;margin:0pt;padding:0pt;"> Outstanding, end of fiscal year </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 861 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;background:#cceeff;margin:0pt;padding:0pt;"> 20.28 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;background:#cceeff;margin:0pt;padding:0pt;"> 3.2 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 888 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt

3pt 0.05pt 0pt;"> 22.10 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;background:#cceeff;margin:0pt;padding:0pt;"> 4.1 </td></tr></table> <table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:3pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;">Represents the weighted average exercise price.</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;">Represents the weighted average remaining contractual term for the number of years until the warrants expire. </td></tr></table> Presented below is a summary of the number of shares authorized, outstanding, and available for future grants under the Company's stock option plans and the Inducement Grant (defined below) as of June 30, 2024 (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.75%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:55.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:41.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Number of Shares </td></tr><tr><td style="vertical-align:bottom;width:55.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Description </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Authorized </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Outstanding </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Available </td></tr><tr><td style="vertical-align:bottom;width:55.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.75%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:55.6%;background:#cceeff;margin:0pt;padding:0pt;"> 2015 Plan </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#cceeff;margin:0pt;padding:0pt;"> 17 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.75%;background:#cceeff;margin:0pt;padding:0pt;"> 17 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:55.6%;margin:0pt;padding:0pt;"> 2016 Plan </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"> 123 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.75%;margin:0pt;padding:0pt;"> 123 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:55.6%;background:#cceeff;margin:0pt;padding:0pt;"> 2019 Plan </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#cceeff;margin:0pt;padding:0pt;"> 200 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.75%;background:#cceeff;margin:0pt;padding:0pt;"> 200 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:55.6%;margin:0pt;padding:0pt;"> 2021 Plan </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;margin:0pt;padding:0pt;"> 10,618 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.75%;margin:0pt;padding:0pt;"> 10,276 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"> 342 </td></tr><tr><td style="vertical-align:bottom;width:55.6%;background:#cceeff;margin:0pt;padding:0pt;"> Inducement Grant </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 275 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 275 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:55.6%;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New

Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 11,233 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 10,891 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 342 </td></tr>
</table>17000170001230001230002000002000001061800010276000342000275000275000112330001089100034200011200000107000005000000 The following table sets forth a summary of the combined activity under all of the Company's stock option plans, including Inducement Grant discussed below, for the fiscal years ended June 30, 2024 and 2023 (shares in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:45.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="6" style="vertical-align:bottom;white-space:nowrap;width:25.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"> </td><td colspan="6" style="vertical-align:bottom;white-space:nowrap;width:25.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:45.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Shares </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Price ⁽¹⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Term ⁽²⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Shares </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Price ⁽¹⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Term ⁽²⁾ </td></tr><tr><td style="vertical-align:bottom;width:45.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.67%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:45.01%;background:#cceeff;margin:0pt;padding:0pt;"> Outstanding, beginning of fiscal year </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"> 8,745 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p

style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.56</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">8.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,506</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:6.71%;background:#cceeff;margin:0pt;padding:0pt;"> 5.24 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;margin:0pt;padding:0pt;"> 9.7 </td></tr><tr><td style="vertical-align:bottom;width:45.01%;margin:0pt;padding:0pt;"> Grants to employees </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"> 2,642 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.67%;margin:0pt;padding:0pt;"> 1.31 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"> 740 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.71%;margin:0pt;padding:0pt;"> 2.00 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:45.01%;background:#cceeff;margin:0pt;padding:0pt;"> Exercises </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"> (82) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> ⁽³⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.67%;background:#cceeff;margin:0pt;padding:0pt;"> 3.02 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.71%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:45.01%;background:#cceeff;margin:0pt;padding:0pt;"> Expired </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"> (110) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.67%;margin:0pt;padding:0pt;"> 6.11 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"> (116) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.71%;margin:0pt;padding:0pt;"> 40.73 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:45.01%;background:#cceeff;margin:0pt;padding:0pt;"> Forfeited </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (304) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.67%;background:#cceeff;margin:0pt;padding:0pt;"> 2.63 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (385) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.71%;background:#cceeff;margin:0pt;padding:0pt;"> 3.75 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:45.01%;margin:0pt;padding:0pt;"> Outstanding, end of fiscal year </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 10,891 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt

0.05pt 0pt;">⁽⁴⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.67%;margin:0pt;padding:0pt;"> 3.82 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"> 8.1 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 8,745 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.71%;margin:0pt;padding:0pt;"> 4.56 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7%;margin:0pt;padding:0pt;"> 8.8 </td></tr><tr><td style="vertical-align:bottom;width:45.01%;background:#cceeff;margin:0pt;padding:0pt;"> Vested, end of fiscal year </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 4,892 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> ⁽⁵⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.67%;background:#cceeff;margin:0pt;padding:0pt;"> 5.39 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;margin:0pt;padding:0pt;"> 7.7 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2,676 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.71%;background:#cceeff;margin:0pt;padding:0pt;"> 6.57 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7%;background:#cceeff;margin:0pt;padding:0pt;"> 8.4 </td></tr></table> <table style="border-collapse:collapse;font-family:'Times New Roman','Times',serif;font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times',serif;font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;">Represents the weighted average exercise price.</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times',serif;font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times',serif;font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;">Represents the weighted average remaining contractual term until the stock options expire.</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times',serif;font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times',serif;font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;">The total intrinsic value (the amount by which the fair market value exceeded the exercise price) of stock options exercised during the year ended June 30, 2024, was $0.1 million.</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times',serif;font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times',serif;font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(4)</td><td style="padding:0pt;">As of June 30, 2024, the intrinsic value of outstanding options was approximately $14.6 million.</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times',serif;font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times',serif;font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(5)</td><td style="padding:0pt;">As of June 30, 2024, the aggregate intrinsic value of vested stock options was approximately $4.1 million.</td></tr></table> 87450004.56P8Y9M18D85060005.24P9Y8M12D26420001.317400002.00820003.021100006.1111600040.733040002.633850003.75108910003.82P8Y1M6D87450004.56P style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:justify;margin:0pt;"> The fair value of stock options was estimated on the dates of grant using the BSM option-pricing model, with the following weighted-average assumptions for the fiscal years ended June 30, 2024 and 2023: <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:69.86%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.31%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:69.86%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.31%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:69.86%;background:#cceeff;margin:0pt;padding:0pt;"> Market price of common stock on grant date </td><td style="vertical-align:bottom;white-

space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.31</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">‌</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.31%;background:#cceeff;margin:0pt;padding:0pt;"> 3.73 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"> ‌ </td></tr><tr><td style="vertical-align:bottom;width:69.86%;margin:0pt;padding:0pt;"> Expected volatility </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"> 99 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.31%;margin:0pt;padding:0pt;"> 91 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"> % </td></tr><tr><td style="vertical-align:bottom;width:69.86%;background:#cceeff;margin:0pt;padding:0pt;"> Risk free interest rate </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;background:#cceeff;margin:0pt;padding:0pt;"> 4.2 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.31%;background:#cceeff;margin:0pt;padding:0pt;"> 3.7 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"> % </td></tr><tr><td style="vertical-align:bottom;width:69.86%;margin:0pt;padding:0pt;"> Expected term (years) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"> 5.6 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.31%;margin:0pt;padding:0pt;"> 6.0 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"> ‌ </td></tr><tr><td style="vertical-align:bottom;width:69.86%;background:#cceeff;margin:0pt;padding:0pt;"> Dividend yield </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;background:#cceeff;margin:0pt;padding:0pt;"> 0 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"> % </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.31%;background:#cceeff;margin:0pt;padding:0pt;"> 0 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"> % </td></tr></table>1,313,730,990,910.0420.037P5Y7M6DP6Y00 Share-based compensation expense is included under the following captions in the consolidated statements of operations for the fiscal years ended June 30, 2024 and 2023 (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.18%;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> ‌ </td></tr><tr><td style="vertical-align:bottom;width:72.18%;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> ‌ </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> ‌ </td></tr><tr><td style="vertical-align:bottom;width:72.18%;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> ‌ </td></tr><tr><td style="vertical-align:bottom;width:72.18%;background:#cceeff;margin:0pt;padding:0pt;"> Research and development </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,379</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">‌</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;background:#cceeff;margin:0pt;padding:0pt;"> 3,243 </td><td style="vertical-align:bottom;white-

space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"> ‌ </td></tr><tr><td style="vertical-align:bottom;width:72.18%;margin:0pt;padding:0pt;"> General and administrative </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 3,981 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 4,025 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"> ‌ </td></tr><tr><td style="vertical-align:bottom;width:72.18%;background:#cceeff;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">7,360</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">‌</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 7,268 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"> ‌ </td></tr>
</table>337900032430003981000402500073600007268000116000000P2Y3M18D2750001.021200000150000000.014600000800000019.50P7Y00. The following table sets forth a summary of activity related to the Legacy Warrants for the fiscal years ended June 30, 2024 and 2023 (shares in thousands): ‌ <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:35.66%;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"> ‌ </td></tr><tr><td style="vertical-align:bottom;width:35.66%;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> 2024 </td><td colspan="6" style="vertical-align:bottom;white-space:nowrap;width:29.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:35.66%;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Shares </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Price ⁽¹⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Term ⁽²⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Shares </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Price ⁽¹⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Term ⁽²⁾ </td></tr><tr><td style="vertical-align:bottom;width:35.66%;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;">

</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:35.66%;background:#cceeff;margin:0pt;padding:0pt;"> Outstanding, beginning of fiscal year </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"> 888 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 22.10</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">4.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,150</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;background:#cceeff;margin:0pt;padding:0pt;"> 22.83 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;background:#cceeff;margin:0pt;padding:0pt;"> 4.2 </td></tr><tr><td style="vertical-align:bottom;width:35.66%;margin:0pt;padding:0pt;"> Expirations </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (27) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;margin:0pt;padding:0pt;"> 78.60 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (262) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;margin:0pt;padding:0pt;"> 25.32 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:35.66%;background:#cceeff;margin:0pt;padding:0pt;"> Outstanding, end of fiscal year </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 861 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;background:#cceeff;margin:0pt;padding:0pt;"> 20.28 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;background:#cceeff;margin:0pt;padding:0pt;"> 3.2 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 888 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.21%;background:#cceeff;margin:0pt;padding:0pt;"> 22.10 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;background:#cceeff;margin:0pt;padding:0pt;"> 4.1 </td></tr></table> <table style="border-collapse:collapse;font-family:'Times New Roman','Times',serif;font-size:10pt;margin-bottom:3pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times',serif;font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;">Represents the weighted average exercise price.</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times',serif;font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times',serif;font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;">Represents the weighted average remaining contractual term for the number of years until the warrants expire. </td></tr></table>
88800022.10P4Y1M6D115000022.83P4Y2M12D2700078.6026200025.3286100020.28P3Y2M12D88800022.10P4Y1M6D NOTE 9 — INCOME TAXES Net Operating Loss Carryforwards The Company files income tax returns in the U.S. federal jurisdiction and in several states including, but not limited to, California, Colorado, and Oregon. The Company's federal and state tax returns for the 2021 fiscal year and forward are subject to examination by taxing authorities. Federal and state laws impose substantial restrictions on the utilization of federal net operation loss ("NOL") carryforwards in the event of an ownership change for income tax purposes, as defined in Section 382 of the Internal Revenue Code ("IRC"). Pursuant to IRC Section 382, annual use of the Company's NOL carryforwards is limited in the event that a cumulative change in ownership of more than 50% occurs within a three-year period. During the fiscal year ended June 30, 2022, the Company completed an IRC Section 382 analysis and concluded that the Company's NOL carryforwards are subject to limitations as a result of past ownership changes. As of June 30, 2024, the Company has U.S. federal net operating loss ("NOL") carryforwards of approximately $171.7 million, of which approximately $33.4 million of NOL carryforwards will never be available for use due to the limitations under IRC section 382 discussed above. The remainder of the Company's NOL carryforwards of $138.3 million consists of (i) $38.0 million that never expires and is currently available to offset taxable income, (ii) $9.6 million that is currently available to offset taxable income but if not utilized expires in 2031 through 2035, (iii) $11.7 million that become available through fiscal year 2038 and that expires by June 30, 2038 if not utilized, and (iv) $79.0 million that never expires. With respect to the $79.0 million of NOL carryforwards that never expire, this amount will become available in varying annual amounts for an aggregate approximately $13.2 million through fiscal year 2038 and $1.2 million annually thereafter. If the Company experiences future ownership changes that meet the aforementioned criteria under Section 382, further limitations will be imposed on the use of all NOL carryforwards existing through the date of such change. The Company also has Colorado and California NOL carryforwards that begin to expire in 2031 and are expected to be subject to similar limitations as those imposed under IRC Section 382. Income Tax Expense For the fiscal years ended June 30, 2024 and 2023, the reconciliation between the income tax benefit computed by applying the statutory U.S. federal income tax rate to the pre-tax loss before income taxes, and total income tax expense recognized in the consolidated financial statements is as follows (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.36%;margin:0pt;padding:0pt;"> <span style="font-

size:1pt;visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:73.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:73.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:73.36%;background:#cceeff;margin:0pt;padding:0pt;"> Income tax benefit at statutory U.S. federal rate </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14,374</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"> 10,875 </td></tr><tr><td style="vertical-align:bottom;width:73.36%;margin:0pt;padding:0pt;"> Income tax benefit attributable to U.S. states </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"> 4,413 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"> 3,468 </td></tr><tr><td style="vertical-align:bottom;width:73.36%;background:#cceeff;margin:0pt;padding:0pt;"> Impact of reduction in Colorado tax rate </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"> (78) </td></tr><tr><td style="vertical-align:bottom;width:73.36%;margin:0pt;padding:0pt;"> Non-taxable derivative loss </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"> (598) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:73.36%;background:#cceeff;margin:0pt;padding:0pt;"> Non-deductible expenses </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"> (505) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"> (442) </td></tr><tr><td style="vertical-align:bottom;width:73.36%;margin:0pt;padding:0pt;"> Stock option expirations </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"> (16) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"> (921) </td></tr><tr><td style="vertical-align:bottom;width:73.36%;background:#cceeff;margin:0pt;padding:0pt;"> NOL expirations </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"> (7,004) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:73.36%;margin:0pt;padding:0pt;"> Other </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times

New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"> (399) </td></tr><tr><td style="vertical-align:bottom;width:73.36%;background:#cceeff;margin:0pt;padding:0pt;"> Change in valuation allowance </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (10,668) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (12,503) </td></tr><tr><td style="vertical-align:bottom;width:73.36%;margin:0pt;padding:0pt;"> Total income tax expense </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td></tr></table> . For the fiscal years ended June 30, 2024 and 2023, the Company did not recognize any current income tax expense or benefit due to a full valuation allowance on its net deferred income tax assets. Deferred Income Tax Assets and Liabilities As of June 30, 2024 and 2023, the income tax effects of temporary differences that give rise to significant deferred income tax assets and liabilities are as follows (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.36%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:73.36%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:73.36%;background:#cceeff;margin:0pt;padding:0pt;"> Deferred income tax assets: </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:73.36%;background:#cceeff;margin:0pt;padding:0pt;"> Net operating loss carryforwards </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 38,942</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"> 40,537 </td></tr><tr><td style="vertical-align:bottom;width:73.36%;background:#cceeff;margin:0pt;padding:0pt;"> Research and experimental costs </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"> 19,213 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"> 9,454 </td></tr><tr><td style="vertical-align:bottom;width:73.36%;margin:0pt;padding:0pt;"> Intangible assets </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"> 6,487 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"> 5,595 </td></tr><tr><td style="vertical-align:bottom;width:73.36%;background:#cceeff;margin:0pt;padding:0pt;"> Share-based compensation </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"> 4,280 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"> 2,884 </td></tr><tr><td style="vertical-align:bottom;width:73.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New

Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Operating lease liabilities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"> 624 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"> 694 </td></tr><tr><td style="vertical-align:bottom;width:73.36%;background:#cceeff;margin:0pt;padding:0pt;"> Accrued expenses and other </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 763 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"> 603 </td></tr><tr><td style="vertical-align:bottom;width:73.36%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"> 59,767 </td></tr><tr><td style="vertical-align:bottom;width:73.36%;margin:0pt;padding:0pt;"> Valuation allowance for deferred income tax assets </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (69,783) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (59,192) </td></tr><tr><td style="vertical-align:bottom;width:73.36%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:73.36%;background:#cceeff;margin:0pt;padding:0pt;"> Deferred income tax assets, net of valuation allowance </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 526 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 575 </td></tr><tr><td style="vertical-align:bottom;width:73.36%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:73.36%;margin:0pt;padding:0pt;"> Deferred income tax liability right-of-use assets </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (526) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (575) </td></tr><tr><td style="vertical-align:bottom;width:73.36%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:73.36%;margin:0pt;padding:0pt;"> Net deferred income tax assets </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt

0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td></tr></table> For the fiscal year ended June 30, 2024, the valuation allowance increased by $10.7 million, primarily as a result of the increase in net operating loss carryforwards and capitalization of research and experimental costs for income tax purposes. In assessing the realizability of deferred income tax assets, management considers whether it is more likely than not that some portion or all of the deferred income tax assets will not be realized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Unrecognized Tax Benefits</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company did not have any unrecognized tax benefits as of June 30, 2024 and 2023. The Company's policy is to account for any interest expense and penalties for unrecognized tax benefits as part of the income tax provision. The Company does not anticipate that unrecognized tax benefits will significantly increase or decrease within the next twelve months.</p>1717000003340000013830000038000000.0960000011700000790000000.079000000.0132000001200000<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For the fiscal years ended June 30, 2024 and 2023, the reconciliation between the income tax benefit computed by applying the statutory U.S. federal income tax rate to the pre-tax loss before income taxes, and total income tax expense recognized in the consolidated financial statements is as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">-</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">-</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">-</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">-</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">-</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">-</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">-</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">-</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">-</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">-</p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">—</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">—</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</p></td></tr><tr><td style="vertical-align:bottom;width:73.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">-</p></td></tr><tr><td style="vertical-align:bottom;width:73.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Income tax benefit at statutory U.S. federal rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"> 14,374 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"> 10,875 </td></tr><tr><td style="vertical-align:bottom;width:73.36%;margin:0pt;padding:0pt;"> Income tax benefit attributable to U.S. states </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"> 4,413 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"> 3,468 </td></tr><tr><td style="vertical-align:bottom;width:73.36%;background:#cceeff;margin:0pt;padding:0pt;"> Impact of reduction in Colorado tax rate </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"> (78) </td></tr><tr><td style="vertical-align:bottom;width:73.36%;margin:0pt;padding:0pt;"> Non-taxable derivative loss </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"> (598) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:73.36%;background:#cceeff;margin:0pt;padding:0pt;"> Non-deductible expenses </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"> (505) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"> (442) </td></tr><tr><td style="vertical-align:bottom;width:73.36%;margin:0pt;padding:0pt;"> Stock option expirations </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> </td><td

style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"> (16) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"> (921) </td></tr><tr><td style="vertical-align:bottom;width:73.36%;background:#cceeff;margin:0pt;padding:0pt;"> NOL expirations </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"> (7,004) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:73.36%;margin:0pt;padding:0pt;"> Other </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"> 4 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (399) </td></tr><tr><td style="vertical-align:bottom;width:73.36%;background:#cceeff;margin:0pt;padding:0pt;"> Change in valuation allowance </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (10,668) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (12,503) </td></tr><tr><td style="vertical-align:bottom;width:73.36%;margin:0pt;padding:0pt;"> Total income tax expense </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td></tr></table>1437400010875000441300034680000-78000-5980000-505000-44200016000921000700400004000-399000-10668000-1250300000 As of June 30, 2024 and 2023, the income tax effects of temporary differences that give rise to significant deferred income tax assets and liabilities are as follows (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.36%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;">
</td></tr><tr><td style="vertical-align:bottom;width:73.36%;margin:0pt;padding:0pt;"> Deferred income tax assets: </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:73.36%;background:#cceeff;margin:0pt;padding:0pt;"> Net operating loss carryforwards </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 38,942</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"> 40,537 </td></tr><tr><td style="vertical-align:bottom;width:73.36%;background:#cceeff;margin:0pt;padding:0pt;"> Research and experimental costs </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"> 19,213 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"> 9,454 </td></tr><tr><td style="vertical-align:bottom;width:73.36%;margin:0pt;padding:0pt;"> Intangible assets </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New

Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"> 6,487 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"> 5,595 </td></tr><tr><td style="vertical-align:bottom;width:73.36%;background:#cceeff;margin:0pt;padding:0pt;"> Share-based compensation </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"> 4,280 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"> 2,884 </td></tr><tr><td style="vertical-align:bottom;width:73.36%;margin:0pt;padding:0pt;"> Operating lease liabilities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"> 624 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"> 694 </td></tr><tr><td style="vertical-align:bottom;width:73.36%;background:#cceeff;margin:0pt;padding:0pt;"> Accrued expenses and other </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 763 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 603 </td></tr><tr><td style="vertical-align:bottom;width:73.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:73.36%;background:#cceeff;margin:0pt;padding:0pt;"> Total deferred income tax assets </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"> 70,309 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"> 59,767 </td></tr><tr><td style="vertical-align:bottom;width:73.36%;margin:0pt;padding:0pt;"> Valuation allowance for deferred income tax assets </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (69,783) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (59,192) </td></tr><tr><td style="vertical-align:bottom;width:73.36%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:73.36%;margin:0pt;padding:0pt;"> Deferred income tax assets, net of valuation allowance </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 526 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 575 </td></tr><tr><td style="vertical-align:bottom;width:73.36%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:73.36%;margin:0pt;padding:0pt;"> Deferred income tax liability right-of-use assets </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (526) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">

</td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (575) </td></tr><tr><td style="vertical-align:bottom;width:73.36%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:73.36%;margin:0pt;padding:0pt;"> Net deferred income tax assets </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td></tr></table>3894200040537000192130009454000648700055950004280000288400062400069400076300060300070309000597670006978300059192000526000575000526000575 NOTE 10 — COMMITMENTS AND CONTINGENCIES Licensing Commitments Please refer to Note 5 for further discussion of commitments to make milestone payments and to pay royalties under license agreements with XOMA and ActiveSite. Employment Agreements As of June 30, 2024, the Company was subject to employment agreements with two officers of the Company and one employee of the Company that provide for aggregate annual base salaries of $1.4 million. The agreements with the Chief Executive Officer and Chief Medical Officer provides that if either of the individuals is terminated outside of a change in control event and without cause, (i) all of their stock options that are subject to ongoing vesting conditions over subsequent periods ranging from 12 to 18 months will immediately vest, and (ii) such stock options will remain exercisable for periods ranging from 6 to 12 months following the occurrence of the termination event. In addition, if either of the executive officers are terminated solely due to a change of control event, all of their respective unvested stock options will immediately vest and all outstanding stock options will remain exercisable for periods ranging from 6 to 12 months following the occurrence of the termination event. The Chief Medical Officer's employment agreement, as amended, provides that upon the occurrence of a termination event other than a change of control, the Company is required to (i) make severance payments equal to 12 months of salary, a pro-rata bonus, and health insurance coverage for 12 months following the termination date, and (ii) all unvested stock options subject to vest over the subsequent 12 month period after the termination event will become immediately exercisable and all outstanding stock options will remain exercisable for 6 months following the termination event. In addition, upon the occurrence of a termination solely due to a change of control event, the Company is required to (i) make severance payments equal to 18 months of salary, a pro-rata bonus, and health insurance coverage for 18 months following the termination event. 401(k) Plan The Company has a defined contribution employee benefit plan under section 401(k) of the Internal Revenue Code (the "401(k) Plan"). The 401(k) Plan covers all eligible employees who are entitled to participate beginning six months after the commencement of employment. The Company matches contributions up to 4% of the participating employee's compensation with such matching contributions vested immediately. Total contributions by the Company to the 401(k) Plan amounted to approximately $0.4 million and $0.3 million for the fiscal years ended June 30, 2024 and 2023, respectively. Legal Matters From time to time, the Company may be involved in litigation relating to claims arising out of operations in the normal course of business. As of June 30, 2024, there were no pending or threatened lawsuits that could reasonably be expected to have a material effect on the Company's results of operations or financial position. At each reporting period, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under ASC 450, Contingencies. Legal fees are expensed as incurred. 211400000P12MP18MP6MP12MP6MP12MP12MP12MP12MP6MP18MP18M0.04400000300000 NOTE 11 — RELATED PARTY TRANSACTIONS Related Party Licensing Agreement On September 15, 2020, the Company entered into an exclusive license agreement with Handok (the "Handok License") for the territory of the Republic of Korea. The Handok License relates to pharmaceutical products in final dosage form containing the pharmaceutical compounds developed or to be developed by the Company, including those related to ersodetug and RZ402. The Handok License is in effect for a period of 20 years after the first commercial sale of each product and requires (i) milestone payments of $0.5 million upon approval of a New Drug Application ("NDA") for each product in the territory, and (ii) the Company will sell products ordered by Handok at a transfer price equal to 70% of the net selling price of the products. To date, no milestone payments have been earned by the Company.</p><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Investors in 2022 Private Placement</p><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Handok and certain of its affiliates were the sole investors in the 2022 Private Placement discussed in Note 7.</p>P20Y5000000.700<p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTE 12 - SUPPLEMENTAL FINANCIAL INFORMATION</p><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Cash and cash equivalents</p><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Cash and cash equivalents consisted of the following as of June 30, 2024 and 2023 (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</p></td></tr><tr><td style="vertical-align:bottom;width:75.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td></tr><tr><td style="vertical-align:bottom;width:75.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"> 61,249 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-

family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,464</p></td></tr><tr><td style="vertical-align:bottom;width:75.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Demand deposits at a single financial institution</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,147</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,091</p></td></tr><tr><td style="vertical-align:bottom;width:75.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,481</p></td></tr><tr><td style="vertical-align:bottom;width:75.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td></tr><tr><td style="vertical-align:bottom;width:75.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 70,396 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 16,036</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The money market funds and commercial paper included in the table above were purchased with an original maturity of three months or less. These investments and the demand deposits are freely available for the Company's immediate and general business use.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Property and Equipment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Property and equipment consisted of the following as of June 30, 2024 and 2023 (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</p></td></tr><tr><td style="vertical-align:bottom;width:75.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"></p></td></tr><tr><td style="vertical-align:bottom;width:75.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Office furniture and equipment </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.03%;background:#cceeff;margin:0pt;padding:0pt;"> 210 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.03%;background:#cceeff;margin:0pt;padding:0pt;"> 210 </td></tr><tr><td style="vertical-align:bottom;width:75.87%;margin:0pt;padding:0pt;"> Less accumulated depreciation </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (107) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (71) </td></tr><tr><td style="vertical-align:bottom;width:75.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.03%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.03%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:75.87%;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 103</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 139 </td></tr></table> . Depreciation expense related to property and equipment amounted to approximately $36,000 and $30,000 for the fiscal years ended June 30, 2024 and 2023, respectively.</p><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Cash and cash equivalents consisted of the following as of June 30, 2024 and 2023 (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</p></td></tr><tr><td style="vertical-align:bottom;width:75.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">.</p></td></tr><tr><td style="vertical-align:bottom;width:75.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"> 61,249 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,464</p></td></tr><tr><td style="vertical-align:bottom;width:75.27%;margin:0pt;padding:0pt;">Demand deposits at a single financial institution</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,147</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,091</p></td></tr><tr><td style="vertical-align:bottom;width:75.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,481</p></td></tr><tr><td style="vertical-align:bottom;width:75.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td></tr><tr><td style="vertical-align:bottom;width:75.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 70,396 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double

#000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 16,036 </td></tr>
</table>612490005464000914700060910004481000703960016036000 Property and equipment consisted of the following as of June 30, 2024 and 2023 (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.87%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:8.03%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;width:75.87%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:75.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.03%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:75.87%;background:#cceeff;margin:0pt;padding:0pt;"> Office furniture and equipment </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 210</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.03%;background:#cceeff;margin:0pt;padding:0pt;"> 210 </td></tr><tr><td style="vertical-align:bottom;width:75.87%;margin:0pt;padding:0pt;"> Less accumulated depreciation </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (107) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (71) </td></tr><tr><td style="vertical-align:bottom;width:75.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:75.87%;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 103</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 139 </td></tr></table>210000210000107000710001030001390003600030000 NOTE 13 — NET LOSS PER SHARE Basic net loss per share is computed by dividing net loss by the weighted average number of outstanding shares of common stock and PWFs during periods when the PFWs are accounted for as equity instruments. Common shares associated with PFWs that are accounted for as equity instruments are included in the computation of basic and diluted net loss per share since the exercise price is negligible and all of the PFWs are fully vested and exercisable. For the calculation of diluted net loss per share for the fiscal year ended June 30, 2024, during the period when PFWs were accounted for as derivative liabilities, such PFWs were excluded from the calculation since the impact of PFWs was antidilutive. Calculation of the weighted average number of shares outstanding for purposes of diluted net loss per share is also required to include the dilutive effect, if any, of stock options, Legacy Warrants, and other common stock equivalents computed using the treasury stock method. For the fiscal years ended June 30, 2024 and 2023, all of such common stock equivalents were antidilutive and excluded from the calculations. In addition, the impact of applying the two-class method related to the Participating Warrants, was antidilutive for the calculation of both basic and diluted net loss per share. Presented below are the calculations of the numerators and the denominators for basic and diluted net loss per share for the fiscal years ended June 30, 2024 and 2023 (in thousands except per share amounts):
<table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.98%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"> <div

style="bottom:0pt;position:absolute;width:100%;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:69.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:69.98%;background:#cceeff;margin:0pt;padding:0pt;"> Calculation of Numerators: </td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:69.98%;margin:0pt;padding:0pt;"> Net loss for calculation of basic and diluted net loss per share </td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (68,459)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (51,787) </td></tr><tr><td style="vertical-align:bottom;width:69.98%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:69.98%;background:#cceeff;margin:0pt;padding:0pt;"> Calculation of Denominators: </td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"> 39,499 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"> 36,605 </td></tr><tr><td style="vertical-align:bottom;width:69.98%;margin:0pt;padding:0pt;"> Weighted average shares related to pre-funded warrants: </td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:69.98%;background:#cceeff;margin:0pt;padding:0pt;"> 2021 PFWs </td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"> 1,195 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"> 1,661 </td></tr><tr><td style="vertical-align:bottom;width:69.98%;margin:0pt;padding:0pt;"> 2022 PFWs </td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"> 10,245 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"> 12,921 </td></tr><tr><td style="vertical-align:bottom;width:69.98%;background:#cceeff;margin:0pt;padding:0pt;"> Exchange PFWs </td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td

style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"> 393 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:69.98%;margin:0pt;padding:0pt;"> 2024 PFWs </td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 133 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"> ⁽¹⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:69.98%;background:#cceeff;margin:0pt;padding:0pt;"> Weighted average shares for basic and diluted net loss per share </td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 51,465 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 51,187 </td></tr><tr><td style="vertical-align:bottom;width:69.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:69.98%;background:#cceeff;margin:0pt;padding:0pt;"> Net loss per share of common stock: </td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:69.98%;margin:0pt;padding:0pt;"> Basic </td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1.33)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (1.01) </td></tr><tr><td style="vertical-align:bottom;width:69.98%;background:#cceeff;margin:0pt;padding:0pt;"> Diluted </td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1.33)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (1.01) </td></tr></table> _____ <table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;">Represents the weighted average number of shares related to the Exchange PFWs discussed in Note 7 for the period when they became equity-classified on May 13, 2024 through June 30, 2024.</td></tr></table> As of June 30, 2024 and 2023, the following potential common stock equivalents were excluded from the calculation of diluted net loss per share since the impact of inclusion was anti-dilutive (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:79.78%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:79.78%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:79.78%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-

align:bottom;width:79.78%;background:#cceeff;margin:0pt;padding:0pt;"> Stock options </td><td style="vertical-align:bottom;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"> 10,891 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"> 8,745 </td></tr><tr><td style="vertical-align:bottom;width:79.78%;margin:0pt;padding:0pt;"> Legacy warrants </td><td style="vertical-align:bottom;width:1.59%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 861 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 888 </td></tr><tr><td style="vertical-align:bottom;width:79.78%;background:#cceeff;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 11,752 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 9,633 </td></tr></table> . Presented below are the calculations of the numerators and the denominators for basic and diluted net loss per share for the fiscal years ended June 30, 2024 and 2023 (in thousands except per share amounts): . . <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.98%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:69.98%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:69.98%;background:#cceeff;margin:0pt;padding:0pt;"> Calculation of Numerators: </td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:69.98%;background:#cceeff;margin:0pt;padding:0pt;"> Net loss for calculation of basic and diluted net loss per share </td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;"> (68,459)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (51,787) </td></tr><tr><td style="vertical-align:bottom;width:69.98%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:69.98%;margin:0pt;padding:0pt;"> Calculation of Denominators: </td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:69.98%;background:#cceeff;margin:0pt;padding:0pt;"> Weighted average number of common shares outstanding </td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"> 39,499 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times

New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"> 36,605 </td></tr><tr><td style="vertical-align:bottom;width:69.98%;margin:0pt;padding:0pt;"> Weighted average shares related to pre-funded warrants: </td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:69.98%;background:#cceeff;margin:0pt;padding:0pt;"> 2021 PFWs </td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"> 1,195 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"> 1,661 </td></tr><tr><td style="vertical-align:bottom;width:69.98%;margin:0pt;padding:0pt;"> 2022 PFWs </td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"> 10,245 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"> 12,921 </td></tr><tr><td style="vertical-align:bottom;width:69.98%;background:#cceeff;margin:0pt;padding:0pt;"> Exchange PFWs </td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"> 393 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:69.98%;margin:0pt;padding:0pt;"> 2024 PFWs </td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 133 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"> ⁽¹⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:69.98%;background:#cceeff;margin:0pt;padding:0pt;"> Weighted average shares for basic and diluted net loss per share </td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 51,465 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 51,187 </td></tr><tr><td style="vertical-align:bottom;width:69.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:69.98%;background:#cceeff;margin:0pt;padding:0pt;"> Net loss per share of common stock: </td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:69.98%;margin:0pt;padding:0pt;"> Basic </td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1.33)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (1.01) </td></tr><tr><td style="vertical-align:bottom;width:69.98%;background:#cceeff;margin:0pt;padding:0pt;"> Diluted </td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (1.33) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-

align:right;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (1.01) </td></tr></table> _____ <table style="border-collapse:collapse;font-family:'Times New Roman','Times',serif;font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times',serif;font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;">Represents the weighted average number of shares related to the Exchange PFWs discussed in Note 7 for the period when they became equity-classified on May 13, 2024 through June 30, 2024.</td></tr></table> -68459000-68459000-51787000-51787000394990003660500011950001661000102450001292100039300013300051465000514650005118700051187000-1.33-1.01-1.33-1.01 As of June 30, 2024 and 2023, the following potential common stock equivalents were excluded from the calculation of diluted net loss per share since the impact of inclusion was anti-dilutive (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:79.78%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:79.78%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:79.78%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:79.78%;background:#cceeff;margin:0pt;padding:0pt;"> Stock options </td><td style="vertical-align:bottom;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;margin:0pt;padding:0pt;"> 10,891 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"> 8,745 </td></tr><tr><td style="vertical-align:bottom;width:79.78%;margin:0pt;padding:0pt;"> Legacy warrants </td><td style="vertical-align:bottom;width:1.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 861 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 888 </td></tr><tr><td style="vertical-align:bottom;width:79.78%;background:#cceeff;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 11,752 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 9,633 </td></tr></table> 1089100087450008610008880001175200096330000 NOTE 14 — FINANCIAL INSTRUMENTS AND SIGNIFICANT CONCENTRATIONS Fair Value Measurements Fair value is defined as the price that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants on the measurement date. When determining fair value, the Company considers the principal or most advantageous market in which it transacts and considers assumptions that market participants would use when pricing the asset or liability. The Company applies the following fair value hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement: Level 1—Quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date. Level 2—Other than quoted prices included in Level 1 that are observable for the asset and liability, either directly or indirectly through market corroboration, for substantially the full term of the asset or liability. Level 3—Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any market activity for the asset or liability at the measurement date. Assets Measured at Fair Value on a Recurring Basis The following table presents information about the Company’s financial assets measured at fair value on a recurring basis and indicates the fair value hierarchy classification of such fair values as of June 30, 2024. <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:39.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> <p style="font-family:'Times New

Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:58.37%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.91%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> . </td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:58.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Fair Value Measurement of Assets as of June 30, 2024 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.91%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Level 1 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Level 2 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Level 3 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.91%;background:#cceeff;margin:0pt;padding:0pt;"> Cash and cash equivalents: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.4%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.91%;margin:0pt;padding:0pt;"> Money market funds </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 61,249</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.4%;margin:0pt;padding:0pt;"> 61,249 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.91%;background:#cceeff;margin:0pt;padding:0pt;"> Marketable debt securities: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.4%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:39.91%;margin:0pt;padding:0pt;"> Corporate commercial paper </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"> 20,929 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.4%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"> 20,929 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-

family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">U.S. Government agencies </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"> 1,997 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.4%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"> 1,997 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.91%;margin:0pt;padding:0pt;"> U.S. Government treasuries </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"> 2,720 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.4%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"> 2,720 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.4%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"> 30,832 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"> 30,832 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.4%;background:#cceeff;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.91%;margin:0pt;padding:0pt;"> Asset-backed securities </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 263 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 263 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.91%;background:#cceeff;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 117,990</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 61,249 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 56,741</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td></tr></table> . The following table presents information about the Company's financial assets measured at fair value on a recurring basis and indicates the fair value hierarchy classification of such fair values as of June 30, 2023. . <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:39.91%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> <p style="font-family:'Times New

Roman','Times','serif';font-size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:58.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Fair Value Measurement of Assets as of June 30, 2023 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Level 1 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Level 2 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Level 3 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.91%;background:#cceeff;margin:0pt;padding:0pt;"> Cash and cash equivalents: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.4%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.91%;margin:0pt;padding:0pt;"> Money market funds </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,464</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:9pt;text-align:center;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.4%;margin:0pt;padding:0pt;"> 5,464 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:9pt;text-align:center;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.91%;background:#cceeff;margin:0pt;padding:0pt;"> Corporate commercial paper </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"> 4,481 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.4%;background:#cceeff;margin:0pt;padding:0pt;"> 4,481 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.91%;margin:0pt;padding:0pt;"> Marketable debt securities: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.91%;background:#cceeff;margin:0pt;padding:0pt;"> Corporate commercial paper </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"> 41,597 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.4%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"> 41,597 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.91%;margin:0pt;padding:0pt;"> U.S. Government agencies </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"> 26,394 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.4%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"> 26,394 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.91%;background:#cceeff;margin:0pt;padding:0pt;"> U.S. Government treasuries </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"> 10,404 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.4%;background:#cceeff;margin:0pt;padding:0pt;"> 10,404 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.91%;margin:0pt;padding:0pt;"> Corporate notes and bonds </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"> 19,240 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.4%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"> 19,240 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.91%;background:#cceeff;margin:0pt;padding:0pt;"> Asset-backed securities </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 4,694 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 4,694 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-

size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:39.91%;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 112,274</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 20,349 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 91,925</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td></tr></table> Marketable debt securities classified as Level 2 within the valuation hierarchy generally consist of U.S. government agency securities, corporate bonds, and commercial paper. The Company determines the fair value of marketable debt securities based upon valuations obtained from third-party pricing sources. Except for the amounts shown in the table above, the Company did not have any other assets measured at fair value on a recurring basis as of June 30, 2024 and 2023. Liabilities Measured at Fair Value on a Recurring Basis For the fiscal years ended June 30, 2024 and 2023, the Company's liabilities that are required to be measured and recorded at fair value on a recurring basis consist of the embedded derivative liability discussed in Note 6 and the warrant derivative liability discussed in Note 7. The warrant derivative liability is classified under Level 2 of the fair value hierarchy and the embedded derivative liability is classified under Level 3 of the fair value hierarchy. Fair value of the warrant liability is predominantly based on the market price of the Company's shares of common stock. Fair value of the embedded derivative liability is determined based on management's assessment of the probability and timing of occurrence for the Exit Events discussed in Note 6 using a discount rate equal to the effective interest rate under the Loan Agreement prior to termination. The fair value of the Exchange PFWs was computed using the BSM option-pricing model. Key inputs to this valuation model as of May 13, 2024 included the exercise price of $0.001 per share, the market price of the Company's common stock of $2.85 per share, the risk-free interest rate of 5.5%, an expected term of 1-day, and historical volatility of 100%. Key inputs to this valuation model as of March 8, 2024 included the exercise price of $0.001 per share, the market price of the Company's common stock of $1.90 per share, the risk-free interest rate of 5.5%, an expected term of 1-day, and historical volatility of 100%.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table sets forth a summary of changes in the fair value of the Company's liabilities for which fair value was determined on a recurring basis for the fiscal years ended June 30, 2024 and 2023 (in thousands):</p><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;text-align:justify;margin:0pt;"></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:61.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:18.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:18.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</p></td></tr><tr><td style="vertical-align:bottom;width:61.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Warrant</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Embedded</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Warrant</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Embedded</p></td></tr><tr><td style="vertical-align:bottom;width:61.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Fair value, beginning of fiscal year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 412</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-

space:nowrap;width:6.55%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 407</p></td></tr><tr><td style="vertical-align:bottom;width:61.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrant liability incurred on March 8, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,697</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">—</p></td></tr><tr><td style="vertical-align:bottom;width:61.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Changes in fair value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,850</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 56</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">—</p></td></tr><tr><td style="vertical-align:bottom;width:61.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Reclassification of warrant derivative liability to equity on May 13, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (8,547)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">—</p></td></tr><tr><td style="vertical-align:bottom;width:61.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Fair value, end of fiscal year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 468</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 412 </td></tr></table> . Due to the relatively short maturity of the respective instruments, the fair value of cash and cash equivalents, accounts payable, and accrued liabilities approximated their carrying values as of June 30, 2024 and 2023. The Company's policy is to recognize asset or liability transfers among Level 1, Level 2 and Level 3 as of the actual date of the events or change. In circumstances that caused the transfer. During the fiscal years ended June 30, 2024 and 2023, the Company did not have any transfers of its assets or liabilities between levels of the fair value hierarchy. Significant Concentrations Financial instruments that subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents and investments in marketable debt securities. The Company maintains its cash in demand accounts at a high-quality financial institution. As of and for the fiscal years ended June 30, 2024 and 2023, cash deposits have exceeded the amount of insurance provided on such deposits by the Federal Deposit Insurance Corporation. . As of June 30, 2024, the Company had an aggregate of $26.6 million invested in marketable debt securities of issuers in the banking and financial services industries. As of June 30, 2023, the Company had an aggregate of $54.0 million invested in marketable debt securities of issuers in the banking and financial services industries, and an aggregate of $26.5 million invested in marketable debt securities of a single agency of the U.S. government. While the Company's investment policy requires investments in highly rated securities, a wide variety of broad economic factors and issuer-specific factors could result in credit agency downgrades below the Company's minimum credit rating requirements that could result in losses regardless of whether the Company elects to sell the securities or hold them until maturity. . <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:39.91%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><div

style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:58.37%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:58.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Fair Value Measurement of Assets as of June 30, 2024 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Level 1 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Level 2 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Level 3 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.91%;background:#cceeff;margin:0pt;padding:0pt;"> Cash and cash equivalents: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.4%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.91%;margin:0pt;padding:0pt;"> Money market funds </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 61,249</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.4%;margin:0pt;padding:0pt;"> 61,249 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.91%;background:#cceeff;margin:0pt;padding:0pt;"> Marketable debt securities: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.4%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt

0pt 0.05pt 0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.91%;margin:0pt;padding:0pt;"> Corporate commercial paper </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"> 20,929 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.4%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"> 20,929 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.91%;background:#cceeff;margin:0pt;padding:0pt;"> U.S. Government agencies </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"> 1,997 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.4%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"> 1,997 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.91%;margin:0pt;padding:0pt;"> U.S. Government treasuries </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"> 2,720 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.4%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"> 2,720 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.91%;background:#cceeff;margin:0pt;padding:0pt;"> Corporate notes and bonds </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"> 30,832 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.4%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"> 30,832 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.91%;margin:0pt;padding:0pt;"> Asset-backed securities </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 263 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 263 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:39.91%;background:#cceeff;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 117,990 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-

size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 61,249</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 56,741 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:39.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:58.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value Measurement of Assets as of June 30, 2023</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 3</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Cash and cash equivalents:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"> 5,464 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,464</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.91%;background:#cceeff;margin:0pt;padding:0pt;"> Corporate commercial paper </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"> 4,481 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:12.4%;background:#cceeff;margin:0pt;padding:0pt;"> 4,481 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.91%;margin:0pt;padding:0pt;"> Marketable debt securities: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.91%;background:#cceeff;margin:0pt;padding:0pt;"> Corporate commercial paper </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"> 41,597 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.4%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"> 41,597 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.91%;margin:0pt;padding:0pt;"> U.S. Government agencies </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"> 26,394 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.4%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"> 26,394 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.91%;background:#cceeff;margin:0pt;padding:0pt;"> U.S. Government treasuries </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"> 10,404 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.4%;background:#cceeff;margin:0pt;padding:0pt;"> 10,404 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.91%;margin:0pt;padding:0pt;"> Corporate notes and bonds </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"> 19,240 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.4%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"> 19,240 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;white-

space:nowrap;width:39.91%;background:#cceeff;margin:0pt;padding:0pt;"> Asset-backed securities </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 4,694 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 4,694 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:39.91%;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 112,274</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:9pt;text-align:center;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 20,349 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 91,925</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:9pt;text-align:center;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td></tr></table>612490006124900020929000209290001997000199700027200002720000308320003083200026300002630001179900006124900056741000546400054640000448100044

style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:justify;margin:0pt;">The following table sets forth a summary of changes in the fair value of the Company's liabilities for which fair value was determined on a recurring basis for the fiscal years ended June 30, 2024 and 2023 (in thousands): . <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.35%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:61.35%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"> . </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:18.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;"> . </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:18.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:61.35%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Warrant </td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Embedded </td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Warrant </td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Embedded </td></tr><tr><td style="vertical-align:bottom;width:61.35%;background:#cceeff;margin:0pt;padding:0pt;"> Fair value, beginning of fiscal year </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;background:#cceeff;margin:0pt;padding:0pt;"> 412 </td><td style="vertical-align:bottom;white-

space:nowrap;width:0.61%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8%;background:#cceeff;margin:0pt;padding:0pt;"> 407 </td></tr><tr><td style="vertical-align:bottom;width:61.35%;margin:0pt;padding:0pt;"> Warrant liability incurred on March 8, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;margin:0pt;padding:0pt;"> 5,697 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:8%;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:61.35%;background:#cceeff;margin:0pt;padding:0pt;"> Changes in fair value </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;background:#cceeff;margin:0pt;padding:0pt;"> 2,850 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;background:#cceeff;margin:0pt;padding:0pt;"> 56 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:8%;background:#cceeff;margin:0pt;padding:0pt;"> 5 </td></tr><tr><td style="vertical-align:bottom;width:61.35%;margin:0pt;padding:0pt;"> Reclassification of warrant derivative liability to equity on May 13, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (8,547) </td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:61.35%;background:#cceeff;margin:0pt;padding:0pt;"> Fair value, end of fiscal year </td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 468 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 412 </td></tr></table>) 412000407000569700028500005600050000-85470004680004120000Financial instruments that subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents and investments in marketable debt securities. The Company maintains its cash in demand accounts at a high-quality financial institution. As of and for the fiscal years ended June 30, 2024 and 2023, cash deposits have exceeded the amount of insurance provided on such deposits by the Federal Deposit Insurance Corporation. 2660000054000000.026500000 NOTE 15 — SUBSEQUENT EVENTS 2024 Private Placement On June 25, 2024, the Company entered into a securities purchase agreement (the "2024 SPA") with Handok and one other investor (the "2024 Purchasers") relating to a private placement (the "2024 Private Placement"), pursuant to which the Company agreed to sell 1,500,000 shares of common stock at a purchase price of $4.00 per share for gross proceeds of $6.0 million. Closing of the 2024 Private Placement occurred in July 2024, whereby the Company received net proceeds of $6.0 million after deduction of underwriting discounts and other offering costs. As required pursuant to the 2024 SPA, the Company filed a registration statement with the U.S. Securities and Exchange Commission ("SEC") in August 2024 to register the shares of common stock issued in the 2024 Private Placement. The Company entered into a registration rights agreement with the 2024 Purchasers whereby the Company was required to have the registration statement (the "2024 Private Placement Registration Statement") declared effective within 60 days after the signing date of the 2024 SPA. The 2024 Private Placement Registration Statement was declared effective by the SEC on August 14, 2024. The Company will be obligated to pay certain liquidated damages to the 2024 Purchasers if the Company fails to maintain the effectiveness of the 2024 Private Placement Registration Statement. Investments in Marketable Debt Securities In July 2024, the Company utilized approximately $59.7 million of cash and cash equivalents to purchase investments in marketable debt securities with maturities that range from October 2024 through December 2025.) Exchange PFW Warrant Exercise) In July 2024, a holder of Exchange PFWs provided notice of cashless exercise of 610,404 Exchange PFWs, which resulted in the issuance of 610,273 shares of common stock.) <p style="font-family:'Times New

Roman','Times','serif';font-size:10pt;margin:0pt;">Executive Compensation On September 10, 2024, the Board of Directors approved an employment agreement, effective September 15, 2024, with the Company's Chief Financial Officer that provides for an annual base salary of $460,000, plus a calendar year target bonus of 40%. The agreement provides that if the Chief Financial Officer is terminated outside of a change in control event and without cause, (i) make severance payments equal to 12 months of base salary, a pro-rata bonus through the termination date, and health insurance coverage for 12 months following the termination date, and (ii) all unvested stock options subject to vest over the subsequent 12 month period after the termination event will become immediately exercisable and all such stock options will remain exercisable for 6 months following the termination event. In addition, upon the occurrence of a termination solely due to a change of control event, the Company is required to (i) make severance payments equal to 18 months of salary, a pro-rata bonus through the termination date, and health insurance coverage for 18 months following the termination event. Effective September 15, 2024, the Board of Directors approved an increase from approximately $557,000 to $625,000 in the annual base compensation set forth in the employment agreement discussed in Note 10 for the Company's Chief Executive Officer. 15000004.006000000.06000000.059700000610404610273460000040P12MP12MP12MP6MP18MP18M557000625000